Cumulative Fifteen-year Index

in Medicine

Volume 1–15 1982–1996

Editors
T. Colton
A. L. Johnson
D. Machin

SMEDDA 1–15 (1996)
ISSN 0277-6715

Statistics in Medicine

EDITORS

Theodore Colton
Boston University School of Public Health, 80 East Concord Street, Boston, Massachusetts 02118, U.S.A.

Tony Johnson
MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge CB2 2SR, U.K.

David Machin
NMRC Clinical Trials and Epidemiology Research Unit, Room 02–14 Bowyer Block, Singapore General Hospital, Singapore 169 608

Deputy Editors

Robert Glynn
Department of Medicine, Harvard Medical School, 900 Commonwealth Avenue East, Boston, Massachusetts 02215, U.S.A.

Joel Greenhouse
Department of Statistics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, U.S.A.

Christopher Palmer
Centre for Applied Medical Statistics, Department of Community Medicine, University of Cambridge, Institute of Public Health, Robinson Way, Cambridge CB2 2SR, U.K.

Sally Stenning
MRC Cancer Trials Office, 5 Shaftesbury Road, Cambridge CB2 2BW, U.K.

Biostatistical Tutorial Editor

Ralph D'Agostino
Department of Mathematics, Boston University, 111 Cummington Street, Boston, Massachusetts 02215, U.S.A.

Statistics in the Medical Literature

Douglas Altman
ICRF Medical Statistics Group, Centre for Statistics in Medicine, Institute of Health Sciences, PO Box 777, Headington, Oxford OX3 7LF, U.K.

Book Review Editor

Niels Keiding
Department of Biostatistics, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark

Editorial Assistants

Suzanne Thompson
Boston University School of Public Health

Margaret Molloy
MRC Cancer Trials Office

AIMS AND SCOPE

The Journal will publish papers on practical applications of statistics and other quantitative methods to medicine and its applied sciences. It will embrace all aspects of the collection, analysis, presentation and interpretation of medical data. Specific areas will include clinical trials, diagnostic studies, quality control, laboratory experiments, epidemiology and health care research. The journal will emphasize the relevance of numerical techniques and will aim to communicate statistical and quantitative ideas in a medical context. Examples of applications of statistics to specific projects, articles explaining new statistical methods and reviews of general topics will be published; papers containing extensive mathematical theory will be excluded. The main criteria for publication will be appropriateness of the statistical method to the particular medical problem and clarity of exposition. The ultimate goal of *Statistics in Medicine* is to enhance communication between statisticians, clinicians and medical researchers with the common purpose of advancing knowledge and understanding of quantitative aspects of medicine. It is intended that both the readers and authors of the Journal include statisticians, clinicians, epidemiologists, health researchers, mathematicians and computer scientists interested in medicine.

EDITORIAL BOARD

Paul S. Albert
NHBLI/NIH,
Rockledge II Room 8223,
6701 Rockledge Blvd.,
Bethesda, MD 20892, USA

D. G. Altman
ICRF Medical Statistics Group,
Centre for Statistics in Medicine,
Institute of Health Sciences,
PO Box 777,
Headington, Oxford OX3 7LF, UK

P. K. Andersen
Department of Biostatistics,
University of Copenhagen,
3, Blegdamsvej,
DK-2200 Copenhagen N, Denmark

P. Armitage
2 Reading Road,
Wallingford,
Oxford OX10 9DP, UK

D. Ashby
Dept. of Statistics and Computational Mathematics,
University of Liverpool,
PO Box 147,
Liverpool L69 3BX, UK

Stuart G. Baker
Biometry Branch, EPN 344
National Cancer Institute,
6130 Executive Blvd., MSC 7354,
Bethesda, MD 20892-7354, USA

P. Bauer
Department of Medical Statistics
University of Vienna,
Schwarzspanier–Straße 17
A-1090 Vienna, Austria

C. Begg
Dept. of Epidemiology and Biostatistics,
Memorial-Sloan Kettering Cancer Center,
1275 York Avenue,
New York, NY 10021, USA

M. J. Campbell
Medical Statistics and Computing,
University of Southampton,
South Academic Block,
Southampton General Hospital,
Southampton SO16 6YD, UK

R. Chen
ATSDR,
1600 Clifton Road E-31,
Atlanta, GA 30333, USA

T. J. Cole
MRC Dunn Nutrition Unit,
Downhams Lane, Milton Road,
Cambridge CB4 1XJ, UK

N. Crichton
Institute of Advanced Nursing Education,
20 Cavendish Square,
London W1M 0AB, UK

S. C. Darby
ICRF Cancer Epidemiology Unit,
University of Oxford,
Gibson Building,
Radcliffe Infirmary,
Oxford OX2 6HE, UK

S. Day
Leo Laboratories Ltd,
Longwick Road,
Princes Risborough,
Bucks, HP27 9RR, UK

Paula Diehr
Biostatistics and Health Services,
University of Washington, SC-32,
Seattle, WA 98195, USA

K. Dietz
Universität Tübingen,
Institut für Medizinische Biometrie,
Westbahnhofstrasse 55,
D-72070 Tübingen, Germany

S. W. Duffy
MRC Biostatistics Unit,
Institute of Public Health,
University Forvie Site,
Robinson Way,
Cambridge CB2 2SR, UK

R. C. Elston
Department of Epidemiology and Biostatistics,
Case Western Reserve University,
MetroHealth Medical Center,
2500 MetroHealth Drive,
Cleveland, OH 44109, USA

B. S. Everitt
Institue of Psychiatry,
De Crespigny Park,
Denmark Hill,
London SE5 8AF, UK

T. M. M. Farley
Development and Research Training in Human Reproduction,
World Health Organization,
1211 Geneva 27, Switzerland

C. P. Farrington
PHLS Communicable Disease Surveillance Centre,
61 Colindale Avenue,
London NW9 5EQ, UK

D. M. Finkelstein
Department of Biostatistics,
Harvard School of Public Health,
677 Huntington Avenue,
Boston, MA 02115, USA

L. S. Freedman
Biometry Branch, DCPC, NCI,
Room 344, Executive Plaza North,
6130 Executive Boulevard,
Bethesda, MD 20892, USA

M. A. Foulkes
Division of AIDS,
NIAID,
6003 Executive Boulevard MSC 7620,
Bethesda, MD 20892–7260, USA

G. Gallus
Institute of Biometry and Medical Statistics,
University of Milan,
Via G Venezian 1,
20133 Milan, Italy

C. Gatsonis
Center for Statistical Sciences,
Brown University,
Box G–H,
Providence, RI 02912, USA

E. A. Gehan
Lombardi Cancer Research Center,
Georgetown University School of Medicine,
2233 Wisconsin Avenue N.W.,
Suite 535,
Washington, D.C. 20007, USA

E. Goetghebeur
Methodology and Statistics,
R. U. Limburg
P.B. 616,
6200 MD Maastricht,
The Netherlands

S. M. Gore
MRC Biostatistics Unit,
Institute of Public Health,
University Forvie Site,
Robinson Way,
Cambridge CB2 2SR, UK

A. L. Gould
Investigative Research–BRIM,
Merck Research Laboratories,
BL3-2,
West Point, PA 19484, USA

S. Greenland
22333 Swenson Drive,
Topanga,
CA 90290, USA

A. P. Grieve
Pfizer Central Research,
Biometrics Department,
Ramsgate Road,
Sandwich, Kent CT13 9NT, UK

J. D. F. Habbema
Dept. of Public Health and Social Medicine,
Erasmus University Rotterdam,
PO Box 1738,
3000 DR Rotterdam, The Netherlands

M. Elizabeth Halloran
Department of Biostatistics,
Rollins School of Public Health,
Emory University,
1518 Clifton Road, NE,
Atlanta, GA 30322, USA

J. Hanley
Department of Epidemiology and Biostatistics,
McGill University,
1020 Pine Avenue West,
Montreal, Quebec H3A 1A2,
Canada

F. E. Harrell Jr.
Division of Biostatistics and Epidemiology
Department of Health Evaluation Sciences,
University of Virginia, Box 600,
Charlottesville, VA 22908, USA

W. W. Hauck
Biostatistics Section,
Division of Clinical Pharmacology,
Thomas Jefferson University,
Sheridan Bldg. #403, 125 S. 9th St.,
Philadelphia, PA 19107, USA

D. F. Heitjan
Division of Biostatistics,
Columbia School of Public Health,
600 W. 168th Street,
New York, NY 10032, USA

Karim F. Hirji
Biomathematics Department,
University of California,
School of Medicine,
10833 Le Conte Avenue,
Los Angeles, CA 90024-1766, USA

M. D. Hughes
Medical Statistics Unit,
London School of Hygiene and Tropical Medicine,
Keppel Street,
London WC1E 7HT, UK

Karen Kafadar
Department of Mathematics, Box 170,
University of Colorado-Denver,
PO Box 173364,
Denver, CO 80217-3364, USA

G. G. Koch
Biostatistics Dept.,
School of Public Health, CB# 7400,
University of North Carolina,
Chapel Hill, NC 27599, USA

H. C. Kraemer
Dept. of Psychiatry and Behavioral Sciences,
Stanford University Medical Center,
Stanford, CA 94305, USA

P. A. Lachenbruch
Division of Biostatistics and Epidemiology,
CBER, Food and Drug Administration,
1401 Rockville Pike, HFM-210,
Rockville, MD 20852, USA

A. B. Lawson
Division of Mathematical Sciences,
University of Abertay,
Bell Street,
Dundee, DD1 1HG, UK

Young Jack Lee
Biometry and Mathematical Statistics Branch,
Prevention Research Division,
NIH Child Health and Human Development,
6130 Executive Boulevard, Room 630,
Bethesda, MD 20892, USA

Stanley A. Lemeshow
Biostatistics and Epidemiology Program,
School of Public Health,
University of Massachusetts,
Arnold House,
Amherst, MA 01003-0430, USA

P. S. Levy
Division of Epidemiology and Biostatistics,
School of Public Health,
University of Illinois at Chicago,
2121 W. Taylor Street,
Chicago, IL 60612, USA

J. A. Lewis
Medicines Control Agency,
Room 1528, Market Towers,
1 Nine Elms Lane,
London SW8 5NQ, UK

R. J. Marshall
Dept. of Community Health,
School of Medicine,
University of Auckland,
Private Bag 92019,
Auckland, New Zealand

Alvaro Muñoz
Department of Epidemiology,
School of Public Health,
Johns Hopkins University,
624 N. Broadway,
Baltimore, MD 21205, USA

G. D. Murray
Medical Statistics Unit,
The University of Edinburgh
Medical School,
Teviot Place,
Edinburgh EH8 9AG, UK

J. M. Neuhaus
Division of Biostatistics,
University of California,
Box 0560,
San Francisco, CA 94143–0560, USA

A. B. J. Nix
Dept. of Mathematical Statistics
and Operational Research,
University College,
PO Box 78, Cardiff CF1 1XL, UK

C. Osmond
MRC Environmental Epidemiology
Unit,
Southampton General Hospital,
Southampton SO9 4XY, UK

S. Piantadosi
Oncology Biostatistics,
Johns Hopkins University
School of Medicine,
Baltimore, MD 21205, USA

S. J. Pocock
Medical Statistics Unit,
London School of Hygiene and
Tropical Medicine,
Keppel Street,
London WC1E 7HT, UK

S. Richardson
INSERM U170,
16 avenue Paul-Vaillant-Couturier,
94807 Villejuif Cedex, France

P. Royston
Department of Medical Statistics and
Evaluation,
Royal Postgraduate Medical School,
Ducane Road,
London W12 0NN, UK

M. Schumacher
Institute of Medical Biometry and
Informatics,
University of Freiburg,
Stefan-Meier-Strasse 26,
D-79104 Freiburg, Germany

Mark R. Segal
Division of Biostatistics,
University of California,
Box 0560,
San Francisco, CA 94143, USA

S. Senn
Department of Statistical Science,
University College London,
Gower Street,
London WC1E 6BT

D. J. Spiegelhalter
MRC Biostatistics Unit,
Institute of Public Health,
University Forvie Site,
Robinson Way,
Cambridge CB2 2SR, UK

T. Tango
Dept. of Epidemiology,
Institute of Public Health,
6-1 Shiro Kanedai 4 Chome,
Minato-Ku,
Tokyo 108, Japan

Peter F. Thall
Section of Biometrics,
Biomathematics Department, Box 237,
University of Texas,
M.D. Anderson Cancer Center,
1515 Holcombe Boulevard,
Houston, TX 77030, USA

S. G. Thompson
Department of Medical Statistics and
Evaluation
Royal Postgraduate Medical School,
Ducane Road,
London W12 0NN, UK

Bruce W. Turnbull
Operations Research and Industrial
Engineering,
Cornell University, 227 E & TC,
Ithaca, NY 14853-3801, USA

L. A. Waller
Division of Biostatistics,
University of Minnesota,
Mayo Building, Box 197,
420 Delaware Street, S.E.,
Minneapolis, MN 55455–0374, USA

J. Whitehead
Dept. of Applied Statistics,
University of Reading,
PO Box 238, Earley Gate 3,
Whiteknights Road,
Reading RG6 2AL, UK

R. F. Woolson
Division of Biostatistics,
Dept. of Preventive Medicine and
Environmental Health,
College of Medicine,
University of Iowa,
Iowa City, IA 52242, USA

STATISTICS IN MEDICINE

CONTENTS

VOLUMES 1–15 1982–1996

Cumulative Fifteen-year Index

Author Index	1
Subject Index	23
Special Issues Index	183
Tutorials in Biostatistics Index and Statistics in the Medical Literature Index	187
Corrections Index	189
Book Review Index	191
Editors	197
Editorial Board Members	199

VOLUME CONTENTS

Volume 1	205
Volume 2	207
Volume 3	211
Volume 4	215
Volume 5	219
Volume 6	225
Volume 7	232
Volume 8	240
Volume 9	251
Volume 10	261
Volume 11	274
Volume 12	286
Volume 13	300
Volume 14	316
Volume 15	331

SMEDDA 1–15 (1996)
ISSN 0277-6715

Statistics in Medicine

Subscriptions

Statistics in Medicine is published semi-monthly by John Wiley & Sons, Ltd.

Subscription Rates

Volume 16 1997 24 issues

US$1,375.00

To subscribe, please contact Journals Subscriptions Department, John Wiley & Sons, Ltd., 1 Oldlands Way, Bognor Regis, West Sussex PO22 9SA, UK
Tel: +44 (0) 1243 779777
Fax: +44 (0) 1243 843232
Email: cs-journals@wiley.co.uk

Sample Copies

If you are interested in subscribing, you may obtain a free sample copy by contacting John Wiley & Sons, Ltd. at the above address.

Services

Advertising

To advertise in *Statistics in Medicine*, contact Caroline Melling, Non-Subscription Sales Manager, John Wiley & Sons, Ltd., Baffins Lane, Chichester, West Sussex PO19 1UD, UK
Tel: +44 (0) 1243 770351
Fax: +44 (0) 1243 770429
Email: info-assets@wiley.co.uk

For US-based advertising enquiries contact Susan Levey, Advertising Department, John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA
Tel: +1 (212) 850 8833, Fax: +1 (212) 850 8888

Mailing Lists

Our high quality, profiled subscription lists may be rented for use with targeted mailing campaigns. For a quotation, contact Caroline Melling at the above UK address.

Reprints

Do you wish to purchase reprints of any article from *Statistics in Medicine*? Reprints from this journal or any previous issue are available to order. Contact Caroline Melling at the above UK address for details of this service.

Copyright

Copyright © 1997 John Wiley & Sons, Ltd.

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except as described below, without the permission in writing of the Publisher.

Copying of articles is not permitted except for personal and internal use, to the extent permitted by national copyright law, or under the terms of a licence issued by the national Reproduction Rights Organization (such as Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 9HE, UK or Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970, USA). Requests for permission for other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale, and other enquiries should be addressed to the Publisher.

Statements and opinions expressed in the articles and communications are those of the individual contributors and not the statements and opinions of John Wiley & Sons, Ltd. Wiley assumes no responsibility or liability for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained herein. Wiley expressly disclaims any implied warranties of merchantability or fitness for a particular purpose. If expert assistance is required, the services of a competent professional person should be sought.

Abstracting and Indexing

Statistics in Medicine is covered by the following abstracting and indexing services: BIOSIS, Cambridge Scientific Abstracts, Chronic Diseases in Canada, Current Awareness in Biological Sciences, Current Contents, Current Index to Statistics, Engineering in Medicine and Biology, Excerpta Medica, Executive Sciences Inst. Inc., Paediatric and Perinatal Epidemiology, SCISEARCH Database, Statistical Theory and Method Abstracts.

Production Information

Production Details

Printed on acid-free paper.

Typeset by Macmillan India Ltd.

Printed and bound in Great Britain by Page Bros, Norwich.

Identification Statement

Statistics in Medicine (ISSN 0277-6715/USPS 680-830) is published semi-monthly by John Wiley & Sons, Ltd., Baffins Lane, Chichester, West Sussex PO19 1UD, UK.
Periodicals postage paid at Jamaica NY 11431. Air freight and mailing in the USA by Publications Expediting Services Inc., 200 Meacham Ave., Elmont, NY 11003.
USA Postmaster – send address changes to *Statistics in Medicine*, c/o Publications Expediting Services Inc., 200 Meacham Ave., Elmont, NY 11003.

AUTHOR INDEX

Notes: Bold numbers followed by ordinary numbers refer to volumes **1** to **15** and the first page of individual papers. (L) after some page numbers identifies a letter. (C) after some page numbers identifies a correction.

Aaby, P., **11** 579
Aalen, O. O., **7** 1121, **8** 907, **10** 1227, **12** 1569, **13** 2383(L), **14** 1819
Abbott, R. D., **4** 227, **7** 219
Abel, U., **6** 127
Abrams, D. I., **13** 2107
Abrams, K., **13** 1459
Abt, K., **10** 777, **15** 183
Abt, M., **14** 1807
Achcar, J. A., **4** 509
Ackermann-Liebrich, U., **10** 1481
Addy, C. L., **13** 1071
Adell, R., **13** 43
Adelstein, A., **3** 7
Ades, A. E., **13** 1881, 2359, **14** 257
Afifi, A. A., **5** 653, **8** 1269
Agresti, A., **5** 15, **8** 1209, **11** 101, **12** 1969
Ahmadi, S., **14** 735
Ahn, C. W., **14** 1567
Ahnn, S., **14** 2273
Aickin, M., **13** 245, **15** 1647
AIDS Community Demonstration Projects, **12** 219
Akazawa, K., **9** 1117(L)
Albers, W., **9** 1353
Albert, A., **2** 95, **7** 525
Albert, J. M., **13** 2323, **15** 2371
Albert, P. S., **12** 1555, **13** 453
Alberts, D., **12** 339
Aldrich, T. E., **11** 761, **15** 1921
Alexander, F. E., **8** 743
Alho, J. M., **11** 923, **12** 989(L)
Alho, O. P., **15** 1519
Alioum, A., **14** 27
Allardice, G., **13** 2009
Allen, J. R., **7** 395
Allen, L. H., **8** 1523
Allen, L. J., **12** 229
Allred, E., **11** 799
Alpérovitch, A., **14** 1353
Alter, M., **3** 225
Altman, D. G., **1** 59, **7** 629, **8** 771, **10** 733, 797(L), 1897, **12** 917, **13** 301
Altmann, M., **13** 53
Amara, I. A., **8** 487, **11** 1843
Ambrosioni, E., **4** 361
Ames, D., **8** 1317
Amini, S. B., **1** 267
Andersen, J., **15** 2191
Andersen, P. K., **5** 243, **7** 661, **8** 771, **10** 1061, 1931, **13** 1189
Andersen, U., **13** 1189
Anderson, B., **6** 3
Anderson, J. J., **15** 537
Anderson, J. R., **4** 107, 237(L), **8** 947
Anderson, K., **4** 107, **7** 205, **9** 1501
Anderson, S., **5** 203, **10** 959
Anderson, S. J., **14** 1235, 1985, 2273
Andersson, B., **14** 3
Andes, N., **14** 481
Andrew, J. E., **15** 987
Andrews, V., **2** 87
Annesi, I., **8** 1515
Anscombe, F. J., **9** 703
Anson, J., **7** 895
Anthony, H. M., **6** 761
Appleton, D., **14** 109
Appleton, D. R., **9** 1013, **14** 185
Aragona, E., **4** 345
Arcà, M., **11** 1657
Arena, V. C., **6** 71
Arheart, K. L., **13** 1201
Ariet, M., **11** 243
Arjas, E., **15** 1757, 2235
Arminger, G., **11** 1195
Armitage, P., **1** 345, **10** 925, **14** 111
Armstrong, B. G., **8** 1151
Armstrong, J., **10** 1993
Arnesen, E., **4** 413
Arriagada, R., **13** 1415
Ashby, D., **8** 1317, **9** 1057
Ashby, M., **11** 67
Auclair, P., **9** 1287 (C) **10** 487
Auquier, A., **4** 287, **13** 1415
Auranen, K., **15** 2235
Aurengo, A. H., **13** 185
Ayers, L. W., **12** 301
Ayuthya, S., **14** 2445
Azen, S. P., **6** 689, **8** 217, 518(L), **10** 473, 1465, **14** 841

Babiker, A., **13** 1679
Babiker, A. G. A. G., **10** 1025
Bacchetti, P., **11** 67, **13** 1901, 1921
Bachelot, A., **12** 39
Badalamenti, A. F., **11** 231
Badler, C., **15** 741
Baeten, S., **12** 1543
Bailar, J. C., **7** 1003
Bailey, B., **15** 1325
Bailey, K., **6** 351, **7** 337
Bailey, N. T. J., **13** 1933
Bailey, R. C., **10** 521
Baird, D. D., **10** 255, **12** 867, **13** 671
Baker, S. G., **7** 965, **11** 455, 643, **12** 165, **13** 609, 2269 (C) **14** 1841
Bakketeig, L. S., **10** 1003
Barbujani, G., **3** 239, **4** 391(L)
Baretta, R., **2** 259
Barlow, P., **5** 403
Barlow, W., **8** 927, **10** 1465
Barnard, G., **8** 1469, **9** 373, 601, **10** 1322(L)
Barnett, O., **14** 1785
Barnwell, G. M., **3** 101

Barón, A. E., 10 757, 11 1624(L)
Barry, D., 15 2603
Bartelink, H., 13 1329
Barthel, P., 8 1393
Bartko, J. J., 13 737
Bartsch, G. E., 11 1719
Baskerville, J. C., 3 45
Bass, S, M., 9 505
Bassein, L., 4 361
Bassett, D, R., 9 301
Basu, A., 14 347
Basu, S., 14 347
Bateman, D. N., 6 863
Bauer, H. R., 9 1143
Bauer, P., 10 871, 14 1595
Baughman, A. L., 11 557(L)
Baum, M., 13 1459
Baumrind, S., 4 47
Bayer, T., 6 939
Beacon, H., 15 2717
Beal, S. L., 10 303
Bean, J. A., 1 37, 6 61, 14 1831
Beaumont, J., 4 105(L)
Becher, H., 9 1339, 10 375, 11 1747
Beck, R. W., 15 1107
Becker, M. P., 8 1199, 11 101
Becker, N. G., 10 1527, 13 1865, 1945, 2043, 15 1779
Becker, S., 8 987, 10 152(L)
Beckett, L. A., 11 1187
Bednarski, T., 15 1033
Begaud, B., 10 991
Begg, C. B., 4 1, 129, 6 411, 10 1887, 13 211, 15 1299
Begg, M. D., 14 1889
Behar, S., 2 413(L)
Belanger, A. J., 9 1501, 14 1757
Belin, T. R., 14 747
Belissant, E., 9 907
Bell, C. M. J., 2 363, 6 901
Bell, D. Y., 8 189
Bell, R., 11 133(L)
Beller, E., 12 2343
Bellinger, D., 11 799
Bellissant, E., 10 989
Bello, A. L., 11 1623(L), 13 1793(L)
Bellocco, R., 13 163
Belsey, E. M., 10 267
Beltangady, M. S., 8 937
Bendel, R. B., 12 1853
Benhamou, E., 9 529
Benichou, J., 5 375, 465, 9 907, 10 989, 1753, 13 651
Benini, L., 4 303
Benjamini, Y., 9 811
Bennett, B., 2 477, 4 535
Bennett, D. E., 7 765
Bennett, S., 2 273, 11 603
Beno, M., 14 1941
Benson, C., 11 1367
Bentley, G. R., 14 1843
Bentley, J. M., 2 59
Beral, V., 2 455, 3 7
Berenson, M. L., 4 543(L)
Bergman, U., 10 565
Bergmann, E., 6 823
Bergmann, K., 6 823
Berkelman, R. L., 8 393
Berkey, C. S., 12 403, 14 395, 15 537
Berlin, J. A., 8 141
Berman, S., 13 231
Bernardinelli, L., 11 983, 14 2411, 2433
Berntsen, R. F., 10 405
Berridge, D. M., 10 1703, 15 2751
Berrier, J., 6 315, 733
Berry, D. A., 2 331, 4 497, 521, 12 1377, 13 1313, 14 231, 381
Berry, G., 10 749
Bertelsen, C. A., 4 527
Berzuini, C., 13 823
Bezemer, P. D., 2 191
Bhargava, A., 11 533, 13 113
Biagini, M. R., 11 1731
Bigger, Jr., J. T., 11 125
Biggeri, A., 14 2363
Billard, L., 9 1433
Binet, J.-L., 5 465
Bingham, S. F., 3 435
Birkett, M. A., 13 2455
Bithell, J. F., 7 857, 9 691, 10 1745, 14 2309
Bjertness, E., 14 1819
Bjørnstad, J. F., 10 405
Blackburn, H., 3 401
Blackwelder, W. C., 4 227, 12 461, 691
Blackwood, L., 7 975
Blair, R. C., 11 491, 507, 12 2233, 15 1107
Blaiss, L., 14 247
Bland, J. M., 5 193
Blank, S. G., 13 275
Blaylock, J., 15 23
Bléry, C., 6 813
Blettner, M., 9 1339, 10 1511, 12 1325, 14 1315
Blin, P., 7 1147
Bloch, D. A., 5 663, 8 539, 13 876(L), 14 1129, 15 1421
Bluhmki, E., 12 1063
Blumberg, M. S., 10 637
Blumenson, L. E., 7 457
Blumenstein, B. A., 12 1535
Blumstein, Z., 15 759
Boateng, F., 15 1747
Boen, J. R., 8 1413(L)
Boerma, G. J. M., 4 369
Böhning, D., 7 865, 11 1289, 12 1943, 1965, 2248(L), 14 2445, 15 919
Boice, J. D., Jr., 10 1511
Boissel, J.-P., 14 987
Bonadonna, G., 3 333
Bonellie, S. R., 15 2657
Bongaarts, J., 8 103, 10 161
Boracchi, P., 9 737
Borghi, C., 4 361
Bosch, E. G., 9 787
Bossi, A., 4 379
Bossuyt, P. M. M., 9 1229
Bostick, R. M., 13 1619
Botha, J. L., 8 785
Botman, S. L., 14 669
Bouckaert, A., 12 1543, 14 2191
Bouis, H., 11 533
Boyle, P., 5 527 (C) 6 535
Bracken, M. B., 11 1171, 15 37
Bradstreet, T. E., 12 633
Braga, M., 14 2363
Brambilla, P., 2 259
Brand, R., 11 2077
Brandenhoff, P., 6 3
Brandt, E. N., 8 137
Brant, L. J., 10 1453, 11 863, 13 587
Braun, T., 11 1579
Braun-Fahrlander, C., 10 1481
Breeze, E., 1 361
Brenn, T., 4 413
Brenner, H., 15 1377
Breslow, N., 7 7, 361, 8 977, 9 615

Brettle, R. P., 14 1365
Bristol, D. R., 5 387, 7 451(L), 8 803, 9 293, 803, 11 975(L)
Brittain, E., 8 161, 9 65
Broemeling, L. D., 10 1159(L)
Brook, R. H., 11 475
Brookmeyer, R., 2 485, 4 509, 5 127, 8 1, 23, 11 1569
Brooks, M. M., 14 2227, 15 2135
Broome, F. R., 15 1961
Brown, B. W., 3 307, 5 211, 6 483, 8 487
Brown, H. K., 13 1601
Brown, Jr., B. W., 14 2249
Brown, M. B., 10 329, 14 311
Brown, W. A., 11 685
Browne, R. H., 14 1933
Brownson, R. C., 14 629
Brunet, R. C., 13 357
Brunham, R. C., 14 769
Brunier, H., 14 885
Brunier, H. C., 13 2493
Bryant, J., 14 2099
Bufalino, R., 4 265
Buist, A. S., 7 11, 685
Bull, K., 15 157
Buncher, R., 13 2205
Buoncristiani, J. F., 13 143
Burciaga, C., 12 365
Buring, J. E., 4 111, 6 397, 9 29, 10 1585
Burke, G., 13 1471
Burns, A., 10 423
Burroughs, A. K., 11 1731
Burton, D., 12 365
Burton, P. R., 13 1699
Busse, H., 6 823
Butler, S. M., 11 1981
Büttner, P., 13 2465
Buwalda, M., 7 739
Buyse, M., 6 565, 12 509, 15 2797
Buzdar, A., 3 333
Byar, D., 3 361, 4 255, 7 1243, 8 1027, 9 55, 213, 903, 943, 10 663
Byar, D. P., 12 1629
Byers, R. H., 8 831, 11 831
Byington, R. P., 11 1041

C. Cox., 14 1191
Cain, K. C., 11 783
Califf, R. M., 3 143, 375
Callaghan, T., 12 2343
Calzolari, E., 3 239, 4 391(L)
Campbell, G., 13 499
Campbell, M. J., 2 223, 4 353, 9 1039, 10 241, 11 1624(L), 13 3, 875(L), 15 1065(L)
Campbell, M. K., 10 383
Canada, A. T., 7 471
Canner, P., 3 423, 6 255
Cantor, A. B., 11 931
Caplan, R. A., 9 1103 (C) 11 1401
Capocaccia, R., 8 201, 12 2395
Cappelleri, J. C., 15 113(L)
Carey, V., 10 1993, 11 939
Carey, V. J., 12 2133
Carlin, B. P., 15 1093
Carlin, J. B., 10 1527, 11 141
Carlson, N., 10 267
Caro, J. J., 13 201, 213
Caroll, R. J., 8 1075
Carothers, A. D., 10 141, 14 1797
Carr, G. J., 11 1033
Carré, A., 14 2459
Carriere, K. C., 13 1063
Carroll, R. J., 9 585(L), 11 1633, 13 623, 1265, 14 1437, 15 1069
Carson, J. L., 10 565
Cartensen, B., 15 2177
Carter, H. B., 13 587
Carter, R. L., 11 243
Carter, S. K., 5 441
Cartwright, A., 5 607
Carvalho, M. S., 15 1885
Cascinelli, N., 4 265
Cascioli, R., 15 2669
Castellana, J. V., 5 387, 7 451(L), 9 293
Castillo-Chavez, C., 11 1533
Cates, W., 2 25
Catford, J. C., 4 175 (C) 5 1, 189, 5 139, 155
Caudill, S. P., 8 295, 14 531, 585
Cavallini, G., 4 303
Cha, S., 11 5
Cha, S. S., 14 2217
Chaffin, D. O., 8 871 (C) 9 339, 9 342(L)
Chakraborty, R., 2 13, 6 629
Chalmers, T. C., 6 315, 733, 8 141, 10 971, 15 1263
Chambless, L. E., 9 385, 12 1213 (C) 13 99, 14 1693
Chan, L. S., 2 447
Chang, C.-T., 14 955
Chang, H.-G. H., 9 287
Chang, M. N., 8 563, 13 1807
Chang, V. T., 8 563
Chao, X., 13 1945
Chappell, R., 10 1945
Charlton, J. R. H., 4 11
Charny, M., 6 869
Charpak, Y., 4 279, 6 813
Chassagne, D., 6 785
Chastang, C., 4 279, 287, 5 375, 465, 6 795, 813, 7 1243, 9 907, 10 989
Chastang, J. F., 7 983
Chaturvedi, N., 13 1635
Chaudhary, M. A., 15 1447
Chavez, A., 8 1523
Cheadle, A., 11 1009, 14 1491
Chen, C.-H., 4 39
Chen, D., 10 565
Chen, H.-H., 14 1531
Chen, J. J., 15 1217
Chen, K., 12 2133
Chen, R., 3 173, 4 389(L), 5 98(L), 6 517, 7 998(L), 12 1807
Chen, R. T., 12 249
Chen, T. T., 7 671, 8 1095, 13 431, 1799
Cheney, E., 11 1409
Cheney, F. W., 9 1103 (C) 11 1401
Chengchang, L., 13 1313
Cheung, S. H., 13 2261
Cheuvart, B., 10 65
Chevret, S., 10 1647, 12 1093
Chi, E. M., 10 1115, 11 1033
Chi, G. Y. H., 7 877
Chi, P. Y., 5 387, 7 451(L)
Chiarotti, F., 11 591, 13 163
Chiew, M. K., 2 79
Chilvers, C. E. D., 7 1165, 14 151
Chinchilli, V. M., 13 1841, 15 1619
Chinn, S., 9 351
Chiogna, M., 15 157
Chisholm, E. M., 4 337

Chmiel, J., 12 2133
Chmiel, J. S., 9 505, 10 1993, 11 939, 12 153, 13 2127
Choi, S. C., 7 929, 14 2675
Chomy, P., 13 1415
Chon, Y., 13 969
Chow, A., 14 1081
Chow, S.-C., 8 883, 9 549 (C) 11 425, 10 1543, 12 1999, 15 659
Christensen, F., 7 639
Christian, M. C., 13 1799
Chuang, C., 3 273, 5 15, 6 583
Chuang-Stein, C., 8 571, 10 323 (C) 10 1155, 1349, 11 1075, 14 2509
Chunge, R. N., 9 1211
Ciampi, A., 5 85
Ciminera, J. L., 12 1033, 1047
Cislaghi, C., 14 2363
Clark, C. M., 10 505
Clark, G. M., 2 497, 8 813, 9 1118(L), 15 103
Clark, W. B., 10 1089
Clark, W. S., 8 831
Clarke, M. J., 14 2057
Clarke, W. R., 7 47
Clayden, A. D., 9 1031
Clayton, D., 2 229, 4 238(L), 327, 445, 6 449, 469, 7 819, 12 925, 937, 13 823, 14 2411, 2433
Clayton, J. F., 4 106(L)
Cleary, J., 10 423
Cleophas, T. J. M., 10 489(L)
Cliff, A. D., 11 1409
Close, E. R., 15 1837
Cnaan, A., 8 1255, 9 1222(L)
Coates, A., 6 667
Cohen, A., 8 1485, 11 963, 14 935, 1785
Cohen, B. L., 14 327(L)
Cohen, G. R., 13 2189
Colditz, G. A., 8 441, 455, 14 395
Coldman, A. J., 11 1579
Cole, B. F., 12 975, 14 1771
Cole, T. J., 11 1305, 13 2477
Coleman, D. A., 2 363, 6 901
Collett, D., 6 853, 12 955
Collins, J. F., 3 435
Collins, J. W., 15 1951
Collins, R., 3 409, 6 245
Cologne, J. B., 8 871 (C) 9 339, 9 342(L)
Colpaert, A., 15 2561
Colton, T., 8 255, 487, 14 715, 15 1983
Com-Nougue, C., 8 593, 12 1353
Commenges, D., 4 91, 10 1775, 11 1767, 12 1317, 14 27
Conaway, M. R., 11 799
Congdon, P., 14 1859
Conn, J. M., 8 263
Connell, L. T., 13 1583
Connelly, R. R., 12 1807
Connett, J. E., 6 53, 13 945
Cook, N., 10 1585
Cook, N. R., 11 1187, 15 2013
Cook, P. A., 13 2249
Cook, R. J., 14 2081
Cook, T., 6 599
Cooper, G. R., 8 295
Copelan, E. A., 12 2315
Copenhaver, M. D., 11 1065
Cormack, R. S., 10 1321(L)
Cornell, R. G., 15 2455
Costa, F. V., 4 361
Costanza, M. C., 10 53
Coste, J., 14 331, 2565
Costello, R. J., 13 1583
Cottone, M., 4 345
Coutinho, R. A., 9 721
Cox, C., 3 273, 7 435
Cox, D. R., 9 681
Cox, L. H., 15 1895
CPMP Working Party on Efficacy of Medicinal Products, 14 1659
Crichton, N. J., 6 805, 945, 8 1351
Croasdale, M., 9 529
Croner, C. M., 15 1961
Crouchley, R., 14 1447
Crowder, M., 3 165
Crowley, J., 12 451, 13 1391, 1411
Crowley, J. J., 11 1367
Cruz, O. G., 15 1885
Cuesta, C., 15 741
Cui, J.-S., 15 1779
Cumberland, W. G., 11 633, 14 445(L)
Cupples, L. A., 7 205, 9 1501, 14 1731
Curnow, R. N., 6 113, 728
Cusenza, E., 12 129
Cutler, J. A., 11 427, 453
Cuzick, J., 4 87, 547(L), 13 1679

Dabrowska, D. M., 11 1465
D'Agostino, Jr., R. B., 14 2205
D'Agostino, R., 1 41, 6 79, 7 205, 9 377, 1501, 10 1, 27
D'Agostino, R. B., 11 1801, 1955, 12 2169, 14 1731, 1757, 15 477
Dahlberg, S., 11 853
Dahm, P. F., 14 2581
Dai, W. S., 10 565
Damiano, A., 8 23
Damsgaard, M. T., 10 285
Dan, B. B., 7 1003
Darby, S. C., 5 539, 9 681
D'Arcangues, C., 10 241
Dardanoni, G., 4 345
Darif, M., 13 1619
Darrow, W. W., 8 831
Davey Smith, G., 11 953
Davidian, M., 13 1165
Davis, A. B., 12 777
Davis, B. R., 11 1705
Davis, C. E., 9 97
Davis, C. S., 7 109, 10 1555, 1959, 15 2509
Davis, J. E., 14 481
Davis, M. J., 12 1171
Davis, R. B., 8 947
Davis, R. L., 12 481
Davis, V. G., 11 1041
Dawes, P. T., 12 1171
Dawson, J. D., 13 1853
Dawson, R., 13 1089, 14 1913
Dawson-Saunders, E. K., 7 1003
Day, N. E., 5 127, 8 1371, 1529, 9 677, 11 307, 14 1531, 2619(L)
Day, R., 14 2099
Day, R. S., 15 2307
Day, S. J., 7 1187, 10 33, 801(L), 13 2455
de Boo, Th. M., 6 843
de Cani, J. S., 9 1439
De Gruttola, V., 8 35
de Haan, B. J., 11 1425
De Jonge, H., 2 155
de Macedo, M. M. A., 14 605
de Mouzon, J., 12 39

de Stavola, B., 6 881, 7 1013
De Stavola, B. L., 13 301
de Vet, H. C. W., 7 1171
Decousus, H., 14 987
Decroix, G., 4 279
DeGruttola, V., 13 2021, 15 2289
Dekker, J. M., 12 1733
Demétrio, C. G. B., 13 873(L)
DeMets, D. L., 3 445, 6 341, 753, 8 1191, 9 881, 11 1391, 13 1341, 2323, 14 1961
Denby, L., 13 275
Dennis, N. R., 2 87
Dent, C. W., 12 365
Dersimonian, R., 7 965, 9 423 (C) 12 1269, 11 643, 15 1237
Derzko, G., 14 1057
Des Jarlais, D., 13 231
Desmonts, J. M., 7 947
Desouza, C. M., 10 1241
Detels, R. R., 15 2307
Detre, K., 12 1185
Detre, K. M., 3 389
Detsky, A. S., 9 173
Devidas, M., 12 881
Devine, O. J., 13 1119
Dewar, R., 5 49
Dewulf, L., 15 1123
Deyton, L., 13 2107
Diamond, J. J., 3 353
Dickson, D., 11 2147
Diehr, P., 11 1009, 12 329, 14 1491
Diem, J. E., 7 19
Dietz, E., 15 919
Dietz, K., 13 1899, 1901, 1991
Difranco, D. M., 12 1665
Diggle, P. J., 8 3, 14 2335
Dighiero, G., 5 465
Dignam, J. J., 14 1985
Dijkgraaf, M. G. W., 9 721
DiMe Study Group, 15 2561
Ding, Y., 14 1505
Dinse, G. E., 13 689
Dippel, D. W. J., 9 1229
Dittus, R., 15 1875
Divine, G. W., 6 591
Dix, D., 7 377
Dixon, D. O., 6 591, 10 21, 11 13, 863
Dixon, M. F., 8 1416(L)
Dobbins, T. W., 11 1333
Dobson, A. J., 7 613, 9 385, 10 457, 11 295
Dockery, D. W., 12 403
Does, R. J. M. M., 9 1353
Doksum, K. A., 11 1465
Doll, R., 1 337, 9 681
Donald, A., 6 43, 491
Donaldson, N., 13 2249
Donev, A. N., 15 1435
Donnelly, C. A., 14 2393
Donner, A., 1 261, 3 199 (C) 9 1228, 6 43, 441, 491, 647, 8 599, 1455, 10 383, 1981, 11 159, 743, 1511, 12 1643(L), 13 1253
Doornbos, G., 12 1895
Doré, C. J., 10 797(L)
Dorey, F. J., 6 679, 11 813, 12 1589
Dorse, C., 7 619
Dowdle, W. R., 14 455
Downer, R. G., 15 907
Downham, D. Y., 7 387, 8 1416(L)
Downs, A. M., 8 963
Doyle, J. T., 9 287
Drane, J. W., 11 761
Drane, W., 15 1921
Draper, D., 11 475
Draper, G., 14 2487
Drescher, K., 9 765
Drewett, R. F., 12 949
D'Souza, M. F., 4 11
du Boulay, G. H., 4 311
Dubin, N., 1 15, 13 231, 1241
Dubois, J. P., 8 1327
Duchene, A. G., 9 115
Duffy, B. J., 1 305
Duffy, D. L., 11 1530(L)
Duffy, S. W., 8 1529, 11 307, 13 379, 14 1531, 2619(L)
Duggan, J., 9 1
DuMouchel, W. H., 14 679
Duncan, D. B., 10 21, 11 863
Dunn, G., 7 805, 9 341(L)
Dunne, A., 14 1949
Dunnett, C. W., 10 939, 11 1057, 15 1729
Dunstan, F. D. J., 10 855, 981, 1719
Dupont, W. D., 5 629, 8 244, 641
Durrleman, S., 8 551
Dutton, R. C., 15 1199
Dwyer, J. H., 7 177
Dyba, T., 13 1513
Dyer, A. R., 5 303

Easterbrook, P. J., 11 345
Easton, D. F., 10 1025
Eastwood, B. J., 15 2523
Eaton, T., 9 137
Ebbutt, A., 15 2617
Eberhardt, M. S., 14 643
Eberle, E., 10 457
Eberlein, K., 4 111
Ebrahimi, N., 15 1557
Edmunds, W. J., 15 2215
Edwardes, M., 13 1693(L)
Edwardes, M. D. deB., 14 1609(L)
Egidi, V., 8 201
Eick, S. G., 14 231
Eide, G. E., 12 91(L), 15 1771
Eisen, S. A., 12 1693
Eisenberg, B., 8 83, 10 131
Ekholm, A., 11 271(L)
El-Sadr, W., 14 1889
Elandt-Johnson, R. C., 8 703
Elashoff, J. D., 7 877
Elashoff, M., 15 2425
Elashoff, R. M., 5 653, 6 31, 7 765, 8 1269, 10 1137, 13 1211, 1539
Eliasziw, M., 6 441, 647, 10 1981, 11 1511, 13 1253
Ellenberg, J. H., 7 717, 10 1595, 13 399, 557, 14 1615
Ellenberg, S., 6 217, 7 571, 8 405, 9 145, 13 1437
Ellenberg, S. S., 11 131(L), 12 461, 13 405, 417
Elliott, P., 15 1867, 1927
Ellis, S. H., 2 183
Elston, R. C., 11 727, 12 685
Elton, R. A., 12 2179
Elwood, J. M., 14 821
Emerson, J. C., 12 3
Emerson, J. D., 6 101, 15 1465
Emerson, P. A., 6 805
Emerson, S., 6 361
Emerson, S. S., 12 3, 339
Emrich, L. J., 8 153
Enas, G. G., 12 471, 14 1099
Engelgau, M. E., 15 323

Ensign, L. G., 13 1727
Epstein, L. D., 15 463, 1171
Eriksson, J., 15 1587
Eriksson, B., 13 43
Ershow, A. G., 7 363
Escobar, M. D., 15 1365
Esinhart, J. D., 15 1619
Espeland, M. A., 7 403, 11 1041, 15 607
Essers, J. G. A., 11 2043
Estéve, J., 9 529
Estève, J., 13 1274
Estey, E. H., 12 1197, 14 357
Etcheverry, B., 12 1317
Etzioni, R., 13 2311
Eudey, T. L., 12 1079
Evans, A. T., 10 443
Evans, D. A., 11 1187
Evans, S. J. W., 9 1069, 10 801(L)
Everitt, B. S., 10 1315
Ewell, M., 15 2379
Ewens, W. J., 5 281
Ezzati, T. M., 14 571
Ezzet, F., 10 901

Facey, K. M., 9 1277 (C) 10 1001, 853(L)
Falissard, B., 10 949, 12 51
Falk, R. W., 13 2279(L)
Faraggi, D., 13 719, 14 73, 15 2203
Faraone, S. V., 11 685
Farley, T. M. M., 5 475
Farrell, P. M., 15 449
Farrington, C. P., 9 953, 1327, 1447, 10 1733, 11 1591, 15 283
Faucett, C. L., 15 1663
Fay, M. P., 15 429
Fayers, P., 12 1643(L)
Fayers, P. M., 2 429, 7 1165, 13 2249
Fearn, T., 11 269(L)
Fears, T. R., 9 1475, 11 547, 1759
Fedorov, V. V., 14 2609
Feduska, N. J., 11 1465
Feigl, P., 1 191
Feingold, M., 15 953
Feinleib, M., 7 177, 12 207
Feinstein, A. R., 3 341, 14 1263(L), 15 1273
Feldman, H. A., 13 61
Feltz, C. J., 15 647
Feng, Z., 11 1607, 15 1793
Fennerty, B., 12 339
Fermanian, J., 14 331
Fernández, E., 15 305
Ferris, Jr., B., 12 403
Fescharek, R., 12 2383
Feuer, E. J., 11 455, 13 1755
Fidler, V., 5 199(L), 7 739
Fielding, K. L., 13 2009, 14 1365
Fife, D., 10 1427
Filippazzo, M. G., 4 345
Filloon, T. G., 14 925
Findlay, J. G., 7 941, 8 1303(L)
Finkelstein, D. M., 13 1747
Finney, D. J., 1 5, 153, 2 113, 9 639
Fischl, M. A., 12 835
Fish, D., 14 769
Fisher, E. S., 13 1781
Fisher, L. D., 5 619, 11 1881
Fitzmaurice, G. M., 13 1233
Flack, V. F., 12 1079, 15 127
Flahault, A., 7 1147
Flanders, W. D., 9 423 (C) 12 1269, 969, 10 739
Flay, B. R., 12 365
Fleiss, J. L., 1 353, 11 125
Fleming, T. R., 6 361, 12 565, 13 955, 1423
Fletcher, D. J., 9 1121
Fogg, L. F., 9 253
Follman, D., 14 1163, 15 2367
Follman, D. A., 13 1441
Follmann, D., 11 427, 453, 13 467
Forbes, J., 3 249, 6 667
Ford, I., 10 1711, 14 735
Forey, B. A., 15 581
Forthofer, R., 13 113
Fosdick, L., 13 1619
Foulkes, M. A., 13 405
Fox, T. L., 2 331
Framingham Eye Studies Group., 15 145
France, L. A., 10 1099 (C) 10 1633
Francom, S. F., 8 571
Frank, J., 14 841
Frank, J. A., 13 453
Frank, O., 10 161
Franklin, R. C. G., 15 157
Frankowski, R. F., 8 937
Franti, C. E., 6 961
Franzosi, M. G., 9 17
Fraser, P., 2 455
Freedman, J. A., 15 607
Freedman, L., 1 121 (C) 2 1, 2 167, 5 1, 98(L), 7 1013, 1165, 9 213, 829, 943, 10 800(L)
Freedman, L. S., 11 23, 167, 1271, 12 165, 1501, 13 709, 1297, 1371, 1479, 1815
Freeman, P. R., 8 1421, 10 491(L), 12 1443
Frey, C. M., 13 1755
Friedewald, W. T., 9 9
Friedlander, Y., 12 993
Friedman, L., 3 305, 12 425
Friedman, M. A., 6 307
Fries, J. F., 12 1005
Frisén, M., 11 1489
Frison, L., 11 1685
Frölich, J., 12 1063
Fry, J. S., 10 799(L)
Fryer, J. G., 6 945
Fuller, R. K., 15 1421
Fuller, W. A., 8 1109, 1133
Furberg, C. D., 6 295, 11 443
Fusaro, R. E., 11 67, 12 843

Gabriel, K. R., 9 469
Gaffney, M., 12 129
Gagnon, D. R., 14 1731
Gail, M. H., 7 363, 8 59, 1027, 10 1167, 1819, 11 1633, 12 1239, 13 399, 479, 623, 14 2581, 15 1069, 2273
Galai, N., 12 2133
Galavotti, C., 12 219
Galbraith, R. F., 7 889
Gallus, G., 5 565, 7 997(L)
Gamel, J. W., 9 1007
Gange, S. J., 14 1961, 15 2323
Ganguly, S. S., 14 1545
Gankema, M., 12 1895
Gans, D. J., 1 131
Garattini, S., 9 17
Gardner, M. J., 1 245 (C) 2 315, 3 113
Garewal, H., 12 339
Gargiullo, P. M., 14 51 (C) 14 1841

Garner, J. B., 10 767, 13 1827
Garrison, C. Z., 13 1071
Gart, J. J., 10 1257
Gaston, M. H., 9 45
Gastwirth, J. L., 13 747, 14 1641, 15 2095
Gatewood, L. C., 13 53
Gatsonis, C., 11 1377, 15 1807
Gatsonis, C. A., 15 1687
Gauvreau, K., 13 2021
Gay, N. J., 15 1567
Gaynor, J. J., 11 455
Gebski, V., 6 667
Gebski, V. J., 12 2343
Gefeller, O., 11 2083, 12 91(L)
Gehan, E., 3 225, 315, 9 871
Gehan, E. A., 13 1727
Geisser, S., 14 1621
Gelber, R. D., 6 371, 9 1259, 11 439, 12 975, 14 1771
Geller, N. L., 12 543, 13 663, 859, 1353, 1441, 15 1313
Gennings, C., 15 429
Gent, M., 15 1729
Gentleman, R. C., 13 805
George, E. O., 12 881
George, S. L., 4 39, 12 435, 13 1313, 1369, 1411
George, V. T., 10 1295, 12 685
Getson, A. J., 12 481
Ghirardini, A., 11 591, 13 163
Ghislandi, M., 14 2433
Ghitany, M. E., 14 39
Gibiansky, E., 14 955
Gibson, J. M., 8 1479
Giefer, E. E., 2 381
Giesecke, J., 10 1313
Gilbert, E. S., 8 173
Gilks, W. R., 11 1443, 12 1703
Gilles, F. H., 14 1307
Gillespie, B. W., 15 953
Gillings, D. B., 8 487
Gillman, M. W., 11 1187
Gilson, J. C., 3 73
Giltinan, D. M., 13 1165
Girard, P., 14 987
Gitomer, S. L., 2 397
Gladen, B. C., 5 557
Glasziou, P., 15 969
Glasziou, P. P., 9 1259
Glaz, J., 12 1829, 1845
Gleser, L. J., 8 1127, 15 2493
Glidden, D., 13 955
Glynn, R. J., 13 1023, 1781
Goddard, M. J., 9 325
Godwin, J., 6 245
Goetghebeur, E., 15 2191
Goetghebeur, E. J. T., 15 2813
Goldberg, J., 1 145, 12 1693
Goldberg, M., 5 49
Goldhirsch, A., 6 371, 11 439, 12 975, 14 1771
Golding, J., 5 113
Goldman, A. I., 3 153
Goldman, L. R., 15 683
Goldstein, D. J., 14 1099
Goldstein, H., 12 949, 13 1643
Goldstein, L., 12 661
Golini, A., 8 201
Göller, G., 14 1009
González-Manteiga, W., 15 305
Goodman, P. J., 11 1367
Goodman, S. N., 11 875, 14 1149
Goodwin, G. D., 10 53
Goot, R. E., 13 1575
Gordon, D., 10 423
Gordon, M. E., 12 111
Gordon, N. H., 9 397, 11 2063
Gordon, R. D., 8 1291
Gore, S. M., 1 93 (C) 3 97, 14 1365, 15 75
Gorman, J., 14 1889
Gottschau, A., 14 2727
Gough, K., 8 891(L)
Gould, A. L., 8 583, 11 55, 2017, 12 481, 2009, 14 1039, 2239
Goutis, C., 11 269(L)
Grady, J. J., 14 1397
Graham, D. F., 10 33
Graham, P., 14 299
Grambsch, P., 13 1619
Grambsch, P. M., 10 697
Grandits, G. A., 13 1619
Grassi, M., 13 2407
Graubard, B. I., 7 1087, 11 167, 13 509
Gray, R., 6 137, 245
Green, J., 2 79, 7 443
Green, M., 14 2487
Green, M. R., 13 1313
Green, M. S., 4 53, 7 519
Green, P. J., 11 1305
Green, S., 12 451, 13 1391
Green, S. B., 3 361, 9 943, 13 1479, 15 1069
Green, S. J., 6 361, 11 853
Greenberg, M., 12 1763
Greene, H. L., 10 1621
Greenhouse, J., 15 1365
Greenhouse, J. B., 6 167, 11 37, 1377, 14 1379, 15 2077
Greenhouse, S. W., 9 371, 893, 13 401, 14 1641
Greenland, S., 1 217 (C) 2 1, 2 243, 3 131, 4 117, 5 579, 6 193, 701 (C) 13 99, 7 745, 8 669, 825, 845, 9 247, 10 79, 739, 1069, 11 219, 559(L), 1209, 1263(L), 12 717, 13 989, 1665, 14 2131, 15 513, 1161
Greenwood, R. M., 7 1165
Grender, J. M., 11 727, 12 69, 13 931
Grieve, A. P., 13 905
Griffin, P. D., 10 177
Griffiths, K., 2 123, 141, 5 183, 6 425
Grimes, D. A., 2 25
Grimson, R., 15 783
Grimson, R. C., 5 271, 11 761, 12 1773, 15 851
Grizzle, J., 15 1793
Grizzle, J. E., 11 1607
Groeneveld, H. T., 7 955
Grønnesby, J. K., 10 1003
Groom, G. V., 2 123, 5 183
Groshen, S., 5 271, 14 841
Gross, M. A., 9 627
Grossman, J., 13 1815
Grouin, J.-M., 14 1057
Grove, W. M., 9 559
Grover, F. L., 13 1501
Guess, H. A., 13 1807
Guggenmoos-Holzmann, I., 12 2191, 14 2285(L)
Guinee, V., 1 191
Gülich, A., 15 183
Gulsvik, A., 15 1771
Gustafson, P., 14 2523
Gustafsson, G., 15 707
Gustavsson, G., 14 3
Guttler, F., 6 3

Habbema, J. D. F., 2 199, 279, 9 1229, 1243

Haber, M., 10 1573, 12 249
Haber, M. J., 13 357
Hackl, P., 14 2609
Hadgu, A., 3 293, 11 1503
Hadjinicola, G., 12 661
Hadorn, D. C., 11 475
Hafner, K. B., 7 471, 8 891(L)
Haggett, P., 11 1409
Haie-Meder, C., 14 2701
Hakulinen, T., 13 1513
Hall, D. B., 8 273
Hall, H. I., 15 943
Halloran, M. E., 10 1573, 12 249, 13 357, 15 2405
Hallstrom, A., 9 1081, 10 1621, 14 1927, 2227, 15 2135
Halperin, M., 4 227, 7 289, 9 881
Halpern, A. C., 10 565
Halpern, J., 5 211, 6 483, 14 2249
Halsey, N. A., 14 777
Hamilton, J. M., 8 405
Hamilton, M. A., 7 535
Hammermeister, K. E., 13 1501
Hand, D. J., 10 1315
Hanis, C. L., 6 629
Hankey, B. F., 11 455
Hanley, J. A., 15 1575
Hansen, B., 11 579
Hansen, B. E., 13 2517
Hansen, L. S., 10 1061
Hardy, R. J., 15 619
Harrell, F. E., 3 143, 375
Harrell, Jr., F. E., 14 2119, 15 361
Harrington, D., 13 1411
Harrington, D. P., 9 1517
Harris, R. I., 12 2248(L)
Harshfield, G. A., 13 1201
Hartigan, P., 9 125
Hartwell, T., 11 1041
Hartz, A., 2 381, 3 302(L), 4 109(L)
Hartzel, J., 15 2573
Harvey, H. A., 11 673
Hasabelnaby, N. A., 8 1109, 1133
Hasford, J., 11 2147
Hashimoto, Y., 10 303
Haskey, J., 2 455
Hassani, H., 15 2617
Hastie, T. J., 8 785
Hathaway, D. K., 12 2169
Hatton, F., 7 947
Hauck, W., 5 203, 8 599, 10 711, 959
Hauck, W. W., 11 67
Haviland, M. G., 9 363, 383
Hawkins, B. S., 13 2393
Hawkins, C. M., 11 1705
Hay, Jr., W. W., 15 2107
Hayashi, M., 10 839
Haybittle, J., 2 415(L), 14 2503(L)
Hayden, C. L., 11 515, 12 265
Hayes, R., 13 2345
Hayes, R. J., 7 915
Hazout, S., 7 1147
He, D., 15 463
He, D. Y., 12 153
He, Y., 13 2127
Healy, B., 13 403
Healy, M. J. R., 2 413(L), 8 893, 9 633, 13 1643
Hearne, E. M. III,, 2 497
Heathcote, C. R., 11 295
Hebel, J. R., 7 423
Hebert, P. R., 6 397
Hedges, L. V., 6 381
Heeren, T., 6 79, 10 1, 27
Heilbron, D. C., 11 67
Heinzl, H., 15 2589
Heisterkamp, S. H., 8 963, 9 721, 11 1425, 12 1895
Heitjan, D. F., 10 1075, 11 673
Held, P., 9 1, 73
Helfenstein, U., 5 37, 10 1481
Helms, R. W., 11 1889, 14 1397
Hempenius, A. L., 6 501
Hempfling, A., 11 1289
Henderson, R., 14 161
Henderson, W. G., 12 1693, 13 1501
Hendricks Brown, C., 12 289
Hendricks, S. A., 15 1951
Hendriks, J. C. M., 11 1425
Hennekens, C., 4 111, 6 397, 9 29, 199, 10 1585
Hennekens, C. H., 11 1187
Herman, W. H., 15 323
Hermans, J., 2 199, 13 2517
Herndon, II, J. E., 14 2119
Herndon, J. L., 7 1045, 8 323
Herschkorn, S. J., 8 93
Herson, J., 5 441, 8 403, 11 1, 12 555
Hertzberg, V. S., 5 619, 14 693
Hervada, X., 15 305
Herzberg, A. M., 12 1629
Hess, K. R., 13 1045, 14 1707
Hessol, N. A., 11 831
Hethcote, H. W., 8 831
Heuch, I., 12 13
Heyse, J. F., 12 1033, 1047, 13 1807
Heyting, A., 11 2043
Higgins, I. T. T., 3 73
Higgins, J. P. T., 15 2733
Hildebrand, H., 10 1361
Hilden, J., 5 669(L), 6 745, 9 1229, 1243, 10 285, 15 969
Hill, C., 4 295
Hill, I. D., 1 297
Hill, Jr., R. H., 14 585
Hill, M. A., 8 217
Hiller, R., 15 145
Hillis, A., 8 427
Hillis, S. L., 14 2023
Hilsenbeck, S. G., 15 103
Hilton, J. F., 15 631
Hilton, S., 15 1349
Himsworth, H., 1 301
Hinberg, I., 9 325
Hinde, J. P., 8 1351
Hine, T. J., 12 967
Hire, D., 11 1041
Hirji, K. F., 7 765, 9 835, 10 1137, 13 1539, 14 2261
Hirschberg, J. G., 10 1273
Hirst, K., 15 2107
Hirtz, D. G., 10 1595
Hixson, L., 12 339
Hjalmars, U., 14 3, 15 707
Hjortland, M., 12 789
Hlatky, M. A., 3 375, 10 647
Hoaglin, D. C., 14 395, 15 537, 1465
Hochberg, Y., 9 811
Hoehler, F. K., 3 225
Hoffman, K. L., 8 367, 14 571
Hoffmann, R. G., 2 381, 4 109(L)
Hogan, C., 13 2107
Hogg, S. A., 5 85
Hogh, B., 14 2727
Hoitsma, A. J., 3 219
Holford, T., 12 1185, 15 37

Holford, T. R., 11 1171, 13 23, 15 565
Holland, B., 13 2261
Holland, W. W., 1 361
Holleman, E., 15 1875
Holm, S., 13 2437
Holme, I., 7 1109
Holmes, H. H., 15 1837
Holt, E. A., 14 777
Hook, E. B., 3 287, 10 717
Hoover, D. R., 10 1993, 11 939, 12 153, 13 2127, 15 2307
Hopkins, D. R., 12 197
Hopper, J. L., 7 581
Hornberger, J. C., 14 2249
Hornung, R., 4 105(L)
Hosmer, D. W., 7 759, 14 2161
Hosmer, T., 1 145
Hoth, D. F., 12 461
Hougaard, P., 4 29
Houghton, J., 13 1459
Houts, P. S., 11 673
Howe, G. R., 8 1151
Howel, D., 7 1157
Hsieh, C., 15 1545
Hsieh, C.-C., 4 23, 7 1073, 10 361
Hsieh, F. Y., 6 577, 7 1195, 8 795, 11 1091
Hsu, H., 8 121
Hubert, B., 10 1493
Hudec, M., 2 287
Huel, G., 5 171
Hughes, J. M., 12 355
Hughes, M. D., 7 1231, 9 657, 11 1731, 12 901, 1651, 15 2053
Hui, H., 1 145
Hui, S. L., 8 229, 10 505, 511, 1213
Hung, H. M., 15 233
Hung, H. M. J., 11 703, 12 645
Hunsberger, S., 13 635, 663
Hunter, W. G., 4 509
Husan, F., 15 659
Husebye, E., 10 1227
Husing, R., 11 1465
Hutchinson, T. P., 6 529(L)
Huther, M. L., 10 1621
Hwang, E., 15 1489
Hwang, I. K., 8 583, 9 1439, 12 481
Hwang, J.-S., 15 93
Hyatt, Jr., R. R., 14 655

Ichida, J. M., 12 301
Ingram, D. D., 8 525, 9 853(L)
Inman, W. H. W., 15 987
Innocent, P. R., 4 311
Inskip, H., 2 455, 3 7
Inskip, H. M., 11 1789(L)
International Collaberative Group on Clinical Trial Registries (ICG-CTR), 12 1085(L)
Inui, T. S., 10 653
Irgens, L. M., 12 13
Irwig, L. M., 7 955
Islam, M. N., 15 837
Iyengar, S., 15 2161

Jack, S. S., 14 669
Jackson, K. L., 13 1071
Jackson, R. T., 12 2333
Jacob, R. G., 7 697
Jacobowitz, R., 4 227
Jacobson, L. P., 15 2323
Jacquez, G., 15 783
Jacquez, G. M., 12 1751, 1931, 1967, 14 2343, 15 873, 951, 1935
Jager, J. C., 8 963, 9 721, 11 1425
Jagger, C., 10 395
Jais, J. P., 6 795
Jamart, J., 12 185(L)
James, K. E., 15 1421
James, M. K., 15 607
James, S., 10 1123
Jamison, P. M., 12 355
Janosky, J. E., 11 1403(L)
Jarjoura, D., 9 1199
Jaro, M. A., 14 491
Jayatunga, R., 14 257
Jennett, W. B., 5 403
Jennings, B., 3 45
Jewell, N. P., 9 1387, 10 151(L), 11 67, 13 1101, 2081
Jørgensen, B., 7 639, 8 766(L)
Job, J. S., 14 777
Jöckel, K.-H., 9 765
Joffe, M. M., 14 2131
Johnson, G., 9 125
Johnson, L. R., 7 685
Johnson, T., 3 97
Johnson, W., 14 1621
Johnson, W. D., 10 1295, 11 727, 12 69, 13 931, 14 1901
Johnson, W. O., 8 725
Johnston, B., 11 1023
Jones, B., 6 555, 911, 10 1607, 14 1025, 15 443, 527, 1435
Jones, D. R., 1 73, 2 183, 429, 14 137, 1655
Jones, M. A., 12 229
Jones, N. M. B., 13 2503
Jones, P. W., 12 1171
Jones, R. H., 7 1289, 14 1235, 1975, 15 61
Jones, R. N., 3 73
Jones, S. E., 3 333
Jones, W. R., 10 177
Jørgensen, B., 15 823
Joseph, M., 10 565
Judkins, D. R., 14 571
Julious, S. A., 13 3, 15 1065(L)
Julius, S., 9 301
Jung, S.-H., 14 275, 2217

Kaaks, R., 13 127, 15 2781
Kafadar, K., 11 1551, 12 311, 13 569, 15 2539
Kahana, E., 3 225
Kaider, A., 15 2589
Kaiser, L., 8 1183
Kalbfleisch, J. D., 7 149
Kaldor, J., 4 238(L), 327, 8 1371, 13 2043
Kaldor, J. M., 15 2069
Kalish, L. A., 4 129
Kalyandrug, S., 13 719
Kamby, C., 11 281
Kamen, D. S., 13 1727
Kannel, W. B., 7 205, 9 1501
Kaplan, E. H., 13 2179
Kaplan, J. E., 5 355
Karakostas, K. X., 14 1145(L)
Karantzas, M. E., 14 1291
Karara, A. H., 14 955
Kark, J. D., 12 993, 15 1143
Karlberg, J., 6 185
Karon, J. M., 8 323, 10 1341, 12 311
Karrison, T., 14 2537, 15 171
Karvonen, M., 15 2561
Kass, R. E., 6 167
Kates, L., 5 85
Katz, B., 7 795, 8 229, 10 505
Katz, B. P., 11 565, 15 1875

Katz, J., **15** 1349
Katzman, R., **8** 1537
Katzoff, M., **8** 335
Kault, D., **15** 221
Kay, C., **2** 123, **5** 183
Kay, R., **2** 41, 415(L), **10** 1099 (C) **10** 1633
Kaye, W. E., **15** 943
Keeler, E. B., **11** 475
Keene, O. N., **14** 811
Keiding, N., **5** 327, **6** 939, **9** 1221(L), **10** 733, 1061, **11** 281, **12** 2315, **14** 1265
Keller, M. B., **7** 727
Keller, M. D., **12** 301
Kelly-Hayes, M., **14** 1757
Kelsall, J. E., **14** 2335
Kemp, K. W., **2** 123, 141, **5** 183, **6** 425
Kempton, R. A., **13** 1601
Kenward, M., **11** 1967
Kenward, M. G., **6** 555, 911, **10** 1607
Keough, M. E., **11** 1187
Kern, D. H., **4** 527
Kerr, G. R., **1** 93 (C) **3** 97
Keselman, H. J., **3** 185
Keselman, J. C., **3** 185
Kessler, M., **11** 231
Keyes, L. L., **13** 343
Khamis, H. J., **7** 591
Kheifets, L. I., **12** 1755, 1931
Khurshid, A., **15** 1
Kiely, J. L., **12** 377
Kim, D. K., **13** 2059
Kim, H. M., **13** 2141, **15** 2475
Kim, K., **11** 1391, 1477, **13** 1149, **14** 1341, **15** 1507
Kim, M., **13** 231
Kim, M. Y., **14** 1437
Kimber, H., **3** 165
Kingman, A., **13** 769
Kingsley, L., **11** 939, **13** 2127
Kingsley, L. A., **9** 505, **12** 153
Kinoti, S. N., **9** 1211
Kirby, R. S., **15** 1859
Kirby, S. P. J., **10** 141
Kitchin, R. M., **10** 749
Kjærsgaard-Andersen, P., **7** 639, **8** 766(L)
Klar, J., **7** 759
Klar, N., **13** 1253
Klein, J. P., **12** 2315, **14** 1265
Klein, R., **14** 1961
Kleinman, J. C., **8** 525, 997, **9** 853(L), **12** 377
Klett, C. J., **3** 435
Kline, G., **10** 119
Kline, J., **4** 469
Klingberg, M. A., **3** 173
Knox, E. G., **1** 183, **2** 1
Knuiman, M. W., **9** 1221(L)
Koch, G. G., **2** 397, **7** 109, 471, 877, **8** 487, **10** 13, **11** 1843, **13** 343
Koehler, K. J., **9** 409
Koene, R. A. P., **3** 219
Koenig, K. L., **14** 1437
Koepsell, T., **14** 1491
Koepsell, T. D., **10** 653, **11** 1009, **12** 329
Kohlmeier, L., **11** 1195
Kohn, K. W., **13** 719
Kok, F. J., **12** 1733
Kolassa, J. E., **14** 1577
Komornik, J., **14** 1941
Kongerud, J., **13** 1771
Korn, E. L., **4** 47, 527, **5** 255, **6** 679, **7** 1087, **9** 487, **11** 813, **12** 893, **13** 509, 1799
Kosinski, A. S., **11** 783
Kosorok, M. R., **15** 449
Kost, G. J., **5** 347
Koutsoukos, A. D., **13** 719
Koziol, J. A., **1** 83
Kraemer, H. C., **11** 317, **13** 876(L), **14** 721, **15** 1421
Kragt, H., **11** 2077
Krailo, M. D., **6** 119
Krakauer, H., **10** 521
Kramar, A., **6** 785, **14** 2701
Kramer, S., **3** 353
Kraus, J. F., **6** 961
Kreiner, S., **14** 1265
Krishnamurthy, R., **15** 1907
Krishnamurti, D., **15** 1907
Kristiansen, S., **10** 843
Kronborg, D., **11** 579
Kronmal, R. A., **11** 783
Kryscio, R. J., **12** 1813, **15** 747
Kübler, J., **9** 1527
Kubota, K., **15** 987
Kuha, J., **13** 1135
Kühn, A., **14** 1583
Kulldorff, M., **14** 799, **15** 707
Künneke, M., **5** 503
Kupper, L. L., **10** 443
Kurashina, S., **6** 709
Kuritz, S. J., **7** 507
Kusek, J. W., **7** 1
Kushler, R. H., **10** 329, **14** 311
Kushner, H. B., **15** 1635
Kuulasmaa, K., **10** 457

Laara, E., **15** 1519
Lachenbruch, P. A., **7** 467, 549, **11** 1521, **15** 343
Lachin, J. M., **5** 73, **11** 1151, 1239, **12** 2219
Lagakos, S., **15** 2425
Lagakos, S. W., **7** 257, **8** 35, **9** 1417, **13** 2141, **15** 2475
Lagazio, C., **14** 2363
Lai, D., **14** 1393(L)
Lai, M.-Y., **10** 1465
Laird, N. M., **7** 305, **8** 141, **9** 1517, **11** 1967, **14** 283
Lakatos, E., **8** 415, **11** 179
Lambert, P., **15** 1695
Lan, K. K. G., **4** 227, **8** 1191, **11** 179, **12** 753, 2219, **13** 945, 1341
Lan, S., **15** 1545
Lancar, R., **14** 2701
Lancashire, R., **1** 183
Landis, J. R., **3** 73, **7** 109, 507, **8** 571, **14** 413, **15** 1227(L), 2573
Landis, P. K., **13** 587
Lane, M., **8** 331
Lane, W. W., **1** 191
Lanes, S. F., **10** 1181
Lang, J. M., **9** 87, **10** 1585
Lange, M., **14** 283
Lange, N., **11** 1801, 2001, **15** 389
Langefeld, C. D., **15** 607
Langholz, B., **10** 473
Langs, R. J., **11** 231
Lanzarone, F., **4** 345
Laor, A., **11** 963
Laplanche, A., **4** 295
Laporte-Simitsidis, S., **14** 987
Larntz, K., **15** 2445
Larsen, S. O., **13** 177
Laska, E., **15** 1635
Laska, E. M., **10** 17
Lassauzet, M.-L. G., **8** 725
Lasserre, V., **10** 909

Lau, J., **15** 1263
Lauer, R. M., **7** 47
LaValley, M. P., **15** 2289
Lavange, L. M., **13** 343
Lavin, P. T., **11** 515, **12** 265
Lavori, P. W., **7** 727, **13** 1089, **14** 1913
Law, C. G., **11** 1569
Law, M. G., **15** 2069
Lawless, J. F., **7** 149, **13** 805
Lawrence, C. E., **10** 423
Lawrence, C. J., **6** 159, **10** 831
Lawrence, D. N., **7** 395, **13** 2155
Lawson, A., **4** 544(L), **5** 199(L), **15** 1591(L)
Lawson, A. B., **12** 1249, **14** 2291, 2383, 2473
Lawson, M. G., **14** 1745
Lazar, P., **5** 171
Lazaro, C. G., **11** 115
Le, C. T., **5** 393, 637, **9** 1495, **10** 1267
Le Cessie, S., **9** 1303, **12** 1733
Le Chevalier, T., **13** 1415
Le, N. D., **15** 727
Learmont, J., **13** 2043
Lebeau, B., **4** 279
Leclerc, A., **7** 983, **8** 1546(L)
Lecoutre, B., **14** 1057
Lee, C. V., **15** 943
Lee, E. W., **13** 1241, **15** 1187
Lee, J. J., **5** 653, **8** 1269
Lee, J. W., **13** 101
Lee, K. K., **15** 1421
Lee, K. L., **3** 143, 375, **10** 617, **15** 361
Lee, M.-L., **9** 1501, **10** 433
Lee, P. N., **10** 799(L), **15** 581
Lee, S. R., **15** 197
Lee, S.-Y., **15** 1049
Lee, W. C., **15** 273
Lee, Y. J., **10** 1595, **12** 675
Lefante, J. J., **9** 437
Lehmacher, W., **10** 891
Lehoczky, J. P., **7** 697
Lehr, R., **11** 1099
Leigh, J. P., **12** 1005
Leijnse, B., **2** 131
Lellouch, J., **8** 1515, **10** 949, **12** 51
Lemeshow, S., **7** 759, **14** 2161
Lemp, G. F., **8** 831
Lenfant, C., **9** 5
Leppard, P., **7** 483, **12** 767
Lert, F., **7** 983
Lesaffre, E., **7** 525, **10** 1391, **12** 1063, **15** 1123
Leske, M. C., **5** 573
Lesser, M. L., **1** 277, **14** 1683, **15** 2127
Letenneur, L., **11** 1767
Letrait, S., **7** 1147
Leung, O., **12** 2343
Leverett, D. H., **7** 403
Levin, B., **4** 469
Levin, H., **6** 315, 733
Leviton, A., **11** 799
Levy, P. S., **1** 145, **8** 1225, 1537
Lew, R. A., **8** 1225
Lewis, J. A., **8** 1302(L), **10** 1099 (C) **10** 1633, **14** 127, 1025, 1655, **15** 527
Lewis, P. A., **6** 869
Lewis, S. M., **9** 1121
Lewis, T., **12** 229
Liang, K.-Y., **10** 1197, **11** 1825, **13** 541
Liberati, A., **13** 1485
Lie, R. T., **12** 13
Liestø, K., **13** 1189
Light, R. J., **6** 221
Lilienfeld, A. M., **1** 325
Lilienfeld, D. E., **3** 15
Lim, L. L.-Y., **8** 861, **9** 1417
Lin, D. Y., **12** 835, **13** 2233
Lin, H.-M., **15** 2053
Lin, R. S., **15** 273
Lindeman, K. S., **13** 2269
Lindgren, B. R., **9** 1495, **10** 1267
Lindsey, J. C., **13** 805
Lindsey, J. K., **15** 443, 527
Lindstrom, M. J., **14** 2009
Lininger, L. L., **9** 287
Linn, S., **15** 933
Linnet, K., **6** 147, **8** 609, **9** 1463
Linton, K. L. P., **14** 1961
Linzmaier, A., **8** 1393
Lipsitz, S., **7** 95, **9** 1517, **11** 769
Lipsitz, S. R., **13** 143, 1149, 1233
Littenberg, B., **12** 1293
Little, M. P., **15** 1003
Little, R. J. A., **7** 347, **12** 1589
Litvak, E., **13** 1905
Liu, G., **15** 1605
Liu, J.-P., **10** 1375, **11** 881, **14** 853, 1067
Liu, L., **15** 1757
Liu, P. Y., **13** 1391
Liu, S., **15** 1023
Liu, W. T., **8** 1537
Liu, X., **10** 1197
Liukkonen, J. R., **7** 19
Lloyd, C. J., **7** 1297
Lo, C. K., **12** 229
Logan, T. F., **14** 2099
Logeay, P., **7** 983
Logerfo, J. P., **10** 653
Logue, E., **9** 1199
Lolonis, P., **15** 717, 1907
Longford, N. T., **13** 889
Longini, I. M., **8** 831, **9** 969, **10** 1573
Longini, Jr., I. M., **11** 831, **12** 249, **13** 357, 2097
Longton, G., **10** 413
Lorenz, W., **5** 503
Lotto, A., **9** 17
Louis, T. A., **3** 1, **7** 29 (C) **8** 248, **10** 599, 811, **11** 1981, **13** 1119, 1619
Loumaye, E., **12** 1543
Low, H. C., **2** 79, **7** 443
Lowe, D., **2** 167
Lu, I. L., **14** 2675
Lu, W.-S., **15** 1397
Lu, Y., **14** 1831
Lu-Yao, G., **13** 1781
Lubin, J. H., **7** 363
Lubsen, J., **6** 927
Luce, D., **7** 983
Lui, K.-J., **5** 355, **7** 395, **8** 259, 263, 1231, **9** 1167, 1485, **10** 463, **11** 209, 633, **12** 1125, **14** 445(L), 1471, 2051, **15** 671
Luna del Castillo,, **8** 243(L)
Lund, E., **14** 267
Lundbye-Christensen, S., **15** 823
Lundin, F., **10** 565
Lusher, J. M., **10** 433
Lustbader, E. D., **4** 425
Luus, H. G., **12** 1109
Luxenburg, O., **15** 759
Iverson, N., **1** 145
Lye, M. S., **6** 853
Lyles, R. H., **14** 1693
Lynch, J. T., **14** 511

Lyons, M. J., 12 1693

Macaskill, P., 2 167
Maccario, J., 14 1353
Maccubbin, P. A., 9 287
Machado, S. G., 13 2289
Macfarlane, S. B. J., 1 205
Machin, D., 2 87, 4 175 (C) 5 1, 189, 5 139, 155, 7 1165, 9 999, 10 241, 12 497, 13 875(L), 1385, 2249, 14 2503(L)
Machlin, S. R., 8 997
MacKenzie, T. A., 11 1321
MacKinnon, D. P., 14 591
Mackisack, M., 11 295
MacNeill, I. B., 14 821
Madans, J. H., 14 643
Magee, E., 14 1177
Magel, R. C., 14 863
Mager, H., 14 1009
Malcolm, E., 14 2627
Madans, J. H., 8 997
Madsen, E. B., 4 29
Madsen, K. S., 5 231
Maggioni, A., 9 17
Magnus, P., 10 1003
Magnusson, I., 10 1089
Mahrer, J. M., 14 863
Majumder, P. P., 2 13, 4 163, 9 573
Makuch, R., 3 35, 4 247(L), 7 843, 8 619
Malani, H. M., 13 1101
Maldonado, G., 13 989
Maller, R., 14 39
Mallet, A., 13 185
Mallows, C. L., 13 275
Mandelli, C., 5 565
Manning, G., 9 1447
Manor, O., 15 1143
Mantel, N., 2 259, 323, 355, 3 173, 225, 4 241(L), 8 665, 9 369, 627, 12 1807
Manton, K. G., 1 163, 7 239, 293, 325, 10 1043
Mao, Y., 14 821
Mapleson, W. W., 5 363
Marchi, M., 5 565, 14 2363
Marcuson, R., 2 327
Marder, K., 14 2555
Marenghini, A., 4 345
Margolis, P. A., 13 343
Marienfeld, C. J., 4 201
Marinez, Y. N., 3 101
Marinos, A. T., 14 1291
Marion, S. A., 12 617
Mariotti, S., 15 2669
Mariotto, A. B., 14 1513
Maritz, J. S., 4 145, 5 200(L)
Mark, D. B., 3 375, 15 361
Mark, S. D., 12 1605, 13 479, 15 1069
Marks, R. G., 1 49, 2 414(L), 7 1003, 10 1089
Markus, R. A., 14 841
Marler, M. R., 7 697
Marmor, M., 13 231
Marocchi, A., 2 259
Marschner, I. C., 13 1865, 1959, 2369, 15 497
Marsh, M. J., 13 2393
Marshall, G., 13 1501, 14 1975
Marshall, J. R., 8 1041
Marshall, R. J., 4 337, 5 517, 7 1223, 8 1024(L), 12 2333, 14 2645
Marshall, R. W., 10 1719
Marshall, S., 9 1229
Martin Andres, A., 8 243(L)
Martin, C. F., 12 229
Martin, C. J., 6 613
Martin, D. C., 12 329, 14 1491
Martin, D. K., 15 607
Martin, G. J., 13 1015
Martin, S. W., 11 751, 14 83
Martinez-Schnell, B., 8 1497, 12 355
Martuzzi, M., 15 1867
Marubini, E., 2 295, 4 265, 9 737
Maskarinec, G., 15 699
Mason, J. O., 8 253
Mason, J. W., 9 193
Mason, T. J., 14 473
Massey, J. T., 8 367, 14 571
Mastro, T. D., 13 2097
Mather, F. J., 8 813, 9 1118(L)
Matthews, H., 12 481
Matthews, J. N. S., 8 633(L), 9 1121, 10 691, 11 1624(L), 12 27, 14 115
Matthews, J. P., 11 2123
Mattie, A. S., 14 511
Mau, J., 5 491, 7 1267
Mauger, D. T., 14 311
Mauger, E. A., 14 1553
Mauri, F., 9 17
MaWhinney, S., 13 2031
Maxwell, D. A., 1 83
Maxwell, S. E., 12 101
May, W. L., 14 1901
Mayeux, R., 14 2555
Mays, J. R., 15 747
Mazza, J., 3 45
Mazzuca, S. A., 2 417
McBride, M. L., 11 1579
McBride, R., 14 1927
McCabe, G. P., 2 417, 8 1301(L)
McCamant, L. E., 7 685
McClatchey, M. W., 7 1289
McConnaughey, D. R., 10 255
McCrory, S. J., 10 1711
McDonald, C., 2 417, 8 1301(L), 10 505, 511, 541
McDonald, S., 14 955
McDowall, M., 2 467, 3 7
McFarland, H. F., 13 453
McGee, D. L., 12 339
McGee, D. L., 4 239(L), 8 263, 379
McGilchrist, C. A., 15 2253
McGovern, P. G., 9 409
McHugh, R., 3 215, 6 53
McIntosh, M. W., 15 1713
McKay, L. A., 13 23, 15 565
McKeigue, P., 13 1635
McKinlay, S. M., 13 61
McKnight, B., 12 825
McKnight, R. H., 15 747
McLachlan, G. J., 4 244(L), 8 1291
McLaughlin, C. G., 10 1405
McLaughlin, J. R., 13 379
McLean, I. W., 9 1007
McLerran, D., 15 1793
McMahan, C. A., 3 101
McMahon, L. F., Jr., 10 1405
McMahon, R. P., 13 859
McManus, I. C., 2 253
McNeil, A. J., 15 75
McNeil, D., 6 667
McPherson, K., 1 25, 9 595
McPherson, S., 13 113
McShane, L. M., 11 1343, 13 523
McSherry, D. M. G., 5 497
Medley, G. F., 13 1881, 15 2215

Mehta, C. R., 15 2095
Meier, P., 3 473, 6 329, 9 13, 12 1519
Meisner, M., 15 1635
Meisner, M. J., 10 17
Melfi, C. A., 15 1875
Members of the Urological Working Party Renal Carcinoma Subgroup, 12 2249
Ménarés, J., 7 1147
Mendelman, P. M., 8 871 (C) 9 339, 9 342(L)
Mendoza-Blanco, J. R., 15 2161
Mengersen, K. L., 14 545
Mentré, F., 13 185
Merkouriou, S., 7 377
Merlé, Y., 13 185
Merom, D. L., 12 993
Merrill, D. W., 7 491, 12 1953, 15 1837
Messerer, D., 7 1139
Metha, C. R., 14 2143
Metzler, C. M., 10 961
Meyer, J. S., 11 455
Meyskens, Jr., F., 13 245
Mezzanotte, G., 9 737
Mian, I. U. H., 14 83, 15 1409
Micciolo, R., 4 303
Michalek, J. E., 2 315, 8 653, 675
Mickey, R. M., 8 189, 10 53
Midthune, D., 13 1799
Miettinen, O., 2 267, 4 213, 388(L)
Miettinen, O. S., 13 201, 213
Mihalko, D., 2 315, 8 653, 675
Miike, R., 10 711
Mikl, J., 14 499
Mikulecky, M., 14 1941
Milani, S., 4 379
Miller, D., 14 821
Miller, G. E., 15 647
Miller, J. N., 8 441, 455
Miller, J. P., 5 231
Miller, M. E., 7 109, 10 1213, 15 607
Miller, S. T., 13 1201
Milliken, G. A., 14 701
Milner, P. C., 7 1061
Milton, R. C., 8 1433
Minder, C. E., 15 1033
Minkin, S., 12 989(L), 14 1081
Mismetti, P., 14 987
Mittlböck, M., 15 1987
Mocarelli, P., 2 259
Mock, P., 9 463(L), 10 749
Modan, B., 15 759
Mode, C. J., 10 1427
Modvig, J., 10 285
Moertel, C. G., 3 455
Moeschberger, M. L., 12 241
Mohberg, N. R., 10 1349, 11 1075
Mohr, M. S., 12 1953
Molenberghs, G., 10 1391, 15 1123
Møller, S., 14 911
Mollie, A., 10 95
Monfort, C., 14 2487
Monnet, I., 13 1415
Monsour, M. J., 10 443
Montague, E., 3 333
Montasser, M., 7 443
Montomoli, C., 11 983, 14 2411, 2433
Moodaley, L. C., 9 1103
Moody, J. B., 1 205
Moolgavkar, S. H., 4 425
Moon, T. E., 3 333, 5 435
Moore, D. H., 7 765
Moore, R., 14 1927
Moore, T. F., 14 571
Morabito, A., 2 295, 4 265
Moreau, T., 8 1515, 10 1755
Morel, J. G., 11 491, 507
Morgan, B., 14 2599
Morgan, T. M., 6 31, 295, 11 443
Morgenstern, H., 2 387, 4 541
Mori, M., 11 621, 12 737
Morrell, C. H., 10 1453, 13 587
Morris, R. D., 12 1915, 15 893
Morton, B. A., 4 311
Morton, R. H., 1 139
Moses, L., 3 1, 10 629
Moses, L. E., 12 1293
Moses, S., 14 769
Moss, S., 5 127
Mosteller, F., 8 441, 455, 14 395, 15 1465
Motika, M., 13 2043
Moulton, L. H., 14 777
Moussa, M. A. A., 5 319, 7 559
Mowinckel, P., 15 1587
Moyé, L. A., 11 1705
Mueller, T. B., 13 1089
Muir, C. S., 4 63
Muirhead, C., 14 2487
Muirhead, C. R., 15 1003
Mulder, C., 2 191
Mulder, P. G. H., 6 501
Müller, R., 13 2465
Müller, W. G., 14 2609
Mulshine, J., 7 843
Multicenter AIDS Cohort Study, 12 153
Munasinghe, R. L., 12 1915, 15 893
Mundel, G., 12 229
Muñoz, A., 4 457, 7 59, 9 505, 10 492(L), 1993, 11 939, 12 2133, 13 2127, 15 463, 1171, 2323, 2459
Murphy, J. R., 13 391
Murphy, S. A., 14 1843
Murphy, W. C., 7 403
Murray, G. D., 5 103, 403, 7 941, 8 1303(L), 9 1063
Murray, L. S., 5 403
Murrells, T. J., 4 175 (C) 5 1, 189, 5 139, 155, 9 999
Musch, D. C., 3 73
Muse, A. G., 14 499
Musey, P. I., 10 255
Musselman, D. M., 11 1075
Mussi, A., 4 361
Mutanen, P., 8 1023(L)
Mwatha, A., 13 1895(L)
Myers, M. W., 12 461

Nagalingam, R., 6 315, 733
Nagarwalla, N., 14 799, 15 707, 845
Nagelkerke, N. J. D., 5 199(L), 7 739, 9 1211, 13 1895(L), 14 769
Naik-Nimbalkar, U. V., 14 1545
Nakamura, T., 9 1117(L)
Nam, J.-M., 9 1475, 11 547, 1759, 13 79, 14 2037
Naukkarinen, A., 15 2561
Naus, J., 7 1171, 12 1829
Neaton, J. D., 9 115, 11 1719, 13 2107, 15 2445
Nedelman, J., 10 423
Nedelman, J. R., 14 955
Neff, N., 6 197
Nelder, J. A., 11 559(L)

Nelson, D. O., **15** 683
Nelson, K. B., **10** 1595
Netelenbos, J. C., **2** 191
Neuhaus, J. M., **11** 67, **12** 1019, 1259
Neutra, R., **12** 1757
Neutra, R. R., **15** 683
Neville, P., **11** 1465
Newcombe, R. G., **7** 1179, **9** 1045, **11** 560(L), **13** 1283(L), **15** 2143
Newman, C. E., **1** 73
Newman, G. B., **10** 801(L)
Newman, S. C., **6** 527(L), **7** 787
Newnham, P., **3** 85
Newstead, S. V., **13** 1865
Newton, M. A., **13** 839
Nguyen, H. H., **12** 1033, 1047
Nichaman, M., **13** 113
Nielsen, J. P., **12** 843
Niland, J., **6** 689, **8** 518(L), **10** 473
Nix, A. B. J., **2** 123, 141, **5** 183, **6** 425, **10** 855, 981
Nobre, F. F., **14** 605, **15** 1885
Nokes, D. J., **15** 2215
Normolle, D. P., **12** 2025
Norrie, J., **14** 735
Norton, L., **6** 333
Norwood, P. K., **7** 1023
Nose, Y., **9** 1117(L)
Novikov, I., **15** 759
Nurminen, M., **4** 213, **8** 1023(L), 1241

Oakes, D., **2** 305
Obrams, G. I., **12** 789
O'Brien, F., **14** 1365
O'Brien, P. C., **10** 9, 697, **11** 447, 503, **12** 2245
O'Connell, J. B., **9** 193
Odaka, N., **10** 1993
Oden, N., **11** 1131, **14** 17, **15** 783, 851
Oden, N. L., **10** 1303, **12** 1795
Odom-Maryon, T., **10** 473, **14** 1567
Odoroff, C. L., **9** 469
O'Fallon, J. R., **13** 1453
O'Gorman, T. W., **11** 193, **12** 143, **14** 431
O'Hagan, A., **9** 1103
O'Hanesian, M. A., **14** 1843
Ohmann, C., **5** 503
Oja, H., **15** 1519
Oler, J., **2** 59
Oliver, R. T. D., **13** 2249
Olkin, I., **14** 457, **15** 1253, 2493
Olschewski, M., **6** 773, **9** 749, **10** 1915, **15** 263
Olshen, R. A., **2** 345
Olson, D. R., **12** 393
Oman, P., **11** 1615
Omenaas, E., **15** 1771
O'Neill, R. T., **7** 1279, **12** 601, **13** 1493, **14** 1117
O'Neill, T. J., **7** 483, **12** 767
Oortmarssen, G. J. van, **2** 279
O'Quigley, J., **10** 1647
Orav, E. J., **10** 599
O'Reilly, K. R., **12** 219
O'Shaughnessy, C. D., **15** 837
Osipova, T. T., **13** 1575
Osman, M. I., **12** 2247(L)
Osmond, C., **1** 245, **3** 113
Otero, X. L., **15** 305
Ottenbacher, K. J., **10** 1565
Overall, J. E., **8** 1479, **9** 379
Overturf, G. D., **2** 447
Ozminkowski, R. J., **7** 1207

Paddle, G. M., **2** 477
Padian, N. S., **8** 93
Pagano, M., **13** 1901, 1905, 2021, 2031
Pagliaro, L., **4** 345
Paik, M. C., **14** 1889
Pajak, T., **13** 1411
Pal, N., **9** 573
Pallansch, M. A., **11** 1253
Palmatier, M., **13** 523
Palmer, C. R., **10** 1327
Palmer, J., **10** 1159(L)
Palmer, N., **7** 1165
Palmer, R. H., **10** 599
Palombi, M., **11** 591, **13** 163
Palta, M., **1** 267, **6** 599, **13** 2219
Park, T., **12** 1723
Parker, R. A., **5** 261, **7** 1031, **8** 285, 1305(L), **11** 1253, **14** 1683
Parmar, M. K., **13** 1815
Parmar, M. K. B., **12** 165, 497, 1501, **13** 1297, 1371
Pascutto, C., **14** 2433
Passamonti, M. E., **15** 741
Pasternack, B. S., **14** 1437
Patel, H. I., **9** 803, **15** 117, 1739
Patel, N. R., **14** 2143
Pater, J. L., **12** 505, **13** 1337
Patte, C., **12** 1353
Patterson, C. C., **9** 385
Patti, C., **4** 345
Paul, S. R., **8** 1455, **11** 159
Pauler, D. K., **15** 1365
Paull, K. D., **13** 719
Pawitan, Y., **9** 1081
Pearson, J. D., **13** 587
Pearson, L. M., **4** 497
Peckova, M., **14** 2227, **15** 2135
Pedersen, N. W., **7** 639
Peduzzi, P., **9** 125, **12** 1185
Pee, D., **13** 623, **14** 2581, **15** 1069
Pee, D. Y.-W., **9** 829, **10** 800(L), 1167
Pejovic, M. H., **6** 785
Pelto, G. H., **8** 1523
Peng, Y., **15** 2307
Pepe, M. S., **8** 1167, **13** 955, 2311
Percy, D. F., **12** 967
Peritz, E., **11** 845(L)
Permutt, T., **9** 1455
Perrin, E. B., **12** 329
Perucci, C. A., **11** 1657
Peterman, T. A., **7** 395
Peters, T. J., **5** 113, **9** 1023
Peterson, D., **13** 53
Peterson, H. B., **12** 355
Petiot, J.-F., **5** 171
Petkau, A. J., **15** 727
Peto, J., **10** 1025
Peto, R., **3** 409, **6** 233, 245
Petri, H., **7** 1171, **10** 577
Petroni, G. R., **10** 1405
Phair, J. P., **15** 2307
Phatarfod, R. M., **13** 2337
Phelps, S. J., **10** 351
Phillips, A. N., **9** 1189, **11** 953
Piantadosi, S., **7** 1243, **8** 59, **12** 1239, **14** 1149, **15** 1605
Pickering, R. M., **3** 249, **11** 1225
Pickle, L. W., **14** 615
Pickles, A., **14** 1447
Piedbois, P., **15** 2797
Piegorsch, W. W., **13** 153
Pigeon, J. G., **11** 1065
Pignon, J., **13** 1415

Pinsky, C. M., 3 325
Piper, J., 10 141
Pitkäniemi, J., 15 2561
Piubello, W., 4 303
Plantinga, A. D., 6 843
Platz, H., 2 287
Ploeg, R. J., 13 2517
Plu, G., 11 2133
Plummer, D., 4 311
Plummer, F. A., 14 769
Plummer, M., 12 925, 937
Pobel, D., 14 2459
Pocock, S. J., 1 93 (C) 3 97, 7 1231, 9 657, 1189, 11 1685, 1731, 12 1459, 14 209, 15 249, 1285
Podgor, M. J., 5 573, 13 747, 15 145, 2095
Poletto, L., 15 741
Polissar, L., 1 191
Pool, J., 12 1733
Poos, M. J. J. C., 9 721
Port, F. K., 14 1553
Posner, K. L., 9 1103 (C) 11 1401
Potter, J. D., 13 1619
Powles, T. J., 3 333
Pozen, M. W., 1 41
Pratt, C. M., 9 137
Praus, M., 12 2383
Prentice, R. L., 7 275, 8 431, 1167, 9 161, 13 955, 15 1849
Prescott, P., 13 11, 15 987
Preston, D., 8 59
Price, W. H., 4 106(L)
Probstfield, J., 8 415, 11 1041
Prorok, P. C., 13 569, 14 2715
Proschan, M., 13 859
Proschan, M. A., 13 1441, 15 1059
Prospero, L., 11 591
Province, M. A., 5 231, 7 185
Pryor, D. B., 3 143, 375, 10 617
Psaty, B. M., 10 653, 11 1009
Pullum, T. W., 10 191
Puterman, M. L., 9 273
Pyne, D. A., 3 15

Quade, D., 8 311
Quan, H., 12 675

Raab, G. M., 12 2179, 13 2009, 15 2657
Raboud, J., 8 977
Rach, G. H., 9 237
Racine-Poon, A., 8 1327, 14 971
Radaelli, G., 5 565
Raghunathan, T. E., 10 1417, 13 1525
Raines, B., 9 385
Ramakrishnan, V., 12 1693
Ramaswamy, R., 14 1731
Ranta, J., 15 2235, 2561
Rao, D. C., 7 185
Rao, P. V., 12 2043
Raphael, J. C., 6 795
Rasbash, J., 13 1643
Raskino, C. L., 11 1731
Rasmussen, K., 10 405
Rasmussen, N. Kr., 5 243
Raubertas, R. F., 8 267
Rawlins, M. D., 6 863
Rawson, N. S. B., 14 2627
Rayens, M. K., 12 1813
Raymond, L., 9 529
Raynauld, J.-P., 14 1129
Redmond, C., 13 1411
Reed-Fourquet, L. L., 14 511
Regal, R. R., 3 287, 10 717
Rehm, J., 11 1195
Reintjes, A. G. M., 9 721
Reitman, D., 6 315, 733
Remington, R. D., 11 451
Resnick, M. B., 11 243
Reuben, C. A., 14 643
Reynolds, G. H., 8 343, 353, 397
Reynolds, P., 15 683
Reznikoff, C. A., 13 839
Rezvani, A., 4 295
Rhame, F., 13 2107
Rhodes, P., 4 239(L), 8 379, 9 423 (C) 12 1269, 1167
Rhodes, W. H., 14 655
Riboli, E., 13 127
Richards, G., 2 141, 5 183
Richardson, B. A., 15 127
Richardson, D., 11 1359
Richardson, S., 11 1443, 12 1703, 14 2487
Richardson, S. C., 4 243(L), 8 1545(L), 9 515, 10 95, 1493
Richardson, W., 13 785
Richter, D., 12 283

Rida, W. N., 13 2155, 15 2393
Ridout, M. S., 13 873(L)
Rifkin, R. D., 14 789
Riggan, W., 1 163
Rinaldi, M. G., 7 535
Rindskopf, D., 5 21, 6 530(L)
Rindskopf, W., 5 21
Rinsky, R., 4 105(L)
Ritchie, A., 13 2249
Ritenbaugh, C., 13 245, 15 1647
Ritter, C., 14 2191
Rivière, A., 13 1415
Rivkin, S., 3 333
Rizza, C. R., 9 681
Rizzardi, M., 12 1953
Robertson, C., 5 527 (C) 6 535
Robertson, J. R., 14 1365
Robins, J., 7 773, 8 679, 845, 9 1417, 10 79
Robins, J. M., 12 1605
Robinson, G. A., 13 2289
Robinson, J., 13 1473
Robinson, W. T., 14 955
Rockette, H. E., 6 71
Rockhold, F. W., 12 471
Rodary, C., 8 593, 12 1353
Rodgers, Jr., G. C., 15 747
Rodland, E. A., 15 1587
Roe, D. J., 12 893
Roeback, J. R., 12 1213 (C) 13 99
Roebruck, P., 14 1583
Rogers, W. H., 11 475
Rohan, T. E., 8 1529, 13 379
Röhmel, J., 14 895, 1655
Rolnitzky, L. M., 11 125
Roloff, D. W., 7 1207
Rolph, J. E., 13 889
Rom, D. M., 11 511, 13 1583, 15 1489
Roman, E., 3 7
Rosati, R. A., 3 143, 375
Rosen, O., 14 935
Rosenbaum, P. R., 3 27
Rosenberg, P. S., 7 843, 8 619, 10 1167, 11 1633, 13 1975, 14 2581
Rosenberg, S. H., 9 1007
Rosenberger, W. F., 11 643, 12 2219
Rosenbusch, B., 14 1807

Rosner, B., 4 111, 457, 7 59, 8 1051, 10 492(L), 1441, 1585, 11 1187, 1915, 12 1141, 13 1023, 14 2205
Rosner, B. A., 15 293
Rosner, G. L., 8 505, 14 381
Rosove, M. H., 9 835
Ross, W., 11 1321
Rossing, M., 15 1849
Rossiter, J. E., 10 1693
Rosychuk, R., 15 727
Rothenberg, R., 14 51 (C) 14 1841
Rothenberg, R. B., 7 1031, 8 1305(L), 9 287, 14 629
Rothrock, J., 1 145
Rothwell, S. T., 14 643
Rovelli, F., 9 17
Rowland, A. S., 12 867
Rowlands, R. J., 2 123, 141, 5 183, 6 425
Royston, J. P., 7 629
Royston, P., 8 1304(L), 10 221, 675, 691, 1283, 11 257, 333, 897, 1115, 12 181, 699, 14 1417
Rubens, R., 13 1329
Rubenstein, L. V., 13 1799
Rubin, D. B., 10 585, 11 1809, 14 747
Rubin, G., 11 1533
Rubinstein, L. V., 13 719
Rücker, G., 7 1139, 8 477
Rudy, R. K., 8 259
Ruffié, P., 13 1415
Ruitenberg, E. J., 8 963, 9 721
Rümke, C. L., 2 175
Rusanen, J., 15 2561
Rushton, G., 15 717, 1907
Russek-Cohen, E., 13 87
Rutstein, D. D., 1 309
Rutter, C. M., 13 1211
Ryan, J., 13 11
Ryan, L., 8 1255, 9 1222(L), 10 65, 11 1801, 15 2191
Ryan, L. M., 6 565

Saah, A., 13 2127
Saah, A. J., 9 505, 15 2307
Sacks, H. S., 6 315, 733, 8 141
Saei, A., 15 2253
Šaferis, V., 15 817
Safran, C., 10 559
Sahai, H., 15 1
Sahu, S. K., 12 1853
Salmi, R., 8 757
Salsburg, D., 9 201
Salt, A. T., 14 257
Salvan, A., 9 247
Sampson, A., 15 1747
Sampson, A. R., 7 1023
Sampson, P. D., 9 1103 (C) 11 1401
Samuelsen, S. O., 13 1771
Sánchez Sellero, C., 15 305
Sandor, G. G. S., 9 273
Sandvik, L., 15 1587
Sargent, D. J., 15 1093
Sasieni, P., 11 617, 15 2763
Satariano, E., 15 683
Sato, T., 10 1037, 11 847(L), 1599
Satten, G. A., 13 2097
Sauerbrei, W., 11 2093, 12 1325
Sawilowsky, S., 12 2233
Scalia-Tomba, G., 10 1313
Schaefer, R. L., 2 71, 4 245(L)
Schäfer, D. W., 8 1139
Schafer, H., 8 1381
Schäfer, H., 13 1551 (C) 14 875
Schaffner, K. F., 12 1477
Schall, R., 9 1131, 12 1109
Schatzkin, A., 11 167
Schechter, M. T., 12 617
Schechtman, K. B., 12 111
Scheike, T. H., 12 843
Schellenberg, J. A., 13 2345
Schelp, F.-P., 11 1289, 12 2248(L)
Schemper, M., 7 1257, 9 777, 12 2377, 15 1987, 1999
Schenker, N., 10 585, 12 1589
Schenzle, D., 13 2067
Scherer, J., 10 457
Scheys, I., 12 1063
Schifflers, E., 4 63, 6 449, 469
Schilling, R., 1 317
Schinaia, N., 11 591, 13 163
Schindel, F., 12 2383
Schinnar, R., 10 565
Schlain, B. R., 11 515, 12 265
Schlattmann, P., 11 1289, 12 1943, 1965, 2248(L), 15 919, 931
Schluchter, M. D., 7 317, 9 1175, 11 1861
Schmid, C. H., 12 1141
Schmidt, G., 8 1393
Schmidt, L., 10 285
Schmidt, S. A., 7 639
Schmitz, P. I. M., 2 199
Schmoor, C., 6 773, 12 2351, 15 263
Schneiderman, M. A., 1 307, 9 673, 871
Schnell, D., 8 343, 353
Schnell, D. J., 12 219, 14 1177
Schnitzler, C. M., 8 785
Schoenfeld, D. A., 12 835, 13 1747, 15 2359
Schonberger, L. B., 5 355
Schoolman, H. M., 1 311
Schork, M. A., 9 301
Schork, N. J., 9 301, 13 1563
Schouten, E. G., 12 1733
Schouten, H. J. A., 12 2207
Schroeder, G., 13 1453
Schulgen, G., 8 1401, 10 1915
Schulman, J., 7 491
Schulte, P., 4 105(L)
Schulz, K. F., 2 25
Schumacher, M., 2 41, 415(L), 6 773, 9 749, 1527, 10 1915, 11 2093, 12 2351, 15 263
Schumacher, P., 9 273
Schwab, B., 15 1747
Schwartländer, B., 13 1991
Schwartz, H. A., 14 687
Schwartzbaum, J. A., 10 1273
Schwarz, R. P., 9 447
Schwarz, S., 12 2383
Sciarrino, E., 4 345
Scott, A. J., 14 1961
Scott, G., 8 619
Scribner, R., 14 591
Scuro, L. A., 4 303
Seal, J., 4 91
Sedlak, S. L., 15 1951
See L.-C., 8 3
Seeber, G. U. H., 8 1363
Segal, M. R., 7 601, 8 539, 11 67, 12 1019, 1259, 2153
Seigel, D., 8 427, 1433, 11 269(L)
Seillier-Moiseiwitsc, F., 15 2149
Self, S. G., 7 275, 8 1167
Selik, R. M., 2 25
Selmer, R., 9 1157

Selvin, S., 7 491, 12 1953, 15 1837
Selwyn, M. R., 11 1797, 12 1665
Selzer, J., 2 447
Senn, S., 12 1086(L), 2147(L), 2367, 13 197(L), 217, 293(L), 785, 1181(L), 1715, 2280(L), 14 2283(L), 2661, 15 2689
Senn, S. J., 6 727(L), 7 1099(L), 1203(L), 8 467, 1339, 9 583(L), 1287 (C) 10 487, 10 1157(L), 1361, 1679, 11 715 (C) 11 1619
Seshia, S. S., 11 1023
Seydel, J., 13 1991
Shaddick, G., 15 1927
Shannon, W. D., 14 2099
Shao, J., 8 883, 12 1999
Shapiro, A. P., 7 697
Shapiro, D., 12 1293
Shapiro, S. H., 15 2813
Sharp, S. M., 13 1781
Sharples, L. D., 12 1155
Shaw, M., 10 565
Sheiner, L. B., 10 303, 11 1777
Shemer, J., 15 759
Sheppard, L., 15 1849
Shera, D., 14 1913
Sheridan, J. R., 14 1177
Shetterley, S. S., 8 1523
Shetterly, S. M., 10 493
Shevchenko, I. P., 14 511
Shewmon, D. A., 6 535
Shiboski, S., 15 2337
Shieh, G., 11 243
Shih, W. J., 6 91, 8 583, 9 1439, 10 323 (C) 10 1155, 12 481, 13 261, 14 2239
Shirley, E. A. C., 1 281, 3 85, 4 489
Shoop, G. L., 4 201
Shore, D. L., 8 311
Shoukri, M. M., 11 751, 14 83, 15 1409
Shrager, R., 7 571
Shukla, R., 13 2205
Shuster, J. J., 11 913 (C) 11 1619, 931
Shuttleworth, P., 13 11
Shyu, S.-F., 11 1533
Siemiatycki, J., 5 49
Signorini, D. F., 12 2343
Silcocks, P., 8 765(L)
Siler, W., 2 373
Silliman, N. P., 15 2077
Silver, R., 4 11
Silverberg, A. R., 13 1657
Silvestri, D., 15 2763
Simes, R. J., 5 411, 6 11, 9 1259, 12 2343
Simon, R., 3 35, 305, 6 217, 389, 7 571, 8 551, 813, 9 215, 487, 1118(L), 10 1789, 11 13, 13 417, 431, 1401, 14 73, 1479, 15 2203
Simon, R. M., 13 87, 399, 719, 1799, 14 357
Simon, S., 2 345
Simonetti, R., 4 345
Simpkin, J. M., 7 387, 8 1416(L)
Simpson, J. C., 11 685
Simpson, J. M., 6 863, 14 199
Sinkula, M. S., 10 1349
Siscovick, D., 10 653
Siskind, V., 4 387(L), 15 1535
Sison, C. P., 12 1853
Skalland, L., 2 397
Skeleton, A. G., 15 939
Skene, A. M., 9 919, 11 1103, 2111, 12 1365
Skinner, J., 11 1967
Skjærven, R., 15 2029
Slater, C., 4 397
Smallwood, D. M., 15 23
Smans, M., 4 63
Smeeton, N. C., 8 1416(L)
Smith, B., 15 837
Smith, D., 12 1757
Smith, D. F., 15 683
Smith, D. M., 15 607
Smith, D. P., 4 155, 397
Smith, D. W., 13 1001
Smith, F. B., 8 703
Smith, J. A., 6 53
Smith, L., 10 1441
Smith, M. E., 13 453
Smith, N. T., 15 1199
Smith, P. F., 14 499
Smith, P. G., 3 301(L)
Smith, P. J., 10 113, 11 1503, 1621(L), 12 1683, 15 323
Smith, S. J., 8 295, 14 531, 15 1827, 1985
Smith, T., 13 2345
Smith, T. C., 14 2685
Smith, T. L., 9 777
Smith, T. M. F., 4 175 (C) 5 1, 189, 5 139, 155, 9 999, 15 987
Smith, W. D., 15 1199
Snapinn, S. M., 6 657, 11 659, 12 481
Snider, D. E., 15 1835
Snyder, E. S., 10 565
Sobel, E. L., 14 1307
Soltysik, R. C., 13 1015
Somer, A., 10 45
Somes, G. W., 10 351, 13 1201
Sondak, V. K., 4 527
Song, H., 15 1907
Song, X.-K., 15 823
Songini, M., 14 2433
Sonju, T., 14 1819
Sonksen, P., 14 2599
Sonksen, P. M., 14 257
Sopko, G., 13 859
Sorlie, P., 13 663
Souhami, R. L., 13 1293
South, M. C., 11 307
Southall, D. P., 6 159
Spadea, T., 11 1657
Sparrow, D., 14 2205
Speakman, J. R., 9 1365
Speizer, F., 4 457, 7 95, 601
Sperling, J., 15 1961
Spicer, C. C., 6 159, 945
Spiegelhalter, D. J., 2 33, 207, 5 1, 421, 11 23, 12 1501, 13 1297, 1371, 1815, 14 2685, 15 157
Spiegelman, D., 8 1051
Spira, M., 12 39
Sposto, R., 6 119
Stablein, D. M., 7 929, 9 1425
Stacy, A. W., 12 365
Stallard, E., 1 163, 7 239, 293, 10 1043
Stamhuis, I. H., 2 191
Stamp, M., 12 229
Stampfer, M. J., 4 111
Stander, H., 9 447
Stanek, E. J. III, 8 1523, 9 841, 10 119, 493(L)
Stangl, D. K., 14 2173
Stare, J., 15 1999
Stasny, E. A., 9 1143
Staszewski, R., 9 457, 1541(L), 11 132(L)

Stearns, S. C., 15 1447
Steenland, K., 4 105(L)
Stefanski, L. A., 8 1139, 13 1265
Steffey, D., 12 1125
Stein, G., 5 449
Stein, R. A., 5 97(L)
Stein, Z., 1 105, 14 1889
Steinberg, K. K., 14 531
Steinke, B., 5 491
Stern, R. S., 10 565
Stern, Y., 15 1023
Sterzik, K., 14 1807
Stevenson, J. M., 12 393
Stewart, L. A., 14 2057
Stewart, W. H., 11 1843
Stigum, H., 10 1003
Stijnen, T., 12 2273, 2285
Stiller, C. A., 7 857, 15 1003
Stitt, L. W., 6 885
Stoddard, A. M., 3 261
Stokes, M. E., 2 397
Stolley, P. D., 10 565
Stone, P. H., 13 859
Stone, R. A., 7 649
Storer, B. E., 9 229
Stoskopf, C., 12 283
Støttrup Hansen, E., 9 315
Stovin, P. G. I., 2 33
Straatman, H., 9 237
Stram, D. O., 7 139
Straub, J. P., 2 191
Strauss, N., 14 1479
Strehler, E., 14 1807
Strijbosch, L. W. G., 9 1353
Strocchi, E., 4 361
Strom, B. L., 10 565
Strömberg, U., 12 1989
Stroup, D. F., 7 1045, 8 279, 323, 11 1409, 1551, 14 629
Stroup, N. E., 14 691
Struchiner, C. J., 13 357
Stukel, T. A., 8 517(L), 12 1339, 13 1781
Sturt, E., 3 57
Stylianou, M., 12 543
Su, J. Q., 14 275
Sudbury, A., 13 2337
Suissa, S., 8 757, 14 247
Sullivan, L. M., 15 477
Sullivan Pepe, M., 10 413, 12 737
Sun, J., 15 1387
Sun, L., 15 823
Sun, W.-H., 8 927
Sundet, J. M., 10 1003
Surwit, E., 13 245
Susser, M., 1 105
Sussman, S., 12 365
Sutherland, I., 1 329
Sutton, C. J., 10 395
Svendsen, K. H., 9 115
Svensson, E., 13 2437
Swan, A. V., 1 361
Sweeney, J. A., 15 1365
Swift, M. B., 14 1875
Sylvester, R., 13 1329

Tabar, L., 14 1531, 2619(L)
Taboada, X. A., 15 305
Taft, K. A., 14 591
Tager, I., 4 457, 7 601
Tager, I. B., 12 2153
Takala, A. K., 15 2235
Talamini, G., 4 303
Tallis, G. M., 7 483, 12 767
Tamhane, A. C., 10 939, 11 1057
Tan, M., 15 2037
Tan, S.-J., 10 1137
Tan W. Y., 8 121
Tan, W. Y., 11 831
Tan, W.-Y., 12 1629, 15 197
Tandon, P. K., 9 447, 819
Tang, K. Y., 6 529(L)
Tang, M.-L., 13 1539, 14 2261
Tang, M.-X., 14 2555
Tang, S. C., 15 197
Tango, T., 5 335, 6 709, 8 1509, 14 2323
Tarayre, M., 13 1415
Tate, H., 2 217
Taube, A., 5 585
Tavaré, C. J., 14 1307
Taylor, C., 12 129
Taylor, D. W., 9 787
Taylor, J. A., 13 153
Taylor, J. M. G., 5 29, 8 45, 9 505, 10 1993, 11 939, 12 153, 13 969, 2059, 2127, 14 1205
Taylor, J. O., 11 1187
Teasdale, G. M., 5 403
Teather, D., 4 311
Ten Have, T. R., 13 1841, 14 413, 15 1227(L), 2573
Teo, K. K., 9 73
Terrin, M. L., 9 155
Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), 13 2107
Thacker, S. B., 7 1045, 8 363, 14 531, 629
Thakrar, B., 9 681
Thalabard, J.-C., 11 2133
Thall, P. F., 5 73, 7 571, 9 215, 12 1197, 13 417, 1727, 14 357
The Collaborative Investigation of Duchenne Dystrophy Group, 5 231
The Cooperative Group on CLL of Société Francaise D'Hématologie, 4 287, 5 465
The Cooperative Group on Lung Cancer (GETCB), 4 279
The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome, 6 795
Theobald, C. M., 10 141
Theron, G. B., 9 539
Theune, J. A., 2 191
Theunissen, I., 14 2191
Thiyagarajan, B., 11 1333
Thomas, A., 14 2685
Thomas, D., 5 49, 6 689, 8 518(L)
Thomas, D. C., 15 1663
Thomas, G., 11 2133
Thomas, K., 12 1543
Thomas, N., 13 889
Thompson, E. A., 5 291
Thompson, M. J., 10 1315
Thompson, M. L., 8 1277, 9 539
Thompson, S., 15 2717
Thompson, S. G., 2 147, 9 1189, 11 257, 15 619
Thompson, T. J., 15 323
Thomsen, B. L., 10 733
Thomsen, D. L., 13 1899
Thomson, P. C., 14 1463
Thon, K., 5 503
Thornquist, M., 10 413
Thorogood, J., 13 2517, 14 1999
Thurmond, M. C., 8 725

Tian, J. J., 13 2205
Tielsch, J. M., 9 35
Tierney, W. M., 10 541, 1213
Tijssen, J. G. P., 6 927
Till, S., 14 2599
Tilson, H. H., 10 565
Timm, J., 9 765
Timmel, M. J., 13 1755
Tindall, B., 13 231
Tine, F., 4 345
Tippett, P. A., 2 87
Tiret, L., 7 947
Tognoni, G., 9 17
Tolboom, J. T. B. M., 11 2043
Toledano, A., 15 1807
Tolley, E. A., 10 351
Tomasson, H., 14 1331
Tong, D. M., 14 2509
Toniolo, P. G., 14 1437
Toogood, J. H., 3 45
Tooley, M., 4 11
Torasso, P., 4 317
Toretsky, E. R., 9 73
Tosteson, T. D., 8 1139
Tournade, M.-F., 8 593
Travade, P., 4 287, 5 465
Trewin, V. F., 10 831
Tripathi, R. C., 8 653, 675
Tritchler, D., 6 101
Troendle, J. F., 15 1107
Troy, S. M., 10 1427
True, W., 12 1693
Truman, B. I., 14 695
Trussell, J., 10 201
Tsai, K. T., 15 117
Tsai, W.-Y., 14 2555, 15 1023
Tsakok, A. D., 14 101(L)
Tsauo, J.-Y., 15 93
Tsay, R. S., 6 167
Tse, S.-K., 9 549 (C) 11 425, 10 1543
Tsiatis, A. A., 8 505
Tsouros, A. D., 5 593
Tsuang, M. T., 12 1693
Tsutakawa, R. K., 4 201, 15 1397
Tu, X. M., 13 1905, 15 2161
Tubert, P., 10 991
Tubert-Bitter, P., 14 1129
Tuchais, C., 13 1415
Tukey, J. W., 12 1033, 1047
Tuomilehto, J., 15 2561
Tuominen, J., 13 2531
Turnbull, B. W., 11 1343, 12 1869, 14 3
Turney, E. A., 11 1843
Turri, M., 5 449
Turunen, J., 15 2635
Tweedie, R. L., 14 545
Tyler, C. W., Jr., 2 25
Tzonou, A. J., 14 1291
Tzourio, C., 14 1353

Uebersax, J. S., 9 559
Ulm, K., 8 1393, 10 341, 12 2351
Umbach, D., 11 1533
Umbach, D. M., 15 1333
Umen, A. J., 5 637, 10 1267
Unkelbach, H. D., 4 77
Urbach, P., 12 1421
Urquhart, J., 7 1171, 10 577

Vacek, P. M., 8 189
Vach, W., 14 1315
Valsecchi, M. G., 15 2763
van Bockel, J. H., 13 2517
van den Eeden, S. K., 12 825
van der Tweel, I., 15 2781
Væth, M., 5 327
Valleron, A. J., 7 1147
Valsecchi, M. G., 2 295
Van Den Broek, P., 9 237
van Druten, J. A. M., 6 843, 8 963, 9 721, 11 1425
van Elteren, P., 3 219
van Es, G.-A., 6 927
Van Guilder, M., 8 217
Van Houwelingen, H. C., 12 1733, 2273, 2285, 2305, 13 2427
Van Houwelingen, J. C., 9 1303, 13 2517, 14 1999
van Kappel, A. L., 13 127
van Lier, H. J. J., 3 219, 9 237
Van Lierde, M., 14 2191
van Noord, P. A. H., 15 2781
Van Raden, M., 11 939
van Staveren, W. A., 13 127
Van 'T Hof-Grootenboer, A. E., 9 237
Vandenbroucke, J. P., 12 1733
Vantini, I., 4 303
Variyam, J. N., 15 23
Vázquez Fernández, E., 15 305
Velu, R., 13 2219
Venot, A., 14 331, 2565
Venzon, D. J., 4 425
Verdecchia, A., 8 201, 14 1513
Vermund, S. H., 10 1993
Vernon, P., 10 423
Veronesi, U., 9 737
Verran, J. A., 7 1003
Verter, J., 3 305, 4 227, 9 45, 103
Verweij, P. J. M., 12 2305, 13 2427
Viel, J., 14 2459
Viel, J. F., 14 2383
Vilkauskas, L. A., 15 817
Virtala, E., 15 2561
Visentin, S., 13 2407
Vittinghoff, E., 13 1101
Vollmer, W. M., 7 11, 685
Vollset, S. E., 12 809 (C) 14 875, 13 1539, 14 2261
Von Hoff, D. D., 8 813, 9 1118(L)
Vonesh, E. F., 9 263, 11 243, 1929
Vourc'h, G., 7 947
Vœth, M., 11 1527(L)
Vuorinen, J., 13 2531, 15 2635

Wacholder, S., 13 623, 651
Waclawiw, M. A., 13 541
Wade, A. M., 13 2359, 14 257
Wagner, E. H., 10 653
Wahl, P., 10 653
Wahrendorf, J., 5 547
Wakefield, J., 14 971
Wakefield, J. C., 9 919
Waldhör, T., 15 887
Walker, A. M., 10 1181
Wallenstein, S., 6 197, 12 1829
Waller, J. L., 13 1071
Waller, L. A., 12 1869, 14 3, 2291, 15 765
Walter, E., 14 2565
Walter, S. D., 4 437, 541, 5 61, 6 885, 7 1073, 12 1275, 1885, 13 1037 (C) 15 335
Walters, L., 12 575
Walton-Bowen, K. L., 12 481
Wanderling, J. A., 15 1635
Wang, J.-D., 15 93
Wang, W., 15 659
Wang, X., 12 403
Wang, Y., 14 1205

Wang, Z.-Y., **8** 1537
Wang-Clow, F., **14** 283
Wanner, H. U., **10** 1481
Wanzer Drane, J., **12** 283
Ward, J., **15** 2253
Ward, J. W., **8** 831
Ward, M. M., **12** 1005
Ward, R. J., **9** 1103 (C) **11** 1401
Ware, J. H., **7** 95, **8** 1109, 1133, **9** 881, **14** 283
Wargenau, M., **14** 901 (C) **15** 335
Wartenberg, D., **12** 1763
Wassell, J. T., **12** 241, 301, **15** 1951
Wasserman, L., **14** 1379
Wastell, D. G., **6** 137
Waternaux, C., **11** 799
Watier, L., **10** 1493
Watson, L. F., **10** 1527
Watt-Boolsen, S., **6** 939
Wax, Y., **11** 1273
Way, A. B., **12** 229
Weaver, S., **15** 1227(L)
Weaver, S. L., **14** 413
Webster, K. M., **10** 383
Wedel, H., **4** 227
Weder, A. B., **9** 301
Wee, B. C., **13** 53
Weerasekera, D. R., **11** 603
Weerasooriya, N., **12** 955
Wei, L. J., **7** 139, **11** 1871, **15** 2413
Wei, W.-H., **15** 449
Weightman, R., **14** 1365
Weinberg, C. R., **10** 255, **12** 867, **13** 153, 671, **15** 2029
Weinstein, J. N., **13** 719
Weiss, D. G., **3** 435
Weiss, K. M., **2** 13
Weiss, R. E., **11** 115
Weiss, S., **4** 457, **7** 601, **14** 2205
Weissfeld, L. A., **14** 1985
Weng, C.-S., **10** 1375, **11** 881, **14** 853
Wennberg, J. E., **13** 1781
Wentworth, D., **9** 115
Wentworth, D. N., **13** 2107, **15** 2445
Wesley, M. N., **11** 455
West, C. R., **8** 1317
West, K. P., Jr., **9** 35
Westlake, A. J., **7** 1165
Whaley, F. S., **10** 723
Whipple, J. P., **11** 1065
White, A. A., **14** 615, 697
White, I. R., **13** 1635, **15** 249
White, S. A., **11** 2111
Whitehead, A., **10** 1665, **13** 2503, **15** 2733
Whitehead, J., **1** 73, **2** 183, **5** 459, **7** 619, **8** 861, 1439, **9** 853(L), 1277 (C) **10** 1001, **10** 901, 1665, 1703, **12** 1405, 2257 (C) **13** 871, **13** 1357, 2249, 2493, **14** 885, **15** 2703
Whittemore, A. S., **1** 229, **7** 223, **8** 1151
Wieand, H. S., **8** 563, **13** 1411
Wieand, S., **11** 5, **13** 1453, **14** 2217
Wiggins, A. D., **6** 961
Wigodsky, H., **3** 101
Wilcox, A. J., **10** 255, **13** 671, **15** 1333, 2029
Wilcox, L. S., **12** 355
Wiley, J. A., **8** 93
Wilhelmsen, L., **9** 185
Willan, A. R., **11** 1321
Willard, K., **13** 53
Willett, W., **4** 111, **8** 1031, 1051
Willey, E. S., **10** 351
Williams, C., **14** 2599
Williams, F. L. R., **12** 1249
Williams, G. W., **12** 481
Williams, O. D., **3** 469
Williams, P. L., **15** 2341
Williamson, G. D., **8** 323, **14** 713
Williamson, J., **15** 1507
Williford, W. O., **3** 435
Wills, K. M., **4** 311
Willson, J. K. V., **11** 2063
Wilson, D. W., **2** 123, 141, **5** 183, **6** 425
Wilson, H. G., **14** 51 (C) **14** 1841
Wilson, P. D., **7** 73, 417, 423, **14** 1219
Wiltse, C. G., **6** 61
Wing, S., **10** 1043
Winn, D. M., **2** 387
Witte, J. S., **15** 1161
Wittes, J., **3** 305, **8** 161, 415, **9** 1, 65, **11** 427, 453, **12** 419, 1185
Wittes, R., **3** 305, **6** 269
Wittie, P. S., **15** 1921
Wojdyla, D., **15** 741
Wolf, M., **13** 1391
Wolf, P. A., **14** 1757
Wolf, T., **4** 77
Wolfe, R. A., **10** 1405, **14** 1553
Won Lee, J., **14** 2111
Wong, M. A., **2** 345
Wong, S.-C., **8** 1537
Wong, W. K., **15** 343
Woodbury, M. A., **7** 239, 293, 325
Woodrow, J. C., **2** 79, **7** 443
Woodward, E. G., **9** 1103
Woodworth, G. G., **11** 621
Woolson, R. E., **6** 61
Woolson, R. F., **1** 37, **11** 193, 621, **12** 143
Worsley, K. J., **8** 1414(L)
Wortman, P. M., **7** 1207
Wright, E. A., **10** 599
Wu, M. C., **7** 1, 337, **13** 635, 759, 945
Wu, S.-Q., **13** 839
Wulff, H. R., **6** 3
Wyld, R., **14** 1365
Wylie, B., **13** 2043
Wypij, D., **12** 403

Xiong, X., **15** 2037
Xu, J., **15** 2459
Xu, J.-L., **14** 2715

Yakovlev, A. Yu, **13** 983(L), 1575
Yan, P., **13** 805
Yang, M. C. K., **10** 1089, **12** 2043
Yang, S.-Y., **13** 2189
Yao, Q., **15** 2413
Yao, T.-J., **13** 2219
Yarnold, P. R., **13** 1015
Yashin, A. I., **7** 325
Yateman, N. A., **11** 1103, **12** 1365
Yoshimura, I., **10** 839
Young, G. P., **7** 581
Young, M. A., **9** 253
Young, P., **14** 2599

Young, R. J., **5** 593
Yu, E. S. H., **8** 1537
Yu, K. F., **15** 1595(L)
Yuen, K., **11** 2123
Yuen, P., **13** 2249, **14** 2503(L)
Yurik, T., **15** 2445
Yusuf, S., **3** 409, **6** 217, 281, **9** 1, 73

Zaczyk, R., **5** 503
Zagar, A. J., **10** 7
Zahl, P.-H., **14** 1249
Zahurak, M. L., **14** 1149
Zaidi, A., **8** 343, 353, 1497
Zedeler, K., **11** 281
Zeger, S., **15** 1349
Zeger, S. L., **7** 161, **8** 3, **10** 45 (C) **13** 1897, **11** 1825
Zelen, M., **3** 399, **5** 261, **9** 645
Zelterman, D., **8** 1011, **10** 1267, **12** 881
Zerbe, G. O., **13** 759, **15** 2107
Zhang, H., **15** 37
Zhang, M.-Y., **8** 1537
Zhang, Z., **13** 23, **15** 565
Zhao, G., **15** 51
Zhao, L., **13** 1149
Zhao, L. P., **11** 769
Zhen, B., **13** 391
Zheng, T., **15** 565
Zhou, S., **14** 39
Zhou, S. Y. J., **12** 153, 2133
Zhou, X. H., **15** 1687
Zhou, X.-H., **13** 1737, **15** 1875
Ziade, M. F. M., **12** 1171
Zielhuis, G. A., **9** 237
Zion, G., **13** 769
Zipfel, A., **10** 807
Zlabinger, G., **15** 2589
Zucchini, W., **8** 1277, **9** 1131
Zucker, D., **13** 635
Zucker, D. M., **12** 753, **13** 759
Zwinderman, A. H., **9** 931
Zwinderman, K. H., **12** 2273

SUBJECT INDEX*

Notes: Bold numbers followed by ordinary numbers refer to volume number **1** to **15** and the first page of individual papers. Example: 'Additive hazard models, **4** 353, **5** 539' refers to volume **4** page 353 and volume **5** page 539. The page ranges shown indicate collections of papers on particular topics. (L) after some page numbers identifies letters. When using the index for an obscure subject, best results are obtained by first preparing a list of associated topics before proceeding with the search. A search can be augmented as necessary, by reference to the Author Index located on page 1, Contents lists for the fifteen volumes are located on page 205. Book Reviews and Corrections to Published Papers are listed separately on pages 199 and 189 respectively.

75/75 rule bioequivalence, **11** 1333
Abbreviated injury scale (AIS), **15** 933
Abdominal pain, **5** 497; **6** 945; **8** 1351
Aberrations disease incidence, **8** 323, 331
Abortion
  complications, **2** 25
  data analysis, **8** 285
  Joint Program for Study (JPSA III), **2** 25
  Markov models, **5** 243
  risk estimation, **10** 285
  scan statistic distribution, **6** 197
  spontaneous, **4** 469; **5** 557; **6** 197
Absolute residuals, **12** 917
Absolute risk
  logistic risk score, **9** 385
  radiation exposure analysis, **5** 539
  relative risk, **8** 641; **10** 1025, 1745
Accelerated cure model, **14** 2111
Accelerated failure time model, **11** 1871; **13** 2233
Accelerated life model, **8** 845
Acceptable upper limits, **9** 237
Accident and emergency
  medicine, **8** 1351
  services, **7** 1061
Accidents
  domestic, **8** 263
  injuries surveillance, **8** 388, 389
  motor-vehicles, **8** 757
  seat-belt systems study, **8** 379
  time series analysis, **8** 1497
Accuracy
  assay variability estimation, **10** 1543
  clinical trials, **9** 115, 125, 145
  diagnostic factors, **5** 503; **9** 559; **10** 1887
  indices ROC curves, **8** 1277
  interlaboratory studies, **10** 843
  measurement error, **8** 893
ACE algorithm, **10** 697
ACES *see* Active control equivalence studies
2-Acetylaminofluorene (2-AAF) low-dose response data, **12** 881
Acquired immunodeficiency syndrome *see* AIDS
Action potentials, neuron, **4** 91
Active control equivalence studies (ACES), **12** 2367
Adaptive rejection sampling, **11** 1443
Adaptive treatment allocation, **5** 211; **14** 231
Additive hazard models, **4** 353; **5** 539
Additive model
  breast cancer, **14** 267
  measurement error, **13** 1265
  unadjusted relative risk, **13** 1501
Additivity
  benefit/lead time effects, **13** 569
  drug, **4** 77; **13** 2289
  radiation effects, **14** 1941
Adjustment
  attributable risk, **11** 2083
  covariates, **6** 31, 255, 911
  rates, **6** 61, 193; **7** 223
  risk ratio, **5** 579
Adjuvant chemotherapy clinical trial, **12** 51
Admissions, psychiatric, **5** 243
Adverse effects
  drug reactions, **6** 863; **7** 1023, 1171; **12** 2383
  monitoring, **12** 2383; **15** 987
  treatment, **6** 745, 863
Aetiological factors, **2** 223
Affective illness, **7** 727
Age
  AIDS
    incubation, **13** 1975; **15** 2459

* Compiled by INDEXING SPECIALISTS, 202 Church Road, Hove, East Sussex, BN3 2DJ, U.K.

Age (*cont.*)
AIDS (*cont.*)
progression, **12** 2087, 2099
birth abnormality incidence, **14** 1797
cancer
competing mortality trials, **10** 65
incidence models, **13** 23; **15** 1003
children AIDS surveillance, **13** 2031
cohort studies, **10** 1043
community intervention studies, **10** 53
ecological variables, **13** 1755
epidemiologic study confounder, **12** 1989
hazardous exposure estimation, **10** 79
HIV incidence, **13** 1881
in vitro fertilization effects, **12** 1543
longitudinal studies, **13** 2219
median error, **10** 1313
radiation-dose risk, **10** 1511
standardized rates
generation effects, **3** 113
lung cancer, **7** 223
Monte Carlo study, **6** 61
mortality ratios, **3** 7
temporal variations, **6** 449, 469
visual acuity changes, **14** 257
Age-period-cohort model
autoregressive, **15** 273
cancer, **6** 449, 469; **13** 23
generation effects, **3** 113
HIV, **13** 1975; **14** 1513
lung cancer incidence, **15** 565
lung function decline, **7** 685
mortality, **6** 709; **14** 821
multistage model, **13** 23
predictive chemosensitivity assay, **5** 527
two time scales, **13** 823
Age-related reference centiles
child growth charts, **13** 2477
construction, **12** 917
significance, **13** 2359
Age-specific rates, **2** 455; **3** 7, 113; **4** 63, 201; **5** 573
AIDS incidence, **13** 1959
birth incidence, **14** 1797
confidence intervals, **14** 1875
hepatitis B transmission, **15** 2215
macular degeneration, **15** 2095
malaria incidence, **14** 2727
mortality maps, **14** 615
mortality rates, **13** 1119
postpartum disease risk, **15** 1545
sampling, **13** 2369
serological surveys, **15** 1567
survival curves, **14** 1731
weighted-ratio smoother, **15** 2539
Agency for Toxic Substances and Disease Registry *see* Centers for Disease Control and Prevention
Aggregation
data
clinical trials, **6** 733
dental caries, **6** 823
exposure effects, **15** 1849
mortality ratios, **6** 565
proportional hazards models, **7** 613
publication bias, **6** 11
disease clustering, **12** 1869
disease rates, **12** 1915
ecologic studies, **11** 1209
familial, **7** 185
minimum sample size, **11** 1767
Aggression preventative trials, **12** 289
Agranulocytosis, **15** 1535
Agreement
binary assessments, **12** 165
data, **8** 1199; **9** 559, 835, 1103
index majority, **4** 47
interobserver, **11** 101
intrinsic, **7** 639; **8** 1416–1417(L)
kappa statistic, **11** 1511
observer, **4** 47; **7** 639; **8** 1416–1417(L)
procedures, **13** 737; **14** 299, 2285–2288(L)
subjective ranking analysis, **11** 427–454
AIC *see* Akaike information criterion
Aickin's alpha reliability measures, **12** 2191
AIDS (Acquired immunodeficiency syndrome)
see also CD4 lymphocyte counts; HIV; Res. Application Conf.
age-specific incidence, **13** 1975
anonymous record linkage, **14** 499
back-calculation, **11** 831
back-projection, **13** 1865, 1945, 1959, 1991
binomial distribution uses, **5** 355
categorical response data, **8** 1209
clinical trials, **15** 2445
endpoint, **13** 2107
Europe, **12** 509, 521
surrogate markers, **13** 1423; **14** 2619–2620(L)
clustering trends, **12** 311
cohort studies, **10** 1993
contact tests, **5** 271
covariates induction time effect, **13** 2021
databases study, **10** 559
2',3'-Didanosine trial, **15** 2289
doubly-censored data, **11** 1569; **13** 2081
drug compliance, **13** 2141
dynamic model, **11** 1425
epidemic models, **8** 1–139
epidemiology methods, **9** 1387, 1417, 1433
Extended Public Health Surveillance of HIV Disease (workshop), **12** 2061–2130
haemophilia association, **8** 1509; **9** 681
health care implications, **8** 137
heterogeneous model, **8** 93
HIV testing rates, **15** 497
incidence, **8** 23, 103, 963, 1509

backcalculation, **13** 1975; **14** 1505, 1513
curve model, **12** 1317
data, **13** 1865; **14** 27
projection, **11** 1633
incubation, **13** 1959; **15** 2459, 2669
incubation model, **7** 395; **10** 1733
incubation period distribution, **13** 969
incubation time estimation, **11** 939
infection study, **8** 45, 83
infection trends, **15** 1779
interval-censored failure time, **15** 1387
intervention
effectiveness, **13** 2127
study methods, **13** 2107–2187
trials, **14** 1177
Kaposi's sarcoma, **15** 1171
longitudinal studies, **14** 1205; **15** 2359, 2367
marker-dependent hazard estimation, **12** 843
markers, diagnosis time, **13** 2059
Markov model analysis, **8** 831
mean-squared error estimates, **10** 1167
monitoring models, **8** 3
multiple decrement models, **15** 2307
multiple imputation methods, **10** 585
multiple reading procedures, **7** 549
non-compliance, **15** 2475
non-parametric analysis, **13** 2043
non-parametric estimation, **13** 2081
pathogenesis model, **13** 2067
PCP trial, **15** 2341
perinatally acquired latency, **13** 2031
play the winner, **15** 2413
predictive diagnostics, **15** 2149
prevention models, **8** 59
prevention trials, **13** 955
projection methods, **10** 1527
public health modelling, **13** 1933
registries, **11** 345
reporting delay, **8** 259, 963; **15** 305
risk, variable infectivity, **10** 131
robust Bayesian monitoring, **15** 1093
sample size estimation, **10** 1993
screening tests, **8** 1225; **13** 1905
seroconversion times estimation, **9** 505; **11** 591
sexual partners distribution, **15** 221
short-term influences, **13** 1921
spread, **5** 271; **8** 103, 121
Statistical Issues in HIV/AIDS Research Symposium, **15** 2269–2491
stochastic processes, **10** 1427
surrogate endpoints, **12** 835
surveillance, **13** 1905, 1921
survival endpoint information, **13** 1747
survival function, **10** 413
therapies observational data, **15** 2273
TIGER/S, **12** 1953
transfusion-related data, **13** 2043
treatment changes, **15** 2425
Air pollution, **8** 1139, 1149; **15** 823
AIS *see* Abbreviated injury scale
Aitken acceleration technique multivariate, **12** 1665
Akaike information criterion
birthweight, **15** 1333
blood pressure measurements, **11** 1187
correspondence analysis, **13** 2407
Cox regression, **13** 2427
cross-validation, **12** 2305
dog triglyceride data, **15** 1695
mortality ratios, **10** 1043
neural network model, **14** 73
non-nested regression models, **11** 1321
normal ranges, **5** 335
Akritas test, **11** 193
Alarms statistical surveillance, **11** 1489
Alaska infant mortality, **14** 481
Alcohol, **7** 1223
consumption
birth defects, **15** 2095
measurement error models, **15** 293
measurement error models, **12** 1141
myocardial infarction risk, **12** 2333
Alcoholic pancreatitis, **4** 303
Alcoholism
disulfiram, **15** 1421
sleep patterns study, **9** 811
Alert systems post-marketing surveillance, **12** 2383
Algorithms
see also Expectation maximization algorithm; Markov Chain Monte Carlo algorithm
ACE, **10** 697
acute myocardial infarction, **9** 125, 145
ALLVALUE, **8** 217
anonymous record linkage, **14** 499
AUTOMATCH, **14** 491
automatic classification, **3** 261
clinical trials simulator, **9** 787
cluster analysis, **15** 817
complete cases, **8** 217
contiguity algorithm, **15** 1885
crossover trials, **15** 1435
data augmentation, **15** 2161
DEMP, **15** 1837
disease rates, **12** 1915
Dorfman-Alf, **9** 325
ECM, **14** 747
EMS, **13** 1865
epidemiological methods, **8** 189
Fisher scoring, **9** 1175, 1517
geographical density estimates, **9** 691
grouping contiguous zones, **5** 171
ISS, **15** 933
maximum likelihood estimators, **15** 919
Metropolis-Hastings, **15** 1757
mortality rates estimation, **9** 1199
multiple imputation, **9** 505
Newton scoring algorithm, **15** 823

Algorithms (*cont.*)
Newton-Raphson, **13** 609, 651
ovulation estimation, **10** 255
principle curves, **13** 1101
PulseFit, **10** 329
quasi-Newton, **9** 681
recursive partitioning, **8** 947
robust non-linear bioassay analysis, **12** 2025
run-in strategy, **12** 111
SECM, **14** 747
stepwise, **10** 711
survival data, **8** 947
transformation, **7** 491
tree-structured, **8** 947
Alleles disease, **5** 281
Allocation methods
adaptive, **3** 45; **5** 211
balancing
adaptive assignment comparison, **14** 231
cost per sample differences, **9** 1475
efficiency, **9** 943
modified replacement randomization, **6** 127
otitis media study, **9** 237
prognostic factors, **3** 219
case-control studies, **9** 1475
clinical trials, **10** 1679, 1789; **14** 2661; **15** 113–116(L)
designs, **4** 497; **5** 319; **7** 471
methodology review, **4** 129
optimal sample allocation, **15** 2523
play the winner, **15** 2135, 2413
randomized clinical trials, **6** 127, 241
sample size estimation, **6** 577; **7** 559
sequential procedures, **5** 211
survival analysis, **6** 119
unbalanced, **14** 901, 909
Allocation ratio sample size calculations, **12** 2257
Allocation rules, **2** 95; **7** 525
ALLVALUE algorithm, **8** 217
Alpha spending function, **15** 1739
Alpha statistic *see* Aickin's alpha; Cronbach's alpha
Alpha-fetoprotein, **8** 391
Alpha-interferon clinical trial, **13** 2249
Alternative medicine, **6** 761
Alzheimer's disease, **10** 1711; **14** 1353; **15** 1023
Ambulatory blood pressure monitoring clinical trial, **12** 1665
American Statistical Association, **9** 863; **11** 1797–2040
Amersham model, **5** 183
Among-class variation
cluster number estimation, **11** 751
crossover trials, **11** 727
Amosite miners, **7** 955
Anaemia, **2** 223; **6** 689
Anaesthesia, **7** 947
interrater reliability, **9** 1103
prediction accuracy, **15** 1199
Analgesics
binary data model, **6** 555
clinical trials, **3** 273; **5** 15
crossover trials, **6** 555
regression models, **7** 435
therapy efficacy evaluation, **6** 657
treatment effects estimation, **7** 1179
Analysis as-randomized non-adherence, **12** 1185
Analysis of covariance, **15** 477
ANOVA comparisons, **3** 85
background data use, **1** 281
baseline balance test, **13** 1715
baseline measurements, **8** 1339
clinical trials, **8** 467; **10** 797–799(L), 1157–1159(L)
conditional size/covariate imbalance, **12** 101
crossover trials, **6** 911; **10** 1361
intra-individual variation, **13** 2280–2285(L); **14** 2283–2285(L)
measurement error models, **8** 1075
ranked data, **13** 261
repeated measures, **11** 1685
survival analysis, **9** 293; **14** 735
toxiology studies, **3** 85
weighted least squares, **11** 1843
Analysis of variance
ANCOVA comparisons, **3** 85
assay variability estimation, **10** 1543
balanced incomplete blocks design, **13** 11
bioequivalence, **15** 2635
changeover designs, **7** 471
clinical trials, **10** 1595; **13** 2393
coronary heart disease, **12** 967
crossover trials, **10** 1099, 1361
design effect determination, **10** 53
factorial analysis, **10** 1565
field trials, **13** 61
Fisher's random allocation, **13** 217
Friedman test, **4** 145; **5** 199–200(L)
hospital mortality variation, **13** 1001
influential observations, **13** 1211
intraclass correlations, **11** 1607; **13** 2465
intracluster correlation estimator, **13** 1253
Kalamazoo trial data, **13** 785
mean smoking rates, **12** 329
measurement error, **8** 893
model misspecification, **14** 1693
multiple comparison procedures, **10** 1
ordinal scores, **8** 785
random effects model, **4** 145
repeated crossover design, **14** 1067, 1079
repeated measures
crossover trials, **6** 911
diagnostic tests, **6** 441
GEE approach, **11** 1033
latent class model, **11** 2111
longitudinal studies, **6** 599
mixture models, **14** 747

quasi *t*-quantile, **13** 1657
reliability studies, **6** 647
ROC curves, **8** 1277; **15** 1807
sample size estimation, **7** 467; **10** 33
toxiology studies, **3** 85
univariate analysis, **9** 437, 819
visual analogue scale, **12** 1275
Ancillary risk factors, **11** 1443
ANCOVA *see* Analysis of covariance
Anderson-Darling test, **11** 897
Angina pectoris
crossover studies, **10** 1099
logistic regression power, **7** 519
prescription event monitoring, **15** 987
survival analysis, **9** 293
Angioedema, **9** 893
Angiography, **4** 53; **5** 593; **12** 1155
Angle chart quality control, **6** 425
Angle transformation, **7** 865
Animal tumours, **1** 83
Ankylosing spondylitis study, **2** 79; **5** 539
Anonymous record linkage AIDS, **14** 499
ANOVA *see* Analysis of variance
Anthropometry, **4** 379; **11** 1289
Anti-inflammatory drugs, **5** 449
Antiarrhythmic drugs, **2** 331; **8** 1393
Antibiotics, **5** 449
Antibody response, **2** 447
Anticonvulsants, **4** 77
Antidepressants, **7** 1171
Antiepileptic drug trial, **8** 1327
Antigens, **2** 79; **5** 281; **7** 443; **10** 1775
Antimicrobial agents, **6** 91; **7** 535, 745; **12** 301
Antimicrobic susceptibility test, **7** 535
Antiretroviral therapy
AIDS intervention, **13** 2107, 2127
effect on CD4 counts, **12** 2133
APC *see* Age-period-cohort model
Approximate optimal design, **9** 237
Arcsine transformation, **7** 865; **12** 809
ARE *see* Asymptotic relative efficiency
Area based data environmental epidemiology, **12** 1249
Area between curves (ABC), **11** 1289; **12** 2247–2248(L)
Area under curves (AUC)
bioequivalence, **15** 2635
clinical pharmacology studies, **12** 633
plasma concentration, **11** 1333
Argentina breast cancer mortality, **15** 741
ARIMA *see* Autoregressive integrated moving averages
Arjas plot, **12** 1569
ARL *see* Average run length
ARMA, **5** 593; **6** 167; **7** 29, 357, 1045, 1061
Armitage, Professor Peter
AIDS development model, **9** 681
bibliography, **9** 709
clinical trials, **9** 595, 601, 657, 703
multistage model, **9** 677
personal addendum, **9** 591
personal recollection, **9** 673
pock count variability, **9** 615
Armitage-Doll multistage model, **9** 677
age effect on cancer, **13** 23; **15** 1003
lung cancer incidence, **15** 565
Arrhythmias, **8** 1393; **11** 963
Artefacts EEG readings, **10** 1719
Arteriography, **5** 619; **8** 1291
Artery stenosis, **8** 1291
Arthritis, **15** 537
psoriatic, **7** 443
registry, **11** 345
treatment side effects study, **9** 803
Artificial intelligence, **4** 317; **5** 497
Artificial nesting regression equations, **11** 1321
ASA *see* American Statistical Association
Asbestos, **7** 955
Ascertainment process
genetic epidemiology, **5** 291
pedigree analysis bias, **4** 163
twin studies bias, **6** 961
Aspartame headaches, **12** 825
Aspirin
cardiovascular disease prevention, **4** 111
interstudy differences, **6** 351
myocardial infarction study, **6** 255, 351
Assays
dilution, **7** 535
direct, **6** 583
drug, **7** 805
leukaemia therapy study, **14** 1081, 1097
linear homoscedastic, **14** 1949
parallel-line, **5** 363
predictive chemosensitivity, **4** 527
recombinant proteins, **13** 1165
virus neutralization, **11** 1253
Assessment
medical care, **3** 353
pain, **5** 15
risk, **5** 49
Assigned share *see* Attributable risk
Association
agreement data analysis, **8** 1199
case-control studies, **15** 2603
confounding sample size effects, **9** 765
contingency tables, **10** 1555
distribution-free estimators, **11** 1151
geographical correlations, **9** 515
measurement, **7** 591; **8** 619, 765(L), 766(L)
models, **14** 413; **15** 1227–1229(L)
paired binary data regression, **9** 1517
prediction accuracy, **15** 1199
row and column effects model, **5** 15
tests, **7** 257, 443, 1297

Assortative mixing HIV epidemic dynamics, **11** 1657
Asthma
  crossover trials, **10** 1115, 1361
  falsification issue, **10** 1679
  misclassification, **10** 1181
  multicentre clinical trials, **12** 1033, 1047
  parallel trial balance concepts, **13** 1715
  preference trial, **15** 443
  rank tests, **4** 145
  therapy evaluation, **3** 45
  treatments, **8** 1183, 1339
Asymmetric least squares percentile regression, **14** 777
Asymmetry measures skewness & kurtosis, **11** 333
Asymptomatic Cardiac Ischemia Pilot study, **13** 859
Asymptotes longitudinal data, **15** 61
Asymptotic bias, **12** 1213
Asymptotic confidence intervals, **12** 91–94(L)
Asymptotic covariance formulae, **13** 1265
Asymptotic distribution theory, **14** 2273
Asymptotic maximum likelihood methods, **12** 617
Asymptotic normal distribution, **12** 3
Asymptotic normality, **12** 2009
Asymptotic relative efficiency, **8** 1515; **13** 479; **14** 1307
Asymptotic standard errors, **13** 113
Asymptotic test coefficients of variation, **15** 647
Asymptotic theory
  multiple test procedures, **11** 511
  optimal sample size determination, **11** 547
Atenolol, **7** 697
Atherosclerosis
  carotid artery measurement, **11** 1041
  risk in communities study, **13** 663
Atrial Pacing, **7** 109
ATSDR symposia *see* Centers for Disease Control and Prevention
Attenuation
  dietary assessment, **12** 925
  estimates correction, **13** 1265
  measurement error
    colon cancer study, **8** 1151, 1165
    covariance analysis, **8** 1075
    dietary assessment, **12** 937
    linear regression, **14** 789
    non-differential exposure, **8** 1031
    time to response data, **8** 1167, 1179
Attributable fractions, **15** 1519
  estimates, **13** 2345
Attributable risk
  see also Relative risk; Risk
  adjusted estimators, **11** 2083
  adjustment methods, **10** 1753
  assigned share, **12** 94–96(L)
  bias estimation, **3** 131; **7** 1073
  case-control studies, **12** 91–94(L)
  confidence intervals, **7** 507
  Cox proportional hazards model, **8** 525
  cross-sectional studies, **14** 51
  epidemiology, **10** 1819
  estimation bias, **14** 1331
  estimation methods, **1** 229; **7** 507; **8** 845
  extrapolation method, **7** 717
  inverse sampling, **14** 2051
  logistic regression, **8** 525
  misclassification, **7** 1073
  variance estimators, **6** 701
Attribute analysis decision trees, **9** 1229
Attrition
  bias regression models, **12** 1005
  longitudinal studies, **14** 283
  patient longitudinal data, **11** 2029
Audit data Bayesian analysis, **12** 2179
Australia
  AIDS incidence data, **13** 1865
  methadone programme, **15** 2253
Autocorrelation
  see also Spatial autocorrelation
  autoregressive models, **8** 1523
  bias correction, **7** 417
  blood pressure study, **7** 423
  Box-Jenkins models
    forecasting factors, **7** 1061
    heart rate analysis, **6** 159
    infectious disease study, **5** 37
    threshold construction study, **10** 1493
    time series analyses, **5** 593; **7** 1045; **8** 353, 1497
  death analysis, **6** 159
  dietary intake, **13** 113
  disease models, **5** 37
  epidemiology, **5** 171
  field trials, **13** 61
  forecasting factors, **7** 1061
  heart rate analysis, **6** 159
  hypothesis testing, **6** 689; **8** 517–519(L)
  longitudinal data, **8** 1523; **11** 1929
  mortality, **7** 1045
  non-linear models, **6** 167
  repeated measures models, **13** 1643
  sickle cell anaemia, **6** 689
  spatial data, **9** 515; **13** 1037; **14** 2343
  time series analyses, **5** 593; **6** 167; **7** 106, 1045; **8** 1497
  time-dependent variables, **6** 689; **8** 517–519(L)
  two-parameter HIV infection markers, **12** 2133
  visual assessment, **12** 1275
AUTOMATCH Record Linkage System algorithm, **14** 491
Automated comparison data verification, **12** 1535
Automobile studies, **8** 379, 757, 1497
Autoregression
  see also Regression
  BP tracking correlations, **11** 1187

errors, **11** 1929
moving average, **11** 1409, 1929
steady state departures, **11** 515
time series regression relationships, **12** 1555
tumour biomarker data, **12** 265
Autoregressive integrated moving average models
Box-Jenkins approach
forecasting, **7** 1061
heart rate analysis, **6** 159
infectious disease study, **5** 37
threshold construction, **10** 1493
time series analysis, **5** 593; **7** 1045; **8** 353, 1497
EEG artefacts detection, **10** 1719
gonorrhea study, **8** 343
mortality rates, **8** 335
time series analyses
injury study, **8** 1497
respiratory diseases, **10** 1481
syphilis surveillance, **8** 353
threshold construction, **10** 1493
Autoregressive models
age-period-cohort, **15** 273
bias correction, **7** 417
blood pressure study, **7** 423
Box-Jenkins approach, **5** 37
covariance matrix, **14** 1397
discrete time, **13** 1643
forecasting factors, **7** 1061
growth curve models, **7** 73
infectious diseases surveillance, **5** 37
longitudinal data, **7** 19, 59, 161, 177; **8** 1523
lung function tests, **7** 29
missing data analysis, **7** 59, 317, 357
mortality, **7** 239, 293, 1045
prior failure rates, **13** 823
pulmonary function, **7** 19, 29, 59
repeated measurement analysis, **7** 29, 87
respiratory function, **14** 2205
time series analyses
Box-Jenkins study, **5** 37
computer tomography impact, **5** 593
correction estimation, **1** 49
forecasting factors, **7** 1061
longitudinal data, **4** 457; **8** 1523; **10** 492–495(L)
mortality, **7** 239, 293, 1045
Autosomal recessive diseases, **9** 573
Auxiliary endpoint variables clinical trials, **13** 955
Average bioequivalence, **12** 1109
Average run length (ARL) surveillance, **11** 1489; **12** 13
Axial symmetry, **5** 199(L), 200(L)
Azathioprine, **7** 629
AZT (Zidovudine)
AIDS mortality, **15** 2273
CD4 lymphocyte counts, **15** 75
HIV incubation distributions, **15** 197
HIV transmission, **15** 2413
HIV treatment
beta-squared-M, **12** 2087
CD4 counts, **12** 2065, 2099, 2133
changes, **15** 2053
IgA, **12** 2099
surrogate endpoints, **12** 835

Baby unit intensive care, **7** 1207
Bacchetti method HIV incubation, **15** 197
Bacille Calmette-Guérin (BCG), **1** 329; **3** 325; **14** 395; **15** 1465
Back injury intervention trial, **15** 1951
Back-projection
AIDS incidence data, **13** 1865, 1945, 1975
auxiliary data AIDS cases, **13** 1959
German AIDS data, **13** 1991
HIV incidence, **15** 513
HIV testing rates, **15** 497
Backcalculation
AIDS incidence, **11** 1633; **14** 1505, 1513
AIDS projection, **8** 23
HIV infection rates, **15** 2669
HIV to AIDS progression, **12** 617
stage-specific numbers, **11** 831
Backward elimination, **11** 2093
Bailey-Makeham model, **10** 521
Balaam's crossover design, **11** 1967; **12** 69
Balanced allocation methods
case-control studies, **7** 1475
changeover designs, **7** 471
intervention studies, **9** 943
otitis media study, **9** 237
randomized clinical trials, **6** 127, 241; **13** 1715; **14** 231
review, **4** 129
sample size calculation methods, **6** 577
sequential procedures, **5** 211
survival trials, **6** 119
Balanced covariate clinical trials, **7** 1243
Balanced incomplete blocks design, **13** 11
Balancing score clinical trial drop-outs, **11** 2043
Banded model
BP tracking correlations, **11** 1187
longitudinal data, **11** 2033
Bandwidths cluster analysis, **14** 2335
Barthel index, **12** 1063
Bartholomew's test, **4** 489
Bartlett's correction, **7** 387; **8** 1415–1416(L)
Barton method cluster analysis, **15** 943
Base comparison logit models, **3** 273; **5** 15
Baseline covariate model, **11** 1731
Baseline hazard function, **13** 2233; **14** 2119
Baseline measurements
adjustment methods, **8** 1183; **11** 1624–1626(L)
censored data, **15** 953
clinical trials, **8** 1339
cluster analysis, **15** 807

Baseline measurements (*cont.*)
comparisons, **10** 797–799(L), 1157–1159(L)
crossover trials, **10** 1361; **11** 727; **14** 1025, 1053
data collection methods, **9** 103
databases methodology, **10** 617
HIV infection models, **9** 721
homogeneity test, **13** 1715
intervention trials, **9** 943; **14** 1177
meta-analytic monitoring, **15** 1273
misclassification, **10** 361
missing covariate values, **13** 301
placebo effect, **7** 1203(L)
regression towards the mean, **12** 1086–1089(L)
risk factors, **11** 783
sampling design, **10** 1945
two-period crossover design, **15** 117
Baseline period clinical trials, **5** 231
Batch-to-batch variation, **8** 883, 893
Bayesian inference
see also Bayesian monitoring scheme; Empirical Bayes; Full Bayes; Hierarchical Bayes
age-period-cohort models, **15** 273
AIDS epidemic, **8** 45
binary data, **12** 2179
bioequivalence, **10** 961; **11** 1777
biopharmaceutical research, **10** 811
bivariate survival data, **14** 2523
calibration, **13** 1165
cancer screening, **12** 1197
cancer study, **4** 201; **10** 95, 1241
case-control studies, **5** 261; **7** 1223; **8** 1023–1024(L)
CD4 lymphocyte counts, **15** 75
change-point process, **10** 221, 1159–1160(L)
CHART trials, **13** 1297
clinical epidemiology, **14** 1263(L)
clinical trials
cancer, **11** 1–53
causal efficacy, **12** 1477
cost-effectivity, **14** 2249
exclusion criterion, **1** 261
group sequential designs, **14** 381
methodology review, **10** 1789
monitoring, **14** 357, 747, 1057, 1065, 1379
optimal designs, **4** 497
phase I, **11** 1377
prediction evaluation, **5** 421
reporting, **12** 1651
sample size estimation, **5** 1
small trials, **14** 115
stopping rules, **7** 1231
competing risks analysis, **15** 1557
confidence intervals, **9** 657; **10** 443
contingency tables, **10** 991
continual reassessment method, **12** 1093; **13** 1799; **14** 1149
correspondence analysis, **8** 1351
databases methodology, **10** 617
decision analysis, **9** 1229
descriptive data analysis, **10** 777
diagnosis, **6** 353, 805; **7** 1289; **8** 609, 1351
disease mapping, **12** 1895; **14** 2411, 2487
disease prevalence estimation, **8** 1225
disease risk analysis, **11** 1443
dose determination, **10** 1647; **14** 885, 897
early stopping, **13** 1313
empirical models, **7** 697; **8** 3, 173, 189; **10** 811
epidemiology bibliography, **10** 1819
frequentism, **12** 1405
gene location, **13** 839
growth curve, **11** 2001
hazard regression, **15** 1757
Hib bacteria transmission, **15** 2235
hierarchical models
binary response data, **9** 919
bivariate survival data, **14** 2523
childhood leukaemia incidence, **14** 2487
decision making, **14** 2173
disease maps, **14** 2411
dose recommendation, **14** 971
prediction, **14** 2173
repeated measures experiments, **13** 1841
HIV epidemic data, **13** 2009
HIV infection model, **8** 45
incomplete administrative lists, **10** 113
independence models, **5** 497, 503; **6** 805, 945; **8** 1351
information criterion, **15** 1333
interim analysis, **4** 521; **10** 925
iodine thyroid kinetics estimation, **13** 185
latent class analysis, **9** 559
LD50 bioassay, **14** 841
logistic regression, **9** 1091
longitudinal data, **11** 1809, 1825, 1965–2023; **14** 1205
lung function comparisons, **8** 861
maximum penalized likelihood estimate, **13** 969
measurement error, **12** 1141, 1703
medical follow-up data, **4** 509
meta-analysis, **11** 141; **14** 137, 2685; **15** 2733
mixture survival model, **15** 2077
mortality rates, **4** 201; **10** 95
multiple comparison, **10** 1; **11** 863
multiple imputation methods, **9** 505; **10** 585
multiple tests sensitivity, **8** 1231
NHLBI clinical trials, **9** 881, 903
osteosarcoma study, **12** 1501
phase II trials, **13** 417
pooling controls, **10** 1417
population risk, **15** 1713
pre-eclampsia studies, **15** 1237
predictive values, **15** 463
prevalence, **15** 2161
prevalence estimates, **11** 1621–1622(L)
prior information, **12** 2009
random effects model, **8** 189

randomization, **13** 217
relative risk estimation, **11** 983
repeated events analysis, **10** 1227
replication probability, **11** 875
sample sizes, **13** 2493
smoothing procedures, **14** 1205
space-time disease patterns, **14** 2433
subjective/frequentist probabilities, **13** 1699
survival multiple time scales, **13** 823
time series analysis diseases, **10** 1481
training, **14** 199
treatment evaluation, **7** 697
trial monitoring, **13** 1371
two-by-two tables, **13** 1525
two-period crossover design, **13** 905, 2531
vaccine efficacy, **15** 2379
variance components study, **10** 599
Bayesian monitoring scheme, **13** 1371; **15** 1093
bioequivalence, **14** 1057, 1065
mixture models, **14** 747
robust methods, **14** 1379
toxicity studies, **13** 2311
BCG *see* Bacille Calmette-Guérin
Behaviour
efficacy, **13** 357
frailty model, **13** 1679
HIV risk, **15** 2323, 2337
time-to-pregnancy, **13** 671
Behaviour time-to-pregnancy study, **13** 671
Behrens-Fisher problem, **13** 1657
Benefit time estimation, **13** 569
Berkson models, **7** 257, 289, 297; **8** 1075; **12** 1703
Bernoulli model
in vitro fertilization, **12** 1543
interval censored data, **15** 283
Bernoulli variables, **11** 923; **12** 143
binary regression, **12** 1141
Besag and Newell's test cluster analysis, **14** 2291, 2309; **15** 727, 765
Beta distribution
Bayesian analysis, **7** 1223
clustered binary responses, **13** 1241
contingency tables, **10** 991
HIV transmission study, **8** 93
medical audit, **12** 2179
multiple tests, **7** 1031; **8** 1231
new treatment success rate, **13** 2493
phase II clinical trials analysis, **10** 989
power loss investigation, **7** 457
regression analysis, **8** 1363
Beta imputation threshold-crossing data, **12** 1589
Beta-binomial model, **6** 491; **8** 1363
correlated binomial variates, **11** 1607
longitudinal data, **11** 1915
low-dose response data, **12** 881
Beta-blockers
clinical trials, **3** 409
heart attack trial, **3** 445; **6** 753; **8** 1191; **10** 925; **12** 2219; **13** 1341
meta-analyses, **6** 315, 733
myocardial infarction, **11** 141
randomized trials, **6** 233, 281, 305
Beta-geometric model
retrospective time-to-event studies, **12** 867
time-to-pregnancy study, **13** 671
Beta2-microglobulin HIV infection marker, **12** 843, 2061, 2065, 2087, 2099, 2133
Betacarotene cancer study, **4** 111
Betrend model, **7** 185
Between-group difference intra-individual variation, **12** 1213
Between-patient variation non-nested regression models, **11** 1321
Bias
see also Publication bias
across-wave imputation, **12** 355
adverse drug reactions, **12** 2383
age-related mortality trials, **10** 65
AIDS estimates, **10** 1167
ascertainment, **4** 163; **6** 961
assay variability estimation, **10** 1543
attrition, **12** 1005
back injury intervention trial, **15** 1951
Bayesian methods, **10** 811
bioequivalence, **11** 1777; **14** 853
calibration curve, **5** 183
case-control studies, **10** 653; **14** 769
case-crossover designs, **12** 2333
CD4 lymphocyte counts, **13** 1101; **14** 1889
clinical trials, **9** 193, 657; **10** 1789; **11** 2043; **12** 2343
cohort studies, **2** 25
coin designs, **5** 211
common odds ratio estimators, **14** 1567
confidence interval estimation, **13** 1071
confounding, **3** 131
contingency table estimators, **8** 987
correction, **2** 71; **4** 243–245(L), 437
covariate imbalance, **10** 797–799(L), 1157–1159(L)
crossover trials
censored data, **15** 953
degrees of freedom, **10** 1361
failure time data, **10** 1099
phase III, **14** 1025, 1053
residual effects, **10** 891
data quality comparisons, **8** 367
data reanalysis, **8** 653–677
databases analyses, **10** 511, 541, 629
deaths expected number, **5** 327
density equalisation, **15** 1837
detection, **8** 1095; **13** 2219
diagnostic tests, **8** 609; **10** 1887
differential recall bias, **15** 2603
dose escalation studies, **15** 1605

Bias (*cont.*)
dose-response evaluation, **14** 987, 1007, 1595
double-blind clinical trials, **15** 1747
dropout, **7** 29
drugs effects study, **10** 577
dual frame design, **14** 571
ecologic studies, **11** 1209; **14** 327–330(L)
efficacy estimate, **10** 45; **13** 357
epidemiology bibliography, **10** 1819
error linear models, **10** 1197
estimation method, **7** 1231, 1243
failure times, **15** 2475
generalized linear models, **10** 1069
guidelines, **14** 1655, 1659
hazard ratio estimation, **9** 1167; **10** 749
historical control study, **10** 839
HIV study, **10** 423, 1167
interim analysis, **10** 925
kappa estimation, **10** 1303, 1465; **15** 1409
lead-time, **2** 279; **6** 885
length, **2** 279; **6** 885; **7** 395; **8** 1255
limited failure population model, **9** 409
linear model estimation, **15** 1647
logistic regression, **2** 71; **4** 243–245(L), 437; **14** 1437
longitudinal studies, **11** 1825; **14** 283
matched designs, **12** 993
maximum likelihood, **10** 723; **13** 177
measurement error, **8** 893, 1031
median age calculation, **10** 1313
menstruation study, **14** 1843
meta-analyses
clinical trials, **6** 733
cohort design, **6** 11
dose-response relationships, **14** 545
mortality rates, **6** 565
problems, **10** 971
research synthesis, **15** 1253
method comparison studies, **10** 981
misclassification
categorical data, **8** 1095
epidemiology, **10** 361
vaccine studies, **9** 1327
misreports population data, **10** 191
misselection subsampling, **9** 1339
missing data, **9** 777; **14** 2675; **15** 127
model misspecification, **14** 1693
multiple reports methods, **8** 1041
non-adherence, **12** 1185
normal reference ranges, **10** 691
observational data, **15** 2273
observers, **8** 893
odds ratio, **9** 1131; **10** 1273
omitted variables, **11** 1195
one-step (Peto) method, **9** 247
order statistics study, **10** 855
ordinary least squares, **12** 1213
overdiagnosis, **2** 279
paired availability design, **13** 2269
passive follow-up registries, **12** 767
phase II clinical trials, **9** 215
pooling, **13** 1089
population risk, **15** 1713
prediction, **7** 843
preference factor, **8** 477
prescription event monitoring, **15** 987
proportional measurement errors, **9** 1463
random-digit dialling surveys, **11** 1009
randomized clinical trials, **10** 1595
reference test, **4** 53
regression model, **10** 637
relative odds estimation, **11** 953
relative risk estimates, **8** 1071
repeated measures, **11** 1685
response to treatment, **15** 2797
retrospective studies, **12** 867
review diagnostic test, **6** 411
risk adjustment methods, **10** 1753
risk scores, **14** 1331
sample proportions, **8** 563
sample size, **10** 151–153(L), 1993; **15** 1587
scaling measurement error, **12** 937
scoring systems, **8** 415
SCPRT, **15** 2037
screening effectiveness studies, **9** 969
selection, **13** 557
blood pressure study, **7** 417, 423
cancer study, **6** 389
diagnostic tests, **4** 53
heart disease surveillance, **4** 53
historical control studies, **3** 225, 315
meta-analyses, **6** 245, 315; **7** 1207
placebo effect, **7** 1203(L); **8** 1301–1302(L)
pooling clinical trials, **6** 389
psychiatry study, **7** 727
randomized trials, **6** 127, 251, 389
screening tests, **4** 53
single consent designs, **3** 215
survival analysis, **7** 1207
treatment effects, **7** 1179; **8** 477
variance estimation, **7** 417
sequential monitoring, **14** 1927
smoking habits misclassification, **15** 581
smoothing geographical data, **15** 2539
Spearman-Karber statistic, **14** 841
SSPE risk estimation, **10** 1733
surgery innovations evaluation, **8** 455
survival analysis, **9** 293, 1259; **15** 2797
susceptibility, **3** 341
therapy evaluation, **8** 441; **10** 647
time to response, **3** 35
time-to-pregnancy study, **13** 671, 683
treatment changes, **15** 2069
treatments comparison, **10** 663
unpublished studies, **15** 2493
vaccine efficacy estimation, **10** 1573

validation group, **4** 53
variance components study, **10** 599, 1441
verification, **6** 411
predictive values, **13** 1737
withdrawal, **7** 941; **8** 1302–1303(L)
Yates's continuity correction, **9** 363–383
Biased coin design (BCD), **12** 2343
Bibliographies
Armitage, P., **9** 709
clinical trials methodology, **10** 1789
correlated categorical data, **11** 67
epidemiology statistical models, **10** 1819
Hill, A. B., **1** 369; **12** 797
Newell, D., **14** 223
Big stick design, **12** 2343
Bile acids, serum, **6** 147
Bilirubin, serum, **7** 629
Bimodality, **2** 253
Binary data
analysis of variance, **11** 1033
Bayesian analysis, **12** 2179
chance-correlated agreement measures, **12** 2191
diagnostic consensus, **11** 317
dysplasia study, **12** 165
independent diagnostic classifications, **15** 1377
longitudinal, **11** 1915, 1981
menstrual diary data, **12** 955
random effects meta-analysis, **15** 2733
stochastic model, **15** 2617
survival curve representation, **11** 455
Binary occupancy models disease clusters, **12** 1773
Binary regression
continuous outcomes, **14** 247
design effects, **12** 1259
exact logistic, **14** 2143
Binary response
case-crossover designs, **12** 2333
cluster number estimation, **11** 751
correlated categorical data, **11** 67
cumulative sums, **11** 1115
low-dose response, **12** 881
Binary test regret graphs, **15** 969
Binary time-dependent covariates Cox proportional hazards model, **15** 2589
Binary variables, **13** 101
association, **8** 619; **14** 413; **15** 1227–1229(L)
attributable risk adjustment, **10** 1753
Bayesian analysis, **9** 1091
case-base studies, **8** 1241
chi-squared adjustment, **10** 1981
clinical trials, **4** 497; **7** 571; **8** 563
confidence intervals, **7** 773, 1267
contingency tables, **7** 1297
correlation in large groups, **15** 1187
crossover trials, **6** 555
diabetes, **7** 671
dose-response evaluation, **7** 955
epidemology, **7** 955
equivalence trials, **7** 1267
estimators comparison, **10** 723
exact logistic regression, **14** 2143
exposure factors, **7** 773, 955, 1073
hierarchical models, **9** 919
homogeneity tests, **10** 1257
independence testing, **7** 1297
interactions, **7** 1257
latent variable models, **7** 975
liver function study, **7** 671, 843
measurement-error model, **8** 1139, 1149
meta-analyses, **10** 1665
missing data, **7** 929
multiple treatments comparisons, **14** 2509
multivariate probit analysis, **10** 1391
optimal design clinical trials, **4** 497
P-values, **7** 1297
paired data regression methods, **9** 1517
parallel-group design, **7** 1187
partitioning methods, **5** 517
phase II clinical trials, **9** 215; **10** 1327
placebo effect, **7** 1187
power, **7** 457
prognostic factors, **7** 843
random effects model, **10** 901
recurrent conditions trial, **8** 1439
relative risk estimation, **10** 1745
repeated measurement analysis, **10** 1959
sequential phase II/III trials, **9** 229
side effects incidence model, **9** 803
survival, **9** 487, 1157
titration study, **10** 323
treatment efficacy, **7** 1267
two-stage trials, **7** 571
ulcer study, **7** 1187
Yates's continuity correction, **9** 363–383
Binocular data kappa estimation, **12** 2207
Binomial distribution, **15** 1867
AIDS study, **5** 355
change-point tests, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
comparative studies, **10** 1137
confidence intervals, **10** 443; **12** 809
mortality rates error, **9** 1199
multiple treatments comparisons, **14** 2509
negative, **6** 823; **14** 1471
P-value power gains, **8** 1469
pair-matched studies, **12** 699
pooling controls, **10** 1417
power evaluation, **8** 1469
prevalence estimation, **12** 685
relative risk, **12** 2285
response correlation, **12** 355
surveillance system tests, **8** 311
two-treatment crossover design, **12** 825
variation factors, **6** 491

Binomial model
correlated variates, **11** 1607
mark-recapture model, **11** 1533
recurrence rates, **12** 339
Binomial trials, **9** 1447; **10** 405, 1137; **11** 913
Binormal model ROC analysis, **15** 1575
Bioassays
LD50 design, **14** 841
robust non-linear analysis algorithm, **12** 2025
toxicity procedures Markov chain modelling, **12** 661
Bioavailability, **9** 549; **10** 961, 1375
75/75 rule, **11** 1333
bioequivalence, **11** 1777; **12** 1109
direct formulation effect, **11** 881
dose-response relationship, **11** 683
Biochemical data optimal checking procedures, **11** 1343
Biochemical markers, **5** 547
Bioequivalence, **5** 203; **9** 549; **10** 959, 961, 1375
75/75 rule, **11** 1333
bias, **14** 853
crossover data, **13** 2531
direct formulation effect, **11** 881
dose-response, **11** 1777
mixed model framework, **15** 2635
repeated crossover design, **14** 1067, 1079
two formulation comparisons, **12** 1109
two-sided tests, **15** 1729
Biographies, **13** 785
Greenhouse, S. W., **14** 1613, 1615
Newell, D., **14** 111
Biological factors infant mortality, **4** 175, 189; **5** 139, 155
Biological marker, **13** 1423
dietary assessment, **12** 925, 937
Biomedical journals
clinical trials methodology, **10** 1897
Cox regression review, **10** 1931
statistics, **1** 59; **3** 97; **6** 3; **7** 1003
Biopharmaceutical data random effects models, **11** 1809
Biopharmaceutical research, **10** 811
Biopsy, **2** 33
Biostatisticians
medical research, **14** 1683
U.S. legal cases, **14** 1641
Biostatistics citations analysis, **13** 3
Biostatistics tutorials *see* Tutorials in biostatistics
Biplots, **9** 469
Birth
cohort analysis, **4** 63
heart disease diagnosis, **15** 157
malformations
change-point testing, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
monitoring efficiency, **6** 517; **7** 997–999(L)
surveillance, **3** 239; **4** 389–391(L); **5** 98–99(L), 565
mortality rates, **15** 1907
mortality/morbidity model, **14** 2191
mother's alcohol consumption, **15** 2095
scan test, **15** 845
shared transient causes, **15** 2029
spatial analysis, **15** 717
time-dependent disease risk, **15** 1545
weight prediction, **14** 2645
Birth control *see* Contraception; Fertility
Birthweight, **1** 105; **7** 1207
centile curves, **15** 2657
distributions, **15** 1333
low birthweight prediction, **15** 37
maternal smoking, **11** 643
mental development, **11** 243
perinatal care, **12** 377
Bisection method AIDS projections, **11** 1425
Biserial correlation coefficient, **7** 955
Bivariate data
Bayesian analysis, **14** 2523
contingency table model, **13** 969
cumulative probit regression model, **14** 1341
Dale model, **15** 1123
failure time model, **15** 1171
global odds ratio regression model, **15** 1507
independence tests, **14** 1621
logistic regression, **15** 1409
random effects model, **12** 2273
survival model, **12** 241
Bivariate markers non-parametric hazard estimators, **12** 843
Bladder cancer, **14** 431; **15** 2069, 2509
birth cohort analysis, **4** 63
clinical trials sample size, **1** 121; **5** 1
factorial designs, **4** 111
frailty model, **13** 1679
missing data, **15** 2509
prediction, **5** 421
regression analysis, **8** 1363; **14** 431
supressor genes, **13** 839
therapy comparisons, **7** 1013
treatment changes, **15** 2069
variation models, **6** 449
Blinding
assessment index, **15** 1421
clinical trials, **10** 1679; **13** 217, 357; **15** 1747
longitudinal trials, **14** 2239
treatment allocation, **14** 2661; **15** 113–116(L)
Blocked experiment design, **4** 47
Blocking record linkage, **14** 491
Blood
pre-natal lead levels, **11** 799
testing, **13** 2337
transfusions, **5** 355; **7** 395; **15** 1663
Blood flow analysis, **8** 1011
Blood gas, **5** 347

Blood pressure
Afro-Caribbeans/Europeans, **13** 1635
antihypertensive drug trials, **11** 2147
automatic recording devices, **4** 361
bias, **7** 941, 1087; **8** 1302–1303(L)
cardiovascular mortality study, **12** 1989
children, **7** 47, 87, 185, 199; **11** 1187
clinical trials benefits/risks, **10** 1349
confounding effects, **7** 1087
crossover studies, **10** 1115
diagnostic variables, **7** 423
diastolic measurements, **13** 1265
diurnal rhythms definition, **12** 129
error linear models, **10** 1197
Framingham heart study, **7** 205, 219
Gaussian mixed models, **12** 1665
heart disease, **7** 1109
hypertension, **7** 423, 941, 1109; **8** 1302–1303(L)
hypertensives vs. normotensives, **13** 1201
longitudinal data
childhood, **7** 47
familial aggregation, **7** 185, 199
general methods, **7** 29
linear model analysis, **11** 1843
relative risk models, **7** 279
maximum likelihood, **2** 253
measurements, **4** 361; **13** 275; **15** 2013
median analysis, **13** 1635
missing data, **7** 941
monitoring, **13** 1201
multiple Z-tests, **12** 1125
multivariate probit analysis, **10** 1391
Muscatine study, **7** 47
regression variability effect, **10** 1295
relative risk, **7** 275
repeated measurements, **7** 87, 205, 219
survival models, **9** 1157
time trends, **7** 629
tracking correlation, **11** 1187
treatments, **7** 697, 1109
trend assessment models, **7** 185
variance components estimation, **10** 1441
Blunder error factor, **8** 893
BMDP computer package, **14** 1191
blood pressure tracking, **11** 1187
cancer, **8** 743; **9** 325, 871
changeover designs, **8** 891(L)
clinical trials, **9** 871
Cox proportional hazards model, **13** 1045
Cox regression, **9** 1157, 1501
deaths, **8** 263
discriminant analysis, **11** 1023
error investigation, **8** 1137
follow-up data, **11** 1195
Framingham heart study, **9** 1501
logistic regression, **8** 263; **9** 1501
longitudinal data, **11** 1861, 1981, 2033
missing data, **8** 217, 263
multivariate analysis, **10** 1711
platelet transfusions, **11** 2123
Poisson regression, **9** 1157
prediction equation estimation, **10** 119
REGRESS, **12** 143
regression, **8** 217; **9** 1157
repeated measures, **11** 115
ROC curves, **9** 325
screening method analysis, **8** 743
semi-proportional hazards, **11** 1465
short-term survival, **11** 1731
sojourn time estimation, **8** 743
stepwise regression analysis, **10** 711
survival analysis, **9** 1157
treatments covariate interaction, **7** 1257
updated covariates model, **13** 301
variance components study, **10** 599, 1441
Body mass index, **8** 997; **15** 1325
Body size, **7** 47
Body temperature, **6** 167
Bone marrow
biopsy diagnosis study, **8** 1381; **13** 1551
transplants, **4** 1; **10** 413; **12** 737, 2315
Bonferroni inequality
cancer, **11** 13, 37
combination agents, **11** 703
discrete data, **11** 511
log-linear modelling, **11** 101
trend detection, **12** 1125
Bonferroni procedure, **13** 2261
familywise errors, **15** 1107
multiple endpoints, **14** 1163
prognostic factors, **12** 2377
Bonferroni significance tests
adjustment, **8** 1479
confidence intervals, **8** 1485
controlled clinical trials, **10** 777
interaction tests, **7** 467
multiple tests, **9** 811; **10** 939, 1123
multivariate analysis, **10** 1711
quality of life analysis, **9** 819
relative risk regression, **6** 591
Bonferroni-Holm procedure randomized clinical trials, **12** 2351
Book reviews *see* separate index p.**000**
Bootstrap
age-related reference centiles, **12** 917
AIDS incidence, **11** 1633; **12** 311
approximate Bayesian, **14** 1913
bioequivalence, **11** 881; **12** 1109
bounded outcome scores, **12** 1063
cluster analysis, **15** 1793
confidence intervals
AIDS incubation, **13** 969
Bayes, **13** 541
CD4 lymphocyte counts, **13** 1101
clustered binary responses, **13** 1241
cost-effectiveness ratios, **15** 1447

Boostrap (*cont.*)
confidence intervals (*cont.*)
Cox model, **8** 927
LFP survival model, **9** 409
quality performance, **14** 2161
radioimmunoassay concentration, **14** 935, 953
standardized rates, **14** 1875
survival function, **10** 413
correlated binomial variates, **11** 1607
correlations comparison, **8** 1485
covariance matrix estimate, **11** 101
Cox regression model, **8** 771
cystic fibrosis incidence, **15** 449
disease mapping, **12** 1943
epidemiology, **10** 341, 1819
gestational age estimation, **11** 1225
HIV-1 seroconversion, **12** 153
measurement error analysis, **8** 1151, 1165
missing data, **11** 2043
model building, **11** 2093
multiple test procedures, **11** 511
multivariable prognostic models, **15** 361
odds ratios, **9** 1131; **10** 1273
outliers detection, **10** 1375
precision estimates, **13** 1865
procedure, **8** 323, 331, 609
prognostic factors, **7** 843; **12** 2377
repeated events analysis, **10** 1227
repeated measures, **7** 29; **11** 2123
resampling technique, **4** 39; **5** 363; **10** 341
resampling-random regressors, **12** 153
residual confounding, **11** 1747
ROC curve, **13** 499
simulation correction estimates, **13** 1265
smoothing methods, **7** 601
standard errors, **13** 467
surveillance data aberrations, **11** 1551
survival analysis, **12** 1569
tolerance estimates, **14** 1129, 1143
variables, **15** 559
variance components study, **10** 599
variance estimates, **14** 1009
Boundaries
group sequential, **13** 1341
interim monitoring, **13** 1401
map comparisons, **14** 2343
marginal survival, **14** 1985
stopping rules, **13** 1357
t-quantile approximations, **13** 1657
Boundary estimates closed-form estimates, **11** 643
Bounded outcome scores power/sample size, **12** 1063
Bovine leukemia virus, **8** 725
Bowel disease, **3** 455; **6** 785; **8** 1255
Box and whisker plots CD4 counts, **12** 2099
Box-Cox transformation
age-related reference ranges, **13** 2359
centile curves, **13** 2477
data analysis, **14** 811
heart period data, **11** 125
power, **13** 769
reference intervals, **14** 1417
regression analysis, **10** 697
serial CD4 counts, **12** 2099
smoothing centile curves, **11** 1305
three-parameter log-normal distribution, **11** 897
time-specific reference ranges, **10** 675
Box-Jenkins model
forecasting factors, **7** 1061
heart rate analysis, **6** 159
infectious disease study, **5** 37
threshold construction study, **10** 1493
time series analyses, **5** 593; **7** 1045; **8** 353, 1497
BP *see* Blood pressure
BPH *see* Benign prostatic hyperplasia
Bradley-Blackwood procedure, **13** 737
Bradley-Terry model, **12** 1969
Brain death, **6** 535
Brain mapping fMRI, **15** 389
Brain scan, **5** 593
Brain tumours
case control study, **12** 1325
randomized clinical trials, **12** 2351
Breast cancer, **13** 1329, 1459, 1755
absolute risk, **8** 641; **10** 1025
aggregate data study, **15** 1849
alcohol consumption risks, **12** 1141
anatomical sites risk factors, **11** 281
bias, **2** 279; **6** 245, 251, 287
case-control studies, **8** 1179
CCS, **15** 263
clinical trials, **3** 333; **6** 667
cluster analysis, **15** 741
cluster randomization, **11** 307
collinearity diagnosis, **11** 1273
community intervention study, **10** 53
comprehensive cohort studies, **15** 263
confidence intervals, **2** 485
covariates, **4** 25
crude incidence curves, **11** 813
diseases, **2** 41, 415–416(L)
dose-response data, **14** 531
epidemiology, **7** 619; **14** 151
exposure variables, **15** 293
geographical variation, **11** 983
Health Insurance Plan (HIP study), **2** 279
heterogeneity impact, **7** 1121
homogeneity tests, **10** 1257
hormonal risk factors, **14** 267, 1437
interactions, **4** 255
interval censored data, **15** 283
key strategies, **12** 207
large sample size monitoring, **11** 515
longitudinal data, **14** 1235
Manchester study, **2** 41
marginal survival, **14** 1985

measurement error, **8** 1051
meta-analyses, **6** 333
misclassification, **8** 1529
missing covariate values, **9** 777
morbidity estimation, **8** 201
mortality trend assessment, **8** 201
overviews, **6** 233, 265, 333, 337, 371
bias, **6** 245, 251, 287
pooling, **6** 269, 277, 329, 389
postpartum disease risk, **15** 1545
prognostic markers, **11** 281; **15** 103
Q-TWiST, **12** 975
quality of life analysis, **9** 749, 931
radiation effects, **1** 15
randomized trials, **6** 233, 265, 337, 371
bias, **6** 245, 251, 287
pooling, **6** 269, 277, 329, 333, 389
registry, **11** 345
risk techniques, **1** 15; **8** 641
screening effectiveness, **9** 969
sojourn time estimation, **8** 743; **14** 1531
statistical facts, **6** 881
stepwise regression analysis, **10** 711
survival analysis, **14** 1771
confirmatory analysis, **6** 939
cure assessment, **1** 93; **9** 397
diagnosis age factor, **9** 737
heterogeneity impact, **7** 1121
prediction intervals, **2** 485
quality adjusted methods, **9** 1259
screening methods, **2** 279; **6** 885
treatments, **2** 41, 415–416(L)
therapy evaluation, **3** 333
treatments, **2** 41, 415–416(L); **4** 255
tumour marker data, **12** 265
variation models, **6** 469
Breastfeeding fertility regulation, **10** 161
Breslow-Day common odds ratio test, **12** 1293
Breslow-Day score statistic, **11** 159
Brier score, **5** 421; **15** 2149
Bronchitis, **7** 11; **10** 341
Bronchodilators, **8** 1339; **15** 2703
Brownian motion, **11** 1391, 1477; **12** 753, 2219; **15** 2289
Buckley-James estimator, **11** 1871; **14** 2023
Budgeting guidelines research projects, **15** 2127
BUGS computer package, **14** 2685
Burden, **14** 629
Burn-care management survival analysis, **12** 301
Burns, **7** 975
Burt matrix, **8** 1351, 1545–1547(L)
Bypass operations non-adherence, **12** 1185

Caesarian section, **3** 131
Calcification, **7** 619
Calcium for Pre-Eclampsia Prevention (CPEP) meta-analysis, **15** 1233, 1237, 1263
Calendar effects, **8** 1497

CALGB *see* Cancer and Leukemia Group B
Calibration
ANCOVA, **8** 1075
assay parameters, **14** 1949
clinical trials designs, **5** 441
exposure error investigation, **8** 1109
immunoassay curves, **5** 183
lines, **5** 347
models, **5** 421
multivariable prognostic models, **15** 361
non-linear, **13** 1165
prediction values, **9** 1303
radioimmunoassay curves, **14** 935, 953
California score (SIDS), **5** 113
Canada
health care datafiles, **14** 2627
malignant melanoma mortality, **14** 821
monitoring cancer clinical trials, **12** 505, 521
Cancer
see also Breast cancer; individual cancers; Leukaemia; Lung cancer
absolute risk, **10** 1025
age-related mortality adjustment, **10** 65
anal therapy trial, **13** 1459
attributable risk adjustment, **10** 1753
bladder
birth cohort analysis, **4** 63
clinical trials sample size, **1** 121; **5** 1
factorial designs, **4** 111
frailty model, **13** 1679
missing data, **15** 2509
prediction, **5** 421
regression analysis, **8** 1363; **14** 431
sign score regression models, **14** 431
supressor genes, **13** 839
therapy comparisons, **7** 1013
treatment changes, **15** 2069
variation models, **6** 449
bowel, **3** 455; **8** 1255
brain tumours, **11** 345, 2093
carcinogenesis model, **1** 163; **2** 363; **9** 677
case-control studies, **8** 1528; **9** 765; **10** 375
cervix uteri, **3** 113, 353, 359; **5** 127; **6** 785; **13** 1575
chemotherapy
bias, **6** 11, 245, 251
breast, **6** 245, 251, 333
clinical trials, **2** 429; **4** 1, 527; **6** 287; **9** 871
decision theory, **5** 411
dose-response evaluation, **8** 813; **9** 1117–1118(L)
drug combination analysis, **9** 1527
interim analysis, **5** 465
leukaemia, **4** 1
meta-analyses, **6** 11, 333
overviews, **6** 265, 287, 333
bias, **6** 245, 251
pooling, **6** 269, 277, 307, 329, 337

Cancer (*cont.*)
chemotherapy (*cont.*)
prediction utility, **4** 527
prognostic factors, **9** 273
quality of life analysis, **2** 429
randomized trials, **6** 265, 287, 333, 337
bias, **6** 245, 251
pooling, **6** 269, 277, 307, 329, 337
stopping rules effects, **6** 667
survival analysis, **9** 1527
treatments, **8** 1371; **9** 1527
childhood, **7** 649, 857; **15** 683
clinical trials
bias, **4** 1; **6** 11
chemotherapy, **2** 429
classification, **4** 287
covariates, **5** 73; **6** 31
Cox regression, **5** 73
dose-response evaluation, **8** 813
efficiency assessment, **3** 455; **6** 31
endpoints, **8** 405, 431
error, **6** 31
four treatments, **13** 431
interactions treatments, **5** 73
leukaemia, **4** 287
life-table analysis, **8** 907
methodology review, **10** 1789
monitoring, **12** 435, 457, 497, 505, 521
phase II trials, **5** 441
prevention agents, **5** 435
prognostic factors, **4** 279
quality of life, **2** 429
randomization, **4** 279; **6** 31; **9** 645
regression, **8** 907
sample size estimation, **3** 314
sequential methods, **13** 1357; **14** 357, 381
surrogate markers, **13** 1423; **14** 2619–2620(L)
therapy evaluation, **3** 333
treatments, **5** 73
CLUSTER, **15** 943
cluster analysis, **15** 699, 727
cluster investigations, **12** 1757, 1931
colon
case-control study, **8** 1151, 1165; **11** 1759
correlated markers, **14** 2217
Cox analysis, **13** 2233
pooling, **6** 307, 313
prognostic markers, **14** 2217
proportional regression model, **14** 1249
SPRT, **15** 2781
survival analysis, **9** 529; **14** 1249
colorectal, **3** 455; **11** 1–53; **12** 339; **13** 1337; **15** 2797
correlated multiple associations, **11** 219
curability, **1** 93
data reliability, **1** 191
DEMP, **15** 1837
detection, **14** 151
diagnostic tests, **9** 325; **10** 1887
dietary factors, **8** 431; **11** 1273; **15** 1647
disease natural history, **8** 1255
drug combination treatments, **9** 1527
endometrial, **10** 767; **14** 1545
epidemiology, **5** 547; **6** 449, 469
epithelial, **13** 23
exploratory analysis, **15** 807
exposure, **5** 49, 539, 547; **8** 173
face, **6** 881
factorial designs, **4** 111
Four County Childhood Cancer Study, **15** 683, 1837
gastric, **13** 1045; **15** 907
gastrointestinal, **4** 337; **5** 517
geographic regions, **12** 1915
grouped cohort data, **13** 2407
hazardous exposure estimation, **10** 79
head and neck CHART trial, **13** 1297
hepatocellular, **4** 345
Hodgkin's disease, **3** 173, 353, 359; **6** 517; **15** 2191
immunotherapy, **3** 325
incidence prediction, **13** 1513
incidence/mortality, **12** 2395
incomplete subject birthplace data, **12** 3
kernel regression smoothing, **12** 1249
kidney, **5** 255; **13** 2249
larynx, **5** 527; **11** 1747
liver, **6** 307
low-dose response data, **12** 881
lymphoma, **3** 361; **5** 491; **6** 307; **7** 1139
malignant melanoma, **2** 295; **3** 325
mammary tumours fat intake effect, **13** 709
mapping models, **14** 2473
maps
Italy, **14** 2363
U.S., **14** 473
measurement error, **8** 1051, 1151, 1165
measurement methods, **5** 547
melanoma, **4** 63, 265, 527; **7** 765; **9** 999
misclassification models, **14** 1307
monitoring, **2** 217
mortality
age-period-cohort models, **1** 245; **5** 527; **6** 469
Bayesian analysis, **4** 201
cohort studies, **4** 353
interactions risk, **7** 223, 239
Markov models, **7** 325
occupational, **5** 61
radiation factors, **5** 539; **8** 173
rates, **2** 113; **10** 95
smoking study, **7** 223
statistical facts, **6** 881
variation models, **6** 449
multicentre clinical trial, **14** 2523
multiple Poisson rates, **8** 757
multistage model, **13** 23

mycosis fungoides, **3** 361
myeloma, **6** 11, 517
NCI clinical trials, **9** 871, 903
oesophagus, **7** 507, 1223
oral, **2** 287; **13** 623
ordinal regression models, **15** 1807
osteogenic sarcoma, **3** 455
ovarian, **5** 85, 411; **6** 11, 307; **13** 2427; **15** 2763
overviews, **6** 217, 389
paired organs study, **7** 619
pancreatic, **2** 217; **9** 829; **15** 893, 1921
pelvic neutron treatment trial, **13** 1459
phase I clinical trials, **10** 1647; **12** 1093; **14** 911, 923
phase II clinical trials, **5** 441; **9** 215, 907; **10** 989; **13** 1727
physicians' health study (US), **9** 29, 87; **10** 1585
point sources, **15** 1927
pooling methods, **5** 303
prevalence calculation, **11** 1579
prevention agents, **5** 435
prevention trials, **13** 955
prognostic factors, **12** 2377
prostate, **4** 255; **5** 73; **11** 345, 813, 2093
  graphical data, **15** 2539
  multivariable prognostic model, **15** 361
  play the winner, **15** 2413
  ROC curves, **15** 1687
quality of life, **9** 749, 931; **10** 1915
radiation exposure analysis, **8** 173
radiotherapy, **6** 785; **8** 1371
randomized clinical trials, **6** 217
rectal, **6** 565
recurrence, **6** 245, 251; **14** 2701
regional spatial analysis, **13** 1037
registry data, **1** 191; **3** 361, 371; **7** 483; **11** 345; **12** 1249
relative risk estimation, **10** 1745
rhabdomyosarcoma, **11** 761
risk
  analysis, **7** 239, 857
  assessment, **8** 641
  central laboratory, **15** 759
  techniques leukaemia, **10** 1511
screening methods, **14** 2715
  Bayesian strategy, **12** 1197
  disease history estimation, **5** 127
  efficiency assessment, **9** 55, 696
  sojourn time estimation, **8** 743
  survival analysis, **2** 279; **6** 885
  tumour markers assessment, **2** 217
semi annual reports, **11** 1367
sequential clinical trials, **8** 505
skin
  cohort models, **10** 1241
  mortality rates, **14** 821
  survival analysis, **13** 1189
spatial autocorrelation indices, **12** 1885
stomach, **3** 455; **4** 63, 201; **6** 307; **14** 1331
stratified trend test, **9** 829
study designs misselection, **9** 1339
surgical adjuvant therapy, **3** 455
surrogate endpoints, **8** 405, 431
survival analysis, **14** 161
  cross-validation, **12** 2305
  exponential survival trees, **8** 947
  finite mixtures theory, **9** 397
  linear regression model, **8** 907
  quality adjusted, **9** 1259
  transient conditions, **10** 413
temporal risk pattern, **8** 1371
testis, **3** 113, 153
threshold-crossing data, **12** 1589
thyroid, **3** 361; **4** 295; **10** 95
TIGER/S, **12** 1953
toxicity grades, **11** 2063
treatment, **2** 429; **8** 593, 1371; **13** 1293, 1575
trend assessment, **4** 87
triangular test comparisons, **10** 989
tumour
  growth models, **10** 1075
  incidence, **13** 689
  marker assessment, **2** 217
  recurrence rates, **8** 1363
  vaccine trial, **14** 2099
U.S. cancer atlases, **14** 473
uterus, **6** 881
vagina, **5** 261; **7** 1223
x-ray risk, **7** 857
Cancer Chemotherapy National Service Center, **9** 673, 871
Cancer Clinical Trials, Workshop on Early Stopping Rules, **13** 1293–1499
Cancer Therapy Committee, UK monitoring clinical trials, **12** 497, 521
Candida albicans, **7** 535
Capture-recapture *see* Mark-recapture
Carbamazepine concentration, **8** 1327
Carbon dioxide transcutaneous, **5** 347
Carcinoembryonic antigen, **2** 217; **8** 405
Carcinogenesis model, **7** 223
Carcinogenicity experiments
  global tests, **15** 1217
  marked point process, **15** 2751
Carcinogens
  anticancer treatment, **8** 1371
  occupational, **5** 49
Carcinoma
  oropharynx survival analysis, **12** 1569
  recurrance rates, **8** 1363
Cardiac arrest, **4** 29
Cardiac Arrhythmia Suppression Trial (CAST), **9** 1081; **10** 1621; **14** 1927
Cardiff health survey, **6** 869
Cardiff score, SIDS study, **5** 113

Cardiology
chemotherapy prognostic factors, **9** 273
clinical trials, **9** 17, 137
diseases, **8** 1393, 1401
quality of life assessment, **10** 1915
Cardiotoxicity prognostic variables, **9** 273
Cardiovascular diseases
see also Heart disease
bivariate frailty models, **12** 241
clinical trials, **8** 415, 431; **9** 29, 657; **12** 509, 521
Cox proportional hazards model, **7** 613
database Duke University, **3** 375
epidemiology, **3** 15
Framingham heart study, **7** 205, 219
historical controls, **3** 331
hypertension treatment, **7** 1109
intra-individual variation, **12** 1213
mixture analysis, **9** 301
mortality, **4** 111, 397; **6** 501; **7** 239; **12** 1989
normality departure estimation, **10** 1283
patient selection clinical trials, **9** 73
plasma lipid levels, **11** 2033
pooled data study, **9** 1501
randomized trials, **6** 217, 233, 295
response phenomenon, **10** 1621
risk
estimation methods, **7** 717; **8** 641
mortality interaction, **7** 239, 289, 293
surveillance, **8** 391
Carlos-Senning model, **7** 403
Carotid arteries ultrasonographic measurement, **11** 1041
Carrier probability, **2** 87
Carryover effects
antibiotic comparison study, **13** 11
categorical data analysis, **10** 1607
compliance enhancer, **9** 87
crossover trials
conditional analysis, **12** 825
factorial designs, **9** 1121
growth curves, **13** 931
intra-subject variability, **15** 1619
phase III trials, **14** 1025, 1053
preliminary checks, **8** 633(L)
regression to the mean, **11** 727
simple model, **11** 715
three-period design, **6** 555; **7** 471
treatment comparisons, **8** 487
two-period, **6** 911; **7** 1099–1101(L); **8** 1421; **10** 489–491(L), 1361
dose ranging simulation study, **10** 303
latin squares designs, **11** 560(L)
longitudinal data, **11** 1967
phase II trials, **14** 987, 1007
random effects model, **10** 901
sequentially balanced crossover designs, **15** 2143
treatment assignment, **13** 1089
treatment comparisons, **8** 487
within patient analysis, **13** 1601
Cars *see* Automobile studies
CART computer package, **8** 947; **10** 1789; **11** 475
Cartograms, **7** 491
Case definition, **3** 27
Case influence analysis, **11** 1615
Case load weighting attributable risk, **11** 2083
Case-base study, **5** 579
Case-cohort studies, **5** 579; **7** 149, 275
see also Cohort studies
common risk ratio, **11** 1599
risk ratio/rate ratio estimation, **12** 1733; **14** 1609–1610(L)
Case-control studies, **7** 765
absolute risk, **10** 1025
allocation designs, **5** 319
ancillary questions, **9** 97
ascertainment, **13** 1679
Bayesian inference, **5** 261; **7** 1223; **8** 1023–1024(L)
bias assessment, **7** 1087
binary variables, **2** 243; **5** 29; **8** 1241
BPH, **13** 587
breast cancer, **14** 1437
cancer, **7** 223, 619
carcinoma, **4** 345
case definition, **3** 27
case-base studies, **9** 423
CER cervical dysplasia, **13** 245
child leukaemia mortality, **13** 1525
cohort design, **10** 1775
confounding effects, **7** 1087
contingency table estimators, **8** 987
control sample size, **11** 1759
cost, **5** 319
data presentation, **11** 617, 1789–1790(L)
differential recall bias, **15** 2603
discriminant analysis, **2** 229
disease
cluster investigations, **12** 1757
prevention trials efficiency, **9** 161
surveillance, **4** 327; **5** 49
dispersion tests/adjustments, **12** 1683
efficacy vaccines, **7** 1279
efficiency consideration, **5** 29
epidemiology, **5** 579; **8** 845; **10** 1819
estimation methods, **8** 845; **10** 1037
excess risk, **15** 1535
exposure factors, **5** 49; **7** 363
exposure-specific incidence rates, **13** 651, 683
familial aggregation, **11** 1767
genetic susceptibility, **13** 153
haemophilus influenzae vaccine, **13** 1699
heart disease, **2** 477
historical data analysis, **7** 819
homogeneity, **10** 1257
hypertension, **10** 653
interaction tests, **2** 243

inverse sampling, **14** 2051
latent class analysis, **4** 327, 445
likelihood analysis, **7** 149
logistic regression, **4** 425; **14** 769
McNemar test, **11** 1239
Mantel-Haenszel statistic, **6** 701
matching, **8** 825, 977; **12** 993
measurement error analysis, **8** 1151, 1165
medical databases, **2** 355
meta-analysis, **11** 141; **14** 531, 545
misclassification, **4** 327; **7** 1073; **8** 1095, 1528; **14** 1291
misselection subsampling, **9** 1339
missing data models, **14** 1315
model-building strategies, **12** 1325
mortality, **2** 229
multiple controls, **5** 29
multiple hypothesis tests, **14** 585
multiple reports, **8** 1041
national bladder cancer study, **13** 651
nested analysis, **10** 739; **14** 1609–1610(L)
odds ratios, **1** 217; **7** 759, 1223; **14** 2581
optimal sample size determination, **11** 547
ordinal logistic models, **14** 1545
osteoarthrosis assessment, **8** 1417(L)
partial questionnaire design, **13** 623, 647
polychotomous models, **10** 375; **11** 557–559(L)
pooling controls, **10** 1417
postpartum time-dependent disease risk, **15** 1545
power considerations, **2** 243; **3** 27; **4** 117; **5** 29; **6** 53; **7** 363
ratio estimation, **1** 217
relative risk, **14** 1615
  adjustment methods, **5** 579
  dose-response models, **10** 1511
  estimation improvement, **4** 445
  liver function models, **7** 671
  regression methods, **7** 275
  sample size requirements, **7** 759
risk
  adjustment methods, **5** 579; **10** 1753
  attributable estimation, **1** 229; **7** 507
  cancer x ray association, **7** 857
  carcinoma study, **4** 345
  misclassification effects, **7** 1073
  scores, **14** 1331
sample allocation, **9** 1475
sample size
  allocation designs, **5** 319
  confounding effects, **9** 765
  exposure factors, **7** 363; **9** 1485
  formula derivation, **6** 53
  multiple controls efficiency, **5** 29
  multivariate studies, **4** 117
  odds ratio estimation, **7** 759
  relative risk estimation, **7** 759
  tables, **8** 795
  vaccine efficacy estimation, **7** 1279
  sampling, **13** 989
  screening methods, **5** 127
  sign score regression models, **14** 431
  smoking study, **7** 223
  spurious associations, **15** 2603
  stratification, **2** 229; **7** 1087; **9** 1475
  survival-based, **10** 1775
  treatment-induced cancer, **8** 1371
  two-stage studies, **11** 769
  type I error, **6** 53; **7** 363, 759, 1279
  vaccine efficacy, **7** 1279
  variance estimation, **6** 701; **7** 745
  within-person measurement error, **8** 1051
Case-crossover designs, **12** 2333
Case-heterogeneity study, **5** 49
CAST *see* Cardiac Arrhythmia Suppression Trial
Cataract senile, **5** 573
Categorical data
  analysis, **13** 301, 1149
  association models, **8** 1199
  clinical trials
    benefits/risks, **10** 1349
    evaluation, **7** 581
  contingency tables, **15** 2095
  correlated bibliography, **11** 67
  correspondence analysis, **7** 983; **8** 1545–1547(L)
  crossover trials, **10** 1607
  high-risk sexual behaviour, **15** 2323
  interobserver agreement, **11** 101
  latent variable models, **7** 975
  log-linear models, **7** 965
  logistic regression model, **8** 1317
  misclassification, **8** 1095; **11** 271–275(L)
  missing counts, **11** 643
  mortality variation study, **9** 1199
  non-randomly missing data, **11** 799
  regression models, **11** 67; **14** 1341, 2131; **15** 1507
  repeated, **13** 467, 495, 1149
  repeated measurement analysis, **7** 93–173; **8** 1209; **10** 1959
  sample size, **12** 2257; **15** 1065–1066(L)
  survival analysis, **10** 1703
  symmetry models, **9** 1143
  Wilcoxon statistic, **14** 1577
Causal inference, **1** 105
Cause-deleted life tables, **4** 155, 397; **5** 61; **6** 527–528(L)
Cause-specific
  curves, **11** 813
  failure, **7** 965
  mortality, **3** 7; **6** 71
CCS *see* Comprehensive Cohort Studies
CD4 lymphocyte counts, **13** 805, 1101
  see also AIDS; HIV
  age-related reference ranges, **13** 2359
  AIDS illnesses, **15** 2307, 2337
  AIDS pathogenesis model, **13** 2067

CD4 lymphocyte counts (*cont.*)
AZT effect of, **15** 75
censored data/repeated measures model, **15** 1663
clinical implications, **14** 1889
clinical trials endpoint, **13** 2107
empirical Bayes estimators, **15** 2289, 2337
HIV
clinical trials, **15** 2053
hazard estimation, **12** 843
infectivity, **14** 1365
marker, **12** 835, 2065, 2099, 2133
vaccine trials, **13** 2155
HIV-1 tests, **15** 463
measurement error likelihood, **13** 2059
simulations, **13** 405
surrogate end-points 1895–1896(L)
CD8 lymphocytes HIV hazard estimation, **12** 843
CDC *see* Centers for Disease Control and Prevention
CDF *see* Cumulative distribution functions
CEA *see* Carcinoembryonic antigen
CEB *see* Constrained empirical Bayes estimator
Censored data
AIDS study, **7** 395; **9** 1387
allocation methods, **6** 119
Bayesian inference, **4** 509
bias study, **7** 1243
bootstrap resampling, **11** 2093
cancer study, **2** 41; **4** 353; **7** 1139
case-control studies, **10** 739, 1775
change rate analysis, **7** 337
classification procedures, **4** 287
clinical trials, **6** 565
cohort study, **8** 977
combined endpoints, **11** 1705
confidence intervals, **5** 653; **6** 679; **8** 1269
confirmatory analysis, **6** 939
correlated markers, **14** 2217
correspondence analysis, **4** 303
covariates AIDS induction effect, **13** 2021
Cox regression, **5** 73; **10** 1931
crossover trials, **15** 953
cure models, **6** 483; **14** 2111
cure-rate estimation, **11** 931
deaths pooling efficiency, **6** 565
distribution, **5** 255
doubly-censored, **13** 2081
early treatment termination, **9** 1417, 1433
error effects, **6** 31; **8** 1167, 1179
exponential survival trees, **8** 947
failure times, **15** 1387
follow-up studies, **4** 509; **5** 255
frailty models, **14** 1447
generalized linear model, **15** 283
genetic diseases, **14** 1353
Gibbs sampling, **15** 1663
goodness-of-fit models, **14** 1785
group sequential trials, **5** 375; **8** 1191; **11** 1477
hazard ratio point estimation, **9** 1167
heterogeneity tests, **6** 773; **7** 1121
historical controls, **3** 225
history data analysis, **7** 819
HIV infection, **15** 2177
homogenetic variance, **15** 51
immunity study, **14** 39
infection, **3** 165
interim analysis, **5** 465
last case influence, **11** 1615
life-table analysis, **4** 155
limited failure population model, **9** 409
linear rank tests, **14** 2555
litter-matched designs, **2** 315, 323
logrank test, **8** 937
longitudinal studies, **7** 337, 357; **11** 1861, 1871
malaria incidence model, **14** 2727
median age calculation, **10** 1313
menstruation study, **14** 1843
mid-point imputation, **11** 1569
missing data, **7** 357; **8** 217
morbidity estimation, **7** 325
mortality, **6** 501
multiple comparisons, **6** 591
multiple imputation methods, **10** 585
multiwave studies, **10** 1945
neural network model, **14** 73
order statistics study, **10** 855
paired, **11** 193; **14** 275
parametric/non-parametric methods, **13** 635, 647
power, **5** 637; **8** 153
prediction intervals, **2** 485
prognostic factors
leukaemia surveillance, **4** 39
lung cancer study, **4** 279
melanoma surveillance, **2** 295; **4** 265
myocardial infarction, **4** 29
renal study, **2** 295; **5** 637
proportional odds model, **2** 273
quality of life analysis, **9** 931
randomization, **1** 277
regression
Cox proportional hazards, **8** 525, 539
leukaemia infection study, **8** 725
logistic comparisons, **8** 525
prognostic prediction models, **3** 143
survival analysis, **2** 287; **4** 39; **5** 85
relative risk analysis, **9** 287
repeated events analysis, **10** 1227
repeated measurements, **7** 347
residual plots, **14** 2023
respiratory symptoms, **13** 1771
risk factors, **4** 413; **6** 785; **9** 423
sample size, **3** 199; **5** 637; **7** 559; **10** 1993; **14** 2273
sampling design, **10** 1945
score test, **15** 1049
smoking cessation, **12** 1605

space-time cluster analysis, **14** 2383
stopping rules, **6** 667, 927
subjective ranking, **11** 439, 453
survival analysis, **15** 1999
AIDS, **10** 413
angina pectoris trials, **9** 293
cancer, **3** 35, 153; **6** 939
carcinoma study, **2** 287, 295; **5** 85
categorical response, **10** 1703
Cox proportional hazards model, **10** 1931
cure rates, **13** 983–986(L)
diabetes, **7** 661
drug combination study, **9** 1527
estimation methods, **9** 529
follow-up measures, **5** 255
heart disease, **4** 397
leukaemia, **4** 39, 509
lung cancer, **7** 483
model comparisons, **2** 305
myocardial infarction, **4** 29
prediction intervals, **2** 485
prognostic power, **9** 487
quality adjusted, **9** 1259
renal disease, **5** 637
risk factors, **4** 41; **7** 203–302
therapy evaluation, **7** 1013
threshold-crossing, **12** 1589
titration studies, **6** 583
transient state analysis, **6** 795
treatment covariate interaction, **7** 1257
unequal effects, **8** 937
variance components estimation, **10** 1441
Wilcoxon-type tests, **8** 937
withdrawal, **11** 1359
Centers for Disease Control and Prevention, **8** 253
Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry Quantitative Methods for Utilization of Multi-Source Data in Public Health symposium
abstracts, **14** 703
closing remarks, **14** 715
data linkage, **14** 481–530
keynote addresses, **14** 457–479
mapping, **14** 591–627
methodologic issues, **14** 531–589
opening remarks, **14** 455
prologue, **14** 447
session commentaries, **14** 679–702
utilization of special data sets, **14** 629–677
Small Area Statistics in Public Health: Design, Analysis, Graphic and Spatial Methods Symposium, **15** 1827–1986
close of symposium, **15** 1985–1986
closing remarks, **15** 1983–1984
introduction, **15** 1835–1836
poster presentations, **15** 1979–1981
preface, **15** 1827–1828
staff and committees, **15** 1829–1834
Centile curves
birthweight data, **15** 2657
smoothing, **11** 1305
Centile estimates, **9** 539; **10** 675, 691, 1693; **13** 2477
Central laboratories, **9** 125, 145
CEPs *see* Comparative exposure probabilities
CER *see* Comparative exposure ratio
Cerebral disease, **4** 311
Cerebral palsy, **2** 345; **7** 717
Cervical cancer, **13** 379
care quality study, **3** 353, 359
digestive complications, **6** 785
screening, **5** 127
time trends, **3** 113
treatments, **13** 1575
Cervical smears Bayesian analysis, **12** 2179
Chain independence graph, **11** 2001
Chance-corrected agreement observer agreement studies, **14** 299, 2285–2288(L)
Chance-correlated agreement reliability studies, **12** 2191
Change
assessment methods, **7** 915
baseline response, **8** 1183
initial value effect, **7** 915
longitudinal data analysis, **9** 437
quality of life measurement, **9** 931
rate analysis, **7** 337
scores, ANCOVA, **8** 571
Change scale base scores comparison, **12** 2147–2151(L)
Change-point process
Cusum methods, **2** 141
fertile phase identification, **10** 221
neuronal discharge analysis, **4** 91
quality control, **2** 141, 147
registry data, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
time series analysis, **10** 1481
Changeover designs *see* Crossover trials
Chaos theory, **15** 559
CHART *see* Continuous Hyperfractionated Accelerated Radio Therapy
Chemosensitivity assay, **4** 527
Chemotherapy
see also Cancer; Drugs tests
cancer control efficacy, **8** 1371
cardiology prognostic factors, **9** 273
colorectal cancer regimens, **11** 1–53
dose-toxicity evaluation, **9** 1117–1118(L)
mass, **6** 853
ovarian cancer, **12** 2305
randomized clinical trials, **12** 2351
regimen study, **13** 1453
survival analysis, **14** 1771
Chen method, **15** 943

Chest conditions
disease, **6** 805, 813
pain diagnosis, **8** 1351
radiography, **3** 73; **7** 955
Chi-squared tests
binomial comparisons, **10** 1137
change-point testing, **10** 1159–1160(L)
contingency tables, **5** 629
continuity correction, **12** 2207
kappa statistic, **14** 347
nominal association model, **10** 1555
paired data adjustment, **10** 1981
partitioning methods, **3** 273
tables, **8** 243–245(L); **9** 363–383
two sided small sample tests, **12** 777
Chickenpox, **5** 37
Children
see also Infants
AIDS surveillance, **13** 2031
blood pressure, **11** 1187; **15** 2013
cancer studies, **15** 683, 1837
clinical trials, **10** 1595
language development models, **9** 237, 1143
lead exposure study, **9** 811
leukaemia incidence, **9** 691
cluster tests, **14** 2309; **15** 707, 783
Hawaii, **15** 699
natural radiation, **14** 2487
nuclear power plants, **14** 3, 2459
space-time interaction, **14** 2383; **15** 873
malaria incidence, **14** 2727
mortality studies, **9** 981
NCI leukaemia trials, **9** 871
otitis media, **9** 237, 1495; **15** 1519
respiratory diseases, **10** 1481; **15** 1867
sickle cell anaemia trial, **9** 45
surface area estimation, **15** 1325
visual acuity, **14** 257
Chimpanzee studies HIV vaccines, **15** 2371
Chlamydia trachomatis, **7** 795; **8** 229
Chlamydial infection transmission probability estimation, **11** 565
Chlorthalidone, **7** 697
Cholesterol, **13** 1841
cancer associations, **5** 303
cardiovascular disease, **6** 501; **14** 1745
confounding effects, **8** 679
epidemiology, **5** 303
exposure factors, **8** 679
follow-up data, **11** 1195
Healthy People 2000 objectives, **12** 207
heart disease, **8** 295; **12** 967
level model, **14** 1397
logistic regression, **7** 519
marginal models, **7** 139
mortality, **6** 501
normality departure estimation, **10** 1283
partially incomplete data, **11** 1151
pooling results, **5** 303
provisional diagnoses, **10** 1341
regression variability effects, **10** 1295
repeated measurements analysis, **7** 319
risk factors, **7** 717; **8** 295
surveillance, **8** 295
treatment evaluation, **7** 319
Chromosomes, **10** 141
Chronic diseases
incidence/mortality, **12** 2395
morbidity, **8** 201
Chronic obstructive pulmonary disease (COPD) database validity study, **14** 2627
Cigarette smoking *see* Smoking
CIN *see* Cervical intraepithelial neoplasia
Circadian rhythm, **6** 167; **7** 423, 697; **12** 1665
Circularity, **7** 471
Cirrhosis, **4** 345; **6** 709; **7** 629; **8** 771; **15** 2733
Citations information analysis, **13** 3
Classical error model, **12** 1703
Classical linear models, **4** 379
Classification
accuracy models, **13** 1015
association measurement, **8** 619
automatic, **3** 261
Bayesian inference, **6** 945
cancer study, **5** 517
chromosome study, **10** 141
cohort studies errors, **2** 25
contingency tables, **15** 2095
correspondence analysis, **8** 1351
databases study, **10** 637
denominators in small areas, **15** 1921
diagnostic tests, **6** 945
discriminant analysis, **7** 525
epidemiological data, **8** 1095
error, **7** 257, 403, 525, 745, 955, 1073
exposure factors, **7** 1073
facial pain study, **6** 137
geographic correlations, **5** 171
kappa coefficient, **10** 1465
latent class analysis, **3** 249
liver disease, **7** 525
logistic regression, **7** 519
multiple independent, **15** 1377
non-nested regression models, **11** 1321
ordinal models, **10** 383; **11** 131–132(L)
partitioning methods, **5** 517
power, **7** 519
recursive partitioning rule, **2** 345
statistical monitoring methods, **13** 1371
trees, **13** 1501; **15** 157
unclassified data, **8** 1291
uroflowgrams, **13** 261
variance estimation, **7** 745
visual field data, **15** 1349
Classification and Regression Tree (CART) technique, **12** 2351

Clayton-Oakes distribution, **14** 1985
Clemmesen's hook, **6** 469
Clinical chemistry
  bias assessment, **6** 411
  confidence intervals, **5** 347
  cusum techniques, **2** 141
  diagnostic tests, **6** 147, 411; **8** 609
  discriminant analysis, **5** 347
  dose-interpolation study, **5** 183
  monitoring procedures, **2** 141
  normal range estimation, **5** 335
  outliers detection, **5** 335
  placebo effect, **2** 417
  quality control, **2** 123, 131, 141; **4** 369; **6** 425
  reference method, **2** 131
  reference ranges, **7** 377
  regression analysis, **2** 417
  Shewhart's technique, **2** 131; **4** 369
Clinical decision analysis
  Bayesian inference, **5** 497; **6** 805, 945
  chemotherapy, **5** 411
  clinical trials, **9** 1243; **10** 1789
  computer-aided, **5** 497
  data monitoring, **6** 753
  diagnostic tests, **5** 497; **6** 805
  partitioning methods, **5** 517
  patient's viewpoint, **6** 745
  prognostic factors, **5** 403
  review, **9** 1229
  stopping rules effects, **6** 753
  three-decision problem, **6** 101
  treatment evaluation, **5** 411; **6** 745
Clinical pharmacology studies, **12** 633
Clinical practice, **1** 311; **9** 185, 193
Clinical research
  evolutionary programme, **3** 315
  statistical consultation, **3** 1
Clinical trials
  see also Designs . . . ; Randomization..; Sequential . . . ; Stopping rules . . .
  24-hour blood pressure monitoring, **11** 2147
  accrual, **7** 559
  adenomatous colorectal polyps, **12** 339
  adverse treatment effects, **6** 745
  age-related adjustment, **10** 65
  agreement data analysis, **8** 1199
  AIDS
    failure times, **15** 2475
    intervention, **13** 2107–2187
    long-term follow-up, **15** 2359, 2367
    treatment analysis, **14** 1205
    treatment strategies, **13** 405
  allocation methods, **3** 473; **4** 129, 489; **9** 237, 943, 1475
  ambulatory blood pressure monitoring, **12** 1665
  analgesics, **3** 273; **5** 15; **6** 657; **7** 435
  analysis of interactions, **4** 111, 255
  ancillary questions study, **9** 97
  angina crossover study, **13** 905
  antiarrhythmic drug effect, **2** 331
  arthritis repeated measurements, **13** 1149
  aspirin and cardiovascular disease, **4** 111
  assessibility study, **13** 2397
  asthma, **3** 45; **8** 1339
  balanced covariate, **7** 1243
  baseline imbalance, **13** 2280–2285(L); **14** 2283–2285(L)
  baseline measurements, **6** 911; **7** 1203(L); **8** 1183, 1301(L), 1421; **15** 117
  baseline period, **5** 231
  Bayesian analysis, **11** 1–53; **12** 1377
    biopharmaceutical research, **10** 811
    cancer, **12** 1197
    monitoring, **13** 1371; **14** 1057, 1065, 1379
    phase I, **11** 1377
  beta-blockade, **3** 409, 445
  betacarotene and cancer, **4** 111
  bias, **15** 1747
  biased-coin design, **5** 211
  binary response studies, **4** 497; **9** 919
  bioequivalence studies, **10** 959, 961
  biologic efficacy, **10** 45
  bivariate survival data, **14** 2523
  bladder cancer, **15** 2509
  blinding, **10** 1679; **15** 1421
  bootstrap investigation, **8** 771
  breast cancer, **2** 41, 415(L); **3** 333
  bronchodilators, **8** 1339
  calcium pilot study, **13** 1619
  calibration designs, **5** 441
  cancer treatment screening, **12** 1197
  carbamazepine concentration prediction, **8** 1327
  cardiovascular disease, **6** 295; **8** 415
  carryover effects, **2** 397; **7** 471, 1099(L); **8** 487, 1421
  categorical data analysis, **10** 1607
  causation, **12** 1477
  CCS, **15** 263
  CD4 T-cell monitoring, **13** 2059
  central laboratories, **9** 125, 145
  change-over design, **2** 397
  cholesterol, **6** 241
  classification reliability, **13** 261
  clinical equivalence, **7** 1267
  clinical practice relationship, **13** 1485
  clustered observations, **13** 509
  coefficients of variation, **15** 647
  colorectal cancer, **10** 65
  combination drugs, **11** 1065
  combined endpoints, **11** 1705
  community trials, **4** 11; **6** 43
  COMPACT computer package, **7** 1165
  comparative binomial trials, **9** 1447
  compartment models, **8** 1011
  complementary medicine, **6** 761

Clinical trials (*cont.*)
compliance, **5** 435
run-in phase use, **9** 87, 103
treatments, **4** 11
computer systems, **9** 137
conduct and philosophy, **1** 311, 337, 353, 361
consent designs randomized, **3** 215
continuous outcomes, **14** 247
contraceptives, **12** 955
control sample size, **11** 1759
coronary artery disease, **13** 499
coronary artery surgery, **3** 389
coronary drug project, **3** 423
correlation anomalies, **10** 1315
costs, **3** 433, 473; **9** 97
central laboratories, **9** 125, 145
compliance run-in phase use, **9** 87
cost-effectiveness analysis, **9** 173; **14** 2249
data collection, **3** 423; **4** 469; **9** 101–152
design issues, **9** 53–100
developing countries, **9** 35
disease prevention trials, **9** 161
effectiveness analysis, **9** 173; **14** 2249
efficiency workshop, **9** 1–199
endpoints efficient use, **9** 155
GISSI cardiology trial, **9** 17
NHLBI trials overview, **9** 9
patient selection, **9** 73
phase II trials, **5** 441
physicians' health study (US), **9** 29, 87
quality assurance methods, **9** 115
randomized trials, **3** 409; **5** 663
repeated measures designs, **5** 663
results applicability, **9** 193
sample size requirements, **3** 435; **5** 663
sickle cell anaemia trial, **9** 45
strata-matching studies, **9** 1475
workshop proceedings, **9** 1–199
covariance, **8** 467, 571
covariates
errors, **6** 31
inbalance, **10** 797–799(L), 1157–1159(L)
omitted, **8** 1107; **9** 777
Cox model/regression trees, **12** 2351
critical reflections, **2** 175
cross-protocol comparisons, **3** 333
crossover trials, **13** 1063
see also Crossover trials
baseline measurements, **6** 911; **11** 727
binary variables, **6** 555
blood pressure measurements, **4** 361
carryover effects, **7** 1099–1101(L); **8** 633(L)
covariances, **6** 911
design, **15** 1435
factorial, **9** 1121
modelling, **15** 1435
sample size estimation, **3** 199
sequentially balanced three-squares, **15** 2143
'simple carry-over' model, **11** 715
therapy evaluation, **3** 45; **8** 441
three-period design, **6** 555; **7** 471
treatment evaluation, **7** 471; **8** 487
two-period design, **8** 487, 1421
crude incidence curves, **11** 813
data collection, **9** 101–151
displays, **1** 131
monitoring, **3** 445, 453; **6** 753; **7** 1165, 1231
quality control, **3** 101, 423, 469; **7** 1165; **9** 115, 145
data monitoring, **12** 415–616, 2219
databases
humongous analysis, **10** 511
medical, **2** 355
meta-analysis, **6** 11
observational studies, **3** 375; **10** 663
practice, **10** 541
publication bias, **6** 11
therapy evaluation, **3** 333
variance components, **10** 599
decision aids, **2** 207
decision rules, **6** 753
decision theory, **14** 231
deficiencies, **2** 155
delayed randomization, **7** 1013
dependent variables, **8** 1433
depressive disorder treatment, **13** 1089
DerSimonion and Laird method, **8** 141
descriptive data analysis, **10** 777
developing countries vitamin A trial, **9** 35
diagnostic tests, **10** 1341, 1887
disease
indicators, **10** 1061
natural history, **8** 1255
prevention large trials, **9** 161
dose escalation studies, **15** 1605
dose ranging simulation study, **10** 303
dose-response evaluation, **3** 359; **9** 1353; **14** 1595
dose-toxicity evaluation, **8** 813; **9** 1117–1118(L)
drop-outs, **3** 199, 435; **11** 2043; **12** 2248–2250(L); **15** 1123
drug combination tests, **8** 1479
drug compliance assessment, **13** 2141
drug regulation, **14** 127
dynamic balanced randomization, **12** 2343
early termination *see* Stopping rules
EEG readings artefacts, **10** 1719
efficacy, **11** 1057; **13** 2323
efficiency, **3** 445, 453, 455, 473; **4** 129
eligibility criteria, **3** 421
epilepsy, **8** 1327
equivalence, **7** 1267; **8** 593
error, **8** 477; **10** 1789
type I, **7** 457, 559, 571, 1231
estimation issues, **9** 657
ethics, **2** 175; **3** 315; **12** 1459

european carotid endarterectomy, **13** 1459
event probabilities, **11** 1719
event rate combinations, **8** 141
evidence strength of, **7** 1267
exact power computations, **13** 1539
exclusion of patients from, **1** 261
explanatory, **7** 1179
factorial designs
  crossover trials, **9** 1121
  methodology review, **10** 1789
  non-compliance effects, **8** 161
  physicians' health study, **9** 29
  reciprocal control approach, **9** 55
  subadditivity effects, **8** 161
  survival analysis, **6** 773
  two-by-two approach, **4** 111
falsification issues, **10** 1679; **11** 1263–1265(L)
fertility regulating vaccine, **10** 177
Fisher's exact test, **8** 1469
Fisher's game, **13** 217
fixed sample design, **5** 375
frequentist approach, **12** 1405
futility testing, **10** 405
future applications, **1** 361
gastroenterology, **7** 581
generalizability, **3** 307, 313
GISSI cardiology trial, **9** 17
glaucoma, **8** 427, 431
grading variable, **8** 1433
graphical representation, **9** 1287
group sequential methods, **14** 381
  Bayesian inference, **4** 521
  bias, **8** 563
  binary variables, **7** 571
  censored data, **5** 375
  confidence intervals, **9** 1277
  data monitoring, **6** 753
  ECOG method, **8** 505; **9** 853–854(L)
  error, **9** 1439
  interim analysis, **4** 521; **9** 1081; **10** 925, 949
  NHLBI developments, **9** 881, 903
  phase II trials, **8** 563; **9** 907
  procedures, **8** 505, 1191
  stopping rules
    bias estimation, **7** 1231
    ECOG impact, **8** 505; **9** 853–854(L)
    efficiency, **3** 353, 445
    methodology assessment, **2** 167; **10** 1789
    monitoring aspects, **6** 753
    myocardial infarction, **6** 927
    NHLBI trials developments, **9** 881
    overviews, **6** 361, 369
    phase III trials, **9** 595
    randomized trials, **10** 405
  treatment comparisons, **5** 375
  two-stage designs, **7** 571
  type I error spending functions, **9** 1439
guidelines, **14** 1655, 1659
haemophiliac study, **10** 433
hayfever, **4** 11
healthy responder phenomenon, **10** 1621
heart diseases, **8** 415, 431; **9** 447
historical controls
  power investigation, **8** 153
  registry data, **3** 225
  therapy evaluation, **3** 315, 325, 331, 385, 467
HIV, **9** 721, 1425, 1433
  CD4-lymphocyte counts, **12** 835
  overlapping enrolment, **15** 2445
  vaccines, **13** 2155
hypertension, **7** 941, 1109; **8** 1302–1303(L)
hypothesis tests, **9** 201, 213; **10** 433, 777, 1679, 1789
imbalance in, **1** 267, 277
incomplete factorial designs, **12** 1629
injury severity, **11** 1171
integrated programme, **5** 459
intention-to-treat, **3** 341, 347, 371, 409, 467; **8** 1302–1303(L)
inter-trial comparisons, **3** 333
interaction
  factorial designs, **4** 111
  interpretation, **10** 1565
  qualitative, **6** 329, 351, 359, 371, 387
  quantitative, **6** 329, 359, 371, 387
  stratum-covariate, **5** 73; **6** 221, 233, 371, 381, 773
  treatment-covariate, **4** 111, 255
interim analysis, **1** 25; **10** 925, 949; **11** 23, 37, 55
  Bayesian inference, **4** 521
  cancer study, **1** 73; **2** 183
  classical approach, **4** 521
  confirmatory analysis, **6** 939
  data monitoring aspects, **6** 753
  ECOG trials, **8** 505
  error, **5** 387; **7** 451(L)
  estimation bias, **7** 1231
  group sequential designs, **8** 505, 1191
  journal developments, **10** 1897
  leukaemia study, **5** 465
  power effects, **5** 387; **7** 451(L)
  stopping rules, **6** 361, 369, 927; **7** 1231
  survival analysis, **6** 939
  treatment evaluation, **1** 73; **2** 183; **5** 375
interpolation, **1** 131
interpretation relevance, **10** 1679
journal developments, **10** 1897
Kalamazoo hyoscine trial, **13** 785
latent intervention effect, **5** 435
life times analysis, **8** 907
limitations, **3** 307, 375
log transformations, **14** 811
long-term survival, **15** 2763
longitudinal data, **11** 1841–1885; **14** 283
Mantel-Haenszel method, **8** 141; **9** 247

Clinical trials (*cont.*)
marginal models, **7** 319
matched pair designs, **9** 943
mean summary statistics, **13** 197–198(L)
measurement error, **8** 1031, 1075; **9** 583–586(L)
melanoma patient survival time, **13** 391
meta-analysis
Bayesian hierarchical models, **14** 2173
changes, **15** 1263
conference, **15** 1233–1323
individual patient data, **14** 2057
monitoring, **15** 1237, 1273, 1299
multiple outcomes, **15** 537
odds ratios, **11** 2077
ordered responses, **13** 2503
quality adjusted survival, **14** 1771
random effects, **15** 2733
two-by-two tables, **11** 141
Methodological and Ethical Issues in (conference), **12** 1373–1534
methodology ten year review, **10** 1789
missing data
bias, **8** 1302–1303(L)
cardiovascular diseases, **8** 415
cause of death, **15** 2191
drug registration, **2** 155
hypertension trials, **7** 941
multiple imputation strategy, **14** 1913
non-random, **14** 2675
treatment effects, **9** 777
monitoring, **6** 753; **15** 1093, 1285, 2341
monotonic dose-response, **13** 87
multi-stage screening tests, **9** 673
multicentre, **1** 353; **9** 919
data evaluation, **12** 1047
multiple decision procedure, **13** 431, 447
multiple endpoints, **14** 1163
multiple interventions, **13** 1479
multiple testing, **9** 811; **10** 871, 939, 1123
multiplicity problems, **10** 1789
multistate model, **6** 795
myocardial infarction, **3** 409, 423; **6** 351; **8** 415
NCI methods, **9** 871, 903
NHLBI methods, **9** 9, 137, 881, 903
NIH methods, **9** 893, 903
non-compliance, **8** 161; **12** 1185; **15** 2813
non-melanoma skin cancer, **12** 1339
non-randomized controls, **3** 225, 341
observational data, **3** 385, 401, 405
odds ratio trends, **13** 293–296(L)
opiate addiction treatments, **13** 467
opthalmologic disorders, **8** 427
optimal design binary response, **4** 497
optimal sample allocation, **15** 2523
over-the-counter drugs, **10** 1
overviews
hypertension treatment analysis, **7** 1109
meta-analyses, **6** 733; **10** 971, 1665, 1789, 1897
odds ratio presentation, **7** 889
pooling efficiency, **6** 565
publication bias, **6** 11
randomized trials, **6** 217–410
P-values, **9** 601; **12** 1443
parallel group design, **7** 1187
parametric approach, **10** 1665
partitioning methods, **5** 517
patient
accrual, **5** 465
selection, **6** 113; **7** 1179; **9** 73; **13** 557
periodontal disease, **14** 413
Peto method, **8** 141; **9** 247
pharmacology studies, **12** 633
phase I
cancer studies, **10** 1647; **12** 1093
CRM, **14** 1149
dose determination, **14** 885, 897, 911, 923
standard method, **13** 1799
phase II
binary outcomes, **7** 571; **9** 229
cost efficiency, **3** 469
dose-response, **5** 449; **14** 987, 1007
historical controls, **9** 215
methodology review, **10** 1789
randomized, **3** 467; **13** 417; **14** 777
sample sizes, **5** 459; **13** 2493
SCPRT, **15** 2037
screening, **13** 1423
sequential trials, **14** 1479
three-stage design, **13** 1727
treatment efficacy, **10** 1327
triangular test, **9** 907; **10** 989
tumour study, **5** 441
phase III
binary outcomes, **9** 229
crossover trials, **14** 1025, 1053
definitive, **13** 1423
design, **13** 417
dose determination, **14** 895, 897, 901, 909
interim monitoring, **13** 1401, 1411
methodology review, **10** 1789
risks/benefits evaluation, **10** 1349
sample size considerations, **5** 459
sequential designs, **15** 2703
systemic exposure, **14** 955, 969
treatment efficacy, **10** 1327, 1349
philosophy and methodology, **14** 1615
photograph evaluation, **8** 1433
physicians' health study, **9** 29, 87
pilot studies, **3** 435; **9** 65
PiZ emphysema therapy, **13** 635
placebo effect, **2** 417; **6** 113; **7** 1187, 1203(L); **8** 1301(L)
planned vs attained design, **11** 853
planning, **3** 435

play the winner, **15** 2135, 2413
polio vaccine trial efficiency, **9** 13
pooling methods
  cost, **3** 473
  efficiency issues, **6** 565
  hypertension treatment, **7** 1109
  meta-analyses, **6** 733
  odds ratio estimation, **7** 889
  publication bias confrontation, **6** 11
power
  allocation methods, **6** 119; **8** 467
  bias assessment, **9** 247
  birth surveillance, **5** 98–99(L)
  cancer prevention, **5** 435
  cohort studies, **2** 25
  cost-effectiveness, **9** 173
  covariate imbalance effects, **8** 467
  critical reflections, **2** 175
  crossover trials, **7** 1099–1101(L); **8** 487, 633(L), 1421
  drug combination tests, **8** 1479
  epidemiology interaction tests, **2** 243
  equivalence trials, **8** 593
  formulae, **8** 153
  grading images study, **8** 1433
  group sequential tests, **8** 505, 563
  heterogeneity, **6** 773
  interim analysis, **5** 387
  methodology review, **10** 1789
  multivariate studies, **4** 117
  placebo effect, **7** 1187
  randomized trials, **3** 409; **5** 663
  repeated measurements, **5** 663
  sample size
    confidence intervals estimation, **8** 803
    estimation issues, **3** 199; **6** 577; **7** 559
    factorial designs, **8** 161
    grading images, **8** 1433
    hypothesis testing, **8** 803
    logistic regression model, **8** 795
    logrank tests, **1** 121; **5** 97–98(L)
    predictive approach, **5** 1
    randomization, **3** 409; **5** 663
    treatment evaluation, **7** 457
  sphericity test, **2** 497
  stopping rules, **6** 927; **7** 1231
  therapies evaluation, **3** 45
  treatments
    baseline period use, **5** 231
    crossover trials, **8** 1421
    drug combinations, **8** 1479
    estimation method, **7** 1179
    sample size design, **7** 457
    two-stage design, **8** 477
  two-stage trial, **7** 571; **8** 477
pragmatic, **4** 11; **5** 1; **6** 101, 389; **7** 1179
pre-assessment prospects, **5** 669
pre-cardiac transplant mortality, **13** 823
premedicant drugs, **5** 363
prevention, **7** 275
primary biliary cirrhosis, **13** 301
prior knowledge treatments, **1** 25
prognostic variables, **1** 345
proportion bias, **8** 563
publication bias
  cardiovascular trials, **6** 295
  interpretation aid, **4** 1
  meta-analyses, **6** 11, 315, 333, 733
  randomized trials, **6** 221, 229, 327
  stopping rules effects, **6** 361; **7** 1231
  survival analysis, **7** 1207
  variability study, **6** 733
publications accessibility study, **13** 2393
qualitative interactions, **4** 111, 255; **7** 1257
quality of life
  assessment, **10** 1915
  cancer, **2** 429; **9** 749
  global statistics, **9** 819
  measurement, **9** 931
quantitative interactions, **4** 111, 255; **7** 1257
radiation therapy, **3** 353, 359
random effects meta-analysis, **15** 619, 2733
randomization/control, **12** 1421
randomized consent designs, **11** 131–132(L)
rats tumour incidence, **13** 709
reciprocal control designs, **9** 55
recruitment, **3** 435, 469; **7** 559
recurrent complications, **14** 2701
recurrent conditions, **8** 1439
registry data, **3** 225, 361, 371; **6** 11, 327
  directory, **11** 345
  ICG-CTR recommendations, **12** 1085(L)
regression, **6** 113, 727–728(L); **7** 1203
REML, **13** 1601
renal cancer, **13** 2249
repeated events analysis, **10** 1227
repeated measures
  mean summary statistics, **11** 1685
  medical research, **3** 185
  missing data, **7** 139
  non-parametric methods, **10** 1959
  sample size, **5** 663
  semi-parametric methods, **10** 1959
repeated significance tests, **6** 753
replacement randomization, **6** 127
replication, **3** 307
reporting Bayesian analyses, **12** 1651
research synthesis, **15** 1253, 1713
resected colorectal cancer treatment, **13** 1337
response
  phenomenon, **10** 1621
  prediction, **9** 253
  variables, **13** 945
results applicability, **9** 185, 193
robust Bayesian monitoring, **15** 1093
run-in strategy, **12** 111

Clinical trials (*cont.*)
safety, **11** 1075; **14** 1099, 1113, 1117
sample size
allocation methods, **6** 119; **8** 467
alpha-interferon, **13** 2249
ancillary questions efficiency, **9** 97
bias, **8** 477
cancer prevention, **5** 435
confidence intervals, **8** 803
confounding effects, **9** 765
costs, **3** 435
covariate imbalance, **8** 467
critical reflections, **2** 175
crossover trials, **7** 1099–1101(L)
determination, **11** 1391
developing countries study, **9** 35
endpoints study, **8** 415
entry criteria, **13** 859
equivalence, **8** 593
estimation methods, **3** 199; **4** 247(L); **12** 1643(L)
European trials, **12** 509
factorial designs, **8** 161
grading images, **8** 1433
group sequential tests, **8** 505
guidelines, **14** 1655
historical controls, **3** 315
hypothesis testing, **8** 803
interim analysis, **5** 387
internal pilot studies, **15** 1587
journal developments, **10** 1897
logrank tests, **1** 121; **5** 97–98(L)
marketing authorizations, **14** 1659
methodology review, **10** 1789
multiple testing, **10** 871
multivariate studies, **4** 117
phase II trials, **5** 441, 459
phase III trials, **5** 441
placebo effect, **7** 1187
planning, **14** 1039, 1053
power
confidence intervals, **8** 803
designs, **3** 199; **7** 457
factorial designs, **8** 161
grading images, **8** 1433
hypothesis testing, **8** 803
logistic regression model, **8** 795
logrank tests, **1** 121; **5** 97–98(L); **6** 577
predictive approach, **5** 1
randomization, **3** 409; **5** 663
survival analysis, **7** 559
t tests, **6** 577
review, **12** 1643(L)
sequential design, **8** 505; **9** 229, 595
small sample sizes, **14** 115
stopping rules, **6** 667; **7** 1231
stratification, **7** 559
survival analysis, **7** 559
therapies, **3** 45, 315
treatment evaluation, **7** 1179; **8** 477, 593; **10** 33, 1595
tumour study, **5** 411; **8** 593
two-sample design, **15** 1
two-stage trial, **7** 571; **8** 477
vitamin A study, **9** 35
screening methods, **8** 161, 415, 1439; **9** 137; **14** 2099
semiannual reports, **11** 1367
sequential designs, **13** 1357
censored data, **5** 375
treatment comparisons, **5** 375
sequential monitoring, **12** 753; **14** 1927, 2227; **15** 2341
serial multivariate data, **11** 1041
sickle cell anaemia trial, **9** 45
side effects incidences, **9** 803
significance, **9** 201, 213, 703
simulation program (CTS), **9** 787
single-arm, **14** 357
small trials, **14** 115
standard perspective, **12** 1501
starting/stopping, **13** 1473
statistical methods usage, **13** 2393
stochastic curtailment, **3** 445
stochastic model, **15** 2617
stopping rules
alpha-interferon, **13** 2249
Bayesian inference, **9** 657
Bayesian monitoring, **14** 357, 1379
binary variables, **7** 571
cancer study, **3** 455; **6** 667
censored data, **5** 375
chemotherapy study, **6** 667
conditional probability, **11** 659
confidence intervals estimation, **9** 657
cost, **3** 469
data monitoring, **6** 753
decision-theoretic evaluation, **11** 673
diagnostic factors, **10** 1341
drug sponsors, **12** 12
efficiency, **3** 445, 453
ethical issues, **12** 1459
European trials, **12** 509, 521
external evidence, **15** 1285
group sequential designs, **8** 1191; **9** 1081, 1439; **10** 405
interim analysis, **4** 521; **10** 925, 949
meta-analysis, **15** 1263, 1273, 1299
Monte Carlo simulations, **6** 667
multiple testing, **10** 871
multiple treatments, **12** 901
myocardial infarction, **6** 927
NHLBI trials, **9** 881
NIH trials, **9** 903
overviews effects, **6** 361, 369
phase II clinical trials, **10** 1327

placebo effect, **6** 927
repeated events analysis, **10** 1227
sample size, **14** 115
sequential designs
bias estimation, **7** 1231
ECOG study, **8** 505
efficiency, **3** 353, 445
monitoring, **6** 753; **10** 405
myocardial infarction, **6** 927
NHLBI developments, **9** 881
overviews, **6** 361, 369
phase II/III trials, **9** 229, 595
treatments, **1** 73; **2** 183; **5** 375
two-stage designs, **7** 571
stratification, **1** 267; **4** 129; **7** 559, 745, 843, 1257
stratum-covariate interaction, **5** 73; **6** 221, 223, 371, 381, 773
strengths, **3** 307
study duration, **11** 1477
subjective rankings, **11** 427–454
subset analysis, **4** 255
surgery innovation, **8** 455
surrogate endpoints, **8** 403–440
surrogate markers, **14** 2619–2620(L)
survival analysis
angina pectoris trials, **9** 293
cancer cure rates estimation, **9** 397
categorical data, **10** 1703
censoring effects, **8** 937
Cox proportional model, **8** 927; **10** 1931
historical control studies, **8** 153
linear regression model, **8** 907
quality adjusted, **9** 1259
symptomatic conditions, **4** 11
teaching statistics, **5** 193; **9** 1013, 1023, 1063
therapeutic preferences, **3** 45
therapy evaluation
cancer, **3** 333, 359
historical controls, **3** 315
innovation, **8** 441
observational data, **3** 341, 347, 361, 375
radiation, **3** 353, 359
randomized trials, **3** 305, 399, 405
registry data, **3** 361, 371
three-period crossover, **6** 555; **7** 471; **8** 891(L); **15** 127
time factor, **8** 1339
titration studies, **8** 583
toxicity, **8** 813; **10** 1089; **11** 2063; **12** 661
treatments
allocation, **14** 2661; **15** 113–116(L)
changes, **15** 249, 2053, 2069
effectiveness assessment, **12** 1651
treatments-by-centre interaction, **12** 1033
triangular test, **9** 907; **10** 901
tumour study, **3** 371; **5** 411
two-armed bandit, **4** 497
two-period crossover, **7** 1099(L); **13** 931
two-sided tests, **15** 1729
two-stage trial designs, **4** 497; **7** 571; **8** 477; **15** 1739
ulcer study, **7** 877; **8** 1439
withdrawals, **2** 155; **7** 941; **8** 1302–1303(L)
Zelen's design, **3** 215; **7** 1179
Clinically determined dose trials, **11** 685
ClinQuery computer package, **10** 559
CLM *see* Composite linear model
Cloning, **9** 457, 1541(L); **11** 132–133(L)
Clonogenic assay, **4** 527
Clopper-Pearson intervals
confidence intervals, **12** 809
medical audits, **12** 2179
Closed population model, **11** 1533
Closed population size, **3** 287
Closed test procedures, **13** 1583; **14** 901, 909
Closed-form estimates missing counts, **11** 643
Closure principle, **13** 1583
Club foot, **15** 2029
Cluster analysis
see also Vancouver conference
AIDS contact tests, **5** 271
AIDS incidence data, **12** 311
association models, **14** 413; **15** 1227–1229(L)
Bayesian estimates, **14** 2411
binary responses, **13** 1241; **14** 1567; **15** 1595–1600(L)
birth defects, **15** 2029
breast cancer mortality, **15** 741
cancer study, **9** 691
chi-squared adjustment, **10** 1981
childhood leukaemia
cluster tests, **14** 2309; **15** 707, 783
Hawaii, **15** 699
natural radiation, **14** 2487
nuclear power plants, **14** 3, 2459
space-time interaction, **14** 2383; **15** 873
classification, **6** 137
clinical judgement, **13** 1501
clinical trials, **9** 35
cluster definition, **12** 1763
CLUSTER software, **15** 943
cluster-specific models, **15** 2573
community intervention studies, **10** 53
compartment models, **8** 1011
correlated binary responses, **15** 1187
covariates, **14** 2393; **15** 919
data sampling, **8** 1537
DEMP, **15** 1837
design effects, **12** 1259
emergency room visits, **15** 823
epidemiology, **1** 183; **9** 691; **10** 1819
exact logistic regression, **14** 2143
exploratory analysis, **15** 807
extraction mapping, **12** 1249
facial pain study, **6** 137

Cluster analysis (*cont.*)
field trials, **13** 61
focused tests, **14** 2291; **15** 765
Gaussian error, **15** 1793
GEEs, **15** 1951
Hawaii, **15** 699
health department investigations, **12** 1757
hypertension study, **9** 301
imprecise space-time locations, **15** 873
k nearest neighbour, **2** 345; **15** 1935
Mantel-Haenszel adjustment, **6** 491
map projections, **7** 491
mapped data, **12** 1275
MCMC, **14** 2473
methods comparison, **12** 1763
mortality rates, **14** 615
multiple injuries, **15** 933
multivariate, **11** 1915; **15** 1885
number estimation, **11** 751
occupational poisoning, **15** 747
odds ratio adjustment, **6** 491
odds ratio estimation, **8** 599
one-dimensional scan statistic, **12** 1853
overview, **12** 1755
point sources, **15** 727
point-based/area-based tests, **15** 783
population-averaged models, **15** 2573
quadrat analysis software, **15** 939
random graph model, **15** 837
randomization unit, **6** 43; **7** 1195; **8** 599
rare data, **12** 1773
regression models, **3** 143
repeated measurements, **13** 509; **15** 429
RSAC, **15** 893
sampling variance estiamtion, **10** 53
scale effects, **12** 1869
scan statistic, **6** 197; **15** 845
shape invariant model, **14** 2009
small areas, **15** 1921
space-time
Bayesian analysis, **14** 2433
DEMP, **7** 491
Hodgkin's disease, **3** 173
influenza, **7** 1147
k nearest neighbour test, **15** 1935
non-uniformly distributed population, **15** 2561
scan statistic, **6** 197
tests, **14** 2383
sparse, **11** 761
spatial autocorrelation coefficient, **15** 887
spatial data, **7** 1157; **8** 267
Stat! software, **15** 951
statistics/computing workshop, **12** 1751–1968
structured environments, **15** 851
surveillance, **8** 267, 279, 323
Tango's index, **12** 1813
tests, **14** 799, 2323
uniformity, **15** 817
variance components study, **10** 599
vitamin A study, **9** 35
workplaces, **15** 759
CLUSTER FORTRAN computer program, **11** 1915
Cluster randomization
antecedent data, **11** 307
sample size requirements, **11** 743
Cluster scores nursing home institutionalization, **14** 1757
CLUSTER software, **11** 603; **15** 943
Cluster-specific linear model, **13** 509
Cluster-specific logistic model, **14** 413
Cluster-specific model, **11** 67; **15** 2573
CMF *see* Comparative mortality figures
CMS *see* Composite measurement scales
Cochran test, **4** 117; **5** 629; **8** 141; **9** 1475; **11** 547, 1759
Cochran-Mantel-Haenszel test, **11** 743; **14** 1901
Code of Federal Regulations (US), **9** 645
Coefficient of determination *see* Squared multiple correlation coefficient
Coefficient of variation
asymptotic test, **15** 647
heart rate, **11** 125
Coeliac disease, **2** 79
Cognitive-behavioural programmes prevention of tobacco use, **12** 365
Cohen's kappa *see* Kappa statistic
Cohort studies
see also Case-cohort studies
active life expectancy analysis, **10** 1945
acute otitis media, **15** 1519
additive models, **4** 353
adjusted attributable risk, **11** 2083
age-mortality relationship, **10** 1043
AIDS, **9** 505, 1387; **13** 2127; **15** 1387
allocation design, **5** 319
Alzheimer's disease, **15** 1023
ambidirectional design, **10** 1775
ancillary questions study, **9** 97
bias, **2** 25
binary variables, **7** 773; **8** 1241
birth analysis, **4** 63
blood pressure, **7** 47
cancer
bladder, **4** 63
breast, **8** 431; **15** 263
endpoints study, **8** 431
epidemiology, **10** 1241
mortality, **1** 245; **4** 353
pooling methods, **5** 303
second incidence, **8** 1371
smoking risks, **7** 223
survival estimates, **9** 529
variation models, **6** 449, 469
case-base studies, **8** 1241; **9** 423
case-control studies, **10** 739
cholesterol, **5** 303; **13** 1135

classification error reduction, **2** 25
clinical trial endpoints, **8** 431
cluster sampling, **8** 1537
community intervention trials, **15** 1069
comparative binomial trials, **9** 1447
confidence intervals, **7** 773
confounders, **13** 2219
contingency tables, **8** 987; **10** 151–153(L)
correspondence analysis, **13** 2407
cost, **5** 319
covariate errors, **8** 1167, 1179
cross-sectional data, **4** 63
data reanalysis, **8** 653–677
death infants, **7** 745
disease prevalence prediction, **11** 295
disease prevention trials, **9** 161
epidemiology, **5** 303; **8** 1241; **10** 1819
error classification, **2** 25
exposure factors, **8** 173
exposure/outcome measurements, **13** 379
Framingham heart study, **7** 205
generalized linear models, **10** 1069
hazardous exposure estimation, **10** 79
healthy workers models, **6** 901
heart disease, **14** 643
hepatitis B screening, **8** 391
historical data analysis, **7** 819
HIV
  disease progression, **13** 1101
  vaccine trials, **13** 2155
hypothesis tests, **6** 689
intermediate endpoints, **11** 167
inverse sampling, **14** 2051
likelihood analysis, **7** 149
logistic regression model, **9** 501
lung cancer study, **7** 223
lung function study, **7** 685
matched sets, **8** 977
measurement error, **8** 1051, 1167, 1179
misclassification, **2** 25; **7** 745; **8** 825, 1095; **9** 1327
morbidity estimation, **7** 325
mortality
  cancer, **1** 245; **4** 353
  occupational, **6** 901; **8** 173
  prediction patterns, **2** 363
  prognostic factors, **4** 295
  ratios, **9** 315
  risk interaction, **7** 239, 289, 293
  trend analysis, **6** 709
multiple hypothesis tests, **14** 585
multiplicative models, **4** 353; **13** 989
multistage model, **13** 23
Muscatine study, **7** 47
myocardial infarction, **7** 205
observational data, **3** 401
occupational mortality, **6** 901; **8** 173
odds ratios, **7** 759; **14** 2581
Poisson rates, **8** 757
pooling results, **5** 303; **9** 1501
power, **2** 25; **5** 319; **7** 759, 1279
prognostic factors mortality, **4** 295
radiation effects, **8** 173
random selection design, **10** 1775
recurrent event testing, **8** 517–519(L)
regression analysis, **7** 275; **9** 463–464(L)
relative efficiency, **13** 61
relative risk, **5** 579; **7** 275, 759; **8** 1051; **10** 1267
respiratory function, **14** 2205
risk, **5** 303; **7** 239; **9** 423; **10** 1511
sample size, **2** 25; **5** 319; **7** 759, 1279; **8** 795; **10** 1993
screening effectiveness, **9** 969
selection bias, **13** 557, 603
sickle cell anaemia, **6** 689
smoking effects, **7** 223
time-dependent variables, **6** 689
trends mortality, **6** 709
two-stage studies, **11** 769
vaccine efficacy, **7** 1279; **9** 1327
variance estimation, **7** 745
Cold ischaemic time liver preservation study, **13** 2517
Colitis, **7** 581
Collaboration, **3** 1; **13** 1337
Collinearity diagnosis relative risk regression, **11** 1273
Colon cancer
  case-control study, **8** 1151, 1165; **11** 1759
  correlated markers, **14** 2217
  Cox analysis, **13** 2233
  pooling, **6** 307, 313
  prognostic markers, **14** 2217
  proportional regression model, **14** 1249
  SPRT, **15** 2781
  survival analysis, **9** 529; **14** 1249
Colon polyp recurrence, **4** 117
Colonoscopy adenomatous colorectal polyps, **12** 339
Colony counts, **5** 393
Colorectal cancer
  Bayesian analysis, **11** 1–53
  clinical trial efficiency, **3** 455
  incidence, **12** 339
  survival analysis, **15** 2797
  treatments, **13** 1337
Coma, **5** 103, 403; **6** 535
Combination
  disease clusters, **12** 1773
  drugs
    clinical trial design, **11** 1065
    positive dose-response surface, **11** 703
    preparations, **4** 77
  HIV treatments, **15** 2425
  models, **15** 851
  preparations, **6** 657

Combination (*cont.*)
probabilities, **6** 265, 341, 381, 387
proportions, **6** 565
therapy two-stage testing, **12** 645
Combinatorial test rare event clustering, **11** 761
Combined endpoints, **11** 1705
COMMIT *see* Community Intervention Trial for Smoking Cessation
Committee for Proprietary Medicinal Products, **14** 1655, 1659
Committee of Safety of Medicines (CSM), **6** 863
Common risk ratio case-cohort studies, **11** 1599
Commonality reference centile curves, **11** 1305
Communication theory, **8** 861
Community based clinical trials, **4** 11; **6** 43; **7** 1195; **9** 35
Community Intervention Trial for Smoking Cessation (COMMIT), **9** 943; **13** 509
random-effects model, **13** 61
Community interventions
health promotion, **12** 329
paired *t*-test, **14** 1491
randomization-based inference, **15** 1069
unpaired *t*-test, **15** 1059
Community Programs for Clinical Research on AIDS, **13** 2107
Comorbidity assessment, **14** 721
COMPACT computer package, **7** 1165
Companion of proportions, **5** 261
Comparative experiments, **1** 5
Comparative exposure ratio, **13** 245
Comparative mortality figures (CMF) disease mapping, **12** 1895
Comparative studies
antibiotic formulations, **13** 11
relative risk, **13** 79
repeated measures data, **15** 1143
ROC curves, **15** 1687
treatment effects, **15** 1489
Comparisons
alternative regression models, **13** 1023
attenuation estimates, **13** 1265
baseline measurements, **10** 797–799(L), 1157–1159(L)
Bayes shrinkage/MMPS estimators, **13** 889
binomial trials, **9** 1447; **10** 1137
blood pressure measuring devices, **4** 361
case-control/cohort designs, **10** 1775
CEB estimates, **13** 1119
clinical trials, **9** 1417, 1433; **10** 1349; **13** 2393
closed test procedures, **13** 1583
cluster binary responses, **13** 1241
cohort studies, **3** 113
compartment models, **8** 1011
confidence interval estimation, **13** 1071
contingency table estimators, **8** 987
correlation coefficients, **8** 1485
counts/rates models, **10** 1405
Cox model and Poisson regression, **9** 1157
cross-protocol, **3** 333
crossover trials, **10** 1099
data-systems, **8** 367
diagnostic tests, **6** 147; **8** 609
discriminant procedures, **13** 719
event rates, **8** 517–519(L)
experimental/standard regimens, **13** 1453
factorial ANOVA design, **10** 1565
groups, **13** 2261
hazard ratio estimators, **10** 749
homicide data, **8** 390
hospital mortality test statistics, **13** 1001
hypothesis/significance tests, **9** 201, 213
incidence models, **13** 651, 1881
interrater reliability, **9** 1103
K1 components, **13** 275
kappa calculation methods, **10** 1465
ligand-binding kinetics, **8** 871
likelihood-based/MEE methods, **13** 479, 495
logistic regression, **9** 1091, 1501
longitudinal data, **13** 2219
lung function techniques, **8** 861
maximum likelihood estimators, **10** 723; **13** 989
means, **6** 79; **8** 803
measurement assessment, **9** 351
methods
maximum likelihood, **10** 981
ordered means, **4** 87, 489, 543–547(L)
proportions, **4** 541
rates, **4** 213, 541
variances, **4** 91
mortality data, **3** 113; **10** 1043
MS models serial MRI data, **13** 453
multiple, **6** 71, 591
multiple group, **10** 1025
multiple testing, **8** 1304–1306(L); **10** 891
multiple treatments, **13** 431
observational databases, **10** 663
parametric/non-parametric procedures, **13** 635
periodontal disease progression, **10** 1089
phase I trial designs, **13** 1799
phase II clinical trials, **10** 1327; **13** 1727
Poisson rates, **8** 757
pooled regression models, **9** 1501
power, **13** 769
predictive models, **13** 1501
probability trees, **8** 229
prognostic variables choice, **9** 273
proportions, **7** 457, 929, 1187; **8** 243–245(L), 563, 803, 1469
regression, **8** 525, 539; **9** 463–464(L)
repeated measurement analysis, **10** 1959
response factors, **8** 1401; **10** 1621
risk prediction, **9** 385
ROC curves analyses, **8** 1277
sensitivities, **6** 147
significance tests, **9** 811; **10** 939

survey data quality, **8** 367
survival curves length bias, **13** 569
survival times, **9** 1527; **13** 1357
t-quantile approximations, **13** 1657
test statistics, **13** 945
time series analysis, **10** 1481
time-fixed/updated covariates models, **13** 301
treatments, **9** 1417, 1433; **10** 939, 1349
tumour incidence analyses, **13** 689, 731
two-sample tests, **9** 447
Compartment models, **8** 1011; **11** 1657
Competing risks
cancer, **2** 41; **6** 785; **7** 1121
case-base studies, **9** 423
categorical response data, **7** 965
contraceptive research, **5** 475
disease recurrence, **2** 41
exposure effects, **8** 845
failure time data, **12** 737
heart disease, **4** 397
heterogeneity analysis, **7** 1121
historical data analysis, **7** 819
log-linear models, **7** 965
misclassification, **15** 1557
missing cause of death data, **15** 2191
mortality, **2** 373; **4** 397; **7** 239, 289, 293
myocardial infarction, **4** 29
prognostic factors, **4** 29
registry random losses, **12** 767
survival analysis, **2** 41; **5** 475; **7** 1121
Complementary log-log model design effects, **12** 1259
Complementary medicine, **6** 761; **11** 345
Complete cases
algorithm, **8** 217
missing data mechanisms, **15** 127
Compliance
AIDS clinical trials, **15** 2475
clinical trial treatments, **10** 1595
CT run-in strategy, **12** 111
drugs, **13** 2141, 2323; **15** 659, 2813
physicians' health study, **10** 1585
randomized clinical trials, **9** 103
run-in design, **9** 87
treatments, **4** 11; **9** 1417, 1433
Components of variance, **7** 1195
Composite linear model
incomplete multinomial data, **13** 609, 647
matrix formulae, **13** 609
Composite link matrix expected counts, **13** 609
Composite measurement scales (CMS)
construction, **14** 331
weighting, **14** 2565
Composite orthogonal polynomial repeated measures scores, **11** 2037
Composite response correlated ordinal data, **14** 1961
Compound distribution, **2** 253
Compound mixture model, **7** 483
Compound sampling model, **10** 811
Compound symmetry, **6** 911; **8** 891(L)
BP tracking correlations, **11** 1187
longitudinal data, **11** 1843, 1915, 1967, 2033
repeated measures, **11** 1685
respiratory function, **14** 2205
Comprehensive Cohort Studies, **15** 263
Computer packages, **12** 241
see also BMDP . . .; GLIM . . .; SAS . . .
advances, **15** 1859
BUGS, **14** 2685
CALIS, **13** 127
C.A.MAN, **12** 1965
CART, **8** 947; **11** 475
CAST, **12** 1967
clinical trials
guidelines, **14** 1655, 1659
review, **10** 1789
ClinQuery, **10** 559
CLUSTER, **15** 943
CLUSTER FORTRAN, **11** 1915
CLUSTERS, **11** 603
COMPACT, **7** 1165
cost-effectiveness model, **9** 173
CTS program, **9** 787
DATA DESK, **9** 469
data verification, **12** 1535
data-collection, **9** 115, 137
DIGRAM, **14** 1265
DISMAP, **12** 1965
DismapWin, **15** 919, 931
EGRET, **12** 2147–2151(L); **13** 301
Epi-Info, **11** 1289
EPICURE, **13** 301
EPILOG PLUS, **13** 301
EV CARP, **8** 1137
FISHER, **11** 2123
FORTRAN, **12** 153, 1155; **13** 1539
GAUSS, **10** 1391; **11** 219, 1607, 1633
GEE, **12** 1019; **15** 1807
GENMAX, **9** 409
GENSTAT, **9** 469; **11** 1425; **13** 2503
IMSL, **9** 539; **10** 473; **12** 1125
IMSL-GGPON, **12** 153
JMP, **9** 469
LINCS, **11** 1195
LINDO, **9** 273
LISP-STAT, **11** 115, 939
LISREL, **8** 1137; **11** 1195
MACSPIN, **9** 469
MAPLE, **14** 1553
measurement error corrections, **13** 1135
Minitab, **9** 469, 1063; **10** 675; **11** 923; **14** 199
MLLSA, **9** 559
MULCOX2, **13** 2233
multivariable prognostic models, **15** 361
NONMEM, **11** 1777

Computer packages, (*cont.*)
PANEL, **9** 559
PANMARK, **9** 559
PECAN, **8** 1371
PEST, **15** 2781
PEST2, **12** 2257; **9** 1277
PROC CATMOD, **10** 1273
PROC IML, **11** 1151
PROC MATRIX, **9** 397
quadrat analysis, **15** 939
REML, **8** 891(L); **13** 1601
ROC ANALYZER, **11** 475
S, **12** 1953
S-PLUS, **13** 301; **15** 361
SIMULINK, **14** 185
software development/implementation, **12** 789
SPAN, **14** 2645
SPSS matrix H^2, **12** 2285
SPSS-PC, **15** 933
Stat!, **15** 951
STATA, **11** 475, 897, 1115; **13** 301
statistical graphics software, **12** 1953
Statistician's Report Worksheet, **11** 1367
StatXact, **13** 1539, 2189
SUDAAN, **13** 343; **14** 643
teaching, **9** 1031, 1039, 1043, 1063
TIGER, **12** 1755
updated covariates model, **13** 301
VESPERS-11, **12** 249
Wilcoxon test, **12** 1063
Computer Tomography, **4** 311; **5** 593
liver metastases, **12** 2191
mediastinal metastases, **12** 1293
Computers
databases, **7** 1165
clinical trials, **6** 11
head injury, **5** 103, 403
diagnosis, **4** 311, 317; **5** 497, 503
expenses, **15** 2127
prognosis, **5** 403
tomography, **4** 311; **5** 593
Concentration, **7** 535
Concomitancy physiological pulse series, **12** 2043
Concordance correlation coefficient, **11** 1929
Concordance ratio, **6** 961; **15** 581
Condition indices collinearity diagnosis, **11** 1273
Conditional analysis
crossover designs, **12** 825
McNemar test, **11** 1521
Conditional autoregressive plot, **11** 983
Conditional binomial test, **12** 699
Conditional confidence intervals, **14** 2051
Conditional correlation, **11** 633
Conditional expectation
exponential random variable, **13** 391
poisson time series models, **13** 453
Conditional independence models, **11** 2001; **12** 1703
Conditional likelihood
AIDS incidence, **14** 1505
exact logistic regression, **14** 2143
matched designs, **12** 993
Conditional logistic model, **13** 1023
Conditional maximum likelihood, **12** 1969
Conditional models
longitudinal data, **11** 1861, 1981
rate of change estimation, **11** 621
Conditional posterior densities, **13** 1525
Conditional probability
competing risks failure time data, **12** 737
stopping rule, **11** 659
two-stage studies, **11** 769
Conditional tests, **9** 363–383
baseline balance, **13** 1715
equivalence, **13** 1827
Conditioned life tables, **12** 767
Conferences *see* Special issues
Confidence bounds, **13** 1551
Confidence ellipsoid, **7** 525
Confidence intervals
absolute risk, **10** 1025
adverse drug reaction rate, **7** 1023
age-related reference ranges, **13** 2359
AIDS incidence, **14** 1505
air pollution, **8** 1109, 1127, 1133, 1137
attributable risk, **7** 507
Bayes random effects model, **13** 541
Bayesian methods, **10** 811
binomial, **12** 809; **13** 1283–1285(L), 1693–1698(L)
bioequivalence studies, **10** 959, 961
Bonferroni, **8** 1485
cancer cohort model, **13** 23
case-control studies, **10** 1037
categorical regression models, **14** 2131
cell culture count, **13** 523
censored data, **8** 1269
clinical trials, **9** 657, 1287; **10** 1349, 1789
closed population, **3** 287
comparative binomial trials, **9** 1447
comparative exposure ratio, **13** 245
contingency table estimators, **8** 987
cost-effectiveness ratios, **15** 1447
count data analysis, **9** 615
cross-sectional studies, **14** 51
data reanalysis, **8** 669
diagnostic-test cut-off point, **8** 1381
difference in proportions, **4** 23, 213
disease prevalence, **8** 1225
early stopping, **13** 1341
equipment dose, **5** 363
equivalence definition, **12** 2009
equivalence testing, **5** 203
errors-in-variables, **8** 1071
exact power computation, **14** 2261
excess risk, **15** 1535

expected widths, **12** 809
Fieller's, **13** 759, 2531
first event occurrence, **12** 685
frequentist, **12** 1405; **13** 1699
generalized linear models, **11** 923
genetic diseases model, **14** 1353
hazard ratio estimation, **9** 1167; **10** 749
HIV
  pooled tests, **13** 1905
  seroconversion, **12** 153
hospital quality performance, **14** 2161
incidence aberrations, **8** 323
incidence parameters, **13** 1881
interim analysis, **13** 101
interpretation, **12** 1651
inverse formula, **12** 2025
inverse sampling, **14** 2051
journal developments, **10** 1897
kappa statistic, **10** 767, 1303; **11** 1511; **14** 347
limited failure population model, **9** 409
longitudinal studies, **14** 283
measurement correlations, **9** 1175
median, **13** 1635
median survival times, **14** 275, 2537; **15** 171
meta-analyses, **10** 971
multiple testing, **10** 871, 939
observational data, **8** 273, 279
odds ratio, **4** 213; **7** 745, 889; **10** 1273
Poisson distribution, **10** 457
pooling controls, **10** 1417
population size, **10** 717; **15** 1635
post-test probability, **10** 443
power, **14** 873
prescription event monitoring, **15** 987
prevalence rates, **14** 1471
proportion, **7** 865
protective efficacy of vaccine, **7** 1279
provisional diagnoses, **10** 1341
quality adjusted survival analysis, **9** 1259
quantities of interest, **13** 969
radioimmunoassay calibration, **14** 935, 953
random effects meta-analysis, **15** 619
rate, **7** 865
regression line, **5** 347
relative risk, **8** 1051, 1071, 1528; **10** 1745
renal clinical trial, **13** 2249
risks, **7** 773; **8** 1241; **10** 1511, 1753
ROC plot, **13** 499
sample size, **8** 803; **10** 1993; **11** 269(L)
sequential clinical trials, **9** 1277
significance tests, **9** 201
small health risks, **15** 183
smoothing procedures, **14** 1205
SSPE risk estimation, **10** 1733
standardized mortality ratio, **13** 2189
standardized rates, **14** 1875
stochastic processes, **10** 1427
survival
  analysis, **10** 413
  data, **8** 927
  estimates, **13** 43; **14** 1553
  function, **5** 85, 653
  probability, **6** 679
treatment evaluation, **7** 1267; **8** 1421
two-period crossover trials, **8** 1421
vaccine efficacy, **13** 357; **15** 2379, 2405
variance component study, **10** 599, 1441
weighted proportions, **13** 1071
within-person measurement error, **8** 1051
Confidence regions
  expected square volume minimization, **12** 1999
  multiple treatments, **15** 2509
  sequential monitoring, **15** 2341, 2367
Confidence surface, **11** 703
Confidentiality
  environmental health data, **15** 1895
  GIS, **15** 1961
Confirmatory analyses, **3** 405; **6** 939
Conformity quantitative measurements, **13** 2465
Confounders
  see also Nuisance parameters
  cluster analysis, **14** 2323
  continuous case-control studies, **12** 993
  detection, **13** 2219
  dose-response estimation, **14** 987, 1007
  ecologic study bias, **14** 327–330(L)
  exposure variables, **14** 1437
  misclassification, **14** 1291
  monotonic increase with age, **12** 1989
Confounding
  attributable risk, **11** 2083
  by indication, **15** 2273
  case-control studies sample size, **9** 1485
  clinical trials, **10** 797–799(L), 1157–1159(L)
  cluster analysis, **12** 1763
  data reanalysis, **8** 653–677
  databases analysis, **10** 511
  dental health study, **2** 59
  drug indication, **10** 653
  ecologic study bias, **11** 1209
  epidemiological studies, **8** 679; **10** 1819
  geographical correlations, **9** 515
  initial measurements, **12** 1213
  intended effects, **2** 267; **4** 387–389(L)
  latent class analysis, **4** 327
  log-linear model, **2** 59
  misclassification, **8** 1095, 1528; **10** 1181
  multiple reports, **8** 1041
  neighbourhood, **7** 1087
  odds ratios extraneous factors, **9** 1131
  relative odds estimation bias, **11** 953
  relative risk estimation, **10** 1745
  repeated measurements, **9** 639
  residual, **11** 1747
  sample size effects, **9** 765
  smoking cessation, **12** 1605

Congenital abnormalities, **3** 239; **4** 389–391(L); **5** 98–99(L), 565; **7** 387; **14** 1797
Congenital rubella syndrome, **6** 843
Congenital syphilis, **3** 293
Congestive heart failure, **12** 2009
Consensus
  binary rules, **11** 317
  diagnostic, **11** 317
  subjective ranking analysis, **11** 427–454
Consent designs, **3** 215; **7** 1179; **9** 645
Consistency
  dosage response estimates, **13** 87
  paradox, **12** 2191
  quantitative measurements, **13** 2465
Consonance interval, **7** 1267
Constant ratio design, **11** 547
Constrained equations maximum likelihood, **15** 2573
Constrained estimators
  disease contracted population, **13** 1827
  empirical Bayes, **13** 1119
Consultation, statistical, **3** 1
Contact analysis
  AIDS spread, **5** 271; **8** 103, 121
  HIV transmission, **8** 59, 83, 93
Contiguity algorithm, **15** 1885
Contiguous zones grouping, **5** 171
Contingency tables
  AIDS study, **8** 619
  association models, **8** 1199
  backward elimination, **2** 59
  bias estimation, **8** 987; **10** 723
  binary variables, **9** 1517
  biplots, **9** 469
  bivariate regression model, **14** 1341
  case-control studies, **9** 765; **10** 1775
  categorical data, **8** 1209, 1545–1547(L)
  clinical trials, **8** 583; **13** 2393
  cluster data adjustments, **6** 491
  collapsibility, **2** 59
  conditional association, **2** 79
  confidence intervals estimation, **10** 717
  confounding effects, **2** 59; **9** 765
  crossover designs, **9** 1517
  disease risks estimation, **7** 591
  drug safety, **14** 1113, 1117
  efficient power computation, **13** 1539
  epidemiology bibliography, **10** 1819
  error, **8** 1095
  exposure factors, **9** 1131
  factorial analysis, **10** 1565
  Fisher's exact test, **5** 629; **8** 243–245(L), 1469
  genetic estimation, **7** 591
  Goodman and Kruskal statistic, **8** 619
  homogeneity test, **8** 1455
  independence tests, **7** 1297; **10** 1555; **14** 1621; **15** 2095
  Jewell's estimators, **8** 987
  kappa study, **10** 767
  likelihood ratio tests, **6** 91
  log-linear models, **2** 59
  maximum likelihood, **6** 91; **8** 987; **9** 1517
  misclassification, **8** 1095; **9** 1327
  missing data, **6** 91; **7** 109; **11** 643
  model selection, **2** 59
  odds ratio, **8** 599, 987, 1455; **9** 1131
  ordered categorical data, **13** 2437
  P-values, **5** 629; **8** 243–245(L), 1469
  power, **8** 1469; **10** 1321–1322(L)
  quasi-exact test, **10** 1137
  random models, **10** 991
  regression, **9** 1517
  relative risk, **8** 987
  risk, **8** 987; **9** 765
  sample size, **9** 765
  square, **6** 91
  structural zeros, **14** 1901
  symmetry and quasi-symmetry, **9** 1143
  Yates correction, **9** 363–383; **11** 845–847(L)
Continual reassessment method (CRM), **13** 1799; **15** 1605
  dose determination, **14** 885, 897, 911, 923
  phase I trials, **14** 1149
  simulation study, **12** 1093
Continuation ratio model, **3** 273; **7** 435; **10** 1703; **12** 2257; **13** 1665; **15** 323
Continuity corrected score intervals, **12** 809
Continuity corrected Wald interval, **12** 809
Continuity correction
  binomial data, **7** 929
  contingency tables, **5** 629; **8** 243–245(L)
  missing data, **7** 929
  Yates', **9** 363–383
  z-statistic, **11** 913
Continuous binary regression, **14** 247
Continuous confounders case-control studies, **12** 993
Continuous data
  exposure, **15** 2603
  univariate survival analysis, **15** 2203
Continuous exposures
  case-control studies, **12** 993
  monotonic increase with age, **12** 1989
Continuous Hyperfractionated Accelerated Radio Therapy
  cancer trials, **13** 1297
  unified design, **13** 1815
Continuous mixture model, **15** 1365
Continuous monitoring, **12** 2219
Continuous time autoregressive models
  steady state departures, **11** 515
  tumour biomarker data, **12** 265
Continuous time models, **13** 1643
Continuous variables, **13** 301
Contour mapping missing values, **14** 605

Contraception
Africa sub-Sahara, **10** 161
cancer epidemiology, **14** 151
comparison menstrual diary data, **12** 955
failure, **10** 201
HIV model study, **10** 1003
life-table methods, **5** 475
menstruation, **10** 267
methodology efficacy, **10** 201
model selection, **9** 1131
oral, **7** 275; **10** 1025
pharmaceutical tests, **12** 1999
Poisson variability, **10** 241
probability, **10** 221
Contrasts
orthogonal, **7** 467
tests repeated measures designs, **3** 185
Control-conditional test HIV, **15** 2371
Controls
drug comparisons, **11** 1057
external cohort studies, **4** 295, 353
gonorrhea programmes, **8** 343
multiple case-control studies, **5** 29
treatment phase II trial, **13** 417
treatment comparison, **13** 2261
Convergence
EMS algorithm, **13** 1865
Gibbs sampling algorithm, **13** 1841
prevention trials test statistics, **13** 1807
Convolution equation, **9** 1387, 1433; **13** 1865
Cook's distance statistic, **10** 1719
'Coolfont Projections', **8** 137
Copas' method, **9** 1189
COPD *see* Chronic obstructive pulmonary disease
CORMS *see* Composite orthogonal polynomial repeated measures scores
Corneal transplants, **9** 1091
Cornfield's approach U.S. legal cases, **14** 1641
Coronary artery bypass operations non-adherence, **12** 1185
Coronary artery disease
see also Heart disease
angiography, **12** 1155
arteriography variability, **5** 619
cholesterol risks, **8** 295
databases, **3** 375
discriminant analysis, **7** 519
logistic regresson, **7** 519
prognostic prediction, **3** 143
regression models, **3** 143
screening methods, **4** 53
surgery, **3** 375, 389; **5** 619
validation bias, **4** 53
Coronary Artery Surgery Study (CASS), **3** 375; **5** 619
Coronary Drug Project Aspirin Study (CDPA), **6** 225
Coronary Drug Project (CDP), **3** 423, 445
Coronary heart disease *see* Heart disease
Coronary heart disease (CHD)
Coronary Primary Prevention Trial clinical trial, **12** 111
Corrections
Barlett's, **7** 387
continuity, **5** 629; **7** 929; **8** 243–245(L); **9** 363–383
finite population, **4** 237–242(L)
Corrections to published papers *see* separate index page
Correlations
see also Geographical correlations
binary response variables, **11** 751
binary responses, **15** 1187
binomial variates, **11** 1607
biplots, **9** 469
blood pressure measurements, **15** 2013
cancer mortality rates, **10** 95
categorical, **11** 67
chi-squared test, **10** 1981
clinical trials, **8** 467; **10** 797–799(L), 1157–1159(L)
closed trend test, **13** 1583
cluster analysis, **15** 1793
CMS, **14** 2565
coefficient
biserial, **7** 955
dietary validity studies, **13** 127
familial, **6** 629
hypothesis testing, **6** 3
intraclass, **6** 43, 647
intracluster, **6** 491; **7** 1195
reliability studies, **6** 441
risk relationship, **7** 717
serial, **7** 697
tetrachoric, **7** 955
comparisons, **8** 1485
confidence intervals estimation, **4** 23
continuous prognostic markers, **14** 2217
contradictory derived scales, **10** 1315
counts/rates models, **10** 1405
covariance models, **14** 1397
covariates imbalance tests, **9** 1455
data quality clinical trials, **9** 125
design effects, **12** 1259
disease progression data, **9** 1175
failure times, **14** 1447
fellow eyes, **13** 1023
GEE models, **15** 1951
geographical distribution, **9** 515
heterogenous clustered binary data, **11** 1915
interobserver variation, **8** 765(L), 766(L)
intraclass, **13** 2465; **14** 1693
kappa estimation ophthalmic data, **10** 1303
linear regression, **14** 789
longitudinal, **11** 1825
measurement assessment, **9** 351

Correlations (*cont.*)
method comparison studies, **10** 981
multiple reading procedures, **11** 209
multiple-outcome meta-analysis, **15** 537
multivariate probit analysis, **10** 1391
ordinal regression models, **15** 1807
outliers bioavailabilty studies, **10** 1375
paired binary data regression, **9** 1517
percentile regression, **14** 777
regression to the mean, **10** 1295
relative odds estimation bias, **11** 953
repeated binary responses, **13** 1149
repeated measurements, **10** 1959; **13** 1101
repeated ordinal data, **14** 1961
ROC curves, **15** 1687
sensitivity/specificity, **11** 1503
serial, **2** 497
significance testing, **9** 811; **10** 1123
spatial, **5** 171
SPECT images, **10** 1711
squared, **15** 1987, 1999
time series analyses, **1** 49; **2** 413(L); **8** 1497
tumour growth models, **10** 1075
unequal repeated measures, **11** 1685
variance estimation, **11** 1551
within-person measurement error, **8** 1051
work sampling data, **15** 607
Correspondence analysis, **4** 303; **7** 983; **8** 1351, 1545–1547(L); **13** 2407
Cosinor analysis, **6** 167; **7** 697; **12** 1665; **13** 1201
Cost-effectiveness ratios, **15** 1447
Costs
see also Clinical trials
case-control studies, **5** 319
clinical trials, **14** 2249
cohort studies, **5** 319; **10** 1775
considerations optimal sample size determination, **11** 547
CT run-in strategies, **12** 111
function, **6** 647
longitudinal data, **11** 1889
neural net parameters, **13** 1189
pharmaceutical project prioritization, **15** 2689
risk-ratio estimation efficiency, **4** 541
utility function parameter, **13** 2493
vaccine trial screening, **14** 2099
Count crossover data analysis of variance, **11** 1033
Counting process, **5** 243, 327, 491; **7** 275, 819; **12** 843
Course moderators dose-response relationships, **11** 685
Covariance structure models
dietary assessment, **12** 925
measurement error, **12** 925, 937
Covariances
see also Analysis of covariance
absolute risk, **10** 1025
algorithms, **8** 217
angina pectoris study, **9** 293
case-control studies, **10** 1037
clinical trials, **10** 797–799(L), 1157–1159(L)
confounding control, **8** 679
correlations diseases, **9** 1175
crossover design, **13** 2531
data reanalysis, **8** 653–677
discriminant analysis, **10** 473
error, **8** 1075; **9** 583–586(L)
frailty models, **14** 1447
generalized linear models, **10** 1069
inbalance clinical trials, **8** 467
linear models, **8** 907, 1075; **9** 583–586(L)
log linear model, **8** 571
longitudinal data, **7** 199
matrix
confidence intervals, **14** 2161
dose-response studies, **15** 343
GEE1 parameter estimates, **13** 467
incidence rate estimates, **13** 651
linear Gaussian models, **14** 1219
maximum likelihood estimate, **13** 759
missing data models, **14** 1397
multilevel linear models, **13** 1643
naive parameter estimates, **13** 1135
sequential monitoring, **15** 2341
smoothing procedures, **14** 1235
spatial autocorrelation coefficient, **15** 887
two-period crossover design, **13** 905
measurement error, **8** 1075; **9** 583–586(L)
missing data analysis, **8** 217
outliers bioavailabilty studies, **10** 1375
PQD parameter estimates, **13** 623
pulmonary function study, **8** 189
random effects models, **8** 189
RCR models, **13** 1211
regression methods, **8** 217; **9** 1175
renal disease surveillance, **9** 1175
repeated measurements
analytic methods, **7** 29, 87
crossover designs, **7** 471
epidemiological methods, **7** 601
linear models, **7** 317
longitudinal data analysis, **7** 109, 199
missing data, **7** 317, 357
smoothing procedures, **7** 601
trend assessment models, **7** 185
ROC curves, **9** 325; **15** 1687
sarcoidosis study, **8** 189
smoking information, **8** 997
stochastic models, **8** 121
structure repeated measures, **13** 1601
survival analysis, **9** 293
Covariates
adjusted mixture models, **15** 919
adjustment, **6** 31, 255, 911; **7** 1243
AIDS, induction time effect, **13** 2021
baseline balance tests, **13** 1715

Bayesian meta-analysis, **14** 2685
Bayesian population models, **14** 971
biplots, **9** 469
cancer treatment choice, **13** 1575
case-control studies, **14** 769
censored data, **15** 953
childhood leukaemia incidence, **14** 2487
chronic otitis media risk factors, **9** 1495
clinical trials, **7** 1243
cluster analysis, **14** 2393
confounding sample size, **9** 765
Cox proportional hazards, **9** 1501; **10** 1931; **14** 1707, 2119; **15** 2589
crossover trials, **9** 1121
databases analysis, **10** 511
dependent data, **14** 1819
diabetic retinopathy model, **14** 2599
disease prevention trials, **9** 161
factorial designs, **9** 1121
failure risk effect, **13** 2233
family studies, **13** 1679
foetal studies, **14** 1417
geographical, **9** 515, 691
Gibbs sampling, **15** 1663
goodness-of-fit statistic, **13** 143
hazard regression, **15** 1757
heart disease risk, **14** 1265
high-risk sexual behaviour, **15** 2323
HIV incidence models, **15** 513
human chromosome classification, **10** 141
imbalance
  ANCOVA, **12** 101
  tests, **9** 1455; **10** 797–799(L), 1157–1159(L)
importance measurement, **9** 633
influences, **12** 2099
internal/external, **13** 301
iodine thyroid uptake, **13** 185
linear measurement error models, **8** 1075
liver transplant study, **10** 733
logistic regression, **9** 1501; **15** 1987
malarial risk, **13** 2345
measurement error, **8** 1151, 1165, 1167; **12** 1703
median survival times, **14** 2537; **15** 171
misclassification, **10** 1181
missing covariate values, **9** 777
missing data models, **14** 1315
mixture survival model, **15** 2077
model comparison, **14** 735
multiple, **8** 1515
multiple significance testing, **9** 811
multivariate regression models, **15** 2013
observer agreement studies, **14** 299, 2285–2288(L)
omission clinical trials, **8** 1107
paired binary data regression, **9** 1517
patient selection, **9** 73
pooled regression models, **9** 1501
potential confounder, **12** 1989
predictive values, **15** 463
proportional hazards regression, **15** 1033
random effects model, **14** 395
relative risk prediction, **9** 287
repeated measurements, **9** 639
semi-proportional hazards model, **15** 1771
strata-matching studies, **9** 1475
stratified trend test, **9** 829
stratum interaction, **5** 73; **6** 221, 233, 371, 381, 773
survival analysis, **9** 487; **10** 733, 1931; **14** 161
systemic exposure, **14** 955, 969
time-dependent, **4** 29; **7** 139, 169, 205, 297
time-varying, **9** 1221–1222(L); **14** 1843
transplantation multistate model, **13** 2517
unrestricted survival times, **13** 391
Coverage functions confidence intervals, **12** 809
Coverage probability, **13** 2189
common odds ratio, **14** 1567
confidence interval estimation, **14** 1875
kappa statistic, **14** 347
median survival times, **14** 2537
population size, **15** 1635
Cox proportional hazards model, **12** 1733, 2133
abortions data, **5** 243
absolute risk, **8** 641; **10** 1025
age-adjustment, **14** 1731
age-related competing mortality trials, **10** 65
AIDS cohort study, **13** 2127
AIDS incubation period, **13** 969
angina pectoris, **9** 293
association tests, **7** 257, 289
Bayesian analysis, **11** 13, 37
bias study, **7** 1243
bootstrap investigation, **8** 771
bootstrap resampling, **11** 2093
burn-care management, **12** 301
cancer study, **1** 93; **2** 183; **9** 529
carcinoma study, **2** 287
cardiovascular disease, **14** 1745
case-cohort designs, **14** 1609–1610(L)
case-control studies, **10** 739
categorical data, **10** 1703
CD4 lymphocyte counts, **15** 2289
cell distributional patterns, **13** 523
censored data, **2** 287; **5** 85; **15** 953
change rate analysis, **7** 337
CIN/HPV, **13** 379
classification, **4** 287
clinical trials, **8** 771, 813
cohort studies efficiency, **8** 977
comparisons, **6** 591; **8** 525, 539
confidence intervals, **8** 927
coronary heart disease risk, **9** 287
correspondence analysis, **4** 303
counting process, **5** 491
covariate interactions, **5** 73; **7** 1257; **14** 735
cross-validation, **11** 475; **12** 2305

Cox proportional hazards model (*cont.*)
crossover studies, **10** 1099; **15** 527
cubic spline functions, **15** 2589
cumulative hazards functions, **11** 1465
databases methodology, **10** 617
diabetes, **7** 661; **14** 1975
differential prognostic influence, **11** 281
discriminant analysis, **4** 413
disease history study, **8** 1255; **9** 1221–1222(L)
dose-toxicity relationships, **9** 1117–1118(L)
drug combinations analysis, **9** 1527
drug safety, **14** 1113, 1117
endpoint treatment relationship, **13** 955
epidemiology, **5** 303; **8** 703; **10** 521, 1819
error effect, **6** 31
estimator comparison, **10** 749
explained variation, **15** 1999
exponential survival time, **13** 391
exposure analysis radiation, **5** 539
Framingham heart study, **7** 205, 219, 289
generalized approach, **14** 1191
goodness of fit tests, **8** 893
graphical analysis, **14** 1707
grouped data analysis, **7** 613
heart disease, **4** 413; **9** 1157
heterogeneity, **6** 773
historical controls studies, **3** 225
historical data analysis, **7** 819
interval censored data, **13** 1771
kidney graft survival, **14** 1999
last case influence, **11** 1615
leukaemia surveillance, **4** 287
linear regression model, **8** 907
liver transplant study, **10** 733
logistic regression, **4** 413; **8** 525; **9** 463–464(L); **10** 1213
long-term survival, **15** 2763
longitudinal studies, **8** 1515
marked point process, **15** 2751
measurement errors, **8** 1075
melanoma study, **4** 265
meta-analyses, **10** 1665
misclassification, **14** 1307
mismodelling effects, **7** 257, 289
missing values, **9** 777
monitoring devices efficacy, **10** 351
morbidity estimation, **7** 325
mortality analysis, **4** 295; **6** 501
multistate analysis, **12** 2315
multivariable prognostic models, **15** 361
multivariate failure times, **13** 2233
myocardial infarction, **4** 29
NCI clinical trials, **9** 871, 903
neural nets, **13** 1189; **14** 73
non-parametric Bayesian approach, **15** 1757
nursing home institutionalization, **14** 1757
penalized likelihood, **13** 2427
person-time data, **9** 463–464(L)
Poisson regression comparisons, **9** 1157
pooled logistic regression, **9** 1501
post marital bereavement study, **10** 395
prediction rules error rates, **9** 1303
predictive ability comparison, **11** 125
prognostic factors, **12** 2377
cancer surveillance, **4** 279
heart disease, **4** 303
leukaemia surveillance, **4** 39, 287
melanoma study, **4** 265
myocardial infarction, **4** 29
prediction estimation, **3** 143
renal disease, **5** 637
quality adjusted survival analysis, **12** 975
radiation exposure, **8** 173
rate ratio estimation, **12** 1733
regression tree comparison, **12** 2351
renal disease, **5** 637
residual confounding, **11** 1747
restricted cubic splines, **14** 2119
review, **10** 1931
risk factors, **4** 413; **7** 297; **11** 783; **12** 1589; **13** 2517; **14** 643
robust method, **15** 1033
sample size, **7** 559
score test, **15** 1049
semi-proportional model, **15** 1771
sequential monitoring, **14** 2227
sequential trials, **2** 183
smoking, **8** 997; **12** 1605
sparse stratified data, **12** 2285
surrogate endpoints, **12** 835
survival curves, **11** 455
survival time estimates, **13** 1747
survival-data analysis, **14** 161
therapies, **7** 1013
threshold-crossing data, **12** 1589
time scales, **13** 823
time-by-covariate interactions, **13** 1045
transient effects, **14** 1553
treatment
changes, **15** 2069
covariate interaction, **7** 1257
parameters, **12** 1353
tree techniques, **8** 539
updated covariates, **13** 301
validation methods, **4** 39
variation measures, **9** 487
Cox-Snell residuals, **14** 1785
CPCRA *see* Community Programs for Clinical Research on AIDS
CPEP *see* Calcium for Pre-Eclampsia Prevention
CPMP *see* Committee for Proprietary Medicinal Products
CPPT *see* Coronary Primary Prevention Trial
Cramèr-Slucky theorem additivity tests, **14** 1941
Cramer-Von Mises statistic, **7** 1031
Creatine kinase, **7** 377

Creatinine, **7** 629
Credible interval
  Bayesian approach, **12** 1405
  odds ratio, **7** 1223
Crime methadone programme, **15** 2253
Criterion-based methods pulse detection, **14** 311
Critical points closed trend test, **13** 1583
CRM *see* Continual reassessment method
Crocidolite miners, **7** 955
Cronbach's alpha index correlation, **12** 365
Cross-product statistic, **15** 873
Cross-sectional studies
  adjusted attributable risk, **11** 2083
  age-specific disease, **13** 2369
  analytical methods, **11** 1825, 1889
  child growth charts, **13** 2477
  community intervention trials, **15** 1069
  confounding examination, **7** 1087
  geographical coherence, **11** 1409
  HIV transmission, **14** 1365
  irregular data, **4** 63
  lens opacities, **15** 145
  longitudinal data, **13** 2219
  lung function tests, **7** 685
  maximum likelihood estimation, **9** 539
  prevented fraction, **14** 51
  quality adjusted survival, **15** 93
  relative efficiency, **13** 61
  sample size formulae, **15** 1
  surveys, **4** 155
Cross-validation, **9** 1189, 1303
  AIDS incubation times, **13** 969
  assessment error, **13** 2205
  discriminant procedures, **13** 719
  fertility prediction, **14** 1807
  log-likelihood, **13** 2427
  mortality prediction models, **11** 475
  multivariable prognostic models, **15** 361
  survival analysis, **12** 2305; **15** 2203
Crossover trials, **12** 69
  see also Clinical trials; Two-period crossover design
  Balaam's design, **11** 1967
  baseline measurements, **6** 911
  between-patients contrast, **13** 905
  binary variables, **6** 555; **9** 1517
  bioavailability, **9** 549; **12** 1109
  bioequivalence study, **13** 2531; **14** 853
  blood pressure measurements, **4** 361
  carryover effects, **7** 1099–1101(L); **8** 633(L); **10** 1361
  categorical data analyses, **2** 397; **10** 1607
  censored data, **15** 953
  cerebrovascular deficiency, **13** 541
  clinical trials, **14** 115
  cluster analysis, **13** 509; **15** 2573
  conditional analysis, **12** 825
  design, **15** 1435
  direct formulation effect, **11** 881
  dose ranging simulation study, **10** 303
  drug regulation, **14** 127
  duration data, **15** 527
  factorial designs, **9** 1121
  failure time data, **11** 975–977(L)
  generalized estimating equations, **11** 1033
  graphical presentation, **9** 1287
  HIV, **15** 2053
  information recovery, **10** 1115
  intra-subject variability, **15** 1619
  latin squares designs, **11** 560(L)
  linear models, **10** 909
  log transformations, **14** 811
  longitudinal data, **11** 1825, 1967
  methodology review, **10** 1789
  modelling, **15** 1435
  multivariate response, **12** 69
  non-parametric analyses, **2** 397
  phase III, **14** 1025, 1053
  placebo effect, **8** 487; **10** 1679
  power, **12** 1239
  random effects model, **10** 901; **12** 2147–2151(L)
  regression methods, **9** 1517; **11** 727; **12** 1086–1089(L)
  REML, **13** 1601
  repeated measurements, **9** 639; **14** 1067, 1079
  residual effects, **10** 891
  sample size requirement, **3** 199
  sequentially balanced, **15** 2143
  simple carryover model, **11** 715
  survival analysis, **10** 1099; **14** 735
  therapeutic preferences, **15** 443
  therapy evaluation, **3** 45; **8** 441
  three-period designs, **6** 555; **7** 471; **8** 891(L); **13** 1063; **15** 127
  treatment allocation, **14** 2661; **15** 113–116(L)
  treatment comparisons, **8** 487; **15** 1489
  two-period design
    bioequivalence, **14** 1067, 1079
    phase III, **14** 1025, 1053
    power, **10** 489–491(L)
    treatment comparisons, **8** 487
Crow and Gardner method confidence intervals, **13** 2189
Crude incidence curves, **11** 813
CS *see* Cluster-specific model
Cubic splines, **8** 551
  curves, **11** 1305
  description, **13** 2205
  functions, **15** 2589
  proportional hazards model, **14** 2119
  radioimmunoassay calibration, **14** 935, 953
  regression model, **14** 655
  time-by-covariate interactions, **13** 1045
Cuff pressure wideband external pulse, **13** 275

Cumulative distribution functions clinical trials
interim analysis, **11** 55
Cumulative hazard functions
rate estimator, **12** 2315
semi-proportional hazards, **11** 1465
survival curve representation, **11** 455
Cumulative incidence
AIDS, **11** 591
curves, **11** 813
Kaplan-Meier curve alternative, **12** 737
Cumulative models
AIDS infection, **14** 1889
bivariate regression, **14** 1341
dependant data, **14** 1819
hazards, **14** 1707
logistic regression, **8** 525
logit, **7** 109; **8** 1209, 1317; **13** 609; **15** 2573
odds, **5** 15; **13** 1665; **14** 1191
Cumulative regression plots survival analysis, **12** 1569
Cumulative sum method (CUSUM)
abortions data, **4** 469
adverse drug reactions, **12** 2383
average run lengths, **12** 13
birth defects
monitoring, **6** 517; **7** 997–999(L); **10** 1089
surveillance, **3** 239; **4** 389–391(L); **5** 98–99(L), 565
efficiency, **6** 517; **7** 997–999(L)
fertility detection, **10** 221
gamma-method comparison, **12** 13
homogeneity, **4** 469
logistic regression, **11** 1115
monitoring, **2** 141; **6** 517; **7** 997–999(L)
quality control, **2** 141; **6** 425
set technique comparisons, **3** 239; **4** 389–391(L); **5** 98–99(L), 565; **6** 517; **7** 997–999(L)
surveillance, **5** 565; **8** 267, 311; **11** 1489
threshold construction, **10** 1493
time trends, **7** 629
Cure models, **1** 93; **3** 153; **6** 483; **14** 2111
Cure-rate censored survival data, **11** 931
Curtailment stochastic, **6** 667, 753, 927
Curvature components age-period-cohort model, **6** 709
Curve fitting
immunoassay, **5** 183
repeated measures data, **15** 1143
Cuscore test exploratory analysis, **15** 807
CUSUM *see* Cumulative sum method
Cuzick test, **9** 829; **10** 799–800(L); **14** 863
Cuzick-Edwards test cluster analysis, **15** 783, 873
CVAE *see* Cross-validation assessment error
Cystic fibrosis incidence, **15** 449
Cytogenetic analysis, **13** 839
Cytology, **5** 127; **6** 885
Cytomegalovirus disease, **15** 2307

D-optimal designs
assays, **7** 805
plaque pH profiles, **14** 2609
Daily life-table method, **5** 475
Damped exponential model CD4 counts, **12** 2133
Damped exponential variance-covariance piecewise linear regression, **12** 2099
Dampened hazard model, **12** 617
Dapsone, **7** 739
Data augmentation, **11** 1809; **15** 2161
Data collection
AIDS epidemiology, **9** 1387
alcohol problems, **14** 591
analysis, **10** 777
antihypertension study, **10** 323
bias assessment, **6** 11
blood pressure, **10** 1197; **13** 1201
bone-marrow transplant study, **10** 413
cancer case-control studies, **10** 375
censored data, **10** 1441
central laboratories, **9** 125, 145
clinical trials
cost, **3** 469
display methods, **1** 131
monitoring, **6** 753; **7** 1165, 1231
NIH cardiology study, **9** 137
pooling efficicency, **6** 565
publication bias confrontation, **6** 11
research, **10** 559
workshop proceedings, **6** 217–410; **9** 101–151
cohort study, **6** 11
controlled clinical trials, **10** 777
databases methodology, **10** 629
dental study, **6** 823
developing countries studies, **9** 35
disease prevention trials, **9** 161
dual frame design, **14** 571
elderly hearing thresholds, **10** 1453
epidemiological, **7** 613; **14** 511
geriatric patients, **10** 831
heterogeneity analysis, **6** 773
HIV study, **10** 423, 473
hormone pulses, **10** 329
how much to collect, **3** 423; **9** 103, 145
longitudinal, **1** 131
mammary tumours fat intake effect, **13** 709
meta-analyses, **6** 11; **14** 2057
migraine headache, **10** 1197
monitoring devices study, **10** 351
ophthalmic grades, **10** 1303
pooling methods, **6** 11, 565
PPS/MMPS, **13** 889
practice databases, **10** 541
prescription event monitoring, **15** 987
prognostic factors, **6** 773
pulmonary function study, **7** 613
quality assurance, **1** 191; **3** 101; **9** 115, 145; **10** 629

quality control, **3** 101, 423, 469; **7** 1165; **8** 367
randomized clinical trials, **9** 104
registry, **6** 11
respiratory disorder study, **13** 1771
smoothing procedures, **7** 613
SPECT images analysis, **10** 1711
survival analysis, **6** 773
verification, **12** 1535
DATA DESK computer package, **9** 469
Data editing, **3** 101
Data linkage studies AIDS mortality, **15** 2273
Data management system, **3** 101
Data monitoring *Clinical Trials* (workshop), **12** 415–616
Data monitoring committees (DMCs), **3** 445, 453; **10** 925, 1341
see also Monitoring
anal cancer trial, **13** 1459
Canadian trial groups, **12** 505, 521
cancer, **12** 435, 457
CHART cancer trials, **13** 1297
composition, **12** 543
drug sponsor's view, **12** 481, 493
Europe, **12** 509, 521
external DMCs, **12** 471, 503
independence, moral case, **12** 575, 581
independent, **13** 1401, 1411
NIH questionnaire, **12** 543, 553
operation, **12** 527
pelvic cancer trial, **13** 1459
pharmaceutical industry, **12** 493, 555, 571
randomized clinical trials, **12** 425, 433
Southwest Oncology Group, **12** 451, 457
spending functions, **12** 2219
SWOG, **13** 1391
UK experience, **12** 497, 521
Data safety monitoring boards (DSMBs), **12** 419, 433, 527
Data splitting, **15** 361
Databases
alcohol study, **14** 591
cardiovascular disease, **3** 375
clinical trials computer, **6** 11
computer, **7** 1165
diagnostic methodology, **10** 1887
drugs effects bias, **10** 577
GIS, **15** 1961
head injury, **5** 103, 403
health-care, **10** 585
humongous analysis, **10** 511
medical, **2** 355
methodology, **10** 617, 629, 637
observational, **10** 663
practice, **10** 541
protocol studies, **3** 333
reanalysis, **8** 653–677
record linking, **14** 481, 491, 499, 511, 687
Stevens-Johnson syndrome study, **10** 565
therapy evaluation, **3** 385, 405; **10** 647
TIGER, **12** 1953
validity study, **14** 2627
variance components, **10** 599
Day care centres acute otitis media, **15** 1519
Day-to-day variance repeated measures, **11** 2035
de Finetti Theorem, **11** 141
de Moivre theorem additivity tests, **14** 1941
DEALE model life-expectancy, **9** 173
Death
see also Mortality
cancer age-related adjustment, **10** 65
cardiac surgery, **13** 1501
cardiac therapy, **8** 1393
certificates, **8** 390; **12** 1249
children AIDS pre-diagnosis rate, **13** 2031
chronic disease estimation, **8** 201
competing risks analysis, **15** 1557
declaration, **6** 535
endpoints efficient use, **9** 155
excess death rate models, **9** 737
hazard ratio breast cancer, **13** 1329
HIV population model study, **10** 1003
home injuries, **8** 263
homicide data comparison, **8** 390
infant mortality analysis, **9** 981
melanoma tumour size, **9** 999
missing cause of death data, **15** 2191
Poisson distribution, **4** 201
probability multistate survival models, **12** 2315
proportionate mortality ratio, **9** 315
rates
age-adjusted, **2** 455
calculation methods, **2** 381
cancer, **2** 113
conditional, **2** 41
crude, **3** 113
excess, **1** 93; **2** 363
proportional hazards, **11** 1103
relative, **5** 327
shrinkage estimate, **13** 1119
standardized, **3** 113
relative risk homogeneity, **10** 1267
seat-belt systems study, **8** 379
survival analysis, **9** 487, 529
time series, **8** 335, 1497
trials endpoint risk, **13** 2107
Decay rate outlier detection, **11** 2133
Decision theory
adaptive treatment allocation, **14** 231
Bayesian analysis
analysing, **9** 1229
cancer, **11** 5, 37
colorectal cancer, **11** 23
diagnosis, **5** 497; **6** 945
hierarchical models, **14** 2173
teaching, **6** 805
uncertainty, **12** 1405

Decision theory (*cont.*)
bioequivalence studies, **10** 959, 961
chemotherapy, **5** 411
clinical trials, **14** 231
analysis review, **9** 1229
diagnosis, **5** 497; **6** 945
methodology review, **9** 1243; **10** 1789
prognosis, **5** 403
statistician interaction, **1** 311
treatment selection, **5** 411; **6** 745
computer-aided, **2** 207; **5** 403, 497, 517; **6** 805, 945
data monitoring, **6** 753
diagnostic tests, **5** 497, 517; **6** 805; **7** 1289; **9** 1229, 1243
linear homoscedastic assays, **14** 1949
measurement error, **8** 893
multiple comparisons, **11** 863
odds ratio, **10** 1273
partitioning methods, **5** 517
pharmaceutical project prioritization, **15** 2689
phase I cancer trials, **10** 1647
phase II clinical trials, **10** 1327
screening application, **9** 1229; **14** 2099
stopping rules, **6** 753; **11** 659, 673
three problem approach, **6** 101
treatment evaluation, **5** 411; **6** 745
variance estimation, **8** 229
Decision thresholds regret graphs, **15** 969
Decision trees
pattern classification, **3** 261
variance estimation, **8** 229
Deff *see* Design effect
Delaunay triangulation, **15** 1837
Delta method
maximum tolerated dose, **11** 2063
surveillance data aberrations, **11** 1551
transmission probability estimation, **11** 565
variance estimate, **12** 153
Delta-beta menstrual diary data, **12** 955
Dementia studies, **8** 1317, 1537
Deming's regression method, **9** 1463; **10** 981
Demography, **7** 491; **8** 103, 273; **10** 1003
DEMP *see* Density equalizing map projections
Dendrograms, **6** 137; **12** 311
Denmark HIV in homosexual men, **15** 2177
Density
centiles-based, **9** 539; **10** 1693
estimation techniques, **10** 1745
Density curve area between curves, **11** 1289
Density equalizing map projections (DEMP), **12** 1915; **15** 1837
Density estimation survival analysis, **12** 1569
Dental factors
caries, **6** 823; **7** 403
correlations, **10** 1315
disease
monitoring methods, **10** 1089
progression, **14** 413; **15** 1227–1229(L)
sample size, **12** 1079
elastase concentration, **11** 1503
filling lifetimes, **14** 1819
log-linear model, **2** 59
malocclusion, **4** 47
plaque pH profiles, **14** 2609
plaque regrowth, **4** 145
Rural Dental Health Study, **2** 59
students teaching, **9** 1013, 1069
Depot-medroxyprogesterone acetate (DMPA or Depot Provera) dose comparison, **12** 955
Depression, **7** 727; **8** 1317
predictive diagnostics, **15** 2149
prevention trial, **15** 2077
seasonal affective disorder, **12** 1555
Dermatoglyphics, **7** 591
Dermatomyositis, **7** 1157
DerSimonian-Laird estimator, **8** 141; **15** 1465
Descriptive statistics skewness and kurtosis, **11** 333
Designs
aggregate data studies, **15** 1849
assay, **7** 805
binary regression models, **12** 1259
CALGB lung cancer trial, **13** 1313
CHART cancer trials, **13** 1297
clinical trials
ancillary questions, **9** 97
ANOVA design, **10** 1565
baseline measurements, **8** 1183, 1339
Bayesian sequential, **14** 357, 381
bias assessment, **7** 1243; **8** 441, 455
binomial comparisons, **7** 1187
cancer prevention, **5** 435
case-control studies, **9** 765
central laboratories, **9** 125, 145
clinical trials simulator, **9** 787
cluster randomization, **8** 599
combination drugs, **11** 1065
comparative binomial trials, **9** 1447
cost, **5** 663; **9** 53–100, 173
crossover trials
carryover problem, **10** 1361
categorical data analysis, **10** 1607
dose-ranging simulation study, **10** 303
factorial designs, **9** 1121
graphical presentation, **9** 1287
information recovery, **10** 1115
linear models, **10** 909
methodology review, **10** 1789
placebo effects, **8** 487
residual effects, **10** 891
three-period design, **7** 471
two-period design, **10** 489–491(L)
data collection, **9** 103, 125, 145
data reanalysis, **8** 653–677
decision analysis, **5** 411; **9** 1243
developing countries studies, **9** 35

disease prevention efficiency, **9** 161
dose ranging simulation study, **10** 303
dose-response models, **9** 1353
endpoints efficient use, **9** 155
estimation issues, **9** 657
factorial, **4** 111; **8** 161; **9** 29, 55, 1121; **10** 1565
fertility regulating vaccines, **10** 177
GISSI cardiology trial, **9** 17
group sequential, **8** 1191; **9** 853–854(L), 1081, 1439; **10** 405, 1789
guidelines, **14** 1655, 1659
heterogeneity analysis, **6** 773
historically controlled, **8** 153
incomplete blocks, **8** 871
innovations studies, **8** 441, 455
interim analysis, **10** 1789
Latin square, **8** 487
linear regression model, **8** 907
matched case-control method, **8** 379
matched pair randomization, **9** 943
medical journals review, **10** 1897
meta-analyses, **10** 1789
methodology review, **10** 1789
multi-stage tests, **9** 673
multicentre binary response studies, **9** 919
multiple comparison procedures, **10** 1
NCI methods, **9** 871, 903
NHLBI methods, **9** 881, 903
NIH methods, **9** 893, 903
optimal binary variables, **4** 497
P-value interpretation, **9** 601
parallel-groups graphs use, **9** 1287
patient selection, **9** 73
phase I cancer trials, **10** 1647
phase II trials, **5** 441; **9** 215, 907; **10** 1327, 1789
physicians' health study, **9** 29, 87
pilot studies use, **9** 65, 215, 765
placebo effect, **7** 1187
polio vaccine trial, **9** 13
power loss, **7** 457
preoperative tests, **6** 813
quality of life analysis, **9** 749
randomization, **6** 127; **10** 777, 1621
  baseline comparisons, **10** 797–799(L), 1157–1159(L)
  consent design, **9** 645
  covariate imbalance effects, **8** 467
  disease indicators, **10** 1061
  interim analysis, **10** 949
  treatment allocation methods, **4** 129; **5** 211; **6** 119; **8** 467
reciprocal control designs, **9** 55
repeated measurements analysis, **5** 663
response prediction, **9** 253
results applicability, **9** 185, 193
run-in phase use, **9** 87, 103
  sample size, **5** 1, 663; **6** 577; **7** 467, 559
  sequential methods
    confidence intervals, **9** 1277
    ECOG study, **8** 505
    lung cancer study, **1** 73
    phase II/III trials, **9** 229
    stopping rules, **9** 595
    treatment comparisons, **5** 375
  sickle cell anaemia trial efficiency, **9** 45
  stopping rules, **6** 667; **7** 1231
  strata-matching studies, **9** 1475
  stratification cluster analysis, **6** 43
  survival analysis, **7** 559
  teaching statistics, **9** 1013, 1023, 1063
  therapy comparisons, **6** 761; **8** 441, 455
  treatment evaluation, **7** 1179
  two-stage trial, **7** 571
  ulcer prevention, **7** 877
  Zelen, **8** 477
community intervention trials, **15** 1069
comorbidity trials, **14** 721
comparative exposure ratio, **13** 245
crossover trials, **14** 127; **15** 1435
dose escalation studies, **15** 1605
epidemiological studies, **5** 319, 579
field trial studies, **13** 61
focused clustering studies, **15** 765
HIV vaccine trials, **13** 2155
LD50 bioassay, **14** 841
Mantel-Haenszel adjustments, **11** 603
meta-analysis conference, **15** 1233–1323
paired availability, **13** 2269
phase II trials, **15** 2037
planned vs. attained, **11** 853
questionnaires, **5** 607; **6** 613
renal cancer trial (MRC), **13** 2249
sampling, **14** 571
selection bias, **13** 557
three-squares crossover trials, **15** 2143
two-stage studies, **11** 769; **15** 1739
Detectability
  parasitic infections, **9** 1211
  smallest effect multivariate studies, **4** 117
Detectable preclinical phase (DPCP), **6** 885
Detection limits linear homoscedastic assays, **14** 1949
Determination, multiple coefficient, **7** 519
Deterministic model
  measles epidemic analysis, **12** 229
  threshold-crossing data, **12** 1589
  transmission probability estimation, **11** 565
Developing countries clinical trials, **9** 35
Deviance estimates, **13** 1827
Diabetes
  age-period-cohort analysis, **6** 709
  cardiovascular disease, **14** 1745
  county-level mortality rates, **12** 393
  early clinical trials, **9** 893, 903

Diabetes (*cont.*)
hemodialysis, **5** 637
liver function data, **7** 671
multi-state models, **7** 661
multivariate failure time data, **13** 2233
nocturnal hypoglycaemia risk, **14** 247
retinopathy study
bivariate cumulative probit regression model, **14** 1341
correlated ordinal measures, **14** 1961
early stopping rules, **3** 445
global odds ratio regression model, **15** 1507
interim analyses, **11** 55
mixture model, **14** 2599
multi-state models, **14** 1975
surrogate endpoints, **8** 427
ROC curves, **15** 323
space-time disease mapping, **14** 2433; **15** 2561
Diagnosis
acute coronary heart disease, **1** 41
AIDS
CD4 T-cell monitoring, **13** 2059
Kaposi's sarcoma, **15** 1171
Bayes theorem, **13** 201, 211, 213
Bayesian inference, **6** 945
Bayesian predictive values, **15** 463
binormal model, **15** 1575
blood pressure study, **7** 423
cancer, **2** 217
children AIDS surveillance, **13** 2031
clinical trials endpoint, **13** 2107
computer-aided, **4** 311, 317; **5** 497, 503
coronary heart disease, **2** 413(L)
decision-aids, **2** 207
dental study, **7** 403
discriminant analysis, **7** 525
laboratory reference limits, **2** 191
latent class analysis, **6** 529–531(L)
methodology improvements, **7** 727
multiple 'independent' classifications, **15** 1377
multiple reading procedures, **7** 549
myocardial infarction, **2** 199
positive/negative predictive values, **13** 1737
predictive value equality, **12** 185
probability of particular, **2** 87
reference ranges, **7** 377
regret graphs, **15** 969
short-term influences, AIDS, **13** 1921
statistical, **4** 311
studies quantative marker, **13** 1551
teaching statistics, **6** 805
tests
agreement data, **9** 559, 1103
Bayesian inference, **5** 503
bias effect, **4** 53; **6** 411
cancer screening, **8** 743
case-control studies, **4** 425; **5** 127; **10** 653
comparisons, **6** 147
confidence intervals, **10** 443
correspondence analysis, **8** 1351
cut-off point construction, **8** 1381
decision analysis, **9** 1243
dental study, **7** 403
disease
equality tests, **4** 535
prevalence estimation, **8** 1225
screening tests, **4** 53
equality tests, **4** 535
error, **7** 257, 403, 525, 745, 955
graphical presentation, **5** 585
interrater agreement, **9** 835
laboratory studies, **10** 843
latent class analysis, **5** 21
logistic regression, **7** 519; **10** 1213
measurement assessment, **9** 351
methodology, **7** 727; **10** 1887
misclassified data, **9** 1327
mixture models, **8** 1291
monitoring, **10** 351, 1341
multiple, **8** 1231
multiple reading procedures, **7** 549
osteoarthrosis assessment, **7** 639; **8** 1416–1417(L)
outliers detection, **4** 425
P-value misuse, **8** 1413–1414(L)
parasitic infection dynamics, **9** 1211
partitioning methods, **5** 517
power, **6** 147
preoperative tests, **6** 813
prognostic variables, **9** 273
ROC curves, **9** 325; **12** 1293
sample size, **6** 147
scoring rules, **8** 609
sensitivity, **7** 739, 1289; **8** 1231, 1381
specificity, **7** 739, 1289
unclassified data, **8** 1277, 1291
vaccine studies, **9** 1327
variation estimation, **7** 639; **8** 1416–1417(L)
Diagnosis Related Groups, **11** 1321
Dialysis data statistical model, **14** 185
Diary methods
dietary assessment, **12** 925
menstruation, **12** 955
Diastolic blood pressure *see* Blood pressure
Dichotomous variables
behaviour change predictors, **12** 219
cluster number estimation, **11** 751
menstrual dysfunction indicators, **12** 355
2',3'-Didanosine trial, **15** 2289
Diet
see also Nutrition
cancer studies, **11** 1273; **15** 1647, 1849
case-control study, **8** 1179
clinical trials endpoints, **8** 431
confounding examination, **7** 1087
intervention programme, **13** 113

measurement error
case-control data, **8** 1151, 1165
covariance structure model, **12** 925, 937
logistic regression, **8** 1051, 1071
non-differential exposure, **8** 1031
ordinal exposure variables, **15** 293
misclassification study, **8** 1528
nutrition knowledge model, **15** 23
questionnaire assessments accuracy, **13** 127
renal disease, **11** 1861
triglyceride responses, **15** 1695
tumour development, **13** 709
validity studies, **13** 127
variation, **11** 533
DIET FIT *see* Dietary Fat Intervention Trial
Dietary Fat Intervention Trial, **9** 161
Diethylstilbestrol, **5** 73, 261; **7** 1223
Dietz, Molineaux and Thomas model, **6** 853
Difference in proportions confidence interval, **4** 23, 213
Differential mortality, **5** 573
Differential recall bias, **15** 2603
Diffusion model, **7** 1147
Digit preference model, **11** 1225
Digoxin, **7** 629
DIGRAM computer package, **14** 1265
Dilution assays, **9** 1353
Dioxin, **2** 259
Direct formulation effect, **11** 881
Direct standardization incidence rates, **12** 3
Direct substitution disease risk analysis, **11** 1443
Direct treatment effect
see also Treatment effect
carryover model, **11** 715
regression to the mean, **11** 727
Directed acyclic graph relative risk estimation, **11** 983
Directed Markov assumption, **12** 1703
Directional effects spatial data, **12** 1795
Dirichlet-multinomial model, **14** 357; **15** 2323
Disability, **7** 325, 661; **14** 629
Disagreement index pair, **4** 47
Discharge policies myocardial infarction, **4** 29
Discharge sequences, **4** 91
Disclosure small population data, **15** 1895
Discontinuation rate, **5** 475
Discordance
McNemar test, **11** 1521
ratio, **6** 961
Discordant pair sample size pair-matched studies, **12** 699
Discrete data
longitudinal studies, **11** 1825, 1981
multiple test procedures, **11** 511
Discrete time systems laboratory analyses monitoring, **11** 1343
Discriminant analysis
allocation rules, **2** 95
Alzheimer's disease, **10** 1711
cardiology, **9** 273
classification, **6** 137; **8** 1291; **10** 383
confidence intervals, **5** 347
covariance matrices, **10** 141
Cox regression comparisons, **4** 413
death study, **6** 159
decision theory, **9** 273
error rates, **7** 525
facial pain study, **6** 137
fertility prediction, **14** 1807
Fourier series density estimation, **10** 473
heart disease, **1** 41; **4** 413
heart rate analysis, **6** 159
hypertension, **8** 1291
kernel method, **2** 199
linear, **2** 199; **13** 719
logistic, **1** 41; **2** 199; **4** 413; **7** 525
marker variable bias, **15** 1747
mixture models, **8** 1291
mortality study, **2** 229
multiple group, **10** 757
multivariable optimal SCD, **13** 1015
multivariable prognostic models, **15** 361
multivariate response curves, **2** 95
myocardial infarction, **2** 95, 199
NCI anti-tumour drug screen, **13** 719, 731
ordered variables, **11** 1023
ordinal models, **10** 383
power evaluation, **7** 519
predictive accuracy, **13** 1501
prognostic factors, **9** 273
quadratic, **2** 199
rank transformation, **12** 143; **13** 1793–1795(L)
regression comparisons, **4** 413
risk factors, **4** 413; **11** 783
sampling, **2** 229
Discrimination
limits, **6** 147
U.S. legal cases, **14** 1641
Diseases
AIDS serum immunoglobins model, **13** 805
alleles, **5** 281
autosomal recessive diseases, **9** 573
clinical trials, **9** 645
clustering *see* Cluster analysis
curability, **1** 93
diagnostic factors, **9** 835
eradication case histories, **12** 197
genetic susceptibility, **13** 153
incidence
estimation, **5** 573; **13** 1513
seroprevalence data, **13** 1881
infectious secondary attack rates, **13** 1563
inherited, **3** 57
maintenance therapies trial, **8** 1439
malaria estimations, **13** 2345
monitoring, **6** 197

Diseases (*cont.*)
mortality, **6** 71, 233
natural history studies, **8** 1255
notifiable, **8** 323
pathway patterns, **13** 245
pooling controls, **10** 1417
prevention
cancer risks, **8** 641
clinical trials, **8** 431; **9** 161
diagnostic factors, **8** 609
HIV screening models, **8** 59
scoring rules, **8** 609
prognostic scoring sensitivity, **9** 1189
progression
correlations, **9** 1175
survival distribution, **13** 1747
quality of life analysis, **9** 749
rates
adjustment, **1** 217
geographic regions, **12** 1915
spatial patterns, **12** 1885
recurrence, **2** 13, 41
risk
ancillary risk factors, **11** 1443
diet effects, **11** 1273
geographical variation, **11** 983
screening tests, **8** 1225
staging, **4** 265, 279, 287; **5** 465
stochastic processes, **10** 1427
surveillance, **8** 253–400
Alzheimer's, **10** 1711
cancer screening, **8** 743
case studies, **9** 423, 1485
community intervention studies, **10** 53
confounding control, **8** 679
crossover trials, **10** 1099
epidemiology bibliography, **10** 1819
indicators survival analysis, **10** 1061
infection models, **9** 263, 953
misclassification, **10** 361, 1181
mixed multi-normal distributions, **9** 301
observational data, **8** 273, 279
occurrence aberrations, **8** 323, 331
periodontal disease progression, **10** 1089
prognostic factors, **9** 487
reporting delays, **8** 259
respiratory time series, **10** 1481
risk adjustment methods, **10** 1753
Salmonella alert threshold, **10** 1493
spatial data, **8** 267, 279
time series analysis, **8** 343
transient condition qualifier, **10** 413
survival analysis, **9** 1221–1222(L)
time series surveillance, **8** 353
vaccine efficacy estimation, **10** 1573
DismapWin computer package, **15** 919, 931
Dispersion tests survival and case-control studies, **12** 1683
Distance model, **8** 571
Distributed models AIDS projections, **11** 1425
Distribution
acute manifestation episodes, **13** 859
AIDS, **10** 1167; **13** 2031
incubation, **11** 1633; **13** 969; **15** 2459
sexual partners, **15** 221
asymptotic, **8** 1415–1416(L); **12** 3; **14** 2273
beta
Bayesian analysis, **7** 1223
contingency tables, **10** 991
HIV transmission study, **8** 93
multiple tests, **7** 1031; **8** 1231
phase II clinical trials, **10** 989
power loss investigation, **7** 457
regression analysis, **8** 1363
beta-binomial, **6** 491
bimodal, **2** 253
binomial
AIDS study, **5** 355
change-point tests, **7** 387; **8** 1414–1416(L); **10** 1159–1169(L)
comparative studies, **10** 1137
confidence intervals, **10** 443
negative approach, **6** 823
pooling controls, **10** 1417
power evaluation, **8** 1469
surveillance system tests, **8** 311
variation factors, **6** 491
birthweights, **15** 1333
bootstrap technique, **8** 771, 1485
censoring, **5** 255
Clayton-Oakes, **14** 1985
cluster randomization, **8** 599
compound, **2** 253
confidence, **7** 1267
demographic model, **8** 103
disease survival, **13** 1747
drug combination tests, **8** 1479
empirical Q-Q plots, **12** 289
Erlangian, **11** 831
experimental, **8** 153
exponential *see* Exponential distribution
F family, generalized, **5** 85
F-distribution, **13** 1071
failure times, **15** 2475
finite mixtures theory, **9** 397
follow-up data, **8** 703
frequency, **13** 301
Freund, **14** 1985
gamma, **8** 103
alternative test procedures effects, **13** 769
dog triglyceride data, **15** 1695
HIV infection model, **8** 103
mixing model, **7** 1121
modified frailty model, **12** 241
multistage model, **13** 23
sequences neuronal discharge, **4** 91

SSPE risks, **10** 1733
gamma/log-normal, **13** 769
Gaussian, **8** 3; **9** 505; **10** 831
percentile estimates, **12** 403
pushback procedure, **12** 1033
random effects, **11** 1981
generalized *F* family, **5** 85
geographic units, **8** 267, 279
geometric, **12** 685, 2043
Gompertz, **9** 397; **10** 1043, 1075; **11** 931; **14** 1859
group discriminant analysis, **10** 757
hazard rates, **10** 1043
HIV, **8** 45; **10** 1003, 1167; **15** 197
hyperprior, **13** 1841; **14** 2411
hypothesis testing, **13** 1563
incubation, **15** 197
induction time, **8** 35
infant mortality, **14** 481
information content, **8** 861
inter-arrival, **12** 2043
IVDU length bias, **10** 423
Johnson density system, **9** 539
log-logistic
HIV/AIDS incubation model, **13** 163
infection curve, **12** 617
stage-specific numbers, **11** 831
log-normal, **8** 725; **9** 505, 999
bioequivalence study, **13** 2531
continuous outcomes, **14** 247
direct formulation effect, **11** 881
longitudinal data, **11** 1861
test procedures comparisons, **13** 769
three-parameter, **11** 897
logistic
medical audit, **12** 2179
ROC curve, **12** 1293
median age error, **10** 1313
mixed multi-normal, **9** 301
mixing, **7** 1121
multi-normal, **10** 1123
multinomial, **8** 23
negative binomial, **6** 823
prevalence rates, **14** 1471
regression model, **13** 1755
normal, **10** 1283, 1665, 1693
clinical chemistry ranges, **5** 335
departure estimation, **10** 1283
dog triglyceride data, **15** 1695
group sequential testing, **13** 101
order statistics study, **10** 855
reference ranges, **10** 691
two-sample tests type I error/power, **13** 747
P-values, **8** 1304–1306(L)
Pareto, **7** 483
permutation tests, **9** 1081
piecewise exponential, **6** 501
piecewise linear distributions, **11** 1103; **12** 617; **15** 2289
marker path model, **12** 2099, 2133
Poisson *see* Poisson distribution
posterior *see* Posterior distribution
prior *see* Prior distribution
Quasi-binomial distribution I, **15** 837
reference ranges, **10** 691
renal venous renin ratio, **8** 1291
ROC curves non-normal data, **9** 325
run length, **8** 311
sample size estimation, **10** 1993
sampling, **10** 811, 1945
scan statistic, **6** 197
sojourn time, **8** 743
spatial, **7** 491
SSPE incidence risk, **10** 1733
Student's *t*-distribution, **12** 1033
survival, **2** 305
Weibull *see* Weibull distribution
Wishart, **8** 1327; **9** 919
Distribution-free tests, **4** 145; **13** 769
confidence interval estimation, **5** 653
growth curve analysis, **1** 83
incomplete data, **11** 1151
stratified data analysis, **6** 43
Wilcoxon approach, **4** 87, 543(L); **5** 199–200(L)
Disturbed highest derivative polynomials, **14** 1219
Disulfiram alcohol cessation, **15** 1421
Diuretics, **6** 269, 277
Diurnal rhythms harmonic regression analysis, **12** 129
DMC *see* Data monitoring committees
DMT *see* Molineaux and Thomas Dietz
DNA independence tests, **14** 1621
Donors high risk, **5** 355
Dorfman blood tests scheme, **13** 2337
Dorfman-Alf algorithm, **9** 325
Dose
equipotent, **5** 363
escalation schemes, **11** 2063; **15** 1605
interpolation immunoassay, **5** 183
maximum tolerated, **11** 1377, 2063
toxicity, **11** 813
Dose-finding trial simple carryover model, **11** 715
Dose-response, **11** 685, 703
adaptive design, **14** 1595
assessment methods comparisons, **10** 1647
Bayesian inference, **11** 1377; **14** 885, 897
best dose selection, **13** 87; **14** 925, 933
binary variables, **7** 955
biochemical reference ranges, **10** 831
bioequivalence, **11** 1777
clinical trials, **10** 1789; **13** 2323
closed test procedures, **13** 1583; **14** 901, 909
combination analysis, **4** 77
combination drugs, **11** 703, 1065; **15** 233
confounding factors, **14** 987, 1007

Dose-response (*cont.*)
CRM, **14** 911, 923
design methods, **9** 1353
drug combinations, **13** 2289
drug safety, **14** 1113, 1117
efficacy, **5** 449
exact power computation, **14** 2261
experimental design, **11** 685
historical control study, **10** 839
leukaemia therapy, **14** 1081, 1097
maximum tolerance, **13** 1799; **14** 1149
meta-analysis, **14** 531, 545, 679
model risk techniques, **10** 151
one-parameter models, **12** 1093
optimal sample allocation, **15** 2523
phase III trials, **14** 895, 897
population models, **14** 971
radiation combination, **14** 1941
randomized trials, **6** 241
receptor assay designs, **7** 805
repeated measurements, **9** 639
simulation study, **10** 303
study design, **15** 343
survival time models, **9** 1527
titration studies, **6** 583; **8** 583; **9** 103; **10** 323
toxicity evaluation, **9** 1117–1118(L)
two-parameter models, **12** 1093
Doseage low-dose response data, **12** 881
Double keying data verification, **12** 1535
Double triangular test, **15** 2703
Doubling rules, **10** 1321–1322(L)
Doubling time, **8** 3, 35; **13** 587
Doubly censored data mid-point imputation, **11** 1569
Doubly-labelled water, **9** 1365
Down's syndrome
age-specific rates, **14** 1797
model-based screening, **11** 257
surveillance method, **12** 13
Drinking water, **6** 823
Drop-outs
see also Missing data
bias, **7** 29
crossover trials, **15** 527
efficacy titration studies, **10** 323
longitudinal clinical trials, **12** 2248–2250(L)
two-treatment crossover design, **12** 825
Drug abuse
see also Intravenous drug users
HIV epidemic dynamics, **11** 1657
needle infection dynamics, **13** 2179
price relationship, **14** 655
Drugs
75/75 rule, **11** 1333
antihypertension, **11** 2147
bioequivalence, **11** 1777; **15** 2635
combinations, **11** 1065; **15** 233, 2425
compliance assessment, **13** 2141
development, **12** 1501; **15** 2689
diurnal rhythms effect, **12** 129
dose-response relationship, **11** 685, 703
exposure *see* Bioavailability
maximum tolerated dose, **11** 2063
metabolism data model, **14** 185
methadone programme, **15** 2253
organ pharmacokinetics, **14** 1009
patient compliance, **15** 659, 2813
pre-clinical trials, **13** 2289
prescription event monitoring, **15** 987
reactions alert systems, **12** 2383
regulation, **14** 127
safety, **11** 1075; **14** 1113, 1117
shelf life estimation, **11** 2001
toxicity/efficacy study, **14** 1129, 1143
users HIV positive, **12** 2065, 2087, 2099
Drugs tests, **8** 883, 1479
adverse reactions, **1** 153; **6** 863; **7** 1023, 1171; **10** 831, 991
ANOVA design, **10** 1565
assay validation estimation, **10** 1543
AZT, **15** 75, 197, 2053, 2273, 2413
Bayesian analysis, **10** 811
bioavailability studies, **9** 549
bioequivalence studies, **10** 959, 961
channelling bias, **10** 577
clinical trials, **10** 777, 1595
combination preparation, **4** 77
crossover trials, **9** 1121; **10** 1099, 1361
2',3'-Didanosine, **15** 2289
disulfiram, **15** 1421
dose-response models, **9** 1353
early treatment termination, **9** 1417, 1433
epilepsy trials, **10** 1719
evaluation, **2** 155
factorial designs, **9** 1121; **10** 1565
failure time analysis, **10** 1703
haemophilia study, **10** 433
joint action model, **4** 77
lidocaine intervention trial, **10** 405
mass administration (MDA), **6** 853
meta-analyses, **10** 971
monitoring, **1** 153
multiple testing, **10** 871, 939
outliers detection, **10** 1375
over-the-counter trials, **10** 1
phase I cancer trials, **10** 1647
physicians' health study (US), **10** 1585
placebo effect, **2** 417
post marketing surveillance, **7** 1023
practice databases, **10** 541
prescription, **6** 863; **7** 1171
provisional diagnoses, **10** 1341
registration, **2** 155
registry data, **6** 863
repeated measurements, **9** 639
response phenomenon, **10** 1621

survival time models, **9** 1527
titration studies analysis, **10** 323
DSMBs *see* Data safety monitoring boards
Dual frame design sampling, **14** 571
Dual measurement data, **8** 1041
Duchenne muscular dystrophy, **2** 87; **5** 231
Duncan's multiple range test, **4** 489
Dunnett's test, **4** 489; **14** 2509
Duodenal ulcer, **7** 877
Duration
crossover trials, **15** 527
treatment comparison, **7** 1013
Durbin-Watson statistics regression model selection, **12** 1665
Dynamic balanced randomization clinical trials, **12** 2343
Dynamic error component models, **11** 533
Dynamic programming optimal checking procedures, **11** 1343
Dysmenorrhea, **6** 555; **15** 2573
Dyspepsia, **2** 207

EAAS *see* Electrothermal atomic ...
Ear infections, **15** 1519
Early termination *see* Clinical trials stopping rules; Stopping rules
Eastern Cooperative Oncology Group (ECOG), **4** 1; **8** 505; **9** 853–854(L)
ECGs *see* Electrocardiograms
Echo-planar imaging human brain mapping, **15** 389
Echoencephalography (EE), **5** 593
ECM algorithm *see* Expectation conditional maximization
ECOG *see* Eastern Cooperative...
Ecological studies, **9** 515, 1199
aggregate data studies comparison, **15** 1849
AIDS, **15** 2273
biases, **11** 1209
GIS, **15** 1921
Ederer-Myers-Mantel (EMM) test, **11** 761; **12** 1813; **15** 747
Edge-effects, **13** 2359; **14** 2383
Edgeworth expansion, **12** 1813
Editorials, **1** 1; **3** 97
Editors biomedical statistics journals, **7** 1003
Educational Attainment, **7** 435
EEG *see* Electroencephalography
Effect modification
attributable risk, **11** 2083
ecologic study bias, **11** 1209
odds ratios, **9** 1131
Effect size, **6** 221
Efficacy
AIDS incidence, **11** 1633; **13** 1959
AIDS intervention, **13** 2127
anti-hypertensive treatment, **10** 653
antiarrhymic drugs, **8** 1393
approximate likelihood inference, **13** 1619
blood tests, **13** 2337
case-control study PQD, **13** 623
changeover designs, **8** 891(L)
clinical trials, **9** 35; **10** 45, 871
estimation, **13** 2323
guidelines, **14** 1655, 1659
combination drug treatment, **8** 1479
contraceptive methods, **10** 201
covariate imbalance problem, **8** 467
crossover trials, **10** 1099, 1115; **13** 1063
diagnostic tests, **6** 411
drop-outs titration studies, **10** 323
drug combinations, **13** 2289
drug trials, **11** 1057
drugs compliance assessment, **13** 2141
efficacy score statistic, **13** 2503
error linear models, **10** 1197
experimental design, **14** 1057, 1065
fertility regulating vaccine study, **10** 177
Fluvoxamine study, **15** 1123
GISSI cardiology trial, **9** 17
HIV vaccines, **9** 1425, 1433; **13** 2155; **15** 2371, 2379, 2393, 2405
hypothesis/significance tests, **9** 201, 213
interim analysis, **10** 925
long-term follow-up, **15** 2359
monitoring devices, **10** 351
multicentre binary response studies, **9** 919
multiple endpoints trials, **14** 1163
multiple testing, **10** 871
over-the-counter drugs tests, **10** 1
phase II trials, **9** 215, 907; **10** 1327
placebo clinical trials, **10** 777
platelet transfusions, **11** 2123
polio vaccine trial, **9** 13
power computations 2 x 2 tables, **13** 1539
prevention trials, **13** 1807
protective vaccination, **7** 1279
provisional diagnoses, **10** 1341
quality of life analysis, **9** 749, 819
randomization factor, **8** 467
rank transformation, **13** 1793–1795(L)
sequential phase II/III trials, **9** 229
sickle cell anaemia trial, **9** 45
side effects incidence model, **9** 803
significance levels, **9** 703
surgery innovation, **8** 455
survival analysis, **9** 397
therapies, **8** 441; **10** 647
toxicity relationship, **14** 925, 933, 1129, 1143
treatment
bias, **7** 1243
clinical trials, **4** 1, 11; **10** 1349, 1595
confidence intervals, **7** 1267
decision theory, **6** 101
drugs tests, **5** 449
equivalence trials, **8** 593
estimations, **7** 1179

Efficacy (*cont.*)
treatment (*cont.*)
factorial designs, **8** 161
handwashing protocol comparisons, **5** 393
interactions, **7** 1257
phase III trials, **8** 583
randomized trials, **2** 267; **3** 307, 409; **4** 387–389(L); **10** 405
response predictions, **9** 253
sample size determination, **5** 1
stopping rules, **7** 1231
therapies, **3** 45; **6** 657, 761
titration studies, **8** 583
two-stage trial, **8** 477
trial results applicability, **9** 185, 193
two-sample tests, **9** 447
two-sided tests, **15** 1729
two-treatments effect, **8** 1421
vaccine studies, **7** 1279; **9** 1327; **10** 1573; **13** 357; **14** 395
Efficiency
case-control studies, **5** 29; **10** 1775
clinical trials, **9** 173
ancillary questions study, **9** 97
compliance run-in phase, **9** 87, 103
cost, **3** 469, 473; **9** 173
covariate error effect, **6** 31
crossover trials, **9** 1121
data collection, **9** 103, 115, 125, 137, 145
design issues, **9** 53–100
developing countries studies, **9** 35
disease prevention trials, **9** 161
endpoints use, **9** 155
factorial designs, **9** 55, 1121
GISSI clinical trial, **9** 17
improvements, **3** 455
internal pilot studies, **9** 65
matched pair clinical trials, **9** 943
measurement error effect, **6** 31
misselection subsampling, **9** 1339
missing covariate values, **9** 777
NHLBI trials overview, **9** 9
patient selection, **9** 73
physicians' health study, **9** 29, 87
pilot studies use, **9** 65
polio vaccine clinical trial, **9** 13
quality assurance methods, **9** 115
randomization, **6** 31; **9** 645
screening effectiveness studies, **9** 969
sequential clinical trials, **9** 595
sickle cell anaemia trial, **9** 45
strata-matching studies, **9** 1475
treatment allocation methods, **4** 129
workshop proceedings, **9** 1–199
cohort studies controls, **8** 977
Cox proportional hazards model, **8** 1515
diagnostic tests, **5** 21
homogeneity tests, **10** 1257
logistic regression model, **8** 1515
monitoring systems, **6** 517; **7** 997–999(L)
order statistics study, **10** 855
phase I clinical cancer trials, **10** 1647
pooling controls, **10** 1417
robust independence tests, **15** 2095
sampling design, **10** 1945
Efron and Feldman approach non-compliance, **15** 2813
EGRET computer package, **13** 301
Eigenvalues RA transition matrix, **12** 1171
Elderly
active life expectancy assessment, **10** 1945
dementia, **8** 1317, 1537
hearing threshold models, **10** 1453
marital bereavement risk, **10** 395
Electrocardiogram
see also Heart disease
premature ventricular counts, **11** 963
pulse length, **13** 275
recordings, **3** 423; **4** 53; **8** 1393
Electroencephalography artefacts detection, **10** 1719
Electrothermal atomic absorption spectrophotometry, **11** 1343
Eligibility criteria
clinical trials, **3** 421; **9** 73, 103, 145
disease prevention trials, **9** 161
randomized clinical trials, **9** 87
ELISA test, **7** 549; **15** 2161
EM algorithm *see* Expectation maximization algorithm
Embryo viability *in vitro* fertilization, **12** 1543
Emergency medicine surveillance, **8** 388
Emergency room visits longitudinal study, **15** 823
EMIP *see* European Myocardial Infarction Project
EMM *see* Ederer-Myers-Mantel
EMP procedure consistent estimates, **13** 479
Emphysema, **7** 11
Empirical Bayes, **7** 697; **8** 3, 173, 189; **10** 811; **12** 27
see also Bayesian inference
age-adjustment methods, **14** 615
CD4 lymphocyte counts, **15** 2289, 2337
corrected, **12** 937
correlated multiple associations, **11** 219
county-level mortality rates, **12** 393
dependent data, **14** 1819
diagnostic probabilities, **13** 201
discriminant analysis, **13** 719
disease mapping, **12** 1895; **14** 2363; **15** 919
HIV infection incidence, **12** 1317
hospital mortality rates estimation, **13** 889
knee replacement rates, **15** 1875
longitudinal data, **11** 1965–2023
lung cancer mortality rates, **15** 1397
medical audits, **12** 2179
mixture models, **12** 1943

multiple exposure studies, **12** 717
parameter estimates, **13** 1619
penalized likelihood, **15** 907
posterior probability, **13** 1501
prior information, **12** 2009
prognostic model, **14** 1999
random effects model binary response, **13** 541
rate of change estimation, **11** 621
relative risk estimation, **11** 983
serial data, **12** 27
shrinkage estimator, **13** 889
small area disease prevalence, **15** 1867
smoothing procedures, **14** 1235
stabilization procedure, **13** 1119
suppressor gene probability, **13** 839
time series regression relationships, **12** 1555
toxicity studies, **13** 2311
two-period crossover two baselines, **13** 905
Empirical Q-Q plots, **12** 289
Empirical rejection rates, **12** 181
Empirical semi-variogram plot, **11** 2111
Empirical velocities, **12** 403
EMS algorithm, **13** 1865; **15** 197
Endocrinology outlier detection methods, **11** 2133
Endometrial cancer, **10** 767; **14** 1545
Endoscopy, **7** 877
Endpoints
AIDS clinical trials, **15** 2359, 2367
antiretroviral trials, **13** 2107
breast cancer trial, **13** 1329
clinical trials, **9** 9, 657; **10** 1341, 1789; **11** 1705
data collection, **9** 103, 145
disease prevention trials, **9** 161
efficient use, **9** 155
intermediate/surrogate, **11** 167
multinormal probabilities, **10** 1123
proliferative index data, **13** 1619
quality of life, **9** 749, 819; **10** 1915
reciprocal control designs, **9** 55
sequential studies, **13** 1357
surrogate CD4-lymphocyte counts, **12** 835
surrogate markers, **13** 1423; **14** 2619–2620(L)
survival, **13** 1453
Energy expenditure measurement, **9** 1365
Energy intake between and within subject variation, **11** 533
Environmental health, **5** 393
confidentiality, **15** 1895
extraction mapping, **12** 1249
GIS, **15** 1921, 1961
hazards, **1** 163
pollution, **15** 1927
risk factors, **2** 13, 373; **7** 491, 649
Environmental tobacco smoke (ETS), **15** 2603
Enzyme kinetics comparison tests, **8** 871
EORTC *see* European Organization for Research and Treatment of Cancer
Epi-Info computer package, **11** 1289
EPICURE computer package, **13** 301
Epidemiology, **8** 639–769
abortion, **4** 469
age period cohort models, **6** 449, 469
AIDS
binomial distribution uses, **5** 355
cohort studies, **10** 1993
contact tests, **5** 271
databases study, **10** 559
distribution estimation, **9** 505
early treatment termination, **9** 1417
epidemic models, **8** 1–139
incidence, **14** 1505
incidence projection, **11** 1633
incubation model, **7** 395; **10** 1733
Markov model analysis, **8** 831
mean-squared error estimates, **10** 1167
projection methods, **10** 1527
reporting delays, **8** 259, 279, 963
statistical issues, **9** 1387, 1433
time-lag adjustment methods, **8** 259
allocation designs, **5** 319
ARMA models, **7** 29
association tests, **7** 257, 289
autoregressive models
growth curve models, **7** 73, 87
longitudinal data analysis, **7** 59, 177
missing data analysis, **7** 317
pulmonary function study, **4** 457; **7** 19
repeated measurement analysis, **7** 29, 87
back-projection HIV, **13** 1945
baseline comparisons, **7** 205, 219
Bayesian inference, **4** 509; **5** 261; **7** 177, 1223; **8** 1023–1024(L); **14** 1263(L)
bias
attributable risk estimation, **3** 131
autoregressive models, **7** 59
confounding examination, **7** 1087
drug allocation methods, **10** 577
morbidity ratios, **3** 131; **6** 193
repeated measurement analysis, **7** 29, 59
screening tests, **4** 53
selection correction, **7** 417
bibliography statistical models, **10** 1819
binary variables, **7** 161
binomial distribution, **5** 355
bioequivalence studies, **10** 959
birthweight distributions, **15** 1333
blood pressure
children, **7** 47, 87, 169, 185, 199
diagnostic factors, **7** 423
familial agrregation, **7** 185, 199
Framingham heart study, **7** 205, 239
Muscatine study, **7** 47
myocardial infarction, **7** 205
risk factors, **7** 205, 239, 275, 297
temporal trends, **7** 185
treatment effects analysis, **7** 697

Epidemiology (*cont.*)
bone disorder analysis, **8** 785
bootstrap investigation, **7** 29, 87, 89
bovine leukemia virus, **8** 725
Box-Jenkins model, **5** 37
breast cancer, **7** 619; **14** 267
cancer
Bradford Hill's influence, **1** 325
cohort models, **10** 1421
controversies, **14** 151
measurement methods, **5** 547
paired organs studies, **7** 619
risk factors, **7** 239
smoking effects, **7** 223
statistical facts, **6** 881
treatment risk study, **8** 1371
variation models, **6** 449, 469
carcinogenesis multistage model, **9** 677
cardiovascular, **3** 15
case fraction estimates, **8** 845
case-base studies, **8** 1241
case-cohort studies, **7** 149
case-control studies
allocation methods, **5** 319
asymptotic analysis, **7** 765
Bayesian inference, **5** 261
efficiency consideration, **5** 29
estimation equation approach, **10** 1037
exact analysis, **7** 765
multiple control consideration, **5** 29
power considerations, **5** 29; **6** 53
sample size estimation, **5** 29; **6** 53
screening methods, **5** 127
survival-based, **10** 1775
categorical data, **7** 95–169
cause, **12** 1477
censored data, **10** 1441
change-point analysis, **7** 337, 387
children
AIDS latency, **13** 2031
blood pressure, **7** 47, 87, 177, 185, 199
pulmonary function, **7** 59, 95, 139
cholesterol, **7** 139, 239, 297
chronic disease study, **8** 201
clinical trial reports, **13** 2393
cluster analysis, **3** 173; **6** 491; **7** 491; **12** 1751–1968; **14** 799
CMS construction, **14** 331
Cohen's kappa standard error, **10** 767
cohort studies, **4** 63; **7** 257, 275; **8** 977; **10** 1241, 1775
collinearity diagnosis, **11** 1273
colon cancer model, **14** 1249
comorbidity, **14** 721
comparative analysis, **4** 213
confidence intervals, **4** 23; **7** 759, 773
confounding effects, **7** 1087; **8** 679
congenital rubella syndrome, **2** 1
contingency tables, **7** 169
contour mapping, **14** 605
correlations, **7** 47, 87, 161, 185, 717
covariances, **7** 29, 87, 95, 169, 185, 317
covariate measurement errors, **8** 1167, 1179; **12** 1703
Cox proportional hazards model
association tests, **7** 257, 289
change rate analysis, **7** 337
Framingham heart study, **7** 205, 219, 289
grouped data analysis, **7** 613
heart disease risks, **4** 413
logistic regression, **8** 525; **9** 463–464(L)
longitudinal data analysis, **7** 199
mismodelling effects, **7** 257, 289
cumulative logits, **7** 109
cusum techniques, **4** 469
cystic fibrosis, **15** 449
data reanalysis, **8** 653–677
database linkage, **14** 511
decade review, **10** 1819
dental study, **6** 823; **7** 403; **13** 769
detection methods, **1** 183
developing countries clinical trials, **9** 35
diabetes study, **7** 661
diagnostic tests
blood pressure, **7** 423
graphical approach, **5** 585
methodology review, **10** 1887
reliability assessment, **7** 403
repeated measurements, **7** 29
disability effects, **7** 325
discriminant analysis, **4** 413; **7** 519; **12** 143
diseases
contingency table estimation, **7** 591
diagnostic reliability assessment, **7** 403
incidence rate estimation, **7** 403
likelihood analysis, **7** 149
mapping, **15** 919
morbidity estimation, **7** 325; **8** 201
natural history, **8** 1255
prevention trials efficiency, **9** 161
relative risk models, **7** 275
risk analysis, **11** 1443
distributional models, **7** 177
dose-response data, **14** 531
drugs effects, **6** 863; **7** 109, 139; **10** 577
ecologic studies, **11** 1209
EM algorithm, **7** 19, 169, 305
error
dental study, **7** 403
measurement, **7** 177, 257, 275, 297
reduction method, **2** 25
repeated measurement analysis, **7** 29
errors-in-variables workshop, **8** 1027–1179
exposure study, **5** 49, 539, 547; **7** 363, 955; **13** 651
extraction mapping, **12** 1249

familial aggregation, **7** 185; **11** 1767
Framingham heart study, **7** 205, 219, 239, 289
Gaussian variables, **7** 161
generalized linear models, **10** 1069
genetic, **2** 13; **5** 291; **6** 629; **7** 185, 199, 591
geographical, **5** 171; **9** 515, 691; **10** 521; **11** 1409
growth curve models, **7** 73, 87
heart disease
  Cox proportional hazards model, **7** 613
  Framingham study, **7** 205, 219, 289
  hypertension treatment study, **7** 1109
  mortality analysis, **6** 501; **7** 239
  risk factors selection, **4** 413
hepatitis B virus, **15** 2215
Hib bacteria infection, **15** 2235
history data analysis, **7** 95, 819
HIV
  AIDS comparisons, **9** 1433
  distribution estimation, **9** 505
  epidemic dynamics, **11** 1657; **13** 2009
  haemophilia association, **8** 1509; **9** 681
  incidence, **14** 1513
  incubation model, **9** 1387
  infection models, **8** 45; **9** 721, 1387
  Markov models, **8** 831
  mean-squared error estimates, **10** 1167
  prevention models, **8** 59
  seroconversion times estimation, **9** 505
  stochastic processes, **10** 1427
  transmission models, **8** 35; **9** 1387; **10** 1003; **13** 2097
  vaccine developments, **9** 1425, 1433
Hodgkin's disease cluster analysis, **3** 173
homogeneity tests, **4** 469; **7** 109, 169
hypertension study, **7** 47
hypospadias study, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
hypothesis testing, **6** 61; **7** 109, 139, 1349
incidence aberrations, **8** 323, 331
incidence rates, **12** 3
indices case-control studies, **14** 1291
infection models, **9** 263, 953
influenza estimations, **7** 1045, 1147
interactions, **2** 243, 355; **7** 239, 293
interobserver variation, **8** 765–766(L)
ischaemic heart disease, **4** 397
journal developments, **10** 1897
k nearest neighbour test, **15** 1935
Kalman filtering, **7** 73, 87
kappa statistic, **3** 73
latent class analysis, **4** 327, 445
latent variable models, **7** 177, 975
leukaemia relative risks, **10** 1511
life lost estimation, **10** 79
likelihood analysis, **7** 149, 161
likelihood-ratio test, **7** 289, 387
linear models
  catgorical data, **7** 95, 109, 139, 161
  change rate analysis, **7** 337
  mismodelling effects, **7** 257, 289
  missing data analysis, **7** 317
log-linear model, **7** 161, 965
log-logistic regression, **8** 725
logistic regression
  adequacy assessment, **4** 425
  case-control studies, **7** 765
  Cox regression, **4** 413; **8** 525; **9** 463–464(L)
  discriminant analysis comparisons, **4** 413
  Framingham heart study, **7** 205
  hypothesis testing, **4** 337
  longitudinal data analysis, **7** 161
  mismodelling effects, **7** 257, 289
  power evaluation, **7** 519
  smoking effects, **7** 223
  variance estimation, **7** 199
longitudinal studies
  autoregressive model, **4** 457; **8** 1523
  power, **9** 437
  regression models, **8** 1515; **13** 2219
lung function, **7** 11, 87, 297, 685; **8** 189
malaria study, **6** 853
Mantel-Haenszel statistic, **1** 37; **6** 491; **7** 109
mapped data, **12** 1275
marginal models, **7** 87, 95, 139, 161, 169
mark-recapture model, **11** 1533
Markov models, **7** 95, 325, 819
matched case-control studies, **10** 375
maximum likelihood, **7** 73, 149, 161, 305, 317, 325
measles
  immunity, **12** 229
  incubation period, **11** 579
measurement error, **8** 1031, 1075; **9** 583–586(L)
medical databases, **2** 355
medical interventions, **13** 1635
Medicare surveillance, **10** 521
meta-analysis, **14** 137
misclassification
  association tests, **7** 257
  case-control study, **8** 1529
  categorical data, **8** 1095
  covariates asthma study, **10** 1181
  matched-pair studies, **8** 825
  non-differential factors, **7** 1073; **10** 361
  variance estimation, **7** 745
mismodelling effects, **7** 257, 289
misselection subsampling, **9** 1339
missing data
  autoregression, **4** 457; **7** 59, 73, 317
  blood pressure study, **7** 199, 219
  change rate analysis, **7** 337
  familial aggregation, **7** 185
  Framingham heart study, **7** 219
  growth curves models, **7** 73

Epidemiology (*cont.*)
missing data (*cont.*)
heart disease, **7** 219
homogeneity tests, **7** 109
Kalman filtering, **7** 73
linear models, **7** 317
longitudinal studies, **7** 305–361
Mantel-Haenszel statistic, **7** 109
marginal models, **7** 139
maximum likelihood, **7** 305, 317, 325
morbidity estimation, **7** 325
ordinal data, **7** 109
pulmonary function study, **4** 457; **7** 59
quasi-likelihood, **7** 139
regression methods, **7** 59, 199
repeated measurement analysis, **7** 139
smoking study, **7** 199
trend assessment models, **7** 185
mixed effects models, **7** 161
model building strategies, **12** 1325
monitoring post-alarm data, **12** 1807
mortality
analysis, **8** 997
cancer study, **4** 201, 353
cause-deleted analysis, **5** 61
comparisons, **2** 381; **3** 7; **4** 295
diabetes study, **7** 661
disease incidence estimation, **5** 573
index evaluation, **6** 71
intervention study, **6** 501
likelihood analysis, **7** 149
morbidity estimation, **7** 325; **8** 201
perinatal study, **2** 229
risk interaction, **7** 239, 293
multi-state models, **7** 149
multiple comparisons, **6** 71
multiple exposures, **12** 717
multiple Poisson rates, **8** 757
multiple reports, **8** 1041
multiple tests, **7** 139; **10** 939
multivariate models, **7** 29
Muscatine blood pressure study, **7** 47
odds ratios, **6** 491; **7** 759, 1223; **9** 1131
omitted variable bias, **11** 1195
ordinal data, **7** 109; **14** 1545
perinatal mortality study, **2** 229
placebo effect, **7** 109
pneumonia estimation, **7** 1045
Poisson models, **7** 199, 819
polio vaccine trial efficiency, **9** 13
pooled study results, **7** 205; **9** 247
power, **3** 27; **5** 303; **6** 53; **7** 363, 519
practice databases, **10** 541
predictions, **7** 205, 289
prenatal infections, **2** 1
prevalence estimation, **11** 1579, 1591
process model, **7** 177
prognostic factors, **2** 223
proportional odds, **7** 95, 109
proportionate mortality ratio, **9** 315
public health surveillance, **11** 1551
pulmonary function studies, **4** 457; **7** 19, 59, 87, 169
quasi-likelihood models, **7** 139, 161
Quetelet's index, **7** 239
random effects models, **7** 29, 87, 317, 337
random graph model, **15** 837
randomization, **2** 267; **4** 387–389(L)
rare event clustering, **11** 761
ratio smoother, **15** 2539
ratios, **1** 217; **6** 961
regression
autoregressive models, **7** 59, 73, 317
cancer study, **7** 223
change rate analysis, **7** 337
cohort studies, **7** 275
covariances, **7** 317
growth curves, **7** 73
Kalman filtering, **7** 73
linear models, **7** 317
longitudinal data analysis, **7** 161, 199
multinomial models, **7** 435
prevention trials, **7** 275
pulmonary function study, **7** 19
relative risk, **7** 275
smoking study, **7** 223
relative odds estimation bias, **11** 953
relative risk, **10** 1745
Cox model application, **9** 287
estimation, **4** 445; **11** 983
familial data, **2** 13
function estimation, **10** 1745
interaction tests, **2** 243
latent class analysis, **4** 327, 445
pooling study results, **5** 303
prediction factors, **9** 287
reliability data, **4** 445
repeated measurement analysis
baseline comparisons, **7** 205, 219
categorical data, **7** 95–169
Framingham heart study, **7** 205, 219
longitudinal data, **7** 11–87
missing data, **7** 139, 305–361
model application, **7** 347
residual confounding, **11** 1747
residual plots, **8** 703
respiratory diseases, **10** 1481
retrospective studies, **7** 149; **12** 867
review, **10** 1819
risk
adjustment ratios, **5** 579
assessment methods, **8** 641
attributable, **7** 507, 717, 1073
cancer x-ray associations, **7** 857
carcinoma study, **4** 345
cohort studies, **7** 275

confounding effects, **7** 1087
disease surveillance, **7** 325
environmental, **7** 649
factor/disease incidence, **11** 783
Framingham heart study, **7** 205, 219, 289
hazard function, **7** 239
heart disease, **4** 413
homogeneity, **10** 1267
mismodelling effects, **7** 257
mortality interaction, **7** 239, 289, 293
myocardial infarction, **7** 205, 219
network methods, **13** 53
prevention trials, **7** 275
ratio binary data, **8** 1241
scores, **14** 1331
smoking study, **7** 205, 223, 239, 289, 297
survival analysis, **7** 205, 219
rubella, **2** 1
Salmonella surveillance, **10** 1493
sample size, **6** 53; **7** 363, 759; **8** 795
sampling cluster designs, **8** 1537
San Seriffe game, **1** 205
scan statistic, **6** 197; **15** 845
screening tests, **4** 53; **8** 743, 1225
sequential *t*-tests, **15** 2781
skin cancer forecasts, **14** 821
SM surveillance system, **8** 311
smoking effects
catgorical data analysis, **7** 95, 169
covariate omission, **7** 199
Framingham heart study, **7** 205
lung cancer, **7** 223, 289
mortality risk interaction, **7** 239, 289
risk factors, **7** 297
smoothing procedures, **7** 601
SSPE risk estimation, **10** 1733
standardized mortality ratios, **6** 193
stepwise regression analyses, **10** 711
Stevens-Johnson syndrome study, **10** 565
stochastic process, **7** 239
strata-matching studies, **9** 1475
stratified trend test, **9** 829
structured environments, **15** 851
surveillance, **8** 253–400
survival analysis
Bayesian analysis, **4** 509
cancer registry data, **7** 483
diabetes study, **7** 661
Framingham heart study, **7** 205, 219, 289
mortality risk interaction, **7** 239, 289
multistate models, **7** 661
pooling study results, **5** 303
risk factors, **7** 239, 289, 293, 297
symmetry tests, **7** 109
teaching statistics, **6** 869
temporal trends, **7** 185
theoretical biostatistics application, **12** 789
threshold assessment, **10** 341, 1493
time series analyses, **7** 59, 317, 1045
time-dependent variables, **7** 109, 205, 297
training, **14** 199
transitional models, **7** 95, 161
treatment evaluation, **7** 109, 139, 205
tree-based analysis, **15** 37
trend assessment, **2** 147; **3** 113; **7** 185, 317
USA cancer atlases, **14** 473
vaccine studies, **6** 843; **9** 1327; **10** 1573
variability assessment, **7** 47, 87, 169
variances, **6** 701; **7** 87, 199, 745; **10** 1441
variation models, **6** 449, 469
Wald statistics, **7** 109
whooping cough, **3** 165
workshop proceedings, **7** 1–361
Epidemiology Program Office, **8** 253
Epilepsy, **8** 1327; **10** 1719
EPILOG PLUS computer package, **13** 301
Episodic events synchronization study, **12** 2043
Epithelial cancer, **13** 23
EPSDT programme, **15** 1447
Equipment biostatistics budget, **15** 2127
Equipotent dose, **5** 363
Equivalence
active control studies, **12** 2367
clinical trials, **7** 1267; **8** 593; **10** 1679; **12** 2009
curves, **5** 203
maintenance therapy, **12** 1353
range, **5** 203, 421
Equivalence tests
comparisons, **14** 1583
intraclass correlation, **13** 2465
one/two-sided, **13** 1827
optimal sample allocation, **15** 2523
proportion of similar responses, **15** 1489
sample size, **14** 1831
sequential designs, **15** 2703
stratified trials, **14** 2037
two-sided, **13** 1827; **15** 1729
Erlangian distribution, **11** 831
Error
see also Errors-in-variables; Measurement error; Power
absolute risk, **10** 1025
AIDS epidemiology, **9** 1387
assay variability estimation, **10** 1543
association measurement, **8** 619
autocorrelation risk, **8** 1523; **10** 492–495(L)
bioequivalence studies, **10** 959, 961
biopharmaceutical research, **10** 811
blunder factor, **8** 893
cardiac transplantation study, **2** 33
CD4 lymphocyte counts, **13** 1101; **14** 1889
CD4 T-cell numbers, **13** 2059
censoring models, **7** 337, 357
classification, **7** 257, 403, 525, 745, 955; **15** 157
clinical trials
allocation methods, **6** 119

Error (*cont.*)
clinical trials (*cont.*)
binary variables, **7** 571; **9** 229
historical controls, **9** 215
phase II, **9** 215, 229; **10** 989, 1327
phase III, **9** 229
power loss evaluation, **7** 457
review, **10** 1789
stopping rules, **7** 1231
survival analysis, **6** 773; **7** 559
treatment efficacy, **10** 1327
triangular tests, **10** 989
two-stage designs, **7** 571; **8** 477
cluster randomization, **7** 1195
Cohen's kappa, **10** 767
competing risks analysis, **15** 1557
counts/rates models, **10** 1405
covariates imbalance tests, **9** 1455
crossover trials, **10** 891, 1361
data
quality assurance, **9** 115, 125, 145
surveys, **8** 367
databases methodology, **10** 617
diagnostic classifications, **15** 1377
diagnostic tests, **6** 147; **8** 609
differential recall bias, **15** 2603
discriminant analysis, **2** 95; **10** 141
EEG readings detection, **10** 1719
elderly hearing models, **10** 1453
energy expenditure measures, **9** 1365
epidemiology bibliography, **10** 1819
experimentwise, **7** 1031
exposure variables, **14** 1437
factorial ANOVA design, **10** 1565
familywise errors, **15** 1107
Fisher's exact test, **8** 1469; **10** 1321–1322(L)
Gaussian cluster analysis, **15** 1793
generalized t and rank-sum statistics, **11** 491–509
group sequential procedures, **8** 1191
HIV infection probability model, **13** 2097
hypothesis/significance tests, **9** 201, 213
image grading records, **8** 1433
interaction test, **7** 467
interim analysis, **10** 925, 949
interlaboratory studies, **10** 843
interrater reliability, **9** 1103
intra-individual variation, **12** 1213
journal developments, **10** 1897
limited failure population model, **9** 409
linear models, **9** 583–586(L); **10** 1197
logistic regression validation, **10** 1213
logrank test, **6** 483, 577
longitudinal analysis, **8** 1523
matched pair clinical trials, **9** 943
measurement
cluster analysis, **14** 2393
correction, **12** 1703
dietary assessment, **12** 925, 937
event probabilities, **11** 1719
intra-individual variations, **14** 2283–2285(L)
linear regression, **14** 789
logistic regression, **14** 769
repeated measures, **11** 1685
risk factors, **11** 783
median age calculation, **10** 1313
meta-analysis, **10** 971
method comparison studies, **10** 981
misclassification, **9** 1327; **10** 361
misselection subsampling, **9** 1339
missing covariate values, **9** 777
monitoring methodology, **10** 1089
multiple significance tests, **9** 811; **10** 939
multiple testing, **10** 1; **11** 13, 511
multivariable prognostic models, **15** 361
normality departure estimation, **10** 1283
ophthalmic data, **10** 1303
order statistics study, **10** 855
parasitic infection dynamics, **9** 1211
phase II clinical trials, **9** 215, 229; **10** 989, 1327
pilot studies clinical trials, **9** 65
placebo effect, **8** 1301(L)
pock count variability study, **9** 615
population data misreports, **10** 191
prediction
methods, **13** 2205
sources, **13** 1513
value, **9** 1303
rates
data verification, **12** 1535
multi-armed trials, **13** 1441
regression, **10** 697, 1123, 1295
reliabiity studies, **6** 441, 647
replication probability, **11** 875
research synthesis, **15** 1713
risk techniques, **10** 1511
sampling databases, **10** 629
sequential trials, **9** 229, 1277
significance tests, **10** 1123
statistical models, **1** 59; **7** 1003; **8** 23; **9** 1303
survival data variation, **9** 487
t-test, **6** 577; **12** 2233
t-tests, **15** 2781
time-dependent events, **6** 689
treatment termination, **9** 1417, 1433
tumour growth models, **10** 1075
type I, **11** 55; **13** 945, 1023, 1815; **15** 233
case-control studies, **6** 53; **7** 363, 759, 1279
clinical trials, **10** 1, 1123
cluster analysis, **15** 807
control-conditional test, **15** 2371
data monitoring, **12** 2219
diagnostic tests, **8** 1381
drug combination evaluation, **8** 1479
equivalence, **12** 2009; **14** 1583
experimentwise, **7** 1031
GEE, **15** 1951

interim analysis, **10** 925, 949
inverse sampling, **15** 671
longitudinal trials, **14** 2239
multiple treatments comparisons, **14** 2509
optimal cutpoint selection, **15** 2203
quasi-exact tests, **10** 1137
randomized trials, **14** 2081
regression methods, **10** 697
sample size, **14** 1039, 1053
spending function, **9** 1439; **12** 51
t-tests, **12** 2233
two sided small sample tests, **12** 777
unpaired *t*-test, **15** 1059
type II
equivalence trials, **12** 2009
sample size, **14** 1039, 1053
type III avoidance, **14** 115
vaccine studies, **9** 1327; **10** 1573
Wilcoxon test, **6** 483
within-person, **8** 1031, 1051
Yates's continuity correction, **9** 363–383
Errors-in-variables
cohort studies, **8** 1167, 1179
covariates, **8** 1151, 1165, 1167, 1179
indoor air pollution, **8** 1109, 1127, 1133, 1137
linear measurement error models, **8** 1075
linear relationship estimation, **9** 1463
measurement error, **8** 1031, 1139, 1149
measurement methods assessment, **9** 351
misclassified categorical data, **8** 1095
multiple measurement, **8** 1041
pulmonary function, **8** 1109, 1127, 1133, 1137
regression, **8** 1139, 1149, 1151, 1165
risk factors, **11** 783
within-person measurement error, **8** 1051
workshop report, **8** 1027–1179
Erythrocyte count, **7** 377
Essence design matrix intentionally incomplete data, **11** 1889
Estimates distance test, **9** 549
Estimating equation
see also Generalized estimating equations
two-stage studies, **11** 769
Estimations
absolute risk, **10** 1025
AIDS
backcalculation, **10** 1167
categorical response data, **8** 1209
epidemiological studies, **9** 1387
etiological fractions, **8** 845
illnesses, **15** 2307
incidence, **8** 1509; **14** 1505
incubation period, **10** 1733
projection methods, **10** 1527
repeated measurement models, **8** 1209
screening tests, **8** 1225
seroconversion times, **9** 505
alcohol problems, **14** 591
assay validation variability, **10** 1543
association models, **14** 413
attenuation corrections, **13** 1265
attributable blood fraction, **13** 2345
attributable risk adjustment, **10** 1753
baseline/crude incidence rates, **13** 651
Bayesian methods, **4** 201; **10** 113, 811; **13** 201
bias clinical trials, **7** 1231
cancer
mortality rates, **10** 95
treatment-induced, **8** 1371
case-control studies, **10** 739, 1037
categorical regression models, **14** 2131
CD4 lymphocyte counts, **13** 1101; **14** 1889; **15** 2289, 2337
centiles
curves, **10** 1693
maximum likelihood method, **9** 539
CIN/HPV parameters, **13** 379
clinical trials issues, **9** 657; **10** 1789
cluster analysis, **14** 2393; **15** 1793
clustered binary responses, **13** 1241
Cohen's kappa standard error, **10** 767
cohort studies unseen sample, **10** 1993
combination, meta-analysis, **14** 137
common odds ratio, **14** 1567; **15** 1595–1600(L)
community interventions, **14** 1491
comparative exposure probabilities, **13** 245
compartment models, **8** 1011
confidence intervals, **14** 2161
continuous outcomes, **14** 247
correlation parameters, **13** 1149
CRM, **14** 911, 923
crossover trials, **10** 1115, 1361; **13** 1063
cure rates parametric methods, **13** 983–986(L)
death: missing cause data, **15** 2191
diabetic retinopathy model, **14** 2599
disease indicators analysis, **10** 1061
disease mapping, **14** 2363
disease process characteristics, **13** 805
dose-response, **10** 323; **14** 987, 1007
doubly-censored data, **13** 2081
drug abuse incidence, **14** 655
drugs action, **13** 2289
dual frame design, **14** 571
efficacy clinical trials, **10** 45
elderly hearing models, **10** 1453
empirical Bayes, **4** 201; **10** 95
epidemiological studies, **10** 341, 361
error
linear models, **10** 1197
questionnaire, **13** 127
events person-years, **13** 379
excess fraction, **15** 1519
exposure effects, **15** 1849
failure time, **15** 2475
Fourier series density, **10** 473
frailty parameters, **13** 1679

Estimations (*cont.*)
genetic interactions, **13** 153; **14** 1353
geographical densities, **9** 691
hazard model parameters, **13** 301; **14** 1307, 1553
hazard ratio methods, **9** 1167; **10** 749
hazardous exposure life loss, **10** 79
Hib bacteria transmission, **15** 2235
hierarchical models variances, **13** 1841
HIV
backcalculation, **10** 1167
incidence, **13** 1933–2020; **14** 1513; **15** 497
infection probability model, **13** 2097
infection rates, **15** 2669
model study, **10** 1003
stochastic methods, **10** 1427
type I infection period, **13** 231
homogeneity, **10** 1257; **15** 51
hormone pulses identification, **10** 329
human body surface area, **15** 1325
immunity proportions, **14** 39
incidence densities risk factors, **13** 343
incomplete lists, **10** 113
infection risk SSPE incidence, **10** 1733
interlaboratory studies, **10** 843
interobserver variation, **8** 1417(L)
intra-assay variance parameters, **13** 1165
intrasubject variability, **14** 1067, 1079
Jackknife estimates, **8** 1011, 1199
Jewell's estimators, **8** 987; **10** 151–153(L)
K1 component, **13** 275
kappa statistic, **10** 1303, 1465
LD50 bioassay, **14** 841
lead-time/screening benefit, **13** 569, 603; **14** 2715
leukaemia remission, **14** 1081, 1097
linear models, **10** 909; **14** 1219; **15** 1647
logistic regression, **14** 1437
long-term survival, **15** 2763
longitudinal studies, **14** 283
maximum likelihood, **10** 267, 723, 981
mean sojourn time, **14** 1531
measurement correlations, **9** 1175
menstruation study, **14** 1843
meta-analysis, **10** 1665
minimum therapeutically effective dose, **14** 925, 933
misclassification effect, **7** 1073
model misspecification, **14** 1693
monitoring devices study, **10** 351
mortality rates, **4** 201; **10** 1043; **14** 821
non-parametric, **8** 907; **14** 275
normality departure, **10** 1283
odds ratios, **9** 1131, 1339; **14** 545, 2581
one-step (Peto) method, **9** 247
order statistics study, **10** 855
ordinal regression model, **15** 1807
organ pharmacokinetics, **14** 1009
ovulation, **10** 255
parameters group comparisons, **13** 1201
parasitic infection dynamics, **9** 1211
patient numbers, **14** 115
percentile regression, **14** 777
population model parameters, **14** 971
population risk, **15** 1713
population size, **15** 1635
PQD parameter, **13** 623
prediction equations, **10** 119
prediction rules error rates, **9** 1303
predictive values, **15** 2013
procedures longitudinal data, **11** 1929
prognostic scoring sensitivity, **9** 1189
proportional measurement errors, **9** 1463
PSA velocity, **13** 587
quality adjusted survival, **15** 93
random effects model, **15** 1465
randomization analysis, **13** 217
registers by birthdates, **13** 177
regression attenuation, **14** 789
regression parameters, **13** 1023
regression variability, **10** 1295
relative risk, **8** 1051; **10** 1745
reporting delay equations, **8** 963
residual plots, **14** 2023
risk, **9** 287, 423; **10** 361, 1511; **14** 1331
robust methods, **15** 1033
sample size
drug efficacy, **10** 45
equivalence tests, **13** 1827
errors, **14** 1039, 1053
factorial designs, **10** 33
pilot studies, **14** 1933
repeated measures, **13** 1233
sampling variance, **10** 53
screening effectiveness studies, **9** 969
seroconversion/AIDS, **13** 163
shape invariant model, **14** 2009
small area prevalence, **15** 1867
smoothing procedures, **14** 1205
standardized rates, **10** 1069
suppressor genes number, **13** 839
survey analysis, **14** 669
survival analysis, **9** 397, 529; **10** 413, 733; **13** 1747
systemic exposure, **14** 955, 969
thyroid kinetic parameters, **13** 185
treatment effects, **9** 1121
tumour growth models, **10** 1075
unpublished studies, **15** 2493
vaccine efficacy, **10** 1573
variance components, **10** 599, 1441
vital rates Pakistan, **10** 191
wedge sampling mask, **13** 523
weighted prevalence, **13** 1071
Ethical considerations
clinical trials
clinical decision, **9** 1243

logrank scores, **3** 315
phase II trials, **10** 1327
randomized consent designs, **9** 645
sample size, **2** 175
stopping rules, **13** 1459
early stopping, **13** 1401
experimentation, **1** 5
historical control studies, **3** 315
HIV vaccine development, **9** 1425
medical, **1** 59, 277, 345
non-compliance, **15** 2813
play the winner strategy, **15** 2135
teaching statistics, **9** 1013
treatment, **3** 385
trial results applicability, **9** 185
Ethics in clinical trials (conference), **12** 1373–1534
Etiologic fraction *see* Attributable risk
ETS *see* Environmental tobacco smoke
EU model, **12** 1543
EUL model, **12** 1543
European Myocardial Infarction Project, **12** 471
European Organization for Research and Treatment of Cancer, **13** 1329
EV CARP computer package, **8** 1137
Evaluation
achieving change, **12** 197
AIDS Community Demonstration Projects, **12** 219
combination preparations, **6** 657
community trials, **4** 11
diagnostic tests, **6** 411; **13** 499, 533
health care, **4** 387(L), 388(L)
intervention/prevention strategies, **12** 197, 207
risk adjustment, **13** 1001
sexual behaviour change, **12** 219
therapy workshop proceedings, **3** 305–475
treatment, **4** 11; **6** 657
Event history data, **7** 95, 149, 819
crossover trials, **15** 527
Event probabilities risk factor intervention trials, **11** 1719
Event rates
combinations, **8** 141
equivalence trials, **12** 2009
logrank test, **11** 1091
Evidence strength in clinical trials, **7** 1267
Evolutionary research programme, **3** 315
Exact binomial approach, **15** 2733
Exact Fisher test *see* Fisher's exact test
Exact methods *see* Combinatorial methods
Exact power computation dose-response studies, **14** 2261
Exact tests, **13** 1539; **15** 1, 671, 2371
Exact unconditional tables, **11** 913
Examination effects *see* Time-period effects
Excess death rate, **1** 93; **9** 737
Excess fraction, **15** 1519
Excess intensity model, **14** 1249
Excess ratio, **6** 701
Excess risk
case-control studies, **15** 1535
HIV infection, **15** 2177
leukaemia study, **7** 649
radiation exposure, **8** 173
Exchangeability, confounding control, **8** 679
Exchangeable correlation structure, **12** 355
Exchangeable prior, **11** 983
Exercise stress tests, **2** 327; **9** 293
Expectation conditional maximization longitudinal data, **11** 1809
Expectation conditional maximization algorithm, **14** 747
Expectation maximization algorithm
age-related mortality adjustment, **10** 65
AIDS
back-projection methods, **10** 1527
incidence model, **13** 1991
Bayesian inference, **10** 811, 1241
biopsy analysis, **2** 33
birthweight model, **15** 1333
cardiac transplantation, **2** 33
case-control sample, **13** 523
classification, **3** 249
clinical trials muscular dystrophy, **5** 231
covariance matrix, **13** 759
diagnostic accuracy, **9** 559
EEG readings artefacts, **10** 1719
elderly hearing models, **10** 1453
epidemiology chronic diseases, **4** 327
epilepsy study, **8** 1327
glucose utilization, **15** 2107
historical data analysis, **7** 819
HIV back-projection, **13** 1959
latent class analysis, **3** 249; **4** 327, 445; **9** 559
longitudinal data
censored data, **11** 1861
computational aspects, **11** 1809
missing data, **7** 305
non-linear models, **11** 1929
random effects models, **11** 1981
rate of change, **14** 2239
maximization procedure, **13** 609
maximum likelihood estimates, **13** 453
misclassification methods, **8** 1095
missing data, **6** 91; **7** 305; **14** 1315
multiple regression model, **8** 217
multivariate components model, **12** 2273
muscular dystrophy surveillance, **5** 231
non-randomly missing data, **11** 799
pooling controls, **10** 1417
population risk, **15** 1713
pulmonary function study, **7** 19
RCR model variance parameters, **13** 1211
record linkage parameters, **14** 491
relative risk improvements, **4** 445
repeated measures, **11** 2039, 2111

Expectation maximization algorithm (*cont.*)
sample size, **14** 1039, 1053
time series forecasting, **8** 335
titration studies, **8** 583; **10** 323
treatment evaluation, **5** 231
unclassified data, **8** 1291
Expected mortality *see* Mortality
Expected square volume minimization, **12** 1999
Expected utility regret graphs, **15** 969
Experimental designs
see also Clinical trials; Designs
ambidirectional design status, **10** 1775
ANCOVA model imbalance, **12** 101
assays, **7** 805
Bayesian estimation, **13** 185
Bayesian inference, **14** 1057, 1065
binary data case-base, **8** 1241
case studies, **9** 423, 765
clinical trials simulator, **9** 787
community intervention studies, **10** 53
covariates imbalance tests, **9** 1455
crossover trials, **10** 909
diagnostic agreement, **9** 559
dose-response models, **9** 1353; **11** 685
epidemiology bibliography, **10** 1819
ethics, **1** 5
geographical correlation studies, **9** 515
growth curve models, **9** 841
information time factor, **8** 1191
longitudinal studies, **9** 437
measurement assessment, **9** 351
measurement error factor, **8** 893
misclassification vaccine studies, **9** 1327
misselection two-stage sampling, **9** 1339
NHLBI model, **12** 425
phase II trials, **13** 417; **14** 987, 1007
pilot studies, **9** 65, 215, 765
plaque pH profiles, **14** 2609
prediction equations development, **10** 119
repeated measurements, **9** 639
ROC curves analyses, **8** 1277
sample size, **14** 1039, 1053
sampling multiwave studies, **10** 1945
selection bias, **13** 557
sequential phase II/III trials, **9** 229
significance testing, **9** 703
split-plot, **1** 139
teaching statistics, **9** 1013, 1023, 1063
three-group, **8** 1479
Expert systems, **4** 311, 317; **5** 497
Explained variation
logistic regression, **15** 1987
survival analysis, **15** 1999
Explanatory trials, **7** 1179; **11** 2043
Exploratory data analysis
cancer, **15** 807
CD4 lymphocyte counts, **15** 2289
Stat! software, **15** 951
Exponential distribution, **15** 1695
age-related reference ranges, **13** 2359
AIDS study, **8** 35
AIDS/HIV incubation model, **13** 163
bias, **7** 1243; **9** 1167
censored data, **8** 977
clinical trials, **7** 559
confidence limits, **12** 685
control efficency, **8** 977
covariate omitance effect, **7** 1243
deaths clinical trials, **6** 565
error, **9** 1439
exposure factors, **8** 977
exposure/outcome development, **13** 379
group sequential designs, **9** 1439
hazard rate ratio, **9** 1167
HIV study, **8** 35
lung cancer survival times, **13** 1313
maximum likelihood, **9** 1167
models, **7** 435, 1297; **8** 947, 963
mortality, **6** 501
partitioning methods, **8** 947
pooling efficiency, **6** 565
prognostic factors, **5** 637
renal disease study, **5** 637
sampling designs, **10** 1945
survival analysis, **5** 637; **6** 501, 565; **7** 559, 1243; **8** 947
treatment effects, **7** 1243
two-sample tests type I error/power, **13** 747
Exponential mixture model, **15** 2077
Exponential model
gestational age, **11** 1225
optimal checking procedures, **11** 1343
sample size calculation, **11** 179
Exponential survival model, **12** 339; **13** 391; **14** 1553
Exposure
binary variables, **7** 773, 1073
case-control studies, **9** 1485
case-heterogeneity studies, **5** 49
cohort studies, **10** 1993
confounders, **12** 1989
continuous, **7** 363
covariates, **14** 955, 969
disease risk analysis, **11** 1443, 2083
effects, **15** 1849
efficacy, **13** 357
environmental tobacco smoke, **15** 2603
epidemiological designs, **12** 1703
measurement error corrections, **13** 1135
misclassification, **14** 1291
mortality ratio bias, **6** 193
radiation analyses, **5** 539; **8** 173
variables, **14** 1437; **15** 293
External controls cohort studies, **4** 295, 353
External trials meta-analysis, **15** 2733

Extra-binomial variation prevalence estimation, **11** 1591
Extra-Poisson regression model, **15** 1875
Extracranial to Intracranial Arterial Anastomosis trial, **9** 893, 903
Extraction mapping
childhood leukaemia incidence, **14** 2459
environmental epidemiology, **12** 1249
Extraneous factors, odds ratios, **9** 1131
Extrapyramidal reaction, **6** 863
Eyes
see also Vision
chi-squared test adjustments, **10** 1981
corneal transplants, **9** 1091
disorders surrogate observations, **8** 427
global odds ratio regression model, **15** 1507
kappa estimation, **10** 1303
macular degeneration, **15** 2095
tracking models, **15** 1365
visual field, **11** 1131; **15** 1349

F family, generalized, **5** 85
F ratio multiple comparisons, **11** 863
F-distribution, **13** 1071
F-tests
factorial ANOVA design, **10** 1565
non-linear regression, **10** 697
Facial pain, **6** 137
Factorial designs, **13** 1479
analysis of variability, **4** 379
ANOVA approach, **10** 1565
clinical trials
efficiency, **9** 29
infection dynamics estimation, **9** 1121
methodology review, **10** 1789
physicians' health study, **9** 29
survival analysis, **6** 773
treatment effects, **8** 161
two-by-two design, **4** 111
combination drug studies, **11** 1065; **15** 233
HIV study, **10** 1003
HIV treatment, **15** 2445, 2455
interaction interpretation, **11** 1403(L)
randomized clinical trials, **12** 1629
reciprocal control designs, **9** 55
sample size estimation, **10** 33
two stage testing, **12** 645
Fail-safe *N* approach unpublished studies, **15** 2493
Failure time, **13** 2233; **14** 275; **15** 1387, 2413, 2475
see also Survival analysis
False negative rate screening, **8** 743
Falsification clinical trials, **10** 1679; **11** 1263–1265(L); **12** 2367
Familial data
correlations, **6** 629
diagnostic methods, **7** 727
disease aggregation, **7** 185
epidemiology bibliography, **10** 1819
frailty models, **13** 1679
Hib bacteria transmission, **15** 2235
minimum sample size, **11** 1767
risk factors, **2** 13
Family-wise error rate, **15** 1107
closed test procedures, **13** 1583
multi-armed trial monitoring, **13** 1441
type I control, **13** 2261
Farone common odds ratio test, **12** 1293
FARS *see* Fatal Accident Rep...
Fat intake, **8** 1051; **15** 293
Fatal Accident Reporting System, **8** 379
Fatty acids, **15** 1143
FDA *see* Food and Drug Administration
Feasibility regions, **14** 1291
Fermi-Dirac models, **12** 1773
Fertility
abortion risk estimation, **10** 285
contraception study, **10** 201, 241
determinants sub-Saharan Africa, **10** 161
error adjustment methods, **10** 191
fertile phase identification, **10** 221
menstruration patterns, **10** 267
ovulation day estimation, **10** 255
prediction, **14** 1807
regulating vaccines, **10** 177
Fertilization regression model, **12** 1543
F^H statistic joint significance testing, **12** 1665
Fibonacci search scheme, **11** 2063
Fibre nutrition knowledge model, **15** 23
Fieller's confidence interval, **13** 2531
Fieller's test
bioequivalence, **15** 2635
cost-effectiveness ratios, **15** 1447
sequential monitoring of clinical trials, **15** 2341
Fieller's theorem, **5** 363
Bayesian methods, **11** 1377
confidence intervals, **12** 153
intermediate endpoint, **11** 167
Fingerprint pattern, **7** 591
Finite mixtures survival analysis, **9** 397
Finite population correction, **4** 237–242(L)
Finkelstein's score test, **15** 1387
Finland diabetes mellitus, **15** 2561
First occurrence prevalence estimation, **12** 685
First-order linear regression coefficient, **12** 27
FISHER computer program, **11** 2123
Fisher tests
dose-response evaluation, **14** 1595
information matrix, **13** 185
LSD procedure monitoring analogue, **13** 1441
randomization game Devil or Nature?, **13** 217
t-test analysis, **13** 785
Fisher's exact test, **15** 2371
contingency tables, **5** 629; **8** 243–245(L); **9** 363–383; **11** 845–847(L)
hypothesis testing, **9** 201

Fisher's exact test (*cont.*)
independence tests, **7** 1297
multinomial trials, **11** 913
multiple test procedures, **11** 511
power evaluation, **8** 1469; **10** 1321–1322(L)
quasi-exact test, **10** 1137
significance tests, **9** 213, 703
two sided small sample tests, **12** 777
U.S. legal cases, **14** 1641
Yates's correction, **9** 363–383
Fisher's information matrix outlier detection, **11** 2133
Fisher's information statistic, **10** 1665, 1945; **13** 2503
asymptotic likelihood theory, **12** 3
ordered categorical data, **14** 1577
Fisher's method combining probabilities, **6** 265, 381, 387
Fisher's scoring, **9** 1175, 1517; **12** 1723
FIVNAT French IVF association, **12** 39
Fixed dose trials dose-response relationships, **11** 685
Fixed effects models, **13** 1211, 1601
clinical trials, **6** 341, 381; **9** 657
hearing thresholds study, **10** 1453
intentionally incomplete data, **11** 1889
meta-analysis, **10** 1665; **14** 137
mortality variation, **9** 1199
Flemming-Harrington-O'Brien test, **11** 673
Flexibility conditional probability stopping rule, **11** 659
Floor effects ANCOVA, **15** 477
Flowgrams, **13** 261
Flunarizine, **7** 1171
Fluoride, **2** 113; **6** 823; **7** 403
Fluvoxamine longitudinal study, **15** 1123
fMRI *see* Functional magnetic resonance imaging
Focused tests, **14** 2291, 2323; **15** 727, 765
Foetuses
age-related reference centiles, **12** 917
development, **14** 1417
distress, **12** 27
monitoring, **3** 131
movement, **11** 307
Fokker-Planck equation, **7** 239
Follow-up studies
AIDS clinical trials, **15** 2359, 2367
allocation methods, **5** 319
autoregressive models, **7** 59, 73, 87, 317
baseline comparisons, **7** 205, 219
Bayesian analysis, **4** 509
bias, **7** 29, 417
blood pressure, **7** 47, 87, 169, 185, 199
diagnostic variables, **7** 423
familial aggregation, **7** 185, 199
Framingham heart study, **7** 205, 239
Muscatine study, **7** 47
myocardial infarction, **7** 205
risk factors, **7** 203, 239, 275, 297
screening methods, **9** 1157
treatment effects analysis, **7** 697
cancer study, **7** 223, 239
case-cohort studies, **7** 149
categorical data, **7** 95–169
change rate analysis, **6** 599; **7** 337
children
blood pressure, **7** 47, 87, 169, 185, 199
longitudinal studies, **7** 177
pulmonary function, **7** 59, 95, 139
clinical trials efficiency, **9** 87
cohort studies, **7** 275
competing risk analysis, **6** 785
confidence intervals, **7** 773
confounding control, **8** 679
contraception, **5** 475
correlations, **7** 29; **8** 1485
correspondence analysis, **4** 303
covariates, **7** 169
data collection, **9** 103
disability effects, **7** 325
disease surveillance, **7** 149, 325; **9** 161
drug safety, **14** 1113, 1117
EM algorithm, **7** 19, 169, 305
epidemiological data plots, **8** 703
error, **7** 29
familial aggregation, **7** 185
Framingham heart study, **7** 205, 219
GENSTAT analysis, **2** 223
growth curve models, **6** 185; **7** 73, 87
hypothesis testing, **6** 689
interactions risk/mortality, **7** 239, 293
Kalman filtering, **7** 73, 87
life-table analysis, **4** 157; **5** 475
likelihood analysis, **7** 149, 161
linear models, **7** 95, 161, 317, 337
liver function, **7** 671, 685
logistic regression, **4** 227
longitudinal data, **7** 177; **8** 1515, 1523; **9** 437
lung function study, **7** 11, 87
Mantel-Haenzsel statistic, **7** 109
marginal models, **7** 87, 95, 139, 161, 169
maximum likelihood, **7** 305, 317, 325
misclassification, **7** 745; **9** 1327
mismodelling effects, **7** 257
missing data, **7** 139, 305–357; **15** 2191
mortality, **4** 295; **7** 149, 239, 289, 293, 325
multi-state models, **7** 149
multiple tests, **7** 139
Muscatine blood pressure study, **7** 47
ommitted variable bias, **11** 1195
ordinal data, **7** 109
ovarian cancer, **15** 2763
passive survival analysis, **7** 483
pooling methods, **5** 303
prevention trials, **7** 275
prognostic factors, **2** 223

proportional odds, **7** 95, 109
pulmonary function, **7** 19, 59, 87, 169, 357
random effects models, **7** 87, 337
regression, **7** 19, 59, 161, 199; **8** 525; **9** 853(L)
relative risks models, **7** 275
repeated measurements
analytic methods, **7** 11–87
categorical data, **7** 95–169
Framingham heart study, **7** 205, 219, 289
missing data, **7** 139, 305–361
retrospective studies, **7** 149
risk, **7** 223, 239, 275, 289, 293, 297
sample size formulae, **8** 1537
sampling design, **10** 1945
smoking effects, **7** 223, 289; **8** 997
smoothing procedures, **7** 601
surveys, **2** 223
survival analysis, **4** 509; **5** 255, 637; **7** 297
time series analysis, **7** 59
time-dependent variables, **6** 689
transient state models, **6** 795
transitional models, **7** 95
trend assessment model, **7** 185
trial safety, **14** 1099, 1113
vaccine efficacy, **9** 1327
variability assessment, **7** 87
variances, **7** 199, 745
ventilatory study, **6** 795
Food and Drug Administration (FDA)
data monitoring, **12** 527, 601, 609
safety guidelines, **14** 1099, 1113, 1117
Forced expiratory volume
baseline measurements, **8** 1183, 1339
change rate analysis, **7** 337
pulmonary function, **7** 11, 19, 685
smoothing procedures, **7** 601
Forced vital capacity (FVC), **7** 11, 685; **8** 189
Forecasting
ARIMA model, **8** 1497
Salmonella threshold construction, **10** 1493
time series analysis diseases, **10** 1481
Formulation effect bioavailability/bioequivalence, **11** 881
FORTRAN computer program, **13** 1539
Forward selection, **11** 2093
Four County Childhood Cancer Study, **15** 683, 1837
Four parameter logistic model
radioimmunoassay calibration, **14** 935, 953
robust parameter estimates computation, **12** 2025
Four-stage estimation cluster analysis, **15** 1793
Fourfold tables, odds ratio, **4** 437
Fourier coefficients, **12** 129
Fourier methods, **15** 389
Fourier series, **10** 473; **13** 1201
Fractional factorial designs, **12** 1629
Fractions, misclassification effect, **7** 1073
Fractures disease clusters, **12** 1773
Frailty models, **7** 819, 1121
dependence parameter, **12** 241
dependent data, **14** 1819
family studies, **13** 1679
life-table analysis, **14** 1859
multivariate data, **14** 1447
related failure times, **13** 2233
Framingham Eye Study lens opacities, **15** 145
Framingham heart study
bivariate models, **12** 241
cholesterol, **8** 295
covariate techniques, **7** 205, 219
elderly people, **14** 1745
general stochastic process formulation, **7** 239
institutionalization model, **14** 1757
panel studies, **14** 1265
regression analysis, **9** 1501
summary statistics, **12** 2169
survival curves, **14** 1731
Free-living subjects energy balance, **9** 1365
Freeman-Tukey test multiple treatments comparisons, **14** 2509
Frequency distribution, **13** 301
Frequency-matched case-control studies, **11** 1759
Frequentist approach, **11** 1, 23, 37, 875
clinical trials, **12** 1405; **14** 381
confidence intervals, **9** 657
early stopping, **13** 1313
growth curve analysis, **11** 2001
LD50 bioassay, **14** 841
medical audits, **12** 2179
null hypothesis persistence, **12** 1377
toxicity study, **13** 2311
Freund distribution marginal survival, **14** 1985
Friedman tests ANOVA, **4** 145; **5** 199–200(L)
Full Bayes
disease mapping, **14** 2363, 2411
random-effects meta-analysis, **14** 2685
Full span longitudinal design, **11** 1889
Functional decline model, **15** 1023
Functional forms, **12** 2099
Functional magnetic resonance imaging (fMRI), **15** 389
Furosemide, **11** 1777
Fuzzy sets, **15** 873

G-estimation, **12** 1605; **15** 2813
G-test statistic smoking cessation, **12** 1605
Gail's test, **13** 2407
Gain function dose determination, **14** 885, 897
Gait measurement, **2** 345
Gallstones, **7** 139
Gambia hepatitis B virus, **15** 2215
Gamma distribution
alternative test procedures effects, **13** 769
dog triglyceride data, **15** 1695
HIV infection model, **8** 103
mixing model, **7** 1121

Gamma distribution (*cont.*)
modified frailty model, **12** 241
multistage model, **13** 23
sequences neuronal discharge, **4** 91
SSPE risks, **10** 1733
Gamma-method, **12** 13
Gamma-Poisson mixture model, **13** 859
Gastric cancer, **13** 1045; **15** 907
Gastric ulcer, **1** 337
Gastroenterology, **5** 503, 517, 585; **6** 269; **7** 581
Gastrointestinal cancer, **4** 337; **5** 517
GAUSS computer program, **8** 189; **10** 1391; **11** 219, 1607, 1633
Gauss-Legendre quadrature, **12** 617
Gauss-Newton algorithm, **12** 2025
Gaussian approximation Bayesian analysis, **12** 717
Gaussian distribution, **9** 505; **10** 831; **11** 1981; **12** 403, 1033
Gaussian error cluster analysis, **15** 1793
Gaussian kernel smoother incidence data, **12** 311
Gaussian mixed models blood pressure data, **12** 1665
Gaussian pseudo-random variates AIDS incidence, **12** 311
Gaussian quadrature method, **12** 675
Geary's *c* statistic, **12** 1885
GEE *see* Generalized estimating equation
Gehan scores censored data, **15** 953
Gehan statistic, **8** 539; **11** 1705
Gehan-Breslow statistic sequential monitoring, **14** 2227
Gehan-Wilcoxon test, **8** 937; **11** 193
Gender smoking prevalence data, **15** 565
Genealogy, **5** 291
General Medical Council Education Committee, **9** 1031
General parametric method, **15** 2733
General tests cluster analysis, **14** 2323
Generalization analysis, **9** 1229
Generalized bilinear model, **11** 1225
Generalized correspondence analysis *see* Correspondence analysis
Generalized EM, **11** 1809
Generalized estimating equation, **13** 467
analysis of variance, **11** 1033
behaviour change, **12** 219
cluster analysis, **15** 1793
correlated observations, **11** 1503
correlated ordinal data, **14** 1961
fixed effects, **13** 541, 1211
geographically clustered data, **15** 1951
global tests, **15** 1217
HIV transmission, **14** 1365
homogenity of proportions, **13** 1253
longitudinal data, **11** 1825, 2001; **13** 1781
ordinal regression models, **15** 1807
population-averaged CL model, **15** 2573
repeated categorical data, **13** 1149
repeated measurements, **12** 1723
second-order, **15** 145
survival models, **12** 1019
tubal sterilization, **12** 355
unequally spaced binary data, **12** 289
Generalized *F* family, **5** 85
Generalized iterative Bayesian simulation, **11** 1809
Generalized least squares, **8** 189
see also Least squares
bioequivalence, **15** 2635
distribution-free estimators, **11** 1151
iterative algorithm, **13** 1643
longitudinal data, **11** 1861, 1929, 1967, 1981
multiple-outcome meta-analysis, **15** 537
omitted variable bias, **11** 1195
repeated measures, **11** 115
variance function estimation, **13** 1165
Generalized linear interactive modelling *see* GLIM
Generalized linear models
see also Linear models
additive hazards, **4** 353
binary responses, **12** 1259
cancer study, **4** 353
categorical data, **7** 95
cohort study cancer, **4** 353
covariance analysis, **8** 1075
data analysis, **10** 511; **14** 811
epidemiology bibliography, **10** 1819
error, **8** 1075; **9** 583–586(L); **10** 1197
estimation, **10** 1069
explained variation, **15** 1987, 1999
exposure assessment error, **8** 1109, 1127, 1133, 1137
factorial designs, **4** 379
GENSTAT analysis, **2** 223
historical data analysis, **7** 819
interval censored data, **15** 283
ligand-binding kinetics, **8** 871
likelihood ratio test, **12** 989(L)
longitudinal data, **7** 139; **11** 1825, 1929
measurement error, **8** 1075
mortality cancer study, **4** 353
multiplicative hazards, **4** 353
prevalence estimation, **11** 1591
prognostic factors, **2** 223
repeated measurements, **7** 29, 95, 139; **10** 1959
ROC curves, **15** 323
space-time disease mapping, **14** 2433
standardized mortality ratio, **12** 1895
standardized parameters estimation, **11** 559–560(L)
treatment-covariate interaction, **7** 1257
ventricular premature beats, **11** 963
Generalized linear random coefficient regression, **13** 1211
Generalized logistic models, **12** 881
Generalized Michaelis-Menten response surface, **15** 2107

Generalized multivariate analysis of variance, **11** 2031
Generalized rank-sum test, **9** 447; **11** 491–509
Generalized signed rank test, **11** 193
Generalized *t*-tests, **9** 447; **11** 491–509; **12** 2233, 2245
Generalized tests, **13** 747
Generalized variance, **12** 1999
Generalized Whittemore's test, **15** 2561
Genetics
  censored data, **14** 1353
  counselling, **2** 87
  epidemiology
    bibliography, **10** 1819
    contingency table estimation, **7** 591
    correlation estimation, **6** 629
    relative risk efficiency, **2** 13
    review, **5** 291
    sampling adjustments, **6** 629
    trend assessment models, **7** 185, 199
  familial aggregation, **11** 1767
  human
    bias, **4** 163
    contingency tables estimation, **7** 591
    correlation estimation models, **6** 629
    discordance ratios estimation, **6** 961
    disease association, **3** 57; **7** 443
    epidemiological models, **5** 291
    haplotype test, **5** 281
    HLA antigens associations, **7** 443
    linkage analysis, **3** 57
    multiple probands, **4** 163
    pedigree analysis, **4** 163
    psoriasis associations, **7** 443
    sampling design, **6** 629
    trends assessment models, **7** 185
Geneva-Bern compartmental model, **13** 1933
GENMAX computer package, **9** 409
Genotype population prevalence estimation, **12** 685
GENSTAT computer package, **2** 223; **9** 469; **11** 1425; **13** 2503
Geographic information systems (GIS), **15** 1961
  birth defects, **15** 717
  childhood leukaemia incidence, **15** 707
  Generalized Whittemore's test, **15** 2561
  infant mortality, **14** 481
  small area analysis, **15** 1859, 1921
Geographical correlations
  cancer study, **10** 95, 1241
  cohort models, **10** 1241
  density estimations, **9** 691
  epidemiologic surveillance, **10** 521
  fertility determinants Africa, **10** 161
  heart disease study, **9** 1199
  mortality rates, **9** 1199; **10** 95, 637
  significance tests, **9** 515
  spatial models, **10** 95
Geographical data, **12** 1869
  distribution, **8** 267, 279, 599
  epidemiology, **5** 171; **9** 515, 691; **10** 521
  measles morbidity, **11** 1409
  relative risk estimation, **11** 983
  smoothing procedures, **15** 2539
Geometric distribution
  prevalence estimation, **12** 685
  truncated inter-arrival model, **12** 2043
German-Austrian multicentre study, **6** 255
Germany
  AIDS data back-project, **13** 1991
  ALL/AUL study, **7** 1139
Gestation
  see also Abortion; Fertility; Pregnancy
  multivariate anlaysis, **1** 105
Gestational age
  birthweight centile curves, **15** 2657
  digit preference model, **11** 1225
  newborn mortality, **14** 2191
Gibbs sampling, **15** 1663
  Bayesian meta-analysis, **14** 2685
  Bayesian posterior estimates, **13** 1841
  CD4 estimates AIDS diagnosis, **13** 2059
  childhood leukaemia, **14** 2487
  coronary disease transition rates, **12** 1155
  disease mapping, **14** 2473
  disease risk analysis, **11** 1443
  longitudinal data, **11** 1809, 1825, 2001
  measurement error problems, **12** 1703
  posterior distribution draws, **13** 1525
  RCR model parameters, **13** 1211
  relative risk estimation, **11** 983
GIBS *see* Generalized iterative Bayesian simulation
Girshick-Rubin test, **2** 141
GIS *see* Geographic information systems
GISSI
  clinical trials, **9** 17, 145, 185
  large, simple trials, **13** 405
Glasgow
  coma scale, **5** 103, 403
  dyspepsia system, **2** 207
Glaucoma
  surrogate observations, **8** 427
  visual field data, **15** 1349
GLIM computer package, **14** 247; **15** 283
  absolute risk estimation, **10** 1025
  agreement data, **8** 1199
  AIDS, **8** 3, 23
  antigen investigation, **7** 443
  bootstrap resampling, **12** 153
  cancer study, **8** 1371
  categorical data, **10** 1607; **11** 799
  clinical trials, **5** 363; **8** 1439
  comparisons, **9** 463–464(L)
  correction to published papers, **9** 339
  counts/rates models, **10** 1405
  digit preference, **11** 1225
  disease association investigation, **7** 443

GLIM computer package (*cont.*)
generalized linear models, **11** 923, 1591
incidence prediction models, **13** 1513
latent class model, **11** 2111
ligand-binding kinetics, **9** 341–342(L)
log-linear models, **11** 101; **12** 219
logistic regression, **9** 1091
maximum likelihood estimates, **13** 2407, 2503
mortality study, **9** 981
platelet transfusions, **11** 2123
pock count variability, **9** 615
Poisson variability model, **10** 241
regression, **8** 1363, 1371; **9** 1157
relative risk estimation, **10** 1745
SSPE risks estimation, **10** 1733
statistical analysis software, **12** 1969
survival analysis, **9** 737
temporal effects estimation, **8** 1371
treatment comparisons, **8** 1439
tumour study, **8** 1363
Global odds ratio regression model, **15** 1507
Global tests, **13** 1441
see also Omnibus test
combination drug studies, **15** 233
multiple tumour data, **15** 1217
quality of life data, **9** 819
Global Two-stage Method, **13** 1165
Global type I error semi-sequential analysis, **12** 51
GLS *see* Generalized least squares
Glucose challenge, **2** 95
Glucose utilization, **15** 2107
GMANOVA *see* Generalized multivariate analysis of variance
Goetghebeur-Ryan method, **15** 2191
Gold standards sensitivity/specificity, **11** 1503
Gompertz distribution, **9** 397; **10** 1043, 1075; **11** 931; **14** 1859
Gonorrhea time series analysis, **8** 343
Good Behaviour Game preventative trials, **12** 289
Goodman and Kruskal statistic, **8** 619
Goodness-of-fit
combining two-by-two tables, **14** 1901
confidence intervals, **3** 287
covariance models, **14** 1397
Cox proportional hazards model, **13** 1045
kappa statistic, **13** 876–880(L); **14** 347
long-term survival studies, **15** 2763
mammary tumour incidence models, **13** 709
mathematical models, **14** 267
multi-state models, **13** 805
negative binomial regression model, **13** 1755
parametric regression models, **14** 1785
predictive diagnostics, **15** 2149
proportional hazards assumption, **13** 301
random effects model, **13** 2219
repeated ordinal model, **15** 1123
RIR parameters, **13** 1881
test statistic, **13** 143
Graft failure renal transplant, **12** 2285
Graft-versus-host-disease (GVHD) competing risks failure time data, **12** 737
Grant applications, **15** 2127
Grant review bodies, **12** 789
Graphical analysis, **14** 1265
Cox proportional hazards model, **14** 1707
cumulative hazard functions, **11** 1465
disease risk analysis, **11** 1443
ellipse agreement method, **13** 737
flow data, **13** 261
goodness-of-fit models, **14** 1785
longitudinal data, **11** 2001
RCR model assumptions, **13** 1211
shape invariant model, **14** 2009
survival curves, **11** 455
WEP signals, **13** 275
Graphical presentation
active life expectancy, **10** 1945
AIDS estimates, **10** 1167
AIDS incubation period, **13** 969
biochemical reference ranges, **10** 831
bioequivalence studies, **10** 961
biplots, **9** 469
cancer cohort models, **10** 1241
centiles, **9** 539; **10** 1693
clinical trials, **9** 787, 1287
confounding control, **8** 679
controlled clinical trials, **10** 777
correlations, **10** 1315
crossover trials, **10** 909
decision analysis, **9** 1229, 1243
diagnostic tests, **5** 585
disease monitoring methodology, **10** 1089
dose-finding studies, **10** 1647
EEG readings, **10** 1719
elderly hearing models, **10** 1453
epidemiological data plots, **8** 703
geographical risk surfaces, **9** 691
hazard ratio comparison, **10** 749
HIV, **10** 1167, 1427
infection force model, **9** 953
logistic regression, **8** 1317; **10** 1213
method comparison studies, **10** 981
misclassification, **10** 361
mortality rates, **10** 1043
multilogit model, **9** 981
multiple significance testing, **9** 811
normality departure estimation, **10** 1283
odds-ratios, **7** 889
order statistics study, **10** 855
outliers bioavailability studies, **10** 1375
overviews, **6** 341, 349
posterior inference prior beliefs, **13** 905
quality of life analysis, **9** 749
relative risks, **10** 1025
residual analysis, **10** 843
response phenomenon, **10** 1621

risk techniques, **8** 641; **10** 1511
Salmonella surveillance, **10** 1493
SSPE risk estimation, **10** 1733
survival analysis, **3** 35; **10** 733
threshold construction, **10** 1493
time series analysis diseases, **10** 1481
time-specific reference ranges, **10** 675
treatments, **10** 1349, 1595
two-way tables, **13** 2407
variables set covering, **9** 273
Green Tobacco Sickness, **15** 747
Greenhouse, Samuel biography, **14** 1613, 1615
Greenhouse-Geisser procedure, **3** 185
Greenhouse-Mantel confidence bounds, **13** 1551
Greenwood variance formula, **6** 679; **8** 1269; **12** 1353; **13** 43; **15** 51
Greenwood-Yule measure, **12** 249
Grimson's test cluster analysis, **15** 783
Grizzle, Starmer, Koch estimation, **13** 479; **14** 1901
Grizzle test, **10** 891
Group comparison crude incidence curves, **11** 813
Group randomized studies correlated binomial variates, **11** 1607
Group selection Morgan-Sonquist procedure, **2** 295
Group sequential methods, **12** 51
see also Clinical trials
alpha spending function, **13** 1341; **15** 1739
Bayesian inference, **14** 381
Bayesian statistics, **11** 23
boundaries approach, **13** 1341, 1357, 1369
early stopping, **11** 673; **13** 1313
interim analysis, **11** 55
logrank procedure, **11** 1359
monitoring clinical trials, **12** 2219
multivariate observations, **13** 101
phase II trials, **15** 2037
problems, **13** 1371
sample size determination, **11** 1391
study duration, **11** 1477
unified, **13** 1815
Group testing prevalence estimation, **11** 1591
Grouped data, **7** 535
contiguous zones, **5** 171
survival analysis models, **9** 737
validation bias, **4** 53
Groups comparison, **13** 2261
Growth curve models, **15** 2657
additional data, **13** 2477
autoregression, **7** 73, 87
change rates analysis, **6** 599
coefficients estimation, **13** 931
human analysis, **6** 185
Kalman filtering, **7** 73, 87
longitudinal data, **7** 305, 317; **11** 1955, 2001
maximum likelihood estimation, **7** 73, 305
missing data, **7** 317
multivariate analysis, **7** 317
muscular dystrophy study, **5** 231
observation prediction, **13** 2205
paired analyses, **1** 83
random coefficient analysis, **11** 243
symmetry tests, **1** 83
tracking, **12** 2153
treatment evaluation, **5** 231
tumour surveillance, **1** 83
two-step method, **9** 841
Growth velocity longitudinal data, **12** 403
Guaranteed survival, **3** 225
Guidelines statistical presentation, **1** 59; **3** 97
Guillain-Barre syndrome, **6** 795

Haemodialysis, **5** 637
Haemoglobin HIV infection marker, **12** 2087
Haemophilia
AIDS, **8** 1509; **9** 681; **10** 1527; **11** 591
clinical trials, **10** 433
HIV, **12** 2065, 2087, 2099; **13** 163
Haemorrhage
gastrointestinal, **5** 503; **6** 269
intra-cranial, **6** 315
Haemostasis registry, **11** 345
Hailperin-Rüger test, **10** 777
Hakulinen and Tenkanen risk model, **10** 65
Halperin, Max, **9** 863–870
Hamilton Rating Scale for Depression, **11** 2043
Handwashing protocols, **5** 393
Hanford nuclear plant study, **8** 173
Haplotypes, **5** 281
Hardy-Weinberg frequencies, **5** 281; **7** 591
Harmonic regression analysis, **6** 167
diurnal rhythms, **12** 129
time series regression relationships, **12** 1555
Harrell's *c* index concordant predictive discrimination, **12** 1693
Hausman test, **11** 1195; **13** 2219
Hawaii cluster analysis, **15** 699
Hayfever, **4** 11
Hazards
see also Cox proportional hazards...
absolute risk, **8** 641
additive model, **4** 353; **5** 539
AIDS, **9** 505, 681, 1387
attrition bias, **12** 1005
cancer recurrence study, **2** 41
cohort studies, **4** 353; **10** 1043
competing risks, **2** 373
convergent functions, **2** 273
early treatment termination, **9** 1417, 1433
epidemiological data, **8** 703
exposure effects analysis, **8** 173
finite mixtures theory, **9** 397
frailty models, **14** 1859
Framingham heart study, **7** 239, 289
function, **12** 617, 737; **13** 163, 301
group sequential monitoring, **9** 1081

Hazards (*cont.*)
historical data analysis, **7** 819
HIV, **10** 1003; **13** 163, 1975
intensity function preference, **8** 907
life expectation loss estimation, **10** 79
life-table analysis, **2** 373
logistic regression comparisons, **8** 525
lymphoma study, **5** 491
Markov model, **5** 491
melanoma tumour size, **9** 999
morbidity estimation, **7** 325
mortality, **2** 373; **3** 301–302(L); **7** 239, 289, 293; **10** 1043
multiplicative model, **4** 353
myocardial infarction surveillance, **4** 29
non-parametric statistics, **12** 843
occupational, **2** 477; **15** 747, 759
penalized likelihood, **13** 2427
person-time data, **9** 463–464(L)
population relapse, **13** 1089
prognosis evaluation, **4** 29
proportional assumption, **13** 1045
quadratic function, **7** 239
quality of life analysis, **9** 931
radiation factors, **5** 539; **8** 173
rate ratios estimation, **9** 1167; **10** 749
ratio
estimator comparison, **11** 847–848(L)
mid-point imputation, **11** 1569
PCP trial, **15** 2341
vaccine efficacy, **13** 357
regression trees comparisons, **8** 539
residuals plots, **8** 703
risk mortality, **7** 239, 289, 293
stratum-covariate interaction, **5** 73
survival analysis, **13** 43, 2383–2384(L)
cure models, **3** 153
drug combination time models, **9** 1527
estimation methods, **9** 529
grouped data models, **9** 737
model comparisons, **2** 305
proportional odds model, **2** 273
quality adjusted, **9** 1259
treatment effect assessment, **2** 41
trials endpoint risk, **13** 2107
Head
circumference at birth, **4** 379
injury, **5** 103, 403; **7** 929
Headaches aspartame, **12** 825
Health care
see also Public health surveillance
AIDS, **8** 137, 253–397
environmental hazards, **1** 163
evaluation, **4** 387–388(L)
forecasting factors, **7** 1061
occupational hazards, **1** 317
radiation therapy patterns, **3** 353
Health Care Financing Administration, **13** 1001
Health department disease cluster investigations, **12** 1757
Health Insurance Plan, **1** 15; **6** 885
Health promotion community intervention studies, **12** 329
Health strategies Healthy People 2000 , **12** 207
Health survey, **6** 869; **7** 983
Healthy People 2000 goals, **12** 207
Healthy worker effect, **5** 61; **6** 901
Healy models, **15** 2657
Heart
muscle biopsy, **2** 33
rate, **6** 159; **11** 125
transplantations, **2** 33; **3** 35; **14** 2023; **15** 2589
Heart disease
see also Cardiac. . .; Framingham heart study; Myocardial. . .
angina, **4** 53; **9** 293; **15** 987
antiarrhythmic drug efficacy, **8** 1393
arteriography variability, **5** 619
aspirin study, **6** 255
BHAT, **8** 1191
bias estimation, **4** 53
cardiac transplants, **12** 1155
cardiovascular, **8** 391
case-control study, **10** 653
CAST trial interim monitoring, **9** 1081
cholesterol risks, **8** 295
classification trees, **15** 157
clinical trials, **9** 87, 103, 125, 137, 657
coronary, **2** 413(L); **9** 87, 125, 287, 385, 1157
blood pressure study, **13** 1265
care units, **4** 387–389(L)
longitudinal data, **12** 2169
multivariate analysis, **12** 967
primary prevention trial, **9** 87
risk factors, **14** 643
coronary drug project (CDP), **3** 423, 445
correlation methods, **7** 717
Cox proportional hazards, **4** 413; **7** 613
data monitoring, **12** 471, 2219
databases, **10** 617; **14** 2627
diagnostic variables, **1** 41
discriminant analysis comparisons, **4** 413
disease evolution/prevalence prediction, **11** 295
diurnal rhythms definition, **12** 129
event probabilities, **11** 1719
factorial designs, **4** 111
failure time data, **10** 1099
follow-up data, **11** 1195
Framingham study, **7** 20, 219
geographic grouping, **5** 171
GISSI clinical trial, **9** 17
hypertension, **7** 1109
intermediate endpoint validation, **11** 167
ischaemic, **2** 147, 477; **4** 397; **15** 1885
laboratory data analysis, **2** 147

latent class analysis, **5** 21
leisure time activity study, **14** 299, 2285–2288(L)
logistic regression model, **1** 41; **4** 413
longitudinal data, **11** 1981
mortality, **6** 501, 709; **9** 1199; **11** 475
NHLBI, **9** 881; **12** 425
overviews, **6** 217, 233, 255, 281, 295
patient selection clinical trials, **9** 73
patient well-being assessment, **8** 1401
physicians' health study, **9** 29, 87; **10** 1585
pooled data study, **9** 1501
prognostic factors, **4** 29; **9** 1189
provisional diagnoses, **10** 1341
quality of life analysis, **9** 819
randomized clinical trials, **9** 447
registries, **11** 345
relative risk, **7** 717
risk factors, **11** 783
  assessment, **8** 295, 641; **9** 287
  attributable estimation, **7** 717
  Cox proportional hazards, **4** 413
  discriminant analysis, **4** 413
  logistic regression model, **4** 413
  prediction, **9** 385
run-in trials, **9** 87
screening tests, **4** 53
subjective rankings, **11** 427
surrogate endpoints, **8** 415, 431
survival models comparisons, **9** 1157
therapy evaluation, **10** 647
treatment changes, **15** 249
treatment evaluation, **7** 1109
trial results applicability, **9** 185, 193
variation, **6** 351
Heartburn, **2** 397
Heel length, **4** 379
Heidelberg Well-Being questionnaire, **9** 749
Height
  surface area estimation, **15** 1325
  velocity, **13** 2477
Heparin clinical trial, **15** 1729
Hepatitis cluster randomization, **11** 307
Hepatitis B, **8** 391; **12** 1943; **15** 2215
Hepatocellular cancer, **4** 345
Hereditary disease, **3** 57
Heterogeneity
  clinical trials
    hypertension study, **7** 1109
    myocardial infarction, **6** 351
    randomized methods, **6** 287, 329, 349, 395
  controls, **6** 221
  covariate adjusted mixture models, **15** 919
  dose-response relationships, **11** 685
  eye-tracking models, **15** 1365
  HIV models, **9** 721; **10** 1003
  inter-study variation analysis, **6** 351
  longitudinal data, **12** 1339
  measurement assessment, **9** 351
  meta-analyses, **10** 971, 1665; **15** 1263, 1273
  misclassification, **10** 1181
  mixed multi-normal distributions, **9** 301
  mixture models, **12** 1943
  multicentre binary variables, **9** 919
  patient selection clinical trials, **9** 73
  quality of life assessment, **10** 1915
  random effects meta-analysis, **15** 2733
  repeated events analysis, **10** 1227
  risk, **5** 557
  spatial patterns, **12** 1885
  survival analysis, **7** 1207; **9** 529
  treatments hypertension, **7** 1109
  two-sample tests, **9** 447
  variance, **4** 379
Heterogeneous diagonal parameter model, **11** 101
Heterogeneous Poisson process
  disease clusters, **12** 1249
  disease mapping, **14** 2459, 2473
Heterogeneous uniform association model, **11** 101
Heteroscedasticity
  dietary assessment, **12** 925
  Moran's *I*, **15** 887
  multicentre trials, **12** 1047
Heterosexuals
  drug users interaction HIV risk, **11** 1657
  HIV positive, **12** 2065, 2087, 2099
Hexagonal mosaic, **7** 1157
Hib bacteria within family infections, **15** 2235
Hierarchical Bayes
  bivariate survival data, **14** 2523
  childhood leukaemia model, **14** 2487
  decision theory, **14** 2173
  disease mapping, **14** 2411
  dose-determination, **14** 971
  modelling, **11** 2001
Hierarchical models
  hazard regression, **15** 1757
  log-linear, **11** 799
  mortality ratios, **15** 1397
  multiple exposure studies, **12** 717
  normal model, **11** 141
  polynomial, **11** 703
  simulation, **15** 1161
Highest posterior density (HPD) transition rates, **12** 1155
Hill, Sir Austin Bradford
  bibliography, **1** 369; **12** 797
  biography, **1** 297, 305, 307, 309
  clinical trials, **1** 337, 345, 353, 361
  clinician and statistician, **1** 311
  epidemiology, **1** 325
  obituary, **12** 795
  occupational health, **1** 317
  Statistics in Medicine origins, **1** 301
Hinkley's method *see* V-mask
Hip joints variation assessment, **7** 639; **8** 1416–1417(L)

Hip prostheses loosening crude incidence curves, **11** 813
Hip replacements threshold-crossing data, **12** 1589
Histogram peri-stimulus time, **4** 91
Histopathology osteoarthrosis, **8** 1417(L)
Historical control studies, **13** 417
  cancer immunotherapy, **3** 325
  ethics, **3** 315
  laboratory data analysis, **10** 839
  limitations, **3** 315
  medical registers, **3** 225, 361, 389
  pooling methods, **10** 1417
  power evaluation, **8** 153
  prognostic factors, **3** 225, 341, 361
  randomized trials, **1** 345
  selection bias, **3** 225, 315
  therapy evaluation
    cancer, **3** 325, 331
    clinical trials, **3** 401, 455
    heart disease, **3** 331
    observational data, **3** 341, 361, 401
    registry data, **3** 225, 361
    strengths/weaknesses, **3** 315
    surgery studies, **3** 389
  use of, **12** 1373
HIV (Human immunodeficiency virus)
  see also AIDS; CD4 lymphocyte counts; Res. Application Conf.
  age-related reference ranges, **13** 2359
  AIDS
    comparisons, **9** 505, 681, 1387, 1433
    epidemic models, **8** 1–137
    incubation, **15** 2459
    incubation model, **7** 395
    onset, **11** 591
    Progression estimate methods, **13** 163
  Australia, **15** 2253
  AZT trial, **15** 2413
  back-projection, AIDS, **13** 1945, 1959, 1991
  backcalculation, **13** 1975; **14** 1505; **15** 2669
  CD4-lymphocyte counts
    AZT, **15** 75
    cohort studies, **13** 1101
    empirical Bayes estimators, **15** 2289
    homosexuals, **14** 1889
    IDUs, **14** 1889
    surrogate endpoints, **12** 835; **13** 1895–1896(L)
  diagnostic tests efficacy, **7** 549
  disease state models, **13** 805
  doubly censored data, **11** 1569
  dynamic model, **11** 1425
  early-stage treatments, **13** 405
  effectiveness studies, **13** 2081–2106
  epidemic dynamics, **11** 1657
  Extending Public Health Surveillance of HIV disease (workshop), **12** 2061–2130
  high-risk sexual behaviour, **15** 2323, 2337
  homosexuals, **15** 2177
  immunotherapeutic study, **13** 1583
  incidence curve estimations, **12** 1317
  incidence modelling, **15** 513
  incidence projection methods, **10** 1527
  incidence/mortality, **12** 2395
  incubation distributions, **15** 197
  infection, **8** 45, 83, 103; **9** 721; **10** 131
  infection curves proportionality assumption, **13** 1865
  infection probability estimation, **13** 2097; **14** 1513
  infection trends, **15** 1779
  intervention trials, **14** 1177
  intravenous drug users tests, **13** 2009
  length bias model, **10** 423
  Markov model analysis, **8** 831
  maximum effective dose example, **13** 87
  mean-squared error estimates, **10** 1167
  morbidity, **15** 2307
  multiple reading procedures, **7** 549
  needle exchange programmes, **13** 2179
  newborn seroprevalence data, **13** 1881
  non-parametric analysis, **13** 2043
  odds ratio order, **10** 1273
  optimal drug dosage, **13** 405
  overlapping enrolment, **15** 2445
  perinatally acquired latency, **13** 2031
  predictive diagnostics, **15** 2149
  prevalence estimation, **11** 1633
  prevention models, **8** 59
  progression to AIDS, **12** 617, 2061, 2065, 2099
  public health surveillance, **12** 2061, 2065; **13** 1933
  registries, **11** 345
  risk, **15** 2307
    assessment, **13** 53
    variable infectivity, **10** 131
  screening tests, **13** 1905; **15** 2161
  seroconversion, **9** 505; **13** 2021
  space-time interaction, **15** 1935
  stage-specific numbers, **11** 831
  Statistical Issues in HIV/AIDS Research Symposium, **15** 2269–2491
  stochastic processes, **10** 1427
  study cohorts, **12** 2065
  test data in forecasts, **13** 200
  testing rates, **15** 497
  time since exposure estimation, **11** 939
  transfusion-related data, **13** 2043
  transmission, **8** 59, 83, 93
    estimation, **14** 1365
    model, **8** 35; **9** 721; **10** 1003
  treatment changes, **15** 2425
  type 1, **12** 2133
    increase incidence, **12** 153
    infection time estimation, **13** 231
    tests, **15** 463
  uncontrolled treatment changes, **15** 2053

vaccination, **13** 2155; **15** 2393, 2405
vaccine study, **9** 1425, 1433; **13** 357; **15** 2371, 2379
HLA (histocompatibility antigens), **2** 79; **5** 281; **7** 443; **10** 1775
Hochberg's procedure, **9** 811
Hocking model, **13** 759
Hodges-Lehmann location shift, **11** 1151
Hodgkin's disease, **3** 173, 353, 359; **6** 517; **11** 983; **15** 2191
Holm test, **9** 811; **10** 777, 871, 939; **15** 1107
Home injuries, **8** 263
Homicide data, **8** 390, 1497
Homogeneity
adjusted attributable risk, **11** 2083
case-control studies, **10** 1257
contingency tables, **9** 363–383
covariate, **8** 467
cumulative sum test, **4** 469
distribution-free estimators, **11** 1151
generalized linear models, **10** 1069
hypertension study, **9** 301
hypothesis, **13** 1583
marginal, **6** 91; **7** 109; **8** 1209, 1455
meta-analysis, **11** 2077
multi-normal distribution, **9** 301
odds ratio estimations, **7** 889
pre-eclampsia studies, **15** 1237
proportions methods, **13** 1253
randomized trials, **9** 73
relative risk cohort studies, **10** 1267
small sample performance, **11** 159
treatments meta-analyses, **10** 1665
vaccine efficacy estimation, **10** 1573
Yates's correction, **9** 363–383
Homoscedasticity, **4** 379
Homosexuals, **8** 59, 121, 259
AIDS incidence, **15** 2273, 2307, 2323, 2669
HIV, **12** 2065, 2087, 2099; **15** 2177
Hormones
cancer risks, **14** 267
growth models, **6** 185
measurements, **1** 49
ovulation day estimation, **10** 255
pregnancy prediction, **14** 185
pulse secretion study, **14** 311
pulses detection model, **10** 329
receptors, **7** 805
secretory pulses, **11** 2133
Hosmer-Lemeshow statistic, **7** 519, 947
Hospitals
admissions, **7** 787
patient classification, **11** 1321
quality performance, **14** 2161
Hotelling's T^2, **10** 1375, 1711; **12** 1665, 2153
Household infections, **15** 837, 851
HPV *see* Human papillomavirus
Huber's loss function, **12** 2025
Human body surface area estimation, **15** 1325
Human genetics *see* Genetics
Human immunodeficiency virus *see* HIV
Human papillomavirus, **13** 379
Human *T*-lymphotropic virus (HTLV-III), **5** 355
Humphrey perimeter, **11** 1131
Hybrid epidemiologic design *see* Case-cohort
Hydrogen energy expenditure measures, **9** 1365
Hypergeometric model, **11** 1533
Hyperprior distributions, **13** 1841; **14** 2411
Hypertension
24 hour blood pressure data, **11** 1843, 2147
bias correction, **7** 941; **8** 1302–1304(L)
blood pressure study, **7** 47, 423, 697; **13** 1635
change assessment methods, **7** 915
children at risk, **11** 1187
classification models, **8** 1291
clinical trials, **7** 941; **8** 1302–1304(L); **10** 1349
cluster randomization, **11** 307
crossover studies, **10** 1115
database problems, **10** 653
detection and follow-up program, **7** 423
discriminant analysis, **8** 1291
heart disease risk study, **7** 1109
meta-analyses, **10** 1665
mixed multi-normal distribution, **9** 301
mixture models, **8** 1291
multicentre clinical trials, **12** 1033, 1047; **13** 1601
multicentre meta-analysis, **15** 619
Muscatine study, **7** 47
renal study, **8** 1291
significance testing, **10** 1123
titration studies analysis, **10** 323
treatment changes, **15** 249
treatment evaluation, **7** 1109
Hypospadias change-point test, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
Hypothesis testing, **15** 817
best dose selection, **13** 87
bioequivalence studies, **10** 961
change-point test, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
chi-squared adjustments, **10** 1981
clinical trials, **9** 601, 703; **10** 433, 777, 1679, 1789
closed test procedures, **13** 1583
comparative binomial trials, **9** 1447
crossover trials, **10** 891
decision theory problems, **6** 101
discriminant analysis, **4** 337
doctors knowledge assessment, **6** 3
drugs tests, **10** 991
equivalence tests, **13** 1827
factorial ANOVA design, **10** 1565
group sequential designs, **13** 1815
historical control study, **10** 839
independence testing, **10** 1555

Hypothesis testing (*cont.*)
interim analysis, **10** 925, 949
logistic regression, **4** 337; **10** 1213
longitudinal studies, **9** 437
LR statistic distribution, **13** 1563
meta-analyses, **10** 1665
mixed multi-normal distributions, **9** 301
multiple tests, **7** 1031; **8** 1304–1306(L); **9** 811; **10** 871, 939
P-value misuse, **8** 1413–1414(L)
parallel treatment profiles, **13** 931
periodontal disease progression, **10** 1089
phase II clinical trials, **10** 989
population medians, **13** 1635
prevention trials, **13** 1807
risk homogeneity, **10** 1267
sample size, **8** 803; **10** 463
signed rank tests, **4** 145; **5** 199–200(L)
significance, **9** 201, 213, 627; **10** 1123
step-down procedure, **13** 2261
three-stage phase II trials, **13** 1727
transition intensity model, **13** 805
transitional behaviour, **13** 467
Hysterectomy investigation, **8** 977

I^*_{pop} cluster analysis, **15** 783
ICDA codes for trauma, **1** 145
ICG-CTR *see* International Collaborative Group on Clinical Trials Registries
ICM *see* Iterated conditional modes
Identificability problem
cancer variation models, **6** 449, 469
mortality trends, **6** 709
Identity-by-descent (IBD) scores, **9** 573
IDIFF statistic, **12** 1795
Idiometric regression, **7** 697
IDUs *see* Intravenous drug users
IgA *see* Immunoglobulin A
Ignorable non-response model, **7** 305, 357
Illness-death process, **7** 149, 661; **8** 201
Image grading trial, **8** 1433
Imaginary training sample, **13** 905
Imbalance patient allocation, **6** 119, 127, 241, 577
Immediate response sample size determination, **11** 1391
Immune response virus neutralization assays, **11** 1253
Immunity, **2** 1; **4** 279; **14** 39
Immunization
hepatitis B, **15** 2215
programmes, **9** 953, 1425, 1433
Immunoassay dose interpolation, **5** 183
Immunoglobulin A (IgA) HIV infection marker, **12** 2061, 2065, 2087, 2099
Immunological markers HIV indicators, **12** 2065, 2087, 2099, 2133
Immunosafety birth control vaccine, **10** 177
Immunotherapy, **1** 83; **3** 325; **4** 279
Impact, Hypertension Information Project (IHI), **7** 423
Impurity function, **15** 37
Imputation methods
AIDS study, **9** 505, 1387
HIV study, **9** 505
missing data, **8** 263, 279; **9** 777
treatment effects evaluation, **9** 777
IMSL computer package, **9** 539; **10** 473
In vitro fertilization (IVF)
national registry, **12** 39
regression model, **12** 1543
success prediction, **14** 1807
Inborn-outborn status, **7** 1207
Incidence, **7** 403, 727; **13** 379, 1119, 1745
AIDS
backcalculation, **14** 1505; **15** 2669
epidemic models, **8** 1–139
haemophilia association, **8** 1509
HIV comparisons, **9** 1387
HIV vaccine development, **9** 1425
infection trends, **15** 1779
mortality rates, **15** 2273
projection methods, **10** 1527
report correction, **8** 963
reporting delay, **15** 305
risk and morbidity, **15** 2307
sexual behaviour, **15** 221, 2323
time lag adjustment model, **8** 259
animal tumours dose-effect, **13** 689
ante/neonatal seroprevalence data, **13** 1881
cancer, **11** 1579
age specific rates, **4** 63
age-period cohort models, **5** 527; **6** 449, 469
birth cohort analysis, **4** 63
models, **15** 1003
morbidity estimation methods, **8** 201
screening programmes, **8** 743
smoking effects, **7** 223, 289
temporal effects estimation, **8** 1371
treatment-induced, **8** 1371
trends estimation, **8** 201
variation models, **6** 449, 469
case-control study, **5** 127
curves, **11** 813; **12** 1317
cystic fibrosis, **15** 449
densities risk factors, **13** 343
disease
aberrations, **8** 323, 331
attributable risk estimation, **7** 507
dental study, **7** 403
diagnostic tests, **5** 727; **7** 403
estimation methods, **5** 573; **7** 403
likelihood analysis, **7** 149
rates estimation, **13** 2369
exposure-specific, **13** 651
gonorrhea study, **8** 343
HIV, **13** 1933–2020; **15** 497, 513, 1779

home injury, **8** 263
leukaemia, **15** 1003
lung cancer, **15** 273, 565
mortality relationship, **12** 2395
Poisson rates, **8** 757
predictions observations, **13** 1513
probabilities screening trials, **13** 569
screening effectiveness studies, **9** 969
short-term influence models, **13** 1921
side effects, **9** 803
Incident cohort, **11** 939
Income nutrient intake consequences, **11** 533
Incomplete adjustment residual confounding, **11** 1747
Incomplete data
see also Drop-outs; Missing data
intentional, **11** 1889
longitudinal, **11** 1887–1963
multivariate, **11** 1151
rate of change estimation, **11** 621
serial multivariate data, **11** 1041
Incomplete factorial designs, **12** 1629
Incubation distributions
AIDS, **11** 1633; **15** 2459
model, **13** 2043
Incubation period
AIDS
cohort studies, **10** 1993
demographic impact, **8** 103
paediatric transfusion, **7** 395
short-term projection, **8** 23
statistical issues, **9** 1387, 1433
doubly censored data, **11** 1569
measles, **11** 579
Independence
contingency tables, **15** 2095
estimating equations, **13** 479
multi-rater agreement model, **11** 101
statistical, **7** 1289
testing, **14** 1621
Independent increments model, **7** 29
Independent samples *t*-test, **6** 79
Index
additivity, **14** 1941
birth, **14** 1797
blindness, **15** 1421
Karnofsky, **12** 2351, 2377
majority agreement, **4** 47
morbidity, **7** 787
mortality, **6** 71
pair disagreement, **4** 47
plot, **7** 629
risk, **7** 947
Sullivan's, **7** 787
validity, **5** 585
Youden, **5** 585; **7** 519; **14** 1463
Indirect standardization, **6** 61, 193, 449
Indistinguishability hypothesis, **4** 337
Individual bioequivalence, **11** 1777; **12** 1109
Individual level studies
biases, **11** 1209
smoking risks, **14** 327–330(L)
Individual patient data meta-analysis, **14** 2057
Indoor-air pollution, **8** 1109, 1127, 1133, 1137
Induction time distribution, **8** 35
Industrial chemicals and health, **2** 477
Industrial cohort study, **6** 901
Inequivalence, clinical trials, **8** 593
Infancy-childhood-puberty model, **6** 185
Infant mortality
birthweight factor, **12** 377
Healthy People 2000 objectives, **12** 207
rates, **15** 1907
Infants
see also Children
cancer, **10** 1745
kidney study, **10** 1693
mortality
logit models, **4** 175, 189; **5** 139, 155; **9** 981
perinatal study, **2** 229
survey, **8** 387
polio vaccine trial efficiency, **9** 13
retrolental fibroplasia trial, **9** 893
speech sounds models, **9** 1143
vitamin A clinical trial, **9** 35
Infection
curves, **11** 1633
diseases, **3** 165; **5** 37; **6** 843; **7** 1147; **12** 461, 469; **13** 2233
HIV
indicators, **12** 2065, 2087, 2099, 2133
mean-squared error estimates, **10** 1167
probability analysis, **8** 83
projection methods, **10** 1527
risk infectivity effect, **10** 131
statistical issues, **9** 1387, 1433
stochastic processes, **10** 1427
transmission model, **8** 35, 93, 103; **9** 721; **10** 1003
U.S models, **8** 45
vaccines, **9** 1425, 1433; **15** 2393, 2405
Markov model, **8** 831
measles
mumps and rubella model, **9** 953
SSPE risk, **10** 1733
parasitic estimation, **9** 1211
peritonitis rates models, **9** 263
Salmonella threshold construction, **10** 1493
sexually transmitted diseases, **11** 565
times, **11** 1569
vaccine efficacy estimation, **10** 1573
within families, **15** 2235
Inference
see also Bayesian inference
analysis of medical studies, **13** 1699
binomial comparisons, **10** 1137

Inference (*cont.*)
censored data, **11** 1871
data reanalysis, **8** 653–677
descriptive data anlysis, **10** 777
exact logistic regression, **14** 2143
frequentist approach, **13** 2311
goodness of fit, **11** 1511
induction/deduction relevance, **10** 1679
log transformations, **14** 811
P-values, **8** 1469
paired ROC plots, **13** 499
random-effects model parameters, **13** 541
significance testing, **9** 703
statistical
clinical trial reports, **6** 745
decision making problems, **6** 101
P-value misuse, **8** 1413–1414(L)
randomized trials, **6** 277, 369, 387
teaching aids, **5** 193
treatment effect models, **13** 905
Infertility *in vitro* fertilization, **12** 1543
Influence analysis decision trees, **9** 1229
Influence diagram disease risk analysis, **11** 1443
Influenza, **7** 1045, 1147, 1267; **13** 1563; **15** 837
Information criterion *see* Akaike... Bayesian...
Information surface combination drug trials, **11** 1065
Information technology
databases, **10** 541
medical systems, **2** 207
teaching statistics, **9** 1031, 1039, 1043, 1063
Information theory, **8** 861, 977
Informational complexity psychotherapy, **11** 231
Informative censoring
see also Right censoring
longitudinal data, **11** 1861
rate of change estimation, **11** 621
Inhalers crossover study, **15** 2573
Inheritance
censored data model, **14** 1353
disease association, **3** 57
familial aggregation, **7** 185, 199
frailty model, **13** 1679
pedigree analysis, **4** 163
sampling designs, **6** 629
trend assessment models, **7** 185, 199
Inhibitory concentration, **7** 535
Injecting drug users *see* Intravenous drug users
Injuries, **1** 145; **8** 263, 388, 1497; **11** 1171
Injury severity score (ISS), **15** 933
Innovations test designs studies, **8** 441, 455
Innovative method, **12** 355–414
Inosiplex, **3** 225
Instability laboratory assay, **4** 369
Institut Gustave Roussy (Villejuif), France adjuvant chemotherapy clinical trial, **12** 51
Instituto Nazionale dei Tumori (INT), **9** 737
Instrumental variables
air pollution, **8** 1109, 1127, 1133, 1137
attrition bias, **12** 1005
diagnostic test procedures, **7** 739
estimation, **13** 1265
Insulin glucose utilization, **15** 2107
Integrated moving average geographical coherence, **11** 1409
Intelligence artificial, **4** 317; **5** 497
Intensive care units, **7** 1207; **14** 2161
Intention-to-treat
AIDS clinical trials, **15** 2445
clinical trials, **3** 341, 347, 371, 409, 467
non-compliance, **12** 1185; **15** 2813
treatment changes, **15** 249, 2069
treatment effect estimation, **7** 1179
Inter-arrival distribution
permutation test, **12** 2043
truncated geometric, **12** 2043
Inter-study variation, **6** 287, 329, 349, 351, 359, 395
Interactions
analysis of variance, **7** 467; **10** 1565
clinical trials, **3** 409; **4** 111, 255; **9** 73
clinician/statistician, **3** 1
crossover trials, **10** 1361; **12** 825
cummulative hazard functions, **11** 1465
drug combinations, **13** 2289
epidemiological studies, **2** 243, 355
exposure-covariate, **6** 193
factorial designs, **8** 161; **9** 55; **10** 1565; **11** 1403(L)
qualitative, **6** 329, 351, 359, 371, 387
quantitative, **6** 329, 359, 371, 387
regression models, **13** 2407
sexually transmitted diseases, **11** 1533
statisticians and editors, **7** 1003
stratum-covariate, **5** 73; **6** 221, 233, 371, 381, 773
treatment covariate, **7** 843, 1257
treatment-period, **6** 911; **7** 1099(L)
Interclass correlation coefficient, **13** 737
Interim analysis, **13** 1401
see also Clinical trials
alpha spending function, **13** 1341, 1353
Bayesian inference, **11** 23, 37; **14** 1057, 1065
CALGB lung cancer trial, **13** 1313
CHART cancer trials, **13** 1297
clinical trials, **11** 55; **12** 2219; **15** 1299
dose determination, **14** 901, 909
dose-response evaluation, **14** 1595
early stopping, **13** 1493
EORTC breast cancer trial, **13** 1329
equivalence tests, **15** 2703
group sequential trials, **11** 1485
industry-sponsored trials, **12** 471, 481
information time, **13** 1441
longitudinal trials, **14** 2239

lung cancer trial, **13** 1415
MRC renal cancer trial, **13** 2249
multivariate observations, **13** 101
PCP trial, **15** 2341
robust Bayesian approaches, **15** 1093
sample size, **11** 55, 1391; **14** 1039, 1053
stopping rules, **11** 659, 673; **12** 901
succession procedure, **12** 51
surrogate information time, **13** 945
SWOG early stopping, **13** 1391
two-stage clinical trials, **15** 1739
Intermediate trials, **15** 2379
International Bone Marow Transplant Registry, **4** 1
International Cancer Research Data Bank (ICRDB), **6** 11
International Classification of Diseases
cardiovascular disease revision, **4** 397
International Collaborative Group on Clinical Trials Registries (ICG-CTR) consensus recommendations, **12** 1085(L)
International Society for Clinical Biostatistics
3rd Conference, Rotterdam
committees, **2** 111
papers, **2** 113–305
preface, **2** 109
5th Conference, San Marino
committees, **4** 253
papers, **4** 255–397
preface, **4** 251
6th Conference, Dusseldorf
committees, **5** 401
papers, **5** 403–553
preface, **5** 399
7th Conference, Cardiff
committees, **6** 731
papers, **6** 733–869
preface, **6** 729
8th Conference, Gothenberg
committees, **7** 1107
papers, **7** 1109–1176; **9** 719–784
preface, **7** 1105
9th Conference, Innsbruck
committees, **8** 13, 1315
papers, **8** 1317–1401; **9** 719–784; **12** 2395–2415
preface, **8** 1313
10th Conference, Maastricht
committees, **9** 1229
papers, **9** 1229–1365; **11** 2043
preface, **9** 1229; **11** 2041
11th Conference, Nîmes
committees, **10** 1645
papers, **10** 1647–1782; **11** 2063–2145; **13** 2531–2545
preface, **10** 1643; **11** 2041
13th Conference, Copenhagen
committees, **12** 2255
papers, **12** 2257–2341; **13** 2437–2529
preface, **12** 2253
14th Conference, Cambridge
committees, **13** 2391
papers, **13** 2393–2436; **14** 2661–2712
preface, **13** 2389
15th Conference, Basle papers, **14** 2627–2659; **15** 2781
16th Conference, Barcelona papers, **15** 2689
International Society for Clinical Biostatistics/Society for Clinical Trials Joint Meeting, Brussels papers, **12** 2343–2393
International Society for Pediatric Oncology, **8** 593
International Study of Infarct Survival, **13** 405
cardiology trial, **9** 17, 145, 185
randomized trials, **3** 409
Interobserver variation
agreement data analysis, **8** 1199
arteriographic readings, **5** 619
association models, **8** 1199
binary variables, **7** 955
chance-correlated agreement measures, **12** 2191
correlation coefficient, **13** 2465
database uses, **5** 103
dental study, **4** 47; **7** 403
diagnostic tests, **6** 411; **7** 403, 955
estimation methods, **7** 639; **8** 765–767(L), 1416–1417(L)
experimental design, **4** 47
exposure-response relationships, **7** 955
head injury study, **5** 103
kappa statistic, **11** 1511
kappa-type analysis, **3** 73
ordered categorical response, **13** 2437
radiological assessment, **7** 639; **8** 765–767(L), 1416–1417(L)
Interpolation
clinical studies, **1** 131
immunoassay dose, **5** 183
Interrater agreement
diagnostic tests, **7** 403(L); **9** 835(L)
kappa
calculation methods, **10** 1303, 1465
type analysis, **3** 73
reliability measurement, **9** 1103
Intersection-union problems, **11** 1057
Interval
censored data, **7** 1139; **8** 725; **9** 409; **10** 1945
combined endpoints, **11** 1705
failure time, **15** 1387
generalized linear models, **15** 283
HIV, **13** 163; **15** 2177
longitudinal studies, **13** 1771
malaria, **14** 2727
threshold-crossing data, **12** 1589
consensus binary/interval ratings, **11** 317
discrimination, **5** 347
estimation
AIDS incidence, **14** 1505

Interval (*cont.*)
estimation (*cont.*)
unified group sequential tests, **13** 1815
estimations, **4** 23
measles/SSPE estimations, **10** 1733
tolerance, **5** 347
Intervention analysis
community study, **7** 1195
corrected estimator, **12** 1213
event probabilities, **11** 1719
Good Behaviour Game, **12** 289
intermediate endpoints, **11** 167
latent effect, **5** 345
NCHS role, **12** 207
Statistical Methods for Evaluation of (symposium), **12** 191–414
time series models, **8** 343, 1497; **10** 1481
Intervention trials, **15** 1951
acute disease study Norway, **10** 405
AIDS, **13** 2107, 2187; **14** 1177
clinical trials benefits/risks, **10** 1349
cost and efficiency, **9** 35
disease prevention efficiency, **9** 161
epidemiologic surveillance, **10** 521
HIV transmission model, **9** 721
incidence count, **13** 1479
Lung Health Study, **13** 945
matched pair randomization, **9** 943
odds ratio estimation, **8** 599
oesophageal dysplasia, **13** 479
patient selection, **9** 73
Intra-individual variation, **12** 1213; **13** 2280–2285(L); **14** 1067, 1079, 2283–2285(L)
Intra-subject variability crossover trials, **15** 1619
Intraclass correlation
coefficients, **6** 43, 441, 647; **9** 351; **13** 2465
correlated binomial variates, **11** 1607
model misspecification, **14** 1693
Intracluster correlation, **6** 491; **7** 1195; **11** 751, 1767
Intracranial aneurysms, **9** 1229
Intralaboratory variation, **8** 295
Intraocular melanoma, **9** 999
Intraocular pressure, **8** 427
Intravenous drug users, **10** 423
see also Drug users
AIDS incidence, **15** 2273, 2669
HIV positive, **12** 2065, 2087, 2099
Intraventricular haemorrhage, **2** 167
Intrinsic agreement, **7** 639
Inventory of Cancer Prevention Trials, **11** 345
Inverse confidence intervals formula, **12** 2025
Inverse estimation, **5** 347; **12** 2025
Inverse Mills ratio (IMR) attrition bias, **12** 1005
Inverse polynomial multilevel statistical model, **12** 949
Inverse sampling, **15** 671
conditional confidence intervals, **14** 2051
population prevalence, **12** 685
prevalence rates, **14** 1471
Ionizing radiation, **5** 539; **8** 173
IPF *see* Iterative proportional fitting
Iron-binding proteins, **4** 425
Irradiation X-ray, **7** 857
Irreversibility brain death, **6** 535
Irwin's rules power, **10** 1321–1322(L)
ISCB *see* International Society for Clinical Biostatistics
Ischaemic attacks trial, **3** 409
Ischaemic heart disease study, **2** 147, 477; **4** 397; **9** 1189; **10** 521
ISIS *see* International Study of Infarct Survival
Isobolograms, **13** 2289
Isotonic nearest neighbour spread estimator, **12** 2025
Isotonic regression, **7** 649; **11** 1171; **12** 1989; **13** 87
Isotopes energy expenditure measures, **9** 1365
Isotropic spherical semivariogram, **13** 523
Israel laboratory workers study, **15** 759
ISS *see* Injury severity score
Italy
cancer maps, **14** 2363
HIV study, **14** 1513; **15** 2669
Item non-response *see* Missing data
Item-response models, **12** 1969
Iterated conditional modes, **11** 1809
Iterative proportional fitting, **11** 1809
Iterative simulation, **11** 1809
Iteratively reweighted least squares, **11** 1033, 1929
IVDU *see* Intravenous drug users
IVF *see In vitro* fertilization

Jacard coefficient, **6** 137
Jackknife, **13** 2437
Cohen's kappa, **11** 1530–1532(L)
kappa statistics, **12** 2207
mixed models, **11** 2027
risk scores, **14** 1331
risk screening, **11** 257
surveillance data aberrations, **11** 1551
variance estimates
association models, **8** 1199
censoring, **7** 1257
compartment model, **8** 1011
interrater reliability, **9** 1103
log-linear modelling, **11** 101
measurement errors, **9** 1463
Japan AIDS incidence projections, **8** 1509
Jenss negative exponential growth curve, **11** 1929
Jewell's estimators, **8** 987; **10** 151–153(L)
JMP computer package, **9** 469
Job-exposure matrices disease risk analysis, **11** 1443
Johnson density system, **9** 539
Join-count statistic, **15** 873

Joint action model, **4** 77
Joint disease survey, **8** 785
Joint Program for Study of Abortion, **2** 25
Jonckheere-Terpstra test, **14** 863
Jonckheere's test, **4** 489
  Wilcoxon-type tests, **14** 445–446(L)
Journals
  Cox regression, **10** 1931
  developments review, **10** 1897
  medical statistics, **1** 59; **3** 97; **6** 3; **7** 1003; **8** 1413(L)
Jump process, **7** 325

K1 waveform component, **13** 2233
k nearest neighbour
  DEMP, **15** 1837
  discriminant analysis, **13** 719
  space-time interaction, **15** 1935
k-ratio *t* tests multiple comparisons, **11** 863
k-sample tests
  coefficients of variation, **15** 647
  comparison, **14** 863
Kalamazoo trial analysis, **13** 785
Kalman filter, **7** 73; **8** 335; **14** 1219, 1235
  CAR model, **12** 265
  emergency room visits, **15** 823
  recursive algorithm, **11** 515
Kaplan-Meier survival estimates
  age-adjusted curves, **14** 1731
  AIDS clinical trials, **13** 2107, 2127
  AIDS incubation, **13** 805; **15** 2459
  AIDS progression, **11** 591
  AZT, **15** 2413
  cancer clinical trials, **7** 1139
  censored data, **9** 293, 1417; **10** 413, 1313; **12** 1353
  clinical trials, **10** 1595
  competing risks failure time data, **12** 737
  confidence intervals, **6** 679; **15** 171
  covariates, **14** 2537
  Cox model comparison, **14** 1707
  crossover studies, **10** 1099
  cure-rate estimation, **11** 931
  curves, **6** 679
  data variation, **9** 487
  depression prevention, **15** 2077
  discrete hazard estimation, **11** 455
  doubly censored data, **11** 1569
  failure times, **15** 2475
  follow-up times, **11** 1527–1529(L)
  goodness-of-fit models, **14** 1785
  HIV in homosexual men, **15** 2177
  HIV incubation distributions, **15** 197
  kidney graft survival, **14** 1999
  liver transplantation, **10** 733; **13** 2517
  p-value adjustment, **15** 103
  QAS, **12** 975
  quality adjusted analysis, **9** 1259
  randomized clinical trials, **12** 2351
  skin graft trial, **14** 275
  threshold-crossing data, **12** 1589
Kaposi's sarcoma, **12** 2065, 2087; **15** 1171, 2307
Kappa statistic
  blindness assessment, **15** 1421
  calculation methods, **10** 1465
  diagnostic classifications, **15** 1377
  estimation, **12** 2207
  goodness-of-fit tests, **14** 347
  inference procedures, **11** 1511
  interobserver variation analysis, **3** 73
  interrater agreement, **4** 47; **9** 1103
  maximum likelihood estimation, **15** 1409
  misclassification models, **14** 1307
  multi-rater agreement, **11** 101
  observer agreement studies, **14** 299, 2285–2288(L)
  ophthalmic data, **10** 1303
  ordinal rating scales, **13** 2437
  rank tests, **8** 1401
  reliability measures, **12** 2191
  response curve measurements, **8** 1401
  standard error, **10** 767; **11** 1530–1532(L)
  variation estimation methods, **7** 639; **8** 765–767(L), 1416–1417(L)
Karnofsky index, **2** 429
  prognostic factors, **12** 2377
  randomized clinical trials, **12** 2351
Kaunas-Rotterdam intervention study (KRIS), **6** 501
Kay models survival analysis, **10** 1061
Kepner and Randles test, **4** 91
Keratoconus, corneal transplants, **9** 1091
Kernels
  density estimation methods, **10** 1693
  geographical densities, **9** 691
  leukaemia mapping, **14** 2459
  smoothing
    AIDS application, **12** 843
    environmental epidemiology, **12** 1249
    Gaussian, **12** 311
    survival analysis, **12** 1569
  spatial variations, **14** 2335
Key number method, **12** 2343
Keyed research data verification, **12** 1535
Kidney transplantation, **2** 295; **3** 219; **13** 2427; **15** 2589
  see also Renal Studies
  cummulative hazard functions, **11** 1465
  graft failure, **12** 2285
  prognostic model, **14** 1999
  randomized trials, **14** 2081
  rate of change estimation, **11** 621
  survival analysis, **12** 1569; **14** 1553
Kiel lymphoma study, **7** 1139
Kinetic data analysis, **8** 871; **9** 339, 341–342(L)
Knee replacement rates, **15** 1875

Knowledge representation, systems, **4** 317
Knox test, **15** 873
  cluster analysis, **15** 943
  space-time clustering, **15** 1935
Kolmogorov-Smirnov test, **12** 2043
  area between curves, **11** 1289
  confidence bands, **13** 499
  psychotherapy states, **11** 231
  survival study, **12** 1365
Koziol rank statistic, **13** 635
Kriging prediction cluster analysis, **14** 2393
Kuhn-Tucker conditions, **11** 1633
Kullback-Leibler distance, **11** 37, 1321
Kullback-Leibler error rate, **9** 1303
Kurtosis data description, **11** 333

L-moments, **11** 333
La Hague nuclear facility leukaemia incidence, **14** 2383, 2459
Laboratory determinations
  accuracy estimation, **10** 843
  diagnostic tests, **8** 1381; **10** 1887
  historical control study, **10** 839
  multivariate analysis, **2** 259
  optimal checking procedures, **11** 1343
  percentiles, **2** 191
  reference values, **2** 191; **4** 369; **5** 335; **6** 147; **7** 377
  time trends, **2** 147
Laboratory monitoring *see* Monitoring
Lactate dehydrogenase, **8** 1381
Lactation models, **12** 949
Lagrange's method of undetermined multipliers, **12** 1969
Laguerre polynomials, **15** 61
Laird-Ware algorithm, **11** 1981; **12** 1665; **13** 759
Lan-DeMets alpha spending function, **15** 1739
Lan-DeMets procedure, **8** 1191; **12** 2219; **13** 1441
Landmark method lead-time bias, **15** 2797
Language development, **9** 237, 1143
Laplace approximation, **11** 1377
Laplace transform, **12** 2395
Laryngeal cancer, **5** 527; **11** 1747; **12** 1249
Last case influence, **11** 1615
Last observation carried forward, **11** 2043
Latency neuronal response, **4** 91
Latent class analysis, **11** 2111
  chance-corrected agreement measures, **12** 2191
  chronic disease epidemiology study, **4** 327
  classification study, **3** 249
  diagnosis, **5** 21; **6** 529–531(L); **9** 559
  misclassification adjustment, **10** 1197
  relative risk improvement, **4** 445
Latent intervention effect, **5** 435
Latent variable models, **7** 177, 975; **10** 1607; **15** 23
  see also Covariance structure models
Latin squares, **13** 11; **15** 2143
  crossover studies, **11** 560(L)
  designs, **8** 487
  longitudinal data, **11** 1967
  simple carryover model, **11** 715
Laws
  medicine, **2** 113
  mortality, **7** 895
Le test, **14** 863
Lead
  blood, **7** 1087
  exposure effects study, **9** 811
  levels learning difficulties, **11** 799
Lead-time
  bias, **6** 885
  estimation, **13** 569
  interval, **6** 885
  non-parametric estimation, **14** 2715
  screening, **6** 885; **8** 743; **9** 969
Learning difficulties pre-natal blood lead levels, **11** 799
Least significant difference test, **4** 489
Least squares
  see also Generalized least squares
  attrition bias, **12** 1005
  incomplete factorial designs, **12** 1629
  serial multivariate data, **11** 1041
  spinal cord injuries, **11** 1171
Leave-one-out regression coefficients, **12** 2305
Legal cases biostatistical concepts, **14** 1641
Length bias model, **6** 885; **7** 395; **8** 1255; **9** 969; **10** 423
Lens opacities trial, **8** 1433
Lepage procedure, **13** 747
Leprosy, **7** 739
Leucine, **5** 231
Leukaemia
  Bayesian analysis, **4** 509
  bias clinical trials, **4** 1
  bootstrap investigation, **4** 39
  breast cancer surveillance, **7** 1121
  censored data, **7** 1139
  childhood incidence, **14** 3, 2309, 2383, 2459, 2487
  classification, **4** 287
  clinical trials, **4** 1; **8** 405; **9** 871
  cluster analysis, **7** 491; **14** 3, 799
    children, **15** 699, 707, 783, 873
    focused, **15** 765
  Cox proportional hazards, **4** 39
  density estimation application, **9** 691
  disease clustering, **12** 1869
  endpoints, **7** 1139; **8** 405
  exposure radiation factors, **5** 539
  heterogeneity tests, **7** 1121
  historical controls, **3** 325
  interim analysis, **5** 465
  mice hazard regression, **15** 1757
  MVK model, **15** 1003
  prognostic factors, **4** 39

proportional hazards regression model, **13** 1045
radiation exposure analysis, **5** 539
regression models, **8** 725
relative risk, **10** 1511, 1745
remission models, **14** 1081, 1097
risk environmental, **7** 649
survival analysis, **4** 509; **7** 1121
survival trees, **8** 947
vaccination study, **1** 329
Levelling AIDS incidence estimation, **11** 1633
Levenberg-Marquardt algorithm logit-log estimation, **12** 2025
Leverage matched-pairs, **4** 425
Lexis diagram, **6** 469; **8** 103; **13** 823
LFP *see* Limited failure population
Liang-Zeger method longitudinal data, **12** 1339
Liberia malaria incidence, **14** 2727
Life expectation, **7** 895; **10** 79
Life quality *see* Quality of life
Life Span Study (LSS), **5** 539
Life support, **6** 535
Life times analysis *see* Survival analysis
Life-table analysis, **7** 895
cause-deleted, **4** 155, 397; **6** 527–528(L)
censoring distributions, **5** 255
contraceptive analysis, **5** 475; **10** 201
dependent observations, **13** 43, 2383–2384(L)
frailty models, **14** 1859
IVF attempts, **12** 39
longitudinal data, **11** 2029
Markov models, **7** 787
mortality analysis, **5** 61
rate, **5** 475
regression models, **11** 939
risk ratios, **9** 423
Sullivan's index, **7** 787
titration studies, **10** 323
usage clinical trial reports, **13** 2393
Ligand-binding kinetics, **7** 805; **8** 871; **9** 339, 341–342(L)
Likelihood data analysis
auxiliary endpoint data, **13** 955
children AIDS diagnosis, **13** 2031
Cox regression model, **13** 2427
drugs compliance assessment, **13** 2141
random effects model, **12** 2273
Likelihood distance, **9** 549; **10** 1375
Likelihood model meta-analysis, **15** 619
Likelihood ratio
AIDS/HIV incidence, **15** 1779
cardiovascular disease study, **14** 1745
cluster analysis, **14** 799
F-statistic, **12** 69
fertility prediction, **14** 1807
fixed sample, **13** 1563
generalized linear models, **11** 923; **12** 989(L)
goodness of fit test, **12** 617
homogenity of proportions, **13** 1253
model misspecification, **14** 1693
model parameters, **13** 2359
odds ratio homogeneity tests, **11** 159
qualitative interactions, **12** 1239
risk screening, **11** 257
Likelihood ratio R^2, **15** 1987
Likelihood score test
optimal sample allocation, **15** 2523
prospective relative risk analysis, **12** 691
Limited dilution cloning, **9** 457, 1541(L); **11** 132–133(L)
Limited failure population model, **9** 409
Limits discrimination, **6** 147
LINCS computer program, **11** 1195
LINDO computer package, **9** 273
Linear controlled variable model, **13** 1101
Linear covariance structure, **11** 1889
Linear discriminant analysis, **10** 757; **11** 1023
Linear logistic models
mammary tumour incidence, **13** 709
menstrual diary data, **12** 955
meta-analysis clinical trials, **13** 2503
MMPS national death rate, **13** 889
Linear minimum mean square error estimator, **11** 621
Linear minimum variance unbiased estimator, **11** 621
Linear models
see also Generalized linear models; Linear regression models
blood pressure measurements, **15** 2013
clinical trial reports, **13** 2393
cluster analysis, **15** 1793
conditional, **13** 635
crossover trials, **10** 909
dental study, **7** 403
diagnostic factors, **7** 403
elderly hearing thresholds, **10** 1453
empirical Bayes method, **10** 811
extrapolation, **13** 1513
Gaussian, **14** 1219
laboratory studies, **10** 843
longitudinal data, **11** 1843, 1871
meta-analysis, **14** 137
mixed-effects PSA/BPH, **13** 587
multilevel, **13** 1643
multivariate reliability structures, **15** 1647
ommitted variable bias, **11** 1195
ordinal data, **14** 1177
parameter estimation, **13** 1601
random-effects, **11** 1861
relative risk, **8** 173, 927
residual plots, **14** 2023
risk methods, **10** 1511
serial multi-site data, **11** 1041
stochastic regression coefficients, **13** 759
time series regression relationships, **12** 1555
tumour growth study, **10** 1075

Linear programming, **9** 273
Linear random effects model information provision, **12** 753
Linear rank tests doubly censored data, **14** 2555
Linear regression models, **14** 2023
  see also Generalized linear model
  ANCOVA, **8** 1075; **9** 583–586(L)
  assays optimal designs, **7** 805
  attrition bias, **12** 1005
  autoregression, **7** 59
  change rates analysis, **6** 599
  classical, **4** 379
  correlation estimations, **9** 1175
  crossover trials, **10** 909
  data monitoring study, **5** 347
  dental study, **7** 403
  design effects, **12** 1259
  diagnostic reliability assessment, **7** 403
  discriminant analysis, **5** 347
  dose-response design methods, **9** 1353
  elderly hearing thresholds, **10** 1453
  empirical Bayes method, **10** 811
  epidemiological methods, **7** 601
  error, **7** 257; **8** 1075; **9** 583
  exponential damping, **9** 999
  interval estimation, **5** 347
  laboratory studies, **10** 843
  life time analysis, **8** 907
  logistic, **8** 1363; **10** 323
  longitudinal studies, **7** 19, 59; **9** 1175
  measurement error, **8** 1075; **9** 583–586(L)
  median age calculation, **10** 1313
  meta-analysis, **11** 2077
  misclassification effects, **7** 257
  mismodelling effects, **7** 257
  missing data, **11** 2043
  monotonically increasing confounders, **12** 1989
  multiple imputation study, **10** 585
  non-nested models, **11** 1321
  ordered variables, **11** 1023
  pock count variability, **9** 615
  pulmonary function study, **7** 19, 601
  random-effects model, **11** 2039
  relative risk, **8** 173, 927
  repeated measures, **11** 2123
  risk factors, **11** 783
  risk methods case-control study, **10** 1511
  smoothing methods, **7** 601
  survival analysis, **8** 907; **9** 999; **12** 1569
  trend detection, **12** 1125
  tumour study, **8** 1363; **9** 999; **10** 1075
Linear risk score tests cluster analysis, **14** 2309
Linear-interpolation imputation threshold-crossing data, **12** 1589
Lineweaver-Burk plot, **7** 805
Link functions
  generalized linear models, **11** 963
  repeated measures, **11** 1033
Linkage
  analysis, **3** 57; **5** 291
  non-random segregation, **9** 573
Linking
  anonymous records, **14** 499
  data base records, **8** 391
  HIV transmission model, **9** 721
  multi-source data, **14** 481, 491, 511, 687
Linoleic acid, **6** 599
Lipid levels longitudinal data, **11** 2033
LISP-STAT computer package, **11** 115, 939
LISREL computer package, **8** 1137; **11** 1195
Litter effects, **2** 315, 323, 325
Liver
  cancer, **6** 307
  cirrhosis trial, **8** 771; **10** 1061
  contingency tables, **10** 991
  diseases, **7** 525; **13** 1737; **15** 2215
  function study, **4** 317; **7** 671, 843
  metastases, **7** 843; **12** 2191
  transplant survival analysis, **10** 733
  transplantation data, **13** 2517
LLP (linear, log-linear & product) model, **7** 403
LMS method, **11** 1305; **13** 2477; **15** 2657
Local regression (loess) model CD4 counts, **12** 2133
Local unconditional variance McNemar test, **11** 1239
Locally most powerful (LMP) test, **9** 573
Locally-weighted running-line smoother, **11** 1115; **12** 1683
Location-scale cumulative odds models, **14** 1191
Location-shift model bounded outcome scores, **12** 1063
Loess *see* Local regression
Log cumulative hazards, **11** 1465
Log hazard ratio
  cubic splines, **15** 2589
  scale, **13** 1297
  sequential monitoring of clinical trials, **15** 2341
Log odds ratio
  differential recall bias, **15** 2603
  random effects meta-analysis, **15** 2733
Log relative risk test optimal sample allocation, **15** 2523
Log-likelihood
  cross-validated, **12** 2305
  proportional hazards model, **14** 2119
Log-linear models
  age-period cohort models, **6** 449, 469
  agreement data analysis, **8** 1199
  AIDS incidence, **15** 1779
  AIDS monitoring methods, **8** 3
  AIDS reporting delay, **15** 305
  association models, **8** 1199
  binary variables, **6** 555; **7** 975
  cancer study, **6** 449, 469, 785

categorical data, **7** 965; **8** 1095; **12** 2147–2151(L)
change analysis, **8** 571
competing risks analysis, **6** 785
confidence intervals, **3** 287; **10** 717
contingency tables, **2** 229; **13** 2407; **14** 769
crossover trials analysis, **10** 1607
database analysis, **8** 653
dental study, **2** 59; **7** 403
diabetes study, **7** 671
diagnostic reliability assessment, **7** 403
discriminant analysis, **2** 229
disease, **5** 49; **7** 591
drift model, **6** 449, 469
efficacy prediction, **9** 253
epidemiology, **8** 653, 1095
exposure disease interactions, **5** 49
genetics, **7** 591
growth curve models, **13** 2205
historical data analysis, **7** 819
HIV incidence, **15** 1779
interobserver variation estimation, **7** 639
kappa's standard error, **10** 767
latent variable models, **7** 975
liver function study, **7** 671
longitudinal studies, **7** 161, 305; **11** 1871
medical data analysis, **7** 975
menstrual diary data, **12** 955
misclassification methods review, **8** 1095
missing data, **7** 305; **11** 643, 799
mixed, **14** 2487
mortality analysis, **2** 229; **6** 501
ordered categorical response data, **8** 1209
ordinal data, **8** 571
pairwise interobserver agreement, **11** 101
population size estimation, **3** 287
prediction treatment efficacy, **9** 253
radiological assessment, **7** 639
relative risk estimation, **10** 1745
repeated measurement analysis, **7** 347, 975; **8** 1209
response data, **8** 1209
risks cancer, **6** 785
treatment evaluation, **8** 571; **9** 253
two-process form, **7** 965
variation models cancer, **6** 449, 469
Log-logistic distribution
HIV/AIDS incubation model, **13** 163
infection curve, **12** 617
stage-specific numbers, **11** 831
Log-logistic regression model, **8** 725
Log-normal distribution
bioequivalence study, **13** 2531
continuous outcomes, **14** 247
direct formulation effect, **11** 881
longitudinal data, **11** 1861
test procedures comparisons, **13** 769
three-parameter, **11** 897
Log-normal model, **8** 725; **9** 505, 999
AIDS incubation, **15** 2459
bioequivalence, **15** 2635
dog triglyceride data, **15** 1695
Log-ratio analysis
clinical trials, **13** 2503
coronary heart disease, **12** 967
Logarithmic marker paths HIV, **12** 2099
Logarithmic score predictive diagnostics, **15** 2149
Logarithmic transformation, **9** 325; **10** 675, **11** 881; **12** 691; **13** 769; **14** 811
Loggers lung function tests, **7** 685
Logistic approximation, **13** 1135
Logistic distribution
medical audit, **12** 2179
ROC curve, **12** 1293
Logistic models, **13** 541
design effects, **12** 1259
glaucoma status, **15** 1349
infection curve, **12** 617
low-dose response data, **12** 881
matched designs, **12** 993
predictive diagnostics, **15** 2149
Logistic regression model
see also Regression
abortion study, **5** 243
absolute risk, **10** 1025
adequacy assessment, **4** 425
antigen-disease association, **2** 79
association measurement, **8** 619
attributable risk adjustment, **10** 1753
baseline measurements, **7** 205
Bayesian analysis, **9** 1091
bias, **2** 71; **4** 243–245(L)
binary variables, **7** 843; **9** 1517; **10** 723
blood pressure measurements, **15** 2013
cancer clinical trials, **10** 1647
case-control studies, **4** 425; **7** 765; **10** 739, 1037; **14** 769
categorical data, **7** 95
chronic otitis media risk factors, **9** 1495
classification, **2** 59; **10** 383
coefficient estimates, **11** 953
collinearity diagnosis, **11** 1273
comparative exposure ratio, **13** 245
confidence intervals, **11** 923; **14** 2161; **15** 1535
continuous covariates, **11** 1115
correspondence analysis, **7** 983; **8** 1545–1547(L)
covariance analysis, **8** 1075
Cox proportional hazards, **4** 413; **8** 525
cross-validation performance, **11** 475
crossover designs, **12** 825
CS PA analysis, **13** 509
database uses, **5** 103
diagnostic tests, **1** 41; **7** 739
differential recall bias, **15** 2603
discriminant analysis, **4** 413; **7** 519, 525
discrimination, **2** 199

Logistic regression model (*cont.*)
disease risk analysis, **11** 1443
disease-antigen association, **2** 79
dose-finding methods, **10** 1647
dose-interpolation study, **5** 183
drug reactions, **6** 863
epidemiology, **3** 15; **4** 237–242(L), 413; **10** 341, 1819
event probabilities, **11** 1719
exact, **14** 2143
exact power computation, **14** 2261
excess fraction estimation, **15** 1519
explained variation, **15** 1987
exposure study, **5** 49; **14** 1437
exposure-specific incidence rates, **13** 651
GEE method, **12** 219
genetic susceptibility/behaviour, **13** 153
GENSTAT analysis, **2** 223
heart disease, **1** 41; **4** 413
historical data analysis, **7** 819
hypothesis testing, **4** 337
interval estimators, **12** 809
intervention effect, **12** 289
latent class analysis, **4** 327
latent variable model, **9** 931
liver function tests, **7** 843
longitudinal studies, **7** 161, 199; **8** 1515; **11** 1981
lung cancer study, **7** 223
malarial parasite densities, **13** 2345
maximum likelihood estimation, **2** 71
mean-adjusted ratios, **12** 377
measles epidemic analysis, **12** 229
measurement error, **8** 1151, 1165; **12** 1141; **13** 1135
mismodelling effects, **7** 257
missing data, **8** 263; **11** 2043; **14** 1315
mortality, **6** 501; **10** 637
multiple exposure studies, **12** 717
multiple tumour data, **15** 1217
multivariate probit analysis, **10** 1391
nurses health survey, **7** 983
observer agreement studies, **14** 299, 2285–2288(L)
odds ratio, **4** 437; **10** 1273
ophthalmologic data simulation, **13** 1023
ordered variables, **11** 1023
ordinal data, **8** 785; **14** 1545
partitioned survival time, **13** 1189
person-time data, **9** 463–464(L), 853(L)
physicians' health study (US), **10** 1585
placebo effect, **7** 1187
pneumoconiosis study, **13** 1665
polychotomous, **10** 375, 757
pooled data model, **9** 1501
population factors, **4** 237–242(L)
population relapse hazard, **13** 1089
power evaluation, **7** 519
prediction, **5** 421
anaesthesia outcome, **7** 947
error rate rules, **9** 1303
heart disease, **1** 41
prognostic factors, **2** 223; **7** 843; **9** 273, 1189
prospective studies, **4** 227
psychiatry study, **5** 243; **8** 1317
radioimmunoassay calibration, **14** 935, 953
recurrent conditions trial, **8** 1439
relative risk analysis, **9** 287
repeated measurement analysis, **7** 205
residual confounding, **11** 1747
resistance time analysis, **3** 165
risk
assessment method, **2** 71
epidemiology, **4** 237–242(L)
factors, **11** 783; **13** 343, 2517
heart disease, **4** 413
mortality interaction, **7** 239, 289, 293
prediction factors, **7** 947; **9** 385
smoking effects, **7** 223
risk ratio and rate ratio estimation, **12** 1733
risk scores, **14** 1331
sample size, **8** 795; **9** 765; **12** 1079, 2257
SCD susceptibility, **13** 1015
smoking cessation, **12** 1605
smoking risks, **7** 223, 289
sparse stratified data, **12** 2285
spatial analysis, **14** 2393
stepwise analysis, **12** 143
summary statistics, **12** 2169; **14** 2169(L)
titration studies, **6** 583
tumour recurrence rates, **8** 1363
twin identification, **12** 1693
validation techniques, **10** 1213
visual acuity, **14** 257
within-person error, **8** 1051, 1071
Logistic transformation, **2** 79; **6** 43; **7** 443
Logit link function response correlation, **12** 355
Logit models, **13** 467
Bayesian methods, **11** 1377
categorical data, **7** 109; **8** 1209
chi-squared comparisons, **3** 273
clinical chemistry, **5** 183
continuation ratios, **7** 435
distribution-free fitting, **12** 1969
empirical transformation, **12** 1293
longitudinal data analysis, **7** 109
maximum tolerated dose, **11** 2063
mortality, **4** 175, 189; **5** 139, 155; **9** 981
ordered categorical response data, **8** 1209
ordinal pain data, **3** 273; **5** 15
regression model, **7** 435
repeated measurement, **7** 109; **8** 1209
Logit regression attrition bias, **12** 1005
Logit-log model, **5** 183; **12** 2025
Logit-Wald method confidence intervals, **12** 809
Logrank test statistic, **10** 749; **12** 51, 737

allocation methods, **7** 559
cancer study, **1** 73; **2** 183
censoring effects, **8** 937
clinical trials
  cancer study, **1** 73, 121; **2** 183; **9** 871
  NIH developments, **9** 903
  pooling efficiency, **6** 565
  sample size, **1** 121; **5** 97–98(L); **7** 55
  sequential analysis, **1** 73; **2** 183
  stratification, **1** 267
contraceptive research, **5** 475
correlated markers, **14** 2217
Cox proportional hazards model, **8** 539
cure-rate models, **6** 483
doubly censored data, **11** 1569
early treatment termination, **9** 1417
experimental/standard regimen, **13** 1453
group sequential trials, **8** 505; **9** 1081
hazard ratio estimators, **11** 847–848(L)
imbalanced allocation effects, **6** 147
interval-censored failure time, **15** 1387
life-table analysis, **5** 475
litter-matched data, **2** 315
logistic regression comparisons, **8** 539
monitoring procedures, **9** 1081
multivariate failure time analysis, **13** 2233
play the winner strategy, **15** 2135
power
  clinical trials, **1** 121; **5** 97–98(L)
  sample size estimation, **6** 577
  survival analysis, **6** 119; **8** 937
  treatment comparisons, **1** 267; **6** 773
  Wilcoxon comparisons, **6** 483
sample size, **6** 577; **8** 937; **11** 179, 1091; **14** 2273
scoring systems, **2** 315
sequential monitoring, **12** 753; **14** 2227
sequential trials, **1** 73; **2** 183
stopping rules effects, **8** 505
study duration, **11** 1477
survival study, **1** 73; **2** 315; **6** 119; **9** 293; **12** 1365; **13** 1441
test statistics, **13** 1357
treatment evaluation, **1** 267; **2** 183; **13** 1747
treatment parameters, **12** 1353
univariate survival analysis, **15** 2203
vaccine efficacy, **13** 2155
London School of Hygiene, **1** 297
Longini-Koopman model, **13** 1563; **15** 837
Longitudinal Data Analysis, **11** 1797–2040
  introduction, **11** 1797
  keynote address, **11** 1808
  overview, **11** 1801
  poster session abstracts, **11** 2025
  Session 1: clinical trials, survival analysis, **11** 1841–1885
  Session 2: incomplete, multivariate, non-linear, **11** 1887–1963
  Session 3: Bayes/Empirical Bayes, **11** 1965–2023
  speakers and discussants, **11** 1799
  tutorial, **11** 1823
Longitudinal studies
  see also Repeated measures
  24 hour ambulatory blood pressure, **12** 1665
  abortions data, **5** 243
  accelerated failure time model, **11** 1871
  analysis, **11** 1809, 1825; **12** 633; **13** 1781
  attrition bias, **12** 1005
  autoregressive models, **4** 457; **7** 59; **8** 1523; **10** 492–495(L)
  baseline comparisons, **7** 205, 219
  bias, **7** 417
  blood pressure
    children, **7** 47, 87, 169, 185, 199
    diagnostic model, **7** 423
    Framingham heart study, **7** 205, 239
    risk, **7** 205, 239, 275, 297
    tracking correlations, **11** 1187
  categorical data, **7** 95–169
  CD4 lymphocyte counts, **15** 2289
  centile estimates, **9** 539
  change rate analysis, **6** 599; **7** 337; **9** 437
  change/initial-value relationship, **13** 759
  changeover designs, **7** 471
  child growth charts, **13** 2477
  clinical studies, **1** 131
  cluster sampling, **8** 1537
  clustered binary data, **14** 413
  cohort studies, **7** 275
  community intervention trials, **15** 1069
  competing risks analysis, **6** 785
  confounding control, **8** 679
  contour mapping, **14** 605
  correlation comparisons, **8** 1485
  covariance models, **14** 1397
  crossover designs, **11** 1967
  databases analysis, **10** 511
  disability effects, **7** 325
  disease surveillance, **7** 149, 325
  drop-outs, **11** 2043; **12** 2248–2250(L); **15** 1123
  drugs compliance assessment, **13** 2141
  elderly hearing models, **10** 1453
  EM algorithm extensions, **11** 1809
  emergency room visits, **15** 823
  epidemiology
    bibliography, **10** 1819
    data plots, **8** 703
    workshop proceedings, **7** 11–361
  Framingham heart study, **7** 205, 219
  functional decline model, **15** 1023
  generalized estimating equations, **11** 1033
  GMANOVA, **11** 2031
  growth curve models, **6** 185; **7** 73, 87; **13** 2205
  head injury study, **5** 103
  health study, **7** 177

Longitudinal studies (*cont.*)
height velocity standards, **12** 403
hierarchical Bayes modelling, **11** 2001
HIV, **13** 231; **14** 1365
hypothesis testing, **6** 689
informative censoring, **11** 1861
intentionally incomplete designs, **11** 1889
interactions mortality/risk, **7** 239, 293
interim analysis, **14** 2239
interval censoring, **13** 1771
interval counts, **12** 1339
intravenous drug users, **10** 423
Kalman filtering, **7** 73
Laguerre polynomials, **15** 61
latent variable models, **7** 975
likelihood analysis, **7** 149
linear models, **7** 317; **14** 1219
liver function, **7** 671
log-linear model, **7** 965
lung function, **7** 11, 685
Mantel-Haenszel statistic, **7** 109
marginal models, **7** 95, 139, 161
measurement correlations, **9** 1175
menstruation study, **12** 355; **14** 1843
misclassification, **7** 745
mismodelling effects, **7** 257
missing data
autoregressive model, **4** 457; **8** 1523
computational aspects, **11** 1809
full span designs, **11** 1889
informatively censored data, **11** 1861
workshop report, **7** 177
mixed effects models, **9** 263
mixed-model analysis, **11** 2027
mortality, **7** 149, 239, 293, 325
multilevel statistical model, **12** 949
multivariate methods, **11** 1915
Muscatine blood pressure study, **7** 47
NHLBI clinical trials, **9** 881, 903
non-linear models, **11** 1929
ordinal data, **7** 109
parasitic infection dynamics, **9** 1211
percentile regression, **14** 777
plasma lipid levels, **11** 2033
premature ventricular counts, **11** 963
prostate disease, **13** 587
psychiatry study, **5** 243
pulmonary function, **7** 19; **8** 189
quality of life, **10** 1915; **15** 2717
ramus height example, **13** 759
random effects models, **8** 189; **11** 1981
rate of change estimation, **11** 621
RCR models, **13** 1211
reference intervals, **14** 1417
regression models, **13** 2219
regression trees, **12** 2153
repeated measurement analysis, **15** 1143
analytic methodology, **7** 11–87
binary variables, **7** 975
categorical data, **7** 95–169, 1099; **8** 1209
clinical trials application, **10** 1959
Framingham heart study, **7** 205, 219
missing data, **7** 139, 305–361
respiratory function, **14** 2205
risk
analysis, **8** 1515
attributable, **7** 507, 717, 1073
cohort studies, **7** 275
confounding effects, **7** 1087
environmental, **7** 649
Framingham heart study, **7** 205, 219, 289
mismodelling effects, **7** 257, 289
mortality interaction, **7** 239, 289, 293
prediction factors, **7** 289; **9** 385
prevention trials, **7** 275
smoking effects, **7** 223, 289
survival analysis, **7** 297
smoothing procedures, **7** 601; **14** 1205, 1235
summary statistics, **12** 2169; **14** 2169(L)
survival analysis, **7** 297
symposium, **11** 1797–2040
systematic attrition, **11** 2029
temporal trends, **7** 185
time-dependent variables, **6** 689
time-period effects, **12** 893
transient state models, **6** 795
transitional models, **7** 95
treatment evaluation, **5** 231
two stage sampling design, **13** 1071
variances estimation, **7** 199, 745
workshop report, **7** 177
Loss functions, **6** 101; **9** 487; **15** 2657
Loss probabilities, **13** 839
Low-dose response data generalized logistic models, **12** 881
Lower respiratory illness study, **13** 343
Lowess *see* Locally-weighted running-line smoother
LR *see* Likelihood ratio
LRI *see* Lower Respiratory Illness
Lu model diagnostic inconsistency, **7** 403
Ludwig III breast cancer trial, **9** 1259
Lung cancer
absolute risk, **8** 641; **10** 1025
age-period-cohort model, **5** 527; **15** 273
age/exposure interaction, **13** 2407
bias study, **3** 35; **7** 1243
binary variables, **7** 843
carcinogenesis model, **9** 677; **13** 23
case-control studies, **9** 765, 1339
CHART trial, **13** 1297
cigarette smoking, **15** 565
cluster analysis, **7** 491
cohort studies, **4** 63
covariate omission effect, **7** 1243
cross-sectional studies, **4** 63

data analysis, **1** 163
diagnostic factors, **7** 843
error, **6** 31
ETS, **15** 2603
explained variation, **15** 1999
geographical correlations, **9** 515
graphical presentation, **3** 35
leukemia group B trial, **13** 1313
Markov models, **7** 325
morbidity estimation, **8** 201
mortality rates, **8** 201; **13** 823; **15** 1397
non small cell, **13** 1313
passive smoking studies, **14** 545
power determination method, **4** 117
prognostic factors, **4** 279; **7** 843
proportional hazards regression, **15** 1033
proportional odds model, **2** 273
quality of life, **15** 2717
randomized trials, **4** 279
registry data, **7** 483
relative risk conversion, **8** 641
risk factors, **1** 229; **7** 297
sample size determination method, **4** 117
screening trials efficiency, **9** 55
sequential clinical trials, **1** 73; **2** 183
significance tests, **9** 515
small cell, **13** 1415
smoking risks, **7** 223, 289; **11** 141; **14** 327–330(L)
spousal smoking, **15** 581
survival analysis, **2** 273; **3** 35; **7** 297, 483; **14** 161
susceptibility example, **13** 153
treatment evaluation, **1** 73; **2** 183
trend assessment, **3** 113
variation, **6** 449
Lung disease, **15** 1771
Lung function
analytic methods comparisons, **7** 19
assessment techniques, **8** 861
autoregressive models, **7** 59
baseline measurements, **8** 1339
bronchodilators study, **8** 1339
change rate analysis, **7** 337
clinical trials, **8** 1183
cross-sectional comparisons, **7** 685
epidemiological methods, **7** 601
longitudinal data, **7** 11, 19, 29, 59, 139, 685
measurement errors, **8** 1109, 1127, 1133, 1137
prognostic factors, **7** 11
repeated measurements, **7** 11, 19, 29, 59, 139
smoothing methods, **7** 601
Luteinizing hormone, **11** 2133
Lyme disease, **15** 783
Lymphocytes
see also CD4...
HIV hazard estimation, **12** 843
HIV surrogate endpoint, **12** 835
Lymphocytic leukaemia MVK model, **15** 1003
Lymphoma
disease cluster, **15** 873
survival data analysis, **8** 947

M. avium illness, **15** 2307
M-estimates (unbiased estimating equations), **13** 1265
M-estimator *see* Maximum-likelihood-like estimator
McCullagh model, **13** 479
MacMahon method, **13** 1265
McNemar test
case-control studies, **6** 53; **13** 663
failure time data, **10** 1099
generalization, **12** 2207
hypothesis of no effect, **12** 1969
incomplete paired binomial data, **7** 929
matched case-control studies, **11** 1239
non-independent matched pair data, **10** 1981
pair-matched studies, **12** 699
sample size, **11** 1521; **14** 1831
trauma study, **14** 1463
MACS *see* Multicenter AIDS Cohort Study
MACSPIN computer package, **9** 469
Magnetic resonance imaging (MRI), **12** 2191; **13** 453; **15** 389
Mahalanobis distance, **12** 925, 1665; **13** 719
Mailback questionnaires response improvement, **12** 283
Maintenance studies, **13** 1089
Majority agreement index, **4** 47
Majority rule, **7** 549
Malaria, **6** 853; **13** 2345
contour mapping, **14** 605
maternal antibodies, **14** 2727
Malformations
congenital
change-point test, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
monitoring efficiency, **6** 517; **7** 997–999(L)
surveillance methods, **3** 239; **5** 98–99(L), 565
Malignant hyperpyrexia, **1** 139
Mallya-Mace index (MMI) RA activity measure, **12** 1171
Malnutrition nutritional anthropometry, **11** 1289
Malocclusion dental, **4** 47
Mammary tumours, **13** 709, 731
Mammography, **1** 15
Manic-depression, **5** 327
Mann-Whitney statistic
clinical trials meta-analysis, **13** 2503
distribution-free estimators, **11** 1151
repeated ordinal responses, **15** 429
ROC curves, **9** 325
therapy comparisons, **8** 441, 455
trend, **4** 87
Wilcoxon-type tests, **14** 445–446(L)
MANOVA *see* Multivariate analysis of variance

Mantel logrank test, **8** 937
Mantel test
  cluster analysis, **15** 873
  space-time clustering, **15** 1935
Mantel-Ciminera procedure, **2** 315, 323, 325
Mantel-Haenszel statistic
  allocation methods, **5** 211
  attributable risk, **10** 1753; **11** 2083
  case-control studies, **8** 1529; **10** 1037
  case-crossover designs, **12** 2333
  categorical data, **7** 109; **8** 1095
  clinical trials, **6** 341, 565; **8** 141
  cluster analysis, **8** 599
  common odds ratio, **14** 1567; **15** 1595–1600(L)
  confidence intervals, **13** 2189
  confounding sample size effects, **9** 765
  contingency tables, **5** 629; **7** 591; **8** 1455; **9** 369
  Cox proportional comparisons, **8** 539
  database study, **8** 653, 665; **10** 617
  discrete hazard estimation, **11** 455
  equality tests, **1** 37
  Fisher's exact test, **5** 629
  generalized linear models, **10** 1069
  hypertension study, **7** 1109
  intermediate endpoint validation, **11** 167
  litter-matched designs, **2** 315
  matched case-control data, **11** 617
  meta-analyses, **10** 971; **12** 2273
  misclassification, **8** 1095, 1529
  monitoring devices comparison, **10** 351
  NCI clinical trials, **9** 871, 903
  odds ratios, **8** 599, 1455; **9** 1131; **10** 1037; **11** 159
  optimal sample size determination, **11** 547
  pooled results, **6** 341, 565; **8** 141; **9** 247
  rate comparison methods, **1** 37
  rate ratio, **13** 989
  ratio estimation, **1** 217
  regression comparisons, **8** 539
  risk estimation, **7** 507
  ROC curve, **12** 1293
  sample size requirements, **11** 743
  sparse stratified data, **12** 2285
  stratified analysis, **2** 259
  stratified case-cohort studies, **11** 1599
  stratified multistage surveys, **11** 603
  variance estimation, **6** 701
  Yates's correction, **9** 369–383
MAPLE computer package, **14** 1553
Maps, **14** 697
  alcohol problems, **14** 591
  contour, **14** 605
  demographic, **7** 491
  density equalizing map projections, **15** 1837
  digital mapping, **15** 1961
  exploratory tools, **14** 2363
  MCMC methods, **14** 2473
  mortality rates, **14** 615
  multiple comparisons, **14** 2503–2505(L)
  small area, **15** 1859, 1867
  spatial clustering assessment, **12** 1275
  traffic accident occurance, **14** 2445
Marginal covariates Weibull distribution, **12** 241
Marginal data distributions
  bounding procedures, **14** 1985
  initial uncertainty profile, **12** 2009
Marginal estimating equations, **13** 479
Marginal frequencies, **9** 363–383
Marginal homogeneity, **6** 91; **7** 109; **8** 1209; **13** 609
Marginal maximum likelihood estimates, **12** 1969
Marginal models
  extended, **12** 1723
  longitudinal data, **11** 1825, 1981
  multivariate failure times, **13** 2233
  ophthalmologic data simulation, **13** 1023
  parameters estimation, **13** 1149
  repeated categorical data, **13** 467
  second-order GEEs, **15** 145
  survival data, **12** 1019
  work sampling data, **15** 607
Marginal probability
  competing risks failure time data, **12** 737
  kappa estimation, **12** 2207
  McNemar test, **11** 1521
  population-averaged model, **12** 1969
  subject-specific model, **12** 1969
Marginal tables multi-rater agreement, **11** 101
Mark-recapture model sexually transmitted diseases, **11** 1533
Marked point process, **15** 2751
Marker paths HIV infection, **12** 2061, 2099
Marker tracking HIV-1, **12** 2133
Marker-dependent hazard estimation AIDS application, **12** 843
Markers
  biochemical, **5** 547
  genetic association, **3** 57
  HIV to AIDS, **12** 2065, 2087
  time-dependent covariates, **12** 2087
Markov Chain Monte Carlo algorithm, **13** 839
  bivariate survival data, **14** 2523
  CD4 lymphocyte counts, **15** 75
  childhood leukaemia incidence, **14** 2487
  cluster analysis, **14** 2473
  Gibbs sampling, **15** 1663
  hazard regression, **15** 1757
  population models, **14** 971; **15** 1713
Markov model
  abortion study, **5** 243
  AIDS study, **8** 59, 103, 831
  average run length estimation, **12** 13
  behaviour change stages, **12** 219
  beta-squared-M/IgA, **12** 2127
  bioassay toxicity procedures, **12** 661

breast cancer, **14** 1531
cancer clinical trials, **9** 749
categorical data, **7** 95, 169, 965
CIN/HPV, **13** 379
clinical trials, **7** 581; **9** 749
counting process, **5** 491
databases methodology, **10** 617
diabetic retinopathy, **14** 1975
diagnostic tests estimators, **8** 1231
diseases, **8** 59; **10** 1061; **11** 295
epidemiology bibliography, **10** 1819
fluctuating mean EM algorithm, **13** 453
Framingham heart study, **7** 205
Hib bacteria transmission, **15** 2235
historical data analysis, **7** 819
HIV, **8** 59, 103, 831; **13** 53
infection rate analysis, **13** 2233
liver function model, **7** 671
log-linear model, **7** 965
longitudinal data, **11** 1809, 1825; **12** 265
lymphoma study, **5** 491
migraine study, **15** 2617
morbidity assessment, **7** 325, 787
mortality interpretation, **7** 787; **9** 315
multi-state, **13** 805
multiple reading procedures, **11** 209
multiple tests, **8** 1231
optimal checking procedures, **11** 1343
ordered categorical response, **8** 785
parasitic infection dynamics, **9** 1211
prevention model, **8** 59
proportionate mortality ratio, **9** 315
psychiatry admission study, **5** 243
psychotherapy states, **11** 231
quality of life analysis, **9** 749
random walk model, **7** 581
regression, **8** 785
repeated measurement analysis, **7** 347
sample size calculation, **11** 179
screening models, **8** 59
side effects incidence, **9** 803
stage-specific numbers, **11** 831
Sullivan's index interpretation, **7** 787
survival analysis, **7** 661; **10** 413
transient state models, **6** 795
transition rates, **12** 1155
treatment comparisons, **9** 803
ulcer prevention models, **7** 877
ventilatory study, **6** 795
Marshall-Olkin models, **11** 281
Martingales
HIV vaccines, **15** 2393, 2405
long-term survival, **15** 2763
survival analysis, **12** 1569
Matched case-control studies *see* Case-control studies
Matched-pair studies Bradley-Terry logit model, **12** 1969
Matching
anonymous records, **14** 499
case-control studies
allocation methods, **9** 1475
comparisons, **12** 993
logistic regression model, **4** 425
number of controls, **5** 29
sample size, **9** 765
screening data, **5** 127
cohort study, **8** 977
community interventions, **14** 1491; **15** 1069
database records, **14** 491, 511
pair studies, **12** 699
confidence intervals estimation, **4** 23
efficiency gain, **9** 943
logistic regression adequacy, **4** 425
McNemar test, **10** 1981
misclassification correction, **8** 825
power estimation, **6** 53
sample size estimation, **6** 53
small randomized studies, **12** 329
table presentation, **11** 617
Maternal
age congenital abnormalities, **14** 1797
infant survey 1988, **8** 387
services, **5** 607; **6** 613
weight, **1** 105
Mathen-Chakraborty statistic, **15** 851
Matrix occupancy models, **12** 1773
Maximally effective dose, **8** 583
Maximum likelihood
abortion estimation, **10** 287
absolute risk, **10** 1025
age visual acuity, **14** 257
age-related reference ranges, **13** 2289
AIDS, **10** 1167, 1527
assay variability estimation, **10** 1543
asymptotic covariance matrix, **13** 391
asymptotic normal distribution, **12** 3
Bayes estimator, **13** 889
bias correction, **2** 71
binary frailty model, **13** 1679
biopharmaceutical research, **10** 811
birthweight model, **15** 1333
bivariate models, **12** 241; **14** 1341
blood pressure distribution, **2** 253
cancer models, **10** 1241; **13** 23
case-control studies, **4** 425; **10** 1037, 1511; **13** 623
case-crossover designs, **12** 2333
CD4 estimates AIDS diagnosis, **13** 2059
censored data, **9** 409; **10** 1441
centile estimates, **9** 539
CLM, **13** 609
cluster analysis, **14** 2309, 2393; **15** 1793
combining two-by-two tables, **14** 1901
comparative binomial trials, **9** 1447
compartment models, **8** 1011

Maximum likelihood (*cont.*)
consistent estimates, **13** 87
crossover trials, **10** 901, 909, 1115; **15** 1619
diabetic retinopathy model, **14** 2599
disease indicators analysis, **10** 1061
disease mapping, **14** 2411
drugs compliance, **13** 2141
dynamic random effects model, **13** 113
elderly hearing models, **10** 1453
epidemiological study, **10** 341
equivalence tests, **13** 1827
error linear models, **10** 1197
frailty models, **14** 1819
generalized linear models, **10** 1069
global odds ratio regression model, **15** 1507
growth curve models, **13** 759
hazard ratio point estimation, **9** 1167
hierarchical regression, **15** 1161
HIV backcalculation, **13** 1975
HIV estimates, **10** 1167
HIV incubation times, **13** 163
HIV infection trends, **15** 1779
homogeneity tests, **10** 1257
IDU AIDS group, **13** 2009
incidence parameters, **13** 1881
incidence rates, **13** 651
independence testing, **10** 1555
infection rates models, **9** 263
interrater agreement, **9** 835
iterative generalized least squares, **13** 1643
Jewell's estimators, **8** 987; **10** 151–153(L)
kappa coefficient, **14** 83; **15** 1409
latent class analysis, **4** 445
latent logistic regression model, **9** 931
length bias, **10** 423
logistic regression, **2** 71; **4** 425; **9** 1091; **10** 723; **13** 1023; **14** 2143
Longini-Koopman model parameters, **13** 1563
longitudinal data analysis, **8** 189
M-estimator, **12** 2025
measurement correlations, **9** 1175
measurement errors, **8** 1075
meta-analysis, **13** 2503
method comparison studies, **10** 981
missing data analysis, **14** 1315; **15** 127
mixture survival model, **15** 2077
model misspecification, **14** 1693
multilevel model, **12** 27
multiple exposure studies, **12** 717
multiplicative-model exposure coefficient, **13** 989
multivariate probit analysis, **10** 1391
negative binomial regression coefficients, **13** 1755
Newton-Raphson algorithm, **12** 2133
non-linear models, **14** 1191
non-parametric (NPML), **13** 185, 1771, 2081; **14** 2555
normal sampling distribution, **13** 1699
odds ratios, **4** 437; **14** 2581
otitis media risk factors, **9** 1495
outliers detection, **9** 549
paired binary data, **9** 1517
parasitic infection dynamics, **9** 1211
piecewise constant hazard models, **13** 823
Poisson time series models, **13** 453
pooling results, **9** 247; **10** 1417
population risk, **15** 1713
predictive values, **13** 1737
prescription event monitoring, **15** 987
prognostic scoring sensitivity, **9** 1189
random effects models, **10** 901; **12** 1969
reference ranges, **10** 831
registers estimator, **13** 177
relative risk improvements, **4** 445
repeated events analysis, **10** 1227
repeated measurements, **12** 1723
residual, **13** 1601
restricted, **12** 1665; **13** 1211
risk techniques, **10** 1511
sample size estimation, **10** 1993
score test, **13** 79
semi-parametric cystic fibrosis incidence, **15** 449
smoothing parameters, **13** 969; **14** 1235
space-time disease mapping, **14** 2433
stochastic model, **15** 2617
stratified trials, **14** 2037
survival analysis, **9** 397, 529, 999
time series analysis, **8** 353
transition intensity parameters, **13** 805
transition rates, **12** 1155
tumour growth models, **10** 1075
unpublished studies, **15** 2493
variance components, **10** 1441
Maximum likelihood ratio (MLR) test, **14** 2309
Maximum plasma concentration 75/75 rule, **11** 1333
Maximum tolerated dose
Bayesian methods, **11** 1377
CRM, **14** 1149
phase I clinical trial, **12** 661
toxicity grades, **11** 2063
Maxwell-Boltzmann models, **12** 1773
MCMC *see* Markov Chain Monte Carlo algorithm
MDI *see* Mental Development Index
Mean changes repeated measures, **11** 1685
Mean difference distribution-free estimators, **11** 1151
Mean response model, **11** 2063
Mean-square contingency coefficient, **7** 591
Mean-squared error
AIDS estimates, **10** 1167
assay variability estimation, **10** 1543
hazard ratio point estimation, **9** 1167
HIV estimates, **10** 1167
kappa statistic, **10** 1303, 1465

LD50 bioassay, **14** 841
maximum likelihood comparisons, **10** 723
penalized likelihood, **15** 907
pooling controls, **10** 1417
prediction error estimation, **9** 1303
reference ranges estimation, **10** 691
robust meta-analysis, **15** 1465
time series analysis diseases, **10** 1481
variance components, **10** 1441
Means
see also Regression...
acute manifestation episodes, **13** 859
comparison, **6** 79
ordered, **4** 87, 489, 543–547(L); **5** 199(L)
treatment arms, **13** 1441
Measles
epidemic analysis, **12** 229
geographical coherence, **11** 1409
incubation period analysis, **11** 579
infection force model, **9** 953
SSPE risk estimation, **10** 1733
vaccine efficacy estimation, **10** 1573
Measurement error
see also Error; Errors-in-variables
assessment, **8** 893, 1031, 1051
association tests, **7** 257
attenuation, **13** 1265
binary variables, **7** 955
blood pressure study, **7** 275
case-control studies, **4** 445
change assessment methods, **7** 915
clinical trials, **6** 31, 647
cluster analysis, **14** 2393
cohort studies, **7** 275
correction, **12** 1703; **13** 1135
correlations, **9** 1175
covariate effect, **6** 31
dietary assessment, **12** 917, 937
epidomiology studies, **8** 1031
event probabilities, **11** 1719
exposure-response relationships, **7** 955
Gaussian deviate, **13** 61
HIV screening, **13** 1905
imprecision, **11** 953
intra-individual variations, **12** 1213; **13** 2280–2285(L); **14** 2283–2285(L)
linear regression, **14** 789
logistic regression, **14** 769
longitudinal studies, **7** 177
models, **8** 1075
ordinal exposure variables, **15** 293
prevention trials, **7** 275
relative risk models, **7** 275
reliability studies cost, **6** 647
repeated measures, **11** 1685
risk factors, **11** 783
survival analysis, **13** 2059
within-person, **8** 1051
Measurement methods, **13** 737
see also Repeated measurements
accuracy interlaboratory studies, **10** 843
assessment, **9** 351
blood pressure prediction, **15** 2013
CMS, **14** 331, 2565
correlation estimates error, **9** 1175
databases, **10** 629
energy expenditure, **9** 1365
epidemiology bibliography, **10** 1819
explained variation, **15** 1987, 1999
generalized linear models, **9** 583–586(L)
indices menstruation patterns, **10** 267
linear relationship estimation, **9** 1463
plaque pH profiles, **14** 2609
Measurement model epidemiological designs, **12** 1703
Mechanistic models AIDS projections, **11** 1425
Median
analysis, **13** 1635; **14** 275
confidence limits, **8** 1269
splitting, **14** 873
survival times, **15** 171
Median effect model remission induction therapy, **14** 1081, 1097
Median probability *see* Mid-*P* test
Mediastinal nodes, **12** 1293
Medical audit Bayesian analysis, **12** 2179
Medical care *see* Health care
Medical records
maternity monitoring, **6** 613
registry data, **3** 225, 361, 371, 389
Medical Research Council (MRC), **1** 297, 301, 317, 329
hypertension trial, **15** 249
Medical statistics, **1** 1, 301, 311
Medical students, training
future developments, **9** 1063, 1069, 1077
methodology, **9** 1045, 1057, 1061, 1069
what to teach, **9** 1013, 1023, 1029, 1069
who, when, where, how, **9** 1031, 1039, 1043, 1069
Medicare
databases analyses, **10** 511, 637
epidemiologic surveillance, **10** 521
Medicare Mortality Predictor System estimator, **13** 889
Medication event monitoring systems (MEMS), **15** 2813
Medicine, law, **2** 113
MEE *see* Marginal estimating equations
Memory test analysis, **13** 1657
MEMS *see* Medication event monitoring systems
Mendelian segregation model, **7** 591
Menstruation, **10** 221, 267; **13** 1189; **14** 1843
diary data modelling, **12** 955
dysmenorrhea study, **15** 2573
tubal sterilization, **12** 355

Mental Development Index low birth-weight infants, **11** 243
Mental health preventative trials, **12** 289
Meta-analyses, **14** 137
see also Research synthesis
animal experiments, **13** 709
Bayesian analysis, **11** 141; **12** 1377
bias evaluation, **6** 11
bivariate approach, **12** 2273
breast cancer survival data, **14** 1771
cancer study, **6** 11
clinical trials, **13** 2503; **14** 115
changes, **15** 1263
external evidence, **15** 1285
monitoring, **15** 1237, 1273, 1299
clinical trials registries, **11** 345
clustered observations, **13** 509
cohort design, **6** 11
dose-response, **14** 531, 679
efficiency, **6** 565
estimation issues, **9** 657
external trials, **15** 2733
heart disease risk assessment, **7** 1109
hypertension study, **7** 1109
independent studies, **14** 457
individual patient data, **14** 2057
journal developments review, **10** 1897
lung cancer studies, **14** 545
measurement error models, **13** 1265
methodology developments, **10** 1789
multiple-outcomes, **15** 537
odd ratio trends, **13** 293–296(L)
odds ratio, **7** 889; **11** 2077
parametric approach, **10** 1665
pooling methods, **6** 11, 565; **8** 141
problems, **10** 971
random effects, **15** 619, 1263, 2733
random-effects, **14** 2685
randomized trials workshop, **6** 217–410
regression model, **14** 395
replication variability, **6** 733
research synthesis, **15** 1253
risk differences, **15** 1465
surveys, **14** 669
survival analysis, **7** 1207
treatment evaluation, **7** 1109
unpublished studies, **15** 2493
Meta-Analysis in the Design and Monitoring of Clinical Trials (conference), **15** 1233–1323
Metastases differential prognostic influence, **11** 281
Methadone programme, **15** 2253
Method of moments, **13** 1619
Metoclopramide, **6** 863
Metropolis-Hastings algorithm, **15** 1757
Metropolis-Hastings sampler, **14** 2473
Michaelis-Menten response surface, **15** 2107
Michaelis-Menton kinetic model, **7** 805; **8** 871; **9** 341–342(L)
Micro-organisms, **6** 91
Microcephalia, **3** 27
Microcomputers, **5** 193
$\beta_2$microglobulins HIV infection marker, **12** 843, 2061, 2065, 2087, 2099, 2133
Mid-*P* test
common odds ratio model, **13** 1539
confidence intervals, **12** 809
standardized mortality ratio, **13** 2189
two sided small sample tests, **12** 777
Midpoint imputation
doubly censored data, **11** 1569
threshold-crossing data, **12** 1589
Midpoint method McNemar test, **11** 1521
Miettinen's estimator relative risk, **12** 1733
MIGET *see* Multiple inert gas...
Migraine, **10** 1197
familial aggregation, **11** 1767
stochastic model, **15** 2617
Mild Hypertension Study, **9** 115
Min test, **10** 17, 27; **11** 1057
Miners, **7** 955; **8** 388
Minimax approach, **10** 1327
Minimization
absolute variability, **13** 2369
back-propagation algorithm, **13** 1189
randomization, **12** 2343
Minimum detectable concentration assays, **13** 1165
Minimum inhibitory concentration, **7** 535
Minimum therapeutically effective dose, **14** 925, 933
Minimum variance unbiased estimator, **11** 881
Minitab computer package, **9** 469, 1063; **10** 675; **11** 923; **14** 199
Miscarriage scaling model, **10** 285
Misclassification
association tests, **7** 257
case-control studies, **8** 1529; **14** 1291
categorical data, **11** 271–275(L)
channelling bias, **10** 577
classification trees, **15** 157
cohort studies, **2** 25; **9** 1327
competing risks analysis, **15** 1557
covariates asthma study, **10** 1181
Cox regression review, **10** 1931
data adjustment bias, **10** 191
data quality assurance methods, **9** 115, 145
dichotomous variable, **14** 1307
ecologic study bias, **11** 1209; **14** 327–330(L)
epidemiology, **4** 327; **8** 1095; **10** 1819
error linear models, **10** 1197
gestational age, **11** 1225
interrater reliability, **9** 1103
latent class analysis, **4** 327
Mantel-Haenszel statistic, **8** 1529
matched-pair studies, **8** 825
maximum likelihood approach, **8** 1529
measurement assessment, **9** 351

multiple group discrimination, **10** 757; **11** 1623–1624(L)
multiple reports, **8** 1041, 1071
non-differential effects, **7** 1073; **10** 361
odds ratios, **14** 2581
population data Pakistan, **10** 191
prediction rules error rates, **9** 1303
proportionate mortality ratio, **9** 315
regression to the mean, **10** 1295
sample size calculations, **12** 2257
smoking habits, **15** 581
surveillance, **8** 263
tumour vaccine trial, **14** 2099
unclassified data, **8** 1291
vaccine studies, **9** 1327; **14** 2099
Mismodelling, **7** 257
Misselection subsampling adjustment, **9** 1339
Missing data
see also Attrition bias; Incomplete data
AIDS epidemiology, **9** 1387
autoregressive models, **4** 457; **8** 1523
block design, **8** 871
blood pressure measurements, **11** 2147
cancer registry data, **7** 483
categorical data, **11** 799
cause of death data, **15** 2191
centile estimates, **9** 539
classification, **13** 479; **15** 157
clinical trials, **2** 155; **7** 941; **8** 583; **10** 1595
closed-form estimates, **11** 643
community intervention trials, **15** 1069
contingency tables, **6** 91; **7** 109
contour mapping, **14** 605
covariance models, **14** 1397
covariate error, **8** 1107
crossover trials, **10** 1099
databases, **10** 511, 541, 617
dental study, **7** 403
diabetes study, **7** 671
diagnostic reliability assessment, **7** 403
direct standardization of incidence rates, **12** 3
drop-outs, **11** 2043
epidemiology bibliography, **10** 1819
GEE/MLE comparison, **12** 1723
hazard regression, **15** 1757
HIV screening, **15** 2161
homogeneity tests, **10** 1257
hypertension trials, **8** 1302–1303(L)
incomplete administrative lists, **10** 113
independence tests, **14** 1621
interrater agreement, **9** 835
liver function model, **7** 671
logistic regression, **14** 1315
longitudinal studies
autoregressive model, **4** 457; **8** 1523
computational aspects, **11** 1809
full span designs, **11** 1889
informatively censored data, **11** 1861
workshop report, **7** 177
Markov Chain Monte Carlo algorithm, **13** 839
mechanism model, **13** 609
multiple imputation, **9** 505; **10** 585; **12** 1589; **14** 1913
multiple treatments, **15** 2509
multivariable prognostic models, **15** 361
non-compliance in clinical trials, **15** 2813
non-random, **14** 2675
observational studies, **5** 103
ordinal regression models, **15** 1807
paired observations, **7** 929
penetrance genes, **2** 13
practice databases, **10** 541
predictive models, **13** 1501
probability imputation technique, **9** 777
pulmonary function study, **4** 457
quality of life analysis, **9** 931; **15** 2717
registry data cancer study, **7** 483
regression, **8** 217, 539
repeated measurement analysis, **10** 1959
reporting delay factor, **8** 963
ROC curves, **15** 1687
side effects incidence model, **9** 803
SSPE infection adjustment, **10** 1733
stratified summary statistics, **13** 1853
surrogate endpoints, **8** 415
surveillance, **8** 263, 279
surveys, **7** 727
survival analysis, **7** 483; **9** 529
three-period designs, **13** 1063; **15** 127
time-period effects, **12** 893
tree-based analysis, **15** 37
trend assessment models, **7** 185
Misspecification
ecologic study bias, **11** 1209; **14** 327–330(L)
longitudinal data, **11** 1929
models, **14** 1693
residual confounding, **11** 1747
Mitofsky-Waksberg method, **11** 1009
Mitoxantrone data, **8** 813
Mixed effects cumulative logit model, **15** 2573
Mixed effects non-linear models, **11** 1929
Mixing distribution, **7** 1121
Mixing pattern HIV epidemic dynamics, **11** 1657
Mixture model
bioequivalence, **15** 2635
cancer study, **7** 483
covariate adjusted, **15** 919
depression prevention trial, **15** 2077
diabetic retinopathy, **14** 2599
disease mapping, **12** 1943
eye-tracking data, **15** 1365
hypertension, **9** 301
longitudinal data, **11** 1889, 2027
multiple statistical tests, **7** 1031
partially unclassified data, **8** 1291
serological surveys, **15** 1567

Mixture ratio, drugs, **4** 77
ML *see* Maximum likelihood
MLLSA computer package, **9** 559
MMPS *see* Medicare Mortality Predictor System
Modalities ROC curves, **8** 1277
Models
  see also Cox proportional hazards. . .; Log-Linear. . .; Logistic regression. . .; Regression. . .
  accelerated failure time, **2** 287
  accelerated life, **8** 845
  additive hazards, **4** 353; **5** 539
  age-period-cohort
    autoregressive, **15** 273
    cancer, **6** 449, 469
    generation effects, **3** 113
    HIV incidence, **13** 1975
    lung function decline, **7** 685
    mortality trends, **6** 709
    multistage model, **13** 23
    predictive chemosensitivity assay, **5** 527
  age-related mortality, **10** 65
  aggregate data, **15** 1849
  AIDS
    diagnosis, **13** 1921
    drugs compliance, **13** 2141
    epidemiology, **8** 1–139; **9** 1387, 1433
    incidence, **13** 1933, 1991
    incubation, **15** 2459
    intervention, **14** 1177
    reporting delay, **15** 305
  alcohol problems, **14** 591
  Amersham, **5** 183
  ARIMA
    Box Jenkins approach, **5** 37
    EEG artefacts detection, **10** 1719
    time series analyses
      gonorrhea study, **8** 343
      injury study, **8** 1497
      mortality study, **8** 335
      respiratory disease, **10** 1481
      syphilis surveillance, **8** 353
      threshold construction, **10** 1493
  ARMA, **5** 593; **6** 167; **7** 29, 357, 1045, 1061
  Armitage-Doll multistage model, **9** 677
  association, **5** 15; **8** 1199; **14** 413; **15** 1227–1229(L)
  autoregression
    bias correction, **7** 417
    blood pressure study, **7** 423
    Box-Jenkins approach, **5** 37
    forecasting factors, **7** 1061
    growth curve models, **7** 73
    infectious diseases surveillance, **5** 37
    longitudinal data, **7** 19, 59, 161, 177; **8** 1523
    lung function tests, **7** 29
    missing data, **7** 59, 317, 357
    mortality, **7** 239, 293, 1045
    pulmonary function, **7** 19, 29, 59
    repeated measurements, **7** 29, 87
    risk, **7** 239, 293
    time series analyses
      Box-Jenkins study, **5** 73
      computer tomography impact, **5** 593
      correction estimation, **1** 49
      forecasting factors, **7** 1061
      gonorrhea study, **8** 343
      longitudinal data, **4** 457; **8** 1523; **10** 492–495(L)
      mortality estimation, **7** 1045; **8** 335
      syphilis study, **8** 353
  back-projection, **13** 1945
  Bailey-Makeham, **10** 521
  balanced probability, **14** 491
  base-comparison, **5** 15
  Bayes, **11** 37
    change-point, **10** 221, 1159–1160(L)
    empirical, **7** 697; **8** 3, 173, 189; **10** 811
    hierarchical model, **9** 919; **14** 971, 2173
    independence, **5** 497, 503; **6** 805, 945; **8** 1351
    predictive values, **15** 463
    random-effects, **14** 2685
  Berkson, **7** 257, 289, 297; **8** 1075
  betrend, **7** 185
  binary time-dependent covariates, **15** 2589
  binormal, **15** 1575
  bioequivalence, **14** 853; **15** 2635
  birth defects, **15** 2029
  birthweight distributions, **15** 1333
  bivariate regression model, **14** 1341
  bivariate survival data, **14** 2523
  Box-Jenkins
    forecasting factors, **7** 1061
    heart rate analysis, **6** 159
    infectious disease study, **5** 37
    threshold construction study, **10** 1493
    time series analyses, **5** 593; **7** 1045; **8** 353, 1497
  breast cancer, **14** 267, 1531
  cancer, **1** 245; **9** 737; **10** 65, 1241
  cancer screening, **14** 2715
  carcinogenesis, **1** 163; **2** 363; **9** 677
  cardiovascular disease study, **14** 1745
  Carlos-Sennin, **7** 403
  case control studies, **12** 1325
  categorical regression models, **14** 2131
  CD4-lymphocyte count, **13** 231, 805, 1101; **14** 1889; **15** 75
  censoring, **7** 337, 347, 357
  chronic otitis media risk factors, **9** 1495
  classical linear, **4** 379
  clinical trials, **9** 787; **10** 1789
  cluster analysis, **14** 2291; **15** 1793
  cluster effect, **13** 509
  clustered ordinal response data, **15** 2573
  CMS, **14** 2565

comparison, **14** 735
compartment, **8** 1011
competing risks, **4** 29; **15** 1557
confidence intervals, **10** 717
congenital abnormalities, **14** 1797
contingency tables, **10** 991
continuation ratio, **3** 273; **7** 435; **10** 1703
continuous covariates, **11** 1115
continuous time autoregression, **11** 515; **12** 265
correlated categorical data, **11** 67
correlated multiple associations, **11** 219
correlated ordinal data, **14** 1961
cost-effectiveness analysis, **9** 173
counts/rates, **10** 1405
covariance models, **14** 1397
covariates
  effects, **14** 299, 2285–2288(L)
  inbalance factor, **8** 467
  repeatedly measured, **15** 1663
crossover designs
  linear models, **10** 909
  modelling, **15** 1435
  outlier detection, **9** 549
  random effects, **10** 901
  residual effects, **10** 891
  treatments comparison, **8** 487
cubic splines, **8** 551; **14** 655
cumulative logistic regression, **8** 525
cumulative logit, **7** 109; **8** 1209, 1317
cumulative odds, **5** 15
cure, **1** 93; **3** 153; **6** 483; **14** 2111
cystic fibrosis incidence, **15** 449
damped exponential linear, **9** 953
DEALE, **9** 173
demographic, **8** 103
dependent censoring model, **15** 1049
depression prevention trial, **15** 2077
Dietz, Molineaux and Thomas, **6** 853
diffusion, **7** 1147
Dirichlet-multinomial, **14** 357; **15** 2323
disability, **7** 661
disease clusters, **15** 783, 851
disease manifestation, **2** 13
disease mapping, **14** 2473
disease monitoring methodology, **10** 1089
distance, **8** 571
dose determination, **14** 885, 897
dose escalation studies, **15** 1605
dose-response, **12** 1093
  case-control study, **10** 1511
  confounding factors, **14** 987, 1007
  design methods, **9** 1353
  meta-analysis, **14** 531, 545
  psychopharmacologic research, **11** 685
  simulation study, **10** 303
dummy variable, **14** 655
duration data, **15** 527
dynamic error component, **11** 533
effective dose model, **14** 925, 933
EMAX dose-response, **13** 2289
emergency room visits, **15** 823
empirical Bayes, **7** 697; **8** 3, 173, 189; **10** 811
epidemiology, **3** 165; **10** 1789, 1819; **14** 605
errors-in-variables regression, **9** 1463
excess fraction estimation, **15** 1519
exponential decay, **14** 1553
exponential distribution, **7** 435, 1297; **8** 963
exposure-specific incidence rates, **13** 651
eye-tracking data, **15** 1365
failure time distributions, **15** 2475
field trials unifying model, **13** 61
finite mixtures, **9** 397
fixed effects
  clinical trials, **9** 657
  estimation issues, **9** 657
  full span designs, **11** 1889
  hearing thresholds, **10** 1453
  heart disease, **9** 1199
  meta-analyses, **10** 1665; **14** 137
  mortality variation study, **9** 1199
  pooling clinical trials, **6** 341, 381
  random coefficient regression modelling, **13** 1211
  randomized clinical trials, **6** 341; **10** 1665
  REM1, **13** 1601
foetal development, **14** 1417
frailty, **7** 819, 1121
functional decline, **15** 1023
gamma mixing, **7** 1121
gene-environment interactions, **13** 153
generalized linear, **10** 511, 1069, 1197
genetic, **5** 291; **6** 629; **14** 1353
geographical correlation studies, **9** 515
global odds ratio regression, **15** 1507
goodness-of-fit, **14** 1785
graphical designs, **14** 1265
growth curve
  autoregression, **7** 73, 87
  change rate analysis, **6** 599
  distribution-free tests, **1** 83
  human study, **6** 185
  Kalman filtering, **7** 73, 87
  longitudinal data analysis, **7** 305, 317
  maximum likelihood method, **7** 73, 305
  missing data, **7** 317
  multivariate analysis, **7** 317
  muscular dystrophy study, **5** 231
  treatment evaluation, **5** 231
  tumour surveillance, **1** 83
  two-step method, **9** 841
Hagerstrand diffusion, **14** 605
hepatitis B transmission, **15** 2215
Hib bacteria transmission, **15** 2235
hierarchical, **9** 919; **15** 1161
HIV
  epidemic dynamics, **11** 1657

Models (*cont.*)
HIV (*cont.*)
incidence, **14** 1513; **15** 513
incubation, **13** 2043, 2067; **15** 197
infection
demographic impact, **8** 103
linked risk groups, **9** 721
partner number, **8** 83
probability model, **13** 2097
sexual behaviour, **15** 2323
United States, **8** 45
variable infectivity, **10** 131
length bias model, **10** 423
prevention, **8** 59
testing rates, **15** 497
transmission, **8** 93; **10** 1003; **14** 1365
treatment, **15** 2425
vaccine development, **9** 1425, 1433
hormone pulses data, **10** 329; **14** 311
household infections, **15** 837
hypothesis/significance tests, **9** 201, 213
idiometric regression, **7** 697
illness-death, **7** 149, 661; **8** 201
incomplete data, **10** 65
independent Bayes
correspondence analysis, **8** 1351
decision making process, **5** 497
diagnosis, **5** 503; **6** 805, 945; **8** 1351
independent increments, **7** 29
infancy-childhood-puberty, **6** 185
infection
HIV, **8** 45, 83, 103; **9** 721; **10** 131; **15** 2323
transmission, **12** 249
infectious diseases, **3** 165; **9** 953
intermediate event times, **15** 1171
interrater reliability, **9** 1103
interval censored data, **15** 283
intervention, **10** 1481
intra-subject variability, **15** 1619
isotonic regression, **7** 649
joint action for drugs, **4** 77
Kaplan-Meier, **9** 487
Kay, **10** 1061
kidney graft survival, **14** 1999
knee replacement rates, **15** 1875
latent class analysis
chronic disease epidemiology, **4** 327
classification study, **3** 249
diagnosis, **5** 21; **6** 529–531(L); **9** 559
misclassification adjustment, **10** 1197
relative risk improvement, **4** 445
latent logistic regression, **9** 931
latent variable, **10** 1607
length bias, **10** 423
leukaemia, **15** 1003, 1757
life-table analysis, **14** 1859
limited failure population, **9** 409
linear
blood pressure measurements, **15** 2013
clinical trial reports, **13** 2393
cluster analysis, **15** 1793
conditional, **13** 635
crossover trials, **10** 909
dental study, **7** 403
diagnostic factors, **7** 403
elderly hearing thresholds, **10** 1453
empirical Bayes method, **10** 811
estimation, **15** 1647
extrapolation, **13** 1513
Gaussian, **14** 1219
laboratory studies, **10** 843
longitudinal data, **11** 1843, 1871
meta-analysis, **14** 137
mixed-effects, **13** 587
multilevel, **13** 1643
multivariate reliability structures, **15** 1647
ommitted variable bias, **11** 1195
ordinal data, **14** 1177
parameter estimation, **13** 1601
random-effects, **11** 1861
relative risk, **8** 173, 927
residual plots, **14** 2023
risk methods, **10** 1511
serial multi-site data, **11** 1041
stochastic regression coefficients, **13** 759
time series regression relationships, **12** 1555
tumour growth study, **10** 1075
linear logistic, **8** 1363; **10** 323
linear relative risk, **8** 173, 927
LLP, **7** 403
location-scale cumulative odds, **14** 1191
log-logistic regression, **8** 725
log-normal, **8** 725; **9** 505, 999
logistic, **2** 79, 199; **3** 165; **10** 1647; **15** 2149
logit
Bayesian methods, **11** 1377
categorical data, **7** 109; **8** 1209
chi-squared comparisons, **3** 273
clinical chemistry, **5** 183
continuation ratios, **7** 435
distribution-free fitting, **12** 1969
empirical transformation, **12** 1293
longitudinal data analysis, **7** 109
maximum tolerated dose, **11** 2063
mortality
methodology, **4** 175
neonatal study, **5** 139; **9** 981
post-neonatal study, **5** 155; **9** 981
stillbirths study, **4** 189; **9** 981
ordered data, **8** 1209
ordinal data, **3** 273; **5** 15; **14** 1545
regression methods, **7** 435
repeated measurements, **7** 109; **8** 1209
logit-log, **5** 183
long-term survival, **15** 2763

longitudinal
CD4 counts, **15** 2289
curves, **15** 61
data analysis, **12** 265
respiratory function, **14** 2205
Lu, **7** 403
lung cancer incidence, **15** 565
lung function, **8** 861
malaria incidence, **14** 2727
malignant melanoma, **14** 821
marked point process, **15** 2751
marker variable bias, **15** 1747
Markov
abortion study, **5** 243
AIDS study, **8** 59, 103, 831
categorical data, **7** 95, 169, 965
clinical trials, **7** 581; **9** 749
counting process, **5** 491
databases methodology, **10** 617
diagnostic factors, **8** 1231
disease studies, **8** 59; **10** 1061
epidemiology bibliography, **10** 1819
Framingham heart study, **7** 205
historical data analysis, **7** 819
HIV study, **8** 59, 103, 831
liver function study, **7** 671
lymphoma study, **5** 491
morbidity estimation, **7** 325, 787
mortality, **7** 787; **9** 315
multiple tests, **8** 1231
ordered categorical response, **8** 785
parasitic infection dynamics, **9** 1211
psychiatry admissions study, **5** 243
quality of life analysis, **9** 749
random walk model, **7** 581
regression, **8** 785
repeated measurement analysis, **7** 347
screening methods, **8** 59
side effects incidence, **9** 809
survival analysis, **7** 661; **10** 413
transient state models, **6** 795
treatment comparisons, **9** 803
ulcer prevention models, **7** 877
ventilatory study, **6** 795
measurement error
AIDS diagnosis, **13** 2059
Bayesian estimation, **13** 185
covariance analysis, **8** 1075
dietary questionnaires, **13** 127
ordinal exposure variables, **15** 293
regression, **8** 1139, 1149
Mendelian segregation, **7** 591
menstrual diary data, **12** 955
meta analysis, **11** 141
methadone programme evaluation, **15** 2253
Michaelis-Menten, **7** 805; **8** 871; **9** 341–342(L); **15** 2107
miscarriage scaling, **10** 285
misclassification, **9** 1327; **10** 191; **14** 1307
missing data, **14** 283
misspecification, **13** 2219; **14** 1693
mixed effects, **14** 841, 955, 969
cumulative logit model, **15** 2573
gamma model, **9** 263
linear model, **10** 1453
non-linear models, **11** 1929
mixture
bioequivalence, **15** 2635
cancer study, **7** 483
covariate adjusted, **15** 919
depression prevention trial, **15** 2077
diabetic retinopathy, **14** 2599
disease mapping, **12** 1943
eye-tracking data, **15** 1365
hypertension, **9** 301
longitudinal data, **11** 1889, 2027
multiple statistical tests, **7** 1031
partially unclassified data, **8** 1291
serological surveys, **15** 1567
mortality
age trajectory analyses, **10** 1043
age-period-cohort, **1** 245; **6** 709
cancer, **1** 245; **10** 65
competing risk, **2** 373
heart disease variation, **9** 1199
infection vaccine, **9** 953
prediction, **11** 475
moving average
biological rhythm data, **6** 167
Box-Jenkins methods, **5** 37
clinical chemistry, **6** 425
error, **6** 167
forecasting, **7** 1061
hormonal data, **1** 49
infectious diseases, **5** 37
longitudinal data, **7** 29, 357
missing data analysis, **7** 357
mortality estimations, **7** 1045
quality control, **6** 425
randomness tests, **7** 795
repeated measurement analysis, **7** 29
runs tests, **7** 795
smoothed data analysis, **7** 795
time series analysis, **1** 49; **5** 593; **7** 1045
multi-level, **15** 2717
multi-rater agreement, **11** 101
multigroup transmission HIV, **9** 721
multinomial logistic, **10** 383
multiple imputation methods, **9** 505
multiple linear regression, **7** 601; **8** 217
multiple tumour data, **15** 1217
multiplicative, **4** 353; **6** 61; **10** 1745
multistage, **7** 223; **9** 677
multistate, **3** 35; **6** 795; **7** 149, 661, 819, 965
multistate Markov model, **14** 1975
multivariable prognostic models, **15** 361

Models (*cont.*)
multivariate regression, **15** 2013
MVK, **15** 1003
neural network, **14** 73
neuron nets, **13** 1189
newborn mortality, **14** 2191
NHLBI clinical trials, **9** 881
nominal association, **10** 1555
non-negative data, **15** 1695
non-response, **7** 305, 347, 357
normal discriminant, **10** 383
nursing home institutionalization, **14** 1757
nutrition knowledge, **15** 23
observational data, **8** 273
odds ratios extraneous factors, **9** 1131
one-way nested, **11** 633
ordered logistic, **8** 1317
ordinal
classification, **10** 383
regression, **15** 1807
orthogonal polynomial, **10** 697
paired binary data regression, **9** 1517
parametric, **8** 23; **11** 939
patient compliance effect, **15** 659
pharmacokinetics, **14** 1009
piecewise exponential, **9** 1157
plaque pH profiles, **14** 2609
point source disease risk, **15** 1927
Poisson
abortion data analysis, **8** 285
age-period-cohort model, **5** 527
AIDS incidence, **8** 3, 23
blood pressure, **9** 1157
cancer study, **5** 527; **7** 223
case-control studies, **10** 739
childhood cancer, **15** 683
childhood leukaemia, **14** 2487
CIN/HPV, **13** 379
confidence intervals, **15** 2379
contraceptives, **10** 241
covariate modification, **13** 2407
Cox proportional hazards, **9** 1157
epidemiology, **7** 223; **10** 1819
logistic regression comparisons, **9** 853(L)
lung cancer, **7** 223; **15** 1397
measurement error, **8** 1075
peritonitis rates analysis, **9** 263
recurrent events, **14** 2081
relapsing-remitting disease counts, **13** 453
risk ratio/rate ratio estimation, **12** 1733
risks, **7** 223, 289; **13** 343
small area prevalence, **15** 1867
standardized rate estimators, **10** 1069
surveillance data, **8** 285, 331
survival models, **12** 1019
tumour recurrence rates, **8** 1363
Poisson regression
abortions data analysis, **8** 285
age-period-cohort model, **5** 527
AIDS incidence, **8** 3, 23
blood pressure, **9** 1157
cancer study, **5** 527; **7** 223
case-control studies, **10** 739
childhood cancer, **15** 683
childhood leukaemia, **14** 2487
CIN/HPV, **13** 379
confidence intervals, **15** 2379
contraceptives, **10** 241
covariate modification, **13** 2407
Cox proportional hazards, **9** 1157
epidemiology, **7** 223, 233; **10** 1819
logistic regression, **9** 853(L)
lung cancer study, **7** 223; **15** 1397
measurement error, **8** 1075
peritonitis rates analysis, **9** 263
recurrent events, **14** 2081
relapsing-remitting disease counts, **13** 453
risks, **7** 223, 289; **13** 343
small area prevalence, **15** 1867
smoking risks, **7** 223
standardized rate estimators, **10** 1069
surveillance data, **8** 285, 331
tumour recurrence rates, **8** 1363
polychotomous logistic regression, **5** 49; **10** 375, 757
polynomial, **13** 23, 931; **14** 1235
pooled logistic regression, **9** 1501
population mixing, **8** 59
population risk, **15** 1713
prenatal infection, **2** 1
prevention HIV, **8** 59
probit model
ANCOVA, **8** 1075
attrition bias, **12** 1005
Bayesian methods, **11** 1377
binomial comparisons, **7** 1187
design effects, **12** 1259
longitudinal data, **11** 1861
measurement error
confidence intervals, **8** 1051
generalized linear model, **8** 1075
logistic regression, **8** 1051
non-differential exposure, **8** 1031, 1071
regression, **8** 1139, 1149
relative risk correction, **8** 1051
multivariate, **10** 1391
placebo effects, **7** 1187
relative risk coreectiion, **8** 1501
product, **7** 403
prognostic, **3** 143; **9** 487; **10** 647
proportional-odds, **2** 273; **7** 95, 109; **8** 785; **10** 901
Q-TWiST model, **14** 1771
quality adjusted survival analysis, **9** 1259
quality of life change, **9** 931
quasi-symmetry, **9** 1143

radioimmunoassay calibration, **14** 935, 953
random coefficient regression, **7** 697
random effects, **11** 579
  analysis of variance, **4** 145
  assay variation estimation, **10** 1543
  Bayesian methods, **10** 811, 1241; **12** 2179
  CD4 lymphocyte counts, **15** 2289, 2337
  clinical trials, **8** 141; **9** 657
  correlation estimation, **9** 1175
  dynamic, **13** 113
  epilepsy study, **8** 1327
  foetal development, **14** 1417
  growth curves, **15** 75
  historical control analysis, **7** 819
  incubation period analysis, **11** 579
  likelihood based method, **12** 2273
  linear, **11** 2039; **13** 635, 945, 1619
  logistic, **14** 1365
  longitudinal data
    computational aspects, **11** 1809
    linear Gaussian models, **14** 1219
    non-linear models, **11** 1929
    non-parametric priors, **11** 1981
    tutorial, **11** 1825
  meta-analysis
    Bayesian approach, **15** 2733
    Bayesian approaches, **14** 2685
    clinical trials, **15** 1263
    dose-response, **14** 679
    likelihood approach, **15** 619
    review, **14** 137
  mortality, **4** 201
  omitted variables, **13** 2219
  ordinal responses, **10** 901; **12** 2147–2151(L)
  pooling methods comparisons, **8** 141
  prediction models, **8** 1327
  pulmonary function study, **8** 189
  repeated categorical responses, **12** 1969
  repeated measures data, **15** 1143
  response to treatment/survival time relationship, **15** 2797
  risk difference, **15** 1465
  shape invariant, **14** 2009
  stratified summary statistics, **13** 1853
  treatment estimation issues, **9** 657
  two-stage application, **8** 189
random walk, **7** 581; **12** 265
randomized consent trials, **9** 645
Rasch, **7** 975
reaction time, **14** 747
record linkage, **14** 491
relapsing-remitting disease counts, **13** 453
relative risk, **8** 173; **10** 65
remission induction therapy, **14** 1081, 1097
repeated events analysis, **10** 1227
repeated measures, **11** 115; **15** 1143
repeated ordinal responses, **15** 1123
replicate variance structure, **12** 2025
reporting delays, **8** 259, 279, 963
restricted cubic splines, **14** 2119
retrend, **7** 185
risk competition, **8** 845
risk screening, **11** 257
ROC curve, **12** 1293
sampling, **10** 811
screening programmes, **8** 743
semi-proportional hazards model, **15** 1771
serological surveys, **15** 1567
shape invariant, **14** 2009
sign score regression, **14** 431
simple carryover, **11** 715
smoothing procedures, **14** 1205
space-time cluster analysis, **14** 2383
space-time interactions, **15** 1935
spatial
  cancer mortality rates, **10** 95
  processing, **14** 481
spatial-temporal stationary, **14** 605
spinal cord injuries, **11** 1171
spousal smoking, **15** 581
Stage, **11** 1633
statistical predictive value, **9** 1303
statistical issues, **14** 185
stochastic
  AIDS epidemic, **8** 45, 121
  categorical data analysis, **7** 95
  CD4 lymphocyte counts, **15** 2289
  chromosome loss, **13** 839
  clinical trials evaluation, **7** 581
  counting process, **5** 491
  diabetes study, **7** 661, 671
  disease transmission simulations, **13** 53
  HIV incubation, **15** 197
  HIV infection, **8** 45, 831
  liver function tests, **7** 671, 761
  lymphoma study, **5** 491
  measles epidemic analysis, **12** 229
  morbidity estimation, **7** 325
  mortality, **7** 239, 293
  random walk models, **7** 581
  repeated binary data, **15** 2617
  risk, **7** 239, 293
  survival analysis, **7** 661
  vaccine effect prediction, **6** 843
superpopulation, **8** 679
surface infant mortality, **14** 481
survival estimates, **14** 1249; **15** 1171
  AIDS, **7** 395; **9** 681
  cancer, **4** 353; **9** 529
  comparisons, **2** 305
  Cox proportional hazards, **10** 1931
  drug combination analysis, **9** 1527
  oral fixtures, **13** 43
Susceptible-Exposed-Infectious-Removed (SEIR), **12** 229
symmetry, **7** 671; **9** 1143

Models (*cont.*)
therapeutic preferences, **15** 443
time series
autoregression, **4** 457; **7** 59
Box-Jenkins approach, **5** 37
forecasting methods, **8** 335
injury models, **8** 1497
regression methods, **8** 335
time-fixed, **13** 301
Time-Since-Infection, **11** 1633
time-to-pregnancy study, **13** 671
transfer function, **8** 335, 353, 1497
transient state, **3** 35; **6** 795
transmission
HIV
AIDS issues, **9** 1387
disease prevention methods, **8** 59
infection analysis, **8** 83, 93; **9** 721
spread assessment, **8** 103; **10** 1003
vaccine development, **9** 1425, 1433
malaria, **6** 853
treatment changes, **15** 249, 2053
treatment order selection, **13** 431
tumour growth, **1** 83, 163; **10** 1075
two-period crossover design, **13** 905; **14** 1067, 1079
two-stage parametric regression, **9** 681
unpublished studies estimation, **15** 2493
updated covariates survival, **13** 301
vaccine action, **12** 249
vaccine trial screening, **14** 2099
variance components, **10** 599, 843, 1227
visual acuity, **14** 257
visual fields, **15** 1349
Weibull survival, **4** 509; **10** 663
weighted non-linear regression, **7** 59
Modified Cholesky decomposition with pivoting, **12** 2025
Modified ratio estimation, **15** 1187
Modified *t* tests power/error, **12** 2233, 2245
Mojena's test, **6** 137
Moment method intraclass correlation, **11** 1607
MONICA *see* Monitoring Trends & Determinants of Cardiovascular Disease
Monitoring
see also Surveillance
adverse drug reactions, **12** 2383
air pollution, **8** 1109, 1127, 1133, 1137
ambulatory blood pressure, **13** 1201
Bayesian clinical trials, **13** 1371, 1385
proportions, **14** 1057, 1065
robust methods, **14** 1379
single-arm clinical trials, **14** 357
cancer, **2** 217
CHART cancer trials, **13** 1297
child growth, **13** 2477
clinical trials, **10** 405, 1789; **12** 415–616, 1459; **13** 1401, 1493
external evidence, **15** 1285
guidelines, **14** 1655, 1659
meta-analysis, **15** 1233–1323
multiple endpoints, **15** 2341, 2367
robust Bayesian approaches, **15** 1093
controlled trials unified method, **13** 1815
data
clinical trials, **6** 753; **7** 1231
quality evaluation, **7** 1165; **8** 367
devices efficacy, **10** 351
disease, **6** 197
DMBs randomized CTs, **12** 419, 433
DMCs, **12** 451, 457, 575, 581
drug reactions, **1** 153
DSMBs, **12** 419, 433
EORTC breast cancer trial, **13** 1329
foetal, **3** 131
interim analysis, **10** 925
laboratory
clinical chemistry, **4** 369; **6** 147, 425
confidence intervals estimation, **5** 347
cusum techniques, **2** 141
diagnostic tests, **6** 147
discriminant analysis, **5** 347
measurement methods, **9** 351
quality control, **2** 123, 131, 141; **4** 369; **6** 425
reference ranges, **7** 377
measurement methods, **9** 351
multi-armed trials, **13** 1441
NHLBI model, **12** 425
observer measurement error, **8** 893
optimal checking procedures, **11** 1343
patient, **6** 813
periodontal disease progression, **10** 1089
Peto-Peto-Prentice statistic, **14** 2227
pilot toxicity study, **13** 2311
prescription event monitoring, **15** 987
prevention trials multiple outcomes, **13** 1479
prior distribution, **13** 1371
provisional diagnoses, **10** 1341
renal carcinoma trial, **13** 2249
safety considerations, **14** 1099, 1113
sequential, **14** 1927
systems rare events, **6** 517; **7** 997(L), 998(L)
trial test statistics, **13** 1357
Monitoring committee data, **3** 445, 453; **10** 925, 1341
Monitoring Trends & Determinants of Cardiovascular Disease (MONICA), **11** 295
Monotherapy two-stage testing, **12** 645
Monotonicity
cumulative sums, **11** 1115
discriminant analysis, **11** 1023
missing data, **11** 2043
Monte Carlo simulations
see also Simulations
age-related adjustments, **10** 65
animal tumour trend tests, **13** 689

assay variability estimation, **10** 1543
bias evaluation, **7** 59, 1243
binomial proportions, **14** 1463
birth defects, **15** 717, 1907
blood pressure, **7** 915
bounded outcome scores, **12** 1063
cancer study, **6** 667
censored data, **5** 653; **11** 193
change rate analysis, **7** 387, 915
chi-squared adjustment, **10** 1981
clinical trials, **6** 927; **7** 581, 1231; **8** 153; **9** 787
cluster analysis, **14** 799, 2323; **15** 727
cluster randomization, **8** 599
combination drug studies, **15** 233
conditional probability stopping rule, **11** 659
confidence intervals, **5** 653; **7** 865
correlated markers, **14** 2217
correlations study, **8** 1485
covariate omission, **9** 777
dose-finding studies, **10** 1647
dose-response evaluation, **14** 1595
drugs tests, **7** 1171; **8** 1479
efficacy therapies, **6** 657
event probabilities, **11** 1719
exact power computations, **13** 1539
familywise errors, **15** 1107
frailty models, **14** 1447
GEE/MLE comparison, **12** 1723
generalized t and rank-sum, **11** 491
geographical correlations, **9** 515
Greenhouse-Mantel confidence bounds, **13** 1551
hazard ratio point estimation, **9** 1167
historical control study, **10** 839
HIV
  incubation distributions, **15** 197
  stochastic processes, **10** 1427; **13** 53
homogenetic estimations, **15** 51
hypothesis testing, **12** 1125
infant mortality, **15** 1907
k-sample tests, **14** 863
kappa coefficient, **11** 1511; **14** 83; **15** 1409
leukaemia incidence, **14** 3
longitudinal data, **11** 1809, 2001
Mantel-Haenszel statistic, **7** 507
measurement error, **12** 1141
meta-analysis, **11** 141
missing data, **7** 1243; **9** 777; **14** 283
multiple regression model, **8** 217
multiple test procedures, **11** 511
multivariate failure time, **13** 2233
myocardial infarction, **6** 927
normality departure estimation, **10** 1283
outliers detection, **10** 1375
periodontal disease progression, **10** 1089
photographic image grading, **8** 1433
placebo effect, **6** 927
pock count variability study, **9** 615
pooling methods, **6** 657
predictive value calibration, **9** 1303
radiation exposure, **8** 173
rare event clustering, **11** 761
registry data, **8** 1415–1416(L)
regression techniques, **7** 59
relative risk models, **7** 275
risk estimation, **7** 507
runs test, **7** 795
sample size
  confidence intervals, **7** 865
  determination, **11** 1091
  logistic regression, **8** 795
  McNemar's test, **14** 1831
  pilot studies, **14** 1933
  stopping rules, **6** 667
  survival distributions, **14** 2273
sensitivity, **13** 1525
sequence analysis, **7** 1171
serial multivariate data, **11** 1041
spatial autocorrelation coefficient, **15** 887
specialized tests, **4** 489
stopping rules, **6** 667, 927; **7** 1231
survival data, **5** 653; **7** 1243; **8** 937; **9** 409
t tests, **12** 2233
therapies evaluation, **6** 657
tumour growth models, **10** 1075
two-sample tests, **9** 447
two-stage studies, **11** 769
variance components study, **10** 599
Moolgavkar, Venzon and Knudson (MVK) model, **15** 1003
Moran's *I*, **12** 1885
  cluster analysis, **15** 741, 783, 873
  heteroscedasticity, **15** 887
  population density adjustment, **14** 17; **15** 1591–1594(L)
Morbidity, **3** 131; **7** 325, 787; **8** 201, 997
  AIDS illnesses, **15** 2307
  comorbidity, **14** 721
  extraction mapping, **12** 1249
  heart disease multiple data sources, **14** 643
  newborns, **14** 2191
  surveillance, **14** 629
Morgan-Sonquist procedure, **2** 295
Mortality
  see also Death
  abortions analysis, **8** 285
  age trajectory cohort studies, **10** 1043
  age-period-cohort models, **6** 709
  age-related/cancer trials, **10** 65
  AIDS, **15** 2273
  analysis, **4** 155, 425
  asthma study misclassification, **10** 1181
  breast cancer, **13** 1755; **15** 741
  calculation methods, **2** 381; **3** 301(L); **4** 105–109(L); **5** 327
  cancer, **2** 279; **4** 353; **9** 737; **10** 95
  cardiovascular, **4** 111, 397

Mortality (*cont.*)
case-control studies, **10** 739
cause-deleted, **5** 61; **6** 527(L)
cause-specific, **6** 71, 233; **7** 965
chronic disease estimation, **8** 201
clinical trials, **6** 251; **9** 35, 155
cohort studies, **6** 709
community intervention studies, **10** 53
condition specific vs. all-cause, **13** 1459
cystic fibrosis, **15** 449
databases study, **10** 637
design effect, **10** 53
developing countries study, **9** 35
diabetes study, **7** 661
differential, **5** 573
discriminant analysis, **2** 229
disease mapping, **12** 1895
epidemiological studies, **8** 679; **10** 521
expected, **2** 381; **3** 301(L); **4** 105–109(L); **5** 327; **13** 1479
extraction mapping, **12** 1249
frailty models, **14** 1859
Framingham heart study, **7** 239, 293
geographic areas, **12** 1931
hazardous exposure estimation, **10** 79
heart disease, **7** 205, 219, 613; **9** 1199
home injuries, **8** 263
incidence relationship, **12** 2395
index, **2** 455; **6** 71
infants
geographical distribution, **14** 481
logit models, **4** 175, 189; **5** 139, 155; **9** 981
perinatal study, **2** 229
spatial patterns, **15** 1907
surveillance, **8** 387
infection force model, **9** 953
influenza estimations, **7** 1045
kidney transplantation, **14** 1553
life-table analysis, **2** 373; **4** 155; **7** 895
likelihood analysis, **7** 149
liver transplant study, **10** 733
lung cancer, **15** 273
manic-depression, **5** 327
marginal extended quasi-likelihood, **15** 1397
Markov model, **7** 787
melanoma tumour size, **9** 999
meta-analyses, **10** 971
morbidity estimation, **7** 325
multilogit models, **9** 981
multistate models, **7** 149, 661
neonatal study, **5** 139, 155
newborns, **14** 2191
odds ratio, **5** 61
perinatal study, **2** 229
person-years methods, **5** 327
physicians' health study (US), **10** 1585
pneumonia estimations, **7** 1045
post marital bereavement study, **10** 395
post-neonatal study, **5** 155
prostate cancer, **15** 2539
quality adjusted survival, **15** 93
quality of life analysis, **9** 931
radiation exposure analysis, **8** 173
rates, **13** 889, 1119; **14** 615
age-period-cohort models, **1** 245; **6** 709
Bayes estimation, **4** 201
calculation methods, **2** 381; **4** 105–109(L)
cancer study, **1** 163, 245; **4** 201
cohort studies, **4** 295; **6** 709
county-level, **12** 393
equality tests, **1** 37
excess death, **1** 93; **9** 737
health data analysis, **1** 163
intervention study, **6** 501
life-table analysis, **6** 527–528(L)
Mantel-Haenszel statistics, **1** 37
population comparisons, **4** 295
trend assessment models, **6** 709
ratio proportional, **2** 455, 467; **3** 7; **5** 61; **6** 71
relative, **5** 327; **7** 661
response phenomenon, **10** 1621
risk
homogeneity, **10** 1267
interaction, **7** 239, 293
screening effectiveness studies, **9** 969
seat-belt systems study, **8** 379
smoking covariate, **8** 997
spatial partitioning, **15** 1885
Sullivan's index interpretation, **7** 787
surgery patients, **13** 1001
surveillance, **14** 629
survival analysis
curve representation, **7** 895
estimation methods, **9** 529
models comparisons, **9** 1157
time series analysis, **7** 1045; **8** 335, 1497
trends, **6** 709; **14** 821
Mosaic, hexagonal, **7** 1157
Most probable number adjustment, **11** 1253
Mosteller-Tukey procedure, **12** 1047
Motor vehicles *see* Automobile studies
Motor-neurone data statistical model, **14** 185
Moving average model
see also Autoregressive...
biological rhythm data, **6** 167
Box-Jenkins methods, **5** 37
clinical chemistry, **6** 425
correlations time series analysis, **1** 49
error, **6** 167
forecasting, **7** 1061
hormonal data time series, **1** 49
infectious diseases, **5** 37
longitudinal data, **7** 29, 357
missing data analysis, **7** 357
mortality estimations, **7** 1045
quality control, **6** 425

randomness tests, **7** 795
repeated measurement analysis, **7** 29
runs tests, **7** 795
smoothed data analysis, **7** 795
time series analysis, **1** 49; **5** 593; **7** 1045
Moving interval average, **11** 2147
MRC *see* Medical Research Council
MRFIT *see* Multiple Risk Factor Intervention Trial
MRI *see* Magnetic resonance imaging
MS *see* Multiple Sclerosis
MSE *see* Mean-squared error
Mselini joint disease, **8** 785
MULCOX2, computer package, **13** 2233
Multi-Cohort Analysis Project Workshop, **12** 2061, 2065, 2087, 2099
Multi-grade toxicity scheme, **11** 2063
Multi-rater agreement categorical scale, **11** 101
Multi-way tables, **13** 2393
Multicentre AIDS Cohort Study
HIV-1 seroconversion incidence, **12** 153
interventions, **13** 2127
multiple decrement models, **15** 2307
sexual behaviour, **15** 2323, 2337
vaccine trials, **13** 2155
Multicentre clinical trials, **1** 353
blindness, **15** 1421
cancer, **14** 2523
data monitoring, **12** 1459
drug regulation, **14** 127
Mosteller-Tukey procedure, **12** 1047
pushback procedure, **12** 1033
REML, **13** 1601
treatment allocation, **14** 2661
Multicentre studies
heart failure, **12** 1365
semiannual reports, **11** 1367
serial multivariate data, **11** 1041
stopping rules, **11** 853
Multicollinearity, **3** 293
Multidimensional scaling heartbeat trends, **13** 275
Multilevel models
inverse polynomial, **12** 949
marker functional form, **12** 2099
quality of life, **15** 2717
Multinomial models
birthweight, **15** 1333
exact unconditional tables, **11** 913
sampling, **11** 2083
Multinomial variables
AIDS incidence, **8** 23; **12** 1317
contingency tables analysis, **9** 363–383
McNemar test, **11** 1239
Multiple...
comparisons
associations, **11** 219
disease mapping, **14** 2503–2505(L)
drugs/controls, **11** 1057
interaction tests, **7** 467
k-ratio *t* tests, **11** 863
mixture models, **7** 1031; **8** 1304–1306(L)
mortality index evaluation, **6** 71
optimal sample allocation, **15** 2523
ordered means tests, **4** 489
over-the-counter drugs, **10** 1
relative risk regression, **6** 591
repeated measures designs, **3** 185
sample size estimation, **7** 467
stochastic model, **15** 2617
survival analysis, **10** 1025
therapy efficacy evaluation, **6** 657
treatments, **14** 2509
trend tests, **4** 489
controls, **5** 29
decrement models, **15** 2307
diagnostic tests, **7** 1289; **8** 1231
doses patient compliance, **15** 659
effects model, **12** 1931
endpoints
familywise errors, **15** 1107
meta-analysis, **15** 537
multivariate tests, **14** 1163
sequential monitoring, **15** 2341
subjective rankings, **11** 427–454
exposure studies hierarchical methods, **12** 717
frailties, **13** 1679
group discrimination, **10** 757; **11** 1623–1624(L)
hypotheses, **14** 585
imputation, **9** 505; **10** 585
cystic fibrosis, **15** 449
longitudinal data, **11** 1809
threshold-crossing data, **12** 1589
time since exposure, **11** 939
imputation strategy missing data, **14** 1913
'independent' diagnostic classifications, **15** 1377
inert gas elimination, **8** 861
injuries ISS, **15** 933
linear regression model, **7** 601; **8** 217
logistic-regression parameters estimation, **12** 717
outcomes prevention trials, **13** 1479
pool sizes, **11** 1591
probands, **4** 163
range tests, **4** 489; **13** 431, 1441
raters, reliability measures, **9** 1103
ratings, **11** 317
reading, **7** 549; **11** 209
regression, **1** 49; **9** 633
Risk Factor Intervention Trial (MRFIT) smoking cessation, **12** 1605
risk factors, **4** 117; **9** 115
stage tests, **8** 757; **9** 673
test procedures dose determination, **14** 901, 909
testing
Bayesian subset analysis, **11** 13
discrete data, **11** 511
tests
clinical trials, **10** 871, 1123

Multiple... (*cont.*)
tests (*cont.*)
crossover trials, **10** 891
P-plots, **7** 1031; **8** 1304–1306(L)
power evaluation, **9** 811
quality of life analysis, **9** 819
step-down significance procedure, **10** 939
trauma, **1** 145
Multiple sclerosis disease activity, **13** 453
Multiple-inference problems hierarchical approach, **12** 717
Multiplicative bias measurement error, **12** 937
Multiplicative models, **4** 353; **6** 61; **10** 1745
breast cancer, **14** 267
exponential/logistic, **14** 821
HIV infection intensities, **13** 1865
log transformations, **14** 811
standardized parameters, **13** 989
two time scales, **13** 823
two-way tables, **13** 2407
Multiplicative overdispersion regression diagnostics, **12** 1339
Multistage models, **7** 223; **9** 677; **13** 23
Multistate models, **13** 805
discrete-time serial categorical response, **7** 965
event history data, **7** 819
likelihood analysis, **7** 149
liver transplantations, **13** 2517
survival analysis, **3** 35; **7** 661
transient state model, **6** 795
Multivariable prognostic models, **15** 361
Multivariate analysis of variance (MANOVA), **15** 2717
Multivariate data
analysis, **1** 105; **2** 259
childhood cancer, **15** 683
classification, **3** 249
clinical trials, **10** 1789; **14** 357
cluster analysis gait patterns, **2** 345
clustered binary data, **11** 1915
composite measurement scales, **14** 331
correlation significance tests, **9** 515
crossover designs analysis, **12** 69
discriminant analysis, **2** 95, 199, 229; **10** 475, 757
drug safety, **11** 1075
failure time, **13** 2223
frailty models, **14** 1447
graphical presentation, **9** 469
growth curve models, **9** 841
incomplete data, **11** 1041, 1151
laboratory determinations, **2** 259
longitudinal data, **11** 1887–1963, 2033
measurement error, **12** 1141
missing data analysis, **7** 317
multi-level models, **15** 2717
multiple endpoints, **14** 1163
non-linear models, **11** 1929
normal probabilities evaluation, **13** 431
normal range, **8** 1393
normal samples bayesian analysis, **13** 905
parameter estimation analysis, **13** 931
permutation tests, **2** 327
primary mechanism identification, **13** 719
probit analysis, **10** 1391
rate-ratio estimation, **12** 1733
reliability structures, **15** 1647
response curves, **2** 95
robust inference, **12** 1019
second-order GEEs, **15** 145
signed rank statistic, **1** 83
significance tests, **9** 515, 811
smallest detectable effect, **4** 117
spatial partitioning, **15** 1885
SPECT images analysis, **10** 1711
stratified analysis, **2** 259
Multivariate general linear model crossover design applications, **12** 69
Multivariate growth curve *see* Generalized multivariate analysis of variance
Multivariate test procedures, **12** 1125
Multiwave studies, **10** 1945
Multiway summary tables, **9** 1157
Mumps, **5** 37; **9** 953
Murder US homicide data comparisons, **8** 390
Murine tumour, **1** 83
Murphy's law, **9** 457, 1541(L)
Muscatine Study, **7** 47
Muscles
fibres, **1** 139; **7** 1157
inflammatory disorders, **7** 1157
strength score, **5** 231
Muscular dystrophy, **2** 87; **5** 231
MVK *see* Moolgavkar, Venzon...
Myocardial infarction
see also Heart disease
alcohol, **12** 2333
beta-blockers effects, **11** 141
case-control studies, **12** 993
clinical trials, **1** 337; **3** 409, 423; **8** 415; **12** 509, 521
confidence interval estimation, **10** 457
databases study, **10** 599, 637, 653
disease prevalence, **11** 295
EMIP trial, **12** 471
epidemiologic surveillance, **10** 521
hospital discharge policies, **4** 29
lidocaine intervention trial, **10** 405
multivariate probit analysis, **10** 1391
physicians' health study (US), **10** 1585
Rotterdam Study of Imminent (IMIR), **2** 199
survival predictors, **11** 125
survival trial simulation study, **12** 1365
ventricular premature beats, **11** 963
Myocarditis Treatment Trial, **9** 193

Naive estimators, **13** 1737
Naive scoring rules, **8** 609
Nasopharyngeal carcinoma, **11** 1759
National AIDS registry, **12** 2065
National Cancer Institute (NCI), **3** 305; **6** 217; **9** 871, 903
  anti-tumour drug screen, **13** 719
  Canada clinical trials group, **13** 1337
  cancer atlases, **14** 473
  phase III trials, **13** 1401
  Surveillance, Epidemiology and End Results programme, **13** 1755
National Center for Health Statistics, **8** 253, 367, 997
  health status monitoring, **12** 207
National Cooperative Gallstone Study (NCGS), **7** 139
National External Quality Assessment Scheme, **2** 123
National Health Interview Survey (NHIS), **14** 571, 669
National Health and Nutrition Examination Survey (NHANES), **7** 1087; **8** 295, 525, 997; **12** 1019
National Heart, Lung and Blood Institute (NHLBI)
  clinical trials workshop, **9** 1–199
  data monitoring, **12** 425, 433, 527
  epidemiological studies, **7** 1
  field trial design, **13** 61
  longitudinal data analysis, **7** 1
  methodology developments, **9** 881, 903
  randomized clinical trials, **6** 217
  therapy evaluation, **3** 305
National Institute of Allergy and Infectious Diseases, **12** 461, 469
  Statistical Issues in HIV/AIDS Research Symposium, **15** 2269–2491
National Institutes of Health
  budgeting, **15** 2127
  clinical trials, **9** 137, 893, 903
  Current Topics in Biostatistics 1993, **13** 399
  data monitoring survey, **12** 543, 553
  papers discussion, **13** 447, 495, 553, 603, 647, 683, 731
  statisticians, **13** 401
National Maternal and Infant Health Survey (NMIHS), **8** 387
NAUC *see* Normal area under the curve
NCHS *see* National Centre for Health Statistics
NCI *see* National Cancer Institute
Nearest neighbourhood rule, **2** 345; **7** 601
Negative binomial distribution, **6** 823; **13** 1755; **14** 1471
Negative studies, **5** 203
Negative trinomial analysis, **11** 307
Nelson-Aalen plot dependent data, **14** 1819
Neonatal study, **1** 205
  discharge record, **3** 249
  intensive care, **7** 1207
  mortality, **5** 139, 155; **12** 717
  nutrition, **6** 599
  survival analysis, **7** 1207
Neopterin HIV infection marker, **12** 2065, 2133
Nephroblastoma, **8** 593
Nephropathy, **7** 661
Nested case-control/case-cohort design comparison, **12** 1733
Network analytic methods, **13** 53
Neural channel density theory, **11** 1131
Neural network, **13** 719, 1189; **14** 73
Neuro-imaging fMRI, **15** 389
Neurodiagnostic techniques, **5** 593
Neurological assessment spinal cord injuries, **11** 1171
Neuron distributional patterns, **13** 523
Neuronal discharge sequence, **4** 91
Neurosurgery registry, **11** 345
Neurotransmitters, **7** 805
Neutralizing activity virus neutralization assays, **11** 1253
New Drug Application (NDA), **8** 883; **11** 1075
Newell, David
  biography, **14** 111
  publications, **14** 223
Newton method, **11** 923; **12** 249
Newton scoring algorithm, **15** 823
Newton-Raphson method, **10** 1453, 1693; **13** 609, 651
  bivariate data, **12** 241
  cure rate estimation, **11** 931
  last case influence, **11** 1615
  latent class model, **11** 2111
  likelihood estimates, **12** 339
  log-likelihood function, **12** 393
  longitudinal data, **11** 1915
  maximum likelihoods, **11** 115
  toxicity grades, **11** 2063
Neyman-Pearson test, **9** 201, 213, 601; **10** 757
  ACES, **12** 2367
  cost-effective trials, **14** 2249
  frequentism, **12** 1377
Neyman-Scott problem, **12** 1943
NHANES *see* National Health and Nutrit...
NHIS *see* National Health Interview Survey
NHLBI *see* National Heart...
NIAID *see* National Institute of Allergy and Infectious Diseases
NIH *see* National Institutes of Health
Nitrogen urine excretion dietary assessment, **12** 937
Nitrogen dioxide measurement, **8** 1139, 1149
Nitrous oxide pregnancy effects, **12** 867
NMIHS *see* National Maternal...
Nominal data
  contingency table models, **10** 1555
  interrater reliability, **9** 1103
Nominal dispersion departure from, **12** 1683

Nominal significance level unified group sequential tests, **13** 1815
Nomograms sample size estimation, **10** 33
Non-compliance
  clinical trials, **12** 1185; **15** 2813
  factorial design power, **8** 161
  methadone programme, **15** 2253
Non-hierarchical logistic models, **13** 153
Non-linear analysis algorithm bioassays, **12** 2025
Non-linear data
  ANCOVA model implications, **12** 101
  longitudinal, **11** 1887–1963
Non-linear mixed effects model, **15** 2107
Non-linear relationships polynomial model, **12** 101
Non-linearity
  calibration inference, **13** 1165
  regression models, **13** 2219; **14** 1191
Non-nested regression models, **11** 1321
Non-normality minimal computation algorithm, **12** 181
Non-parametric statistics, **8** 907
  AIDS intervention, **13** 2127
  area between curves, **11** 1289
  bounded outcome scores, **12** 1063
  censored data, **13** 1635
  clinical trial reports, **13** 2393
  confidence intervals, **5** 85, 653
  correlated markers, **14** 2217
  cure-rates censored survival data, **11** 931
  data analysis, **14** 811
  discriminant analysis, **11** 1023
  doubly-censored data, **13** 2081
  estimation procedures, **13** 635
  failure time estimations, **15** 2475
  gender/peak-year-specific, **12** 403
  hazard estimators, **12** 843
  hazard regression, **15** 1757
  HIV incubation distributions, **15** 197
  interval-censored failure time, **15** 1387
  intraclass correlation coefficents, **13** 2465
  lead-time estimation, **14** 2715
  linear regression model, **12** 1569
  maximum likelihood
    AIDS, **13** 2081
    Bayesian estimation model, **13** 185
    DismapWin, **15** 919
    linear rank tests, **14** 2555
    random effects models, **11** 1981
    respiratory symptoms, **13** 1771
  multiple treatment groups, **15** 2509
  paired observations, **14** 275
  recurrent complications, **14** 2701
  ROC, **15** 1199
  spatial variations, **14** 2335
  statistical power effect, **13** 769
  transfusion-related data, **13** 2043
  trend tests, **14** 445–446(L)
  two-period crossover design, **15** 117
  two-sample tests, **13** 747; **15** 429
Non-proportional hazards model, **11** 179
Non-random missing data, **14** 2675
Non-random segregation, **9** 573
Non-randomized studies, **3** 225, 341, 389
Non-response models, **7** 305, 347, 357; **11** 1009
Non-reversible diseases incidence/mortality, **12** 2395
Non-specific anti-inflammatory drugs (NSAID), **5** 449
NONMEM computer program, **11** 1777
Normal area under the curve, **13** 185
Normal distribution
  clinical chemistry ranges, **5** 335
  departure estimation, **10** 1283
  dog triglyceride data, **15** 1695
  group sequential testing, **13** 101
  order statistics study, **10** 855
  reference ranges, **10** 691
  two-sample tests type I error/power, **13** 747
North Central Cancer Treatment Group, **11** 1–53
Northwick Park Heart Study (NPHS), **2** 147
Norway
  birth defects, **15** 2029
  colon cancer model, **14** 1249
Nosocomial infections burn-care units, **12** 301
Notifiable diseases, **8** 323, 331
NPML *see* Maximum likelihood non-parametric
NSAID *see* Non-specific anti-inflammatory...
Nuclear medicine ROC curves, **8** 1277
Nuclear plants, **7** 491, 649; **14** 2309, 2383, 2459
Nuisance parameters
  bias effect, **12** 1969
  clinical pharmacology studies, **12** 645
  epidemiologic analysis, **12** 717
  incidence rate effect, **12** 3
  pair-matched studies, **12** 699
Numerical integration play the winner, **15** 2135
Numerical taxonomy, **6** 137
Nurses health survey, **7** 983; **8** 1545
Nursing homes intervention trial, **15** 1951
Nutrition
  see also Dietary assessment
  area between curves, **11** 1289
  case-control studies, **8** 1167, 1179
  confounding examination, **7** 1087
  energy expenditure, **9** 1365
  longitudinal analysis, **8** 1523
  measurement error
    analysis, **8** 1151, 1165
    confidence intervals, **8** 1051
    correction, **8** 1031, 1071; **13** 1135
    models, **15** 293
  neonatal study, **6** 599
  nutrition knowledge model, **15** 23
  variation between and within individuals, **11** 533

Nutritional anthropometry area between curves (ABC), **12** 2247–2248(L)

O'Brien test, **15** 631
O'Brien two-sample tests, **9** 447; **10** 697, 1123
O'Brien-Flemming procedure, **13** 1441
  data monitoring, **12** 2219
  P-values, **12** 675
  sample size determination, **11** 1391
  stopping rules, **11** 23, 659, 673
Observational data
  abortion study, **5** 243
  AIDS therapies, **15** 2273
  analysis, **8** 273, 279
  bias correction, **7** 417
  bioavailability studies outliers, **9** 549
  biplots, **9** 469
  blood pressure study, **7** 423
  cancer study, **6** 733; **7** 1139
  change rates analysis, **6** 599
  cluster effect, **13** 509
  cluster sampling, **8** 1537
  competing risks analysis, **6** 785
  confidence intervals estimation, **7** 773
  confounding control, **8** 679
  covariate effects, **14** 299, 2285–2288(L)
  databases uses, **5** 103
  disease prevention trials, **9** 161
  epidemiology, **7** 601
    bibliography, **10** 1819
    data plots, **8** 703
    longitudinal data, **7** 1–361
  estimation issues, **9** 657
  group sequential procedures, **8** 1191
  growth curve model, **13** 2205
  head injury study, **5** 103
  healthy responder phenomenon, **10** 1621
  heart attack patients, **8** 1401
  human growth models, **6** 185
  hypothesis tests, **6** 689; **9** 201, 213
  interobserver variation, **8** 765–766(L), 1199, 1417(L)
  kappa coeficient, **10** 1465
  limitations studies, **3** 361
  liver function models, **7** 671
  long-term survival, **15** 2763
  longitudinal analysis, **8** 1515, 1523
  lung function study, **7** 685
  marker variable bias, **15** 1747
  measurement error, **8** 893
  median failure times, **14** 275
  muscular dystrophy study, **5** 231
  non-parametric estimation, **13** 2081
  opthalmologic disorders, **8** 427
  parasitic infection dynamics, **9** 1211
  phase I clinical cancer trials, **10** 1647
  pooled study results, **9** 247
  psychiatric, **5** 243; **8** 1317
  randomized trials, **3** 347, 385, 399, 401, 405
  rank variance, **13** 2437
  regression models, **8** 525
  repeated measurements, **9** 639
  risk analysis, **9** 287
  screening effectiveness studies, **9** 969
  selection bias, **13** 557
  significance investigation, **9** 627
  smoothing methods, **7** 601
  speech sounds models, **9** 1143
  study design outcomes, **8** 455
  survival analysis, **6** 733; **9** 293
  therapy evaluation
    cancer, **3** 405
    clinical trials, **3** 399
    experimental studies, **3** 401
    Ordinal response regression methods, **8** 785
    randomization, **3** 341, 347, 385
    registry data, **3** 361
  transient state models, **6** 795
  treatment evaluation, **5** 231; **13** 1089
  two-period crossover trials, **8** 1421
  variables relative importance, **9** 633
  variance estimation, **7** 745
  ventilatory status analysis, **6** 795
Observed minus expected method, **6** 241, 265, 351
Observer agreement, **4** 47; **12** 165
Observer bias, **8** 893
Obstetric records, **6** 613
Obstetric X-raying, **7** 857
Occlusion, venous, **4** 535
Occupancy models, **12** 1773; **13** 177
Occupational...
  carcinogens, **5** 49
  disorders, **8** 173, 388, 389, 391
  hazards, **2** 363, 477
    Green Tobacco Sickness, **15** 747
    laboratory workers study, **15** 759
  health, **1** 317
  mortality
    adjustment methods, **2** 467
    Bradford Hill's contribution, **1** 317
    calculation methods, **2** 381; **4** 105–109(L)
    cohort studies, **6** 901
    comparisons, **3** 7
    healthy worker effect model, **5** 61; **6** 901
    multiple comparisons, **6** 71
    radiation exposure analysis, **8** 173
    ratios, **9** 315
Occurrence rate confidence limits, **12** 685
Odds estimation bias, **11** 953
Odds ratio
  acute otitis media, **15** 1519
  age-adjustment methods, **2** 455
  agreement data, **8** 1199
  back injury intervention trial, **15** 1951
  Bayesian analysis, **8** 1023–1024(L)

Odds ratio (*cont.*)
binary outcomes, **13** 1771; **14** 1567; **15** 1595–1600(L)
breast cancer, **15** 1545
case-base design, **8** 1241
case-control studies, **10** 1037, 1775
CER clinical trials, **13** 245
comorbidity, **14** 721
confidence interval, **7** 745, 889
confounding sample size effects, **9** 765
contingency tables, **8** 987
credible interval, **7** 1223
data reanalysis, **8** 653, 665
epidemiology bibliography, **10** 1819
equivalence trials, **8** 593; **14** 1583
error, **8** 1095
excess risk, **15** 1535
extraneous factors, **9** 1131
Fisher's exact test, **8** 1469
global odds ratio regression model, **15** 1507
graphical presentation, **7** 889
group randomization, **8** 599
group sequential trial methods, **9** 907
HIV bootstrap, **10** 1273
homogeneity tests, **10** 1257; **11** 159
inference analysis, **13** 1699
Jewell's estimators, **10** 151–153(L)
lens opacities, **15** 145
log estimation, **4** 437
logistic regression, **4** 437
McNemar test, **11** 1521
Mantel-Haenszel adjustment, **11** 603
matched-pair studies, **8** 825
matching designs, **12** 993
maximum likelihood, **4** 437; **10** 723
measurement error analysis, **8** 1151, 1165
meta-analyses, **10** 1665; **11** 2077
misclassification, **8** 1095; **10** 361, 1181; **14** 1291
misselection subsampling, **9** 1339
monitoring devices study, **10** 351
mortality analysis, **5** 61
multi-rater agreement, **11** 101
multiple reports, **8** 1041
multiple two-by-two contingency tables, **8** 1455
one-step (Peto) method, **9** 247
ordinal models, **5** 15; **10** 383; **14** 1545
paired binary data regression, **9** 1517
pooling controls, **10** 1417
pre-eclampsia studies, **15** 1237
proportional model, **8** 785
relative risk, **8** 525; **9** 287; **10** 1745
risk
adjustment methods, **10** 1753
assessment, **13** 53, 2345
prediction, **9** 385
sample size, **8** 795; **15** 1, 1065–1066(L)
seat-belt systems study, **8** 379
small sample performance, **11** 159
strata-matching studies, **9** 1475
surrogate exposure data, **14** 2581
two-by-two tables, **13** 1539
U.S. legal cases, **14** 1641
vaccine trial comparisons, **13** 1827
variance, **6** 491
within-person measurement error, **8** 1051
Oesophagitis, **7** 581
Oestriol assay, **5** 183
Oestrogen replacement therapy, **8** 679
Ohno method cluster analysis, **15** 943
Old people *see* Elderly
Oldham plot, **7** 915
Ommitted variable bias follow-up data, **11** 1195
Omnibus test, **11** 1151
One-parameter dose toxicity models cancer studies, **12** 1093
One-sample testing information requirement, **12** 753
One-sample two-sided sequential *t*-tests, **15** 2781
One-step method bias, **9** 247; **10** 749
Open top designs, **13** 1357
Ophthalmology
chi-squared adjustments, **10** 1981
childhood study, **14** 257
computerized perimetry, **11** 1131
diabetic retinopathy study, **14** 1341, 1961, 1975, 2599; **15** 1507
surrogate observations, **8** 427
Optical density serological surveys, **15** 1567
Optimal checking procedures, **11** 1343
Optimal designs
approximate, **15** 343
treatment allocation, **4** 255, 497; **5** 73; **15** 2523
Optimality
statistical surveillance, **11** 1489
two-stage phase II designs, **11** 853
Oral contraceptives, **7** 275; **10** 1025
Order statistics, **10** 855
skewness & kurtosis, **11** 333
treatment-by-centre interaction, **12** 1033
Ordered logistic regression, **8** 1317
Ordered means
trend tests, **4** 87, 489, 543–547(L); **5** 199(L)
Wilcoxon-type tests, **4** 87, 543–547(L); **5** 199(L)
Ordered response
categorical data
bivariate model, **14** 1341
global odds ratio regression model, **15** 1507
missing data, **13** 479
models, **8** 1209
random walk model, **7** 581
regression, **8** 785
repeated measurements, **10** 1959
sample size, **12** 2257; **15** 1065–1066(L)
Wilcoxon statistic, **14** 1577
combined studies, **13** 2503
interobserver variability, **13** 2437

multinomial, **7** 435
Ordered scores, **5** 15
Ordered variables discriminant analysis, **11** 1023
Ordering stochastic, **8** 571
Ordinal logistic model
case-control studies, **14** 1545
visual acuity, **14** 257
Ordinal model
classification study, **10** 383; **11** 133–134(L)
pain study, **5** 15
Ordinal random effects logit models, **12** 1969
Ordinal regression model
drop-outs, **15** 1123
goodness-of-fit test statistic, **13** 143
logistic, **13** 1665
ROC curves, **15** 1807
Ordinal response
case-control studies, **14** 1545
cluster analysis, **15** 2573
crossover trials random effects model, **12** 2147–2151(L)
exposure, **15** 2603
failure time analysis, **10** 1703
intervention trials, **14** 1177
log-linear model, **8** 571
meta-analyses, **10** 1665
non-linear models, **14** 1191
non-parametric ROC area, **15** 1199
random effects model, **10** 901
regression, **8** 785, 1317
Wilcoxon test, **15** 631
Ordinal variables
regression, **8** 1139, 1149
scales, **6** 79; **7** 109
Ordinary least squares, **9** 1303; **10** 981
see also Least squares
between-group difference, **12** 1213
carryover model, **11** 715
cross-validation performance, **11** 475
dose-response, **13** 2323
drug abuse incidence, **14** 655
generalized *t* tests, **12** 2233
heterogeneous variance, **13** 143
intra-individual variations, **13** 2280–2285(L); **14** 2283–2285(L)
longitudinal data, **11** 1981, 2001
omitted variable bias, **11** 1195
rate of change estimation, **11** 621
Organs
paired, **7** 619
weights toxicology, **1** 281; **3** 85
Oropharynx carcinoma, **8** 907; **12** 1569
Orthodontics, **4** 47
Orthogonal contast, **7** 467
Orthogonal polynomial models, **9** 841; **10** 697
Orthogonal polynomial scores (OPS) clinical pharmacology studies, **12** 633
Osteoarthrosis study
surveys, **8** 785
variation estimation method, **7** 639; **8** 765–767(L), 1416–1417(L)
Osteosarcoma
distal femoral failure, **11** 813
European Intergroup study, **12** 1501
Otitis media, **9** 237, 1495; **15** 1519
Outliers
blood pressure treatments, **7** 697
clinical chemistry, **5** 335
counts/rates models, **10** 1405
detection, **8** 285, 331; **9** 549; **10** 1375
dietary assessment, **12** 925
methods, **11** 2133
EEG readings, **10** 1719
goodness-of-fit models, **14** 1785
identification, **11** 115
interlaboratory studies, **10** 843
longitudinal data, **13** 1211
matched-pair studies, **4** 425
order statistics study, **10** 855
reference ranges, **10** 675
Ovarian cancer
chemotherapy, **12** 2305
Cox regression, **13** 2427
decision theory, **5** 411
pooling, **6** 307
publication bias, **6** 11
regression analysis, **5** 85
survival analysis, **15** 2763
Overall calibration score predictive diagnostics, **15** 2149
Overdispersion, **13** 1619
modelling, **12** 955
mortality rates, **9** 1199
prevalence estimation, **11** 1591
Overlap statistics, **14** 2343
Ovulation, **10** 221, 255
Oxford Record Linkage Score, **5** 113
Oxygen energy expenditure measures, **9** 1365

P-aminobenzoic acid (PABA) dietary assessment, **12** 937
P-values
binomial comparisons, **10** 1137
chi-squared tests, **10** 1981
clinical trials size, **9** 601
confidence intervals, **8** 803; **9** 1277
contingency tables, **10** 991
controlled clinical trials, **10** 777
crossover trials, **10** 891, 1361
databases methodology, **10** 629
hypothesis v. significance, **9** 201, 213
interim analysis, **10** 925, 949
journal developments, **10** 1897
meta-analyses, **10** 971
misuse understanding, **8** 1413–1414(L)

P-values (*cont.*)
multiple tests, **9** 811, 819; **10** 871, 939, 1123
multivariate analysis, **10** 1711
optimally selected cutpoints, **15** 103
outliers bioavailabilty studies, **10** 1375
plots, **7** 1031; **8** 1304–1306(L)
power gains, **8** 1469; **10** 1321–1322(L)
range construction, **10** 675
replication, **11** 875
stepwise regression, **10** 711
PA *see* Population-average analysis
PACS *see* Picture archiving system
Paediatric oncology observed survival rates, **12** 1353
Pain
abdominal, **5** 497; **6** 945
back, **6** 657
correlation anormalities, **10** 1315
dysfunction syndrome temperomandibular, **6** 137
facial, **6** 137
ordinal data, **3** 273; **5** 15
relief, **7** 435, 1179
Pair disagreement index, **4** 47
Pair-matched studies sample size, **12** 699
Paired availability design, **13** 2269
Paired observations, **4** 23; **7** 619, 929
censored, **11** 193
kappa statistic, **12** 2207
median failure times, **14** 275
unpaired *t*-test, **15** 1059
Paired organs, **7** 619
Paired *t*-test, **14** 1491
Pairwise associations, **15** 607
Pairwise monitoring, **13** 1441
Pakistan population data misreports, **10** 191
Palmar keratoses, **13** 1679
Pampallona and Tsiatis test, **15** 2703
Pancreatic cancer, **2** 217; **9** 829; **15** 893, 1921
Pancreatitis, alcoholic, **4** 303
Pancuronium bromide, **2** 167
PANEL computer package, **9** 559
Panel studies recursive graphical models, **14** 1265
Panencephalitis, **3** 225
PANMARK computer package, **9** 559
Parallel plots repeated measures, **11** 115
Parallel-group trial
dose determination, **14** 901, 909
efficacy, **13** 1601
Parallel-line assay, **5** 363
Parameterization polychotomous models, **11** 557–559(L)
Parametric empirical-Bayes method *see* Empirical-Bayes
Parametric model, **8** 23
Parametric tests
estimation procedures, **13** 635
statistical power effect, **13** 769
Parasitic infection dynamics, **9** 1211
Pareto distribution, **7** 483
Parkinsonism, **10** 1115; **14** 2555
Partial likelihood, **13** 2233; **15** 1033
last case influence, **11** 1615
survival-data analysis, **14** 161
Partial matching designs case-control studies, **12** 993
Partial questionnaire design, **13** 623
Partitioned ECM algorithm longitudinal data, **11** 1809
Partitioning methods, **13** 1001
binary indicants, **5** 517
chi-square comparisons, **3** 273
classification, **5** 517
clinical trial monitoring, **15** 1093
decision making, **5** 517
longitudinal data, **12** 2169; **14** 2169(L)
prospective studies, **15** 37
SPAN, **14** 2645
survival analysis, **9** 1259; **12** 975
Parvovirus B19, **15** 1567
Passive follow-up registries resultant bias, **12** 767
Patel-Hoel test, **7** 1257
Path analysis, **1** 105; **7** 185
Path specific survival, **11** 455
Patient treatments
see also Treatments
accrual, clinical trials, **5** 465
care assessment, **3** 353
community trials evaluation, **4** 11
data quality, **1** 191
monitoring methods, **5** 347
selection methods, **6** 113
Patterns
patient care, **3** 353, 359
spatial, **7** 1157
Paull-2 rule multicentre clinical trials, **12** 1047
PCP *see Pneumocystis carinii*, pneumonia
Peak expiratory flow, **8** 1339
Pearl rate, **5** 475; **10** 201
Pearson correlation, **9** 1175
clinical trial reports, **13** 2393
geographical coherence, **11** 1409
measurement consistency, **13** 2465
sample size calculations, **11** 1607
Pearson index, **15** 2689
Pearson residuals, **13** 1755
Pearson's chi-squared statistic, **13** 2289
see also Chi-squared tests
adjusted procedures, **13** 1253
association models, **10** 1555
binomial comparisons, **10** 1137
contingency tables, **9** 363–383
kappa-like statistic, **10** 767
multinomial trials, **11** 913
odds ratio homogeneity tests, **11** 159
SSPE risk estimation, **10** 1733
PEB estimators, **13** 1211

PECAN computer package, **8** 1371
PECM *see* Partitioned ECM
Pedigree analysis, **4** 163; **5** 291; **6** 629
Peer Review, **14** 873
Pelvic cancer, **13** 1459
PEM *see* Prescription event monitoring
Penalized likelihood, **13** 2427
  longitudinal studies, **14** 1205
  maximization, **11** 983
  reference centile curves, **11** 1305
  smoothing methods, **15** 907
Penalized spline HIV incidence, **15** 513
Penetrance, genetic, **4** 163; **5** 281, 291; **7** 591
Pentoarbital metabolism, **7** 471
Peptic ulcer, **5** 421
Percentage change baseline, **8** 1183; **11** 1624–1626(L)
Percentiles
  laboratory determination, **2** 191
  plots, **7** 377
Peri-stimulus time histogram, **4** 91
Perimetry principal components analysis, **11** 1131
Perinatal trials
  mortality study, **2** 229
  registry, **11** 345
Period effects, **13** 23
  crossover designs, **12** 825
  crossover trials, **14** 1025, 1053
Periodic mean model, **13** 453
Periodontal disease, **10** 1089
Peritonitis, infection rates, **9** 263
Permutation tests, **7** 795; **9** 1081; **13** 2269
  familywise errors, **15** 1107
Persantine-aspirin-reinfarction study (PARIS), **6** 255
Person-intervals survival modelling, **11** 1731
Person-time logistic regression models, **8** 525; **9** 463–464(L), 853(L)
Person-years method, **4** 105–109(L); **5** 327; **7** 205, 819; **11** 1579
Personal cholesterol risk, **8** 295
Personnel
  biostatistics budget, **15** 2127
  research staff organization, **9** 137
Pertussis vaccine studies, **9** 1327, 1447; **12** 691
PEST computer programs, **9** 1277; **15** 2781
Peters-Belson regression, **14** 1641
Peto method
  bias, **9** 247; **10** 749
  hazard ratio estimators, **11** 847–848(L)
  meta-analyses, **10** 971; **11** 141
  variance estimation, **15** 51
Peto-Peto logrank tests, **8** 937
Peto-Peto-Prentice statistic, **14** 2227
Peto-Prentice-Wilcoxon test, **11** 1871
PEV *see* Proportion of explained variation
PGF *see* Probability generating function
Pharmaceutical industry
  batch testing, **8** 883
  DMBs, **12** 555, 571
  ethical and logistical issues, **12** 471, 493
  monitoring clinical trials, **12** 471, 481, 493
  project prioritization, **15** 2689
Pharmacokinetics
  bioequivalence variables, **12** 1109
  direct formulation effect, **11** 881
  dose-response relationships, **11** 685
  measurements, **15** 1605
  non-linear models, **11** 1929
  screen, **14** 955, 969
Pharmacology studies CORMS, **11** 2037
Phase I, II, III trials *see under* Clinical trials
Phenotype classification, **3** 261
Phi coefficient, **7** 717
Photographs image grading, **8** 1433
Physicians
  clinical trials, **9** 29, 87; **10** 1585
  decision-making study, **10** 1273
  health study, **4** 111; **9** 29, 87; **12** 111
Physicians Health Study (PHS) clinical trial, **12** 111
Physiological causation simplified generalizations, **12** 1477
Physiological pulse series concomitancy tests, **12** 2043
Picture archiving system (PACS), **15** 1807
Piecewise constant
  incidence models, **13** 1881
  intensities, **13** 1189; **15** 2177
  seasonal affective disorder, **12** 1555
  time scales rate, **13** 823
  transition intensities, **13** 805
Piecewise exponential model, **6** 501; **9** 1157; **15** 171
  gestational age, **11** 1225
  sample size determination, **11** 1103
  survival analysis, **14** 2537
Piecewise linear distributions, **11** 1103; **12** 617, 2099, 2133; **15** 2289
Piecewise polynomial regression, **8** 551
Pike hazard ratio estimator, **10** 749; **11** 847(L)
Pilot studies, **9** 65, 215, 765; **13** 2455
  power estimation, **12** 1063
  sample size, **12** 1079; **14** 1933; **15** 1587
Pitman-Morgan's test, **13** 2531; **15** 2635
Pitman's test, **13** 737
Pityriasis rosea, **1** 183
Placebo effect
  asthma study, **10** 1679
  binomial proportions comparisons, **7** 1187
  bioequivalence studies, **10** 961
  clinical trials, **10** 1595, 1789
  controlled clinical trials, **10** 777
  crossover trials, **8** 487; **10** 1361
  disease indicators analysis, **10** 1061
  drug comparisons, **11** 1057

Placebo effect (*cont.*)
drug efficacy estimation study, **10** 45
efficacy prediction, **9** 253
factorial ANOVA design, **10** 1565
Fisher's game, **13** 217
interim analysis, **10** 925
multiple comparison clinical tests, **10** 1
physicians' health study (US), **10** 1585
provisional diagnoses, **10** 1341
regression analysis, **2** 417; **6** 113; **7** 1203(L); **8** 1301–1302(L)
response phenomenon, **10** 1621
treatment allocation, **14** 2661; **15** 113–116(L)
treatment comparisons, **8** 487
Placental weight, **1** 105
Planning
AIDS health care, **8** 137
research, **1** 5; **3** 1, 315; **14** 1683
Plaque regrowth, **4** 145
Plasma exchange, **6** 795
Plasma lipid levels longitudinal data, **11** 2033
Platelet transfusions efficacy factors, **11** 2123
Play the winner
phase II/III clinical trials, **15** 2413, 2455
power, **15** 2135
Plots. . .
index, **7** 629
Lineweaver-Burk, **7** 805
Oldham, **7** 915
percentile, **7** 337
radial, **7** 889
Plutonium exposure, **7** 491
PMR *see* Proportional mortality ratio
Pneumoconiosis, **3** 73; **7** 955
Pneumocystis carinii
pneumonia (PCP) trials, **15** 2307, 2341, 2445
prophylaxis, **13** 2127
Pneumoencephalography, **5** 593
Pneumonia, **7** 1045; **12** 1915
Pock counts variability study, **9** 615
Pocock procedure, **10** 949; **13** 1441
data monitoring, **12** 2219
group sequential boundary, **11** 23
P-values, **12** 675
sample size determination, **11** 1391
stopping rules, **11** 659, 673
Point estimations, **9** 1167; **10** 797–799(L), 1157–1159(L); **13** 1211
AIDS incidence, **14** 1505
competing risks analysis, **15** 1557
multiple treatment groups, **15** 2509
population size with duplicates, **15** 1635
survival-data analysis, **14** 161
Point exposure studies confounding, **8** 679
Point-event data pollution, **12** 1249
Poisoning Green Tobacco Sickness, **15** 747
Poisson approximation prospective relative risk analysis, **12** 691
Poisson cusum gamma-method alternative, **12** 13
Poisson distribution
adverse drug reactions, **12** 2383
AIDS study, **9** 1387
cancer cohort models, **10** 1241
cell distributional patterns, **13** 523
change-point tests, **7** 387; **10** 1159–1160(L)
confidence intervals, **10** 457; **12** 685; **13** 2189
contingency tables, **10** 991
counts/rates models, **10** 1405
death process, **4** 201
drug reaction, **7** 1023
epidemiology, **9** 691, 1387
heterogeneity tests, **7** 1121
historical data analysis process, **7** 819
HIV incidence, **13** 1945, 2009
hypothesis testing, **6** 689; **8** 517–519(L)
incidence predictions, **13** 1513
limited dilution cloning, **9** 457, 1541(L)
morbidity estimation process, **7** 325
multiple comparison tests, **8** 757
Murphy's law, **9** 1541(L)
postmarketing surveillance, **7** 1023
rate difference model, **12** 2285
relative risk function, **10** 1745
scan statistic process, **6** 197
short memory scheme, **8** 311
significance tests, **8** 757
SSPE risk estimation, **10** 1733
surveillance data, **8** 311, 331
survival analysis, **7** 1121
time series, **13** 453
time-dependent variables, **6** 689; **8** 517–519(L)
two-treatment crossover design, **12** 825
variability, **13** 873–876(L)
Poisson log-linear model, **15** 305
Poisson maximum test
cluster analysis, **14** 2309
leukaemia mapping, **14** 2459
Poisson model
disease incidence, **12** 3
HIV seroconversion, **12** 153
mortality rates, **12** 393
psychotherapy studies, **11** 231
recurrent acute diseases, **12** 339
residual confounding, **11** 1747
ROC curve, **12** 1293
Poisson point process model, **14** 2335
Poisson regression model
see also Extra-Poisson. . .; Regression, Poisson
abortion data analysis, **8** 285
age-period-cohort model, **5** 527
AIDS incidence, **8** 3, 23
blood pressure, **9** 1157
cancer study, **5** 527; **7** 223
case-control studies, **10** 739
childhood cancer, **14** 2487; **15** 683
CIN/HPV, **13** 379

confidence intervals, **15** 2379
contraceptives, **10** 241
covariate modification, **13** 2407
Cox proportional hazards, **9** 1157
epidemiology, **7** 223; **10** 1819
logistic regression comparisons, **9** 853(L)
lung cancer, **7** 223; **15** 1397
measurement error, **8** 1075
peritonitis rates analysis, **9** 263
recurrent events, **14** 2081
relapsing-remitting disease counts, **13** 453
risk ratio/rate ratio estimation, **12** 1733
risks
LRI risk in children, **13** 343
smoking effects, **7** 223, 289
small area prevalence, **15** 1867
standardized rate estimators, **10** 1069
surveillance data, **8** 285, 331
survival models, **12** 1019
tumour recurrence rates, **8** 1363
Poisson-gamma regression method longitudinal interval count data, **12** 1339
Poisson-piecewise splines HIV seroconversion, **12** 153
Police records data, **8** 390
Polio, vaccine trial, **9** 13; **13** 1827
Pollution
environmental, **7** 491
exposure assessment errors, **8** 1109, 1127, 1133, 1137
extraction mapping, **12** 1249
measurement-error model, **8** 1139, 1149
respiratory diseases, **15** 823
Stone's method, **15** 1927
Poly-3 test multiple tumour data, **15** 1217
Polychotomous logistic regression, **5** 49; **10** 375, 757; **11** 557–559(L), 1915
Polygon-based maps, **12** 1953
Polymyositis, **7** 1157
Polynomial model, **13** 2205
age effect on cancer, **13** 23
birthweight centile curves, **15** 2657
longitudinal data, **15** 61
parameter estimation analysis, **13** 931
smoothing procedures, **14** 1235
survivorship curve, **7** 895
Polynomial regression, **8** 551
Polyp, recurrence, **4** 117
Pool-adjacent-violators algorithm, **12** 1989
Pooling
clinical trials, **6** 565; **7** 889, 1109
HIV incidence estimation, **13** 1865, 1905
logistic regression, **9** 1501
meta-analyses, **6** 11, 773
non-randomized studies, **7** 1207
prevalence estimation, **11** 1591
randomized trials workshop, **6** 217–410
safety profiles, **14** 1099, 1113
two-by-two tables, **14** 2037
untreated risk sets, **13** 1089
Popperian philosophy, **11** 1263–1265(L)
Popper's theories, **10** 1679
Population at risk (PAR), **11** 1533; **12** 1915; **15** 1713
Population attributable risk *see* Attributable risk
Population averaged models
categorical data, **11** 67
longitudinal data, **11** 1825, 1929
Population health statistics, **15** 1895
Population-average analysis, **13** 509; **14** 413
association models, **15** 1227–1229(L)
cumulative logit model, **15** 2573
marginal probabilities, **12** 1969
Populations
AIDS epidemiology, **8** 121; **9** 1387
Bayesian hierarchical models, **14** 971
bias misreports Pakistan, **10** 191
bioequivalence studies, **10** 959; **11** 1777; **12** 1109
biopharmaceutical research, **10** 811
cancer cohort models, **10** 1241
case-base studies, **8** 1241
case-control studies, **10** 653, 1257
centile curve calculation, **10** 1693
clinical trials
estimations, **9** 657
guidelines, **14** 1655, 1659
CMS construction, **14** 331
confidence intervals, **3** 287; **10** 717
contingency tables, **10** 991
crossover trials, **10** 909, 1361
databases bias, **10** 577
DEMP, **15** 1837
density Moran's *I* statistic, **14** 17; **15** 1591–1594(L)
developing countries studies, **9** 35
dose ranging simulation, **10** 303
drug safety analysis, **14** 1113, 1117
elderly analysis, **10** 831, 1453
factorial ANOVA design, **10** 1565
fertility determinants Africa, **10** 161
finite correction factor, **4** 237–242(L)
finite mixtures theory, **9** 397
generalized linear models, **10** 1069
geographical density estimates, **9** 691
heart disease mortality rates, **9** 1199
HIV
infection probabilities, **8** 83
Norway study, **10** 1003
transmission model, **9** 721
laboratory data, **10** 839
LFP model, **9** 409
logistic regression, **10** 1213
misclassification, **10** 1181
misselection subsampling, **9** 1339
mixed multi-normal distributions, **9** 301

Populations (*cont.*)
mixing model studies, **8** 59
mortality study, **10** 1043
multiple frame methodology, **10** 113
multiple group discrimination, **10** 757
multivariate probit analysis, **10** 1391
normality departure estimation, **10** 1283
observational data, **8** 273
odds ratios bootstrap, **10** 1273
pooling controls, **10** 1417
power station employees, **2** 477
practice databases, **10** 541
prevalence
confidence limits, **12** 685
incomplete lists, **10** 113
proportionate mortality ratio, **9** 315
radiation exposure, **8** 173
reference ranges, **10** 691
relative risk estimation, **10** 1745
repeated events analysis, **10** 1227
risk
adjustment methods, **10** 1753
prediction factors, **9** 385
sample size estimation, **10** 33, 1993
size estimation with duplicates, **15** 1635
survival analysis, **9** 529
time series analysis diseases, **10** 1481
US homicide data comparison, **8** 390
vaccine efficacy estimation, **10** 1573
variables relative importance, **9** 633
Positive predictive value anonymous record linkage, **14** 499
Post-marketing surveillance alert systems, **12** 2383
Post-neonatal mortality, **5** 155
Post-treatment means repeated measures, **11** 1685
Postal questionnaires, **5** 607; **6** 613
Posterior analysis Bayesian method, **9** 1091
Posterior distribution
Bayesian analysis, **13** 823, 1699; **14** 971, 1057, 1065, 2173
bivariate survival data, **14** 2523
CD4-lymphocyte count, **13** 231
conditional, **13** 905, 1841
dynamic simulation algorithm, **13** 839
group sequential trials, **14** 381
hazard regression, **15** 1757
interest proof, **13** 905
iodine thyroid uptake, **13** 185
lung cancer trial, **13** 1313
marginal tie probabilities, **13** 839
mixture survival model, **15** 2077
toxicity study, **13** 2311
treatment effectiveness, **12** 1651
Postmarket surveillance, **7** 1023
Potentiation, **4** 77; **13** 2289
Poverty health risk, **15** 1885, 1921
Power
see also Clinical trials
aggregate data studies, **15** 1849
ANCOVA, **15** 477
ANOVA interaction test, **7** 467
association models, **14** 413
asymptotic test, **15** 647
baseline change measurements, **8** 1183
batch shelf-life tests, **8** 883
bioequivalence studies, **10** 959, 961; **14** 853
bounded outcome scores, **12** 1063
case-control studies
allocation designs, **5** 319
cohort comparisons, **10** 1775
definition, **3** 27
exposure factors, **7** 363
lung cancer analysis, **4** 117
multiple controls efficiency, **5** 29
sample size estimation, **6** 53; **7** 363
vaccine efficacy estimation, **7** 1279
censoring models, **7** 337, 357
change detection, **9** 437
CIN/HPV, **13** 379
clinical trial reports, **13** 2393
cluster analysis, **12** 1763; **14** 2309, 2323
cluster randomization, **7** 1195
cohort studies
allocation designs, **5** 319
case-control comparisons, **10** 1775
odds ratio estimation, **7** 759
relative risk estimation, **7** 759
vaccine efficacy, **7** 1279
community interventions, **14** 1491
conditional, **13** 663, 683
confidence intervals, **14** 873; **15** 2379
correlated binary responses, **15** 1187
covariate
imbalance tests, **9** 1455
measurement errors, **8** 1167, 1179
crossover trials
carryover effects, **8** 633(L)
phase III, **14** 1025, 1053
residual effects, **10** 891
treatments comparison, **8** 487
two-stage analysis, **8** 1421; **10** 489–491(L)
curves
osteosarcoma study, **12** 1501
sample size formulae, **11** 1091
diagnostic tests, **6** 147; **8** 609, 1381
discriminatory, **7** 519
disease cluster tests, **15** 783
disease monitoring methodology, **10** 1089
dose-response models, **14** 531, 1595
drug combination tests, **8** 1479
early treatment termination, **9** 1417
equivalence tests, **14** 1583; **15** 2703
exact computation, **13** 1539; **14** 2261
exponential survival model, **13** 391
factorial designs, **8** 161
familywise errors, **15** 1107

fertility prediction, **14** 1807
Fisher's exact test, **8** 1469; **10** 1321–1322(L)
focused clustering studies, **15** 765
focused tests, **14** 2291
follow-up treatment comparisons, **13** 859
formulae, **15** 1
GEEs, **15** 1951
generalized t & rank-sum statistics, **11** 491
generalized Wilcoxon test, **6** 483
group sequential tests, **8** 505; **9** 1081
group sequential trials, **14** 381
historical control study, **10** 839
independence testing, **10** 1555
intentionally incomplete data, **11** 1889
interim analysis, **10** 949
inverse sampling, **15** 671
k-sample tests, **14** 863
kappa statistic, **14** 347
logistic regression, **8** 795
logrank test, **1** 121; **5** 97–98(L); **6** 483, 577
longitudinal trials, **14** 2239
loss survival endpoints design, **13** 1453
McNemar test, **11** 1239
missing data, **14** 2675
monitoring clinical trials, **9** 1081
Moran's *I* statistic, **14** 17; **15** 1591–1594(L)
multiple tests, **9** 811; **10** 871, 1123; **14** 901, 909
multiple treatments comparisons, **14** 2509
multivariate tests, **14** 1163
negative studies, **5** 203
non-linear regression, **10** 697
normality departure estimation, **10** 1283
odds ratio, **7** 759; **8** 1455
optimal cutpoint selection, **15** 2203
penalized likelihood, **15** 907
phase II clinical trials, **5** 441; **10** 989
physicians' health study (US), **10** 1585
pilot studies clinical trials, **9** 65
play the winner strategy, **15** 2135
prediction rules error rates, **9** 1303
prevention trials, **13** 1807
probability imputation technique, **9** 777
prognostic variables, **9** 487; **10** 647
provisional diagnoses, **10** 1341
qualitative interactions, **12** 1239
random effects model, **14** 395
randomized play the winner, **15** 2413
randomized trials, **14** 2081
regression models, **13** 1023
relative risk estimation, **7** 759
reliability studies, **6** 441, 647
repeated measures, **5** 663; **11** 1685
runs test, **7** 795
sample size
  confidence intervals, **8** 803
  determination, **14** 1933, 2273
  drug development, **12** 1501
  logistic regression, **8** 795
  logrank test, **1** 121; **5** 97–99(L)
  ordered categorical data, **12** 2257
score test, **13** 79; **15** 1049
SCPRT, **15** 2037
sequential clinical trials, **9** 229, 595
shared haplotypes test, **5** 281
space-time interaction tests, **15** 1935
spatial patterns assessment, **12** 1885
spectra, **6** 159
stratified summary statistics, **13** 1853
stratified trials, **14** 2037
surveillance systems, **8** 311
survival data tests, **8** 937
t-tests, **6** 577; **12** 2233
testing proportions two sided small sample tests, **12** 777
time-dependent events, **6** 689
treatment comparisons, **15** 1489
two-group trials, **15** 2523
two-stage clinical trials, **15** 1739
unified procedure, **13** 1815
unpaired *t*-test, **15** 1059
vaccine efficacy, **7** 1279
Wilcoxon test, **14** 1577; **15** 631
Power station employees, **2** 477
PPS *see* Prospective Payment System
PQD *see* Partial questionnaire design
Practice databases, **10** 541
Pragmatic trials missing data, **11** 2043
Pratt's method confidence intervals, **12** 809
Pre-assessment clinical trials prospects, **5** 669
Pre-coding, forms, **5** 607
Pre-eclampsia studies, **15** 619, 1237, 1263
Precision
  incidence predictions, **13** 1513
  intra-assay profile, **13** 1165
  measurement error, **8** 893
  sample size requirements, **13** 2369
Preclinical studies, **6** 885; **15** 2371, 2751
Prediction
  accuracy non-parametric ROC area, **15** 1199
  AIDS incidence, **8** 3, 1509; **10** 1527
  bias, **7** 843
  binary outcomes, **13** 1501
  biochemical mechanism of action, **13** 719
  blood pressure measurements, **15** 2013
  bootstrap investigation, **8** 771
  cancer incidence, **13** 1513
  CART analysis technique, **8** 947
  causal models, **12** 2315
  chemosensitivity assay, **4** 527
  clinical trials, **5** 1, 421; **10** 1789
  clustering variable, **3** 143
  cross-validation performance, **11** 475
  diagnostic tests
    bias effect, **4** 53; **6** 411
    equality tests, **4** 535
    graphical presentation, **5** 585

Prediction (*cont.*)
latent class analysis, **5** 21
multiple reading procedures, **7** 549
P-value misuse, **8** 1413–1414(L)
sensitivity concepts, **7** 1289
diagnostic tests (*cont.*)
specificity concepts, **7** 1289
drug concentration trial, **8** 1327
equations repeated measures, **10** 119
error rate estimations, **9** 1303
growth curve models, **13** 2205
HIV, **8** 45; **13** 1933
interim analysis, **10** 925
intervals, **2** 485; **7** 773
limits AIDS projections, **11** 1425
logistic models, **15** 2149
logistic regression, **9** 385, 1091; **10** 1213
multivariable prognostic models, **15** 361
neural nets, **13** 1189
primary biliary cirrhosis, **13** 301
prognostic scoring sensitivity, **9** 1189
risk SIDS study, **5** 113
rule, **7** 843
SCD susceptibility, **13** 1015
short-term survival, **11** 1731
survival data, **2** 485; **9** 487
therapy evaluation, **10** 647
time series analysis, **8** 1497
treatment efficacy, **9** 253
unobserved results, **13** 1313
values naive estimators, **13** 1737
visual fields model, **15** 1349
Predictors *see* Covariates
Preference trial, **15** 443
Prefix method random digit dialling surveys, **11** 1009
Pregnancy
alcohol consumption/birth defect study, **15** 2095
bias sources, **13** 671
birthweight centile curves, **15** 2657
birthweight prediction, **14** 2645
calcium supplementation, **15** 1237, 1263
estimated gestational age, **11** 1225
fertility determinants, **10** 161
HIV transmission, **15** 2413
hormone concentration model, **14** 185
low birthweight prediction, **15** 37
pre-eclampsia, **15** 619
rate, **5** 475
retrospective time-to-event studies, **12** 867
termination, **5** 243
time-dependent disease risk, **15** 1545
tocolysis, **11** 2077
weight gain study, **9** 539
Preliminary-test estimates multiple exposure studies, **12** 717
Premedication, **5** 363
Prenatal studies
blood lead levels, **11** 799
infection, **2** 1
nutrition, **1** 105
Prentice-Wilcoxon test, **8** 937; **11** 193
Preoperative tests, **6** 813
Pre-randomization, clinical trials, **9** 645
Prescott method order statistics study, **10** 855
Prescription drugs, **6** 863; **7** 1171
Prescription event monitoring (PEM), **15** 987
Presentation
see also Graphical presentation
clinical trials, **14** 1655, 1659
unmatched case-control data, **11** 1789–1790(L)
Preterm infants, **2** 167
Prevalence
age-specific, **5** 573; **13** 2369
attributable fractions, **13** 2345
Bayesian methods, **11** 1621–1622(L); **15** 2161
cancer, **8** 201, 743; **11** 1579
case-control study, **5** 127
counts piecewise model, **13** 805
diseases, **5** 127, 585; **6** 961; **8** 1225
generalized linear models, **11** 1591
HIV sexual behaviour, **15** 2323
non-rare disease, **15** 1867
non-reversible diseases, **12** 2395
pneumoconiosis study, **13** 1665
rate CIN/HPV, **13** 379
stratum specific, **13** 1071
studies selection bias, **13** 557
Prevalent cohorts
risk estimates, **12** 843
time since exposure, **11** 939
Prevented fraction, **7** 1073; **14** 51
Prevention
cancer agents, **5** 435
clinical trials, **7** 275; **9** 29, 35, 55, 87, 161
cancer, **13** 1423
early stopping, **13** 1479
efficacy measure, **13** 1807
heart disease, **11** 295
HIV models, **8** 59
psychopathology/delinquency/drug use, **12** 289
Statistical Methods for Evaluation of (symposium), **12** 191–414
strategies NCHS role, **12** 207
tobacco/drug use, **12** 365
Primary biliary cirrhosis short term survival prediction, **11** 1731
Principal components analysis, **11** 1131; **13** 719, 1501; **15** 1885
cancer mortality rates, **12** 1931
correspondence analysis, **7** 983; **8** 1545–1547(L)
drug efficacy assessment, **8** 1393
Framingham heart study, **14** 1757
logistic models, **7** 983; **8** 1545–1547(L)

menstruation bleeding patterns, **10** 267
regression models, **3** 143, 293
survey analysis, **7** 983; **8** 1545–1547(L)
Principle curves algorithm, **13** 1101
Prior belief treatment effectiveness, **12** 1651
Prior distribution
Bayes theorem junctures, **13** 201
Bayesian hierarchical models, **14** 2173
Bayesian meta-analysis, **14** 2685
Bayesian monitoring scheme, **13** 1371, 1385; **14** 1379
Bayesian predictive values, **15** 463
CHART cancer trials, **13** 1297
CRM, **14** 911, 923
dose determination, **14** 885, 897
exponential CD4 lymphocyte count, **13** 231
HIV incidence, **15** 513
HIV infection time, **13** 1101
hospital survival odds, **13** 889
iodine thyroid uptake, **13** 185
lung cancer trial, **13** 1313
model inference, **13** 1525
robust Bayesian monitoring, **15** 1093
space-time disease patterns, **14** 2433
suppressor gene, **13** 839
toxicity studies, **13** 2311
uniform, **13** 1699
Prior information event rate equivalence trials sample sizes, **12** 2009
Probabilistic causation determinism, **12** 1477
Probabilities
combining, **6** 265, 341, 381, 387
databases study model, **10** 637
generating function, **9** 573
imputation technique, **9** 777
rejection curves, **10** 961
subjective, **5** 421
understanding, **6** 3, 535
Probability architecture pharmaceutical project prioritization, **15** 2689
Proband studies, **4** 163; **11** 1767
Probit model
ANCOVA, **8** 1075
attrition bias, **12** 1005
Bayesian methods, **11** 1377
binomial comparisons, **7** 1187
design effects, **12** 1259
longitudinal data, **11** 1861
measurement error
confidence intervals, **8** 1051
generalized linear model, **8** 1075
logistic regression, **8** 1051
non-differential exposure, **8** 1031, 1071
regression, **8** 1139, 1149
relative risk correction, **8** 1051
multivariate, **10** 1391
placebo effects, **7** 1187
relative risk correction, **8** 1501
PROC IML computer package, **11** 1151
PROC MATRIX computer package, **9** 397
Proceedings *see* Special issues
Process
change-point, **7** 387; **10** 1159–1160(L)
counting, **5** 243, 327, 491; **7** 275, 819
jump, **7** 325
Markov, **5** 243; **6** 795; **7** 581, 661, 787
Poisson, **6** 197; **7** 325, 819
Product models
dental study, **7** 403
diagnostic reliability assessment, **7** 403
Progesterone assay, **2** 123, 141
Prognostic factors
absolute risk, **10** 1025
association measurement, **8** 619
balanced allocation methods, **9** 237
binary outcome data, **7** 975
breast cancer study, **3** 333
clinical trials, **10** 797–799(L), 1157–1159(L)
computer aids, **5** 403
confounding control, **8** 679
database uses, **3** 333, 375
diagnostic variables, **9** 273
differential influence, **11** 281
disease natural history, **8** 1255
exponential survival trees, **8** 947
GENSTAT analysis, **2** 223
leukaemia surveillance, **4** 39
liver function tests, **7** 843
lung cancer study, **4** 279
melanoma surveillance, **2** 295; **4** 265
missing covariate values, **9** 777
myocardial infarction, **4** 29
observational data, **3** 361, 375
optimally selected cutpoints, **15** 103
prediction models, **3** 143
randomized clinical trials, **12** 2351
registry data, **3** 361
regression, **3** 143; **8** 539, 551
renal disease, **5** 637
sample size calculations, **12** 2257
scoring systems, **9** 1189
smoking variate, **8** 997
staging systems, **5** 465
survival analysis, **5** 637; **6** 773; **9** 487; **12** 2377
therapy evaluation, **3** 333, 361, 375, 421; **10** 647
treatment comparisons, **3** 361
tumour size effects, **9** 999
variance components study, **10** 599
Prognostic index, **9** 1303; **10** 733, 1931; **14** 161, 1999
Progression markers
HIV to AIDS, **12** 2061, 2065
time-dependent covariates, **12** 2087
Progressive disease, **7** 403
Projections, **13** 1755
AIDS, **8** 23, 103; **9** 1387; **10** 1527; **11** 1425

Projections (*cont.*)
HIV, **10** 1427
map, **7** 491
Prolactin assay, **5** 183
Proliferative index, **13** 1619
Promiscuity, HIV infection probability, **8** 83
Propensity score, **11** 2043; **13** 1089
Prophylactic Penicillin Study (PROPS), **9** 45, 103, 155
Prophylaxis, **3** 341
HIV vaccine, **13** 357
measles incubation period, **11** 579
Proportion of explained variation
logistic regression, **15** 1987
prognostic factors, **12** 2377
survival analysis, **15** 1999
Proportional change, **6** 113
Proportional hazards model
see also Cox proportional. . .
Bayesian statistics, **11** 23
cause-specific hazards, **11** 813
collinearity diagnosis, **11** 1273
cummulative hazard functions, **11** 1465
HIV seroconversion times, **12** 2087
lung cancer data, **12** 1683
sample size, **11** 179, 1103
short-term survival prediction, **11** 1731
two-stage design, **11** 5
Proportional mortality ratio, **2** 455, 467; **3** 7; **5** 61; **6** 71; **9** 315
Proportional odds model
categorical data, **7** 95, 109; **8** 785; **12** 2147–2151(L); **13** 2503
random effects, **10** 901
sample size calculations, **12** 2257
survival data, **2** 273
Proportional probability model, **12** 867; **13** 671
Proportional regression model, **14** 1249
Proportions
see also Ratios
binomial comparisons, **10** 1137
combining, **6** 565
comparison, **4** 541; **5** 261; **7** 457, 929, 1187
confidence intervals, **4** 23, 213; **7** 865
contingency tables, **5** 629; **8** 243–245(L)
correlations, **4** 23; **7** 929
Fisher's exact test, **5** 629; **8** 243–245(L)
Goodman and Kruskal statistic, **8** 619
sample bias, **8** 563
stratification, **4** 213
PROPS *see* Prophylactic Penicillin Study
Prospective Payment System, **13** 889
Prospective studies
allocation designs, **5** 319
Bayesian analysis, **4** 509
censoring distribution, **5** 255
correspondence analysis, **4** 303
life-tables analysis, **4** 155; **5** 475
logistic regression model, **3** 15; **4** 227
mortality ratios comparisons, **4** 295
pooling methods, **5** 303
prognostic factors, **5** 637
relative risk, **12** 691
sensitivity/specificity, **11** 1503
survival analysis, **5** 255, 637
tree-based analysis, **15** 37
Prostate cancer, **4** 255; **5** 73; **11** 345, 813, 2093
chance-correlated agreement measures, **12** 2191
graphical data, **15** 2539
multivariable prognostic model, **15** 361
play the winner, **15** 2413
ROC curves, **15** 1687
screening, **9** 55, 325
threshold-crossing data, **12** 1589
Prostate disorders, **13** 587, 603; **14** 73
Prostate specific antigen (PSA) assay threshold-crossing data, **12** 1589
Prostatectomy crude incidence curves, **11** 813
Proteins
creatinine ratio, **8** 1485
energy malnutrition, **11** 1289
intake variation, **11** 533
iron-bonding, **4** 425
Proteinuria, **8** 1485
Proximity measures, **15** 873
PSA *see* Prostate specific antigen
Pseudo non-linear mixed-effects model, **11** 1929
Pseudo-likelihood
case-base designs, **12** 1733
ratio test, **14** 1621
score equations, **13** 651
two-stage studies, **11** 769
variance function estimation, **13** 1165
Pseudo-maximum likelihood estimators (PMLE), **11** 1861; **12** 2285
Psoriasis, **7** 443
Psychiatry
admissions, **5** 243
clinical trials, **14** 1913
dementia study, **8** 1317
efficacy prediction, **9** 253
stochastic progression, **11** 231
time series regression relationships, **12** 1555
Psychoimmunologic studies repeated measures, **11** 2035
Psychometric properties CMS construction, **14** 331
Psychopharmacological research dose-response relationships, **11** 685
Public health surveillance
ARIMA model, **8** 1497
cancer mortality rates, **10** 95
chronic disease control, **14** 629
cluster randomization, **11** 307
commentary, **8** 279
correlated samples, **11** 1551

developing countries clinical trials, **9** 35
geographic information system, **14** 481
GIS, **15** 1921, 1961
GISSI clinical trial methodology, **9** 17
hazardous exposure estimation, **10** 79
health-care databases, **10** 585
HIV, **9** 721; **12** 2061, 2065, 2087, 2099, 2127; **13** 1933
incidence aberrations, **8** 323, 331
intravenous drug users, **10** 423
missing data, **8** 263, 279
NMIHS 1988 survey, **8** 387
observational data, **8** 273, 279
Poisson regression model, **8** 285
polio vaccine trial efficiency, **9** 13
prediction equations estimation, **10** 119
prevalence incomplete lists, **10** 113
reporting delays, **8** 259, 279
respiratory diseases, **10** 1481
Salmonella alert threshold, **10** 1493
sampling design, **10** 1945
screening effectiveness studies, **9** 969
small area analysis, **15** 1859
spatial data, **8** 267, 279
spina bifida study, **10** 717
statistical issues, **8** 259–279
survival analysis, **9** 529; **10** 413
time series analysis, **8** 343
vaccine efficacy estimation, **10** 1573
Publication bias
clinical trials review, **10** 1789
diagnostic methods review, **10** 1887
interpretation aid, **4** 1
meta-analyses, **6** 11, 315, 333, 733
randomized trials, **6** 221, 229, 327, 333
stopping rules effects, **6** 361; **7** 1231
survival analysis, **7** 1207
unpublished papers estimation, **15** 2493
variability study, **6** 733
Publications, **14** 223
see also Book reviews; Publication bias
assessibility study, **13** 2393
citations information analysis, **13** 3
Pulmonary function
analytic methods comparisons, **7** 19
autoregressive models, **4** 457; **7** 59
change rates analysis, **7** 337
clinical trials, **8** 1183
cross-sectional data, **7** 685
disease cluster analysis, **6** 491
longitudinal data, **7** 685; **8** 189
marginal distribution models, **7** 139
measurement error
exposure study, **8** 1109, 1127, 1133, 1137
regression models, **8** 1139, 1149
prognostic factors, **7** 11
repeated measurements, **7** 11, 19, 29, 139
smoothing methods, **7** 601
Pulsatile hormone time series outlier detection methods, **11** 2133
Punctual Kriging, **15** 1907
Pushback procedure treatment-by-centre interaction, **12** 1033

Q-TWiST *see* Quality adjusted time without symptoms and toxicity
QAS *see* Quality adjusted survival
QOL *see* Quality of life
Quadrat analysis software, **15** 939
Qualitative interactions
clinical trials, **4** 111, 255; **7** 1257
power, **12** 1239
randomized trials, **6** 329, 351, 359, 371, 387
Quality adjusted survival (QAS), **12** 975
Quality adjusted time without symptoms and toxicity (Q-TWiST) breast cancer study, **12** 975; **14** 1771
Quality control
accuracy assessment, **2** 141
data, **3** 101, 423, 469
factorial designs, **4** 369
internal factors, **2** 123; **6** 425
laboratory data analysis, **2** 147
optimal checking procedures, **11** 1343
pharmaceutical industry, **12** 1999
programme Dutch, **2** 131
statistical surveillance, **11** 1489
Quality factors, **8** 367
assurance methods, **9** 115
clinical trials data, **7** 1165
data systems, **8** 367
intensive care units, **14** 2161
patient data, **1** 191; **3** 353
Quality of life
cancer clinical trials, **2** 429; **9** 749; **14** 1771
change measurement, **9** 931
clinical decision analysis, **9** 1229
clinical trials overview, **10** 1915
composite measurement scales, **14** 331
global statistics methods, **9** 819
hazardous exposure estimation, **10** 79
multi-level models, **15** 2717
Q-TWiST, **12** 975
quality adjusted survival, **15** 93
stroke patients, **12** 1063
subjective rankings, **11** 427–454
surveys, **8** 1401
survival analysis, **9** 1259; **10** 413
Quangle cusum charts, **6** 425
Quantal responses, **4** 77
Quantile-quantile plots Mahalanobis distances, **12** 1665
Quantiles
epidemiological indices, **14** 1291
prediction intervals, **2** 485

Quantitative interactions
clinical trials, **4** 111, 255; **7** 1257
diagnostic marker, **13** 1551
diagnostic tests, **15** 1575
randomized trials, **6** 329, 359, 371, 387
Quartile confidence limits, **8** 1269
Quasi *t*-quantile approximations, **13** 1657
Quasi-binomial distribution I, **15** 837
Quasi-exact test binomial comparisons, **10** 1137
Quasi-likelihood
error linear models, **10** 1197
mortality rates, **15** 1397
robust covariance estimator, **12** 1339
Quasi-symmetry
speech sounds model, **9** 1143
subject-specific, **12** 1969
Questionnaires
CHART cancer trials, **13** 1297
design, **5** 607; **6** 613
dietary studies, **12** 925; **13** 127
postal, **6** 613
sexual partners, **15** 221

Rabies cluster analysis, **15** 783
RAC *see* Research Application Conference
Radial plots, **7** 889; **10** 1665; **13** 2503
Radiation
chest radiographs, **3** 73; **7** 955
combined effects, **14** 1941
density equalized map projections, **7** 491
environmental risk investigation, **7** 649
exposure, **5** 539
mammographic exposure risks, **1** 15
occupational exposure, **8** 173
therapy
cancer control efficacy, **8** 1371
care study patterns, **3** 353
cervical cancer treatments, **6** 785
competing risks analysis, **6** 785
variation, radiological assessment, **7** 639; **8** 765–767(L), 1416–1417(L)
Radio-immunoassays robust non-linear analysis algorithm, **12** 2025
Radiotherapy breast cancer crude incidence curves, **11** 813
Random agreement, **7** 639
Random calibration, **12** 1589
Random coefficient models, **7** 697; **11** 1929; **12** 893; **13** 1211, 2205
Random components, **13** 1001
Random effects models
analysis of variance, **4** 145
assay variation estimation, **10** 1543
Bayesian methods, **10** 811, 1241; **12** 2179
CD4 lymphocyte counts, **15** 2289, 2337
clinical trials, **8** 141; **9** 657
correlation estimation, **9** 1175
dynamic nutrient intake, **13** 113
epilepsy study, **8** 1327
foetal development, **14** 1417
growth curves, **15** 75
historical data analysis, **7** 819
incubation period analysis, **11** 579
likelihood based method, **12** 2273
linear, **13** 635, 945, 1619
linear regression lines, **11** 2039
logistic, **14** 1365
longitudinal data, **11** 1809, 1825, 1929, 1981, 2033; **14** 1219
meta-analysis, **10** 1665; **11** 141
Bayesian approaches, **14** 2685; **15** 2733
clinical trials, **15** 1263
dose-response, **14** 679
likelihood approach, **15** 619
review, **14** 137
mortality, **4** 201
omitted variables, **13** 2219
ordinal responses, **10** 901; **12** 2147–2151(L)
pooling methods comparisons, **8** 141
prediction models, **8** 1327
pulmonary function study, **8** 189
range prediction, **8** 1327
repeated categorical responses, **12** 1969
repeated measures data, **15** 1143
response to treatment/survival time relationship, **15** 2797
risk difference, **15** 1465
shape invariant, **14** 2009
stratified summary statistics, **13** 1853
treatment estimation issues, **9** 657
two-stage application, **8** 189
Random graph model, **15** 837
Random loss, **12** 767
Random models, contingency tables, **10** 991
Random walk models, **7** 581; **12** 265
Random-digit dialling surveys, **11** 1009
Randomization
allocation methods, **4** 129; **5** 211; **6** 119; **8** 467
alternatives, **13** 2269
bias avoidance, **6** 251
clinical trials, **13** 1459, 1473, 2249
acute disease, **10** 405
adaptive assignment comparison, **14** 231
allocation methods, **8** 467; **9** 237
baseline balance, **13** 1715
baseline comparisons, **10** 797–799(L), 1157–1159(L)
Bayesian analysis, **12** 1377, 1421
benefits/risks, **10** 1349
cancer screening, **13** 569
CCS, **15** 263
changing attitudes, **13** 1485
consent designs, **3** 215; **7** 1179; **9** 645
controlled planning, **10** 777
cost-effectiveness ratios, **15** 1447
covariance imbalance/conditional size, **12** 101

covariate imbalance, **8** 467
Cox model/regression trees, **12** 2351
data collection, **9** 103
databases study, **10** 617, 647, 653, 667
depression prevention, **15** 2077
developing countries studies, **9** 35
diarrhoea prevention, **13** 1807
diseases, **9** 161; **10** 1061
dynamic balanced randomization, **12** 2343
early stopping, **13** 1293
equivalence, **12** 1353
external evidence, **15** 1285
frequentists approach, **12** 1405
graphical presentation, **9** 1287
group sequential trials, **9** 1081; **14** 381
healthy responder phenomenon, **10** 1621
incomplete factorial designs, **12** 1629
intended effects study, **2** 267; **4** 387–389(L)
interim analysis, **10** 949
interpretation relevance, **10** 1679
intervention trials, **10** 405
journal developments, **10** 1897
lung cancer, **13** 1415
matched pair intervention study, **9** 943
measles antibody, **14** 777
measurement errors, **8** 583; **9** 583–586(L)
meta-analyses, **12** 2273
  clinical trials, **15** 1263
  individual patient data, **14** 2057
  monitoring, **15** 1273, 1299
  multiple-outcome, **15** 537
  parametric approach, **10** 1665
  problems, **10** 971
methodological issues, **3** 307; **10** 1789
NCI developments, **9** 871, 903
NHLBI developments, **9** 881
NIH developments, **9** 893, 903
non-compliance, **15** 2813
optimal cancer treatment, **13** 1575
overviews, **6** 233
P-values, **6** 241
patient selection, **9** 73
phase II planning, **9** 215
phase III trials, **5** 459
physicians' health study (US), **9** 29; **10** 1585
play the winner strategy, **15** 2135, 2413, 2455
power, **1** 267; **3** 409; **5** 663
psychiatric disorders, **14** 1913
reciprocal control designs, **9** 55
recurrent conditions trial, **8** 1439
recurrent events, **14** 2081
replacement modification, **6** 127
role, **1** 345
run-in strategies, **12** 111
sample size, **3** 199, 409; **5** 663; **14** 115
savage test, **1** 277
selection bias, **13** 557
sequential monitoring, **14** 1927
  sequential trials, **14** 1479
  smoking/lung function association, **13** 509
  stratification consideration, **7** 559
  study designs effects, **8** 441, 455
  summary statistics, **15** 2797
  surgery study, **3** 389
  therapy evaluation
    databases, **3** 385; **10** 647, 653, 667
    duration comparisons, **7** 1013
    observational studies, **3** 341, 347, 385
    phase II/III trials, **3** 467
  treatment allocation, **13** 417; **14** 2661; **15** 113–116(L)
  treatment changes, **15** 2069
  treatment evaluation, **7** 1179; **10** 663, 1595
  two-stage trial, **8** 477
cluster analysis, **6** 43; **8** 599
community intervention studies, **10** 53; **15** 1069
confounding control effects, **8** 679
covariance analysis, **8** 1075; **9** 583–586(L)
errors dietry measurements, **13** 127
experiments cluster effect, **13** 509
Fisher's game, **13** 217
graphical presentation, **8** 679
group, **6** 43; **7** 1195; **8** 599
public health trials, **11** 307
randomized blocks experiment, **11** 863
randomized consent design, **11** 131–132(L)
randomized parallel groups drop-outs, **11** 2043
repeated measurements, **9** 639
screening trial formulae, **13** 569
stratified cluster designs, **11** 743
two-sided tests, **12** 777
Randomized block design, **3** 185; **12** 2343
Randomized play the winner, **15** 2135, 2413, 2455
Range methods
  balanced allocation, **9** 237
  biochemical, **10** 831
  Duncan's multiple test, **4** 489
  equivalence, **5** 203, 421; **11** 23
  normal clinical chemistry, **5** 335
  normal data, **10** 691
  time-specific, **10** 675
Range test qualitative interactions, **12** 1239
Rank adjacency statistic D spatial patterns, **12** 1885
Rank correlation coefficient mortality maps, **14** 615
Rank preserving structural failure time model (RPSFTM), **12** 1605
Rank tests
  censored data, **11** 193, 1871
  cure models, **14** 2111
  drug efficacy assessment, **8** 1393
  group sequential trials, **9** 1081
  individual slopes, **13** 635
  linear, **2** 315
  multivariate statistics, **1** 83
  observer variability, **13** 2437
  odds ratio, **10** 1273

Rank tests (*cont.*)
prognostic variation, **9** 487
publications accessibility study, **13** 2323
regression, **10** 697
spatial pattern measure, **13** 1037; **14** 1393–1394(L)
toxicity/efficacy study, **14** 1129, 1143
transformations, **13** 769
treatment evaluation, **9** 447
trend tests, **4** 87, 543–547(L)
uroflowgrams class, **13** 261
Wilcoxon approach, **4** 87, 145, 543–547(L); **5** 199–200(L)
Rank transform discrimination method, **11** 1623–1624(L)
variable selection procedures, **12** 143
Rank-sum test, **9** 447, 819
Rankings subjective, **11** 427–454
Rao and Scott's estimator, **14** 1567
Rare disease clusters, **12** 1773
Rasch model, **7** 975
cumulative, **12** 1969
quasi-symmetry model connection, **12** 1969
Rate of change
empirical Bayes inference, **11** 621
time-period effects, **12** 893
Rate difference model, **12** 2285
Rate ratio estimation case-cohort designs, **12** 1733; **14** 1609–1610(L)
Rates
see also Mortality
adverse drug reaction, **7** 1023
age
adjustment methods, **2** 455; **3** 7
specific, **2** 455; **3** 7, 113; **4** 63, 201; **5** 573
standardized, **3** 7, 113; **6** 61, 449, 469; **7** 223
clinical trials events, **8** 141
comparison, **3** 119; **4** 213, 541
confidence interval, **7** 865
death, **5** 327
difference, **4** 213
discontinuation, **5** 475
DMFT, **6** 823
incidence, **7** 403, 727
life-table, **5** 475
multiplicative model, **6** 61
pearl, **5** 475; **10** 201
Poisson comparisons, **8** 757
pregnancy, **5** 475
ratio, **4** 213
recurrent events, **8** 517–519(L)
sexual contact, **8** 59, 83, 93, 121
standardized, **8** 757
Ratings consensus, **11** 317
Ratios
see also Odds ratio; Standardized mortality ratio
association models, **8** 1199
Bayesian analysis, **8** 1023–1024(L)
binary data analysis, **8** 1241
concordance, **6** 961
continuation model, **3** 273; **7** 435
correlated binary outcomes, **13** 1241; **15** 1187
cost effectiveness, **15** 1447
diagnostic likelihood, **13** 201, 211, 213
discordance, **6** 961
disease prevention models, **8** 59
drug efficacy assessment, **8** 1393
excess, **6** 701
generalized linear models, **10** 1069
hazard rates, **9** 1167; **10** 749, 1043
homogeneity tests, **10** 1257; **13** 1253
importance, **13** 1525
incidence densities, **13** 343
likelihood
categorical data analysis, **10** 1607
change-point tests, **8** 1414–1416(L); **10** 1159–1160
chi-squared adjustment, **10** 1981
clinical trials, **9** 601
confidence intervals, **10** 443
crossover trials, **10** 1099, 1607
epidemiology, **10** 341
homogeneity tests, **8** 1455; **10** 1257
independence testing, **10** 1555
length bias model, **10** 423
logistic regression, **9** 931; **10** 375, 1213
Markov model, **9** 803
mortality rates, **10** 1043
otitis media risk factors, **9** 1495
P-value interpretation, **9** 601
pooling test results, **9** 601
repeated events analysis, **10** 1227
threshold assessment, **10** 341
tumour growth model, **10** 1075
variation tests, **8** 883
log hazard function, **13** 1045
mixtures, drugs, **4** 77
mortality, **9** 315, 737, 1199; **10** 1267
population variances, **13** 1841
proportional mortality, **2** 455, 467; **3** 7; **5** 61; **6** 71; **9** 315
protein-creatinine, **8** 1485
rate comparisons, **4** 213
relative survival, **9** 529, 737
risk
adjustment techniques, **5** 579
attributable estimation, **7** 507
Bayesian analysis, **7** 1223
case-base studies, **9** 423
clinical trials, **7** 1231
estimation methods, **8** 845; **9** 423
misclassification effects, **10** 361
sample size tables, **8** 795
sequential probability test, **5** 375
smoothing, **15** 2539
standardized incremental rate, **13** 989

variances measurement assessment, **9** 351
ventilation-perfusion, **8** 861
weight/height, **7** 73
RCR *see* Random coefficient regression
RDA *see* Recommended dietary allowances
Reasoning, expert systems, **5** 497
Receiver operator characteristic curves
binormal model, **15** 1575
confidence bounds, **13** 1551
diagnostic medicine, **10** 1887
diagnostic tests, **6** 411; **12** 1293
generalized linear model, **15** 323
incomplete data, **15** 1687
monitoring devises, **10** 351
mortality prediction models, **11** 475
newborn mortality, **14** 2191
non-normal data, **9** 325
non-parametric, **15** 1199
ordinal rating scales, **13** 2437
ordinal regression models, **15** 1807
plot, **13** 499
statistical analysis, **8** 1277
visual field data, **15** 1349
Receptor, assay, **7** 805
Recessive diseases linkage detection, **9** 573
Reciprocal control designs, **9** 55; **13** 1479
Recommended dietary allowance, **11** 533
Recording devices, blood pressure, **4** 361
Records, obstetric, **6** 613
Recruitment, **9** 73, 137, 145, 1433; **13** 1459
Rectal cancer, **6** 565
Recurrence
cancer, **6** 245, 251
hypothesis testing, **8** 517–519(L)
proportional hazards model, **13** 2233
randomized trials, **14** 2081
standardized summary rates, **13** 1781
time dependent events, **6** 689
tumour data analysis, **8** 1363
Recursive partitioning, **5** 517; **8** 947; **11** 475
Recursive residuals steady state departures, **11** 515
Reed-Muench virus neutralization assays, **11** 1253
Refereeing, **3** 97
Reference centiles, **9** 539
age-related, **12** 917
smoothing curves, **11** 1305
(Reference) fixed sample size test (RFSST), **15** 2037
Reference ranges, **7** 649
clinical chemistry, **2** 131; **5** 335; **6** 147; **7** 377
construction methods, **10** 675, 831
estimation methods, **10** 691
longitudinal studies, **14** 1417
three-parameter log-normal distribution, **11** 897
time-specific, **10** 675
Reference tests, **4** 53; **6** 411
Reference values, laboratory data, **2** 191
Reflection principle data monitoring, **12** 2219
Refusal assertion skill role-playing, **12** 365
Regenstrief, Samuel Nathan, **10** 671
Regional data
health data, **13** 1037; **14** 1393–1394(L)
surveillance, **8** 267, 279
Regional spatial autocorrelation coefficient (RSAC), **15** 893
Registration, drugs, **2** 155
Registry data
cancer, **7** 483
change-point, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
clinical trials, **6** 11, 327; **11** 345
IVF, **12** 39
medical, **3** 225, 361, 371, 389
National AIDS, **12** 2065
non-randomized studies, **3** 389
observational data, **3** 361
passive follow-up, **12** 767
twins, **12** 1693
Regression
see also Cox proportional...; Logistic...; Poisson...; Regression to the mean
alcohol data, **14** 591
ARIMA errors, **8** 1497
attributable risk adjustment, **10** 1753
attrition bias, **12** 1005
autoregressive model, **4** 457
bivariate logistic, **15** 1409
blood pressure measurements, **15** 2013
bootstrap investigation, **8** 771
categorical regression models, **14** 2131
change rate comparisons, **9** 437
change/initial value coefficient, **13** 759
clinical trials, **10** 1789; **13** 2393
clustered data, **13** 509, 553
cocaine price model, **14** 655
confidence intervals, **11** 923
correlated categorical data, **11** 67
counts/rates models, **10** 1405
covariance structure, **8** 217, 1075
crossover designs, **12** 825
Deming's method, **9** 1463; **10** 981
dilution dietary assessment, **12** 925, 937
dose-response studies, **15** 343
ecologic studies, **9** 1199
EEG artefacts detection, **10** 1719
effective dose model, **14** 925, 933
effectiveness index, **12** 365
epidemiology, **10** 521, 1819; **12** 717
error linear models, **10** 1197
errors-in-variables, **9** 1463
exact logistic, **14** 2143
generalized linear, **8** 871
geographical correlation, **9** 515
global odds ratio model, **15** 1507
grouped survival data, **9** 737
growth curve model, **13** 2205

Regression (*cont.*)
harmonic, **6** 167; **12** 129
hierarchical, **14** 1757; **15** 1161
hospital tests, **13** 1001
idiometric, **7** 697
importance of variables, **9** 633
in vitro fertilization, **12** 1543
incidence rate models, **13** 1755
interval censored data, **13** 1771; **15** 2177
inverse, **14** 935, 953
isotonic, **7** 649
journal developments review, **10** 1897
latent logistic model, **9** 931
least squares weighted, **4** 353
linear model, **10** 585
linear/non-linear mixed-effects model, **13** 587
log-logistic, **8** 725
log-normal model, **9** 999
longitudinal data, **8** 1515, 1523; **10** 492–495(L); **13** 2219
maximum likelihood, **9** 1517; **10** 981
measurement error, **8** 1139, 1149, 1151, 1165; **14** 789
meta-analysis, **14** 395
missing values model, **8** 217
multiple analysis, **1** 49
multiple linear model, **2** 331; **8** 217
multivariate probit analysis, **10** 1391
neural net models, **13** 1189
non-linear model, **7** 59; **10** 697
normality departure estimation, **10** 1283
omitted variables, **13** 2219
ordered categorical response, **8** 785
ordered logistic, **8** 1317
ordinal data, **14** 1177
ordinary model, **8** 785
paired binary data, **13** 1023
parametric models, **14** 1785
penalty function, **13** 2427
percentile longitudinal data, **14** 777
periodontal disease, **10** 1089
piecewise exponential models, **9** 1157
placebo effect, **8** 1301(L)
pock count variability study, **9** 615
Poisson
abortions data analysis, **8** 285
age-period-cohort model, **5** 527
AIDS incidence, **8** 3, 23
blood pressure study, **9** 1157
cancer study, **5** 527; **7** 223
case-control studies, **10** 739
contraceptive study, **10** 241
Cox proportional comparisons, **9** 1157
epidemiological studies, **7** 223; **10** 1819
historical data analysis, **7** 819
linear models, **10** 1069
logistic regression, **8** 525; **9** 853(L)
measurement error, **8** 1075
peritonitis rates analysis, **9** 263
risks smoking effects, **7** 223
standardized rates estimator, **10** 1069
surveillance data, **8** 285, 331
tumour recurrence rates, **8** 1363
polynomial, **8** 551; **9** 841
prediction factors, **3** 143; **9** 1303; **10** 119
principal components, **3** 143, 293
prognostic factors, **3** 143; **12** 2377
quadratic, **10** 697
random coefficient, **7** 697
ratio dependence on parameters, **13** 989
recurrent conditions trial, **8** 1439
repeated measurement analysis, **10** 1959
residual confounding, **11** 1747
response to treatment/survival time relationship, **15** 2797
ridge, **3** 293; **9** 1303
samples size tables, **8** 795
sign score models, **14** 431
smoking information, **8** 997
splines, **8** 551
stepwise variable selection
case-heterogeneity studies, **5** 49
clinical trials, **5** 421
Cox proportional hazards, **4** 39; **5** 73
diagnostic factors, **5** 503
examination proposals, **10** 711
independence Bayes model, **5** 503
prediction improvements, **3** 143
progostic factors, **3** 143; **4** 39
reporting proposals, **10** 711
risk factor selection, **4** 413
surveillance epidemiology, **10** 521
survival analysis
censored data, **2** 287
drug combination treatments, **9** 1527
generalized *F* family, **5** 85
models, **2** 305
prevalent cohort, **11** 939
problems, **14** 161
proportional hazards model, **10** 1931
survival model, **13** 1575; **14** 1249
time series, **8** 335; **12** 1555
time-period effects, **12** 893
trees, **8** 539; **12** 2153, 2351
tumour recurrence rates, **8** 1363
two-period crossover design, **15** 117
two-sample tests, **9** 447
two-stage parametric model, **9** 681
U.S. legal cases, **14** 1641
variance components, **10** 1441
weighted linear, **7** 19
Regression to the mean
blood pressure bimodality study, **2** 253
change assessment methods, **7** 915
child growth data, **13** 2477
clinical trials endpoints, **8** 415

crossover trials, **11** 727; **12** 1086–1089(L); **13** 1181–1186(L)
dose-response, **14** 987, 1007
patient entry criteria, **13** 859
placebo effect, **2** 417; **7** 1203(L); **8** 1301–1302(L)
risk factors, **11** 783, 1719
training, **14** 199
treatment correction, **6** 113, 727–728(L)
variability effects, **10** 1295
Regret graphs, **15** 969
Relapse clinical trials, **8** 1439; **12** 2315
Relative cumulative incidence, **13** 357
Relative death rate, **5** 327
Relative efficiency, **6** 517; **7** 59, 997–999(L); **13** 623, 1551
Relative errors, **12** 809
Relative inclusion rate, **13** 1881
Relative mortality, **7** 661
Relative odds estimation, **11** 953
Relative operating characteristic *see* Receiver...
Relative outcome rates, **13** 1781
Relative residual confounding, **11** 1747
Relative risk
see also Attributable risk; Risk/risk factors
absolute risk conversion, **8** 641
adjustment methods, **10** 1753
allocation methods, **5** 319
Bayesian vs. empirical Bayes, **11** 983
bias, **2** 25; **3** 131; **6** 193
binary variables, **2** 243; **7** 363; **8** 825
bioequivalence, **11** 1777
bootstrap, **8** 927
cancer
breast, **7** 1121; **14** 267
environmental investigation, **7** 649
lung, **6** 591; **7** 363
pooling study results, **5** 303
radiation exposure studies, **5** 539
treatments, **8** 1371
x-ray associations, **7** 857
cardiovascular diseases, **7** 275
case-control studies, **14** 1615
allocation methods, **5** 319
attributable risk estimation, **7** 507
interaction tests, **2** 243
latent classs analysis, **4** 445
logistic regression, **4** 425
power study, **2** 243; **3** 27; **7** 363
relative risk techniques, **10** 1511
sample size estimation, **7** 759
vaccines efficacy, **7** 1279
case-crossover designs, **12** 2333
child leukaemia mortality, **13** 1525
cholesterol effects, **5** 303
chronic diseases, **4** 327
CIN/HPV, **13** 379
clinical trials, **3** 199; **7** 275
cluster analysis, **14** 2291, 2309
cohort studies
allocation methods, **5** 319
classification error, **2** 25
control efficiency evaluation, **8** 977
design, **7** 275
mortality, **4** 295
radiation factors, **5** 539; **8** 173
sample size, **7** 759
vaccine efficacy, **7** 1279
collinearity diagnosis, **11** 1273
comparative binomial trials, **9** 1447
confidence intervals, **4** 445; **8** 927
confounding effects, **3** 131
contingency table estimators, **8** 987
correlation estimation, **7** 717
covariate measurement error, **8** 1151, 1165, 1167, 1179
Cox proportional hazards, **6** 591; **8** 525, 927; **9** 287
death radiation effects, **8** 173
diagnostic factors, **4** 425
disease
mapping, **14** 2363, 2411
prevention trials, **9** 161
surveillance, **2** 13; **5** 49
drug safety, **14** 1113, 1117
environmental risk investigation, **7** 649
epidemiology
bibliography, **10** 1819
Cox model application, **9** 287
familial data, **2** 13
function estimation, **10** 1745
heart disease prediction, **9** 289
interaction tests, **2** 243
latent class analysis, **4** 327, 445
pooling study results, **5** 303
reliability data, **4** 445
equivelence tests, **14** 1583
error, **2** 25; **4** 445
estimation bias, **14** 1331
excess risk, **15** 1535
exposure
binary variables, **7** 773, 1073
case-control studies, **7** 363; **9** 1485
case-heterogeneity studies, **5** 49
mortality ratio bias, **6** 193
radiation analyses, **5** 539; **8** 173
exposure-specific rates, **13** 651, 2407
functions, estimation, **10** 1745
geographical density estimates, **9** 691
heart disease, **14** 643
heterogeneity tests, **7** 1121
historical data analysis, **7** 819
HIV infection, **14** 1513; **15** 2177
homogeneity cohort studies, **10** 1267
hypothesis testing, **6** 689
interaction tests, **2** 243

Relative risk (*cont.*)
inverse sampling, **14** 2051
kidney transplant survival, **14** 1553
last case influence, **11** 1615
latent class analysis, **4** 327, 445
leukaemia children, **7** 1121
log-linear models, **7** 403
logistic regression, **4** 327, 425; **8** 173, 525
logistic risk score, **9** 385
lung cancer, **6** 591; **7** 363
McNemar test, **11** 1239
Mantel-Haenszel statistic, **7** 507
Markov models, **7** 819
matching designs, **12** 993
measurement error, **4** 445; **8** 1031, 1051, 1071
covariate effects, **8** 1151, 1165, 1167, 1179
misclassification
cohort studies, **2** 25
latent class analysis, **4** 327
matched-pair studies, **8** 825
maximum likelihood method, **8** 1528
non-differential exposure, **7** 1073
vaccine study, **9** 1327
misselection subsampling, **9** 1339
morbidity estimation, **3** 131; **6** 195
mortality, **2** 455; **4** 295, 425; **8** 173; **12** 1895
multiple reports, **8** 1041
multiplicative-model, **13** 989
one-dimensional scan statistic, **12** 1853
optimal sample allocation, **15** 2523
paired binary data regression, **9** 1517
pooling methods, **5** 303
power, **2** 25, 243; **3** 27; **5** 319; **7** 363
proportionate mortality ratio, **9** 315
prospective analysis, **12** 691
radiation factors, **5** 539; **8** 173
rates mortality, **2** 455
regression, **6** 591; **7** 275, 649, 819; **12** 2087
sample size
allocation methods, **5** 319
censored data, **3** 199
cohort studies, **2** 25
confidence intervals, **15** 183
confounding effect, **9** 765
formulae, **15** 1
odds ratio, **7** 759
vaccine efficacy, **7** 1279
score test, **13** 79
smoking effects, **7** 363
smoking habits, **15** 581
sparse stratified data, **12** 2285
spatial variations, **14** 2335
survival analysis, **6** 773; **7** 1121; **9** 1527
time-dependent variables, **6** 689; **9** 287
tree-based analysis, **15** 37
univariate survival analysis, **15** 2203
vaccine studies, **7** 1279; **9** 1327; **14** 395
vital status sweeps, **14** 1927
x-ray effects, **7** 857
Relative survival, **9** 529, 737
Relative transmission probabilities vaccine efficacy, **13** 357
Relaxation therapy, **7** 697
Reliability coefficient, **7** 955
Reliability structures, **15** 1647
Reliability studies
chance-correlated measures, **12** 2191
kappa statistic, **11** 1511
Reliability tests, **4** 445; **6** 441, 647
Remedial therapy, **3** 341
REML
see also Residual maximum likelihood
computer package, **8** 891(L)
Remotely sensed data GIS, **15** 1961
Renal Studies
see also Kidney transplantation
artery stenosis diagnosis, **8** 1291
cancer, **5** 255
carcinoma clinical trial, **13** 2249
centile curve calculation, **10** 1693
diet effects, **11** 1861
disease
correlations comparison, **8** 1485
progression measures, **9** 1175
relative risk, **10** 1267
failure, **5** 637
Renin secretion, **8** 1291
Repeated measurements
see also Longitudinal data
analysis of variance, **11** 1033
analytic methodology, **7** 11–87
ANOVA, **13** 1657
assessment, **9** 351
autoregressive models, **7** 59, 73, 87
bias correction, **7** 417
binary variables, **7** 975; **13** 1233
blood pressure, **7** 47, 199, 297, 423
cancer study, **7** 223, 1013, 1121; **9** 931
categorical data, **7** 95–169, 965; **8** 1209; **12** 1969
censored data, **7** 337
change rate analysis, **6** 599; **7** 337
chi-squared adjustments, **10** 1981
clinical trials, **7** 275; **9** 931; **10** 1959; **13** 197–198(L)
coefficients of variation, **15** 647
cohort studies, **7** 275
comparative study, **15** 1143
CORMS, **11** 2037
covariance adjustment method, **6** 911
covariance models, **14** 1397
covariate data, **7** 275
Cox regression model, **9** 1501
cross-sectional studies, **7** 685
crossover trials, **6** 911; **7** 471; **11** 1967; **14** 1067, 1079
data analysis, **11** 1843

data monitoring, **12** 2219
day-to-day variance, **11** 2035
design, **2** 497; **3** 185; **5** 663
diabetes study, **7** 671
dietary assessment, **12** 925, 937
disease incidence model, **7** 149
drop-outs, **15** 1123
epidemiology, **7** 11–169, 223, 745
error, **6** 441; **7** 257, 601
estimation formula, **8** 893
experimental methods, **9** 639
Framingham heart study, **7** 205, 219, 289
GEE/MLE, **12** 1723
Gibbs sampling, **15** 1663
growth curve models, **7** 73, 87; **9** 841
health study, **7** 177
height growth study, **13** 1643
hierarchical Bayes modelling, **11** 2001
interactions risk/mortality, **7** 239, 293
Kalman filtering, **7** 73, 87
latent class model, **11** 2111
latent variable models, **7** 975
likelihood analysis, **7** 149
linear models, **6** 911; **7** 139, 317
linear regression lines, **11** 2039
liver function study, **7** 671
log-linear models, **7** 965
logistic regression model, **9** 1501
longitudinal studies, **6** 559; **7** 11–361, 685; **8** 1523; **14** 1205
lung cancer study, **7** 223
lung function study, **7** 11, 297, 601, 685
mean summary statistics, **11** 1685
measurement error, **8** 1031, 1109, 1151, 1165
misclassification, **7** 257, 745
missing data, **7** 59, 139, 305, 317, 357
models, **7** 347
morbidity estimation, **7** 325
mortality, **7** 149, 239, 293, 325
multi-level models, **15** 2717
multi-state models, **7** 149
multiple reports, **8** 1041
multiple treatments, **15** 2509
multivariate data, **11** 1151
Muscatine study, **7** 47
non-linear models, **11** 1929
non-parametric two-sample tests, **15** 429
parallel plots, **11** 115
platelet transfusions, **11** 2123
pooled regression models, **9** 1501
power study, **6** 441
prediction equations development, **10** 119
pulmonary function, **7** 19, 59, 139, 601; **8** 189
quasi-likelihood equation, **7** 139
random effects models, **8** 189
rates change, **6** 599; **11** 621
regression techniques, **6** 599; **10** 1295
reliabilty studies, **6** 647
REML, **13** 1601
residual plots, **11** 115
risk, **7** 239, 275, 289, 293, 297
sample size, **6** 441, 647; **10** 463; **11** 633, 1391
sarcoidosis study, **8** 189
schizophrenic reaction times, **14** 747
short-term survival prediction, **11** 1731
smoking study, **7** 223
smoothing procedures, **7** 601
stochastic model, **15** 2617
summary statistics, **12** 2169; **14** 2169(L)
survival analysis, **7** 297
tracking, **12** 2153
trend assessment model, **7** 185
variances, **7** 417, 745
within-units variances, **13** 1841
Repeated significance tests, **6** 753
Replacement randomization, **6** 127
Replicate measurement model, **13** 1265
Replication
clinical trials, **14** 115
P-values, **11** 875
Report errors *see* Errors-in-variables
Reporting
clinical trials review, **10** 1789
delays, **8** 23, 259, 279, 963; **15** 2669
Resampling technique, **4** 39; **5** 363; **10** 341; **13** 1211; **14** 1009
Research Application Conference, 13th, Proceedings: AIDS and HIV, **13** 1899–2187
incidence estimation, **13** 1933–2020
ineffectivity, **13** 2081–2106
interventions, methods od study, **13** 2107–2187
markers and incubation time, **13** 2021–2042
preface, **13** 1901
screening tests, **13** 1905
seasonal/short-term influences, **13** 1921
Research design data management systems, **3** 101
Research planning, **3** 1; **14** 1683
Research projects
budgeting guidelines, **15** 2127
evolutionary, **3** 315
synthesis, **15** 1253, 1713
Resemblance matrix, **6** 137
Residual confounding, **11** 1747
Residual maximum likelihood (REML), **12** 27, 1665; **13** 1601
bioequivalence, **15** 2635
crossover experiments, **15** 1619
longitudinal data, **11** 1889, 1929, 1967, 1981, 2001
methadone programme, **15** 2253
Residual plots, **11** 115
Cox-Snell, **14** 1785
linear regression model, **14** 2023
Residuals
counts/rates models, **10** 1405
crossover trials, **10** 891, 909

Residuals (*cont.*)
EEG artefacts detection, **10** 1719
generalized plots, **8** 703
interlaboratory studies, **10** 843
martingale-based, **13** 301
matched-pair studies, **4** 425
outliers detection, **10** 1375
RCR model analysis, **13** 1211
recursive, **11** 515
repeated measures model, **13** 1643
Resistance time to infection, **3** 165
Resistant-Exponential model, **14** 1081, 1097
Respiratory diseases, **13** 1771
air pollution, **15** 823
asthma, **15** 443
cancer, **12** 1249
children, **12** 2153; **15** 1867
repeated measurement analysis, **10** 1959
smoking effects, **11** 1915
time-series analysis, **10** 1481
Respiratory function
clinical trials, **8** 1339
longitudinal models, **14** 2205
Respiratory medicine, **7** 95
Response
see also Dose-response relationship
bias surveys, **11** 1009
curves, **2** 95; **8** 1401
profile repeated measurements, **11** 2111
Response effects
clinical trials, **8** 1183; **10** 1621
factorial designs, **9** 55
growth curve models, **9** 841
historical data controls, **9** 215
postal questionnaires, **5** 607
prediction treatments, **9** 253
reciprocal control designs, **9** 55
Response surface models, **11** 1065; **13** 2289; **15** 2107
Restricted maximum likelihood *see* Residual maximum likelihood
Restricted procedure boundaries, **13** 1357
Retinopathy
see also Diabetes; Diabetic Retinopathy Study
surrogate observations, **8** 427
Retrend model, **7** 185
Retrolental fibroplasia trial, **9** 893, 903
Retrospective studies
case-control factors, **7** 363
likelihood analysis, **7** 149
multistate models, **7** 149
sensitivity/specificity, **11** 1503
smoking data, **8** 997
therapy assessment, **3** 353
time-to-event problems, **12** 867
Reviews
clinical trials developments, **10** 1789
diagnostic tests, **6** 411
epidemiology bibliography, **10** 1819
statistical, **7** 1003
RFSST *see* (Reference) fixed sample size test
Rhabdomyosarcoma rare event clustering, **11** 761
Rheumatoid arthritis, **9** 803; **15** 537
activity index, **12** 1171
attrition bias, **12** 1005
registry, **11** 345
Rhythm circadian, **6** 167; **7** 423, 697
Ridge regression, **3** 293; **9** 1303; **14** 1609–1610(L)
Ridit analysis, **13** 2437; **14** 1177
Ridit permutation test, **15** 429
Right censored data, **7** 377; **9** 409
combined endpoints, **11** 1705
rate of change estimation, **11** 621
sequential logrank procedure, **11** 1359
Right-point imputation threshold-crossing data, **12** 1589
Rigoni-Stern, **6** 877, 881
RIR *see* Relative inclusion rate
Risk/risk factors
see also Attributable risk; Probability; Relative risk
abortion, **5** 557
absolute, **5** 539; **8** 641
adjusted attributable estimators, **11** 2083
adjustment methods, **5** 579; **10** 1753
age-adjustment, **14** 1731
aggregate data studies, **15** 1849
AIDS, **8** 3; **9** 505, 681, 1387; **15** 2307
allocation designs, **5** 319
Alzheimer's disease, **14** 1353
anaesthesia study, **7** 947
appraisal function, **14** 1757
area-specific, **14** 2433
assessment, **5** 49; **11** 1377; **13** 53
association measurement, **8** 619
attributable, **14** 51, 1331, 2051
adjustment methods, **10** 1753
bias estimation, **3** 131; **7** 1073
confidence intervals, **7** 507
Cox proportional hazards model, **8** 525
epidemiology, **10** 1819
estimation methods, **1** 229; **7** 507; **8** 845
extrapolation method, **7** 717
logistic regression, **8** 525
misclassification, **7** 1073
variance estimators, **6** 701
aversion, **5** 411
Bayesian analysis, **7** 1223
bias, **2** 71; **3** 131; **7** 1087, 1243
binary variables, **2** 243
biological, **1** 163
birth defects, **15** 1907, 2029
blood pressure study, **7** 297
breast cancer surveillance, **7** 619
cancer
attributable risk estimation, **7** 507

central laboratory, **15** 759
cigarette smoking, **7** 223
GENSTAT, **2** 223
measurement error models, **15** 293
meta-analysis, **5** 303
carcinogen study, **5** 49
carcinogenesis multistage model, **9** 677; **13** 23
carcinoma study, **4** 345
cardiovascular diseases, **6** 501; **14** 1745
case-base studies, **9** 423
case-control studies, **14** 769; **15** 1535
allocation methods, **5** 319
attributable estimation, **7** 507
Bayesian analysis, **7** 1223
carcinoma surveilance, **4** 345
chronic disease surveilance, **4** 327
dose-response models, **10** 1511
estimation methods, **8** 845
nutrition study, **7** 1087
sample size, **7** 363; **9** 1485
survival-based efficiency, **10** 1775
CER greater exposure, **13** 245
cholesterol effects, **5** 303; **8** 295
clinical trials
confidence intervals, **9** 657
cost-effectiveness, **9** 173
developing countries studies, **9** 35
drug safety, **14** 1113
phase III trials, **10** 1349
repeated measures, **7** 275
safety guidelines, **14** 1099
cohort disease prevalence, **11** 295
cohort studies, **5** 319; **7** 275; **8** 977
combining risk differences, **15** 1465
comorbidity, **14** 721
comparative binomial trials, **9** 1447
competing
cancer, **2** 41; **6** 785; **7** 1121
case-base studies, **9** 423
categorical data, **7** 965
contraceptive research, **5** 475
disease recurrence, **2** 41
exposure effects, **8** 845
heart disease, **4** 397
heterogeneity analysis, **7** 1121
historical data analysis, **7** 819
log-linear models, **7** 965
mortality, **2** 373; **4** 397; **7** 239, 289, 293
myocardial infarction, **4** 29
survival analysis, **2** 41; **5** 475; **7** 1121
confounding control, **8** 679
congenital abnormality, **14** 1797
contingency table estimators, **8** 987
control sample size, **11** 1759
conversion methods, **8** 641
correlations, **6** 629; **7** 717; **9** 515
correspondence analysis, **4** 303
covariate errors, **8** 1167, 1179
Cox regression, **4** 413; **9** 1501
death study, **5** 113; **7** 297
dental study, **7** 403
developing countries study, **9** 35
diabetic retinopathy, **14** 1341, 1975
diagnostic factors, **7** 403
difference confidence interval, **7** 773
difference model, **12** 2285
differential prognostic influence, **11** 281
disclosure, **15** 1895
discriminant analysis, **2** 229; **4** 413
diseases, **5** 319; **7** 297; **9** 161; **11** 1443
dose-toxicity models, **9** 1117–1118(L)
environmental, **2** 13; **7** 649
epidemiology, **2** 243; **5** 303; **7** 223, 619; **10** 1819
equivelence tests, **14** 1583
error, **7** 257, 275
excess, **7** 649
exposure factors, **4** 117; **5** 49; **7** 363, 1073
familial data, **2** 13
Framingham heart study, **7** 205, 219, 289
generalized residual plots, **8** 703
genetic epidemiology, **6** 629
geographical estimates, **9** 515, 691
grouped survival data models, **9** 737
heart disease, **14** 643, 1265
aspirin effects, **6** 255
Cox proportional hazards, **4** 413; **7** 613
discriminant analysis, **4** 413
excess incidence investigation, **2** 477
Framingham study, **7** 205, 219
logistic regression, **4** 413
prognostic factors, **2** 223
hepatitis B screening, **8** 391
heterogeneity tests, **5** 49, 557
historical control study, **10** 1417
HIV
back-calculation, **14** 1513
heterosexuals, **10** 1003; **14** 1365
infection dynamics, **9** 721
sexual behaviour, **15** 2323, 2337
trends, **15** 1779
vaccines, **9** 1425, 1433
variable infectivity, **10** 131
homogeneity cohort studies, **10** 1267
hypertension databases analysis, **10** 653
index multifactorial, **7** 947
infant mortality rates, **15** 1907
interaction tests, **2** 243
intervention trials, **11** 1719
ischaemic heart disease, **15** 1885
Jewell's estimators, **10** 151–153(L)
latent class analysis, **4** 327
lens opacities, **15** 145
leukaemia, **4** 39
logistic regression
bias, **2** 71
Cox regression analysis, **9** 1501

Risk/risk factors (*cont.*)
logistic regression (*cont.*)
discriminant analysis, **4** 413
latent class analysis, **4** 327
prospective studies, **3** 15
risk scores, **14** 1331
sample size, **8** 795
logistic risk score, **9** 385
longitudinal studies, **8** 1515
low birthweight, **15** 37
LRI study, **13** 343
lung cancer study, **4** 117; **7** 223
lung function study, **7** 11, 601
Mantel-Haenszel statistic, **7** 507
Markov models, **7** 325, 819
matched-pair studies, **8** 825
maximum likelihood, **2** 71; **6** 961
measurement error
covariate effects, **8** 1151, 1165, 1167, 1179
mismodelling effects, **7** 257
non-differential exposure correction, **8** 1031, 1071
relative risk models, **7** 275
melanoma tumour size, **9** 999
meta-analysis, **14** 545
misclassification
association tests, **7** 257
latent class analysis, **4** 327
Mantel-Haenszel statistic, **8** 1529
maximum likelihood method, **8** 1529
non-differential effects, **7** 1073; **10** 361
vaccine study, **9** 1327
misselection subsampling, **9** 1339
mixed effects models, **9** 263
mixed multi-normal distributions, **9** 301
model-based screening, **11** 257
morbidity estimation, **7** 325
mortality
Cox proportional hazards model, **7** 613
interaction, **7** 239, 289, 293
intervention study, **6** 501
perinatal study, **2** 229
pooling study results, **5** 303
multilogit model, **9** 981
multiple reports, **8** 1041
multistate analysis, **12** 2315
multivariate probit analysis, **10** 1391
myocardial infarction, **2** 95; **7** 205, 219
newborn mortality, **14** 2191
NHANES study, **7** 1087
odds ratio, **7** 507; **9** 1131
otitis media model, **9** 1495
patient selection clinical trials, **9** 73
physicians' health study (US), **10** 1585
pooling methods, **5** 303; **9** 1501; **10** 1417
population risk, **15** 1713
post marital bereavement study, **10** 395
postpartum time-dependency, **15** 1545
power, **2** 243; **4** 117; **7** 363
practice databases, **10** 541
prediction, **5** 113; **7** 297, 947
prognostic factors, **2** 223; **9** 273, 1189
proportionate mortality ratio, **9** 315
public health surveillance, **14** 629
pulmonary function study, **7** 59, 601
radiation exposure, **8** 173
ratios
adjustment techniques, **5** 579
Bayesian analysis, **7** 1223
case-control studies, **7** 507
clinical trials, **7** 1231
confidence intervals, **7** 773
epidemiology estimations, **8** 845, 1241
estimation, **12** 1733; **14** 1609–1610(L)
multivariate studies, **4** 117
sampling techniques, **4** 541; **8** 1241
stratified case-cohort studies, **11** 1599
vaccine trial comparisons, **13** 1827
recurrent event testing, **8** 517–519(L)
regression, **8** 525, 539; **14** 431
relationship, **11** 783
residual confounding, **11** 1747
response phenomenon, **10** 1621
risk of disease relationship, **11** 783
sample size, **4** 117; **5** 319; **7** 363; **8** 795; **9** 765
sampling methods, **6** 629
score, **6** 689
scoring systems, **5** 113
screening effectiveness studies, **9** 969
short-term survival prediction, **11** 1731
smoking effects, **2** 223; **7** 223, 289; **8** 997
smoothing procedures, **7** 601
SSPE surveillance, **10** 1733
standardized morbidity ratios, **3** 131
stratification, **7** 1087
summary statistics, **12** 2169; **14** 2169(L)
surrogate endpoints study, **8** 431
survival analysis
absolute risk study, **10** 1025
angina pectoris trials, **9** 293
bias study, **7** 1243
confidence intervals, **8** 927
Cox proportional hazards, **8** 927; **9** 1157
drug combination analysis models, **9** 1527
exponential trees, **8** 947
Poisson regression model, **9** 1157
quality adjusted, **9** 1259
relative risk models, **9** 1527
treatment effects estimation, **7** 1243
variation measures, **9** 487
synthetic cancer maps, **12** 1931
time-dependent Cox model, **9** 287
tracking, **12** 2153
traffic accident mapping, **14** 2445
treatment-induced cancer, **8** 1371
vaccine studies, **9** 1327; **10** 1573; **13** 1827

x-rays effects, **8** 857
Robust-resistant ROC curve, **12** 1293
Robustness
ANCOVA, **15** 477
t-test, **6** 79
ROC *see* Receiver operator characteristic curves
ROC ANALYZER computer package, **11** 475
Rocky flats plant, **7** 491
Role-playing conversational skill, **12** 365
Rom's procedure, **15** 1107
Rotavirus, **5** 585
Row and column effects association model, **5** 15
RSAC *see* Regional spatial autocorrelation coefficient
Rubella, **2** 1; **6** 843; **9** 953
Rules of thumb confidence intervals, **12** 809
Run length distribution, **8** 311
Run-in phases clinical trials, **9** 29, 103; **10** 1585; **12** 111
Runge-Kutta method, **11** 1425, 1657
Running median methods, **10** 1089
Runs test, **7** 795
Rural Dental Health Study (RDHS), **2** 59
Rushton's approximation, **15** 2781

S-PLUS computer package, **13** 301; **15** 361
Safety
clinical trials, **14** 1099, 1113, 1655, 1659
data multivariate approach, **11** 1075
drugs, **14** 1113, 1117, 1129, 1143; **15** 987
DSMB role, **12** 419, 433
Medicines Committee (CSM), **6** 863
seat-belt systems study, **8** 379
Salk Vaccine Field Trial, **9** 13
Salmonella time-series construction, **10** 1493
Sample size
see also Clinical trials; Sampling
age-specific disease, **13** 2369
aggregate data studies, **15** 1849
ANCOVA model, **12** 101
asymptotic test, **15** 647
attributable risk behaviour, **1** 229
baseline comparisons, **10** 797–799(L), 1157–1159(L)
Bayesian inference, **14** 1057, 1065
binomial comparisons, **9** 1447; **10** 1137
bioequivalence studies, **10** 959, 961; **14** 1067, 1079
birthweight centile curves, **15** 2657
bounded outcome scores, **12** 1063
case-control studies
allocation designs, **5** 319
confounding effects, **9** 765, 1485
exposure factors, **7** 363; **9** 1485
multiple controls efficiency, **5** 29
power estimation, **3** 27; **6** 53; **7** 363
vaccine efficacy estimation, **7** 1279
censoring models, **7** 337, 357
cluster factors, **7** 1195; **8** 1537
cluster number estimation, **11** 751
clustered binary responses, **13** 1241
cohort studies
allocation designs, **5** 319
classification error reduction, **2** 25
estimation methods, **10** 1993
logistic regression tables, **8** 795
odds ratio estimation, **7** 759
relative risk estimation, **7** 759
vaccine efficacy estimation, **7** 1279
combination drug trials, **11** 1065
community intervention trials, **15** 1069
computation, **13** 1539; **14** 1933, 2273
confidence intervals, **8** 803; **11** 269(L); **13** 357
confounding effects, **9** 765, 1485
correlated binomial variates, **11** 1607
cost-effectiveness analysis, **9** 173; **14** 2249
covariate errors, **8** 1167, 1179
cross-sectional studies, **14** 51
crossover trials, **10** 489–491(L), 909
crude estimation, **11** 1099
CT run-in strategies, **12** 111
cure model survival analysis, **3** 153
databases study, **10** 599
descriptive data analysis, **10** 777
determination, **10** 433, 463; **12** 1405
developing countries studies, **9** 35
diagnostic test, **6** 147; **8** 1381
dose determination, **14** 901, 909
dose-response studies, **15** 343
drug combination tests, **8** 1479
drug safety, **14** 1113, 1117
endpoints efficient use, **9** 155
epidemiology studies, **2** 387; **10** 1819
equivalence tests, **13** 1827; **14** 1583, 1831
estimation issues, **9** 657
event rate equivalence trials, **12** 2009
exact, **15** 183
exact conditional test, **15** 671
exact logistic regression, **14** 2143
exact power computation, **14** 2261
exponential survival model, **13** 391
factorial designs, **9** 55, 1121
familial aggregation, **11** 1767
focused clustering studies, **15** 765
formulae, **11** 1091; **15** 1
generalized Wilcoxon test, **6** 483
geographical correlations, **9** 515
group sequential trials, **9** 907, 1433; **11** 1391; **14** 381
hazard ratio point estimation, **9** 1167
historical control studies, **3** 315
HIV vaccine trials, **13** 2155; **15** 2371
HIV, pooled tests, **13** 1905
hypotheses testing, **8** 803
independence testing, **10** 1555
interaction test, **7** 467

Sample size (*cont.*)
interim power evaluation, **11** 55
internal pilot studies, **13** 2455; **15** 1587
intervention studies, **7** 1195
inverse sampling, **14** 2051
kappa coefficient, **10** 1465; **11** 1511; **15** 1409
kinetic enzyme models, **8** 871
logistic regression, **12** 1079; **15** 1987
logrank tests, **6** 483, 577; **8** 937; **11** 179
longitudinal studies, **9** 437; **14** 2239
LR tests, **13** 1563
McNemar test, **11** 1239, 1521
maximum likelihood estimation, **10** 723
measurement errors, **8** 1167, 1179
meta-analyses, **10** 971
misclassification, **14** 1307
misselection adjustment, **9** 1339
multiple comparisons, **14** 2509
multiple significance tests, **10** 939
multivariate studies, **4** 117
NHIS meta-analysis, **14** 669
non-parametric estimation, **14** 275
normality departure estimation, **10** 1283
nuisance parameter effect, **12** 699
odds ratio estimation, **4** 437; **7** 759
odds ratio homogeneity tests, **11** 159
optimal determination, **11** 547
optimal sample allocation, **15** 2523
ordered categorical data, **12** 2257; **15** 1065–1066(L)
p-values, **9** 601; **12** 1443
pair-matched studies, **12** 699
patient selection clinical trials, **9** 73
phase I cancer trials, **10** 1647
phase II clinical trials, **13** 2493; **14** 1479
pilot studies, **9** 65
pock count variability study, **9** 615
prevalence rates, **14** 1471
prevention trials, **13** 1807
proliferative index model, **13** 1619
proportional hazards survival studies, **11** 1103
prospective analysis of relative risk, **12** 691
protective efficacy vaccine, **7** 1279
qualitative interactions, **12** 1239
quantitative diagnostic marker, **13** 1551
randomized trials, **14** 2081
rank adjacency statistic, **12** 1885
rates estimation, **7** 865
reference limits, **2** 191
relative risk estimation, **7** 759
reliability studies, **6** 441, 647
repeated crossover design, **14** 1067, 1079
repeated measures, **5** 663; **11** 633, 1685; **13** 1233
sampling designs, **4** 541; **8** 1537
SCPRT, **15** 2037
sequential trials, **8** 505; **9** 229, 595; **13** 1357
shared haplotypes test, **5** 281
sickle cell anaemia trial, **9** 45
significance investigations, **9** 627
simulation, **8** 1269
small-sample estimators, **10** 151–153(L)
strata-matching studies, **9** 1475; **11** 1759
stratified cluster randomization, **11** 743
stratified prospective studies, **13** 79
stratified trials, **14** 2037
surrogate endpoints strategy, **8** 415
survival curve, **6** 679
t-test, **6** 577
tables, **8** 795; **15** 1
time-period effects, **12** 893
time-specific reference ranges, **10** 675
treatment allocation methods, **10** 1595
treatment equivalence study, **13** 2279–2280(L)
treatment selection, **13** 431
two-sided testing, **12** 777
two-stage clinical trials, **15** 1739
unified procedure, **13** 1815
Sample space ordering, **12** 675
Sampling
binary data case-base studies, **8** 1241
biopharmaceutical research, **10** 811
blood tests, **13** 2337
bootstrap investigation, **8** 771
case-base studies, **9** 423
case-control studies, **10** 739
cell count estimation, **13** 523
clinical trials, **9** 97, 1287
community intervention studies, **10** 53
comorbidity, **14** 721
compartment parameters, **8** 1011
confidence intervals, **9** 1277
Cox regression model, **9** 1501
databases methodology, **10** 629
destructive, **14** 1009
diagnostic tests review, **10** 1897
disease prevention trials, **9** 161
doubly-censored data, **13** 2081
dual frame design, **14** 571
energy expenditure measures, **9** 1365
epidemiology bibliography, **10** 1819
group sequential monitoring, **9** 1081
importance resampling, **13** 1525
interrater reliability, **9** 11
inverse, **14** 1471, 2051
large samples, **8** 1109, 1127, 1133, 1137
logistic regression model, **9** 1501
misclassified categorical data, **8** 1095
misselection adjustment, **9** 1339
multiwave studies, **10** 1945
non-negative data, **15** 1695
non-random pedigree analysis, **4** 163
normal reference ranges, **10** 691
observational data, **8** 273
odds ratios, **9** 1131; **10** 1273
order statistics study, **10** 855
outcome-stratified, **13** 1665

outliers bioavailabilty studies, **10** 1375
polio field trial, **9** 13
pooled regression models, **9** 1501
prediction value error rates, **9** 1303
probability approach, **13** 1539
prognostic scoring sensitivity, **9** 1189
proportional bias, **8** 563
rate hormone pulse detection, **14** 311
ratio determination method, **2** 387
risk renal disease, **10** 1267
secondary attack rates, **13** 1563
single-stage cluster, **8** 1537
strata-matching studies, **9** 1475
survival analysis, **9** 409
two-period crossover trials, **8** 1421
two-sample problem, **13** 747
vaccine efficacy estimation, **10** 1573
variance component study, **10** 599
work sampling data, **15** 607
San Francisco Men's Health Study, **13** 1101
Sarcoidosis, **8** 189
Sarcomas, **8** 1255
SAS computer package
age-adjusted survival curves, **14** 1731
AIDS study, **9** 681; **10** 1167
angina pectoris study, **9** 293
ARIMA model, **8** 335
blood pressure measurements, **11** 2147
cancer study, **9** 325
cardiology, **9** 273
categorical data, **7** 109; **8** 1209; **10** 1607
CATMOD, **9** 981; **11** 1843
change rate analysis, **9** 437
clinical trials meta-analysis, **13** 2503
confidence intervals, **10** 443
Cox proportional hazards, **8** 525; **9** 463–464(L), 853(L)
crossover designs, **12** 69
DATA, **11** 1533
discriminant analysis, **9** 273
dose-response relationships, **11** 685
drugs tests, **8** 1209
failure time analysis, **10** 1099, 1703
forecast factors, **8** 335
GLM, **11** 579, 1843
growth curve models, **9** 841
haemophilia, **9** 681
HIV study, **9** 681; **10** 1167
IML
blood pressure monitoring, **12** 1665
GEE, **11** 963
linear regression lines, **11** 2039
longitudinal data, **11** 1843, 1889
missing data, **11** 2043
rate of change estimation, **11** 621
risk ratio/rate ratio estimation, **12** 1733
in vitro fertilization registry, **12** 39
LIFEREG, **9** 487, 681
location-scale cumulative odds models, **14** 1191
log-linear modelling, **11** 101
LOGIST, **11** 1719
LOGISTIC, **12** 143
logistic regression, **8** 525; **9** 463–464(L), 853(L)
logit models, **8** 1209
longitudinal studies, **9** 437
maximum likelihood, **8** 1209
mortality, **8** 335; **9** 981
NORMAL, **11** 881
ordered response, **8** 1209
PC, **11** 603
PHGLM, **11** 281, 1731, 2093
PHREG, **11** 1731
placebo effect, **8** 1209
Poisson regression, **9** 463–464(L), 853(L)
polychotomous model, **10** 375
power investigation, **9** 437
prediction estimation, **10** 119
PROC CATMOD, **11** 2063; **12** 1969, 2147–2151(L)
PROC LIFEREG, **9** 505
PROC LIFETEST, **14** 1731
PROC LOGISTIC, **12** 1969, 2147–2151(L)
PROC MATRIX, **11** 2063
PROC NLIN, **12** 403
PROC REG, **11** 2063
prognostic factors, **9** 273
proportional hazards model, **13** 301
random-effects models, **11** 1981; **14** 395
RANK, **11** 1843
RANNOR, **11** 1719
RANUNI, **11** 1719
ROC curves, **9** 325
sample size, **9** 437; **10** 33, 961; **11** 633
seroconversion times, **9** 505
STEPDISC, **12** 143
survival analysis, **9** 293
time series analyses, **8** 335
treatment covariate interaction, **7** 1257
trend detection, **12** 1125
TTEST, **11** 1843
tumour screening, **13** 719
variance components estimation, **10** 1441
variation measures, **9** 487
Satellites, **15** 1961
Saturated least squares estimators incomplete factorial designs, **12** 1629
Savage test, **1** 277; **12** 1377
Scales
denominators in small areas, **15** 1921
disease clustering, **12** 1869
measurement error, **12** 937
ordinal, **6** 79
Scan statistic, **6** 197; **8** 267, 323
clustering, **11** 761; **12** 1813, 1829
one-dimensional, **12** 1853
tail probabilities, **12** 1845

Scan statistic (*cont.*)
variable window, **15** 845
SCD *see* Sudden cardiac death
Scenario analysis decision trees, **9** 1229
Scheffe method multiple comparisons, **7** 467
Scheffés test bioequivalence, **15** 2635
Schizophrenia eye-tracking models, **15** 1365
Schoenfield residuals, **14** 1707; **15** 2763
Schuirmann's test, **15** 2635
Schwarz information criterion, **14** 1219; **15** 2077
Scientific interaction clinician/statistician, **3** 1
Score data analysis method, **13** 955
Score equation, **13** 1241
Score statistic
case-control studies, **7** 363
cluster analysis, **14** 2291, 2309
dependent censoring model, **15** 1049
focused cluster analysis, **15** 765
generalized linear models, **11** 923
homogeneity tests, **10** 1257; **13** 805
interval-censored failure time, **15** 1387
likelihood analysis, **7** 149
multiple endpoints, **14** 1163
odds ratio homogeneity tests, **11** 159
ordered, **5** 15
sample size, **13** 79
space-time cluster analysis, **14** 2383
stepwise selection, **11** 2093
stratified trials, **14** 2037
Scores model, **13** 1665; **14** 431, 1331
Scoring systems
bias factor, **8** 415
clinical diagnosis, **8** 1351
diagnostic tests, **8** 609
odds ratio study, **8** 1455
ordinal, **8** 785
photographic image grading, **8** 1433
predictive diagnostics, **15** 2149
psychiatric, **8** 1317
sensitivity, **9** 1189
SIDS prediction, **5** 113
survival analysis, **8** 947
Scotland
birthweight data, **15** 2657
HIV test data in forecasts, **13** 2009
SCPRT *see* Sequential conditional probability ratio test
Screening
benefit estimation, **13** 569
bias correction, **7** 417
blood pressure study, **7** 423; **9** 1157
breast cancer, **1** 15; **8** 431
cancer, **2** 217; **13** 955; **14** 2715
clinical trials, **8** 1439; **9** 673
cancer, **13** 1423; **14** 2619–2620(L)
early stopping, **13** 1479
tumour vaccine, **14** 2099
cohort studies analysis, **9** 969
coronary artery disease tests, **4** 53
correspondence analysis, **8** 1351
cytology study, **5** 127
data collection, **9** 103, 137
diagnostic tests, **6** 813; **7** 1289; **8** 609
disease history estimation, **5** 127
factorial designs, **8** 161
false negative rates, **8** 743
familial intracranial aneurysms, **9** 1229
hepatitis B, **8** 391
HIV, **8** 59; **13** 1905; **15** 2161
logistic regression model, **9** 1157
mass, **2** 279
model-based, **11** 257
myocardial infarction, **8** 415
phase II trial design, **13** 417
Poisson regression model, **9** 1157
predictive diagnostics, **15** 2149
prevalence estimation, **8** 1225
prostate cancer diagnosis, **9** 325
reciprocal control designs, **9** 55
recurrent disorders, **8** 1439
reference centile curves, **11** 1305
sojourn time, **8** 743; **14** 1531
trauma study, **14** 1463
vaccine development, **9** 1425
Search partition analysis (SPAN) subgroup identification, **14** 2645
Seasonal affective disorder (SAD) time series regression relationships, **12** 1555
Seasonal effects, **8** 343
AIDS incidence, **13** 1921
height growth study, **13** 1643
time series regression relationships, **12** 1555
Seat belts, safety study, **8** 379
Secant method generalized linear models, **11** 923
SECM *see* Supplemented ECM
Second-order approximation, **13** 1135
Secondary attack rate, **12** 249; **13** 1563
SEER programme, **8** 255; **12** 3
Segment-based maps, **12** 1953
Segregation
Mendelian model, **7** 591
non-random linkage, **9** 573
SEIR models, **12** 229
Selection
see also Stepwise variables
adjustment errors, **9** 1339
anaesthesia variables, **7** 947
backward elimination, **13** 431
bias
blood pressure study, **7** 417, 423
cancer study, **6** 389
diagnostic tests, **4** 53
heart disease surveillance, **4** 53
historical control studies, **3** 225, 315
meta-analyses, **6** 245, 315; **7** 1207
observational/experimental studies, **13** 557

placebo effect, **7** 1203(L); **8** 1301–1302(L)
pooling clinical trials, **6** 389
psychiatry study, **7** 727
randomized trials, **6** 127, 251, 389
reduction, **13** 2269
screening tests, **4** 53
single consent designs, **3** 215
survival analysis, **7** 1207
treatment changes, **15** 249
treatment evaluation, **7** 1179; **8** 477
variance estimation, **7** 417
cubic spline knots, **13** 1045
diagnostic tests
bias, **4** 53; **6** 411
cancer study, **5** 127
case-control studies, **5** 127
comparisons, **6** 147
efficacy, **6** 411
efficiency, **4** 535; **7** 549
error comparisons, **6** 147
graphical presentation, **5** 585
heart disease, **4** 53
latent class analysis, **5** 21
liver function, **8** 609
logistic regression, **7** 519
multiple tests, **8** 1231
power evaluation, **6** 147; **7** 519
prediction, **4** 535
psychiatry study, **7** 727
sample size evaluation, **6** 147
scoring systems, **8** 609
screening methods, **5** 127
sensitivity estimation, **7** 739, 1289
specificty estimation, **7** 739, 1289
treatment allocation deviations, **7** 1179
validation techniques, **4** 53
ecologic variables, **13** 1755
exact test variables, **7** 765
forward elimination, **13** 431
meta-analyses
bias, **6** 245, 333
cardiovascular diseases, **6** 295
independent studies, **6** 221
methodology, **6** 229, 233, 241, 403
patients, **6** 113; **13** 859
placebo effect, **7** 1203(L); **8** 1301–1302(L)
RCR models, **13** 1211
treatment
decision theory, **5** 411; **6** 101
patient's viewpoint, **6** 745
randomized trials, **6** 287, 337, 359
stratum-covariate interaction, **5** 73
variables, **13** 301; **14** 431
Selenium levels
EAAS, **11** 1343
optimal checking procedures, **11** 1343
Sellafield Reprocessing Plant, **7** 649
SEM *see* Supplemented EM
Semi-Bayes regression epidemiologic studies, **12** 717
Semi-Markov process, **5** 243; **15** 527
Semi-proportional hazards models, **11** 1465; **15** 1771
Semi-sequential analysis group sequential method comparison, **12** 51
Semi-variogram cluster analysis, **14** 2393
Sensitivity
AIDS projections, **11** 1425
Bayesian approach, **11** 37
breast cancer screening, **14** 1531
clinical trials, **9** 125, 1229
comparison, **6** 147
confidence intervals, **8** 1381; **10** 443
correlated observations, **11** 1503
decision analysis, **8** 229
diagnostic marker, **13** 1551
diagnostic tests
agreement analysis, **9** 559
latent class analysis, **5** 21; **6** 529–531(L)
P-value misuse, **8** 1413–1814(L)
review, **10** 1897
screening methods, **8** 1225
differential recall bias, **15** 2603
disease mapping
diabetes, **14** 2411
leukaemia, **14** 2459
distributional assumptions, **13** 1525
drug trials, **11** 1057
equivalence tests, **14** 1831
Fisher's exact test, **5** 629
frailty models, **14** 1859
genetic diseases model, **14** 1353
hierarchical models, **9** 919
HIV model, **10** 1003; **14** 1513
infection force model, **9** 953
liquid suspension assay, **14** 1081, 1097
logistic models, **14** 299, 2285–2288(L)
misclassification, **9** 1327; **10** 361
missing data, **9** 777; **14** 1315
model building strategies, **12** 1325
monitoring devices, **10** 351
multiple comparison testing, **10** 1
naive estimators, **13** 1737
patient selection clinical trials, **9** 73
Poisson regression, **8** 285
prognostic scores risk groups, **9** 1189
ROC curves, **8** 1277; **15** 323
RSAC, **15** 893
screening, **8** 743, 1225
sequential monitoring, **14** 1927
simultaneous confidence regions, **13** 499
surveillance systems, **3** 239; **4** 389–391(L)
time-space clustering techniques, **3** 173
transmission probability estimation, **11** 565
trauma study, **14** 1463

Sensitivity (*cont.*)
vaccine studies, **9** 1327
variance estimation, **8** 229
Sequences gamma neuronal discharge, **4** 91
Sequential clinical trials
see also Group sequential methods
bias investigation, **8** 563
binary variables, **9** 229
Brownian motion, **12** 753
cancer treatments, **1** 73; **2** 183
closed schemes, **9** 673
confidence intervals, **9** 1277
data monitoring aspects, **6** 753
ECOG impact, **8** 505
frequentism, **12** 1405
interim analysis, **4** 521; **10** 925
lung cancer study, **1** 73
methodology review, **10** 1789
monitoring method, **9** 1081
multiple test procedure, **10** 871
NCI methods, **9** 871, 903
NHLBI methods, **9** 881, 903
phase II/III trials, **9** 229
randomization unbalanced effect, **1** 277
sample size calculation, **1** 25
stopping rules
bias estimation, **7** 1231
cancer treatment comparisons, **1** 73
ECOG methods, **8** 505
efficiency, **3** 353, 445
monitoring, **6** 753; **10** 405
myocardial infarction, **6** 927
NHLBI developments, **9** 881
overviews, **6** 361, 369
phase II/III trials, **9** 229, 595
treatments, **1** 73; **2** 183; **5** 375
treatment comparisons, **5** 375
triangular test procedure, **9** 907
type I error spending functions, **9** 1439
Sequential conditional probability ratio test (SCPRT), **15** 2037
Sequential designs, **13** 2249
Bayesian, **14** 357, 381
conditional probability stopping rule, **11** 659
enrolment, **15** 2445
equivalence tests, **15** 2703
gamma-method, **12** 13
phase II trials, **14** 1479
spending functions, **12** 2219
three-squares crossover, **15** 2143
Sequential diagnostic rule, **7** 549
Sequential logrank procedure withdrawal censoring, **11** 1359
Sequential monitoring, **14** 1927, 2227; **15** 2341
Sequential probability ratio tests, **5** 375; **9** 907; **10** 989; **13** 1357; **15** 2781
Sequential *t*-tests, **15** 2781
Sequential test LR statistic, **13** 1563
Serial biomarker data autogregressive models, **11** 515
Serial correlation, **2** 497; **7** 697
Serial data analysis summary measure refinement, **12** 27
Serial dilution methods, **2** 447; **7** 535
Serial mulitvariate data incomplete data, **11** 1041
Serial observations, **7** 581
Seroconversion
AIDS/HIV
CD4 lymphocytes, **13** 1101
epidemiological studies, **9** 1387
haemophiliacs, **9** 681; **13** 163
infection models, **8** 45
marker paths, **12** 2099
prevention models, **8** 59
public health surveillance, **12** 2065
relative risk regression, **12** 2087
sample size estimation, **10** 1993
time distribution estimation, **9** 505
transmission models, **8** 93
type 1, infection time, **13** 231
AZT, **15** 75
time
parametric estmates, **11** 591
since exposure, **11** 939
Serology, **2** 447; **13** 1881; **15** 1567
Serum antitrypsin, **3** 261
Serum bile acids, **6** 147
Serum cholesterol, **3** 423
Serum neutralizing activity, **11** 1253
Serum titre assay, **7** 535
Services
accident and emergency, **7** 1061
maternity, **5** 607
Set covering problems, prognostic, **9** 273
Sets technique
congenital malformations study, **5** 565
Cusum comparisons, **3** 239; **4** 389–391(L); **5** 98–99(L); **6** 517; **7** 997–999(L)
Severity score burden of illness, **13** 1807
Seveso disaster, **2** 259
Sex organ malformation
mother's alcohol consumption, **15** 2095
within-family coincidence, **15** 2029
Sexual behaviour
AIDS incidence, **15** 221
evaluating change, **12** 219
HIV infection, **15** 2323, 2337, 2393
Sexually transmitted diseases
see also AIDS; HIV
case-control study, **14** 769
gonorrhea surveillance, **8** 343
mark-recapture model, **11** 1533
syphilis surveillance, **8** 353
transmission probability estimation, **11** 565
variation estimation, **8** 229
SFMHS *see* San Francisco Men's Health Study

Shannon entropy, **11** 231
Shape invariant model extensions, **14** 2009
Shapiro-Francia statistic, **10** 1283; **11** 897, 1115; **12** 181
Shapiro-Wilk statistic, **10** 1283; **11** 881, 897; **15** 2635
Shared haplotypes test, **5** 281
Sheep, **15** 2107
Sheffield score SIDS prediction, **5** 113
Shelf-life drug tests, **8** 883
SHEP pilot study, **9** 65
Shephard's method contour mapping, **14** 605
Shewhart principle, **2** 131, 141; **4** 369; **6** 425
Shewhart test, **11** 1489
Shewhart-Cusum schemes, **11** 515; **12** 265
Shift work, nurses, **7** 983
Short memory schemes, **8** 311
Shrinkage
  Bayesian analysis, **11** 13
  clinical trials, **7** 1231
  disease mapping, **14** 2363
  estimation
    cross-validation, **12** 2305
    hierarchical methods, **12** 717
  kidney graft survival, **14** 1999
  measurement errors, **8** 1167, 1179
  multivariable prognostic models, **15** 361
  prediction factors, **5** 421; **9** 1303
  risk screening, **11** 257
Sickle cell anaemia, **6** 689; **9** 45
Sickness industrial absence, **1** 317
Side effects
  clinical trials, **9** 87; **10** 1349
  data collection, **9** 103, 145
  Markovian model, **9** 803
  quality of life analysis, **9** 931
SIDS *see* Sudden infant death syndrome
Siegul-Tukey's test, **9** 447
Sigmoid curve bioassay modelling, **12** 2025
Sign score models case-control studies, **14** 431
Sign tests, **8** 1469
Signed rank test, **5** 199(L), 200(L)
Significance estimators, **8** 653–677
Significance level environmental risk factors, **7** 649
Significance tests, **13** 1715
Significant results replication, **11** 875
Similarity measurements, **8** 1401
Simple model unpublished studies, **15** 2493
Simpson's paradox, **3** 361; **12** 1477, 2191
Simulated annealing method, **11** 1871
Simulations
  see also Monte Carlo simulations
  accelerated cure models, **14** 2111
  aggregate data studies, **15** 1849
  AIDS
    mean-squared errors, **10** 1167
    projections, **11** 1425
    reporting delay, **15** 305
ANCOVA, **15** 477
assay calibration, **14** 1949
assay variability estimation, **10** 1543
asymptotic test, **15** 647
attributable risk, **11** 2083
AZT, **15** 2413
back injury intervention trial, **15** 1951
back-projection HIV, **13** 1945
balanced allocation methods, **9** 237
baseline change measurements, **8** 1183
Bayesian calibration, **13** 1165
bioequivalence studies, **10** 961; **13** 2531
birth defects, **15** 717
birthweight, **15** 1333, 2657
bootstrap method, **8** 1485
bounding procedures, **14** 1985
cardiovascular survival studies, **12** 1365
case-base studies, **8** 1241
case-control/cohort comparisons, **10** 1775
CD4 counts, **13** 405
cell count estimators, **13** 523
censored data, **8** 1269; **10** 1441; **15** 953, 1663
clinical trials, **8** 153; **11** 55; **13** 635
cluster analysis, **15** 783, 1793
cluster randomization, **8** 599
cluster-specific estimation, **13** 1241
CMS, **14** 2565
common odds ratio, **14** 1567
community interventions, **14** 1491
confidence interval, **8** 927; **13** 1071; **14** 1875
contingency tables, **8** 1455; **10** 991
contour mapping, **14** 605
correlations study, **8** 1485; **14** 2217; **15** 1187
covariates imbalance tests, **9** 1455
CRM, **14** 911, 923, 1149
CTS program, **9** 787
dependent censoring model, **15** 1049
design effects, **12** 1259
diagnostic test, **8** 1381
disease mapping, **14** 2411
disease risk analysis, **11** 1443
dose ranging designs, **10** 303; **15** 1605
drugs efficacy, **13** 2323
dynamic balanced randomization, **12** 2343
equivalence tests, **15** 2703
excess risk confidence intervals, **15** 1535
explanatory variables, **12** 143
exposure coefficient, **12** 867
failure time distributions, **15** 2475
finite sample properties, **13** 479
follow-up studies, **15** 2359, 2367
goodness-of-fit, **13** 143; **14** 1785
Greenwood variance estimator, **13** 43
group sequential procedures, **8** 1191; **14** 381
hazard ratio comparison, **10** 749
hierarchical regression, **15** 1161
HIV, **10** 1003, 1167, 1427; **15** 1779, 2161
hormone secretion pulses, **14** 311

Simulations (*cont.*)
hospital mortality rates, **13** 889
immunity estimators, **14** 39
independence testing, **10** 1555
internal pilot studies, **9** 65
interval-censored failure time, **15** 1387
intra-individual variation, **12** 1213
kappa coefficient, **10** 1303, 1465; **15** 1409
linear regression model, **8** 907; **13** 1265
log-linear model, **9** 253
logistic regression, **13** 1265
longitudinal data, **8** 1523; **10** 492–495(L); **14** 283, 1219, 2239
LR statistic distribution, **13** 1563
Lyme disease incidence, **14** 17
map comparisons, **14** 2343
median survival times, **14** 2537; **15** 171
menstruation study, **14** 1843
method comparison studies, **10** 981
missing data, **15** 127, 2191
model misspecification, **14** 1703
multigroup transmission model, **9** 721
multivariate survival data, **12** 1019
multivariate tests, **14** 1163
non-linear regression, **10** 697
non-parametric estimation, **14** 275
normality departure estimation, **10** 1283
odds ratio, **8** 1455; **14** 2581
order statistics study, **10** 855
outliers detection, **10** 1375; **11** 2133
p-value adjustment, **15** 103
paired binary data regression, **9** 1517
paired outcomes, **13** 1023
parametric/non-parametric tests, **13** 769
PCP trial, **15** 2341
penalized likelihood, **15** 907
phase I trials, **10** 1647; **13** 1799
phase II trials, **10** 1327; **14** 987, 1007
photo image grading, **8** 1433
play the winner, **15** 2135
poisson time series realizations, **13** 453
pooling controls, **10** 1417
PQD study, **13** 623
prescription event monitoring, **15** 987
prognostic scoring sensitivity, **9** 1189
proportional measurement errors, **9** 1463
provisional diagnoses, **10** 1341
quality adjusted survival, **15** 93
quasi *t*-quantile approximations, **13** 1657
radiation exposure, **8** 173
random censoring patterns, **8** 937
random effects models, **15** 1465
randomized clinical trial, **10** 405
randomized screening trial, **13** 569
recurrent events, **14** 2081
reference intervals, **14** 1417
regression models, **8** 217, 525; **14** 395, 431
robust estimator, **15** 1033
sample size calculation, **11** 179; **14** 1039, 1053
SAS sample size programme, **13** 391
sequential monitoring, **14** 2227
sequential *t*-tests comparison, **15** 2781
sequential trials confidence, **9** 1277
SFMHS, **13** 1101
side effects incidences, **9** 803
simultaneous back-projection methods, **13** 1865
smoothing procedures, **14** 1205
space-time clustering, **15** 2561
spatial autocorrelation coefficient, **15** 887, 893
stopping guidelines, **12** 901
summary statistic functions, **13** 1853
survival analysis, **12** 1569; **13** 1747
survival trees, **8** 947
t-statistic balance, **13** 1715
toxicity grades, **11** 2063
triangular test, **9** 907
tumour lethality rates, **13** 689
two-by-two crossover design, **14** 853
two-sample tests, **13** 747
univariate survival analysis, **15** 2203
USA mortality rates, **13** 1119
vaccine efficacy estimation, **10** 1573
vaccine trial screening, **14** 2099
variance components, **10** 1441
within-person measurement error, **8** 1051
SIMULINK computer package, **14** 185
Single Photon Emission Computed Tomography, **10** 1711
Single-step test multiple comparisons, **11** 1057
Singular grouped cohort values, **13** 2407
Sinusoidal technique, **8** 861
Six Cities Study, **7** 139; **13** 143, 1149
Size
see also Sample size
closed population estimates, **3** 287
Sizewell Nuclear Plants, **7** 649
Skewness, **11** 333; **12** 1651, 2099
Skin cancer, **10** 1241; **13** 1189; **14** 821
Skin conditions, **7** 109
Skin flora, **5** 393
Slash family model inference, **13** 1525
SM schemes *see* Short memory schemes
Small area analysis, **15** 1859
classification methods, **15** 1921
confidentiality, **15** 1895
empirical Bayes estimation, **15** 1867
GIS, **15** 1961
spatial partitioning, **15** 1885
Stone's method, **15** 1927
Small Area Statistics in Public Health: Design, Analysis, Graphic and Spatial Methods Symposium, **15** 1827–1986
close of symposium, **15** 1985–1986
closing remarks, **15** 1983–1984
introduction, **15** 1835–1836
poster presentations, **15** 1979–1981

preface, **15** 1827–1828
staff and committees, **15** 1829–1834
Smallpox 'red treatment', **12** 197
Smirnov statistic, **15** 631
Smoking
age/exposure interaction, **13** 2407
autoregressive models, **4** 457; **7** 59
birthweight, **11** 643
cancer risk analysis, **7** 223, 289, 297; **11** 141; **14** 327–330(L)
cardiovascular disease, **14** 1745
case-control studies, **8** 1528; **9** 1339
categorical data analysis, **7** 95
cessation
causal effect, **12** 1605
data analysis, **9** 409
exposure errors, **8** 1109, 1127, 1133, 1137
lung cancer incidence, **15** 565
lung disease, **15** 1771
lung function study, **7** 11, 685
matched pair clinical trial, **9** 943
mortality analysis, **8** 997
multivariate studies, **4** 117
passive smoking studies, **8** 1199; **13** 343; **14** 545
respiratory disease, **11** 1915
respiratory function, **14** 2205
risk factors, **4** 345; **8** 997
smoothing methods, **7** 601
spousal smoking study, **15** 581
tobacco use prevention, **12** 365
Smoothed data, **7** 795
Smoothing procedures, **7** 601, 843; **8** 551, 785; **13** 969
AIDS incidence data, **12** 311
Bayesian approach, **13** 823
blood pressure profile, **11** 2147
covariance matrix, **11** 1843
cubic smoothing splines, **14** 935, 953
environmental epidemiology, **12** 1249
geographical data, **15** 2539
HIV incidence, **15** 1779
kernel
estimator technique, **12** 843
survival analysis, **12** 1569
locally weighted, **13** 1101, 1201
longitudinal data, **14** 1205, 1219, 1235
penalized likelihood, **15** 907
reference centile curves, **11** 1305
relative risk estimation, **11** 983
scatterplots, **11** 1115
splines method AIDS incidence curve, **12** 1317
Smoothing span, **7** 601
SMR *see* Standardized mortality ratio
Social factors
heart mortality rates, **9** 1199
infant mortality, **4** 175, 189; **5** 139, 155
Society for Clinical Trials/International Society for Clinical Biostatistics Joint Meeting, Brussels, **11** 2141, 2147; **12** 2257–2341
Socioeconomic status study, **13** 343
Software packages *see* Computer packages
Sojourn time, cancer screening, **8** 743; **14** 1531
SOLVD *see* Studies of Left Ventricular...
Sonksen-Silver Acuity System (SSAS) childhood study, **14** 257
Southwest Oncology Group, **11** 853, 1367; **13** 1391
Space theoretical conceptions, **15** 1859
Space-time cluster analysis
Bayesian analysis, **14** 2433
DEMP, **7** 491
Hodgkin's disease, **3** 173
influenza, **7** 1147
k nearest neighbour test, **15** 1935
non-uniformly distributed population, **15** 2561
scan statistic, **6** 197
tests, **14** 2383
Spain
AIDS incidence, **15** 305
Database of Clinical Trials, **11** 345
SPAN computer package, **14** 2645
see also Search partition analysis
Sparse data
pseudo likelihood approach, **12** 2285
rare event clustering, **11** 761
Spatial analysis techniques, **13** 523
infant mortality, **14** 481
Spatial autocorrelation
coefficient, **15** 887, 893
disease mapping, **12** 1943
IDIFF statistic, **12** 1795
indices, **12** 1885
Spatial clustering, **7** 491; **14** 799, 2309, 2323
see also Cluster analysis
focused tests, **14** 2291
mapped data, **12** 1275
occupational poisoning, **15** 747
quadrat analysis software, **15** 939
Spatial data, **13** 523, 553; **14** 1393–1394(L)
birth defects, **15** 717, 1907
cancer mortality rates, **10** 95
cluster analysis, **7** 491; **14** 799, 2309, 2323
focused tests, **14** 2291
mapped data, **12** 1275
occupational poisoning, **15** 747
quadrat analysis software, **15** 939
community intervention efficiency, **9** 943
correlations, **5** 171
covariates, **14** 2393
density estimation, **9** 691
directional effects, **12** 1795
disease patterns, **14** 2289
disease rates, **12** 1885
geographical grouping algorithm, **5** 171
infant mortality, **15** 1907

Spatial data (*cont.*)
longitudinal model, **14** 605
map comparisons, **14** 2343
significance tests, **9** 515
small area analysis, **15** 1859
surveillance analysis, **8** 267
traffic accident mapping, **14** 2445
variations
childhood leukaemia, **14** 2487
relative risk, **14** 2335
Spatial forecasting, **11** 1409
Spatial partitioning, **15** 1885
Spatial scan statistic, **15** 707
Spatial time series analysis, **15** 389
Spearman rank correlation coefficient, **13** 2465
Spearman-Brown formula, **11** 317
Spearman-Kärber, **11** 1171, 1253; **14** 841
Special care baby unit, **7** 1207
Special issues
see also Workshops
Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry symposium, **14** 455–717
International Society for Clinical Biostatistics *see* International...
Longitudinal Data Analysis, **11** 1797–2040
Meta-Analysis in the Design and Monitoring of Clinical Trials, **15** 1233–1323
Methodological and Ethical issues in Clinical Trials (Conference), **12** 1373–1534
Monitoring of Clinical Trials, **12** 415–616
National Institutes of Health, *Conference on Current Topics in Biostatistics*, **13** 399–783
Quantitative Methods for Studying AIDS, **13** 1899–2187
Small Area Statistics in Public Health: Design, Analysis, Graphic and Spatial Methods, **15** 1827–1986
Spatial Disease Patterns, **14** 2289–2505
Statistical Methods in Biopharmacy, **14** 881–1143
Statistical Methods for Evaluation of Intervention and Prevention Strategies, Symposium, **12** 191–414
Statistics and Computing in Disease Clustering, **15** 681–951
Symposium on Statistical Issues in HIV/AIDS Research, **15** 2269–2491
Tutorials in Biostatistics, **15** 343–428
Specificity
confidence intervals, **8** 1381; **10** 443
correlated observations, **11** 1503
diagnostic marker, **13** 1551
diagnostic tests, **9** 559; **10** 1897
frailty, **13** 1679
latent class analysis, **9** 559
logistic models, **14** 299, 2285–2288(L)
misclassification bias, **9** 1327
monitoring devices, **10** 351
ROC curves, **8** 1277; **15** 323
RSAC, **15** 893
simultaneous confidence regions, **13** 499
surveillance, **3** 239; **4** 389–391(L)
trauma study, **14** 1463
VA cooperative studies, **9** 125
vaccine efficacy studies, **9** 1327
SPECT *see* Single Photon Emission Computed Tomography
Spectra, power, **6** 159
Spending function, **12** 2219; **13** 1341
Sphericity, **2** 497; **3** 185; **7** 471
Sphygmomanometer, **4** 361
Spina bifida, **3** 287; **10** 113
Spinal cord injuries severity/level estimation, **11** 1171
Spirometry, **7** 11, 19, 685; **8** 1109
Spliced smoothing, **7** 601
Spline approximation, **15** 197
Spline curves smoothing, **11** 1305
Spline functions, **11** 2147
Splines, cubic, **8** 551
Split-plot design, **1** 139; **5** 393; **6** 911; **12** 633
Split-sample prediction technique, **9** 1303
Splitting at the median, **14** 873
Spontaneous abortion, **4** 469; **5** 557; **6** 197
Sporadics, **2** 13
SPRTs *see* Sequential probability ratio tests
SPSS-PC computer package, **15** 933
Sputum cytology, **8** 1199
Square array, blood test, **13** 2337
Square root scale serial CD4 counts model, **12** 2099
Squared multiple correlation coefficient, **7** 591; **15** 1987, 1999
SSPE *see* Subacute sclerosing panencephalitis
Stability analysis
batch-to-batch variation, **11** 269–270(L)
drug tests, **8** 883
Stage-specific numbers, **11** 831
Stages of change model sexual behaviour, **12** 219
Staggered entry longitudinal data, **11** 1861
Staging AIDS incubation distribution, **11** 1633
Staging, diseases, **4** 265, 279, 287; **5** 465
Standard errors
adjustment, **12** 1683
age-related reference centiles, **12** 917
AIDS incidence, **14** 1505
asymptotic marginal homogeneity, **13** 609
categorical regression models, **14** 2131
clustered data, **13** 509
corrected parameter estimates, **13** 1135
correlated ordinal data, **14** 1961
linear regression, **14** 789
mortality predictions, **14** 821
pushback procedure, **12** 1033
robust calculation, **12** 925

sandwich formula, **12** 289
sign score models, **14** 431
Standard inflation factors collinearity diagnosis, **11** 1273
Standardization
birth incidence, **14** 1797
clinical trial reports, **13** 2393
direct medians, **13** 1635
ecologic study bias, **11** 1209
indirect, **6** 61, 193, 449
parameter estimation, **14** 2131
rates
age-adjustment methods, **2** 455
cancer variation models, **6** 449, 469
equality tests, **1** 37
hypothesis tests, **6** 61
mortality calculation, **2** 381; **4** 105–109(L)
Poisson comparisons, **8** 757
smoking effects, **7** 223
summary rates, **13** 1781
summary ratios estimation, **1** 217
Standardized incidence ratio disease mapping, **14** 2459
Standardized likelihood distribution clinical trial reports, **12** 1651
Standardized mortality ratios
age/area effects, **14** 615
Bayes estimate, **13** 1119
bias assessment, **6** 193; **9** 1327
cancer variation models, **6** 449
childhood leukaemia incidence, **14** 2487
cohort studies, **3** 113; **4** 295
comparisons, **3** 7; **4** 295; **9** 315
confidence intervals, **13** 2189; **14** 1875
correspondence analysis, **13** 2407
database research, **10** 637
disease mapping, **12** 1895, 1943
exposure groups, **12** 1989
healthy worker effect, **5** 61; **6** 901
heart disease mortality variation, **9** 1199
index evaluation, **6** 71
multilogit model, **9** 981
multiplicative model, **9** 737
relative risk, **10** 1267; **11** 983
spatial models cancer, **10** 95
survival analysis, **9** 529
trend interpretation, **3** 113
variance estimation, **6** 701
Standardized parameters estimation, **11** 559–560(L)
Standardized risk difference, **8** 679
Standards, growth, **6** 185
Stat! software, **15** 951
STATA computer package, **11** 475, 897, 1115; **13** 301
State-space models time analysis, **8** 336
Stationarity, Markov chain, **7** 671
Statistical Analysis System *see* SAS
Statistical consultation, **3** 1
Statistical diagnosis, **4** 311
Statistical errors, **7** 1003
Statistical guidelines, **3** 97
Statistical independence, **7** 1289
Statistical inference, **6** 101, 277, 369, 387, 745; **8** 1304–1306(L)
Statistical Issues in HIV/AIDS Research Symposium, **15** 2269–2491
Statistical Methods in Biopharmacy 2nd International Meeting, **14** 881–1143
Statistical review, **7** 1003
Statistical significance teaching, **5** 193
Statisticians, **1** 5, 311
Statistician's Report Worksheet computer program, **11** 1367
Statistics and computing in disease clustering (conference), **15** 681–951
Statistics in the medical literature, **14** 873–874; **15** 559
Statistics in Medicine citations analysis, **13** 3
StatXact computer package, **13** 1539, 2189
Steady states autoregressive models, **11** 515
Stein's method, **11** 55; **12** 1213
Stein's *t*-test, **9** 65
Stenosis, arterial, **5** 619
Step functions, **11** 23, 1023; **12** 617, 2133; **14** 2119
Step length determination, **12** 2025
Step-down multiple significance tests, **10** 939
Step-down procedure, **13** 2261
Stepwise logistic analysis, **13** 1793–1795(L)
Stepwise permutation tests, **15** 1107
Stepwise regression analysis, **10** 711
Stepwise testing procedure, **7** 139, 843
multiple comparisons, **11** 1057
rank transformation, **12** 143
selection methods, **11** 2093
Stepwise variables selection, **13** 1501
Bayesian inference, **5** 503
Cox regression, **4** 413; **8** 771
diagnostic methods, **5** 503
discriminant analysis comparisons, **4** 413
disease/exposure relationship, **5** 49
fertility prediction, **14** 1807
heart risk factors, **4** 413
logistic regression comparisons, **4** 413
model building strategy, **12** 1325
prediction evaluation, **5** 421
prognostic factors identification, **4** 39
risk factors selection, **4** 413
stratum-covariate interaction, **5** 73
Stereoisomers, **13** 785
Stereotype model, **13** 1665
Sterilization, hysterectomy study, **8** 977
Stevens-Johnson syndrome study, **10** 565
Stillbirths, **4** 175, 189; **9** 981
Stochastic curtailment, **11** 23, 55; **13** 663, 683
clinical trials, **6** 667; **10** 1789
early acceptance of null hypothesis, **12** 51

Stochastic curtailment (*cont.*)
interim analysis, **10** 925
monitoring, **6** 753; **9** 1081; **12** 1501
NHLBI clinical trials, **9** 881
NIH clinical trials, **9** 903
stopping rules, **6** 667
Stochastic errors, **15** 2669
Stochastic models
AIDS epidemic, **8** 45, 121
categorical data analysis, **7** 95
CD4 lymphocyte counts, **15** 2289
chromosome loss, **13** 839
clinical trials evaluation, **7** 581
counting process, **5** 491
diabetes study, **7** 661, 671
disease transmission simulations, **13** 53
HIV incubation, **15** 197
HIV infection, **8** 45, 831
infection incidence, **12** 1317
liver function tests, **7** 671
lymphoma study, **5** 491
measles epidemic analysis, **12** 229
morbidity estimation, **7** 325
mortality risk interaction, **7** 239, 293
random walk models, **7** 581
repeated binary data, **15** 2617
risk mortality interaction, **7** 239, 293
survival analysis diabetes study, **7** 661
vaccine effect prediction, **6** 843
Stochastic ordering, **8** 571
Stochastic processes
disease prevalence prediction, **11** 295
distribution-free estimators, **11** 1151
dose-toxicity relationship, **10** 1647
HIV projection, **10** 1427
psychotherapy studies, **11** 231
quality of life analysis, **9** 749; **10** 1915
repeated events analysis, **10** 1227
sequential monitoring, **12** 753
survival curve representation, **11** 455
Stochastic relaxation
see also Gibbs sampler
longitudinal data, **11** 2001
Stoke index (SI) RA activity measure, **12** 1171
Stomach cancer, **3** 455; **4** 63, 201; **6** 307; **12** 3; **14** 1331
Stone's test
cluster analysis, **14** 2291, 2309; **15** 765
leukaemia mapping, **14** 2459
point sources, **15** 1927
Stool frequency, **7** 581
Stopping rules
Bayesian, **11** 23; **12** 1197; **13** 1371
best dose selection, **13** 87
boundaries, **13** 1357
case-control study, **13** 663
clinical trials
alpha-interferon, **13** 2249
Bayesian monitoring, **14** 357, 1379
conditional probability, **11** 659
decision-theoretic evaluation, **11** 673
ethical issues, **12** 1459
European trials, **12** 509, 521
external evidence, **15** 1285
meta-analysis, **15** 1263, 1273, 1299
multiple treatments, **12** 901
sample size, **14** 115
conditional probability, **11** 659
CRM, **14** 1149
decision-theoretic evaluation, **11** 673
dose-response evaluation, **14** 1595
early clinical trials, **13** 1313, 1493
ethical considerations, **13** 1459, 1471
lung cancer study, **13** 1415
phase II trials, **13** 1727
positive/negative results, **13** 1391
prevention trials, **13** 1479
safety considerations, **14** 1099, 1113
workshop on, **13** 1293–1499
experimental regimen, **13** 1453
hypothesis testing, **13** 1815
iterative algorithms, **12** 2025
multiple interventions, **13** 1479
phase II trials, **11** 853
pre-eclampsia studies, **15** 1237
randomized trials, **13** 1293; **14** 381
sequential, **11** 1
study duration, **11** 1477
toxicity studies, **13** 2311
tree-based analysis, **15** 37
Stouffer's method combining probabilities, **6** 341
Strata-matched case-control studies, **11** 1759
Stratification
age, **12** 1989
age-related AIDS hazard rate, **13** 1975
assignment, **12** 101
attributable risk adjustment, **10** 1753
case-control studies, **10** 739, 1037
clinical trials, **1** 267; **4** 129; **7** 559
cluster analysis sample size, **7** 1195
combining two-by-two tables, **14** 1901
common risk ratio, **11** 1599
confidence interval estimation, **13** 1071
confounding bias identification, **7** 1087
covariate interaction assessment, **5** 73
databases methodology, **10** 617, 637
disease history, **8** 1255
distribution-free estimators, **11** 1151
epidemiology bibliography, **10** 1819
group sequential trials, **9** 1081; **11** 1477
interrater reliability measures, **9** 1103
intervention studies, **7** 1195
kappa calculation, **10** 1465
liver function tests, **7** 843
Mantel-Haenzsel adjustment, **11** 603
mark-recapture model, **11** 1533

melanoma survival analysis, **9** 999
misclassification, **10** 1181
odds ratios extraneous factors, **9** 1131
prognostic factors identification, **7** 843
proportional odds model, **13** 2503
proportions rates analysis, **4** 213
pseudo likelihood approach, **12** 2285
quality of life analysis, **9** 931
randomized trials, **6** 241
rates comparative analysis, **4** 213
relative risk techniques, **10** 1511
sample allocation costs, **9** 1475
sample size
cluster randomization, **11** 743
confounding effects, **9** 765
cost considerations, **11** 547
exact power computation, **14** 2273
ordered categorical data, **12** 2257
score test, **13** 79; **14** 2037
sexually transmitted diseases, **11** 1533
standardized rates estimators, **10** 1069
summary statistic tests, **13** 1853
survival analysis, **7** 559
treatment covariate interaction, **7** 1257
trend test, **9** 829; **10** 799–800(L)
vaccine efficacy estimation, **10** 1573
variance estimation, **7** 745
Stratum-covariate interaction, **5** 73; **6** 221, 233, 371, 381, 773
Streamlined clinical trials, **9** 185, 193
Strictly proper scoring rules, **8** 609
Stroke, **6** 233; **9** 893, 903; **12** 1063
Structural equation models *see* Covariance structure models
Structural regression analysis, **13** 2465
Student Kalamazoo trial analysis, **13** 785
Studentized Mahalanobis distances, **12** 925
Studentized residuals direct formulation effect, **11** 881
Student's *t*-distribution treatment-by-centre interaction, **12** 1033
Studies of Left Ventricular Dysfunction, **9** 73, 97, 103
Sub-models, **13** 609
Subacute sclerosing panencephalitis, **10** 1733
Subadditivity, factorial design power, **8** 161
Subgroup analysis
Bayesian analysis, **11** 13, 37
bias avoidance study, **6** 245
cardiovascular trials, **6** 295
clinical trials stopping rules, **6** 361
randomized trials, **6** 233, 241, 277, 371, 379, 397
treatment assessment, **4** 255; **6** 245
Subject-specific models
crossover designs, **12** 825
longitudinal data, **11** 1929
repeated categorical responses, **12** 1969
Subject-to-subject variability crossover designs, **12** 825
Subjective probability, **5** 421
Subsampling misselection adjustment, **9** 1339
Success rate *in vitro* fertilization, **12** 1543
Succession procedure
interim analysis, **12** 51
new group sequential analysis method, **12** 51
SUDAAN computer package, **13** 343; **14** 643
Sudden cardiac death, **13** 1015
Sudden infant death syndrome (SIDS), **5** 113; **6** 159; **7** 745
Sufficient statistics exact logistic regression, **14** 2143
Suicides, **5** 171; **6** 709; **8** 1497
Sullivan's index, **7** 787
Sum rule HIV epidemic dynamics, **11** 1657
Summary statistics, **11** 1685; **15** 2797
confidence interval estimates, **14** 2161
longitudinal data, **14** 2169(L)
refinements, **12** 27
Sunlight effects seasonal affective disorder, **12** 1555
Sup norm test paired ROC plots, **13** 499
Superadditivity factorial designs, **8** 161
Superpopulation model, **8** 679
Supplementation trial familial polyposis, **12** 1339
Supplemented ECM
algorithm, **14** 747
longitudinal data, **11** 1809
Supplemented EM longitudinal data, **11** 1809
Supplies biostatistics budget, **15** 2127
Surface area estimation, **15** 1325
Surrogate endpoint variables
AIDS/cancer trials, **13** 1423, 1437; **14** 2619–2620(L)
CD4 lymphocyte count, **13** 1895–1896(L)
clinical trials, **8** 403–440; **10** 1789; **13** 955
community intervention study, **9** 943
covariate measurement errors, **8** 1167, 1179
Cox proportional hazards, **8** 539
definition, **8** 431
exposure errors, **8** 1109, 1127, 1133, 1137
HIV CD4-lymphocyte counts, **12** 835
measurement error, **8** 1071, 1139, 1149
odds ratios, **14** 2581
prevention trials efficiency, **9** 161
regression trees comparisons, **8** 539
smoking information, **8** 997
Surveillance, **8** 251–400; **15** 2273
see also Cluster analysis
aberrations, **11** 1551
abstracts, **8** 387–392
ARIMA model, **8** 1497
birth defects, **3** 239; **4** 389–391(L); **5** 98–99(L), 565
cardiovascular disease, **8** 391
censoring factor, **8** 938

Surveillance (*cont.*)
cholesterol-based assessment, **8** 295
coordination group, **8** 253
crossover trials, **10** 1099
cusum technique
abortion epidemiology, **4** 469
birth defects, **3** 239; **4** 389–391(L); **5** 98–99(L), 565
disease data analysis, **8** 267
monitoring, **6** 517; **7** 997–999(L)
short memory system, **8** 311
data quality evaluation, **8** 367
definition AIDS, **11** 1633
disease clustering, **12** 1869
drugs tests, **10** 777, 991
healthy responder phenomenon, **10** 1621
HIV epidemic dynamics, **11** 1657
HIV transmission risk, **10** 1003
incidence aberrations, **8** 323, 331
injuries studies, **8** 388, 389
location data analysis, **8** 267
medical care, **10** 521
method evaluation, **11** 1489
missing data, **8** 263, 279
monitoring techniques efficiency, **6** 517
observational data, **8** 273, 279
Poisson regression study, **8** 285
postmarketing, **7** 1023; **10** 541
public health issues, **8** 259–280
registry data change, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
reporting delay factor, **8** 259, 963
Salmonella alert threshold, **10** 1493
seat-belt systems study, **8** 379
sequential procedure, **12** 13
sets technique, **3** 239; **4** 389–391(L); **5** 98–99(L), 565; **7** 997–999(L)
sexually transmitted diseases, **8** 343, 353
SM schemes, **8** 311
spatial data, **8** 267, 279
spatial patterns, **12** 1885
SSPE risk estimation, **10** 1733
statistical methods commentary, **8** 331
Stevens-Johnson syndrome, **10** 565
symposium summary/conclusion, **8** 393, 397
time series analysis, **8** 333–363
Surveillance, Epidemiology, and End Results Program *see* SEER program
Survey effects *see* Time-period effects
Surveys
clinical trials Europe, **12** 509, 521
cross-linked variables, **8** 1317
data monitoring NIH, USA, **12** 543, 553
data quality evaluation, **8** 367
dementia, **8** 1317
depression, **8** 1317
follow-up, **2** 223; **4** 155, 227, 295, 303, 509
health, **7** 983, 1087
mark-recapture model, **11** 1533
meta-analysis, **6** 733; **14** 669
methodology, **6** 869
Mselini joint disease, **8** 785
NMIHS surveillance issues, **8** 383
non-response, **7** 727
patient well-being, **8** 1401
postal, **6** 613
response bias, **11** 1009
sampling design, **10** 1945
teaching methods, **1** 205
Survival adjusted test, **13** 689
Survival analysis
absolute risk, **10** 1025
accelerated failure time model, **11** 1871
age-related adjustment, **10** 65
AIDS, **11** 591
cohort studies, **10** 1993
development model, **9** 681
incubation model, **7** 395
therapies intervention, **13** 2127
algorithm, **2** 295
allocation methods, **6** 119
association measurement, **8** 619
auxiliary variable, **13** 1747
Bayesian analysis, **4** 509; **11** 1–53; **15** 1757
bias, **2** 279; **3** 35; **7** 1243
bivariate parametric model, **15** 1171
bone transplant study, **10** 413
bootstrap confidence intervals, **8** 927
bootstrap investigation, **4** 39
bootstrap resampling, **11** 2093
bovine leukemia virus, **8** 725
breast cancer, **14** 1771, 1985; **15** 263
clinical trials monitoring, **6** 667
confirmatory analysis, **6** 939
curability assessment, **1** 93
prediction interval estimation, **2** 485
prospective studies, **7** 619
screening methods, **2** 279; **6** 885
treatment assessment, **2** 41, 415–416(L)
cancer
hazard models, **4** 353
mortality comparisons, **4** 295
pooling methods, **5** 303; **6** 565
prevalence, **11** 1579
regression models, **2** 287
screening study, **14** 2715
tumour response evaluation, **3** 35
cardiovascular diseases, **4** 397; **6** 501; **12** 1365
case-control design, **10** 1775
censored data
cancer study, **7** 1139
change rate analysis, **7** 337
confidence intervals, **5** 653; **8** 1269
Cox regression, **4** 39, 303
follow-up study, **5** 255
paired data, **11** 193

regression, **5** 85
sequential designs, **5** 375
treatment covariate interaction, **7** 1257
change rate analysis, **7** 337
classification, **4** 287
clinical trials
alllocation designs, **6** 119
breast cancer, **2** 41, 415–416(L)
cancer surveillance, **4** 279; **6** 785
chemotherapy, **6** 667
covariate measurement error, **6** 31
endpoint, **13** 2107
group sequential procedures, **8** 1191
heterogeneity, **6** 773
historical controls, **3** 225
leukaemia, **5** 465
lung cancer, **2** 183; **3** 35
methodology review, **10** 1789
myocardial infarction, **6** 927
pooling efficiency, **6** 565
randomized, **6** 31
relative risk, **6** 591
reports, **13** 2393
sample size, **3** 199; **5** 97–98(L); **7** 559
stopping rules, **6** 361
stratification, **7** 559
cohort studies, **4** 353; **7** 275; **10** 1043
competing risks, **6** 785; **15** 1557
confidence intervals, **2** 485; **5** 653; **6** 679; **8** 1269
confirmatory analysis, **6** 939
confounding control, **8** 679
correspondence analysis, **4** 303
covariates, **14** 2537
interactions, **5** 73; **7** 1257
measurement errors, **6** 31; **8** 1167, 1179
mortality risks, **7** 239, 289, 293
omission effects, **7** 1243
Cox proportional hazards model, **14** 735, 1707
chronic disease surveillance, **4** 303
confidence intervals, **8** 927
estimation comparisons, **8** 539
heart risk factors selection, **4** 413
heterogeneity impact, **6** 773
interaction assessment, **5** 73
intervention study, **6** 501
logistic regression model, **8** 525
methodology review, **10** 1931
myocardial infarction study, **4** 29
Poisson regression comparisons, **9** 1157
pooling study results, **9** 1501
prognostic factors, **4** 39
relative risk comparisons, **6** 591
renal disease surveillance, **5** 637
risk techniques, **10** 1025
stratum/covariate interaction, **5** 73
Cox regression, **12** 975
cross-validation, **12** 2305
crossover trials, **10** 1099
crude incidence curves, **11** 813
cure model, **3** 153; **6** 483; **14** 2111
cure rate estimation, **11** 931
cystic fibrosis, **15** 449
data monitoring, **12** 2219
death study, **6** 565
dependent censoring model, **15** 1049
dependent data, **14** 1819
depression prevention, **15** 2077
diabetes study, **5** 637; **7** 661
differential prognostic influence, **11** 281
discriminant analysis, **4** 413
disease
history studies, **9** 1221–1222(L)
indicators assessment, **10** 1061
recurrence, **2** 41, 415–416(L)
dispersion tests and adjustments, **12** 1683
doubly censored data, **14** 2555
drug combination treatments, **9** 1527
duration data, **15** 527
early treatment termination, **9** 1417; **13** 1401
epidemiology, **5** 303; **8** 703; **10** 521, 1819
error, **6** 31; **7** 257; **9** 1303
expected survival, **11** 1527–1530(L)
explained variation, **9** 487; **15** 1999
exponentially distributed survival times, **12** 1733
finite mixtures theory, **9** 397
follow-up study, **4** 509; **5** 255; **7** 483
frailty models, **14** 1447, 1859
Framingham heart study, **7** 205, 219; **14** 1731
functions, **3** 35; **5** 85, 653
gestational age, **11** 1225
goodness-of-fit models, **14** 1785
graphical presentation, **3** 35; **11** 455
group sequential tests, **8** 505; **9** 1081; **13** 101
grouped data models, **9** 737
hazard ratio estimators, **10** 749
heart disease, **4** 397, 413; **7** 205
heterogeneity impact, **6** 773; **7** 1121
historical controls study, **3** 225; **8** 153
history data analysis, **7** 819
HIV
infection, **15** 2177
stochastic methods, **10** 1427
surrogate endpoint, **12** 835
treatment, **15** 2425
homogenetic variance, **15** 51
immunity study, **14** 39
infant mortality studies, **9** 981
infection resistance analysis, **3** 165
interactions stratum/covariate, **5** 73
interval censored data, **14** 2727; **15** 283
kidney transplantation, **14** 1553, 1999
last case influence, **11** 1615
leukaemia, **4** 39, 287, 509; **5** 465
LFP model, **9** 409

Surveys (*cont.*)
life-tables, **4** 155, 397; **6** 527–528(L); **13** 43, 2383–2384(L)
linear models, **4** 353; **8** 907
litter-matched designs, **2** 315
liver transplant study, **10** 733
logistic regression, **4** 413; **6** 501; **9** 1501
logrank test, **11** 179
allocation methods, **6** 119
cancer treatments comparisons, **2** 183
censoring effects, **8** 937
clinical trials sample size, **5** 97–98(L)
litter-matched data analysis, **2** 315
power evaluation, **6** 483
power investigation, **6** 119
long-term, **15** 2763
longitudinal studies, **8** 1515; **11** 1841–1885, 2029
lung cancer
prognostic factors, **4** 279
proportional odds model, **2** 273
registry data, **7** 483
sequential analysis, **2** 183
smoking effects, **7** 223
treatment, **1** 73; **13** 1313
Markov models, **7** 325
maximum likelihood, **2** 305; **3** 35; **5** 85
median survival times, **15** 171
melanoma surveillance, **4** 265; **9** 999
meta-analyses, **10** 1665
misclassification, **7** 257; **14** 1307
missing data, **7** 347; **15** 2191
models comparisons, **2** 305
monitoring clinical trials, **9** 1081
Monte Carlo simulations, **3** 153; **6** 667
morbidity estimation, **7** 325
mortality
age-trajectory analysis, **10** 1043
cancer cohort study, **4** 353
diabetes study, **7** 661
estimate comparisons, **4** 295
intervention study, **6** 501
morbidity estimation, **7** 325
risk interaction, **7** 239, 293
multi-state Markov models, **14** 1975
multicentre cancer trial, **14** 2523
multiple comparisons, **6** 591
multiple time scales, **13** 823
multistate models, **3** 35; **7** 661; **13** 2517
myocardial infarction, **4** 29; **6** 927; **7** 205, 219
NCI clinical trials, **9** 871, 903
neural nets, **13** 1189; **14** 73
newborn rats teratologic study, **13** 1253
non-parametric functions, **3** 35; **14** 275
non-parametric linear regression model, **12** 1569
non-reversible diseases, **12** 2395
ovarian cancer, **13** 2427
p-value adjustment, **15** 103
permutation test, **2** 327
plotting summary predictions, **12** 2315
Poisson regression model, **9** 1157, 1501
pooling studies, **5** 303; **9** 1501
power, **6** 119, 483; **8** 153
prediction, **2** 485; **3** 143; **9** 1303; **14** 161
prognostic factors, **12** 2377
chronic diseases, **4** 303
heterogeneity impact, **6** 773
historical controls, **3** 225
leukaemia surveillance, **4** 287
lung cancer surveillance, **4** 279
melanoma surveillance, **2** 295; **4** 265
myocardial infarction, **4** 29
prediction improvement, **3** 143
renal disease surveillance, **5** 637
thyroid cancer surveillance, **4** 295
proportional odds, **2** 273
proportional regression model, **14** 1249
prostate cancer, **15** 361, 2413
quality adjusted survival, **15** 93
quality of life, **9** 749, 931, 1259; **10** 1915
randomized clinical trials, **12** 2351; **15** 2069
recurrent complications, **14** 2701
recurrent conditions trial, **8** 1439
registry data, **3** 225; **7** 483; **12** 767
regression
Cox proportional hazards
confidence intervals, **8** 927
estimation comparisons, **8** 539
interaction assessment, **5** 73
logistic regression model, **8** 525
relative risk comparisons, **6** 591
review, **10** 1931
risk techniques, **10** 1025
diabetes study, **7** 661
heart risk factors selection, **4** 413
logistic regression model, **8** 525
mortality analysis, **6** 501
multistate models, **7** 661
prognostic factors, **3** 143; **4** 29, 39, 303
relative risk comparisons, **6** 591
stratum/covariate interaction, **5** 73
relative and net survival estimates, **9** 529
relative risk, **6** 591; **7** 275; **10** 1267
repeated data, **7** 347; **10** 1227
repiratory symptoms, **13** 1771
residual confounding, **11** 1747
response phenomenon, **10** 1621
response to treatment, **15** 2797
risk, **4** 413; **7** 239, 293, 297; **8** 947
robust inference, **12** 1019
robust proportional hazards regression, **15** 1033
sample size, **3** 199; **6** 119, 679; **7** 559; **11** 1103
sampling design, **10** 1945
screening methods, **2** 279; **6** 885; **9** 969; **13** 569
semi-proportional hazards model, **15** 1771
sequential monitoring, **14** 1927

sequential trials, **2** 183; **5** 375
short-term survival, **11** 1731
smoking study, **7** 223
SSPE study, **3** 225
stopping rules, **6** 361, 667, 927
stratification, **5** 73; **7** 297, 559
study duration, **11** 1477
surveillance epidemiology, **10** 521
therapies, **7** 1013
thyroid cancer, **4** 295
time distribution, **1** 73, 93; **2** 305; **5** 85
time series analysis, **8** 1497
time since exposure, **11** 939
time-by-covariate interactions, **13** 1045
transient state model, **6** 795
treatment evaluation, **2** 41, 415–416(L); **5** 375; **7** 1243, 1257; **11** 1103
tree-structured methods, **8** 947
tumour study, **2** 315; **3** 35; **9** 999
univariate, **15** 2203
updated covariates model, **13** 301
ventilation study, **6** 795
Weibull distribution, **6** 31
whooping cough, **3** 165
Wilcoxon tests, **6** 483; **8** 937
withdrawal censoring, **11** 1359
Survival curves, **7** 895; **13** 569
age-adjustment, **14** 1731
AIDS, **15** 2669
Bayesian hierarchical models, **14** 2173
censored data, **15** 953
diabetic retinopathy, **14** 1975
leukaemia, **14** 1081, 1097
proportional hazards model, **14** 2119
public health surveillance, **14** 629
Survival trees, **8** 947
Susceptibility test, **7** 535
Sweden
leukaemia incidence, **14** 3; **15** 707
longitudinal growth study, **6** 185
SWOG *see* Southwest Oncology Group
Symmetric binary weights, **13** 1037; **14** 1393–1394(L)
Symmetry
axial, **5** 199–200(L)
compound, **6** 911; **8** 891(L)
liver function model, **7** 671
multivariate test, **1** 83
speech sounds model, **9** 1143
Symposia *see* Special issues
Symptoms
clinical trials, **4** 11
diagnostic assessment, **8** 1351
Synchronization physiological pulse series, **12** 2043
Synergism, **13** 2289
Synthetic cancer variables (SCVs), **12** 1931
Synthetic risk maps (SRMs), **12** 1931
Syphilis, **3** 293; **4** 536; **8** 353
Systematic attrition longitudinal data, **11** 2029

t-tests
ANCOVA, **15** 477
binomial comparisons, **10** 1137
clinical trials, **9** 65, 447; **13** 2393
covariate imbalance tests, **9** 1455
doubly censored data, **14** 2555
independent samples, **6** 79, 577
k-ratio, **11** 863
multiple significance tests, **10** 939
one-sample two-sided sequential *t*-tests, **15** 2781
over-the-counter drugs, **10** 1
paired
agreement method, **13** 737
community interventions, **14** 1491
power, **10** 1321–1322(L)
reference ranges, **10** 691
robustness, **6** 79
sample size computation, **14** 1933
Student's data, **13** 785
type I error/power, **12** 2233
unpaired, **15** 1059
Tables, **8** 795, 803, 1455; **11** 617, 913
see also Contingency tables
Taconite workers, **3** 73
Tag-recapture *see* Mark-recapture
Tail probabilities scan statistic, **12** 1845
Tail weight skewness & kurtosis, **11** 333
Taiwan lung cancer incidence, **15** 273
Tamoxifen randomized trials, **6** 245, 287, 329, 333, 337, 371, 379
Tango's index clustering in time, **12** 1813
Tarone risk ratio, **11** 1599
Tarone-Ware statistic, **8** 539
Taxonomy, **6** 137
Taylor series
corrected parameter estimates, **13** 1135
cost-effectiveness ratios, **15** 1447
covariance matrix, **13** 343
intermediate endpoint, **11** 167
Mantel-Haenszel adjustment, **11** 603
parameter estimates comparison, **13** 1023
surveillance data aberrations, **11** 1551
survival study sample size, **13** 391
transmission probabilities, **11** 565
Teaching statistics
diagnosis, **6** 805
evaluation, **9** 1045, 1057, 1061, 1069
future developments, **9** 1063, 1069, 1077
medical statistics, **6** 3; **14** 209
non-specialists, **14** 199
significance, **5** 193
survey methodology, **1** 205; **6** 869
what to teach?, **9** 1013, 1023, 1029, 1069
who, when, where, how, **9** 1031, 1039, 1043, 1069
workshop, **9** 1011–1078; **10** 801–802(L)

Teeth disease monitoring, **10** 1089
Telephone prefix method random-digit dialling surveys, **11** 1009
Telescopic respondent rule, **8** 1537
Temazepam, **5** 363
Temperature, **6** 167; **12** 1555
Temperomandibular pain dysfunction syndrome, **6** 137
Temporal clustering, **14** 2323
  occupational poisoning, **15** 747
  quadrat analysis software, **15** 939
Temporal trend, **7** 185, 239, 629; **11** 1719
Temporal turning point
  bootstrap estimate, **12** 153
  Wald confidence interval estimate, **12** 153
Tent graphs, **15** 969
Teratologic studies, **13** 1253
Termination *see* Abortion; Stopping rules
Test-to-reference formulation, **11** 1333
Testicles cancer, **3** 113, 153
Tests
  see also Diagnosis...; Logrank...; Significance...; Wilcoxon...
  Akritas test, **11** 193
  ANCOVA, **9** 293
  Anderson-Darling test, **11** 897
  ANOVA interactions, **7** 467
  association, **7** 257, 443
  asymptotic test coefficients of variation, **15** 647
  Bartholomew's test, **4** 489
  Besag and Newell's test cluster analysis, **14** 2291, 2309; **15** 727, 765
  binary test regret graphs, **15** 969
  bioequivalence assessment, **10** 959
  change-point, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
  chi-squared tests, **9** 363–383
    binomial comparisons, **10** 1137
    change-point testing, **10** 1159–1160(L)
    contingency tables, **5** 629
    continuity correction, **12** 2207
    kappa statistic, **14** 347
    nominal association model, **10** 1555
    paired data adjustment, **10** 1981
    partitioning methods, **3** 273
    tables, **8** 243–245(L); **9** 363–383
    two sided small sample tests, **12** 777
  Cochran test, **4** 117; **5** 629; **8** 141; **9** 1475; **11** 547, 1759
  Cochran-Mantel-Haenszel test, **11** 743
    combining two-by-two tables, **14** 1901
  comparative binomial trials, **9** 1447
  compartment model parameters, **8** 1011
  conditional tests, **9** 363–383
    baseline balance, **13** 1715
    equivalence, **13** 1827
    pair-matched studies, **12** 699
  contrast repeated measures design, **3** 185
  covariates imbalance, **8** 467; **9** 1455
  Cuscore test exploratory analysis, **15** 807
  Cuzick test, **14** 863
  Cuzick-Edwards test cluster analysis, **15** 783, 873
  Cuzick's trend test, **9** 829; **10** 799–800(L)
  diagnostic agreement, **9** 835
  discrete SPRT, **9** 907
  dispersion tests, **12** 1683
  distribution-free tests
    confidence interval estimation, **5** 653
    growth curve analysis, **1** 83
    incomplete data, **11** 1151
    stratified data analysis, **6** 43
    Wilcoxon approach, **4** 87, 543(L); **5** 199–200(L)
  double triangular test, **15** 2703
  Ederer-Myers-Mantel (EMM) test, **11** 761; **12** 1813; **15** 747
  ELISA, **7** 549; **15** 2161
  equal period effects, **13** 931
  equivalence tests, **5** 203
    comparisons, **14** 1583
    intraclass correlation, **13** 2465
    one/two-sided, **13** 1827
    optimal sample allocation, **15** 2523
    proportion of similar responses, **15** 1489
    sample size, **14** 1831
    sequential designs, **15** 2703
    stratified trials, **14** 2037
    two-sided, **15** 1729
  estimates distance, **9** 549
  exact conditional test
    inverse sampling, **15** 671
    sample size computation, **15** 1
  exact tests, **13** 1539
  exact unconditional test, **15** 2371
  F-tests
    factorial ANOVA design, **10** 1565
    non-linear regression, **10** 697
  Fieller's test
    bioequivalence, **15** 2635
    cost-effectiveness ratios, **15** 1447
    sequential monitoring of clinical trials, **15** 2341
  Finkelstein's score test, **15** 1387
  Fisher tests
    dose-response evaluation, **14** 1595
    information matrix, **13** 185
    LSD procedure monitoring analogue, **13** 1441
    randomization game Devil or Nature?, **13** 217
    t-test analysis, **13** 785
  Fisher's exact test, **15** 2371
    contingency tables, **5** 629; **8** 243–245(L); **9** 363–383; **11** 845–847(L)
    hypothesis testing, **9** 201
    independence tests, **7** 1297
    multinomial trials, **11** 913

multiple test procedures, **11** 511
power evaluation, **8** 1469; **10** 1321–1322(L)
quasi-exact test, **10** 1137
significance tests, **9** 213, 703
two sided small sample tests, **12** 777
U.S. legal cases, **14** 1641
Yates's correction, **9** 363–383
Flemming-Harrington-O'Brien test, **11** 673
focused tests cluster analysis, **14** 2291, 2323; **15** 727, 765
frailty existence, **13** 1679
Freeman-Tukey test multiple treatments comparisons, **14** 2509
Friedman tests ANOVA, **4** 145; **5** 199–200(L)
Gail's test, **13** 2407
Gehan-Wilcoxon test, **8** 937; **11** 193
general tests cluster analysis, **14** 2323
generalized rank-sum test, **9** 447
generalized signed rank test, **11** 193
generalized *t*-tests, **9** 447; **11** 491–509; **12** 2233, 2245
generalized tests, **13** 747
generalized Whittemore's test, **15** 2561
geographical correlations, **9** 515
Girshick-Rubin test, **2** 141
global tests, **9** 819; **13** 1441
combination drug studies, **15** 233
multiple tumour data, **15** 1217
quality of life data, **9** 819
Grimson's test cluster analysis, **15** 783
Grizzle test, **10** 891
group sequential, **8** 505; **9** 853–854(L)
Hailperin-Rüger, **10** 777
Hausman test, **11** 1195; **13** 2219
health data spatial patterns, **13** 1037
Heart disease screening tests, **4** 53
Holm test, **9** 811; **10** 777, 871, 939; **15** 1107
homogeneity for counts, **4** 469
hospital mortality rates, **13** 1001
immunity cell-mediated, **4** 279
Jonckheere-Terpstra test, **14** 863
Jonckheere's test, **4** 489; **14** 445–446(L)
k-ratio *t* tests multiple comparisons, **11** 863
k-sample tests
coefficients of variation, **15** 647
comparison, **14** 863
Kepner and Randles test, **4** 91
Knox test, **15** 873
cluster analysis, **15** 943
space-time clustering, **15** 1935
Kolmogorov-Smirnov test, **12** 2043
area between curves, **11** 1289
confidence bands, **13** 499
psychotherapy states, **11** 231
survival study, **12** 1365
Le test, **14** 863
least significant difference test, **4** 489
likelihood distance, **9** 549
likelihood ratio
change-point, **7** 387; **8** 1414–1416(L); **10** 1159–1160(L)
chi-squared adjustments, **10** 1981
confidence intervals, **10** 443
crosssover trials, **10** 1099, 1607
epidemiology, **10** 341
homogeneity tests, **8** 1455; **10** 1257
independence testing, **10** 1555
logistic regression, **9** 931; **10** 375, 1213
mortality rates, **10** 1043
otitis media risks, **9** 1495
P-value interpretation, **9** 601
repeated events analysis, **10** 1227
side effects incidence, **9** 803
tumour growth model, **10** 1075
variation analysis, **8** 883
likelihood score test
optimal sample allocation, **15** 2523
prospective relative risk analysis, **12** 691
linear rank tests doubly censored data, **14** 2555
linear risk score tests cluster analysis, **14** 2309
linkage recessive diseases, **9** 573
longitudinal studies, **9** 437
McNemar test, **4** 23; **6** 53; **7** 929; **10** 1099, 1981; **13** 663
case-control studies, **6** 53; **13** 663
failure time data, **10** 1099
generalization, **12** 2207
hypothesis of no effect, **12** 1969
incomplete paired binomial data, **7** 929
matched case-control studies, **11** 1239
non-independent matched pair data, **10** 1981
pair-matched studies, **12** 699
sample size, **11** 1521; **14** 1831
trauma study, **14** 1463
Mantel test
cluster analysis, **15** 873
space-time clustering, **15** 1935
marginal homogeneity, **6** 91; **7** 109
Mojena's, **6** 137
multiple, **8** 757, 1304–1306(L); **9** 811
nominal association model, **10** 1555
non-random segregation, **9** 573
observational data, **8** 273, 279
odds ratio two-by-two tables, **8** 1455
omitted variables, **13** 2219
one-step (Peto) method bias, **9** 247
P-value interpretation, **9** 601
Patel-Hoel, **7** 1257
patient well-being, **8** 1401
permutation, **7** 795; **9** 1081
pooled HIV screening, **13** 1905
prothrombin index, **10** 1061
rank accelerated cure model, **14** 2111
recruitment problems, **9** 1425
reference, **4** 53; **6** 411
retest reliability, **4** 445; **6** 441, 647

Tests (*cont.*)
ROC curves, **8** 1277
runs, **7** 795; **10** 637
screening, **8** 1225
sequential probability ratio, **5** 375
shared haplotypes, **5** 281
Sharpiro-Francia test, **10** 675
shelf-life, **8** 883
sign, **8** 1469
Stein's *t*-test, **9** 65
step-down procedure, **13** 2261
stratified trend, **9** 829; **10** 799–800(L)
surgery innovations evaluation, **8** 455
surrogate endpoints, **8** 405
surveillance system, **8** 311
survival analysis, **8** 937
susceptibility, **7** 535
therapies evaluation, **8** 441
trend, **4** 87, 489, 543–547(L); **5** 199(L)
triangular, **5** 375; **9** 907, 1277; **10** 989
two-sample tests, **9** 447, 1455
van Elteren, **7** 471
Tetrachoric correlation, **7** 955
Thailand
HIV infection probability model, **13** 2097
road accident mapping, **14** 2445
Thall method longitudinal data, **12** 1339
Theophylline bioequivalence, **11** 1777
Therapeutic equivalence, **2** 167
Therapeutic preferences, **3** 45; **15** 443
Therapeutic range drug concentration, **8** 1327
Therapies
evaluation, **3** 305–475; **8** 441
HIV infection, **15** 2669
prophylactic, **3** 341
remedial, **3** 341
Thoracic disorder, **6** 805, 813
Three decision problem, **6** 101
Three period crossover trial, **6** 555; **7** 471
Three-parameter linear model alcohol intake, **12** 1141
Three-parameter log-normal distribution, **11** 897
Three-parameter logistic model, **15** 2459
Three-period crossover design, **15** 127
Threshold analysis, **15** 2253
concentration, **7** 535
decision theory, **5** 411; **9** 1229
elderly hearing, **10** 1453
epidemiological study, **10** 341
multiple imputation, **10** 585; **12** 1589
quality of life, **12** 975
survival analysis, **9** 1259
time series, **10** 1493
Thrombocytopenia platelet transfusions, **11** 2123
Thrombolysis survival study, **12** 1365
Thrombosis, **11** 345; **14** 457, 1057, 1065
Thyroid cancer, **3** 361; **4** 295; **10** 95
Thyrotoxicosis, **2** 79; **13** 185
Tie probabilities, **13** 839
TIGER *see* Topologically Integrated Geographic Encoding and Referencing
Time allocation biostatisticians, **14** 1683
Time effects repeated measures, **11** 1843
Time series analyses, **13** 453, 495, 1643
alert threshold construction, **10** 1493
autoregressive models, **4** 457; **7** 59
Box-Jenkins models, **5** 37
computer tomography impact, **5** 593
correlations, **1** 49; **2** 413–414(L)
forecasting study, **7** 106
geographical coherence, **11** 1409
heart rate analysis, **6** 159
HIV epidemic dynamics, **11** 1657
hormone secretion pulses, **14** 311
injury models, **8** 1497
mortality estimation, **7** 1045
multivariate data, **7** 317
nonlinear models, **6** 167
outlier detection, **11** 2133
rare event clustering, **11** 761
repeated measurement analysis, **7** 29
respiratory diseases, **10** 1481
seasonal changes, **12** 1555
statistical surveillance, **11** 1489
surveillance data, **8** 335–363, 387; **11** 1551
Time to maximum response (TMAX) clinical pharmacology studies, **12** 633
Time trends
age-specific rates, **4** 63
bias, **13** 671
laboratory determination, **2** 147
longitudinal data, **4** 457
Time without symptoms and toxicity, **9** 749, 1259; **10** 1915
Time-dependent covariates, **11** 455; **13** 301, 2021; **14** 1843
baseline comparisons, **7** 205
categorical data analysis, **7** 139, 169
Cox proportional hazards model, **15** 2589
disease indicators assessment, **10** 1061
disease risk, **15** 1545
dose-toxicity evaluation methods, **8** 813
heart disease risk prediction, **9** 287
heart study, **7** 205
indicator variables, **13** 1045
long-term survival, **15** 2763
longitudinal data analysis, **7** 297
marginal distribution models, **7** 139
multistate analysis, **12** 2315
prognosis evaluation, **4** 29
progression markers, **12** 2087
proportional hazards model, **14** 2119
recurrent events, **6** 689
smoking cessation, **12** 1605
survival analysis, **3** 35; **10** 1931
treatment response, **15** 2797

Time-dependent model, **11** 1731
Time-homogenity models, **13** 805
Time-period effects longitudinal studies, **12** 893
Time-point-by-time-point analysis clinical pharmacology studies, **12** 633
Time-since-exposure, **11** 939
Time-Since-Infection model, **11** 1633
Time-space clustering *see* Space-time...
Time-specific reference ranges, **10** 675
Time-to-event studies, **3** 35; **11** 1705; **12** 867
Tissue rejection, **2** 33
Titration studies, **6** 583; **8** 583
Tobacco smoking *see* Smoking
Tocolysis preterm pregnancy, **11** 2077
TOHMS *see* Treatment of Mild Hypertension...
Tolerance
  dose, **6** 583
  interval, **5** 347
  maximum tolerated dose, **14** 1149
  methods, **10** 1089
  region, **13** 1841; **14** 1129, 1143
Toluene diisocyanate, **7** 19
Tomography *see* Computer Tomography
Topologically Integrated Geographic Encoding and Referencing (TIGER), **12** 1755, 1953; **15** 717, 1961
Totalstat longitudinal data, **12** 2169
Toxic exposure fecundability, **12** 867
Toxic waste GIS, **15** 1961
Toxicity evaluation
  Bayesian methods, **11** 1377
  cancer, **10** 1647
  clinical trials, **8** 813; **12** 661
  crude incidence curves, **11** 813
  grades, **11** 2063
  treatment, **2** 267; **4** 387–389(L); **5** 411, 449
Toxicology studies, **1** 281; **3** 85; **4** 489
  adverse outcome study, **13** 2311
  best dose, **13** 87
  CRM, **14** 911, 923, 1149
  dose-limiting, **13** 1799
  efficacy relationship, **14** 1129, 1143
  minimum therapeutic effective dose, **14** 925, 933
  pre-clinical study, **14** 1009
Toxoplasmic encephalitis, **15** 1093
Tracking
  blood pressure study, **7** 47
  cholesterol risk assessment, **8** 295
  correlation, **11** 1187
  longitudinal data, **11** 2027
  regression trees, **12** 2153
  Trigg's signal, **6** 425
Traffic accident incidence mapping, **14** 2445
Training, **13** 2393
  see also Medical students; Teaching statistics
  biostatistics, **12** 789
  clerical staff, **9** 115
  data collection, **9** 115, 137, 145
  future approach, **9** 1069
  medical statisticians, **14** 209
  non-specialists, **14** 199
  tutorials in biostatistics, **15** 343, 361, 389
Trajectories subjective ranking, **11** 427–454
Transfer function models, **8** 335, 353, 1497
Transformation
  algorithm, **7** 491
  angle, **7** 865
  arcsine, **7** 865
  bioavailability/bioequivalence studies, **11** 881
  bladder cancer cells, **13** 839
  clinical trial reports, **13** 2393
  data, **4** 145; **14** 811
  descriptive statistics, **11** 333
  intra-individual variation, **12** 1213
  logistic, **2** 79; **6** 43; **7** 443
  normal range estimation, **5** 335
  power considerations, **13** 769
  reference intervals, **14** 1417
Transfusions
  blood, **5** 355; **7** 395
  platelet efficacy factors, **11** 2123
Transient effects case-crossover designs, **12** 2333
Transient response, **7** 965
Transient state analysis, **3** 35; **6** 795
Transition intensity, **7** 661; **13** 805
Transition matrix *see* Eigen values
Transition models, **11** 67, 1825; **13** 467
Transition probabilities, **11** 295; **13** 805; **15** 2617
Transmission models, **11** 565, 1657
  hepatitis B virus, **15** 2215
  Hib bacteria, **15** 2235
  HIV, **15** 2393
    AIDS issues, **9** 1387
    disease prevention methods, **8** 59
    infection analysis, **8** 83, 93; **9** 721
    spread assessment, **8** 103; **10** 1003
    vaccine development, **9** 1425, 1433
  malaria, **6** 853
  vaccine efficacy, **12** 249
Transplantation
  see also Kidney transplantation
  bone-marrow, **4** 1
  heart, **2** 33; **3** 35
  organ, **3** 399
Traumatic injuries, **1** 145
Travel biostatistics budget, **15** 2127
Treatment-by-centre interaction
  multicentre clinical trials, **12** 1047
  pushback procedure, **12** 1033
Treatments
  see also Patient treatments
  adaptation, **4** 287
  adverse effects, **6** 745, 863; **7** 1023
  allocation
    balancing factors, **3** 219; **6** 119, 127, 577
    bias, **5** 211

Treatments (*cont.*)
allocation (*cont.*)
binary variables, **4** 497
clinical trials, **4** 129, 497; **10** 1789
crossover trials, **7** 471
deviations, **7** 1179
logrank test, **6** 119, 577
methods, **1** 345; **14** 231, 2661
multiple comparison tests, **4** 489
ordered group means, **4** 489
otitis media, **9** 237
play the winner, **15** 2135, 2413
prognostic factors, **3** 219
randomization, **1** 345; **6** 127
relative risks, **15** 2523
sample size estimation, **6** 577; **7** 559
sequential procedures, **5** 211
significance tests, **4** 489
stratification, **6** 241; **7** 559
survival trials, **6** 119
therapy evaluation, **3** 45
ancillary questions, **9** 97
antiarrhythmic drugs, **8** 1393
atropine effect, **13** 785
balance
allocation, **4** 129; **5** 211; **6** 119
covariates effects, **8** 467
crossover trials, **7** 471
logrank test, **6** 119, 577
prognostic factors, **4** 129; **6** 241
randomization, **6** 127
sample size estimation, **6** 577
survival trials, **6** 119
benefit size estimation, **13** 1401
bias factor, **8** 441, 455
bioequivalence studies, **10** 961
changes, **15** 2053, 2069, 2425, 2455
clinical trials, **10** 1349, 1595, 1789
combination drug efficacy, **8** 1479
comparative studies, **9** 1447; **15** 1489
control comparison, **13** 2261
covariance analysis, **8** 571
covariate
imbalance effects, **8** 467; **9** 1455
interaction, **4** 255; **7** 843, 1257
crossover trials, **15** 1435
baseline measurements, **6** 911
carryover effects, **7** 1099–1101(L); **10** 1361
categorical data analysis, **10** 1607
data analysis, **6** 911
factorial designs, **9** 1121
information recovery, **10** 1115
linear models, **10** 909
residual effects, **10** 891
survival analysis, **10** 1099
CS models, **13** 509
databases evaluation study, **10** 647
decision analysis, **9** 1243
dilution consent designs, **3** 215
disease indicators assessment, **10** 1061
dose-finding methods, **10** 1647
dose-toxicity evaluation, **8** 813; **9** 1117–1118(L)
drug combinations analysis, **9** 1527
duration comparison, **7** 1013
early termination adjustment, **9** 1417, 1433
effects
AIDS incubation, **11** 1633
between group differences, **12** 1213
clinical trial drop-outs, **11** 2043
combined endpoints, **11** 1705
comparison cummulative hazard functions, **11** 1465
crossover designs, **11** 1967; **12** 825
cumulative hazard functions, **11** 1465
data monitoring, **12** 2219
qualitative interactions, **12** 1239
randomized clinical trials, **12** 2351
repeated measures, **11** 1685, 1843, 2111
safety profile, **11** 1075
efficacy
arrhythmias study, **8** 1393
bias, **4** 1; **7** 1243
cancer study, **3** 325, 333, 399; **9** 907
censored data, **7** 1257
clinical trials, **4** 11
confidence intervals estimation, **7** 1267
cost, **3** 433
covariate imbalance, **7** 1243; **8** 467
crossover trials, **8** 1421
databases, **3** 333, 375, 385
decision theory, **6** 101
drug tests, **5** 449
eligibility criteria, **3** 421
equivalence trials, **7** 1267; **8** 593
estimation, **13** 2323
factorial designs, **8** 161
handwashing protocol comparisons, **5** 393
historical controls, **3** 315, 325, 331
missing data analysis, **7** 1243
myocardial infarction, **3** 423
observational data, **3** 341, 361, 375, 401
predictions, **5** 421
radiation factors, **3** 353
randomized clinical trials, **2** 267; **3** 307, 409; **4** 387–389(L)
registry data, **3** 361
sample size determination, **5** 1
surgery study, **3** 389
symptomatic conditions, **4** 11
therapies, **3** 305; **6** 657, 761; **8** 441, 455
two-stage trials, **8** 477
endpoints, **9** 155
epilepsy ECG artefacts detection, **10** 1719
equivalence testing, **13** 2279–2280(L)
equivalence trials, **8** 593
estimation issues, **9** 657

evaluation community trials, **4** 11
factorial designs, **8** 161
GISSI cardiology trial impact, **9** 17
graphical presentation, **9** 1287
HIV changes, **15** 2425, 2455
hypertension study, **8** 585
individual changes, **15** 249
interim analysis, **10** 949
joint potency quantification, **13** 2289
lung cancer study, **13** 1415
maintenance therapies trial, **8** 1439
marker variable bias, **15** 1747
medical decision analysis, **8** 229
melanoma survival analysis, **9** 999
meta-analyses, **10** 971, 1665
missing covariate values, **9** 777
multicentre binary response, **9** 919
multiple comparisons, **14** 2509
multiple groups, **15** 2509
multiple testing, **10** 871, 939
multiple-outcome meta-analysis, **15** 537
NHLBI trials, **9** 137
optimal, **4** 255; **13** 1575
otitis media study, **9** 237
patient selection, **6** 113; **9** 73
phase II clinical trials, **9** 907; **10** 1327
phase III clinical trials, **8** 583
postmarketing surveillance, **7** 1023
prediction, **5** 1, 421; **9** 253
provisional diagnoses, **10** 1341
quality adjusted survival analysis, **9** 1259
quality of life, **9** 749, 819, 931; **10** 1915
randomized clinical trials, **4** 255
randomized consent designs, **9** 645
repeated binary responses, **13** 1233
repeated measurements, **9** 639; **10** 1959
residual estimation, **13** 1063
response, **9** 253; **10** 1621; **15** 2797
run-in trials, **9** 87
screening methods, **9** 137
sequential trials, **9** 595, 1277; **14** 1479
side effects incidence model, **9** 803
significance levels, **9** 703
surrogate information time, **13** 945
surrogate markers, **13** 1423
survival analysis, **9** 397, 1527; **13** 1747
therapeutic preferences, **15** 443
therapy evaluation, **3** 305–475
time-varying, **13** 1089
titration studies, **8** 583
toxicity, **2** 267; **4** 387–389(L); **5** 411, 449
trials
  cancer, **13** 1423
  results applicability, **9** 185, 193
tumour study, **8** 593; **10** 1075
two-sample tests, **9** 447
two-sided tests, **15** 1729
two-stage trial design, **8** 477
  uncontrolled changes, **15** 2053
Tree analysis, **14** 2645; **15** 37
Trees regression tracking, **12** 2153
Trends
  AIDS incidence clustering, **12** 311
  Cochran-Armitage test, **10** 839
  detection linear regression methods, **12** 1125
  disease rates, **3** 113
  epidemiologic surveillance, **10** 521
  stratified test, **9** 829; **10** 799–800(L)
  temporal, **7** 185, 239, 629
  tests, **4** 87, 489, 543–547(L); **5** 199(L)
    carcinogenicity, **15** 1217
    closed, **13** 1583
    comparison, **14** 863
    HIV infection, **15** 1779
    meta-analysis, **11** 2077; **14** 545
    tumour incidence rates, **13** 689
    Wilcoxon-type, **14** 445–446(L)
Triangular sequential design, **13** 2249
Triangular test
  boundaries approach, **13** 1357
  cancer trials, **9** 907
  censored data, **5** 375
  confidence intervals, **9** 1277
  haematology, **10** 989
  oncology, **10** 989
  randomized trials, **13** 1415
Trigg's tracking signal, **6** 425
Triglyceride irregularly sampled profiles, **15** 1695
Trimeprazine, **5** 363
Tromsø Heart Study, **4** 413
Truncation, **7** 915; **12** 2043; **13** 635; **15** 305
Trypanosoma cruzi seropositivity data, **15** 851
Tubal sterilization short/long-term consequences, **12** 355
Tuberculosis, **1** 329, 337; **15** 919, 1465
Tumours
  see also Cancer
  animal toxicity study, **13** 1583
  biomarker data, **11** 515
  cancer prevalence, **11** 1579
  clinical trials endpoints, **8** 405
  global tests, **15** 1217
  growth models, **1** 83, 163; **10** 1075; **13** 23; **14** 185
  independence testing, **10** 1555
  karyotype cell lines, **13** 839
  lethality dose effect, **13** 689
  mammary, **13** 709, 731
  markers, **2** 217
  prognostic markers, **15** 103
  quality of life assessment, **10** 1915
  registry, **11** 345
  regression analysis, **8** 1363
  survival analysis, **9** 999
  treatment effect study, **13** 955
  vaccine trial, **14** 2099

Turnbull estimator, **7** 1139; **13** 1771
Tutorials in biostatistics
  dose-response studies, **15** 343
  human brain mapping, **15** 389
  multivariable prognostic models, **15** 361
Twin studies, **6** 961; **8** 825; **12** 1693; **14** 1621
TWiST *see* Time without symptoms and toxicity
Two one-sided tests procedures bias, **14** 853
Two-armed bandit, **4** 497
Two-by-two tables
  Bayesian analysis, **13** 1525
  combining risk differences, **15** 1465
  common odds ratio, **14** 1567; **15** 1595–1600(L)
  inverse sampling, **14** 2051
  kappa coefficient, **15** 1409
  misclassification, **15** 581
  P values, **13** 2189
  power computations, **13** 1539
  stratified trials, **14** 2037
  structural zeros, **14** 1901
  U.S. legal cases, **14** 1641
Two-group design
  dose-response studies, **15** 343
  optimal sample allocation, **15** 2523
Two-mutation model leukaemia incidence, **15** 1003
Two-parameter auto-correlation function HIV infection markers, **12** 2133
Two-parameter dose-toxicity model cancer studies, **12** 1093
Two-period crossover design, **6** 911; **7** 1099(L); **8** 487, 1421; **10** 901, 1789; **12** 69
  see also Crossover trials
  analgesic drug trial, **13** 1601
  baseline measurements, **13** 905; **15** 117
  bioequivalence, **13** 2531; **15** 2635
  censored data, **15** 953
  phase III, **14** 1025, 1053
  polynomial growth curve, **13** 931
  repeated measurements, **14** 1067, 1079
Two-sample tests, **9** 447, 1455
  cure models, **14** 2111
  doubly censored data, **14** 2555
  equal small sample sizes, **12** 777
  location/scale change alternatives, **13** 747
  repeated measurements, **15** 429
  sequential monitoring, **12** 753
  t test, **12** 2245
  Wilcoxon rank sum test, **12** 1063
Two-sided tests, **15** 1729
Two-stage design, **12** 645; **13** 417
  alpha spending function, **15** 1739
  analysis of, **11** 769
  clinical trials, **4** 497; **7** 571
  confidence bounds, **13** 1551
  crossover trial, **8** 1421
  empirical Bayes estimates, **12** 937
  knee replacement rates, **15** 1875
  pharmaceutical applications, **12** 1999
Two-treatment crossover design conditional analysis, **12** 825
Two-way ANOVA mixed model, **13** 737
Two-way tables, **13** 2407
Type I, II, III errors *see* Error

U statistic, **11** 1705; **12** 1813
Ulcers
  clinical trials, **8** 1439
  peptic, **5** 421
  recurrence, **7** 877, 1187
Ultrasonography
  liver metastases, **12** 2191
  prostate cancer, **12** 2191
  serial multivariate data, **11** 1041
UMP test *see* Uniformly most powerful test
UMVU *See* Uniformly minimum variance...
Unadjusted approach McNemar test, **11** 1521
Unanimity rule, **7** 549; **11** 209
Unbalanced data
  cluster number estimation, **11** 751
  longitudinal data, **8** 189
  sample size allocation, **11** 1091
Uncertainty, HIV infection, **8** 45
Unclassified data, mixture models, **8** 1291
Unconditional methods, **11** 913, 1239, 1521; **13** 1583
Unconditional tests, **13** 1715
Undergraduates *see* Teaching statistics
Unequally timed visits longitudinal data, **11** 1861
Unified method controlled trials, **13** 1815
Uniform imputation threshold-crossing data, **12** 1589
Uniformity cluster analysis, **15** 817
Uniformly minimum variance unbiased estimator (UMVUE), **8** 563; **9** 1167
Uniformly most powerful (UMP) test, **9** 573
Unimodal symmetric likelihood functions, **12** 1651
Unit non-response *see* Missing data
Unit weight models cross-validation performance, **11** 475
United States Bureau of the Census TIGER files, **12** 1953
Univariate analysis, **13** 301
  calibration, **14** 935, 953
  discriminant analysis, **10** 475
  longitudinal data, **11** 1843
  survival, **15** 2203
University Teaching Methods Unit, **9** 1045
Unpaired *t*-test, **15** 1059
Unsaturated least squares estimators, **12** 1629
Unweighted least squares, **11** 1861; **13** 635, 945
  see also Least squares
Urinary metabolites ovulation estimation, **10** 255
Urinary proteins, **8** 1485
Urine nitrogen excretion dietary assessment, **12** 937
USA
  AIDS studies, **8** 45; **13** 1865, 1921; **14** 27, 1505

American Statistical Association, **9** 863
cancer atlases, **14** 473
Centers for Disease Control, **8** 253
clinical trials ethics, **9** 645
injury surveillance W. Virginia, **8** 388
legal cases, **14** 1641
mortality maps, **14** 615
mortality rates simulation, **13** 1119
NCI clinical trials, **9** 871, 903
NHLBI clinical trials, **9** 881, 903
NIH clinical trials, **9** 893, 903
occupational injuries, **8** 389, 1984
Use function
sample size determination, **11** 1391
sequential monitoring, **14** 2227
study duration, **11** 1477
Uterine receptivity *in vitro* fertilization, **12** 1543
Uterus cancer, **6** 881
Utility function, **13** 2493; **14** 2173
Utility theory
clinical trials, **6** 745; **9** 1243
diagnostic factors, **6** 945; **7** 1289
error assessment, **8** 893
independent Bayes approach, **6** 945
QAS, **12** 975
survival analysis, **9** 1259
variance estimation, **8** 229
Utilization studies, **13** 1781
UTMU *see* University Teaching Methods Unit

V-mask, **6** 425; **11** 1489
VA Cooperative Studies, **9** 125
Vaccines
antibody response analysis, **2** 447
bias quantification, **9** 1327
binomial trials, **9** 1447
confidence intervals, **15** 2379, 2405
diptheria/tetanus, **12** 2383
efficacy
direct effect measurement, **12** 249
estimation, **7** 1279; **9** 13; **10** 1573
equivalence tests, **13** 1827
fertility regulation, **10** 177
hepatitis B virus, **15** 2215
HIV study, **9** 1425, 1433
control-conditional, **15** 2371
exposure efficacy, **13** 357
infectiousness, **15** 2393, 2405
statistical issues, **13** 2155
measles, **14** 777
optimal sample allocation, **15** 2523
polio trials, **9** 13
registry, **11** 345
rubella study, **2** 1; **6** 843
SSPE risk estimation, **10** 1733
TB, **14** 395
Vaginal cancer, **5** 261; **7** 1223
Validation
CMS, **14** 331
covariate measurement errors, **8** 1167, 1179
groups
bias, **4** 53
epidemiological design, **12** 1703
health care datafiles, **14** 2627
HIV/AIDS, public health, **13** 1933
incidence rates projection, **13** 1755
intermediate endpoints, **11** 167
linear measurement error, **8** 1075
logistic regression, **7** 947
measurement-error model, **8** 1139, 1149
multiple reports, **8** 1041
multivariable prognostic models, **15** 361
proliferative index model, **13** 1619
record linkage, **14** 511
regression models, **3** 143; **4** 39
relative risk, **8** 1071
selection bias, **13** 557
surrogate markers, **13** 1423
within-person measurement error, **8** 1051
Validity index, **5** 585
van Elteren test, **7** 471
Vanadium depuration analysis, **8** 1011
Vancouver conference, *statistics and computing in disease clustering*
applied studies, **15** 683–763
methods, **15** 807–929
power comparisons, **15** 765–806
preface, **15** 681–682
resources, **15** 931–952
Variability
analysis, **4** 379
dose-response models, **14** 531
heart rate SCD, **13** 1015
interobserver ranking, **13** 2437
intra-assay, **13** 1165
intrasubject, **14** 1067, 1079
K1 component, **13** 275
patient acute manifestation episodes, **13** 859
point estimates, **13** 1211
visual field, **11** 1131
Variables *see* Errors-in-variables; Surrogate endpoint variables
Variance component model, **10** 599, 843, 1227; **11** 67, 579
see also Random effects
Variance decomposition
proportions, **11** 1273
summary statistics, **12** 2169
Variances
acute manifestation episodes, **13** 859
age-related mortality trials, **10** 65
AIDS incidence formula, **14** 27
AIDS studies, **10** 1167, 1993
association measurement, **8** 619
attributable fraction, **6** 701

Variances (*cont.*)
balanced allocation methods, **9** 237
biopharmaceutical research, **10** 811
case-control studies, **9** 1485; **10** 739, 1037
censored data blood pressure, **10** 1441
centile estimates, **9** 539
common odds ratio estimators, **14** 1567; **15** 1595–1600(L)
community intervention studies, **10** 53
comparative binomial trials, **9** 1447
comparison, **4** 91
compartment models, **8** 1011
components, **7** 1195
confidence intervals, **10** 443
control efficiency gains, **8** 977
correlated samples, **11** 1551
counts/rates models, **10** 1405
crossover trials, **9** 1121; **10** 1115; **13** 1063; **14** 1025, 1053
CS analysis, **13** 509
dose-response rate, **10** 323
dual frame design, **14** 571
EMP procedure, **13** 479
estimation
clustered binary responses, **13** 1241
drug safety, **14** 1177
longitudinal data, **13** 1211
NHIS data sets, **14** 669
organ pharmacokinetics and toxicokinetics, **14** 1009
sample size, **14** 1039, 1053
factorial design, **9** 1121; **10** 1115, 1565
Friedman tests, **4** 145; **5** 199–200(L)
generalized linear models, **10** 1069
growth curve models, **9** 841
hazard ratios, **9** 1167; **10** 749
heterogeneity, **4** 379; **13** 143
HIV, **10** 1003, 1167
homogeneity, **10** 1257; **15** 51
hospital mortality rates, **13** 1001; **14** 2161
internal pilot studies, **9** 65; **13** 2455
interrater reliability measures, **9** 1103
kappa statistic, **10** 1303, 1465; **15** 1409
longitudinal studies, **9** 437
McNemar's test, **14** 1831
mean-squared error, **10** 1167
measurement error factor, **8** 893
medical decision analysis, **8** 229
method comparison studies, **10** 981
misselection subsampling, **9** 1339
misspecification, **14** 1693
multi-level models, **15** 2717
multiple significance tests, **10** 939
multivariate failure times, **13** 2233
naive estimators, **13** 1737
odds ratio, **6** 491; **9** 1131
P-value interpretation, **9** 601
patient/treatment differences, **13** 1601
phase II clinical trials, **9** 215
play the winner, **15** 2135
pock count variability study, **9** 615
poisson distributed observations, **13** 1513
pooled study results, **9** 247
prediction rules error rates, **9** 1303
probability trees, **8** 189
proliferative index data, **13** 1619
proportional measurement errors, **9** 1463
quality of life analysis, **9** 819
recurrent outcomes, **13** 1781
risk adjustment methods, **10** 1753
sample size, **9** 1485; **15** 1587
sequential trials, **14** 1479
smoking information, **8** 997
smoothing geographical data, **15** 2539
Spearman-Karber statistic, **14** 841
stochastic models, **8** 121
stratum specific binomial, **13** 1071
survival analysis, **9** 1259
treatment comparisons, **15** 1489
tumour growth models, **10** 1075
UMVU estimator, **8** 563
vaccine efficacy estimation, **10** 1573
within-units Bayesian models, **13** 1841
Variation
AIDS incubation, **15** 2459
among-class, **11** 727, 751
assay validation estimation, **10** 1543
batch stability tests, **8** 883
between-hospital death rates, **13** 889
between-patient, **11** 533, 1321
bioequivalence studies, **10** 959
cancer models, **6** 449, 469; **10** 1241
CD4 count distribution, **13** 405
correlations, **9** 515
counts/rates models, **10** 1405
dietary intake, **13** 113
energy expenditure measures, **9** 1365
epidemiological studies, **10** 521
extra-Poisson negative binomial, **13** 1755
geographical, **9** 515; **10** 521
heart disease mortality rates, **9** 1199
historical control study, **10** 839
HIV infection risk, **10** 131
hospital mortality rates, **13** 1001
inter-study, **6** 287, 329, 349, 351, 359, 395
interobserver *see* Interobserver variation
intralaboratory, **8** 295
knee replacement rates, **15** 1875
laboratory studies, **10** 843
logistic regression, **15** 1987
measurement assessment, **9** 351
measurement error, **8** 893, 1031
meta-analyses, **10** 971
multilogit model, **9** 981
multiple imputation methods, **10** 585
practice databases, **10** 541

regression effects, **10** 1295
repeated events analysis, **10** 1227
seasonal factor, **8** 353
survival analysis, **9** 487; **10** 733; **15** 1999
threshold construction, **10** 1493
two-by-two tables log odds ratio, **13** 1525
within subject, **7** 417, 423, 915
within-class, **11** 533, 727, 751, 1187
Vasodilators, **5** 449
Vegetative state, **6** 535
Venous occlusion, **4** 535
Ventilation-perfusion ratio, **8** 861
Ventricular contraction, **2** 331
Ventricular dilation angiotensin converting enzyme inhibition, **11** 1705
Ventricular premature beats, **8** 1393; **11** 963
Ventriculography, **5** 593
Verification
bias, **6** 411
keyed research data, **12** 1535
Vesnarinone data monitoring, **12** 2219
Veterans Administration
Cooperative Studies Program, **3** 435
Cooperative Urologic Research Group, **4** 255; **5** 73
Lung Study Group, **6** 31
Video review Appleton, D. R. *Designing a Clinical Trial*, **12** 1183
Vietnam Era Twin Registry, **12** 1693
Vinyl chloride monomer (VCM), **6** 901
Viruses
challenge dose, **11** 1253
neutralization assays, **11** 1253
pock count variability study, **9** 615
Vision
see also Eyes
age-related macular degeneration, **15** 2095
childhood study, **14** 257
comparison data verification, **12** 1535
lens opacities, **15** 145
research registry, **11** 345
visual field data, **11** 1131; **15** 1349
Visit effects *see* Time-period effects
Vital rates estimates misreports, **10** 191
Vitamins
A, clinical trials Indonesia, **9** 35
efficacy estimation study, **10** 45
Volume
forced expiratory
baseline measurements, **8** 1183
change rate analysis, **7** 337
pulmonary function, **7** 11, 19, 685
smoothing procedures, **7** 601

Wald boundary data monitoring, **12** 2219
Wald statistic, **4** 117; **7** 109; **13** 2233
backwards elimination, **11** 2093
chi-square test, **15** 2573
confidence intervals, **11** 923; **12** 809
correlated ordinal data, **14** 1961
differential prognostic influence, **11** 281
multi-rater agreement, **11** 101
multi-state Markov models, **14** 1975
prospective analysis of relative risk, **12** 691
single regression, **12** 153
standard normal variable, **12** 1353
Walker-Duncan estimates, **3** 15; **4** 227, 237–242(L)
Waller-Duncan method, **6** 591
Ward's hierarchical method, **6** 137
Washington-Baltimore HIV Research Directory, **11** 345
Water
doubly-labelled, **9** 1365
drinking, **6** 823
fluoridation, **2** 113
hardness, **5** 171
Waveforms/K1 components, **13** 2233
Wedge sampling method, **13** 523
Wei and Johnson combined U statistic, **13** 635
Weibull distribution
age-adjusted survival curves, **14** 1731
age-related AIDS incidence, **13** 1975
AIDS
development model, **9** 681
haemophilia association, **8** 1509; **9** 681
HIV spread assessment, **8** 35
incidence, **8** 1509; **11** 1633; **13** 1975; **15** 2669
incubation, **7** 395; **15** 2459
time-lag adjustment methods, **8** 259
bias study, **7** 1243
cancer incidence rate, **13** 23
censored data, **8** 1269; **9** 293
cohort studies, **8** 977
confidence intervals, **8** 1269
covariate error effect, **6** 31
Cox regression, **5** 85; **8** 525
crossover trials, **15** 527
diagnosis, **8** 1509
dog triglyceride data, **15** 1695
efficiency controls, **8** 977
error effect, **6** 31
failure times, **15** 2475
frailty models, **14** 1859
haemophilia, **8** 1509; **9** 681
hazard rates, **11** 37
heterogeneity, **7** 1121
HIV, **8** 35; **9** 681; **12** 617; **13** 163
inter-event times, **12** 1339
interval censored data, **13** 1771
kidney graft survival, **14** 1999
leukaemia surveillance, **8** 725
limited dilution cloning, **9** 457
limited failure population model (LFP), **9** 409
logistic regression, **8** 525
marginal survival functions, **12** 241
Monte Carlo simulations, **13** 689

mortality rates, **10** 1043
Weibull distribution (*cont.*)
Murphy's law, **9** 457
prognostic factors, **5** 637
regression, **8** 725
renal disease study, **5** 637
repeated events analysis, **10** 1227
reporting delays, **8** 259, 279
sampling design, **10** 1945
seroconversion time, **11** 591
smoking study, **9** 409
SSPE incidence risk, **10** 1733
stage-specific numbers, **11** 831
surveillance data, **8** 279
survival analysis, **12** 1019
angina pectoris trials, **9** 293
Bayesian analysis, **4** 509
bias study, **7** 1243
covariate omission effect, **7** 1243
data variation measures, **9** 487
decision analysis, **9** 1229
heterogeneity impact, **7** 1121
models, **10** 663
renal disease, **5** 637
treatment effect estimation, **7** 1243
time lag adjustment, **8** 259
time since exposure, **11** 939
univariate survival analysis, **15** 2203
variation, **9** 487
Weibull hazard function competing risks failure time data, **12** 737
Weight
see also Birthweight
height ratio, **7** 73
meta-analysis, **14** 491
surface area estimation, **15** 1325
weight loss data analysis, **13** 1211
Weighted analysis serial data, **12** 27
Weighted estimation, **15** 1187
Weighted Kaplan-Meier estimator, **15** 2475
Weighted least squares, **9** 841; **10** 1959; **13** 2323
ANCOVA, **11** 1843
hierarchical regression, **15** 1161
interobserver agreement, **11** 101
longitudinal data, **11** 1861
model, **13** 635, 945
population-averaged CL model, **15** 2573
repeated binary responses, **13** 1233
treatment covariate strata, **12** 1339
Weighted linear regression, **7** 19
Weighted non-linear regression model, **7** 59
Weighted score equation, **13** 1241
Weighted-sum method
attributable risk adjustment, **10** 1753
Poisson parameters, **10** 457
Weighting
CMS, **14** 2565
missing data, **11** 2043
smoothing geographical data, **15** 2539
space-time clustering, **15** 2561
Welch's *t*-test, **9** 447
WEP *see* Wideband external pulse
Western Blot test, **15** 2161
Wheelchair cushions pressure ulcers, **11** 863
Wheeze factor, **7** 95; **8** 1139, 1149
Whitehead's procedure, **15** 2781
Whittemore's formula, **8** 795
Whittemore's test, **15** 2561
Whooping cough, **3** 165; **9** 1327
Wideband external pulse, **13** 275
Wilcox-Russell model birth-weight-specific rates, **12** 377
Wilcoxon tests, **13** 1201
categorical data, **12** 2147–2151(L)
cure-rate models, **6** 483
multiple investigations, **14** 585
NCI trials developments, **9** 871
NIH trials developments, **9** 903
ordinal data, **15** 631
power evaluation, **6** 483; **14** 1577
rank sum, **11** 491, 1151
changeover designs, **7** 471
empirical velocities, **12** 403
hypothesis testing, **6** 689; **8** 517–519(L)
median comparisons, **12** 301
two-sample, **12** 1063
ROC curves, **9** 325
signed-rank, **4** 145; **5** 199–200(L); **12** 633
two-period crossover design, **15** 117
Wilcoxon-type tests
rank-sum approach
censoring effects, **8** 937
trend tests, **4** 87, 543–547(L); **5** 199(L)
stratified approach, **9** 829; **10** 799–800(L)
trend tests, **4** 87, 543–547(L); **5** 199(L); **9** 829; **10** 799–800(L); **14** 445–446(L)
'Wild' observations four-parameter logistic curve effect, **12** 2025
Wilks's likelihood ratio criterion multivariate hypothesis test, **12** 69
Wilks's statistic hypothesis testing, **12** 69
Williams square, **11** 715; **13** 11; **15** 2143
William's test, **4** 489
Winsorized delta method, **11** 1551
Winsorizing meta-analysis, **15** 1465
Wishart distribution, **8** 1327; **9** 919
Withdrawal bias, **7** 941; **8** 1302–1303(L)
Withdrawal censoring, **11** 1359
Withdrawals *see* Missing data
Within cluster correlation, **12** 1259
Within-class variation
BP tracking correlations, **11** 1187
cluster number estimation, **11** 751
crossover trials, **11** 727
Witness, expert statistical, **2** 113
Womble method, **14** 2343

Women's Health Trial, **9** 161
Woods statistic, **8** 1455
Woolf estimator, **8** 599
Work sampling data, **15** 607
Workshops
  see also Special issues
  biostatistical and epidemiologic research, **12** 789
  clinical trials, cost and efficiency
    preface, **9** 1
    proceedings, **9** 9–199
    speakers and discussants, **9** 3
  disease clustering, **12** 1751–1968
  early stopping rules in cancer clinical trials, **13** 1293–1499
  errors-in-variables, **8** 1027–1179
  longitudinal data analysis in epidemiological/clinical studies
    categorical response, **7** 95–169
    committees, **7** 1
    editors, **7** 5
    missing values data analysis, **7** 305–361
    preface, **7** 1
    proceedings, **7** 1–361
    repeated measurements analysis, **7** 11–87
    reviewers, **7** 5
    risk factors and survival, **7** 203–302
    speakers and discussants, **7** 3, 4
    special topics, **7** 175–202
    sponsors, **7** 1
  longitudinal health studies Berlin 23-26 June 1986, **7** 177
  NHLBI clinical trials, **8** 1–199
  overviews, randomized clinical trials
    preface, **6** 217
    proceedings, **6** 217–410
    speakers and discussants, **6** 219
    sponsors, **6** 217
  public health surveillance of HIV, **12** 2061–2130
  teaching statistics
    preface, **9** 1011
    proceedings, **9** 1013–1078
  therapy evaluation
    preface, **3** 305
    proceedings, **3** 305–475
    speakers and discussants, **3** 477
World Health Organization melanoma register, **4** 265

X-rays, **6** 813; **7** 857
Xerophthalmia, vitamin A trials, **9** 35

Yale Health and Aging Project (YHAP), **7** 965
Yates' correction, **11** 845–847(L)
  binomial comparisons, **10** 1137
  contingency tables analysis, **9** 363–383
  Fisher's exact test sensitivity, **5** 629; **8** 243–245(L)
Year 2000 project, **12** 207
Youden index, **5** 585; **7** 519
  regret graphs, **15** 969
  screening comparisons, **14** 1463
Youden square, **13** 11

Z adjusted odds ratios, **12** 377
Z scores, **11** 913, 1289
Z-tests blood pressure studies, **12** 1125
Zelen's design
  clinical trials, **7** 1179; **8** 477
  single consent, **3** 215
Zerbe's modification confidence intervals, **12** 153
Zero interaction, drugs, **13** 2289
Zero skewness estimate, **11** 897
Zidovudine *see* AZT

SPECIAL ISSUES INDEX*

Celebration of Sir Austin Bradford Hill's 85th Birthday; **1**(4), 297–376 (1982)

Proceedings of the Workshop on Evaluation of Therapy, September 1983 (L.Friedman, R.Simon, J.Verter, J.Wittes, R.Wittes); **3**(4), 305–478 (1984)

Proceedings of the Workshop on Methodologic Issues in Overviews of Randomized Clinical Trials, May 1986, (S.Yusuf, R.Simon, S.Ellenberg); **6**(3), 217–410 (1987)

Proceedings of the Workshop on Methods for Longitudinal Data Analysis in Epidemiological and Clinical Studies, September 1986, (M.C.Wu, J.T.Wittes, D.Zucker, J.W.Kusek); **7**(1/2), 1–360 (1988)

Statistical and Mathematical Modelling of the AIDS Epidemic, (R.Brookmeyer); **8**(1), 1–140 (1989)

Symposium on Statistics in Surveillance, May 1988, (G.H.Reynolds, D.L.McGee, D.F.Stroup); **8**(3), 251–400 (1989)

Recent Issues in Clinical Trials; **8**(4), 401–516 (1989)

Recent Issues in Epidemiology; **8**(6), 639–764 (1989)

Workshop on Errors in Variables, October 1987, (D.P.Byar, M.H.Gail); **8**(9), 1027–1180 (1989)

Proceedings of the Workshop on Cost and Efficiency in Clinical Trials, January 1989, (J.Wittes, J.Duggan, P.Held, S.Yusuf); **9**(1/2), 1–200 (1990)

Celebration for Professor Peter Armitage, (C.K.McPherson); **9**(6), 587–716 (1990)

Workshop on Teaching Statistics to Medical Undergraduates, Bristol, September 1989, (S.J.Day, J.L.Hutton, M.J.Gardner); **9**(9), 1011–1078 (1990)

Statistical Problems in Family Planning Research, (T.Farley, D.Machin); **10**(2), 159–298 (1991)

Proceedings of the Third Biennial Regenstrief Conference 'Methods for Using Large Databases in Health Care Research: Problems and Promises', October 1989, (S.L.Hui, C.McDonald, B.Katz); **10**(4), 505–672 (1991)

Statistical Methods in Biopharmacy, Satellite Meeting of the 47th World Session of the International Statistical Institute, Paris, September 1989, (A.Zipfel, J.Cauquil, J.C.Lemarie, J.Macario, D.Moccatti, M.Theoron); **10**(6), 807–1000 (1991)

Symposium on Longitudinal Data Analysis, 19-21 June 1991, (R.B.D'Agostino, N.Lange, L.M.Ryan, M.R.Selwyn); **11**(14/15), 1797-2040 (1992)

* Guest Editors are given in parenthesis.

Symposium on Statistical Methods for Evaluation of Intervention and Prevention Strategies, December 1990, (G.H.Reynolds); **12**(3/4), 191-414 (1993)

Practical Issues in Data Monitoring of Clinical Trials, Bethesda, Maryland, U.S.A., 27-28 January 1992, (S.Ellenberg, N.Geller, R.Simon, S.Yusuf); **12**(5/6), 415-616 (1993)

Methodological and Ethical Issues in Clinical Trials, 27-28 June 1991, (D.Ashby); **12**(15/16), 1373-1534 (1993)

Workshop on Statistics and Computing in Disease Clustering, Port Jefferson, NY, U.S.A., 23-24 July 1992, (G.M.Jacquez, R.C.Grimson, L.I.Kheifets, L.A.Waller, D.E.Wartenberg); **12**(19/20), 1751-1968 (1993)

Workshop on Extending Public Health Surveillance of HIV Disease, (S.M.Gore, V.T.Farewell); **12**(22), 2061-2152 (1993)

National Institutes of Health Conference on Current Topics in Biostatistics, Bethesda, Maryland, U.S.A., 25-26 January 1992, (J.H.Ellenberg, M.H.Gail, R.M.Simon); **13**(5/6/7), 399-784 (1994)

Workshop on Early Stopping Rules in Cancer Clinical Trials, Robinson College, Cambridge, U.K.. 13-15 April 1993, (R.L.Southami, J.Whitehead); **13**(13/14), 1289-1500 (1994)

Proceedings of the Conference Quantitative Methods for Studying AIDS, Blaubeuren, Germany, 14-18 June 1993, (K.Dietz, P.Bacchetti, M.Pagano); **13**(19/20), 1899-2188 (1994)

Aspects of Medical Statistics: A Festschrift for David Newell, (D. Appleton); **14**(2), 109-230 (1995)

Symposium on Quantitative Methods for Utilization of Multi-Source Data in Public Health, (G.D.Williamson, J.T.Massey, H.B.Shulman, W.K.Sieber, S.J.Smith); **14**(5/6/7), 447-718 (1995)

Statistical Methods in Biopharmacy, Choice and Decisions in Development of Pharmaceutical Products, Paris, 6-7 September 1993, (D.Moccatti, L.Darchy, N.Debbas, J.Orvain, C.Papillon-Downey, D.Serrurier, G.Tap); **14**(9/10), 881-1148 (1995)

Spatial Disease Patterns, (A.Lawson, L.Waller, A.Biggeri); **14**(21/22), 2289-2508 (1995)

Conference on Statistics and Computing in Disease Clustering, Vancouver, British Columbia, Canada, 21-22 July 1994, (G.H.Jacquez, R.C.Grimson, L.I.Kheifets, L.A.Waller, D.E.Wartenberg); **15**(7/8/9), 681-952 (1996)

Conference on Meta-Analysis in the Design and Monitoring of Clinical Trials (N.Geller, L.Freedman, Y.J.Lee, R.DerSimonian); **15**(12), 1233-1324 (1996)

Symposium on Small Area Statistics in Public Health: Design, Analysis, Graphic and Spatial Methods (S.Jay Smith); **15**(17/18), 1827-1986 (1996)

Symposium on Statistical Issues in HIV/AIDS Research (M.A.Foulkes, D.O.Dixon, V.DeGruttola and S.Self); **15**(21/22), 2269-2492 (1996)

International Meetings of the International Society for Clinical Biostatistics (ISCB)

3rd Meeting, September 1982 (Rotterdam); **2**(2), 109–312 (1983)
5th Meeting, September 1984 (San Marino); **4**(3), 251–386 (1985)
6th Meeting, September 1985 (Düsseldorf); **5**(5), 399–554 (1986)
7th Meeting, September 1986 (Cardiff); **6**(7), 729–874 (1987)
8th Meeting, September 1987 (Gothenburg); **7**(11), 1105–1176 (1988)
9th Meeting, August–September 1988 (Innsbruck); **8**(11), 1313–1412 (1989)
10th Meeting, September 1989 (Maastricht); **9**(11), 1229–1380 (1990)
11th Meeting, September 1990 (Nîmes); **10**(11), 1643–1782 (1991)
Papers from 10th and 11th Meetings, plus the Joint Meeting with the Society for Clinical Trials, Brussels, Belgium, 8-12 July 1991; **11**(16), 2041-2186 (1992)
13th Meeting, August 1992 (Copenhagen); **12**(24), 2253-2446 (1993)
14th Meeting, September 1993 (Cambridge); **13**(23/24), 2389-2574 (1994)
15th Meeting, July 1994 (Basel); **14**(24), 2625-2762 (1995)
16th Meeting, July-August 1995 (Barcelona); **15**(24), 2633-2854 (1996)

TUTORIALS IN BIOSTATISTICS

Wong, W. K. 'Designing studies for dose response', **15**, 343-359 (1996).

Harrell Jr., F. E., Lee, K. L. and Mark, D. B. 'Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors', **15**, 361-387 (1996).

Lange, N. 'Statistical approaches to human brain mapping by functional magnetic resonance imaging', **15**, 389-428 (1996).

STATISTICS IN THE MEDICAL LITERATURE

Altman, D. 'Statistics in the medical literature: 1', **14**, 873-874 (1995).

Altman, D. 'Statistics in the medical literature: 2', **15**, 559 (1996).

CORRECTIONS INDEX

Pocock, S. J., Gore, S. M. and Kerr, G. R. 'Long term survival analysis: the curability of breast cancer', **1**, 93–104 (1982); **3**(2), roc 97.*

Freedman, L. S. 'Tables of the number of patients required in clinical trials using the logrank test'. **1**, 121–129 (1982); **2**(1), roc 1.

Greenland, S. 'Interpretation and estimation of summary ratios under heterogeneity', **1**, 217–227 (1982); **2**(1), roc 1.

Osmond, C. and Gardner, M. J. 'Age, period and cohort models applied to cancer mortality rates', **1**, 245–259 (1982); **2**(3), roc 315.

Donner, A. 'Approaches to sample size estimation in the design of clinical trials—a review', **3**, 199–214 (1984); **9**, 1228 (1990).

Murrells, T. J., Smith, T. M. F., Catford, J. C. and Machin, D. 'The use of logit models to investigate social and biological factors in infant mortality. I: Methodology', **4**, 175–187 (1985); **5**(1), roc 1.

Murrells, T. J., Catford, J. C., Smith, T. M. F. and Machin, D. 'The use of logit models to investigate social and biological factors in infant mortality. II: Stillbirths', **4**, 189–200 (1985); **5**(1), roc 1.

Robertson, C. and Boyle, P. 'Age, period and cohort models: the use of individual records', **5**, 527–538 (1986); **6**(5), roc 535.

Louis, T. A. 'General method for analysing repeated measures', **7**, 29–45 (1988); **8**, 248 (1989).

Cologne, J. B., Mendelman, P. M. and Chaffin, D. O. 'Statistical comparison of ligand-binding kinetics', **8**, 871–881 (1989); **9**, 339 (1990).

Facey, K. M. and Whitehead, J. 'An improved approximation for calculation of confidence intervals after a sequential clinical trial', **9**, 1277–1285 (1990); **10**, 1001 (1991).

Senn, S. J. and Auclair, P. 'The graphical representation of clinical trials with particular reference to measurements over time', **9**, 1287–1302 (1990); **10**, 487 (1991).

Chuang-Stein, C. and Shih, W. J. 'A note on the analysis of titration studies', **10**, 323–328 (1991); **10**, 1155 (1991).

France, L. A., Lewis, J. A. and Kay, R. 'The analysis of failure time data in crossover studies', **10**, 1099–1113 (1991); **10**, 1633 (1991).

* indicates volume 3 (issue 2), reverse of contents page before page 97.

Chow, S. C. and Tse, S. K. 'Outlier detection in bioavailability/bioequivalence studies', **9**, 549-558 (1990); **11**, 425 (1992).

Posner, K. L., Sampson, P. D., Caplan, R. A., Ward, R. J. and Cheney F. W. 'Measuring interrater reliability among multiple raters: an example of methods for nominal data', **9**, 1103-1115 (1990); **11**, 1401 (1992).

Senn, S. J. 'Is the simple carry-over model useful?', **11**, 715-726 (1992); **11**, 1619 (1992).

Shuster, J. J. 'Exact unconditional tables for significance testing in the 2 × 2 multinominal trial', **11**, 913-922 (1992); **11**, 1619 (1992).

Flanders, W. D., Dersimonian, R. and Rhodes, P. 'Estimation of risk ratios in case-base studies with competing risks', **9**, 423-435 (1990); **12**, 1269 (1993).

Greenland, S. 'Variance estimators for attributable fraction estimates consistent in both large strata and sparse data', **6**, 701-708 (1987); **13**, 99 (1994).

Chambless, L. E. and Roeback, J. R. 'Methods for assessing difference between groups in change when initial measurement is subject to intra-individual variation', **12**, 1213-1237 (1993); **13**, 99 (1994).

Whitehead, J. 'Sample size calculations for ordered categorical data', **12**, 2257-2271 (1993); **13**, 871 (1994).

The cover of the Special Issue of *Statistics in Medicine* entitled 'National Institutes of Health Conference on Current Topics in Biostatistics', **13**, 399-784 (1994), incorrectly gives the date of the Conference as January 1992, but it took place in January 1993. Furthermore, the primary discussants were not adequately acknowledged. We note them here in order of their presentations: Samuel W. Greenhouse, John C. Bailer III, Seymour Geisser, Nathan Mantel, Tavia Gordon, Marvin Zelen, Fred Ederer, Marvin A. Schneiderman.

Zeger, S. L. 'On estimating efficacy in clinical trials', **10**, 45-52 (1991); **13**, 1897 (1994).

Schäfer, H. 'Efficient confidence bounds for ROC curves', **13**, 1551-1561 (1994); **14**, 875 (1995).

Vollset, S. E. 'Confidence intervals for binomial proportion', **12**, 809-824 (1993); **14**, 875 (1995).

Baker, S. G. and Lindeman, K. S. 'The paired availability design: a proposal for evaluating epidural analgesia during labor', **13**, 2269-2278 (1994); **14**, 1841 (1995).

Gargiullo, P. M., Rothenberg, R. B. and Wilson, H. G. 'Confidence intervals, hypothesis tests, and sample sizes for the prevented fraction in cross-sectional studies', **14**, 51-72 (1995); **14**, 1841 (1995).

Walter, S. D. ' A simple test for spatial pattern in regional health data', **13**, 1037-1044 (1994); **15**; 335 (1996).

Wargenau, M. 'Dose finding strategies involving interim analyses and unbalanced treatment allocation', **14**, 901-907 (1995); **15**, 335 (1996).

BOOK REVIEW INDEX*

Abramson, J. H., *Making Sense of Data*, **9** 1008
Adams, J., *Risk*, **15** 1727
Agresti, A., *Categorical Data Analysis*, **11** 1791
Ahlbom, A. and Norrell, S., *Introduction to Modern Epidemiology*, **11** 849
Aitkin, M., Anderson, B. F. and Hinde, J., *Statistical Modelling in GLIM*, **8** 1418
Albert, A. and Harris, E. K., *Multivariate Interpretation of Clinical Laboratory Data*, **7** 1308
Alderson, M. R., *Mortality, Morbidity and Health Statistics*, **9** 1008
Altman, D. G., *Practical Statistics for Medical Research*, **10** 1635
Andersen, B., *Methodological Errors in Medical Research*, **10** 803
Anderson, A. J. B., *Interpreting Data: A First Course in Statistics*, **9** 858
Anderson, E. B., *The Statistical Analysis of Categorical Data (3rd edn)*, **15** 2125
Anderson, P. K., Børgan, Y., Gill, R. D. and Keiding, N., *Statistical Models Based On Counting Processes*, **13** 1797
Appleton, D. R., *Designing a Clinical Trial* (video), **12** 1183
ARME-P, *Methodological Approaches in Pharmacoepidemiology—Application to Spontaneous Reporting*, **15** 1464
Armitage, P. and Berry, G., *Statistical Methods in Medical Research*, **7** 817
Ashton, J., *The Epidemiological Imagination: A Reader*, **15** 231
Bailar, J. C. and Mosteller, F. (eds), *Medical Uses of Statistics*, **7** 1001
Bailer III, J. C. and Mosteller, F. (eds), *Medical Uses of Statistics (2nd edn)*, **13** 1597
Bailey, N. T. J., *The Biomathematics of Malaria*, **3** 93
Band, P. (ed), *Occupational Cancer Epidemiology*, **10** 1786
Bausell, R. B., *Advanced Research Methodology: An Annotated Guide to Sources*, **13** 881
Becker, Niels G., *Analysis of Infectious Disease Data*, **9** 466
Bennett, J. H. (ed), *Statistical Inference and Analysis: Selected Correspondence of R. A. Fisher*, **10** 1326
Bernardo, J. M. and Smith, A. F. M., *Bayesian Theory*, **15** 2124
Berry, D. A., *Statistical Methodology in the Pharmaceutical Sciences*, **9** 1382
Bland, M., *An Introduction to Medical Statistics*, **7** 1307
Bookstein, F. L., *Morphometric Tools for Landmark Data: Geometry and Biology*, **12** 714
Bowling, A., *Measuring Disease: A Review of Disease-Specific Quality of Life Measurement Scales*, **15** 1067
Boyle, P., Muir, C. S., Grundmann, E. (eds), *Cancer Mapping*, **10** 1473
Breslow, N. E. and Day, N. E., *Statistical Methods in Cancer Research. Volume II*, **8** 769
Britton, M. (ed), *Mortality and Geography: A Review in the Mid-1980s England and Wales*, **10** 1473
Brown, R. A. and Beck, J. S., *Medical Statistics on Microcomputers*, **10** 1783
Brown, P. J., *Measurement, Regression and Calibration*, **15** 561–562
Bulman, J. S. and Osborn, J. F., *Statistics in Dentistry*, **10** 1475
Burton, R. F., *Physiology by Numbers: An Encouragement to Quantitative Thinking*, **15** 340
Buyse, M. E., Staquet, M. J. and Sylvester, R. J. (eds), *Cancer Clinical Trials: Methods and Practice*, **3** 303
Buyse, M. E., Staquet, M. J. and Sylvester, R. J. (eds), *Cancer Clinical Trials: Methods and Practice*, **10** 502
Campbell, M. J. and Machin, D., *Medical Statistics: A Commonsense Approach*, **10** 804
Campbell, R. D., *Statistics for Biologists*, **9** 861
Carr-Hill, R. and Pritchard, C., *The Development & Exploitation of Empirical Birthweight Standards*, **5** 397
Carter, W. H., Wampler, G. L. and Stablein, D. M., *Regression Analysis of Survival Data in Cancer Chemotherapy*, **3** 197

* Compiled by Indexing Specialists, 202 Church Road, Hove, East Sussex BN3 2DJ, U.K.

Cartwright, R. A., Alexander, F. E., McKinney, P. A. and Ricketts, T. J., *Leukaemia and Lymphoma. An Atlas of Distribution*, **11** 135
Castillo-Chavez, C. (ed), *Mathematical and Statistical Approaches to AIDS Epidemiology*, **10** 1638
Chalmers, I., Enkin, M. and Keirse, M. J. N. C. (eds), *Effective Care in Pregnancy and Childbirth*, **11** 137
Chalmers, T. C., *Data Analysis for Clinical Medicine: The Quantitative Approach to Patient Care in Gastroenterology*, **9** 343
Checkoway, H., Pearce, N.E. and Crawford-Brown D.J., *Research Methods in Occupational Epidemiology*, **10** 1323
Chow, S.-C. and Lio, J.-P., *Statistical Design and Analysis in Pharmaceutical Science*, **15** 1710
Clayton, D. and Hills, M., *Statistical Models in Epidemiology.*, **15** 104, 1459
Cleveland, W. S., *Visualizing Data*, **15** 1395
Cliff, A. D. and Haggett, P., *Atlas of Disease Distributions: Analytic Approaches to Epidemiological Data*, **10** 1473
Cochrane A. L., *Effectiveness and Efficiency: Random Reflections on Health Services*, **10** 503
Coleman, M. P., Esteve, J., Damiecki, P., Arslan, A. and Renard, H., *Trends in Cancer Incidence and Mortality*, **15** 679
Collett, D., *Modelling Survival Data in Medical Research*, **14** 1147
Crump, B. and Drummond, M., *Evaluating Clinical Evidence: A Handbook for Managers*, **15** 2261
Daly, L. E., Bourke, G. J. and McGilvray, J., *Interpretation and Uses of Medical Statistics*, **13** 297
Darby, S., Doll, R., Pike, M. and Peto, R., *U.K. Smoking Statistics*, **8** 521
Davidian, M. and Giltiman, D. M., *Nonlinear Models for Repeated Measurement Data*, **15** 1462
Dawson-Saunders, B. and Trapp, R. G., *Basic and Clinical Biostatistics*, **10** 1636
DeAngelis, C. (ed), *An Introduction to Clinical Research*, **10** 1325
Desu, M. M. and Raghavarao, D., *Sample Size Methodology*, **11** 562
Diggle, P. J., Liang, K.-Y. and Zeger, S. L., *Analysis of Longitudinal Data*, **15** 1231
Diggle, P. J., *Time Series—A Biostatistical Introduction*, **10** 501
Doll, R., Fraumeni Jun, J. F. and Muir, C. S. (eds), *Trends in Cancer Incidence and Mortality (Cancer Surveys Vol. 19/20)*, **15** 2507
Dowie, J. and Elstein, A., *Professional Judgement: A Reader in Clinical Decision Making*, **8** 1557
Draper, D., Gaver Jun, D. P., Goel, P. K., Greenhouse, J. B., Hedges, L. V., Morris, C. N., Tucker, J. R. and Waternaux, C. M., *Combining Information: Statistical Issues and Opportunities for Research*, **15** 1611
Duffy, J. C., (ed),*Alcohol and Illness: The Epidemiology Viewpoint*, **13** 97
Dunn, G., *Design and Analysis of Reliability Studies: The Statistical Evaluation of Measurement Errors*, **10** 155
Dunn, G. and Everitt, B., *Clinical Biostatistics: An Introduction to Evidence Based Medicine*, **15** 2121
Dunstan, F. and Pickles, J. (eds), *Statistics in Medicine*, **12** 1273
Dwyer, J. H., Manning, F., Lippert P. and Hoffmeister, H. (eds), *Statistical Models for Longitudinal Studies of Health*, **12** 992
Elliot, P., Cuzick, J., English, D. and Stern, R. (eds), *Geographical and Environmental Epidemiology: Methods for Small-area Studies*, **13** 881
Elston, R. C. and Johnson, W. D., *Essentials of Biostatistics*, **7** 1204
Elwood, J. M., *Causal Relationships in Medicine: A Practical System For Critical Appraisal*, **9** 1543
Everitt, B. S., *Statistical Methods for Medical Investigations*, **10** 497
Everitt, B. and Hay, D., *Talking about Statistics: A Psychologist's Guide to Design and Analysis*, **13** 2385
Everitt, B.S., *The Analysis of Contingency Tables* (2nd edn), **12** 187
Eylenbosch, W. J. and Noah, N. D., *Surveillance in Health and Disease*, **9** 465
Fielding, J. W., Powell, J., Allum, W. H., *Clinical Cancer Monographs. Vol. 3*, **9** 857
Fisher, L. D. and van Belle, G., *Biostatistics: A Methodology for the Health Sciences.*, **15** 878
Fisher, R. A., *Statistical Methods, Experimental Design and Scientific Inference*, **10** 503
Fisher, R. J., Coates A. S. and Colebatch, J. H. (eds), *Guidelines for Clinical Trials in Cancer* (2nd edition), **8** 1310
Fleiss, J. L., *The Design and Analysis of Clinical Experiments*, **7** 454
Flemming, T. R. and Harrington, D. P., *Counting Processes and Survival Analysis*, **11** 1792
Forrest, P., *Breast Cancer: The Decision to Screen*, **11** 277
Fox, J., *Health Inequalities in European Countries*, **9** 855
Freeman, D. H. F. Jr, *Applied Categorical Data Analysis*, **8** 523
Gabriel, J-P., Lefévre, C. and Picard, P, (eds), *Stochastic Processes in Epidemic Theory (Lecture Notes in Biomathematics Vol 86)*, **10** 1787
Gardner, M. J. and Altman, D. G., *Statistics with Confidence: Confidence Intervals and Statistical Guidelines*, **9** 344

Gardner, M. J., Winter, P. D. and Barker, D. J. P., *Atlas of Mortality from Selected Diseases in England & Wales 1968-78*, **4** 549
Gardner, M. J., Winter, P. D., Taylor, C. P. and Acheson, E. D., *Atlas of Cancer Mortality in England & Wales 1968-78*, **4** 549
Gart, J. J., Krewisik, D., Lee, P. N., Tarone, R. E. and Wahrendorf, J., *The Design and Analysis of Long-Term Animal Experiments*, **8** 246
Gelman, A., Carlin, J. B., Stern, H. S. and Rubin, D. B., *Bayesian Data Analysis*, **15** 2123
Gilford, D. M., *The Aging Population in the Twenty-First Century: Statistics for Health Policy*, **9** 346
Glantz, S. A., *Primer of Biostatistics (3rd edn.)*, **13** 2287–2288
Glynn, J. R. (ed), *The Lancet—Facts, Figures, and Fallacies: Epidemiological Pitfalls in Medical Research.*, **15** 2622
Goldstone, L. A., *Understanding Medical Statistics*, **4** 249
Gore, S. M. and Altman, D. G., *Statistics in Practice*, **1** 377
Gore, S. M. and Bradley, B. A., *Renal Transplantation: Sense and Sensitization*, **8** 1307
Govindarajulu, Z., *Statistical Techniques in Bioassay*, **8** 1025
Hand, D. J. and Everitt, B. S. (eds), *The Statistical Consultant in Action*, **6** 875
Hand, D. J. and Taylor, C. C., *Multivariate Analysis of Variance and Repeated Measures*, **8** 1559
Harris, E. K. and Albert, A., *Survivorship Analysis for Clinical Studies*, **11** 1628
Harris, E. K. and Boyd, J. C., *Statistical Basis of Reference Values in Laboratory Medicine*, **15** 2266
Hassard, T. H., *Understanding Biostatistics*, **12** 97
Hastie, T. J. and Tibshirani, R. J., *Generalized Additive Models*, **11** 981
Healy, M. J. R., *GLIM: An Introduction*, **8** 1418
Healy, M. J. R., *GLIM: An Introduction*, **10** 503
Heaney, R. P. and Dougherty, C.J., *Research for Health Professionals: Design, Analysis and Ethics*, **9** 1381
Hill, C., Com-Nougué, C., Kramar, A., Moreau, T., O'Quigley, J., Senoussi, R., Chastang, C., *Analyse Statistique des Données de Survie*, **10** 1476
Hirsch, R. P. & Riegelman, R. K., *Statistical First Aid: Interpretation of Health Research Data*, **12** 2252
HMSO, *Short-term Prediction of HIV Infection and AIDS in England and Wales: Report of a Working Group*, **8** 1553
Hoel, D. G. and Yanagawa, T. (eds), *Biostatistics in Cancer Risk Assessment*, **13** 987
Holland, W. W., *European Community Atlas of 'Avoidable Death'*, **8** 635
Holland, W. W., Detels, R. and Knox, G. (eds) *Oxford Textbook of Public Health. Vol 2: Methods of Public Health* (2nd edn), **12** 1273
Holland, W. W. and Stewart, S., *Screening in Health Care: Benefit or Bane?*, **11** 1267
Hosmer, D. W. and Lemeshow, S., *Applied Logistic Regression*, **10** 1162
Hothorn, L. (ed), *Statistical Methods in Toxicology*, **11** 1269
Howell, D. C., *Statistical Methods for Psychology (3rd edn)*, **13** 1083
Howson, C. and Urbach, P., *Scientific Reasoning, The Bayesian Approach*, **10** 1161
Ingelfinger, J. A., Mosteller, F., Thibodeau, L. A. and Ware, J. H., *Biostatistics in Clinical Medicine*, **4** 394
Ingelfinger, J. A., Mosteller, F., Thibodeau, L. A. and Ware, J. H., *Biostatistics in Clinical Medicine*, **9** 861
Ingram, D. and Bloch, B., *Mathematical Methods in Medicine, Part I, Statistical and Analytical Techniques*, **4** 393
Ingram, D. and Bloch, B., *Mathematical Methods in Medicine, Part II, Applications in Clinical Research*, **6** 211
Jager, J. C. and Ruitenberg, E. J. (eds), *Statistical Analysis and Mathematical Modelling of AIDS*, **8** 1549
Jensen, M., Carstensen, B., Glattre, E., Malker, B., Pukkala, E. and Tulinius, H., *Atlas of Cancer Incidence in the Nordic Countries*, **9** 1119
Jewell, N. P., Dietz, K. and Farewell, V. T. (eds), *AIDS Epidemiology: Methodological Issues*, **13** 2387
Jones, B. and Kenward, M. G., *Design and Analysis of Cross-Over Trials*, **9** 1007
Junshi, C., Campbell, C. T., Junyao, L., Peto, R., *Diet, Life-style and Mortality in China: A Study of the Characteristics of 65 Chinese Counties*, **10** 1473
Kahn, H. A., Sempos, C. T., *Statistical Methods in Epidemiology*, **10** 501
Kaplan, E. H. and Brandeau, M. L. (eds), *Modeling the AIDS Epidemic: Planning, Policy and Prediction*, **15** 563–564
Kelley, W. D., Ratliff, T. A. Jr and Nenadic C., *Basic Statistics for Laboratories: A Primer for Laboratory Workers*, **12** 98
Khoury, M. J., Beaty, T. H. and Cohen, B. H., *Fundamentals of Genetic Epidemiology*, **13** 2386
Kirkland, D. J. (ed), *Statistical Evaluation of Mutagenicity Test Data*, **10** 156
Kirkwood, Betty R., *Essential Medical Statistics*, **8** 636

Kish, L., *Living with Risk: the BMA Guide*, **7** 453
Kish, L., *Statistical Designs for Research*, **7** 455
Klein, J. P. & Goel, P. K. (eds), *Survival Analysis: State of the Art*, **12** 1645
Kleinbaum, D. G., *Logistic Regression. A Self-Learning Text*, **15** 339
Kramer, M. S., *Clinical Epidemiology and Biostatics. A Primer. . .*, **9** 856
Krishnamurthy, G. B., Kasovia-Schmitt, P. and Ostroff, D. J., *Statistics. An Interactive Text for the Health and Life Sciences.*, **15** 2621
Laboratory Animal Sci. Assoc. and Universities Fed. for Animal Welfare, *Guidelines on the Care of Laboratory Animals and Their Use for Scientific Purposes. IV*, **10** 1785
Lancaster, H. O., *Quantitative Methods in Biological and Medical Sciences: A Historical Essay*, **15** 562–563
Last J. M. (ed), *A Dictionary of Epidemiology*, **10** 502
Lawless, J. F., *Statistical Models and Methods for Lifetime Data*, **1** 293
Le, C. T. and Boen, J. R., *Health and Numbers—Basic Biostatistical Methods*, **15** 1603
Leaverton, P., *A Review of Biostatistics: A Program for Self-instruction (4th edition)*, **11** 279
Lee, E., *Statistical Methods for Survival Data Analysis (2nd Edition)*, **13** 881
Lehrmacher, W. and Hormann, A., *Software: 3 Konferenz uber die Wissenschaftliche Anwendung von Statistik-Software*, **6** 212
Lemeshow, S., Hosmer, D. W., Klar, J. and Lwanga, S. K., *Adequacy of Sample Size in Health Studies*, **9** 1382
Leventhal, B. J. and Wittes, R. E., *Research Methods in Clinical Oncology*, **9** 1224
Light, R. J. and Pillemer, D. B., *Summing Up. The Science of Reviewing Research*, **5** 289
Lindley, D. V. and Scott, W. F., *New Cambridge Statistical Tables (2nd edn)*, **15** 1604
Llewelyn, H. and Hopkins, A., *Analysing How We Reach Clinical Decisions*, **13** 1597
Lock, S. and Wells, F. (eds), *Fraud and Misconduct in Medical Research*, **13** 987
Long, A. F., *Research into Health and Illness: Issues in Design, Analysis and Practice*, **5** 101
Lynch, H. T. and Tautu, P. (eds), *Recent Progress in the Genetic Epidemiology of Cancer*, **11** 561
McDowell, I. and Newell, C., *Measuring Health: A Guide to Rating Scales and Questionnaires*, **8** 1308
Machin, D. and Campbell, M. J, *Statistical Tables for the Design of Clinical Trials*, **7** 1307
Madansky, A., *Prescriptions for Working Statisticians*, **10** 1637
Magnusson, D., Bergman, L. R., Rudinger, G. and Törestad, B. (eds), *Problems and Methods in Longitudinal Research-Stability and Change*, **13** 881
Magnusson, D. and Bergman, R. (eds), *Data Quality in Longitudinal Research*, **11** 1405
Manly, B. F. J., *Randomization and Monte Carlo Methods in Biology*, **11** 136
Manly, B. F. J., *The Design and Analysis of Research Studies*, **13** 297
Manton, K. G. and Stallard, E., *Chronic Disease Modelling*, **9** 347
Margetts, B. M. and Nelson, M., *Design Concepts in Nutritional Epidemiology*, **13** 1287
Matthews, D. F. and Farewell, V. T., *Using and Understanding Medical Statistics*, **8** 636
Matthews, H. R., Waterhouse, J. A. H., Powell, J., Robertson, J. E. and McConkey, C., *Clinical Cancer Monographs. Vol. 1*, **9** 856
Max, M. B., Portnoy, R. K. and Laska, E. M. (eds), *The Design of Analgesic Clinical Trials*, **11** 1267
Maxwell, S. E., Delany, H. D., *Designing Experiments and Analyzing Data. A Model Comparison Perspective*, **10** 1477
Medico-Pharmaceutical Group, *Clinical Trial Protocol Notes* (2nd printing), **8** 1310
Meinert, C. L., *Clinical Trials: Design, Conduct and Analysis*, **7** 545
Miettinen, O. S., *Symposium on Methodology & Quality Assurance in Cancer Clinical Trials*, **6** 213
Miettinen, O. S., *Theoretical Epidemiology*, **6** 209
Miller, A. J., *Subset Selection in Regression*, **10** 1164
Miller, A. B., Chamberlain, J. , Day, N. E. , Hakama, M. & Prorok, P. C., *Cancer Screening*, **12** 1091
Miura, R. M. (ed), *Some Mathematical Questions in Biology: DNA Sequence Analysis*, **8** 523
Monk, A., *Exploring Statistics with Minitab: A Workbook for the Behavioural Sciences*, **11** 563
Morgan, B. J. T., *Analysis of Quantal Response Data*, **13** 1187
Mould, R. F., *Introductory Medical Statistics*, **9** 1226
Munro, A. J., *Clinical Trial Procedure—Notes for Doctors*, **8** 1310
Neale, M. C. and Cardon, L. R., *Methodology for Genetic Studies of Twins and Families.*, **13** 199
Newcombe, H. B., *Handbook of Record Linkage: Methods for Health*, **8** 638
Nicolosi, A. (ed), *AIDS Epidemiology: Models and Methods*, **13** 2387
Noreen, E. W., *Computer Intensive Methods for Testing Hypotheses*, **10** 499
Olsen, J. and Trichopoulos, D. (eds),*Teaching Epidemiology: What you Should Know and What you Could Do*, **13** 97

Olsen, J., Merletti, F., Snashall, D. and Vuylsteek, K., *Searching for Causes of Work-related Diseases: An Introduction to Epidemiology at the Work Site*, **11** 849
Parkin, D. M., Muir, C. S., Whelan, S. L., Gao, Y. T., Ferlay, J. and Powell, J. (eds), *Cancer Incidence in Five Continents, Volume VI*, **15** 104
Peace, K. E., *Biopharmaceutical Statistics For Drug Development*, **9** 1224
Peace, K. E. (ed), *Biopharmaceutical Sequential Statistical Applications*, **12** 2059
Petitti, D. B., *Meta-Analysis, Decision Analysis and Cost Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine*, **15** 1601
Poynard, T. and Pignon, J., *Duodenal Ulcer. Analysis of 293 Randomized Clinical Trials*, **9** 1225
Ratkowasky, D. A., Evans, M. A. and Alldredge, J. E., *Cross-over Experiments. Design, Analysis and Application.*, **13** 297
Rencher, A. C., *Methods of Multivariate Analysis*, **15** 1711
Rijckevorsel, J. L. A. van and Bijleveld, C. C. J. H. (eds), *A Reader on Applying Statistics in Public Health and Prevention*, **13** 2288
Robin, P. E., Powell, J. and Holme, G. M., *Clinical Cancer Monographs. Vol. 2*, **9** 857
Rondel, R. K., Varley, S. A. and Webb, C. F. (eds), *Clinical Data Management.*, **15** 877
Rose, G., *The Strategy of preventative Medicine*, **12** 2251
Rosenbaum, P. R., *Observational Studies*, **15** 2629
Rosner, B., *Fundamentals of Biostatistics*, **10** 1783
Rothman, K. J., (ed) *Causal Inference*, **10** 498
Rothman, K. J., *Modern Epidemiology*, **7** 818
Rovine, M. J. & von Eye, A., *Applied Computational Statistics in Longitudinal Research*, **12** 1647
Sackett, D. L., Haynes, R. B., Guyatt, G. H., Tugwell, P., *Clinical Epidemiology a Basic Science for Clinical Medicine* (2nd edn), **12** 187
Salsburg, D. S., *The Use of Restricted Significance Tests in Clinical Trials*, **13** 1597
Selvin, S., *Statistical Analysis of Epidemiologic Data*, **13** 1083
Senn, S., *Cross-over Trials in Clinical Research*, **13** 297
Shein-Chung Chow and Jen-Pei Liu, *Design and Analysis of Bioavailability and Bioequivalence Studies*, **12** 2059
Shott, S., *Statistics for Health Professionals*, **11** 1630
Shuster, J. J., *Practical Handbook of Sample Size Guidelines for Clinical Trials*, **12** 1271
Skrabanek, P. and McCormick, J., *Follies and Fallacies in Medicine*, **9** 1223
Smith, P. G. and Morrow, R. H. (eds), *Methods for Field Trials of Interventions against Tropical Diseases: A Toolbox*, **13** 1187
Social Affairs Unit, *Health, Lifestyle and Environment: Countering the Panic*, **12** 1645
Sokal, R. R. and Rohlf, J. F., *Introduction to Biostatistics*, **9** 861
Spilker, B. and Schoenfelder, J., *Presentation of Clinical Data*, **10** 1324
Spilker, B., *Guide to Clinical Trials*, **12** 1648
Sprent, P., *Applied Nonparametric Statistical Methods*, **9** 858
Spriet, A. and Dupin-Spriet, T., *Good Practice of Clinical Drug Trials*, **13** 881
Spriet, A., Dupin-Spriet, T. and Simon, P., *Methodology of Clinical Drug Trials, English Edition*, **15** 337
Steenland, K. (ed), *Case Studies in Occupational Epidemiology.*, **15** 1148
Stein, F., *Anatomy of Clinical Research. An Introduction to Scientific Inquiry in Medicine, Rehabilitation and Related Health Professions*, **10** 1325
Streiner, D. L., Norman, G. R., *Health Measurement Scales: A Practical Guide To Their Development and Use*, **10** 1478
Strike, P. W., *Measurement in Laboratory Medicine: A Primer on Control and Interpretation*, **15** 2265
Strike, P. W., *Statistical Methods in Laboratory Medicine*, **11** 1793
Svensson, E., *Analysis of Systematic and Random Differences Between Paired Ordinal Categorical Data.*, **15** 1726
Swerdlow, A. and Silva, I. dos S., *Atlas of Cancer Incidence in England and Wales: 1968-85.*, **15** 1725
Thompson, E. A. and Hopkins, J., *Pedigree Analysis in Human Genetics*, **9** 348
Timmreck, T. C., *An Introduction to Epidemiology*, **15** 1459
Tomatis, L. (ed), *Cancer: Causes, Occurrence and Control*, **11** 278
Touitou, Y. and Haus, E. (eds), *Biologic Rhythms in Clinical and Laboratory Medicine*, **15** 2262
Tufte, E. R., *Envisioning Information*, **12** 991
United States General Accounting Office, *Cross Design Synthesis: A New Strategy for Medical Effectiveness Research*, **11** 1627
Vollmar, J., *Biometrie in der Chemisch-Pharmazeutischen Industrie*, **15** 1602
von Eye, A. (ed), *Statistical Methods in Longitudinal Research. Vol 1: Principles and Structuring Change*, **11** 979

von Eye, A. (ed), *Statistical Methods in Longitudinal Research. Vol 2: Time series and Categorical Longitudinal Data*, **11** 979
Wald, N., Kiryluk, S., Darby, S., Doll, R., Pike, M. and Peto, R., *U.K. Smoking Statistics*, **8** 521
Walker, A. M., *Observation and Inference: An Introduction to the Methods of Epidemiology*, **11** 980
Wallace, K. H. and Thompson, R. A., *Immunointervention in Man. A Critique of Clinical Trial Methodology*, **12** 1748
Wallace, R. B. and Woolson, R. F. (eds), *The Epidemiologic Study of the Elderly*, **12** 1747
Wang, C., and Dekker, M., *Sense and Nonsence of Statistical Inference*, **15** 103
Wassertheil-Smoller, S., *Biostatistics and Epidemiology—A Primer for Health Professionals*, **10** 1165
Waterman, M. S., *Introduction to Computational Biology: Maps, Sequences and Genomes*, **15** 2264
Westfall, P. H. and Young, S. S., *Resampling-based Multiple Testing*, **13** 1083
Whitehead, J., *The Design and Analysis of Sequential Clinical Trials* (2nd edn), **12** 2057
Williams, C. J.(ed), *Introducing New Treatments for Cancer: Practical, Ethical and Legal Problems*, **12** 713
Wooding, W. M., *Planning Pharmaceutical Trials: Basic Statisical Principles*, **15** 1709
Woodward, M. and Francis, L. M. A., *Statistics for Health Management and Research*, **8** 522
Woolson, R. F., *Statistical Methods for the Analysis of Biomedical Data*, **8** 1309
Zatonski, W., Becker, N., Gottesmann, K., Mykowiecka, A. and Tycznyski, J., *Atlas of Cancer Mortality in Poland 1975-1979*, **9** 1119

EDITORS OF *STATISTICS IN MEDICINE*

Editors

T. Colton	(1982-)
L.S. Freedman	(1982-1993)
A.L. Johnson	(1982-)
D. Machin	(1988-)

Deputy Editors

Robert Glynn	(1995-)
Joel Greenhouse	(1995-)

Book Review Editors

Douglas Altman	(1987-1994)
Niels Keiding	(1995-)

Editorial Assistants

Suzanne Thompson
Margaret Molloy

EDITORIAL BOARD MEMBERS

A.M. Adelstein (1982-1984)
Office of Population, Censuses and Surveys, London, U.K.

R. D'Agostino (1982-1991)
Boston University, U.S.A.

P.S. Albert (1994-)
NHBLI/NIH, Bethesda, U.S.A.

D.G. Altman (1985-)
Institute of Health Sciences, Oxford, U.K.

P.K. Andersen (1995-)
University of Copenhagen, Denmark

C. Anello (1982-1985)
Food and Drugs Administration, Rockville, U.S.A.

P. Armitage (1985-)
Department of Biomathematics, Oxford, U.K.

D. Ashby (1991-)
University of Liverpool, U.K.

J.R. Assenzo (1982-1991)
Upjohn Research Laboratories, Kalamazoo, U.S.A.

N.T.J. Bailey(1982-1989)
World Health Organization, Geneva, Switzerland

S.G. Baker (1994-)
National Cancer Institute, Bethesda, U.S.A.

P. Bauer (1995-)
University of Vienna, Austria

M. Baum (1982-1992)
King's College Hospital Medical School, London, U.K.

C. Begg (1986-)
Dana-Farber Cancer Institute, Boston, U.S.A.

V. Beral (1985-1992)
London School of Hygiene and Tropical Medicine, U.K.

G.E. Bonney (1994-1996)
Fox Cahse Cancer Center, Philadelphia, U.S.A.

R. Brookmeyer (1986-1994)
School of Hygiene and Public Health, Johns Hopkins University, U.S.A.

B.W. Brown Jr. (1982-1989)
Stanford Medical Centre, U.S.A.

R. Buncher (1982-1989)
University of Cincinnati Medical School, U.S.A.

M.J. Campbell (1990-)
University of Southampton, U.K.

B.P. Carlin (1994-1996)
University of Minnesota, U.S.A.

C. Chastang (1987-1992)
Université Paris VII, France

R. Chen (1993-)
Israel Institute for Biological Research, Ness-Ziona, Israel

R.P. Chiacchierini (1991-1995)
Centre for Devices and Radiological Health, Rockville, U.S.A.

D. Clayton (1982-1996)
Institute of Public Health, Cambridge, U.K.

T.J. Cole (1992-)
MRC Dunn Nutrition Ltd., Cambridge, U.K.

N. Crichton (1991-)
Institute of Advanced Nursing Education, London, U.K.

S.C. Darby (1990-)
University of Oxford, U.K.

N.E. Day (1990-1992)
Institute of Public Health, Cambridge, U.K.

S. Day (1990-)
Leo Laboratories Ltd., Princes Risborough, U.K.

P. Diehr (1994-)
University of Washington, U.S.A.

K. Dietz (1982-)
Universität Tübingen, Germany

R. Doll (1982-1986)
Green College, Oxford, U.K.

A. Donner (1986-1991)
University of Western Ontario, Canada

N. Dubin (1991-1996)
New York University School of Medicine, U.S.A.

S.W. Duffy (1993-)
Institute of Public Health, Cambridge, U.K.

W.H. Du Mouchel (1994-)
Columbia University, U.S.A.

S.S. Ellenberg (1990-1996)
National Institute of Allergies and Infectious Diseases, Bethesda, U.S.A.

R.C. Elston (1996-)
Case Western Reserve University, Cleveland, U.S.A.

P.A. Emerson (1982-1984)
Westminster Hospital, London, U.K.

B.S. Everitt (1985-)
Institute of Psychiatry, London, U.K.

T.M.M. Farley (1990-)
World Health Organization, Geneva, Switzerland

C.P. Farrington (1992-)
PHLS Communicable Disease Surveillance Centre, London, U.K.

D.J. Finney (1982-1986)
University of Edinburgh, U.K.

D.M. Finkelstein (1996-)
Harvard School of Public Health, U.S.A.

M.A. Foulkes (1996-)
NIAID, Bethesda, U.S.A.

A.J. Fox (1982-1989)
The City University, London, U.K.

L.S. Freedman (1994-)
Silver Spring, U.S.A.

M.H. Gail (1986-1996)
National Cancer Institute, Bethesda, U.S.A.

G. Gallus (1993-)
University of Milan, Italy

C. Gatsonis (1996-)
Brown University, Providence, U.S.A.

E.A. Gehan (1990-)
MD Anderson Cancer Centre, Houston, U.S.A.

E. Goetghebeur (1995-)
R.U. Limburg, Maastricht, The Netherlands

J. Goldberg (1982-1985
Mt. Sinai School of Medicine, New York, U.S.A.

S.M. Gore (1985-)
Institute of Public Health, Cambridge, U.K.

A.L. Gould (1996-)
Merck Research Laboratories, West Point, U.S.A.

E.R. Greenberg (1982-1991)
Dartmouth Medical School, Hanover, U.S.A.

J.B. Greenhouse(1991-1994)
Carnegie Mellon University, Pittsburgh, U.S.A.

S. Greenland (1986-)
UCLA School of Public Health, U.S.A.

A.P. Grieve (1995-)
Pfizer Central Research, Sandwich, U.K.

J.D.F. Habbema (1985-)
Dept. of Public Health and Social Medicine, Rotterdam, The Netherlands

M.E. Halloran (1994-)
Emory University, Atlanta, U.S.A.

J. Hanley (1996-)
McGill University, Quebec, Canada

F.E. Harrell Jr. (1991-)
Duke University Medical Centre, Durham, U.S.A.

W.W. Hauck (1990-)
University of California at San Francisco, U.S.A.

J.L. Haybittle (1982-1989)
Addenbrookes Hospital, Cambridge, U.K.

D.F. Heitjan (1996-)
Columbia School of Public Health, New York, U.S.A.

C. Hennekens (1982-1991)
Harvard Medical School, U.S.A.

K.F. Hirji (1994-)
University of California, U.S.A.

M.D. Hughes (1990-1996)
London School of Hygiene and Tropical Medicine, U.K.

B. Jarman (1982-1986)
Lisson Grove Health Centre, London, U.K.

K. Kafadar (1994-)
University of Colorado-Denver, U.S.A.

R.E. Kass (1991-1992)
Carnegie Mellon University, Pittsburgh, U.S.A.

N. Keiding (1985-)
Department of Biostatistics, University of Copenhagen, Denmark

K.W. Kemp (1982-1984)
University College, Cardiff, U.K.

J.C. Kleinman (1986-1991)
National Centre for Health Statistics, Hyattsville, U.S.A.

E.G. Knox (1982-1992)
The Medical School, Birmingham, U.K.

G.G. Koch (1990-)
University of North Carolina, U.S.A.

E.L. Korn (1991-1995)
National Cancer Institute, Bethesda, U.S.A.

H.C. Kraemer (1991-)
Stanford University, U.S.A.

P.A. Lachenbruch (1986-)
UCLA School of Public Health, U.S.A.

D.R. Laurence (1982-1984)
University College, London, U.K.

P.E. Leaverton (1994-)
University of South Florida, U.S.A.

Y.J. Lee (1994-)
NIH Child Health and Human Development, Bethesda, U.S.A.

S.A. Lemeshow (1994-)
University of Massachusetts, Amherst, U.S.A.

P.S. Levy (1996-)
University of Illinois at Chicago, U.S.A.

J.A. Lewis (1987-)
Medicines Control Agency, London, U.K.

T.A. Louis (1990-1994)
University of Minnesota, U.S.A.

D. Machin (1987-1988)
University of Southampton, U.K.

R.J. Marshall (1993-)
University of Auckland, New Zealand

E. Marubini (1982-1992)
Instituto di Biometria e Statistica Medica, Milan, Italy

L. Massé (1982-1986)
Ecole Nationale de la Santé Publique, Rennes, France

G. Maude (1993-1996)
London School of Hygiene and Tropical Medicine, U.K.

C.K. McPherson (1982-1994)
London School of Hygiene and Tropical Medicine, U.K.

T.W. Meade (1982-1986)
MRC Epidemiology and Medical Care Unit, Harrow, U.K.

R.C. Milton (1994-1996)
National Eye Institute, Bethesda, U.S.A.

A. Muñoz (1994-)
Johns Hopkins University, U.S.A.

G.D. Murray (1991-)
University of Glasgow, U.K.

J.M. Neuhaus (1996-)
University of California, U.S.A.

A.B.J. Nix (1987-)
University College, Cardiff, U.K.

P. O'Brien (1990-1996)
Mayo Clinic, Rochester, U.S.A.

M. O'Fallon (1982-1985)
Mayo Clinic, Rochester, U.S.A.

C. Osmond (1990-)
University of Southampton, U.K.

S. Paintadosi (1991-)
Johns Hopkins University School of Medicine, U.S.A.

B. Pasternak (1982-1991)
New York University School of Medicine, U.S.A.

S.J. Pocock (1982-)
London School of Hygiene and Tropical Medicine, U.K.

C. Redmond (1982-1985)
School of Public Health, Pittsbugh, U.S.A.

G.H. Reynolds (1990-1996)
Centres for Disease Control, Atlanta, U.S.A.

S. Richardson (1993-)
INSERM U170, Villejuif, France

A. Rimm (1982-1989)
Medical College of Wisconsin, U.S.A.

B. Rosner (1982-1991)
Harvard Medical School, U.S.A.

P. Royston (1989-)
Royal Postgraduate Medical School, London, U.K.

L.M. Ryan (1994-)
Dana-Farber Cancer Institute, Boston, U.S.A.

D.J. Schaid (1991-1996)
Mayo Clinic, Rochester, U.S.A.

E. Schifflers (1987-1994)
Facultée Universitaires N.-O. de la Paix, Namur, Belgium

M.A. Schneiderman (1982-1985)
Clement Associates, Washington D.C., U.S.A.

M. Schumacher (1990-)
University of Freiberg, Germany

M.R. Segal (1994-)
University of California, U.S.A.

D. Seigel (1986-1989)
National Institutes of Health, Bethesda, U.S.A.

S.G. Self (1991-1994)
The Fred Hutchinson Cancer Research Centre, Washington, U.S.A.

S. Senn (1990-)
University College London, UK

R.J. Simes (1987-1992)
Ludwig Institute for Cancer Research, Sydney, Australia

R. Simon (1986-1994)
Biometric Research Branch National Cancer Institute, Bethesda, U.S.A.

D.J. Spiegelhalter (1985-)
Institute of Public Health, Cambridge, U.K.

I. Sutherland (1982-1989)
MRC Biostatistics Unit, Cambridge, U.K.

R.J. Sylvester (1993-1995)
EORTC Data Centre, Brussels, Belgium

T. Tango (1990-)
Institute of Public Health, Tokyo, Japan

P.F. Thall (1994-)
University of Texas, U.S.A.

E.A. Thompson (1990-1994)
University of Washington, U.S.A.

S.G. Thompson (1991-)
Royal Postgraduate Medical School, London, U.K.

B.C. Tilley (1991-1996)
Henry Ford Health Sciences Center, Southfield, U.S.A.

B.W. Turnbull (1994-)
Cornell University, U.S.A.

L.A. Waller (1996-)
University of Minnesota, U.S.A.

J. Whitehead (1990-)
University of Reading, U.K.

G.W. Williams (1991-1995)
Merck Sharp and Dohme Research Laboratories, West Point, U.S.A.

J.K. Wing (1982-1984)
MRC Social Psychiatry Unit, London, U.K.

J. Wittes (1982-1991)
City University of New York, U.S.A.

R.F. Woolson (1990-)
University of Iowa, U.S.A.

M.C. Wu (1991-1996)
National Heart, Lung and Blood Institute, Bethesda, U.S.A.

R. Zentgraf (1982-1989)
Gödecke Aktiengesellschaft, Freiburg, Germany

C. Zipplin (1982-1985)
University of California Medical School, San Francisco, U.S.A.

VOLUME CONTENTS

Volume 1, Issue Nos. 1–4

Volume 1, *Issue No.* 1, January–March 1982

Editorial 1

The Questioning Statistician 5
D. J. Finney

Effect of Different Mammographic Radiation exposures on Predicted Benefits of Screening for Breast Cancer 15
N. Dubin

On Choosing the Number of Interim Analyses in Clinical Trials 25
K. McPherson

Mantel–Haenszel Statistics and Direct Standardization 37
R. F. Woolson and J. A. Bean

The Logistic Function as an Aid in the Detection of Acute Coronary Disease in Emergency Patients (A Case Study) 41
R. B. D'Agostino and M. W. Pozen

Measuring the Correlation Between Time Series of Hormonal Data 49
R. G. Marks

Statistics in Medical Journals 59
D. G. Altman

The Design of a Sequential Clinical Trial for the Comparison of Two Lung Cancer Treatments 73
D. R. Jones, C. E. Newman and J. Whitehead

A Distribution-Free Test for Paired Growth Curve Analyses with Application to an Animal Tumour Immunotherapy Experiment 83
J. A. Koziol and D. A. Maxwell

ANNOUNCEMENT 91

Volume 1, *Issue No.* 2, April–June 1982

Long Term Survival Analysis: The Curability of Breast Cancer 93
S. J. Pocock, S. M. Gore and G. R. Kerr

Third Variable Analysis: Application to Causal Sequences Among Nutrient Intake, Maternal Weight, Birthweight, Placental Weight, and Gestation 105
M. Susser and Z. Stein

Tables of the Number of Patients Required in Clinical Trials Using the Logrank Test 121
L. S. Freedman

A Simple Method Based on Broken-line Interpolation for Displaying Data from Long-term Clinical Trials 131
D. J. Gans

Use of a Designed Experiment for the Study of Muscle Fibre Size 139
R. H. Morton

Severity Measurement in Multiple Trauma by Use of ICDA Conditions 145
P. S. Levy, J. Goldberg, S. Hui, J. Rothrock, N. Iverson and T. Hosmer

The Detection of Adverse Reactions to Therapeutic Drugs 153
D. J. Finney

Strategies for Analysing Ecological Health Data: Models of the Biological Risk of Individuals 163
K. G. Manton, E. Stallard and W. Riggan

Detection of Minimal Epidemics 183
E. G. Knox and R. Lancashire

Volume 1, *Issue No.* 3, July–September 1982

Reliability of Basic Cancer Patient Data 191
P. Feigl, L. Polissar, W. W. Lane and V. Guinee

Neonatal Mortality in San Serriffe: A Game for Teaching Survey Methods 205
S. B. J. Macfarlane and J. B. Moody

Interpretation and Estimation of Summary Ratios under Heterogeneity 217
S. Greenland

Statistical Methods for Estimating Attributable Risk from Retrospective Data 229
A. S. Whittemore

Age, Period and Cohort Models Applied to Cancer Mortality Rates 245
C. Osmond and M. J. Gardner

The Exclusion of Patients from a Clinical Trial 261
A. Donner

Magnitude and Likelihood of Loss Resulting from Non-Stratified Randomization 267
M. Palta and S. B. Amini

The Effect of Unbalanced Randomization on the Progressively Censored Savage Test 277
M. L. Lesser

The Use of Background Data in the Analysis of Covariance 281
E. A. C. Shirley

BOOK REVIEW 293

ANNOUNCEMENT 295

Volume 1, *Issue No.* 4, October–December 1982

Austin Bradford Hill—Ancestry and Early Life 297
I. D. Hill

Bradford Hill and Statistics in Medicine 301
Sir Harold Himsworth

A. B. H.—Young at Heart 305
B. J. Duffy

A Personal Reminiscence 307
M. A. Schneiderman

Teacher and Friend 309
D. D. Rutstein

The Clinician and the Statistician 311
H. M. Schoolman

Bradford Hill's Contribution to Occupational Health 317
R. Schilling

Bradford Hill's Influence on Epidemiology 325
A. M. Lilienfeld

BCG and Vole Bacillus Vaccination in Adolescence and Mortality from Leukaemia 329
I. Sutherland

Clinical Trials: Retrospect and Prospect 337
Sir Richard Doll

The Role of Randomization in Clinical Trials 345
P. Armitage

Multicentre Clinical Trials: Bradford Hill's Contributions and Some Subsequent Developments 353
J. L. Fleiss

Clinical Trials: Some Reflections 361
W. W. Holland, E. Breeze and A. V. Swan

Bibliography: Publications (in English) of Sir Austin Bradford Hill 369

BOOK REVIEW 377

Author Index 379

Subject Index 380

Volume 2, Issue Nos. 1–4

Volume 2, *Issue No.* 1, January–March 1983

Epidemiology of Prenatal Infections: An Extension of the Congenital Rubella Model 1
E. G. Knox

Relative Risks of Diseases in the Presence of Incomplete Penetrance and Sporadics 13
P. P. Majumder, R. Chakraborty and K. M. Weiss

Reducing Classification Errors in Cohort Studies: The Approach and a Practical Application 25
K. F. Schulz, W. Cates Jr., D. A. Grimes, R. M. Selik and C. W. Tyler, Jr.

An Analysis of Repeated Biopsies Following Cardiac Transplantation 33
D. J. Spiegelhalter and P. G. I. Stovin

Unbiased Assessment of Treatment Effects on Disease Recurrence and Survival in Clinical Trials 41
R. Kay and M. Schumacher

Log-Linear Model Selection in a Rural Dental Health Study 59
J. Oler and J. M. Bentley

Bias Correction in Maximum Likelihood Logistic Regression 71
R. L. Schaefer

The Association Between HLA Antigens and the Presence of Certain Diseases 79
J. R. Green, M. K. Chiew, H. C. Low and J. C. Woodrow

On the Standard Error of the Probability of a Particular Diagnosis 87
D. Machin, N. R. Dennis, P. A. Tippett and V. Andrews

Discriminant Analysis Based on Multivariate Response Curves: A Descriptive Approach to Dynamic Allocation 95
A. Albert

ANNOUNCEMENTS 107

Volume 2, *Issue No.* 2, April–June 1983

Papers from the International Society for Clinical Biostatistics Third International Meeting, September 1982

Preface 109

The ISCB 111

KEYNOTE LECTURE

Between Medicine and Law 113
D. J. Finney

CLINICAL CHEMISTRY AND QUALITY CONTROL

The Importance of Internal Quality Control Data in National External Quality Assessment Schemes. Plasma Progesterone Assays 123
C. Kay, K. W. Kemp, A. B. J. Nix, R. J. Rowlands, G. V. Groom, D. W. Wilson and K. Griffiths

Are Definitive (Reference) Methods and Shewhart's Principle the Best Approach Towards Accuracy? 131
B. Leijnse

Application of Cusum Techniques to the Routine Monitoring of Analytical Performance in Clinical Laboratories 141
R. J. Rowlands, K. Griffiths, K. W. Kemp, A. B. J. Nix, G. Richards and D. W. Wilson

A Method of Analysis of Laboratory Data in an Epidemiological Study Where Time Trends are Present 147
S. G. Thompson

CLINICAL TRIALS

Deficiencies in Clinical Reports for Registration of Drugs 155
H. De Jonge

Stopping Rules for Clinical Trials 167
L. S. Freedman, D. Lowe and P. Macaskill

Critical Reflections on Clinical Trials 175
Chr. L. Rümke

The Analysis of a Sequential Clinical Trial for the Comparison of Two Lung Cancer Treatments 183
J. Whitehead, D. R. Jones and S. H. Ellis

DIAGNOSIS

Determining Reference ('Normal') Limits in Medicine: An Application 191
P. D. Bezemer, J. C. Netelenbos, C. Mulder, J. A. Theune, I. H. Stamhuis and J. P. Straub

The Performance of Logistic Discrimination of Myocardial Infarction Data In Comparison with some other Discriminant Analysis Methods 199
P. I. M. Schmitz, J. D. F. Habbema and J. Hermans

Evaluation of Clinical Decision-Aids, with an Application to a System for Dyspepsia 207
D. J. Spiegelhalter

Assessing Tumour Markers 217
H. Tate

EPIDEMIOLOGY

The Analysis Using GENSTAT of Anaemia, Sugar Intake and Quetelet's Index as Prognostic Indicators in Women 223
M. J. Campbell

The Leicestershire Perinatal Mortality Study: A Case Study of Multi-Group Discriminant Analysis with Complex Sampling 229
D. G. Clayton

Tests for Interaction in Epidemiologic Studies: A Review and a Study of Power 243
S. Greenland

Bimodality of Blood Pressure Levels 253
I. C. McManus

Stratified Analysis of Multivariate Clinical Data: Application of a Mantel–Haenszel Approach 259
N. Mantel, P. Mocarelli, A. Marocchi, P. Brambilla and R. Baretta

The Need for Randomization in the Study of Intended Effects 267
O. S. Miettinen

SURVIVAL ANALYSIS

Analysis of Survival Data by the Proportional Odds Model 273
S. Bennett

An Analysis of Survival Differences Between Clinically and Screen-detected Cancer Patients 279
J. D. F. Habbema, G. J. van Oortmarssen and D. J. van Putten

Fitting Regression Models to Censored Survival Data 287
M. Hudec and H. Platz

Prognostic Factors and Risk Groups: Some Results Given by Using an Algorithm Suitable for Censored Survival Data 295
E. Marubini, A. Morabito and M. G. Valsecchi

Comparison of Models for Survival Data 305
D. Oakes

ANNOUNCEMENT 313

Volume 2, *Issue No.* 3, July–September 1983

On the Use of Logrank Scores in the Analysis of Litter-matched Data on Time to Tumour Appearance 315
J. E. Michalek and D. Mihalko

Discussion of the Preceding Article 323
N. Mantel

Simplified Computation of the Multivariate Permutation Test for Arbitrarily Censored Survival Data 327
R. Marcuson

Regression Analysis Applied to PVC Histories: A Statistical Procedure for Evaluating Antiarrhythmic Drug Efficacy 331
D. A. Berry and T. L. Fox

Statistical Analysis of Gait Patterns of Persons with Cerebral Palsy 345
M. A. Wong, S. Simon and R. A. Olshen

Cautions on the Use of Medical Databases 355
N. Mantel

Predicted Mortality Patterns in Cohort Study Populations Exposed to Different Types of Hazard: Can SMRs Show a Dose-response? 363
C. M. J. Bell and D. A. Coleman

Parameters of Mortality in Human Populations with Widely Varying Life Spans 373
W. Siler

A Comparison of Two Methods for Calculating Expected Mortality 381
A. J. Hartz, E. E. Gie[illegible]er and R. G. Hoffmann

A Method for Determining the Sampling Ratio in Epidemiologic Studies 387
H. Morgenstern and D. M. Winn

VOLUME CONTENTS 211

Some Non-parametric and Categorical Data Analyses for a Change-over Design Study and Discussion of Apparent Carry-over Effects 397
G. G. Koch, S. L. Gitomer, L. Skalland and M. E. Stokes

LETTERS TO THE EDITOR 413

ANNOUNCEMENT 416

Volume 2, *Issue No.* 4, October–December 1983

How Much of the Placebo 'Effect' is Really Statistical Regression? 417
C. J. McDonald, S. A. Mazzuca and G. P. McCabe, Jr.

Measuring and Analysing Quality of Life in Cancer Clinical Trials: A Review 429
P. M. Fayers and D. R. Jones

Analysing Antibody Response Based on Data Obtained from Serial Dilution Methods 447
L. S. Chan, G. D. Overturf and J. Selzer

Methods for Age-Adjustment of Rates 455
H. Inskip, V. Beral, P. Fraser and J. Haskey

Adjusting Proportional Mortality Ratios for the Influence of Extraneous Causes of Death 467
M. McDowall

An Investigation of an Excess Incidence of Heart Disease 477
G. M. Paddle and B. Bennett

Prediction Intervals for Survival Data 485
R. Brookmeyer

Validity and Power Investigation of a Test for Serial Correlation in Univariate Repeated Measures Analysis 497
E. M. Hearne, III and G. M. Clark

Author Index 505

Subject Index 506

Volume 3, Issue Nos. 1–4

Volume 3, *Issue No.* 1, January–March 1984

Statistical Consulting in Clinical Research: The Two-Way Street 1
L. Moses and T. A. Louis

A Comparison of Standardized and Proportional Mortality Ratios 7
E. Roman, V. Beral, H. Inskip, M. McDowall and A. Adelstein

The Logistic Analysis of Epidemiologic Prospective Studies: Investigation by Simulation 15
D. E. Lilienfeld and D. A. Pyne

Case Definition and Power in Case-Control Studies 27
P. R. Rosenbaum

A Non-Parametric Graphical Representation of the Relationship Between Survival and the Occurrence of an Event: Application to Responder Versus Non-Responder Bias 35
R. Simon and R. W. Makuch

Clinical Trials Designed to Evaluate Therapeutic Preferences 45
J. C. Baskerville, J. H. Toogood, J. Mazza and B. Jennings

Analysis of Linkage and Association for Diseases of Genetic Aetiology 57
E. Sturt

An Application of Kappa-Type Analyses to Interobserver Variation in Classifying Chest Radiographs for Pneumoconiosis 73
D. C. Musch, J. R. Landis, I. T. T. Higgins, J. C. Gilson and R. N. Jones

The Choice Between Analysis of Variance and Analysis of Covariance with Special Reference to the Analysis of Organ Weights in Toxicology Studies 85
E. A. C. Shirley and P. Newnham

BOOK REVIEW 93

Volume 3, *Issue No.* 2, April–June 1984

Editorial 97

Ensuring Data Quality in Medical Research Through an Integrated Data Management System 101
Y. N. Marinez, C. A. McMahan, G. M. Barnwell and H. Wigodsky

Interpretation of Time Trends in Disease Rates in the Presence of Generation Effects 113
M. J. Gardner and C. Osmond

Bias in Methods for Deriving Standardized Morbidity Ratio and Attributable Fraction Estimates 131
S. Greenland

Regression Modelling Strategies for Improved Prognostic Prediction 143
F. E. Harrell, Jr., K. L. Lee, R. M. Califf, D. B. Pryor and R. A. Rosati

Survivorship Analysis When Cure is a Possibility: A Monte Carlo Study 153
A. I. Goldman

An Analysis of Resistance Times to Infection Under Treatment 165
H. Kimber and M. Crowder

A Study of Three Techniques for Time–Space Clustering in Hodgkin's Disease 173
R. Chen, N. Mantel and M. A. Klingberg

The Analysis of Repeated Measures Designs in Medical Research 185
H. J. Keselman and J. C. Keselman

BOOK REVIEW 197

Volume 3, *Issue No.* 3, July–September 1984

Approaches to Sample Size Estimation in the Design of Clinical Trials—A Review 199
A. Donner

Validity and Treatment Dilution in Zelen's Single Consent Design 215
R. McHugh

Allocation of Treatment to Patients when not all Balancing Factors are Known to the Co-ordinating Centre 219
H. J. J. van Lier, P. van Elteren, A. J. Hoitsma and R. A. P. Koene

Medical Registers as Historical Controls: Analysis of an Open Clinical Trial of Inosiplex in Subacute Sclerosing Panencephalitis 225
F. K. Hoehler, N. Mantel, E. Gehan, E. Kahana and M. Alter

Comparison of Two Statistical Techniques for the Surveillance of Birth Defects Through a Monte Carlo Simulation 239
G. Barbujani and E. Calzolari

A Classification of Scottish Infants Using Latent Class Analysis 249
R. M. Pickering and J. F. Forbes

Automatic Classification of Biomedical Information when Classification Error is Unknown 261
A. M. Stoddard

A Comparison of Chi-square partitioning and Two Logit Analyses of Ordinal Pain Data from a Pharmaceutical Study 273
C. Cox and C. Chuang

Goodness-of-fit Based Confidence Intervals for Estimates of the Size of a Closed Population 287
R. R. Regal and E. B. Hook

An Application of Ridge Regression Analysis in the Study of Syphilis Data 293
A. Hadgu

LETTER TO THE EDITOR 301

BOOK REVIEWS 303

Volume 3, *Issue No.* 4, October–December 1984

PROCEEDINGS OF THE WORKSHOP ON EVALUATION OF THERAPY, SEPTEMBER 1983

Sponsored by the National Cancer Institute and the National Heart, Lung, and Blood Institute, Bethesda, MD 20205, U.S.A.

Preface 305
L. Friedman, R. Simon, J. Verter, J. Wittes and R. Wittes

The Randomized Clinical Trial 307
B. W. Brown, Jr.

Discussion 313

The Evaluation of Therapies: Historical Control Studies 315
E. A. Gehan

Experience with Historical Control Studies in Cancer Immunotherapy 325
C. M. Pinsky

Discussion 331

Using a Database of Protocol Studies to Evaluate Therapy: A Breast Cancer Example 333
T. E. Moon, S. E. Jones, G. Bonadonna, T. J. Powles, S. Rivkin, A. Buzdar and E. Montague

The Role of Observational Studies in the Evaluation of Therapy 341
A. R. Feinstein

Discussion 347

The Patterns of Care Study in Clinical Radiation Therapy—A Retrospective Assessment of Quality of Care 353
S. Kramer and J. J. Diamond

Discussion 359

Using Observational Data From Registries to Compare Treatments: The Fallacy of Omnimetrics 361
S. B. Green and D. P. Byar

Discussion 371

Tying Clinical Research to Patient Care by Use of an Observational Database 375
M. A. Hlatky, K. L. Lee, F. E. Harrell, Jr., R. M. Califf, D. B. Pryor, D. B. Mark and R. A. Rosati

Discussion 385

Non-randomized Studies of Coronary Artery Bypass Surgery 389
K. M. Detre

Commentary 399
M. Zelen

Commentary: Observation versus Experiment 401
H. Blackburn

Discussion 405

Why Do We Need Large, Simple Randomized Trials? 409
S. Yusuf, R. Collins and R. Peto

Discussion 421

How Much Data Should be Collected in a Clinical Trial? Experience of the Coronary Drug Project 423
P. Canner

Discussion 433

Planning Patient Recruitment: Fantasy and Reality 435
J. F. Collins, W. O. Williford, D. G. Weiss, S. F. Bingham and C. J. Klett

Can Early Stopping Procedures Impact Significantly on the Efficiency of Clinical Trials Without Serious Loss of Information 445
D. L. DeMets

Discussion 453

Improving the Efficiency of Clinical Trials: A Medical Perspective 455
C. G. Moertel

Discussion 467

Commentary 469
O. D. Williams

Commentary 473
P. Meier

List of Speakers and Discussants 477

Announcement 479

Author Index 481

Subject Index 483

Volume 4, Issue Nos. 1–4

Volume 4, *Issue No.* 1, January–March 1985

A Measure to Aid in the Interpretation of Published Clinical Trials 1
C. B. Begg

A Community Trial Strategy for Evaluating Treatment for Symptomatic Conditions 11
J. R. H. Charlton, M. F. D'Souza, M. Tooley and R. Silver

Note on Interval Estimation of the Difference Between Proportions from Correlated Series 23
C-C. Hsieh

Dynamic Evaluation of Short-term Prognosis After Myocardial Infarction 29
P. Hougaard and E. B. Madsen

The Bootstrap and Identification of Prognostic Factors Via Cox's Proportional Hazards Regression Model 39
C-H. Chen and S. L. George

Inter-rater Agreement Among Orthodontists in a Blocked Experiment 47
E. L. Korn and S. Baumrind

The Effect of Validation Group Bias on Screening Tests for Coronary Artery Disease 53
M. S. Green

Birth Cohort Analysis Using Irregular Cross-sectional Data: A Technical Note 63
E. Schifflers, M. Smans and C. S. Muir

Dose–Response Analysis of Combination Preparations 77
H. D. Unkelbach and T. Wolf

A Wilcoxon-type Test for Trend 87
J. Cuzick

The Analysis of Neuronal Discharge Sequences: Change-point Estimation and Comparison of Variances 91
D. Commenges and J. Seal

LETTERS TO THE EDITOR 105

ANNOUNCEMENT 110

Volume 4, *Issue No.* 2, April–June 1985

The 2 × 2 Factorial Design: Its Application to a Randomized Trial of Aspirin and Carotene in U.S. Physicians 111
M. J. Stampfer, J. E. Buring, W. Willett, B. Rosner, K. Eberlein and C. H. Hennekens

Power, Sample Size and Smallest Detectable Effect Determination for Multivariate Studies 117
S. Greenland

Treatment Allocation Methods in Clinical Trials: A Review 129
L. A. Kalish and C. B. Begg

Models and the Use of Signed Rank Tests 145
J. S. Maritz

Formulae for Cause-Deleted Life Tables 155
D. P. Smith

Comparison of Ascertainment-Bias Correction Schemes for Pedigrees Ascertained through Multiple Probands 163
P. P. Majumder

The Use of Logit Models to Investigate Social and Biological Factors in Infant Mortality. I: Methodology 175
T. J. Murrells, T. M. F. Smith, J. C. Catford and D. Machin

The Use of Logit Models to Investigate Social and Biological Factors in Infant Mortality. II: Stillbirths 189
T. J. Murrells, J. C. Catford, T. M. F. Smith and D. Machin

Empirical Bayes Estimation of Cancer Mortality Rates 201
R. K. Tsutakawa, G. L. Shoop and C. J. Marienfeld

Comparative Analysis of Two Rates 213
O. Miettinen and M. Nurminen

On the Use of the Logistic Model in Prospective Studies 227
M. Halperin, R. D. Abbott, W. C. Blackwelder, R. Jacobowitz, K. K. G. Lan, J. I. Verter and H. Wedel

LETTERS TO THE EDITOR 237

BOOK REVIEW 249

Volume 4, *Issue No.* 3, July–September 1985

Papers from the International Society for Clinical Biostatistics
Fifth International Meeting, September 1984

Preface 251

The ISCB 253

TREATMENT AND PROGNOSIS

Assessing Apparent Treatment–Covariate Interactions in Randomized Clinical Trials 255
D. P. Byar

Prognostic Factors for Stage I Melanoma of the Skin: A Review 265
N. Cascinelli, E. Marubini, A. Morabito and R. Bufalino

Prognostic Factors from a Randomized Clinical Trial in Resected Lung Cancer 279
C. Chastang, B. Lebeau, Y. Charpak, G. Decroix and The Cooperative Group on Lung Cancer (GETCB)

Critical Discussion of the Assessment of a Three-Stage Prognostic Classification for Chronic Lymphocytic Leukemia 287
C. Chastang, P. Travade, A. Auquier and The Cooperative Group on CLL of Société Francaise D'Hématologie

Comparison of the Mortality of a Cohort with the Mortality of a Reference Population in a Prognostic Study 295
C. Hill, A. Laplanche and A. Rezvani

Correspondence Analysis in a Study of the Clinical Evolution of Uncomplicated Chronic Relapsing Alcoholic Pancreatitis 303
R. Micciolo, I. Vantini, G. Cavallini, W. Piubello, G. Talamini, L. Benini and L. A. Scuro

COMPUTER DIAGNOSIS

Computer Assistance for C. T. Scan Interpretation and Cerebral Disease Diagnosis 311
D. Teather, B. A. Morton, G. H. du Boulay, K. M. Wills, D. Plummer and P. R. Innocent

Knowledge Based Expert Systems for Medical Diagnosis 317
P. Torasso

EPIDEMIOLOGY

Latent Class Analysis in Chronic Disease Epidemiology 327
J. Kaldor and D. Clayton

Hypothesis Testing in the Polychotomous Logistic Model with an Application to Detecting Gastrointestinal Cancer 337
R. J. Marshall and E. M. Chisholm

Assessment of Some Risk Factors for Hepatocellular Carcinoma: A Case Control Study 345
M. G. Filippazzo, E. Aragona, M. Cottone, G. Dardanoni, F. Lanzarone, A. Marenghini, C. Patti, E. Sciarrino, R. Simonetti, F. Tine and L. Pagliaro

Multiplicative and Additive Models with External Controls in a Cohort Study of Cancer Mortality 353
M. J. Campbell

LABORATORY MEDICINE AND BIOSTATISTICS

Comparison of Three Devices for Measuring Blood Pressure 361
L. Bassein, C. Borghi, F. V. Costa, E. Strocchi, A. Mussi and E. Ambrosioni

Are Routine Clinical Chemistry Analyses 'In Control' According to Shewhart's Technique? 369
G. J. M. Boerma

Linear Models for the Analysis of Variability in Factorial Designs: An Application to Anthropometric Indicators 379
A. Bossi and S. Milani

LETTERS TO THE EDITOR 387

BOOK REVIEWS 393

ANNOUNCEMENT 395

Volume 4, *Issue No.* 4, October–December 1985

The Pattern of Ischemic Heart Disease 1931–1980 397
D. P. Smith and C. Slater

Selecting Risk Factors: A Comparison of Discriminant Analysis, Logistic Regression and Cox's Regression Model Using Data from the Tromsø Heart Study 413
T. Brenn and E. Arnesen

Assessing the Adequacy of the Logistic Regression Model for Matched Case-Control Studies 425
S. H. Moolgavkar, E. D. Lustbader and D. J. Venzon

Small Sample Estimation of Log Odds Ratios from Logistic Regression and Fourfold Tables 437
S. D. Walter

Using Test–Retest Reliability Data to Improve Estimates of Relative Risk: An Application of Latent Class Analysis 445
D. Clayton

The Use of an Autoregressive Model for the Analysis of Longitudinal Data in Epidemiologic Studies 457
B. Rosner, A. Muñoz, I. Tager, F. Speizer and S. Weiss

The Cusum Test of Homogeneity with an Application in Spontaneous Abortion Epidemiology 469
B. Levin and J. Kline

The Value of Specialized Tests in Studies where Ordered Group Means are Expected 489
E. A. C. Shirley

Optimal Designs for Clinical Trials with Dichotomous Responses 497
D. A. Berry and L. M. Pearson

An Application of Bayesian Analysis to Medical Follow-up Data 509
J. A. Achcar, R. Brookmeyer and W. G. Hunter

Interim Analyses in Clinical Trials: Cassical vs. Bayesian Approaches 521
D. A. Berry

Analysis of the Clinical Utility of a Predictive Chemosensitivity Assay 527
E. L. Korn, V. K. Sondak, C. A. Bertelsen and D. H. Kern

On Tests for Equality of Predictive Values for *t* Diagnostic Procedures 535
B. M. Bennett

A Note on Optimal Sampling for the Comparison of Proportions or Rates 541
S. D. Walter and H. Morgenstern

LETTERS TO THE EDITOR 543

BOOK REVIEWS 549

ANNOUNCEMENT 550

Author Index 551

Subject Index 553

Volume 5, Issue Nos. 1–6

Volume 5, Issue No. 1, January–February 1986

A Predictive Approach to Selecting the Size of a Clinical Trial, Based on Subjective Clinical Opinion 1
D. J. Spiegelhalter and L. S. Freedman

A New Model for Ordinal Pain Data from a Pharmaceutical Study 15
C. Chuang and A. Agresti

The Value of Latent Class Analysis in Medical Diagnosis 21
D. Rindskopf and W. Rindskopf

Choosing the Number of Controls in a Matched Case-Control Study, some Sample Size, Power and Efficiency Considerations 29
J. M. G. Taylor

Box–Jenkins Modelling of some Viral Infectious Diseases 37
U. Helfenstein

Statistical Methods for Relating several Exposure Factors to several Diseases in Case-Heterogeneity Studies 49
D. C. Thomas, M. Goldberg, R. Dewar and J. Siemiatycki

Cause-deleted Proportional Mortality Analysis and the Healthy Worker Effect 61
S. D. Walter

Assessment of Stratum–Covariate Interactions in Cox's Proportional Hazards Regression Model 73
P. F. Thall and J. M. Lachin

Regression Analysis of Censored Survival Data with the Generalized *F* Family—an Alternative to the Proportional Hazards Model 85
A. Ciampi, S. A. Hogg and L. Kates

LETTERS TO THE EDITOR 97

ANNOUNCEMENT 100

BOOK REVIEW 101

Volume 5, *Issue No.* 2, March–April 1986

Use of an International Data Bank to Compare Outcome Following Severe Head Injury in Different Centres 103
G. D. Murray

Prediction of Sudden Infant Death Syndrome: an Independent Evaluation of Four Scoring Methods 113
T. J. Peters and J. Golding

Case-control Studies for Estimation of the Natural History of Preclinical Disease from Screening Data 127
R. Brookmeyer, N. E. Day and S. Moss

The Use of Logit Models to Investigate Social and Biological Factors in Infant Mortality. III: Neonatal Mortality 139
D. Machin, T. J. Murrells, J. C. Catford and T. M. F. Smith

The Use of Logit Models to Investigate Social and Biological Factors in Infant Mortality. IV: Post-neonatal Mortality 155
D. Machin, T. J. Murrells, J. C. Catford and T. M. F. Smith

Algorithm for the Grouping of Contiguous Geographical Zones 171
G. Huel, J-F. Petiot and P. Lazar

VOLUME CONTENTS 221

Dose-interpolation of Immunoassay Data: Uncertainties Associated with Curve-fitting 183
C. Kay. A. B. J. Nix, K. W. Kemp, R. J. Rowlands, G. Richards, G. V. Groom, K. Griffiths and D. W. Wilson

Computer Simulation of a Clinical Trial as an Aid to Teaching the Concept of Statistical Significance 193
J. M. Bland

LETTERS TO THE EDITOR 199

ANNOUNCEMENTS 201

Volume 5, *Issue No.* 3, May–June 1986

A Proposal for Interpreting and Reporting Negative Studies 203
W. W. Hauck and S. Anderson

Sequential Treatment Allocation Procedures in Clinical Trials—with Particular Attention to the Analysis of Results for the Biased Coin Design 211
J. Halpern and B. Wm. Brown, Jr

The Use of an Extended Baseline Period in the Evaluation of Treatment in a Longitudinal Duchenne Muscular Dystrophy Trial 231
K. S. Madsen, J. P. Miller, M. A. Province and The Collaborative Investigation of Duchenne Dystrophy Group

Psychiatric Admissions and Choice of Abortion 243
P. K. Andersen and N. Kr. Rasmussen

Censoring Distributions as a Measure of Follow-up in Survival Analysis 255
E. L. Korn

Case–control Studies and Bayesian Inference 261
M. Zelen and R. A. Parker

A Statistical Test for Contact Among Individuals in an Epidemic and a Pattern Among Cases of Acquired Immune Deficiency Syndrome 271
R. C. Grimson and S. Groshen

Considerations of Statistical Power in the Shared–haplotypes Test 281
W. J. Ewens

BOOK REVIEW 289

ANNOUNCEMENT 290

Volume 5, *Issue No.* 4, July–August 1986

Genetic Epidemiology: a Review of the Statistical Basis 291
E. A. Thompson

A Method for Combining Results from Several Prospective Epidemiologic Studies 303
A. R. Dyer

Allocation Designs in Cohort and Case-control Studies 319
M. A. A. Moussa

Calculating Expected Mortality 327
N. Keiding and M. Væth

Estimation of Normal Ranges of Clinical Laboratory Data 335
T. Tango

Discrimination and other Statistical Intervals for the Interpretation of *in vivo* Patient Monitoring Data 347
G. J. Kost

The Use of the Binomial Distribution in Establishing an Association between High-risk Donors and Transfusion-associated Aids 355
J. E. Kaplan, L. B. Schonberger and K.-J. Lui

The Use of GLIM and the Bootstrap in Assessing a Clinical Trial of Two Drugs 363
W. W. Mapleson

A Simulation Study of Three Sequential Methods for the Comparison of Two Treatment Groups when the Response Criterion is Censored 375
J. Benichou and C. Chastang

A Clinical Trial with an Interim Analysis 387
P. Y. Chi, D. R. Bristol and J. V. Castellana

Statistical Comparison of Two Handwashing Protocols 393
C. T. Le

BOOK REVIEW 397

Volume 5, *Issue No.* 5, September–October 1986

Papers from the International Society for Clinical Biostatistics
Sixth International Meeting, September 1985

Preface 399

The ISCB 401

PROGNOSIS

Assessing the Performance and Clinical Impact of a Computerized Prognostic System in Severe Head Injury 403
G. D. Murray, L. S. Murray, P. Barlow, G. M. Teasdale and W. B. Jennett

Application of Statistical Decision Theory to Treatment Choices: Implications for the Design and Analysis of Clinical Trials 411
R. J. Simes

Probabilistic Prediction in Patient Management and Clinical Trials 421
D. J. Spiegelhalter

CLINICAL TRIALS

Clinical Trials of Cancer Prevention Agents: True Versus Observed Prevention Effect 435
T. E. Moon

Calibrated Phase II Clinical Trials in Oncology 441
J. Herson and S. K. Carter

The Determination of Practically Useful Doses of New Drugs: some Methodological Considerations 449
M. Turri and G. Stein

Sample Sizes for Phase II and Phase III Clinical Trials: an Integrated Approach 459
J. Whitehead

Patient Accrual and Interim Statistical Analysis in Long-term Randomized Clinical Trials: the French Chronic Lymphocytic Leukemia CLL 80 Protocol as a Case Study 465
C. Chastang, P. Travade, J. Benichou, G. Dighiero, J.-L. Binet and The Cooperative Group on CLL of Société Francaise D'Hématologie

'SURVIVAL' ANALYSIS

Life-table Methods for Contraceptive Research 475
T. M. M. Farley

A Counting Process Approach to the Analysis of the Course of Non-Hodgkin's Lymphoma 491
J. Mau and B. Steinke

DIAGNOSIS

Intelligent Dialogue Based on Statistical Models of Clinical Decision-making 497
D. M. G. McSherry

Selection of Variables using 'Independence Bayes' in Computer-aided Diagnosis of Upper Gastrointestinal Bleeding 503
C. Ohmann, M. Künneke, R. Zaczyk, K. Thon and W. Lorenz

Partitioning Methods for Classification and Decision Making in Medicine 517
R. J. Marshall

EPIDEMIOLOGY

Age, Period and Cohort Models: the Use of Individual Records 527
C. Robertson and P. Boyle

Some Recent Statistical Analyses of Two Long-term Studies of Exposure to Ionizing Radiation 539
S. C. Darby

The Changing Face of Cancer Epidemiology 547
J. Wahrendorf

ANNOUNCEMENT 555

Volume 5, *Issue No.* 6, November–December 1986

On the Role of 'Habitual Aborters' in the Analysis of Spontaneous Abortion 557
B. C. Gladen

On Surveillance Methods for Congenital Malformations 565
G. Gallus, C. Mandelli, M. Marchi and G. Radaelli

Estimating Incidence from Age-specific Prevalence for Irreversible Diseases with Differential Mortality 573
M. J. Podgor and M. C. Leske

Adjustment of Risk Ratios in Case–base Studies (Hybrid Epidemiologic Designs) 579
S. Greenland

Sensitivity, Specificity and Predictive Values: a Graphical Approach 585
A. Taube

Applications of Time-series Analysis: a Case Study on the Impact of Computer Tomography 593
A. D. Tsouros and R. J. Young

Some Experiments with Factors that Might Affect the Response of Mothers to a Postal Questionnaire 607
A. Cartwright

A Model for Variability in Arteriographic Reading 619
V. S. Hertzberg and L. D. Fisher

Sensitivity of Fisher's Exact Test to Minor Perturbations in 2 × 2 Contingency Tables 629
W. D. Dupont

Prognostic Factors, Models and Related Statistical Problems in the Survival of End-stage Renal Disease Patients on Hemodialysis 637
A. J. Umen and C. T. Le

Simultaneous Non-parametric Confidence Intervals for Survival Probabilities from Censored Data 653
A. A. Afifi, R. M. Elashoff and J. J. Lee

Sample Size Requirements and the Cost of a Randomized Clinical Trial with Repeated Measurements 663
D. A. Bloch

LETTER TO THE EDITOR 669

VOLUME CONTENTS 225

Author Index 671

Subject Index 673

Volume 6, Issue Nos. 1–8

Volume 6, *Issue No.* 1, January–February 1987

Preface 1

What do Doctors Know about Statistics? 3
H. R. Wulff, B. Andersen, P. Brandenhoff and F. Guttler

Confronting Publication Bias: a Cohort Design for Meta-analysis 11
R. J. Simes

Effect of Covariate Measurement Error in Randomized Clinical Trials 31
T. M. Morgan and R. M. Elashoff

Analysis of Data Arising from a Stratified Design with the Cluster as Unit of Randomization 43
A. Donner and A. Donald

Sample Size and Power for Pair-matched Case-control Studies 53
J. E. Connett, J. A. Smith and R. B. McHugh

Small Sample Behaviour of Hypothesis Tests Related to Indirect Standardized Rates: a Monte Carlo Study 61
J. A. Bean, C. G. Wiltse and R. E. Woolson

Evaluation of the Proportionate Mortality Index in the Presence of Multiple Comparisons 71
H. E. Rockette and V. C. Arena

Robustness of the Two Independent Samples *t*-Test when Applied to Ordinal Scaled Data 79
T. Heeren and R. D'Agostino

Maximum Likelihood Estimation and Likelihood Ratio Test for Square Tables with Missing Data 91
W. J. Shih

ANNOUNCEMENTS 99

Volume 6, *Issue No.* 2, March 1987

The Three-decision Problem in Medical Decision Making 101
J. D. Emerson and D. Tritchler

Correcting for Regression in Assessing the Response to Treatment in a Selected Population 113
R. N. Curnow

Use of Unequal Allocation in Survival Trials 119
R. Sposto and M. D. Krailo

Modified Replacement Randomization 127
U. Abel

The Numerical Approach to Classification: a Medical Application to Develop a Typology for Facial Pain 137
D. G. Wastell and R. Gray

Comparison of Quantitative Diagnostic Tests: Type I Error, Power, and Sample Size 147
K. Linnet

Statistical Analysis of Heart Rates in Subsequent Victims of Sudden Infant Death Syndrome 159
C. C. Spicer, C. J. Lawrence and D. P. Southall

Fitting Nonlinear Models with Arma Errors to Biological Rhythm Data 167
J. B. Greenhouse, R. E. Kass and R. S. Tsay

On the Modelling of Human Growth 185
J. Karlberg

Bias in Indirectly Adjusted Comparisons due to Taking the Total Study Population as the Reference Group 193
S. Greenland

An Approximation for the Distribution of the Scan Statistic 197
S. Wallenstein and N. Neff

BOOK REVIEWS 209

ANNOUNCEMENTS 215

Volume 6, *Issue No.* 3, April–May 1987

PROCEEDINGS OF THE WORKSHOP ON METHODOLOGIC ISSUES IN OVERVIEWS OF RANDOMIZED CLINICAL TRIALS, MAY 1986

Sponsored by the National Heart, Lung, and Blood Institute and the National Cancer Institute, Bethesda, Maryland, U.S.A.

Preface 217
S. Yusuf, R. Simon and S. Ellenberg

List of Speakers and Discussants 219

Accumulating Evidence from Independent Studies: What we Can Win and What we Can Lose 221
R. J. Light

Discussion 229

Why do we Need Systematic Overviews of Randomized Trials? 233
Modified transcript of an oral presentation by R. Peto

Discussion 241

Avoidance of Large Biases and Large Random Errors in the Assessment of Moderate Treatment Effects: the Need for Systematic Overviews 245
R. Collins, R. Gray, J. Godwin and R. Peto

Discussion 251

An Overview of Six Clinical Trials of Aspirin in Coronary Heart Disease 255
P. L. Canner

Discussion 265

Problems in the Medical Interpretation of Overviews 269
R. E. Wittes

Discussion 277

Obtaining Medically Meaningful Answers from an Overview of Randomized Clinical Trials 281
S. Yusuf

Discussion 287

Lessons from Overviews of Cardiovascular Trials 295
C. D. Furberg and T. M. Morgan

Discussion 305

Potential Pooling Opportunities: Cancer 307
M. A. Friedman

Discussion 313

Meta-analysis of Clinical Trials as a Scientific Discipline. I: Control of Bias and Comparison with Large Co-operative Trials 315
T. C. Chalmers, H. Levin, H. S. Sacks, D. Reitman, J. Berrier and R. Nagalingam

Discussion 327

Commentary 329
P. Meier

Commentary 333
L. Norton

Discussion 337

Methods for Combining Randomized Clinical Trials: Strengths and Limitations 341
D. L. DeMets

Discussion 349

Inter-study Differences: How Should They Influence the Interpretation and Analysis of Results? 351
K. R. Bailey

Discussion 359

Effects on Overviews of Early Stopping Rules for Clinical Trials 361
S. J. Green, T. R. Fleming and S. Emerson

Discussion 369

Interpretation of Results from Subset Analyses within Overviews of Randomized Clinical Trials 371
R. D. Gelber and A. Goldhirsch

Discussion 379

Commentary 381
L. V. Hedges

Discussion 387

The Role of Overviews in Cancer Therapeutics 389
R. Simon

Discussion 395

Implications of Overviews of Randomized Trials 397
C. H. Hennekens, J. E. Buring and P. R. Hebert

Discussion 403

Volume 6, *Issue No.* 4, June 1987

Biases in the Assessment of Diagnostic Tests 411
C. B. Begg

Internal Quality Control in Clinical Chemistry: a Teaching Review 425
A. B. J. Nix, R. J. Rowlands, K. W. Kemp, D. W. Wilson and K. Griffiths

Sample Size Requirements for Reliability Studies 441
A. Donner and M. Eliasziw

Models for Temporal Variation in Cancer Rates. I: Age–Period and Age–Cohort Models 449
D. Clayton and E. Schifflers

Models for Temporal Variation in Cancer Rates. II: Age–Period–Cohort Models 469
D. Clayton and E. Schifflers

Cure Rate Models: Power of the Logrank and Generalized Wilcoxon Tests 483
J. Halpern and B. Wm. Brown Jun.

Adjustments to the Mantel–Haenszel Chi-square Statistic and Odds Ratio Variance Estimator When the Data are Clustered 491
A. Donald and A. Donner

Analysis of Total Mortality in the Rotterdam Sample of the Kaunas–Rotterdam Intervention Study (KRIS) 501
P. G. H. Mulder and A. L. Hempenius

The Relative Efficiency of the Sets and the Cusum Techniques in Monitoring the Occurrence of a Rare Event 517
R. Chen

LETTERS TO THE EDITOR 527

ANNOUNCEMENT 533

Volume 6, *Issue No.* 5, July–August 1987

The Probability of Inevitability: the Inherent Impossibility of Validating Criteria for Brain Death or 'Irreversibility' Through Clinical Studies 535
D. A. Shewmon

Modelling Binary Data from a Three-period Cross-over Trial 555
B. Jones and M. G. Kenward

Issues of Efficiency in Combining Proportions of Deaths from Several Clinical Trials 565
M. Buyse and L. M. Ryan

A Simple Method of Sample Size Calculation for Unequal-sample-size Designs that Use the Logrank or *t*-Test 577
F. Y. Hsieh

The Analysis of a Titration Study 583
C. Chuang

Multiple Comparisons for Relative Risk Regression: Extension of the *k*-Ratio Method 591
D. O. Dixon and G. W. Divine

Some Considerations in the Analysis of Rates of Change in Longitudinal Studies 599
M. Palta and T. Cook

Monitoring Maternity Services by Postal Questionnaire: Congruity Between Mothers' Reports and Their Obstetric Records 613
C. J. Martin

Non-random Sampling in Human Genetics: Estimation of Familial Correlations, Model Testing, and Interpretation 629
R. Chakraborty and C. L. Hanis

Volume 6, *Issue No.* 6, September 1987

A Cost-function Approach to the Design of Reliability Studies 647
M. Eliasziw and A. Donner

Evaluating the Efficacy of a Combination Therapy 657
S. M. Snapinn

Monitoring Distributional Assumptions and Early Stopping for a Prospective Clinical Trial using Monte Carlo Simulation 667
V. Gebski, D. McNeil, A. Coates and J. Forbes

Effective Sample Sizes for Confidence Intervals for Survival Probabilities 679
F. J. Dorey and E. L. Korn

Hypothesis Testing of Time-dependent Recurrent Events 689
J. C. Niland, D. Thomas and S. P. Azen

Variance Estimators for Attributable Fraction Estimates Consistent in Both Large Strata and Sparse Data 701
S. Greenland

Age, Period and Cohort Analysis of Trends in Mortality from Major Diseases in Japan, 1955 to 1979: Peculiarity of the Cohort Born in the Early Showa Era 709
T. Tango and S. Kurashina

LETTERS TO THE EDITOR 727

Volume 6, *Issue No.* 7, October–November 1987

Papers from the International Society for Clinical Biostatistics
Seventh International Meeting, September 1986

Preface 729

The ISCB 731

CLINICAL TRIALS

Meta-analysis of Clinical Trials as a Scientific Discipline. II: Replicate Variability and Comparison of Studies that Agree and Disagree 733
T. C. Chalmers, J. Berrier, H. S. Sacks, H. Levin, D. Reitman and R. Nagalingam

Reporting Clinical Trials from the Viewpoint of a Patient's Choice of Treatment 745
J. Hilden

Practical Aspects in Data Monitoring: a Brief Review 753
D. L. DeMets

Some Methodological Problems in the Assessment of Complementary Therapy 761
H. M. Anthony

'SURVIVAL ANALYSIS'

The Impact of Heterogeneity on the Comparison of Survival Times 773
M. Schumacher, M. Olschewski and C. Schmoor

A Method of Analysis Taking into Account Competing Events: Application to the Study of Digestive Complications Following Irradiation for Cervical Cancer 785
A. Kramar, M. H. Pejovic and D. Chassagne

A Transient State Model for Analysing Ventilatory Status in a Randomized Clinical Trial 795
J. P. Jais, C. Chastang, J. C. Raphael and the French Cooperative Group on plasma exchange in Guillain-Barré Syndrome

TEACHING

A Probability-based Aid for Teaching Medical Students a Logical Approach to Diagnosis 805
N. J. Crichton and P. A. Emerson

Designing a Study for Evaluating a Protocol for the Selective Performance of Preoperative Tests 813
Y. Charpak, C. Bléry and C. Chastang

EPIDEMIOLOGY

Fluoride and Dental Caries: Two Different Statistical Approaches to the Same Data Source 823
H. Busse, E. Bergmann and K. Bergmann

Predicting the Dynamic Effects of Rubella Vaccination Programmes 843
Th. M. de Boo, J. A. M. van Druten and A. D. Plantinga

Modelling the Effect of Intervention on the Transmission of Malaria in East Malaysia 853
D. Collett and M. S. Lye

Using the Adverse Reactions Register to Study the Effects of Age and Sex on Adverse Drug Reactions 863
J. M. Simpson, D. N. Bateman and M. D. Rawlins

The Cardiff Health Survey: Teaching Survey Methodology by Participation 869
P. A. Lewis and M. Charny

BOOK REVIEW 875

Volume 6, *Issue No.* 8, December 1987

Preface 877

Statistical Facts about Cancers on which Doctor Regoni-Stern based his contribution to the Surgeons' Subgroup of the IV Congress of the Italian Scientists on 23 September 1842 881
Translated from *Giornale par Servire al Progressi della Patologia e della Terapeutica, Series 2, Volume 2, pp. 507–517 (1842) by Bianca de Stavola*

Evaluating the Survival of Cancer Cases Detected by Screening 885
S. D. Walter and L. W. Stitt

Models of the Healthy Worker Effect in Industrial Cohorts 901
C. M. J. Bell and D. A. Coleman

The Analysis of Data from 2 × 2 Cross-over Trials with Baseline Measurements 911
M. G. Kenward and B. Jones

Early Termination of Clinical Trials with Prolonged Observation of Individual Patients: a Case Study 927
G.-A. van Es, J. G. P. Tijssen and J. Lubsen

Confirmatory Analysis of Survival Data using Left Truncation of the Life Times of Primary Survivors 939
N. Keiding, T. Bayer and S. Watt-Boolsen

Some Points on the Use of 'Independnet Bayes' to Diagnose Acute Abdominal Pain 945
N. J. Crichton, J. G. Fryer and C. C. Spicer

Improved Estimates of Discordance Ratios in Twin Studies 961
C. E. Franti, A. D. Wiggins and J. F. Kraus

Acknowledgement 971

Author Index 973

Subject Index 975

Volume 7, Issue Nos. 1–12

Volume 7, *Issue No.* 1/2, January–February 1988

PROCEEDINGS OF THE WORKSHOP ON METHODS FOR LONGITUDINAL DATA ANALYSIS IN EPIDEMIOLOGICAL AND CLINICAL STUDIES, SEPTEMBER 1986

Sponsored by the National Heart, Lung and Blood Institute, Bethesda, Maryland, U.S.A.

Editorial i
Preface *M. C. Wu and J. W. Kusek* 1
List of Speakers and Discussants 3
Chairman's Introduction *N. Breslow* 7

METHODS FOR ANALYSING REPEATED MEASUREMENTS

The Use of Lung Function Tests in Identifying Factors that Affect Lung Growth and Aging *A. S. Buist and W. M. Vollmer* 11

A Comparative Study of Three Methods for Analysing Longitudinal Pulmonary Function Data *J. E. Diem and J. R. Liukkonen* 19
General Methods for Analysing Repeated Measures *T. A. Louis* 29
A Longitudinal View of Blood Pressure During Childhood: The Muscatine Study *R. M. Lauer and W. R. Clarke* 47
Autoregressive Modelling for the Analysis of Longitudinal Data with Unequally Spaced Examinations *B. Rosner and A. Muñoz* 59
Autoregressive Growth Curves and Kalman Filtering *P. D. Wilson* 73
Discussion 87

REPEATED CATEGORICAL RESPONSE

Issues in the Analysis of Repeated Categorical Outcomes *J. H. Ware, S. Lipsitz and F. E. Speizer* 95
Some General Methods for the Analysis of Categorical Data in Longitudinal Studies *J. R. Landis, M. E. Miller, C. S. Davis and G. G. Koch* 109
Analysing Repeated Measurements with Possibly Missing Observations by Modelling Marginal Distributions *L. J. Wei and D. O. Stram* 139
Likelihood Analysis of Multi-state Models for Disease Incidence and Mortality *J. D. Kalbfleisch and J. F. Lawless* 149
Commentary *S. L. Zeger* 161
Discussion 169

SPECIAL TOPICS

Report of a Workshop on Statistical Issues in Longitudinal Studies of Health. Held in Berlin (West), 23–26 June 1986 *J. H. Dwyer and M. Feinleib* 177
Familial Aggregation in the Presence of Temporal Trends *M. A. Province and D. C. Rao* 185
Discussion 199

RISK FACTORS AND SURVIVAL

Comparison of Baseline and Repeated Measure Covariate Techniques in the Framingham Heart Study *L. A. Cupples, R. B. D'Agostino, K. Anderson and W. B. Kannel* 205
Commentary on 'Comparison of Baseline and Repeated Measure Covariate Techniques in the Framingham Heart Study' *R. D. Abbott* 219
Effect of Cigarette Smoking in Epidemiological Studies of Lung Cancer *A. S. Whittemore* 223
Models of the Interaction of Mortality and the Evolution of Risk Factor Distribution: A General Stochastic Process Formulation *K. G. Manton, M. A. Woodbury and E. Stallard* 239
Effects of Mismodelling and Mismeasuring Explanatory Variables on Tests of their Association with a Response Variable *S. W. Lagakos* 257
Aspects of the Use of Relative Risk Models in the Design and Analysis of Cohort Studies and Prevention Trials *R. L. Prentice and S. G. Self* 275

Commentary *M. Halperin* 289
Commentary *K. G. Manton, M. A. Woodbury and E. Stallard* 293
Discussion 297

ANALYSIS OF DATA WITH MISSING VALUES

Missing Data in Longitudinal Studies *N. M. Laird* 305
Analysis of Incomplete Multivariate Data using Linear Models with Structured Covariance Matrices *M. D. Schluchter* 317
Estimating Hidden Morbidity via its Effect on Mortality and Disability *M. A. Woodbury, K. G. Manton and A. I. Yashin* 325
Analysing Changes in the Presence of Informative Right Censoring Caused by Death and Withdrawal *M. C. Wu and K. Bailey* 337
Commentary *R. J. A. Little* 347
Discussion 357
Chairman's Concluding Remarks *N. Breslow* 361

Volume 7, *Issue No.* 3, March 1988

Sample Size and Power for Case-control Studies when Exposures are Continuous 363
J. H. Lubin, M. H. Gail and A. G. Ershow

Estimating Reference Ranges in Clinical Pathology: an Objective Approach 377
S. Merkouriou and D. Dix

Testing for a Change-point in Registry Data with an Example on Hypospadias 387
J. M. Simpkin and D. Y. Downham

A Model-based Approach to Characterize the Incubation Period of Paediatric Transfusion-associated Acquired Immunodeficiency Syndrome 395
K.-J. Lui, T. A. Peterman, D. N. Lawrence and J. R. Allen

Assessing Diagnostic Reliability and Estimating Incidence Rates Associated with a Strictly Progressive Disease: Dental Caries 403
M. A. Espeland, W. C. Murphy and D. H. Leverett

Correcting for Selection Bias in Estimation of Within-individual Variance 417
P. D. Wilson

The Probability that Long-term Mean Diastolic Blood Pressure is Extreme: Tables for Black Individuals 423
P. D. Wilson and J. R. Hebel

Multinomial Regression Models Based on Continuation Ratios 435
C. Cox

Investigation of the Associations of a Number of HLA Antigens with Psoriasis and Psoriatic Arthritis 443
J. Green, M. Montasser, H. C. Low and J. C. Woodrow

LETTER TO THE EDITOR 451

ANNOUNCEMENT 452

BOOK REVIEWS 453

Volume 7, *Issue No.* 4, April 1988

Loss of Power from an Optimistic Alternative Hypothesis 457
L. E. Blumenson

A Note on Sample Size Computation for Testing Interactions 467
P. A. Lachenbruch

Some Analysis Strategies for Three-period Changeover Designs with Two Treatments 471
K. B. Hafner, G. G. Koch and A. T. Canada

The Analysis of Survival Data from a Central Cancer Registry with Passive Follow-up 483
G. M. Tallis, P. Leppard and T. J. O'Neill

Density Equalized Map Projections: a Method for Analysing Clustering around a Fixed Point 491
J. Schulman, S. Selvin and D. W. Merrill

Summary Attributable Risk Estimation from Unmatched Case-control Data 507
S. J. Kuritz and J. R. Landis

Evaluating the Discriminatory Power of a Multiple Logistic Regression Model 519
M. S. Green

An Uncertainty Measure in Logistic Discrimination 525
E. Lesaffre and A. Albert

Descriptive Statistical Analyses of Serial Dilution Data 535
M. A. Hamilton and M. G. Rinaldi

BOOK REVIEW 545

ANNOUNCEMENTS 547

Volume 7, *Issue No.* 5, May 1988

Multiple Reading Procedures: the Performance of Diagnostic Tests 549
P. A. Lachenbruch

Planning the Size of Survival Time Clinical Trials with Allowance for Stratification 559
M. A. A. Moussa

Optimal Two-stage Designs for Clinical Trials with Binary Response 571
P. F. Thall, R. Simon, S. S. Ellenberg and R. Shrager

A Random Walk Model for Evaluating Clinical Trials Involving Serial Observations 581
J. L. Hopper and G. P. Young

Contingency Table Estimation of Genetic Parameters and Disease Risks 591
H. J. Khamis

Smoothing Methods for Epidemiologic Analysis 601
M. R. Segal, S. T. Weiss, F. E. Speizer and I. B. Tager

Proportional Hazards Models for Average Data for Groups 613
A. J. Dobson

Prospective Epidemiological Studies Involving Paired Organs 619
J. Whitehead and C. Dorse

ANNOUNCEMENT 627

Volume 7, *Issue No.* 6, June 1988

The Hidden Effect of Time 629
D. G. Altman and J. P. Royston

A New Method of Estimation of Interobserver Variation and its Application to the Radiological Assessment of Osteoarthrosis in Hip Joints 639
P. Kjærsgaard-Andersen, F. Christensen, S. A. Schmidt, N. W. Pedersen and B. Jørgensen

Investigations of Excess Environmental Risks around Putative Sources: Statistical Problems and a Proposed Test 649
R. A. Stone

Multistate Models in Survival Analysis: a Study of Nephropathy and Mortality in Diabetes 661
P. K. Andersen

Modelling the Liver Function Data in Diabetes 671
T. T. Chen

Longitudinal Versus Cross-sectional Estimation of Lung Function Decline—Further Insights 685
W. M. Vollmer, L. R. Johnson, L. E. McCamant and A. S. Buist

The Statistical Analysis of Treatment Effects in 24-hour Ambulatory Blood Pressure Recordings 697
M. R. Marler, R. G. Jacob, J. P. Lehoczky and A. P. Shapiro

The Extrapolation of Attributable Risk to New Populations 717
J. H. Ellenberg

Volume 7, *Issue No.* 7, July 1988

Improving the Aggregate Performance of Psychiatric Diagnostic Methods when not all Subjects Receive the Standard Test 727
P. W. Lavori and M. B. Keller

Instrumental Variables in the Evaluation of Diagnostic Test Procedures when the True Disease State is Unknown 739
N. J. D. Nagelkerke, V. Fidler and M. Buwalda

Variance Estimation for Epidemiologic Effect Estimates Under Misclassification 745
S. Greenland

Sample Size Requirements for Studies Estimating Odds Ratios or Relative Risks 759
S. Lemeshow, D. W. Hosmer, Jr and J. Klar

VOLUME CONTENTS 237

Exact Versus Asymptotic Analysis for a Matched Case-control Study 765
K. F. Hirji, R. M. Elashoff, D. H. Moore, II and D. E. Bennett

Confidence Intervals for Causal Parameters 773
J. M. Robins

A Markov Process Interpretation of Sullivan's Index of Morbidity and Mortality 787
S. C. Newman

A Computer Enhanced Runs Test for Smoothed Data 795
B. P. Katz

'Optimal' Designs for Drug, Neurotransmitter and Hormone Receptor Assays 805
G. Dunn

BOOK REVIEWS 817

Volume 7, *Issue No.* 8, August 1988

The Analysis of Event History Data: a Review of Progress and Outstanding Problems 819
D. Clayton

Identifying Prognostic Factors in Binary Outcome Data: an Application Using Liver Function Tests and Age to Predict Liver Metastases 843
R. W. Makuch, P. S. Rosenberg and J. Mulshine

A New Calculation of the Carcinogenic Risk of Obstetric X-raying 857
J. F. Bithell and C. A. Stiller

Confidence Interval Estimation of a Rate and the Choice of Sample Size 865
D. Böhning

Designing a Clinical Trial to Demonstrate Prevention of Ulcer Recurrence: Modelling Simulation Approaches 877
J. D. Elashoff, G. G. Koch and G. Y. H. Chi

A Note on Graphical Presentation of Estimated Odds Ratios from Several Clinical Trials 889
R. F. Galbraith

The Parameters of Death: a Consideration of the Quantity of Information in a Life Table using a Polynomial Representation of the Survivorship Curve 895
J. Anson

Volume 7, *Issue No.* 9, September 1988

Editorial Announcement 913

Methods for Assessing whether Change Depends on Initial Value 915
R. J. Hayes

Comparing Incomplete Paired Binomial Data under Non-random Mechanisms 929
S. C. Choi and D. M. Stablein

Correcting for the Bias Caused by Drop-outs in Hypertension Trials 941
G. D. Murray and J. G. Findlay

Prediction of Outcome of Anaesthesia in Patients over 40 Years: a Multifactorial Risk Index 947
L. Tiret, F. Hatton, J. M. Desmonts and G. Vourc'h

Exposure–response Relationship for a Dichotomized Response when the Continuous Underlying Variable is not Measured 955
L. M. Irwig and H. T. Groeneveld

Two-process Models for Discrete-time Serial Categorical Response 965
R. Dersimonian and S. G. Baker

Latent Variable Models for the Analysis of Medical Data with Repeated Measures of Binary Variables 975
L. Blackwood

Correspondence Analysis and Logistic Modelling: Complementary use in the Analysis of a Health Survey Among Nurses 983
A. Leclerc, D. Luce, F. Lert, J. F. Chastang and P. Logeay

LETTERS TO THE EDITOR 997

BOOK REVIEW 1001

Volume 7, *Issue No.* 10, October 1988

Interactions Between Statisticians and Biomedical Journal Editors 1003
R. G. Marks, E. K. Dawson-Saunders, J. C. Bailar, B. B. Dan and J. A. Verran

Comparing the Effects of Different Durations of the Same Therapy 1013
L. S. Freedman and B. L. de Stavola

A Statistical Methodology for Postmarketing Surveillance of Adverse Drug Reaction Reports 1023
P. K. Norwood and A. R. Sampson

Identifying Important Results from Multiple Statistical Tests 1031
R. A. Parker and R. B. Rothenberg

Application of Multiple Time Series Analysis to the Estimation of Pneumonia and Influenza Mortality by Age 1962–1983 1045
D. F. Stroup, S. B. Thacker and J. L. Herndon

Forecasting the Demand on Accident and Emergency Departments in Health Districts in the Trent Region 1061
P. C. Milner

The Effect of Non-differential Exposure Misclassification on Estimates of the Attributable and Prevented Fraction 1073
C.-C. Hsieh and S. D. Walter

Examining Neighbourhood Confounding in a Survey: An Example using the National Health and Nutrition Examination Survey II 1087
E. L. Korn and B. I. Graubard

LETTER TO THE EDITOR 1099

ANNOUNCEMENT 1103

Volume 7, *Issue No.* 11, November 1988

Papers from the International Society for Clinical Biostatistics
Eighth International Meeting, September 1987

Preface 1105

The ISCB 1107

Drug Treatment of Mild Hypertension to Reduce the Risk of CHD: is it Worth-while? 1109
I. Holme

Heterogeneity in Survival Analysis 1121
O. O. Aalen

Remission Duration: an Example of Interval-censored Observations 1139
G. Rücker and D. Messerer

Modelling the 1985 Influenza Epidemic in France 1147
A. Flahault, S. Letrait, P. Blin, S. Hazout, J. Ménarés and A. J. Valleron

A Test to Detect Clustering Applied to Muscle Fibres 1157
D. Howel

Improving the Quality of Data in Randomized Clinical Trials: The Compact Computer Package 1165
C. E. D. Chilvers, P. M. Fayers, L. S. Freedman, R. M. Greenwood, D. Machin, N. Palmer and A. J. Westlake

Prescription Sequence Analysis: A New and Fast Method for Assessing Certain Adverse Reactions of Prescription Drugs in Large Populations 1171
H. Petri, H. C. W. de Vet, J. Naus and J. Urquhart

REGULAR PAPERS

Explanatory and Pragmatic Estimates of the Treatment Effect when Deviations from Allocated Treatment Occur 1179
R. G. Newcombe

Optimal Placebo Response Rates for Comparing Two Binomial Proportions 1187
S. J. Day

Sample Size Formulae for Intervention Studies with the Cluster as Unit of Randomization 1195
F. Y. Hsieh

LETTER TO THE EDITOR 1203

BOOK REVIEW 1204

ANNOUNCEMENT 1205

Volume 7, *Issue No.* 12, December 1988

Inborn/outborn Status and Neonatal Survival: A Meta-analysis of Non-randomized Studies 1207
R. J. Ozminkowski, P. M. Wortman and D. W. Roloff

Bayesian Analysis of Case-control Studies 1223
R. J. Marshall

Stopping Rules and Estimation Problems in Clinical Trials 1231
M. D. Hughes and S. J. Pocock

A Quantitative Study of the Bias in Estimating the Treatment Effect Caused by Omitting a Balanced Covariate in Survival Models 1243
C. Chastang, D. Byar and S. Piantadosi

Non-parametric Analysis of Treatment–Covariate Interaction in the Presence of Censoring 1257
M. Schemper

A Statistical Assessment of Clinical Equivalence 1267
J. Mau

On Sample Sizes to Estimate the Protective Efficacy of a Vaccine 1279
R. T. O'Neill

Beyond Sensitivity, Specificity and Statistical Independence 1289
R. H. Jones and M. W. McClatchey

Doubling the One-sided *P*-value in Testing Independence in 2 × 2 Tables Against a Two-sided Alternative 1297
C. J. Lloyd

BOOK REVIEWS 1307

Acknowledgement 1311

Author Index 1313

Subject Index 1315

Volume 8, Issue Nos. 1–12

Volume 8, *Issue No.* 1, January 1989

Special Issue on Statistical and Mathematical Modelling of the AIDS Epidemic
Guest Editor: Ron Brookmeyer

Editors' Note i

Preface 1
R. Brookmeyer

Statistical Methods for Monitoring the AIDS Epidemic 3
S. L. Zeger, L.-C. See and P. J. Diggle

Statistical Methods for Short-term Projections of AIDS Incidence 23
R. Brookmeyer and A. Damiano

The Value of AIDS Incidence Data in Assessing the Spread of HIV Infection 35
V. De Gruttola and S. W. Lagakos

Models for the HIV Infection and AIDS Epidemic in the United States 45
J. M. G. Taylor

Disease Prevention Models of Voluntary Confidential Screening for Human Immunodeficiency Virus (HIV) 59
M. H. Gail, D. Preston and S. Piantadosi

The Number of Partners and the Probability of HIV Infection 83
B. Eisenberg

Heterogeneity in the Probability of HIV Transmission per Sexual Contact: The Case of Male-to-female Transmission in Penile–Vaginal Intercourse 93
J. A. Wiley, S. J. Herschkorn and N. S. Padian

A Model of the Spread of HIV Infection and the Demographic Impact of AIDS 103
J. Bongaarts

Some Stochastic Models of AIDS Spread 121
W. Y. Tan and H. Hsu

Policy Implications of Modelling of the AIDS Epidemic 137
E. N. Brandt

Volume 8, *Issue No.* 2, February 1989

A Comparison of Statistical Methods for Combining Event Rates from Clinical Trials 141
J. A. Berlin, N. M. Laird, H. S. Sacks and T. C. Chalmers

Required Duration and Power Determinations for Historically Controlled Studies of Survival Times 153
L. J. Emrich

Factorial Designs in Clinical Trials: the Effects of Non-compliance and Subadditivity 161
E. Brittain and J. Wittes

Issues in Analysing the Effects of Occupational Exposure to Low Levels of Radiation 173
E. S. Gilbert

Application of a Two-stage Random Effects Model to Longitudinal Pulmonary Function Data from Sarcoidosis Patients 189
P. M. Vacek, R. M. Mickey and D. Y. Bell

A Method for the Estimation of Chronic Disease Morbidity and Trends from Mortality Data 201
A. Verdecchia, R. Capocaccia, V. Egidi and A. Golini

Estimation of Parameters and Missing Values Under a Regression Model with Non-normally Distributed and Non-randomly Incomplete Data 217
S. P. Azen, M. Van Guilder and M. A. Hill

Variance Estimation for Medical Decision Analysis 229
B. P. Katz and S. L. Hui

LETTER TO THE EDITOR 243

BOOK REVIEW 246

ANNOUNCEMENT 247

Corrections 248

Acknowledgement 249

Volume 8, *Issue No.* 3, March 1989

SYMPOSIUM ON STATISTICS IN SURVEILLANCE, MAY 1988
Guest Editors: Gladys H. Reynolds, Daniel L. McGee and Donna F. Stroup

Sponsored by:
CDC Statisticians, Epidemiology Program Office and Surveillance Coordination Group
Centers for Disease Control, Atlanta, Georgia, USA

List of Authors and Discussants 251

Opening Remarks 253
J. O. Mason

Remarks 255
T. Colton

CURRENT STATISTICAL ISSUES IN PUBLIC HEALTH SURVEILLANCE

An Application of a Mathematical Model to Adjust for Time Lag in Case Reporting 259
K.-J. Lui and R. K. Rudy

A Model-based Approach to the Imputation of Missing Data: Home Injury Incidences 263
J. M. Conn, K.-J. Lui and D. L. McGee

An Analysis of Disease Surveillance Data that Uses the Geographic Locations of the Reporting Units 267
R. F. Raubertas

Analysis of Surveillance Data: A Rationale for Statistical Tests with Comments on Confidence Intervals and Statistical Models 273
D. B. Hall

Commentary 279
D. F. Stroup

STATISTICAL METHODS IN THE ANALYSIS OF SURVEILLANCE DATA

Analysis of Surveillance Data with Poisson Regression: A Case Study 285
R. A. Parker

Cholesterol-based Personal Risk Assessment in Coronary Heart Disease 295
S. P. Caudill, S. J. Smith and G. R. Cooper

A Surveillance System Based on a Short Memory Scheme 311
D. L. Shore and D. Quade

Detection of Aberrations in the Occurrence of Notifiable Diseases Surveillance Data 323
D. F. Stroup, G. D. Williamson, J. L. Herndon and J. M. Karon

Commentary 331
M. Lane

TIME SERIES ANALYSIS OF SURVEILLANCE DATA

The Application of Time Series Forecasting Methods to an Estimation Problem Using Provisional Mortality Statistics 335
M. Katzoff

A Time Series Analysis of Gonorrhea Surveillance Data 343
D. Schnell, A. Zaidi and G. Reynolds

Time Series Analysis of Syphilis Surveillance Data 353
A. Zaidi, D. Schnell and G. Reynolds

Commentary 363
S. B. Thacker

MISCELLANEOUS

Monitoring Data Quality Through Comparisons Between Data Systems 367
J. T. Massey and K. L. Hoffman

Estimating Trends in the Effectiveness of Seat Belts in Saving Lives, 1975–1985 379
D. L. McGee and P. Rhodes

ABSTRACTS 387

Summary Remarks 393
R. L. Berkelman

Closing Remarks 397
G. H. Reynolds

Volume 8, *Issue No.* 4, April 1989

RECENT ISSUES IN CLINICAL TRIALS

Preface 401

The Use of Surrogate Endpoints in Clinical Trials (An Introduction to a Series of Four Papers) 403
J. Herson

Surrogate Endpoints in Clinical Trials: Cancer 405
S. S. Ellenberg and J. M. Hamilton

Surrogate Endpoints in Clinical Trials: Cardiovascular Diseases 415
J. Wittes, E. Lakatos and J. Probstfield

Surrogate Endpoints in Clinical Trials: Ophthalmologic Disorders 427
A. Hillis and D. Seigel

Surrogate Endpoints in Clinical Trials: Definition and Operational Criteria 431
R. L. Prentice

How Study Design Affects Outcomes in Comparisons of Therapy. I: Medical 441
G. A. Colditz, J. N. Miller and F. Mosteller

How Study Design Affects Outcomes in Comparisons of Therapy. II: Surgical 455
J. N. Miller, G. A. Colditz and F. Mosteller

Covariate Imbalance and Random Allocation in Clinical Trials 467
S. J. Senn

A Two-stage Trial Design for Testing Treatment, Self-selection and Treatment Preference Effects 477
G. Rücker

A Two-period Crossover Design for the Comparison of Two Active Treatments and Placebo 487
G. G. Koch, I. A. Amara, B. W. Brown, Jr., T. Colton and D. B. Gillings

The Impact that Group Sequential Tests Would Have Made on ECOG Clinical Trials 505
G. L. Rosner and A. A. Tsiatis

LETTERS TO THE EDITOR 517

BOOK REVIEWS 521

Volume 8, *Issue No.* 5, May 1989

Empirical Comparisons of Proportional Hazards and Logistic Regression Models 525
D. D. Ingram and J. C. Kleinman

A Comparison of Estimated Proportional Hazards Models and Regression Trees 539
M. R. Segal and D. A. Bloch

Flexible Regression Models with Cubic Splines 551
S. Durrleman and R. Simon

The Bias of the Sample Proportion Following a Group Sequential Phase II Clinical Trial 563
M. N. Chang, H. S. Wieand and V. T. Chang

A Log-linear Model for Ordinal Data to Characterize Differential Change among Treatments 571
S. F. Francom, C. Chuang-Stein and J. R. Landis

The Analysis of Titration Studies in Phase III Clinical Trials 583
W. J. Shih, A. L. Gould and I. K. Hwang

How to Establish Equivalence between Treatments: A One-sided Clinical Trial in Paediatric Oncology 593
C. Rodary, C. Com-Nougue and M.-F. Tournade

Estimation of a Common Odds Ratio in Paired-cluster Randomization Designs 599
A. Donner and W. Hauck

Assessing Diagnostic Tests by a Strictly Proper Scoring Rule 609
K. Linnet

Goodman and Kruskal's λ: A New Look at an Old Measure of Association 619
R. W. Makuch, P. S. Rosenberg and G. Scott

LETTER TO THE EDITOR 633

BOOK REVIEWS 635

Volume 8, *Issue No.* 6, June 1989

RECENT ISSUES IN EPIDEMIOLOGY

Preface 639

Converting Relative Risks to Absolute Risks: A Graphical Approach 641
W. D. Dupont

Cautions on the Reanalysis of Epidemiologic Databases 653
J. E. Michalek, D. Mihalko and R. C. Tripathi

Comment 665
N. Mantel

Comment: Cautions in the Use of Preliminary-test Estimators 669
S. Greenland

Authors' Reply 675
J. E. Michalek, D. Mihalko and R. C. Tripathi

The Control of Confounding by Intermediate Variables 679
J. Robins

Graphical Generalized Residuals in Fitting Distributions: Applications to Epidemiological Follow-up Data 703
R. C. Elandt-Johnson and F. B. Smith

Regression Models for Time to Seroconversion Following Experimental Bovine Leukaemia Virus Infection 725
M.-L. G. Lassauzet, W. O. Johnson and M. C. Thurmond

Estimation of Sojourn Time Distributions and False Negative Rates in Screening Programmes which Use Two Modalities 743
F. E. Alexander

Unidirectional Multiple Comparisons of Poisson Rates 757
S. Suissa and R. Salmi

LETTER TO THE EDITOR 765

BOOK REVIEW 769

Volume 8, *Issue No.* 7, July 1989

Bootstrap Investigation of the Stability of a Cox Regression Model 771
D. G. Altman and P. K. Andersen

Regression with an Ordered Categorical Response 785
T. J. Hastie, J. L. Botha and C. M. Schnitzler

Sample Size Tables for Logistic Regression 795
F. Y. Hsieh

Sample Sizes for Constructing Confidence Intervals and Testing Hypotheses 803
D. R. Bristol

A Method for the Evaluation of Dose-toxicity Relationships in Clinical Trials 813
F. J. Mather, R. M. Simon, G. M. Clark and D. D. Von Hoff

On Correcting for Misclassification in Twin Studies and Other Matched-pair Studies 825
S. Greenland

Statistical Analysis of the Stages of HIV Infection Using a Markov Model 831
I. M. Longini, W. S. Clark, R. H. Byers, J. W. Ward, W. W. Darrow, G. F. Lemp and H. W. Hethcote

Estimability and Estimation of Excess and Etiologic Fractions 845
J. M. Robins and S. Greenland

Comparison of the Information in Two Lung Function Experiments 861
L. L.-Y. Lim and J. Whitehead

Statistical Comparison of Ligand-binding Kinetics 871
J. B. Cologne, P. M. Mendelman and D. O. Chaffin

Test for Batch-to-batch Variation in Stability Analysis 883
S.-C. Chow and J. Shao

LETTER TO THE EDITOR 891

Volume 8, *Issue No.* 8, August 1989

Measuring Measuring Errors 893
M. J. R. Healy

A Linear Regression Model for the Analysis of Life Times 907
O. O. Aalen

Bootstrapped Confidence Intervals for the Cox Model using a Linear Relative Risk Form 927
W. E. Barlow and W.-H. Sun

Effect of Unequal Censoring on the Size and Power of the Logrank and Wilcoxon Types of Tests for Survival Data 937
M. S. Beltangady and R. F. Frankowski

Exponential Survival Trees 947
R. B. Davis and J. R. Anderson

Correcting Reported Aids Incidence: A Statistical Approach 963
S. H. Heisterkamp, J. C. Jager, E. J. Ruitenberg, J. A. M. Van Druten and A. M. Downs

Efficiency Gains from the Addition of Controls to Matched Sets in Cohort Studies 977
J. Raboud and N. E. Breslow

A Comparison of Maximum Likelihood and Jewell's Estimators of the Odds Ratio and Relative Risk in Single 2 × 2 Tables 987
S. Becker

Validity of Mortality Analysis Based on Retrospective Smoking Information 997
S. R. Machlin, J. C. Kleinman and J. H. Madans

Testing for Central Mixtures of Compartment Model Parameters 1011
D. Zelterman

LETTER TO THE EDITOR 1023

BOOK REVIEW 1025

Volume 8, *Issue No.* 9, September 1989

WORKSHOP ON ERRORS-IN-VARIABLES, 8–9 OCTOBER, 1987
National Institutes of Health, Bethesda, Maryland, USA
Guest Editors: David P. Byar and Mitchell H. Gail

Introduction 1027
D. P. Byar and M. H. Gail

An Overview of Issues Related to the Correction of Non-differential Exposure Measurement Error in Epidemiologic Studies 1031
W. Willett

The Use of Dual or Multiple Reports in Epidemiologic Studies 1041
J. R. Marshall

Correction of Logistic Regression Relative Risk Estimates and Confidence Intervals for Systematic Within-person Measurement Error 1051
B. Rosner, W. C. Willett and D. Spiegelman

Discussion 1 1071

Covariance Analysis in Generalized Linear Measurement Error Models 1075
R. J. Caroll

A Review of Methods for Misclassified Categorical Data in Epidemiology 1095
T. T. Chen

Discussion 2 1107

Indoor Air Pollution and Pulmonary Performance: Investigating Errors in Exposure Assessment 1109
N. A. Hasabelnaby, J. H. Ware and W. A. Fuller

Commentary on "Indoor Air Pollution and Pulmonary Performance: Investigating Errors in Exposure Assessment" 1127
L. J. Gleser

Rejoinder to Comments by Leon Jay Gleser 1133
N. A. Hasabelnaby, J. H. Ware and W. A. Fuller

Discussion 3 1137

A Measurement-error Model for Binary and Ordinal Regression 1139
T. D. Tosteson, L. A. Stefanski and D. W. Schafer

Discussion 4 1149

Analysis of Case-control Data with Covariate Measurement Error: Application to Diet and Colon Cancer 1151
B. G. Armstrong, A. S. Whittemore and G. R. Howe

Discussion 5 1165

Further Results on Covariate Measurement Errors in Cohort Studies with Time to Response Data 1167
M. S. Pepe, S. G. Self and R. L. Prentice

Discussion 6 1179

ANNOUNCEMENT 1181

Volume 8, *Issue No.* 10, October 1989

Adjusting for Baseline: Change or Percentage Change? 1183
L. Kaiser

Group Sequential Procedures: Calendar Versus Information Time 1191
K. K. G. Lan and D. L. Demets

Using Association Models to Analyse Agreement Data: Two Examples 1199
M. P. Becker

VOLUME CONTENTS 249

A Survey of Models for Repeated Ordered Categorical Response Data 1209
A. Agresti

Estimation of Prevalence on the Basis of Screening Tests 1225
R. A. Lew and P. S. Levy

A Discussion on the Conventional Estimator of Sensitivity and Specificity in Multiple Tests 1231
K.-J. Lui

Analysis of Epidemiologic Case–base Studies for Binary Data 1241
M. Nurminen

Survival Analysis in Natural History Studies of Disease 1255
A. Cnaan and L. Ryan

A Note on Confidence Limits for Quartiles with Right Censored Data 1269
R. M. Elashoff, J. J. Lee and A. A. Afifi

On the Statistical Analysis of ROC Curves 1277
M. L. Thompson and W. Zucchini

Mixture Models for Partially Unclassified Data: A Case Study of Renal Venous Renin in Hypertension 1291
G. J. McLachlan and R. D. Gordon

LETTERS TO THE EDITOR 1301

BOOK REVIEWS 1307

Volume 8, *Issue No.* 11, November 1989

Papers from the International Society for Clinical Biostatistics
Ninth International Meeting, August–September 1988

Preface 1313

The ISCB 1315

The Ordered Logistic Regression Model in Psychiatry: Rising Prevalence of Dementia in Old People's Homes 1317
D. Ashby, C. R. West and D. Ames

Predicting the Range of Plasma Carbamazepine Concentrations in Patients with Epilepsy 1327
A. Racine-Poon and J. P. Dubois

The Use of Baselines in Clinical Trials of Bronchodilators 1339
S. J. Senn

Correspondence Analysis as a Screening Method for Indicants for Clinical Diagnosis 1351
N. J. Crichton and J. P. Hinde

On the Regression Analysis of Tumour Recurrence Rates 1363
G. U. H. Seeber

Estimation of Temporal Effects in Treatment-induced Second Cancer 1371
J. M. Kaldor and N. E. Day

Constructing a Cut-off Point for a Quantitative Diagnostic Test 1381
H. Schäfer

Assessing Antiarrhythmic Drug Efficacy: Multivariate Considerations 1393
K. Ulm, G. Schmidt, P. Barthel and A. Linzmaier

A Measure of Similarity for Response Curves Based on Ranks 1401
G. Schulgen

LETTERS TO THE EDITOR 1413

BOOK REVIEW 1418

ANNOUNCEMENT 1420

Volume 8, *Issue No.* 12, December 1989

The Performance of the Two-stage Analysis of Two-treatment, Two-period Crossover Trials 1421
P. R. Freeman

Grading of Images in a Clinical Trial 1433
D. Seigel and R. C. Milton

The Analysis of Relapse Clinical Trials, with Application to a Comparison of Two Ulcer Treatments 1439
J. Whitehead

A Comparison of Tests of Homogeneity of Odds Ratios in K 2×2 Tables 1455
S. R. Paul and A. Donner

On Alleged Gains in Power from Lower P-Values 1469
G. A. Barnard

The Superiority of a Drug Combination Over Each of its Components 1479
J. M. Gibson and J. E. Overall

Comparison of Correlated Correlations 1485
A. Cohen

Time Series Analysis of Injuries 1497
B. Martinez-Schnell and A. Zaidi

Estimation of Haemophilia-associated AIDS Incidence in Japan Using Individual Dates of Diagnosis 1509
T. Tango

Efficiency of the Logistic Regression and Cox Proportional Hazards Models in Longitudinal Studies 1515
I. Annesi, T. Moreau and J. Lellouch

A Cautionary Note on the Use of Autoregressive Models in Analysis of Longitudinal Data 1523
E. J. Stanek III, S. S. Shetterley, L. H. Allen, G. H. Pelto and A. Chavez

Misclassification in More than One Factor in a Case-control Study: A Combination of Mantel–Haenszel and Maximum Likelihood Approaches 1529
S. W. Duffy, T. E. Rohan and N. E. Day

Single-stage Cluster Sampling with a Telescopic Respondent Rule: A Variation Motivated by a Survey of Dementia in Elderly Residents of Shanghai 1537
P. S. Levy, E. S. H. Yu, W. T. Liu, S.-C. Wong, M.-Y. Zhang, Z.-Y. Wang and R. Katzman

LETTERS TO THE EDITOR 1545

EXTENDED REVIEWS 1549

BOOK REVIEWS 1557

Acknowledgement 1561

Author Index 1563

Subject Index 1565

Volume 9, Issue Nos. 1–12

Volume 9, *Issue No.* 1/2, January–February 1990

PROCEEDINGS OF THE WORKSHOP ON COST AND EFFICIENCY IN CLINICAL TRIALS, 18–19 JANUARY, 1989

Sponsored by the National Heart, Lung, and Blood Institute, Bethesda, Maryland, U.S.A.

Editorial i

Preface *P. Held, J. Wittes, J. Duggan and S. Yusuf* 1

List of Speakers and Discussants 3

Introductory Remarks *C. Lenfant* 5

OVERVIEW AND EXAMPLES

Costs of Clinical Trials and the Need for Efficiency: A Brief Overview 9
W. T. Friedewald

Polio Trial: An Early Efficient Clinical Trial *P. Meier* 13

The Case of GISSI in Changing the Attitudes and Practice of Italian Cardiologists *G. Tognoni, M. G. Franzosi, S. Garattini, A. Maggioni, A. Lotto, F. Mauri and F. Rovelli* 17

Cost and Efficiency in Clinical Trials: The U.S. Physicians' Health Study 29
J. E. Buring and C. H. Hennekens

Cost and Efficiency Considerations in Community-based Trials of Vitamin A in Developing Countries *J. M. Tielsch and K. P. West, Jr.* 35

Sickle Cell Anaemia Trial *M. H. Gaston and J. Verter* 45

DESIGN ISSUES

Factorial and Reciprocal Control Designs *D. P. Byar* 55

The Role of Internal Pilot Studies in Increasing the Efficiency of Clinical Trials 65
J. Wittes and E. Brittain

Selection of Patients for Randomized Controlled Trials: Implications of Wide or Narrow Eligibility Criteria *S. Yusuf, P. Held, K. K. Teo and E. R. Toretsky* 73

The Use of a Run-in to Enhance Compliance *J. M. Lang* 87

Efficient Means of Studying Ancillary Questions in Clinical Trials *C. E. Davis* 97

DATA COLLECTION

How Much Data Should we Collect in a Randomized Clinical Trial? *J. Verter* 103

An Examination of the Efficiency of Some Quality Assurance Methods Commonly Employed in Clinical Trials *J. D. Neaton, A. G. Duchene, K. H. Svendsen and D. Wentworth* 115

An Evaluation of Central Laboratories in Three VA Cooperative Studies 125
P. Peduzzi, P. Hartigan and G. Johnson

A Clinic's Perspective on Screening, Recruitment and Data Collection *T. Eaton and C. M. Pratt* 137

Discussion of Papers on Cost and Efficiency of Data Collection in Clinical Trials 145
S. S. Ellenberg

ANALYSES AND APPLICABILITY

Efficient Use of Endpoints in Clinical Trials: A Clinical Perspective *M. L. Terrin* 155

Opportunities for Enhancing Efficiency and Reducing Cost in Large Scale Disease Prevention Trials: A Statistical Perspective *R. L. Prentice* 161

Using Cost-effectiveness Analysis to Improve the Efficiency of Allocating Funds to Clinical Trials *A. S. Detsky* 173

The Applicability of the Results of Streamlined Trials to Clinical Practice 185
L. Wilhelmsen

The Applicability of Results of Streamlined Trials to Clinical Practice: The Myocarditis Treatment Trial *J. B. O'Connell and J. W. Mason* 193

Concluding Remarks of the Chairman *C. Hennekens* 199

VOLUME CONTENTS 253

Volume 9, *Issue No.* 3, March 1990

Hypothesis Versus Significance Testing for Controlled Clinical Trials: A Dialogue 201
D. Salsburg

Comment 213
L. Freedman and D. Byar

Incorporating Historical Control Data in Planning Phase II Clinical Trials 215
P. F. Thall and R. Simon

A Sequential Phase II/III Trial for Binary Outcomes 229
B. E. Storer

The Choice of a Balanced Allocation Method for a Clinical Trial in Otitis Media with Effusion 237
G. A. Zielhuis, H. Straatman, A. E. Van 'T Hof-Grootenboer, H. J. J. Van Lier, G. H. Rach and P. Van Den Broek

Bias in the One-step Method for Pooling Study Results 247
S. Greenland and A. Salvan

Predicting Response to Treatment: Differentiating Active-factor and Non-specific Effects 253
M. A. Young and L. F. Fogg

Modelling Peritonitis Rates and Associated Risk Factors for Individuals on Continuous Ambulatory Peritoneal Dialysis 263
E. F. Vonesh

Optimal Choice of Prognostic Variables with an Application to Cardiac Monitoring Using M-mode Echocardiography 273
M. L. Puterman, P. Schumacher and G. G. S. Sandor

Application of the Cox Model as a Predictor of Relative Risk of Coronary Heart Disease in the Albany Study 287
H.-G. H. Chang, L. L. Lininger, J. T. Doyle, P. A. Maccubbin and R. B. Rothenberg

Survival Analysis Techniques in Angina Pectoris Trials 293
D. R. Bristol and J. V. Castellana

Disease Entities, Mixed Multi-normal Distributions, and the Role of the Hyperkinetic State in the Pathogenesis of Hypertension 301
N. J. Schork, A. B. Weder, M. A. Schork, D. R. Bassett and S. Julius

The Proportionate Mortality Ratio and its Relationship with Measures of Mortality 315
E. Støttrup Hansen

Receiver Operator Characteristic (ROC) Curves and Non-normal Data: An Empirical Study 325
M. J. Goddard and I. Hinberg

CORRECTION 339

LETTERS TO THE EDITOR 341

BOOK REVIEWS 343

ANNOUNCEMENT 350

Volume 9, *Issue No.* 4, April 1990

The Assessment of Methods of Measurement 351
S. Chinn

Yates's Correction for Continuity and the Analysis of 2 × 2 Contingency Tables 363
M. G. Haviland
Comment *N. Mantel* 369
Comment *S. W. Greenhouse* 371
Comment *G. Barnard* 373
Comment *R. B. D'Agostino* 377
Comment *J. E. Overall* 379
Author's Rejoinder *M. G. Haviland* 383

On the Use of a Logistic Risk Score in Predicting Risk of Coronary Heart Disease 385
L. E. Chambless, A. J. Dobson, C. C. Patterson and B. Raines

Application of the Theory of Finite Mixtures for the Estimation of 'Cure' Rates of Treated Cancer Patients 397
N. H. Gordon

An Application of the LFP Survival Model to Smoking Cessation Data 409
K. J. Koehler and P. G. McGovern

Estimation of Risk Ratios in Case-base Studies with Competing Risks 423
W. D. Flanders, R. Dersimonian and P. Rhodes

The Power to Detect Differences in Average Rates of Change in Longitudinal Studies 437
J. J. Lefante

Application of New Two-sample Tests to Data from a Randomized Placebo-controlled Heart-failure Trial 447
P. K. Tandon, H. Stander and R. P. Schwarz, Jr.

Murphy's Law of Limiting Dilution Cloning 457
R. Staszewski

LETTER TO THE EDITOR 463

BOOK REVIEWS 465

Volume 9, *Issue No.* 5, May 1990

Biplots in Biomedical Research 469
K. R. Gabriel and C. L. Odoroff

Measures of Explained Variation for Survival Data 487
E. L. Korn and R. Simon

Estimating the Distribution of Times from HIV Seroconversion to AIDS Using Multiple Imputation 505
J. M. G. Taylor, A. Muñoz, S. M. Bass, A. J. Saah, J. S. Chmiel and L. A. Kingsley

VOLUME CONTENTS 255

A Method for Testing the Significance of Geographical Correlations with Application to Industrial Lung Cancer in France 515
S. Richardson

Relative Survival and the Estimation of Net Survival: Elements for Further Discussion 529
J. Estève, E. Benhamou, M. Croasdale and L. Raymond

Maximum Likelihood Estimation of Reference Centiles 539
M. L. Thompson and G. B. Theron

Outlier Detection in Bioavailability/Bioequivalence Studies 549
S.-C. Chow and S.-K. Tse

Latent Class Analysis of Diagnostic Agreement 559
J. S. Uebersax and W. M. Grove

On a Test of Non-random Segregation Under Linkage for Autosomal Recessive Diseases 573
N. Pal and P. P. Majumder

LETTERS TO THE EDITOR 583

Volume 9, *Issue No.* 6, June 1990

In Honour of Professor Peter Armitage
Guest Editor: Klim McPherson

Dedication 587

Personal Addendum 591

ISCB Dedication Notice 594

Sequential Stopping Rules in Clinical Trials 595
K. McPherson

Must Clinical Trials be Large? The Interpretation of *P*-values and the Combination of Test Results 601
G. A. Barnard

Further Studies in the Variability of Pock Counts 615
N. Breslow

How Much Further Investigation? 627
N. Mantel and M. Adrian Gross

Measuring Importance 633
M. J. R. Healy

Repeated Measurements: What is Measured and What Repeats? 639
D. J. Finney

Randomized Consent Designs for Clinical Trials: an Update 645
M. Zelen

Estimation Issues in Clinical Trials and Overviews 657
S. J. Pocock and M. D. Hughes

Peter Armitage: a Personal Recollection 673
M. A. Schneiderman

The Armitage–Doll Multistage Model of Carcinogenesis 677
N. E. Day

Time from Infection with HIV to Onset of Aids in Patients with Haemophilia in the UK 681
S. C. Darby, R. Doll, B. Thakrar, C. R. Rizza and D. R. Cox

An Application of Density Estimation to Geographical Epidemiology 691
J. F. Bithell

The Summarizing of Clinical Experiments by Significance Levels 703
F. J. Anscombe

BIBLIOGRAPHY 709

Volume 9, *Issue No.* 7, July 1990

EDITORS' NOTE 717

FURTHER PAPERS FROM THE INTERNATIONAL SOCIETY FOR CLINICAL BIOSTATISTICS INTERNATIONAL MEETINGS

HIV Infection Dynamics and Intervention Experiments in Linked Risk Groups 721
J. A. M. Van Druten, A. G. M. Reintjes, J. C. Jager, S. H. Heisterkamp, M. J. J. C. Poos, R. A. Coutinho, M. G. W. Dijkgraaf and E. J. Ruitenberg

Long Term Survival Analysis: Breast Cancer and Age at Diagnosis 737
E. Marubini, G. Mezzanotte, P. Boracchi and U. Veronesi

Statistical Analysis of Quality of Life Data in Cancer Clinical Trials 749
M. Olschewski and M. Schumacher

The Design of Case-control Studies: The Effect of Confounding on Sample Size Requirements 765
K. Drescher, J. Timm and K.-H. Jöckel

Efficient Evaluation of Treatment Effects in the Presence of Missing Covariate Values 777
M. Schemper and T. L. Smith

REGULAR PAPERS

CTS: a Clinical Trials Simulator 787
D. W. Taylor and E. G. Bosch

A Markovian Model for Comparing Incidences of Side Effects 803
D. R. Bristol and H. I. Patel

More Powerful Procedures for Multiple Significance Testing 811
Y. Hochberg and Y. Benjamini

Applications of Global Statistics in Analysing Quality of Life Data 819
P. K. Tandon

A Stratified Wilcoxon-type Test for Trend 829
D. Y.-W. Pee and L. S. Freedman

VOLUME CONTENTS 257

A Note on Interrater Agreement 835
K. F. Hirji and M. H. Rosove

A Two-step Method for Understanding and Fitting Growth Curve Models 841
E. J. Stanek III

LETTERS TO THE EDITOR 853

BOOK REVIEWS 855

SHORT REVIEWS OF NEW EDITIONS 861

Volume 9, *Issue No.* 8, August 1990

Remembrances of Max Halperin 863

Historical and Methodological Developments in Clinical Trials at the National Cancer Institute 871
E. A. Gehan and M. A. Schneiderman

Early Methodological Developments for Clinical Trials at the National Heart, Lung and Blood Institute 881
M. Halperin, D. L. DeMets and J. H. Ware

Some Historical and Methodological Developments in Early Clinical Trials at the National Institutes of Health 893
S. W. Greenhouse

Discussion of Papers on 'Historical and Methodological Developments in Clinical Trials at the National Institutes of Health' 903
D. P. Byar

Application of the Triangular Test to Phase II Cancer Clinical Trials 907
E. Belissant, J. Benichou and C. Chastang

Hierarchical Models for Multicentre Binary Response Studies 919
A. M. Skene and J. C. Wakefield

The Measurement of Change of Quality of Life in Clinical Trials 931
A. H. Zwinderman

Assessing the Gain in Efficiency Due to Matching in a Community Intervention Study 943
L. S. Freedman, S. B. Green and D. P. Byar

Modelling Forces of Infection for Measles, Mumps and Rubella 953
C. P. Farrington

Estimating Benefits of Screening From Observational Cohort Studies 969
W. Dana Flanders and I. M. Longini, Jr.

The Use of Logit Models to Investigate Social and Biological Factors in Infant Mortality. V: A Multilogit Analysis of Stillbirths, Neonatal and Post-neonatal Mortality 981
T. J. Murrells, T. M. F. Smith and D. Machin

Proportion Cured and Mean Log Survival Time as Functions of Tumour Size 999
J. W. Gamel, I. W. McLean and S. H. Rosenberg

BOOK REVIEWS 1007

Volume 9, *Issue No.* 9, September 1990

Workshop on Teaching Statistics to Medical Undergraduates Bristol, UK, September 1989. Guest Editors: Simon J. Day, Jane L. Hutton and Martin J. Gardner

Preface 1011

What Statistics should we Teach Medical Undergraduates and Graduates? 1013
D. R. Appleton

Comment 1023
T. J. Peters

Comment 1029

Who Should Teach Medical Statistics, When, How and Where Should it be Taught? 1031
A. D. Clayden

Response 1039
M. J. Campbell

Comment 1043

Evaluation of Statistics Teaching Given to Medical Undergraduates 1045
R. G. Newcombe

Response 1057
D. Ashby

Comment 1061

How we Should Approach the Future 1063
G. D. Murray

Statistics for Medical Students in the 1990's: How Should we Approach the Future? 1069
S. J. W. Evans

Comment 1077

REGULAR PAPERS

Statistical Interim Monitoring of the Cardiac Arrhythmia Suppression Trial 1081
Y. Pawitan and A. Hallstrom

Practical Bayesian Analysis of a Simple Logistic Regression: Predicting Corneal Transplants 1091
A. O'Hagan, E. G. Woodward and L. C. Moodaley

Measuring Interrater Reliability Among Multiple Raters: An Example of Methods for Nominal Data 1103
K. L. Posner, P. D. Sampson, R. A. Caplan, R. J. Ward and F. W. Cheney

LETTERS TO THE EDITOR 1117

BOOK REVIEW 1119

Volume 9, *Issue No.* 10, October 1990

Factorial Designs for Crossover Clinical Trials 1121
D. J. Fletcher, S. M. Lewis and J. N. S. Matthews

Model Selection and the Estimation of Odds Ratios in the Presence of Extraneous Factors 1131
R. Schall and W. Zucchini

Symmetry and Quasi-symmetry: An Example in Modelling Pairs of Sounds from Children's Early Speech 1143
E. A. Stasny and H. R. Bauer

A Comparison of Poission Regression Models Fitted to Multiway Summary Tables and Cox's Survival Model Using Data from a Blood Pressure Screening in the City of Bergen, Norway 1157
R. Selmer

A Note on Point Ratio Estimation of the Hazard Ratio in Exponential Distributions 1167
K.-J. Lui and P. Rhodes

Estimating Correlation Between Alternative Measures of Disease Progression in a Longitudinal Study 1175
M. D. Schluchter

Prognostic Scores for Detecting a High Risk Group: Estimating the Sensitivity When Applied to New Data 1189
A. N. Phillips, S. G. Thompson and S. J. Pocock

Variation in Heart Disease Mortality Across Census Tracts as a Function of Over-dispersion and Social Class Mixture 1199
D. Jarjoura and E. Logue

Estimation of Parasitic Infection Dynamics when Detectability is Imperfect 1211
N. J. D. Nagelkerke, R. N. Chunge and S. N. Kinoti

LETTER TO THE EDITOR 1221

BOOK REVIEWS 1223

ANNOUNCEMENT 1228

CORRECTION 1228

Volume 9, *Issue No.* 11, November 1990

Papers from the International Society for Clinical Biostatistics
Tenth International Meeting, September 1989

Preface iii

ISCB Committee iv

Analysing Clinical Decision Analyses 1229
J. D. F. Habbema, P. M. M. Bossuyt, D. W. J. Dippel, S. Marshall and J. Hilden

The Marriage of Clinical Trials and Clinical Decision Science 1243
J. Hilden and J. D. F. Habbema

Quality Adjusted Survival Analysis 1259
P. P. Glasziou, R. J. Simes and R. D. Gelber

An Improved Approximation for Calculation of Confidence Intervals after a Sequential Clinical Trial 1277
K. M. Facey and J. Whitehead

The Graphical Representation of Clinical Trials with Particular Reference to Measurements Over Time 1287
S. J. Senn and P. Auclair

Predictive Value of Statistical Models 1303
J. C. Van Houwelingen and S. Le Cessie

Quantifying Misclassification Bias in Cohort Studies of Vaccine Efficacy 1327
C. P. Farrington

Adjusting for Misselection Using Subsampling in Epidemiological Studies 1339
M. Blettner and H. Becher

Design Methods for Some Dose–response Models 1353
L. W. G. Strijbosch, R. J. M. M. Does and W. Albers

Principles, Problems and a Paradox with the Measurement of Energy Expenditure of Free-Living Subjects using Doubly-Labelled Water 1365
J. R. Speakman

BOOK REVIEWS 1381

Volume 9, *Issue No.* 12, December 1990

Preface 1385

Some Statistical Issues in Studies of the Epidemiology of Aids 1387
N. P. Jewell

Adjusting for Early Treatment Termination in Comparative Clinical Trials 1417
S. W. Lagakos, L. L.-Y. Lim and J. M. Robins

Challenges of HIV Vaccine Development 1425
D. M. Stablein

Discussion 1433
L. Billard

Group Sequential Designs using a Family of Type I Error Probability Spending Functions 1439
I. K. Hwang, W. J. Shih and J. S. de Cani

Test Statistics and Sample Size Formulae for Comparative Binomial Trials with Null Hypothesis of Non-zero Risk Difference or Non-unity Relative Risk 1447
C. P. Farrington and G. Manning

Testing for Imbalance of Covariates in Controlled Experiments 1455
T. Permutt

Estimation of the Linear Relationship between the Measurements of Two Methods with Proportional Errors 1463
K. Linnet

Optimum Allocation of Samples in Strata-matching Case-control Studies when Cost Per Sample Differs from Stratum to Stratum 1475
J.-M. Nam and T. R. Fears

Sample Size Determination for Case-control studies: the Influence of the Joint Distribution of Exposure and Confounder 1485
K.-J. Lui

Statistical Methods for Determining Risk Factors of Chronic Otitis Media with Effusion 1495
C. T. Le and B. R. Lindgren

Relation of Pooled Logistic Regression to Time Dependent Cox Regression Analysis: the Framingham Heart Study 1501
R. B. D'Agostino, M.-L. Lee, A. J. Belanger, L. A. Cupples, K. Anderson and W. B. Kannel

Maximum Likelihood Regression Methods for Paired Binary Data 1517
S. R. Lipsitz, N. M. Laird and D. P. Harrington

Survival Time Models for Analysing Drug Combination Treatments 1527
J. Kübler and M. Schumacher

LETTER TO THE EDITOR 1541

BOOK REVIEW 1543

ANNOUNCEMENT 1544

Acknowledgement 1545

Author Index 1547

Subject Index 1549

Volume 10, Issue Nos. 1–12

Volume 10, *Issue No.* 1, January 1991

Multiple Comparisons in Over-the-Counter Drug Clinical Trials with Both Positive and Placebo Controls 1
R. B. D'Agostino and T. C. Heeren

Comment *A. J. Zagar* 7
Comment *P. C. O'Brien* 9
Comment *G. G. Koch* 13
Comment *E. M. Laska and M. J. Meisner* 17
Comment *D. B. Duncan and D. O. Dixon* 21
Author's Rejoinder *R. B. D'Agostino and T. C. Heeren* 27

Sample Size Estimation for Comparing Two or More Treatment Groups in Clinical Trials 33
S. J. Day and D. F. Graham

On Estimating Efficacy From Clinical Trials 45
A. Somer and S. L. Zeger

Estimation of the Design Effect in Community Intervention Studies 53
R. M. Mickey, G. D. Goodwin and M. C. Costanza

Adjusting for Age-related Competing Mortality in Long-term Cancer Clinical Trials 65
B. Cheuvart and L. Ryan

Estimability and Estimation of Expected Years of Life Lost Due to a Hazardous Exposure 79
J. Robins and S. Greenland

Empirical Bayes Estimates of Cancer Mortality Rates Using Spatial Models 95
A. Mollie and S. Richardson

Bayesian Methods for Prevalence Estimation from Incomplete Administration Lists 113
P. J. Smith

Estimating Prediction Equations in Repeated Measures Designs 119
E. J. Stanek III and G. Kline

The Effect of Variable Infectivity on the Risk of HIV Infection 131
B. Eisenberg

Some Methods of Combining Class Information in Multivariate Normal Discrimination for the Classification of Human Chromosomes 141
S. P. J. Kirby, C. M. Theobald, J. Piper and A. D. Carothers

LETTER TO THE EDITOR 151

BOOK REVIEWS 155

Volume 10, *Issue No.* 2, February 1991

Statistical Problems in Family Planning Research
Guest Editors: Tim Farley and David Machin

Editorial 159

Behavioural and Biological Determinants of Fertility Transition in Sub-Saharan Africa 161
O. Frank and J. Bongaarts

The Preliminary Clinical Evaluation of the Safety and Efficacy of a Fertility Regulating Vaccine 177
P. D. Griffin and W. R. Jones

Statistical Methods to Adjust for Date and Age Misreporting to Improve Estimates of Vital Rates in Pakistan 191
T. W. Pullum

Methodological Pitfalls in the Analysis of Contraceptive Failure 201
J. Trussell

Identifying the Fertile Phase of the Human Menstrual Cycle 221
P. Royston

Coping with Extra Poisson Variability in the Analysis of Factors Influencing Vaginal Ring Expulsions 241
M. J. Campbell, D. Machin and C. D'Arcangues

Using the Ratio of Urinary Oestrogen and Progesterone Metabolites to Estimate Day of Ovulation 255
D. D. Baird, C. R. Weinberg, A. J. Wilcox, D. R. McConnaughey and P. I. Musey

The Description of Menstrual Bleeding Patterns: Towards Fewer Measures 267
E. M. Belsey and N. Carlson

Estimation of the Spontaneous Abortion Risk in the Presence of Induced Abortions 285
J. Hilden, J.Modvig, M. T. Damsgaard and L. Schmidt

ANNOUNCEMENT 299

Volume 10, *Issue No.* 3, March 1991

Editor's Note 301

A Simulation Study Comparing Designs for Dose Ranging 303
L. B. Sheiner, Y. Hashimoto and S. L. Beal

A Note on the Analysis of Titration Studies 323
C. Chuang-Stein and W. J. Shih

A Model for the Identification of Hormone Pulses 329
R. H. Kushler and M. B. Brown

A Statistical Method for Assessing a Threshold in Epidemiological Studies 341
K. Ulm

Determining Efficacy of Monitoring Devices: Evaluating New Technologies 351
E. A. Tolley, G. W. Somes, E. S. Willey and S. J. Phelps

The Effect of Non-differential Outcome Misclassification on Estimates of the Attributable and Prevented Fraction 361
C-C. Hsieh

Alternative Parameterization of Polychotomous Models: Theory and Application to Matched Case-control Studies 375
H. Becher

Are Ordinal Models Useful for Classification? 383
M. K. Campbell, A. Donner and K. M. Webster

Death After Marital Bereavement — is the Risk Increased? 395
C. Jagger and C. J. Sutton

Monitoring a Randomized Clinical Trial for Futility: The North-Norwegian Lidocaine Intervention Trial 405
R. F. Berntsen, K. Rasmussen and J. F. Bjørnstad

A Qualifier Q for the Survival Function to Describe the Prevalence of a Transient Condition 413
M. Sullivan Pepe, G. Longton and M. Thornquist

Modelling Length Bias in a Longitudinally-linked Record System on HIV Cases 423
J. Nedelman, A. Burns, J. Cleary, D. Gordon, P. Vernon and C. E. Lawrence

The Problem of Therapeutic Equivalence with Paired Qualitative Data: An Example from a Clinical Trial Using Haemophiliacs with an Inhibitor to Factor VIII 433
M. L. Lee and J. M. Lusher

Confidence Intervals for Post-test Probability 443
M. J. Monsour, A. T. Evans and L. L. Kupper

Confidence Intervals for Weighted Sums of Poisson Parameters 457
A. J. Dobson, K. Kuulasmaa, E. Eberle and J. Scherer

Sample Sizes for Repeated Measurements in Dichotomous Data 463
K-J. Lui

Generalization of Normal Discriminant Analysis using Fourier Series Density Estimators 473
T. Odom-Maryon, B. Langholz, J. Niland, S. Azen and the Transfusion Study Group

CORRECTION 487

LETTERS TO THE EDITOR 489

BOOK REVIEWS 497

Volume 10, *Issue No.* 4, April 1991

PROCEEDINGS OF THE THIRD BIENNIAL REGENSTRIEF CONFERENCE 'METHODS FOR USING LARGE DATABASES IN HEALTH CARE RESEARCH: PROBLEMS AND PROMISES' AT TURKEY RUN STATE PARK, MARSHALL, INDIANA, U.S.A., 23–25 OCTOBER, 1989

Sponsored by the Regenstrief Institute for Health Care, Indianapolis, Indiana, U.S.A.

Preface 505
S. L. Hui, C. McDonald, B. Katz and C. M. Clark

List of Conference Faculty 507

INTRODUCTION
The Analysis of Humongous Databases: Problems and Promises 511
C. J. McDonald and S. L. Hui

SOURCES AND APPLICATIONS OF DATABASES

Epidemiologic Oversight of the Medical Care Provided to Medicare Beneficiaries 521
H. Krakauer and R. C. Bailey

Practice Databases and their Uses in Clinical Research 541
W. M. Tierney and C. J. McDonald

Using Routinely Collected Data for Clinical Research 559
C. Safran

Using a Claims Database to Investigate Drug-induced Stevens–Johnson Syndrome 565
B. L. Strom, J. L. Carson, A. C. Halpern, R. Schinnar, E. S. Snyder, P. D. Stolley, M. Shaw, H. H. Tilson, M. Joseph, W. S. Dai, D. Chen, R. S. Stern, U. Bergman and F. Lundin

Channeling Bias in the Interpretation of Drug Effects 577
H. Petri and J. Urquhart

METHODOLOGIC ISSUES

Multiple Imputation in Health-care Databases: An Overview and Some Applications 585
D. B. Rubin and N. Schenker

Variance Components and their Implications for Statistical Information in Medical Data 599
E. J. Orav, T. A. Louis, R. H. Palmer and E. A. Wright

Methods for the Analysis and Assessment of Clinical Databases: The Clinician's Perspective 617
D. B. Pryor and K. L. Lee

Innovative Methodologies for Research Using Databases 629
L. E. Moses

POTENTIALS AND LIMITATIONS OF DATABASE RESEARCH

Potentials and Limitations of Database Research Illustrated by the QMMP AMI Medicare Mortality Study 637
M. S. Blumberg

Using Databases to Evaluate Therapy 647
M. A. Hlatky

An Approach to Several Problems in Using Large Databases for Population-based Case-control Studies of the Therapeutic Efficacy and Safety of Anti-hypertensive Medicine 653
B. M. Psaty, T. D. Koepsell, D. Siscovick, P. Wahl, J. P. Logerfo, T. S. Inui and E. H. Wagner

Problems with Using Observational Databases to Compare Treatments 663
D. P. Byar

Discussion 667

Dedication 671

ANNOUNCEMENT 673

Volume 10, *Issue No.* 5, May 1991

Constructing Time-specific Reference Ranges 675
P. Royston

Estimation of Reference Ranges from Normal Samples 691
P. Royston and J. N. S. Matthews

The Effects of Transformations and Preliminary Tests for Non-linearity in Regression 697
P. M. Grambsch and P. C. O'Brien

A Proposal for Examining and Reporting Stepwise Regressions 711
W. W. Hauck and R. Miike

The Effects of Model Selection on Confidence Intervals for the Size of a Closed Population 717
R. R. Regal and E. B. Hook

Comparison of Different Maximum Likelihood Estimators in a Small Sample Logistic Regression with Two Independent Binary Variables 723
F. S. Whaley

A Note on the Calculation of Expected Survival, Illustrated by the Survival of Liver Transplant Patients 733
B. L. Thomsen, N. Keiding and D. G. Altman

Analytic Methods for Two-stage Case-control Studies and Other Stratified Designs 739
W. D. Flanders and S. Greenland

A Comparison of Two Simple Hazard Ratio Estimators Based on the Logrank Test 749
G. Berry, R. M. Kitchin and P. A. Mock

Misclassification Among Methods Used for Multiple Group Discrimination—The Effects of Distributional Properties 757
A. E. Barón

The Standard Error of Cohen's Kappa 767
J. B. Garner

Planning Controlled Clinical Trials on the Basis of Descriptive Data Analysis 777
K. Abt

LETTERS TO THE EDITOR 797

BOOK REVIEWS 803

Volume 10, *Issue No.* 6, June 1991

Statistical Methods in Biopharmacy, Satellite Meeting of the 47th World Session of the International Statistical Institute Paris, 7–8 September 1989

Guest Editors: A. Zipfel, J. Cauquil, J. C. Lemarie, J. Maccario, D. Moccatti and M. Theron

Preface 807
A. Zipfel

Scientific and Organizing Committees, and List of Referees 809

Using Empirical Bayes Methods in Biopharmaceutical Research 811
T. A. Louis

The Construction of Biochemical Reference Ranges and the Identification of Possible Adverse Drug Reactions in the Elderly 831
C. J. Lawrence and V. F. Trewin

On the Use of Historical Controls in the Analysis of Laboratory Data 839
I. Yoshimura and M. Hayashi

A Statistical Procedure for the Estimation of Accuracy Parameters in Interlaboratory Studies 843
S. Kristiansen

Estimation of the Mean and Standard Deviation Using Order Statistics 855
F. D. J. Dunstan and A. B. J. Nix

Multiple Testing in Clinical Trials 871
P. Bauer

Analysis of the Crossover Design in the Presence of Residual Effects 891
W. Lehmacher

A Random Effects Model for Ordinal Responses from a Crossover Trial 901
F. Ezzet and J. Whitehead

Determination of Optimal Designs Using Linear Models in Crossover Trials 909
V. Lasserre

Interim Analysis in Clinical Trials 925
P. Armitage

Step-down Multiple Tests for Comparing Treatments with a Control in Unbalanced One-way Layouts 939
C. W. Dunnett and A. C. Tamhane

Some Extensions to a New Approach for Interim Analysis in Clinical Trials 949
B. Falissard and J. Lellouch

Individual Bioequivalence: What Matters to the Patient 959
W. W. Hauck and S. Anderson

Sample Sizes for Bioequivalence Studies 961
C. M. Metzler

Problems Induced by Meta-analyses 971
T. C. Chalmers

Maximum Likelihood Techniques Applied to Method Comparison Studies 981
A. B. J. Nix and F. D. J. Dunstan

Analysis of Phase II Clinical Trials in Haematology and Oncology: Comparison of the Triangular Test to the Usual Methods 989
J. Benichou, E. Bellissant and C. Chastang

Random Models for Margins of a 2×2 Contingency Table and Application to Pharmacovigilance 991
P. Tubert and B. Begaud

CORRECTION 1001

ANNOUNCEMENT 1002

Volume 10, *Issue No.* 7, July 1991

The Potential for Spread of HIV in the Heterosexual Population in Norway: A Model Study 1003
H. Stigum, J. K. Grønnesby, P. Magnus, J. M. Sundet and L. S. Bakketeig

Floating Absolute Risk: An Alternative to Relative Risk in Survival and Case-control Analysis Avoiding an Arbitrary Reference Group 1025
D. F. Easton, J. Peto and A. G. A. G. Babiker

An Estimating Equation Approach for the Analysis of Case-control Studies with Exposure Measured at Several Levels 1037
T. Sato

Analyses of Black and White Differentials in the Age Trajectory of Mortality in Two Closed Cohort Studies 1043
K. G. Manton, E. Stallard and S. Wing

Assessing the Influence of Reversible Disease Indicators on Survival 1061
P. K. Andersen, L. S. Hansen and N. Keiding

Estimating Standardized Parameters from Generalized Linear Models 1069
S. Greenland

Generalized Norton–Simon Models of Tumour Growth 1075
D. F. Heitjan

Evaluation of Statistical Methods for Monitoring Periodontal Disease 1089
M. C. K. Yang, R. G. Marks, W. B. Clark and I. Magnusson

The Analysis of Failure Time Data in Crossover Studies 1099
L. A. France, J. A. Lewis and R. Kay

Recovery of Inter-block Information in Cross-over Trials 1115
E. M. Chi

Approximate Multinormal Probabilities Applied to Correlated Multiple Endpoints in Clinical Trials 1123
S. James

A Quasi-exact Test for Comparing Two Binomial Proportions 1137
K. F. Hirji, S.-J. Tan and R. M. Elashoff

CORRECTION 1155

LETTERS TO THE EDITOR 1157

BOOK REVIEWS 1161

Volume 10, *Issue No.* 8, August 1991

Mean Square Error of Estimates of HIV Prevalence and Short-term AIDS Projections Derived by Backcalculation 1167
P. S. Rosenberg, M. H. Gail and D. Pee

Misclassification of Covariates 1181
A. M. Walker and S. F. Lanes

Adjustment for Non-differential Misclassification Error in the Generalized Linear Model 1197
X. Liu and K.-Y. Liang

Validation Techniques for Logistic Regression Models 1213
M. E. Miller, S. L. Hui and W. M. Tierney

Statistical Analysis of Repeated Events Forming Renewal Processes 1227
O. O. Aalen and E. Husebye

An Empirical Bayes Formulation of Cohort Models in Cancer Epidemiology 1241
C. M. Desouza

Simple Tests of Homogeneity of Controls in Matched Studies 1257
J. J. Gart

Homogeneity of the Relative Risk in Cohort Studies 1267
C. T. Le, B. R. Lindgren, D. Zelterman and A. J. Umen

Exploring the Order of Odds Ratios Using the Bootstrap 1273
J. A. Schwartzbaum and J. G. Hirschberg

Estimating Departure from Normality 1283
P. Royston

Effect of Regression to the Mean in the Presence of Within-subject Variability 1295
W. D. Johnson and V. T. George

Estimating Kappa from Binocular Data 1303
N. L. Oden

A Possible Source of Error in Calculating Median Age at First Occurrence of an Event from a Cumulative Distribution of Reported Ages 1313
G. Scalia-Tomba and J. Giesecke

Contradictory Correlations Between Derived Scales 1315
M. J. Thompson, D. J. Hand and B. S. Everitt

LETTERS TO THE EDITOR 1321

BOOK REVIEWS 1323

Volume 10, *Issue No.* 9, September 1991

A Comparative Phase II Clinical Trials Procedure for Choosing the Best of Three Treatments 1327
C. R. Palmer

Using Provisional Diagnoses in Monitoring a Clinical Trial 1341
J. M. Karon

Three Measures for Simultaneously Evaluating Benefits and Risks Using Categorical Data from Clinical Trials 1349
C. Chuang-Stein, N. R. Mohberg and M. S. Sinkula

Crossover Trials, Degrees of Freedom, the Carryover Problem and its Dual 1361
S. J. Senn and H. Hildebrand

Detection of Outlying Data in Bioavailability/Bioequivalence Studies 1375
J.-P. Liu and C.-S. Weng

Multivariate Probit Analysis: a Neglected Procedure in Medical Statistics 1391
E. Lesaffre and G. Molenberghs

Empirical Evaluation of Statistical Models for Counts or Rates 1405
R. A. Wolfe, G. R. Petroni, C. G. McLaughlin and L. F. McMahon, Jr.

Pooling Controls from Different Studies 1417
T. E. Raghunathan

Stochastic Methods for Short Term Projections of Symptomatic HIV Disease 1427
C. J. Mode, D. Fife and S. M. Troy

Estimation of Variance Components for Censored Data with Applications to Blood Pressure Variability 1441
L. Smith and B. Rosner

Modelling Hearing Thresholds in the Elderly 1453
C. H. Morrell and L. J. Brant

A Comparison of Methods for Calculating a Stratified Kappa 1465
W. Barlow, M.-Y. Lai and S. P. Azen

BOOK REVIEWS 1473

Volume 10, *Issue No.* 10, October 1991

The Environmental Accident at 'Schweizerhalle' and Respiratory Diseases in Children: A Time Series Analysis 1481
U. Helfenstein, U. Ackermann-Liebrich, C. Braun-Fahrländer and H. U. Wanner

A Time Series Construction of an Alert Threshold with Application to *S. Bovismorbificans* in France 1493
L. Watier, S. Richardson and B. Hubert

Radiation Dose and Leukaemia Risk: General Relative Risk Techniques for Dose–response Models in a Matched Case-control Study 1511
M. Blettner and J. D. Boice, Jr.

A Method of Non-parametric Back-projection and its Application to AIDS Data 1527
N. G. Becker, L. F. Watson and J. B. Carlin

On the Estimation of Total Variability in Assay Validation 1543
S.-C. Chow and S.-K. Tse

A One Degree of Freedom Nominal Association Model for Testing Independence in Two-way Contingency Tables 1555
C. S. Davis

Interpretation of Interaction in Factorial Analysis of Variance Design 1565
K. J. Ottenbacher

Estimation of Vaccine Efficacy in Outbreaks of Acute Infectious Diseases 1573
M. Haber, I. M. Longini, Jr. and M. E. Halloran

Estimating the Effect of the Run-in on the Power of the Physicians' Health Study 1585
J. M. Lang, J. E. Buring, B. Rosner, N. Cook and C. H. Hennekens

Analysis of Clinical Trials by Treatment Actually Received: Is it Really an Option? 1595
Y. J. Lee, J. H. Ellenberg, D. G. Hirtz and K. B. Nelson

The Analysis of Categorical Data From Cross-over Trials Using a Latent Variable Model 1607
M. G. Kenward and B. Jones

The Healthy Responder Phenomenon in Non-randomized Clinical Trials 1621
A. P. Hallstrom, H. L. Greene, M. L. Huther and the Cast Investigators

CORRECTION 1633

BOOK REVIEWS 1635

ANNOUNCEMENT 1641

Volume 10, *Issue No.* 11, November 1991

Papers from the International Society for Clinical Biostatistics Eleventh International Meeting, September 1990

Preface 1643

ISCB Committee 1645

Methods for Dose Finding Studies in Cancer Clinical Trials: A Review and Results of a Monte Carlo Study 1647
J. O'Quigley and S. Chevret

A General Parametric Approach to the Meta-analysis of Randomized Clinical Trials 1665
A. Whitehead and J. Whitehead

Falsificationism and Clinical Trials 1679
S. J. Senn

Calculating Centile Curves using Kernel Density Estimation Methods with Application to Infant Kidney Lengths 1693
J. E. Rossiter

Analysis of Failure Time Data with Ordinal Categories of Response 1703
D. M. Berridge and J. Whitehead

Multivariate Analysis of Spect Images with Illustrations in Alzheimer's Disease 1711
S. J. McCrory and I. Ford

The Detection of Artefacts in EEG Series 1719
F. D. J. Dunstan and R. W. Marshall

Subacute Sclerosing Panencephalitis in England and Wales: Transient Effects and Risk Estimates 1733
C. P. Farrington

Estimation of Relative Risk Functions 1745
J. F. Bithell

Methods of Adjustment for Estimating the Attributable Risk in Case-control Studies: A Review 1753
J. Benichou

Comparative Efficiency of a Survival-based Case-control Design and a Random Selection Cohort Design 1775
D. Commenges and T. Moreau

BOOK REVIEWS 1783

Volume 10, *Issue No.* 12, December 1991

Tenth Anniversary Issue

Editorial I

PART I—A DECADE OF ADVANCES IN MEDICAL STATISTICS

A Decade of Progress in Statistical Methodology for Clinical Trials 1789
R. Simon

A Bibliography and Comments on the Use of Statistical Models in Epidemiology in the 1980s 1819
M. H. Gail

Advances in Statistical Methodology for Diagnostic Medicine in the 1980s 1887
C. B. Begg

Statistics in Medical Journals: Developments in the 1980s 1897
D. G. Altman

Assessment of Quality of Life in Clinical Trials 1915
M. Schumacher, M. Olschewski and G. Schulgen

Survival Analysis 1982–1991: The Second Decade of the Proportional Hazards Regression Model 1931
P. K. Andersen

PART II—STATISTICS IN MEDICINE COMPETITION PRIZE-WINNERS

Sampling Design of Multiwave Studies with an Application to the Massachusetts Health Care Panel Study 1945
R. Chappell

Semi-parametric and Non-parametric Methods for the Analysis of Repeated Measurements with Applications to Clinical Trials 1959
C. S. Davis

Application of the McNemar Test to Non-independent Matched Pair Data 1981
M. Eliasziw and A. Donner

The Unseen Sample in Cohort Studies: Estimation of its Size and Effect 1993
D. R. Hoover, A. Muñoz, V. Carey, N.Odaka, J. M. G. Taylor, J. S. Chmiel, J. Armstrong, S. H. Vermund

Acknowledgement 2005

Author Index 2007

Subject Index 2009

Volume 11, Issue Nos. 1–16

Volume 11, *Issue No.* 1, 15 January 1992

Bayesian Analysis of Cancer Clinical Trials: An Introduction to Four Papers 1
J. Herson

Description of the Statistical Aspects of a Study for Advanced Colorectal Cancer Patients 5
S. Wieand and S. Cha

Bayesian Subset Analysis in a Colorectal Cancer Clinical Trial 13
D. O. Dixon and R. Simon

Application of Bayesian Statistics to Decision Making during a Clinical Trial 23
L. S. Freedman and D. J. Spiegelhalter

On some Applications of Bayesian Methods in Cancer Clinical Trials 37
J. B. Greenhouse

Interim Analyses for Monitoring Clinical Trials that do not Materially Affect the Type I Error Rate 55
A. L. Gould

An Annotated Bibliography of Methods for Analysing Correlated Categorical Data 67
M. Ashby, J. M. Neuhaus, W. W. Hauck, P. Bacchetti, D. C. Heilbron, N. P. Jewell, M. R. Segal and R. E. Fusaro

Log-linear Modelling of Pairwise Interobserver Agreement on a Categorical Scale 101
M. P. Becker and A. Agresti

Residual Plots for Repeated Measures 115
R. E. Weiss and C. G. Lazaro

The Correlation between Heart Period Variability and Mean Period Length 125
J. L. Fleiss, J. T. Bigger, Jr. and L. M. Rolnitzky

LETTERS TO THE EDITOR 131

BOOK REVIEWS 135
R. A. Cartwright, F. E. Alexander, P. A. McKinney and T. J. Ricketts, Leukaemia and Lymphoma. An Atlas of Distribution within Areas of England and Wales 1984–1988. *B. F. J. Manly*, Randomization and Monte Carlo Methods in Biology. *I. Chalmers, M. Enkin and M. J. N. C. Keirse (eds.)*, Effective Care in Pregnancy and Childbirth

ANNOUNCEMENT 139

Volume 11, *Issue No.* 2, 30 January 1992

Meta-analysis for 2 × 2 Tables: A Bayesian Approach 141
J. B. Carlin

Small Sample Performance of Tests of Homogeneity of Odds Ratios in K 2 × 2 Tables 159
S. R. Paul and A. Donner

Statistical Validation of Intermediate Endpoints for Chronic Diseases 167
L. S. Freedman, B. I. Graubard and A. Schatzkin

VOLUME CONTENTS 275

A Comparison of Sample Size Methods for the Logrank Statistic 179
E. Lakatos and K. K. G. Lan

A Comparison of Several Tests for Censored Paired Data 193
R. F. Woolson and T. W. O'Gorman

A Note on the Effect of the Intraclass Correlation in the Multiple Reading Procedure with a Unanimity Rule 209
K.-J. Lui

A Semi-Bayes Approach to the Analysis of Correlated Multiple Associations, with an Application to an Occupational Cancer-mortality Study 219
S. Greenland

Stochastic Progression of New States in Psychotherapy 231
A. F. Badalamenti, R. J. Langs and M. Kessler

A Random Coefficient Growth Curve Analysis of Mental Development in Low-birth-weight Infants 243
R. L. Carter, M. B. Resnick, M. Ariet, G. Shieh and E. F. Vonesh

Model-based Screening by Risk with Application to Down's Syndrome 257
P. Royston and S. G. Thompson

LETTERS TO THE EDITOR 269

BOOK REVIEWS 277
P. Forrest, Breast Cancer: The Decision to Screen. *L. Tomatis (ed.)*, Cancer: Causes, Occurrence and Control. *P. Leaverton*, A Review of Biostatistics: A Program for Self-instruction

Volume 11, *Issue No.* 3, 15 February 1992

Differential Influence of Prognostic Factors on the Occurrence of Metastases at Various Anatomical Sites in Human Breast Cancer 281
K. Zedeler, N. Keiding and G. Kamby

Predicting the Prevalence of a Disease in a Cohort at Risk 295
M. Mackisack, A. J. Dobson and C. R. Heathcote

Cluster Randomization in Large Public Health Trials: The Importance of Antecedent Data 307
S. W. Duffy, M. C. South and N. E. Day

How Many Raters? Toward the Most Reliable Diagnositc Consensus 317
H. C. Kraemer

Which Measures of Skewness and Kurtosis are Best? 333
P. Royston

Directory of Registries of Clinical Trials 345
P. J. Easterbrook

CORRECTION 425

Volume 11, *Issue No.* 4, 28 February 1992

The Use of Subjective Rankings in Clinical Trials with an Application to Cardiovascular Disease 427
D. Follmann, J. Wittes and J. A. Cutler

Comment 439
R. D. Gelber and A. Goldhirsch

Comment 443
T. M. Morgan and C. D. Furberg

Comment 447
P. C. O'Brien

Comment 451
R. D. Remington

Rejoinder 453
D. Follmann, J. Wittes and J. A. Cutler

Graphical Representation of Survival Curves Associated with a Binary Non-reversible Time Dependent Covariate 455
E. J. Feuer, B. F. Hankey, J. J. Gaynor, M. N. Wesley, S. G. Baker and J. S. Meyer

Cross-validation Performance of Mortality Prediction Models 475
D. C. Hadorn, D. Draper, W. H. Rogers, E. B. Keeler and R. H. Brook

On the Use of the Generalized *t* and Generalized Rank-sum Statistics in Medical Research 491
R. C. Blair and J. G. Morel

Comment 503
P. C. O'Brien

Rejoinder 507
R. C. Blair and J. G. Morel

Strengthening Some Common Multiple Test Procedures for Discrete Data 511
D. M. Rom

Using an Autoregressive Model to Detect Departures from Steady States in Unequally Spaced Tumour Biomarker Data 515
B. R. Schlain, P. T. Lavin and C. L. Hayden

Maximum Likelihood Estimation of Between and Within Variations in Energy and Protein Intakes from Infancy to Adolescence for the Philippines 533
A. Bhargava and H. Bouis

Optimum Sample Size Determination in Stratified Case-control Studies with Cost Considerations 547
J.-M. Nam and T. R. Fears

LETTERS TO THE EDITOR 557

BOOK REVIEWS 561

Henry T. Lynch and Petre Tautu (eds.), Recent Progress in the Genetic Epidemiology of Cancer. *M. M. Desu and D. Raghavarao*, Sample Size Methodology. *Andrew Monk*, Exploring Statistics with Minitab. A Workbook for the Behavioural Sciences

Volume 11, *Issue No.* 5, March 1992

Estimating Transmission Probabilities for Chlamydial Infection 565
B. P. Katz

Analysis of the Incubation Period for Measles in the Epidemic in Greenland in 1951 Using a Variance Components Model 579
D. Kronborg, B. Hansen and P. Aaby

Effects of Different Parametric Estimates of Seroconversion Time on Analysis of Progression to AIDS among Italian HIV-positive Haemophiliacs 591
F. Chiarotti, M. Palombi, N. Schinaia, A. Ghirardini and L. Prospero

Adjustments to the Mantel–Haenszel Test for Data from Stratified Multistage Surveys 603
D. R. Weerasekera and S. Bennett

A Note on the Presentation of Matched Case-control Data 617
P. Sasieni

Application of Empirical Bayes Inference to Estimation of Rate of Change in the Presence of Informative Right Censoring 621
M. Mori, G. G. Woodworth and R. F. Woolson

Sample Size Requirement for Repeated Measurements in Continuous Data 633
K.-J. Lui and W. G. Cumberland

Closed-form Estimates for Missing Counts in Two-way Contingency Tables 643
S. G. Baker, W. F. Rosenberger and R. Dersimonian

Monitoring Clinical Trials with a Conditional Probability Stopping Rule 659
S. M. Snapinn

A Decision-theoretic Evaluation of Early Stopping Rules 673
D. F. Heitjan, P. S. Houts and H. A. Harvey

Mathematical Models of Complex Dose–response Relationships: Implications for Experimental Design in Psychopharmacologic Research 685
S. V. Faraone, J. C. Simpson and W. A. Brown

On Identifying a Positive Dose-response Surface for Combination Agents 703
H. M. J. Hung

Volume 11, *Issue No.* 6, April 1992

Editors' Note 713

Is the 'Simple Carry-over' Model Useful? 715
S. J. Senn

Regression Toward the Mean in 2 × 2 Crossover Designs with Baseline Measurements 727
J. M. Grender, W. D. Johnson and R. C. Elston

Sample Size Requirements for Stratified Cluster Randomization Designs 743
A. Donner

Estimating the Number of Clusters for the Analysis of Correlated Binary Response Variables from Unbalanced Data 751
M. M. Shoukri and S. W. Martin

Clustering in Sparse Data and an Analysis of Rhabdomyosarcoma Incidence 761
R. C. Grimson, T. E. Aldrich and J. W. Drane

Designs and Analysis of Two-stage Studies 769
L. P. Zhao and S. Lipsitz

Analysing the Relationship Between Change in a Risk Factor and Risk of Disease 783
K. C. Cain, R. A. Kronmal and A. S. Kosinski

Pre-natal Blood Lead Levels and Learning Difficulties in Children: an Analysis of Non-randomly Missing Categorical Data 799
M. R. Conaway, C. Waternaux, E. Allred, D. Bellinger and A. Leviton

Applications of Crude Incidence Curves 813
E. L. Korn and F. J. Dorey

Estimating the Stage-specific Numbers of HIV Infection Using a Markov Model and Back-calculation 831
I. M. Longini, Jr, R. H. Byers, N. A. Hessol and W. Y. Tan

LETTERS TO THE EDITOR 845

BOOK REVIEWS 849
Jørn Olsen, Franco Merletti, David Snashall and Karel Vuylsteek, Searching for Causes of Work-related Diseases. An Introduction to Epidemiology at the Work Site.
Anders Ahlbom and Staffan Norell, Introduction to Modern Epidemiology

Contents of Volume 11, Issues 1–6 v

Volume 11, *Issue No.* 7, May 1992

Editorial 851

Planned versus Attained Design in Phase II Clinical Trials 853
S. J. Green and S. Dahlberg

k-ratio *t* Tests for Multiple Comparisons Involving Several Treatments and a Control 863
L. J. Brant, D. B. Duncan and D. O. Dixon

A Comment on Replication, *P*-values and Evidence 875
S. N. Goodman

Estimation of Direct Formulation Effect under Log-normal Distribution in Bioavailability/bioequivalence Studies 881
J.-P. Liu and C.-S. Weng

Estimation, Reference Ranges and Goodness of Fit for the Three-parameter Log-normal Distribution 897
P. Royston

Exact Unconditional Tables for Significance Testing in the 2×2 Multinomial Trial 913
J. J. Shuster

On the Computation of Likelihood Ratio and Score Test Based Confidence Intervals in Generalized Linear Models 923
J. M. Alho

Parametric versus Non-parametric Methods for Estimating Cure Rates Based on Censored Survival Data 931
A. B. Cantor and J. J. Shuster

Estimation of Time Since Exposure for a Prevalent Cohort 939
A. Muñoz, V. Carey, J. M. G. Taylor, J. S. Chmiel, L. Kingsley, M. Van Raden and D. R. Hoover

Bias in Relative Odds Estimation Owing to Imprecise Measurement of Correlated Exposures 953
A. N. Phillips and G. Davey Smith

Analysis of Premature Ventricular Counts in Long Term ECG Following Myocardial Infarction 963
A. Laor and A. Cohen

LETTERS TO THE EDITOR 975

BOOK REVIEWS 979
Alexander von Eye (ed.), Statistical Methods in Longitudinal Research, Vol. 1: Principles and Structuring Change, Vol. 2: Time Series and Categorical Longitudinal Data. *Alexander M. Walker*, Observation and Inference: an Introduction to the Methods of Epidemiology. *T. J. Hastie and R. J. Tibshirani*, Generalized Additive Models

Volume 11, *Issue No.* 8, 15 June 1992

Empirical Bayes Versus Fully Bayesian Analysis of Geographical Variation in Disease Risk 983
L. Bernardinelli and C. Montomoli

Assessing Response Bias in Random-digit Dialling Surveys: the Telephone-prefix Method 1009
P. Diehr, T. D. Koepsell, A. Cheadle and B. M. Psaty

Discriminant Analysis when all Variables are Ordered 1023
B. Johnston and S. S. Seshia

Analysis of Variance for Repeated Measures Data: a Generalized Estimating Equations Approach 1033
G. J. Carr and E. M. Chi

Analysis Strategies for Serial Multivariate Ultrasonographic Data that are Incomplete 1041
M. A. Espeland, R. P. Byington, D. Hire, V. G. Davis, T. Hartwell and J. Probstfield

Comparisons Between a New Drug and Active and Placebo Controls in an Efficacy Clinical Trial 1057
C. W. Dunnett and A. C. Tamhane

A Method of Designing Clinical Trials for Combination Drugs 1065
J. G. Pigeon, M. D. Copenhaver and J. P. Whipple

Organization and Analysis of Safety Data Using a Multivariate Approach 1075
C. Chuang-Stein, N. R. Mohberg and D. M. Musselman

Comparing Sample Size Formulae for Trials with Unbalanced Allocation Using the Logrank Test 1091
F. Y. Hsieh

Sixteen *S*-squared over *D*-squared: a Relation for Crude Sample Size Estimates 1099
R. Lehr

Sample Sizes for Proportional Hazards Survival Studies with Arbitrary Patient Entry and Loss to Follow-up Distributions 1103
N. A. Yateman and A. M. Skene

The Use of Cusums and Other Techniques in Modelling Continuous Covariates in Logistic Regression 1115
P. Royston

Volume 11, *Issue No.* 9, 30 June 1992

Morphology of the Normal Visual Field in a Population-based Random Sample: Principal Components Analysis 1131
N. Oden

Some Large-sample Distribution-free Estimators and Tests for Multivariate Partially Incomplete Data from Two Populations 1151
J. M. Lachin

A Model for Estimating Level and Net Severity of Spinal Cord Injuries 1171
T. R. Holford and M. B. Bracken

Childhood Blood Pressure Tracking Correlations Corrected for Within-person Variability 1187
M. W. Gillman, N. R. Cook, B. Rosner, L. A. Beckett, D. A. Evans, M. E. Keough, J. O. Taylor and C. H. Hennekens

Using Follow-up Data to Avoid Omitted Variable Bias: An Application to Cardiovascular Epidemiology 1195
J. Rehm, G. Arminger and L. Kohlmeier

Divergent Biases in Ecologic and Individual-level Studies 1209
S. Greenland

Digit Preference in Estimated Gestational Age 1225
R. M. Pickering

Power and Sample Size Evaluation for the McNemar Test with Application to Matched Case-control Studies 1239
J. M. Lachin

Using the Virus Challenge Dose in the Analysis of Virus Neutralization Assays 1253
R. A. Parker and M. A. Pallansch

LETTERS TO THE EDITOR 1263

BOOK REVIEWS 1267

Walter W. Holland and Susie Stewart, Screening in Health Care. Benefit or Bane? *Mitchell B. Max, Russell K. Portnoy and Eugene M. Laska (eds.)*, The Design of Analgesic Clinical Trials. *L. Hothorn (ed.)*, Statistical Methods in Toxicology

Volume 11, *Issue No.* 10, July 1992

Editorial Note 1271
L. S. Freedman

Collinearity Diagnosis for a Relative Risk Regression Analysis: an Application to Assessment of Diet–cancer Relationship in Epidemiological Studies 1273
Y. Wax

The Area Between Curves (ABC)—Measure in Nutritional Anthropometry 1289
D. Böhning, A. Hempfling, F.-P. Schelp and P. Schlattmann

Smoothing Reference Centile Curves: the LMS Method and Penalized Likelihood 1305
T. J. Cole and P. J. Green

Comparing In-patient Classification Systems: a Problem of Non-nested Regression Models 1321
A. R. Willan, W. Ross and T. A. MacKenzie

A Retrospective Assessment of the 75/75 Rule in Bioequivalence 1333
T. W. Dobbins and B. Thiyagarajan

Optimal Checking Procedures for Monitoring Laboratory Analyses 1343
L. M. McShane and B. W. Turnbull

Withdrawal Censoring and the Sequential Logrank Procedure 1359
D. Richardson

Creation of a Semiannual Report for a Multicentre Co-operative Clinical Trials Group 1367
P. J. Goodman, J. J. Crowley and C. Benson

Bayesian Methods for Phase I Clinical Trials 1377
C. Gatsonis and J. B. Greenhouse

Sample Size Determination for Group Sequential Trials with Immediate Response 1391
K. Kim and D. L. Demets

CORRECTION 1401

LETTER TO THE EDITOR 1403

BOOK REVIEW 1405
David Magnusson and Lars R. Bergman (eds.), Data Quality in Longitudinal Research

ANNOUNCEMENT 1407

Volume 11, *Issue No.* 11, August 1992

The Changing Geographical Coherence of Measles Morbidity in the United States, 1962–88 1409
A. D. Cliff, P. Haggett, D. F. Stroup and E. Cheney

Short and Medium Term Projections of the AIDS/HIV Epidemic by a Dynamic Model with an Application to the Risk Group of Homo/bisexual Men in Amsterdam 1425
S. H. Heisterkamp, B. J. de Haan, J. C. Jager, J. A. M. van Druten and J. C. M. Hendriks

Analysis of Disease Risks Using Ancillary Risk Factors, with Application to Job–Exposure Matrices 1443
W. R. Gilks and S. Richardson

Methods for Comparing Cumulative Hazard Functions in a Semi-proportional Hazard Model 1465
D. M. Dabrowska, K. A. Doksum, N. J. Feduska, R. Husing and P. Neville

Study Duration for Group Sequential Clinical Trials with Censored Survival Data Adjusting for Stratification 1477
K. Kim

Evaluations of Methods for Statistical Surveillance 1489
M. Frisén

Sensitivity and Specificity for Correlated Observations 1503
P. J. Smith and A. Hadgu

A Goodness-of-fit Approach to Inference Procedures for the Kappa Statistic: Confidence Interval Construction, Significance-testing and Sample Size Estimation 1511
A. Donner and M. Eliasziw

On the Sample Size for Studies Based Upon McNemar's Test 1521
P. A. Lachenbruch

LETTERS TO THE EDITOR 1527

Contents of Volume 11, Issues 7–11 v

Volume 11, *Issue No.* 12, 15 September 1992

Using Mark–recapture Methodology to Estimate the Size of a Population at Risk for Sexually Transmitted Diseases 1533
G. Rubin, D. Umbach, S.-F. Shyu and C. Castillo-Chavez

Analysis of Aberrations in Public Health Surveillance Data: Estimating Variances on Correlated Samples 1551
K. Kafadar and D. F. Stroup

Effects of Mid-point Imputation on the Analysis of Doubly Censored Data 1569
C. G. Law and R. Brookmeyer

Calculating the Prevalence of Cancer 1579
A. J. Coldman, M. L. McBride and T. Braun

Estimating Prevalence by Group Testing Using Generalized Linear Models 1591
C. P. Farrington

Estimation of a Common Risk Ratio in Stratified Case-cohort Studies 1599
T. Sato

Correlated Binomial Variates: Properties of Estimator of Intraclass Correlation and its Effect on Sample Size Calculation 1607
Z. Feng and J. E. Grizzle

A Note on Last Case Influence Using the Partial Likelihood Approach Under Heavy Censoring 1615
P. Oman

CORRECTIONS 1619

LETTERS TO THE EDITOR 1621

BOOK REVIEWS 1627

United States General Accounting Office, Cross Design Synthesis: A New Strategy for Medical Effectiveness Research. *Eugene K. Harris and Adelin Albert*, Survivorship Analysis for Clinical Studies. *Susan Shott*, Statistics for Health Professionals

ANNOUNCEMENTS 1631

Volume 11, *Issue No.* 13, 30 September 1992

Estimating HIV Prevalence and Projecting AIDS Incidence in the United States: A Model that Accounts for Therapy and Changes in the Surveillance Definition of AIDS 1633
P. S. Rosenberg, M. H. Gail and R. J. Carroll

The Epidemic Dynamics of HIV-1 in Italy: Modelling the Interaction between Intravenous Drug Users and Heterosexual Population 1657
M. Arcà, C. A. Perucci and T. Spadea

Repeated Measures in Clinical Trials: Analysis Using Mean Summary Statistics and its Implications for Design 1685
L. Frison and S. J. Pocock

Analysis of a Clinical Trial Involving a Combined Mortality and Adherence Dependent Interval Censored Endpoint 1705
L. A. Moyé, B. R. Davis and C. M. Hawkins

Impact of Measurement Error and Temporal Variability on the Estimation of Event Probabilities for Risk Factor Intervention Trials 1719
J. D. Neaton and G. E. Bartsch

Prediction of Short-term Survival with an Application in Primary Biliary Cirrhosis 1731
M. D. Hughes, C. L. Raskino, S. J. Pocock, M. R. Biagini and A. K. Burroughs

The Concept of Residual Confounding in Regression Models and Some Applications 1747
H. Becher

Control Sample Size when Cases are Given in Constant Ratio Stratum-matched Case-control Studies 1759
J.-M. Nam and T. R. Fears

Comparison of the Proportions of Affected Relatives of Cases and Controls: Analysis and Minimum Sample Size Formula 1767
D. Commenges and L. Letenneur

Bioequivalence Revisited 1777
L. B. Sheiner

LETTER TO THE EDITOR 1789

BOOK REVIEWS 1791

Alan Agresti, Categorical Data Analysis. *Thomas R. Fleming and David P. Harrington*, Counting Processes and Survival Analysis. *Paul W. Strike*, Statistical Methods in Laboratory Medicine

Volume 11, *Issue No.* 14/15, October–November 1992

Papers from the Symposium on Longitudinal Data Analysis, 19–21 June 1991

Guest Editors: R. B. D'Agostino, N. Lange, L. M. Ryan and M. R. Selwyn

Sponsored by the Biopharmaceutical Section of the American Statistical Association, Fort Lauderdale, Florida, U.S.A.

Introduction to Symposium 1797
M. R. Selwyn

List of Speakers and Discussants 1799

Overview 1801
R. B. D'Agostino, N. Lange and L. Ryan

KEYNOTE ADDRESS

Computational Aspects of Analysing Random Effects/longitudinal Models 1809
D. B. Rubin

TUTORIAL

An Overview of Methods for the Analysis of Longitudinal Data 1825
S. L. Zeger and K.-Y. Liang

SESSION 1: CLINICAL TRIALS, SURVIVAL ANALYSIS

Evaluation of Alternative Statistical Methods for Linear Model Analysis to Compare Two Treatments for 24-hour Blood Pressure Response 1843
E. A. Turney, I. A. Amara, G. G. Koch and W. H. Stewart

Methods for the Analysis of Informatively Censored Longitudinal Data 1861
M. D. Schluchter

The Accelerated Failure Time Model: A Useful Alternative to the Cox Regression Model in Survival Analysis 1871
L. J. Wei

Discussion of Session 1: Clinical Trials, Survival Analysis 1881
L. D. Fisher

SESSION 2: INCOMPLETE, MULTIVARIATE, NON-LINEAR

Intentionally Incomplete Longitudinal Designs: I. Methodology and Comparison of some Full Span Designs 1889
R. W. Helms

Multivariate Methods for Binary Longitudinal Data with Heterogeneous Correlation over Time 1915
B. Rosner

Non-linear Models for the Analysis of Longitudinal Data 1929
E. F. Vonesh

Discussion of Papers of Session 2: Incomplete, Multivariate, Non-linear 1955
R. B. D'Agostino

SESSION 3: BAYES/EMPIRICAL BAYES

An Analysis of Two-period Crossover Designs with Carry-over Effects 1967
N. M. Laird, J. Skinner and M. Kenward

Random Effects Models with Non-parametric Priors 1981
S. M. Butler and T. A. Louis

Graphs and Stochastic Relaxation for Hierarchical Bayes Modelling 2001
N. Lange

Discussion of Papers in Session 3: Bayes/empirical Bayes 2017
A. L. Gould

POSTER SESSION ABSTRACTS

Poster Abstracts 2027

Volume 11, *Issue No* 16, December 1992

Papers from the International Meetings of the International Society for Clinical Biostatistics

Preface 2041

Statistical Handling of Drop-outs in Longitudinal Clinical Trials 2043
A. Heyting, J. T. B. M. Tolboom and J. G. A. Essers

Using Toxicity Grades in the Design and Analysis of Cancer Phase I Clinical Trials 2063
N. H. Gordon and J. K. V. Willson

Importance of Trends in the Interpretation of an Overall Odds Ratio in the Meta-analysis of Clinical Trials 2077
R. Brand and H. Kragt

Comparison of Adjusted Attributable Risk Estimators 2083
O. Gefeller

A Bootstrap Resampling Procedure for Model Building: Application to the Cox Regression Model 2093
W. Sauerbrei and M. Schumacher

A Latent Class Model for Repeated Measurements Experiments 2111
A. M. Skene and S. A. White

Analysis of Factors Influencing the Efficacy of Pooled Platelet Transfusions 2123
J. P. Matthews and K. Yuen

Identification of Pulses in Hormone Time Series using Outlier Detection Methods 2133
G. Thomas, G. Plu and J.-C. Thalabard

24-hour Blood Pressure Measurement in Antihypertensive Drug Trials: Data Requirements and Methods of Analysis 2147
D. Dickson and J. Hasford

Acknowledgement 2159

Author Index 2161

Subject Index 2165

Contents of Volume 11, Issues 12–16 v

Volume 12, Issue Nos. 1–24

Volume 12, *Issue No.* 1, 15 January 1993

Editors' Note 1

Direct Standardization of Incidence Rates in the Presence of Incomplete Data 3
S. S. Emerson and J. C. Emerson

A New Sequential Procedure for Surveillance of Down's Syndrome 13
R. T. Lie, I. Heuch and L. M. Irgens

A Refinement to the Analysis of Serial Data using Summary Measures 27
J. N. S. Matthews

Establishing a National *In Vitro* Fertilization Registry: Methodological Problems and Analysis of Success Rates 39
J. de Mouzon, A. Bachelot and M. Spira

The Succession Procedure for Interim Analysis: Extensions for Early Acceptance of H_0 and for Flexible Times of Analysis 51
B. Falissard and J. Lellouch

Analysis of Crossover Designs with Multivariate Response 69
J. M. Grender and W. D. Johnson

LETTERS TO THE EDITOR 91

BOOK REVIEWS 97
Thomas H. Hassard, Understanding Biostatistics. *William D. Kelley, Thomas A. Ratliff, Jr. and Charles Nenadic,* Basic Statistics for Laboratories. A Primer for Laboratory Workers

Volume 12, *Issue No.* 2, 30 January 1993

Editorial 99

Covariate Imbalance and Conditional Size: Dependence on Model-based Adjustments 101
S. E. Maxwell

A Comprehensive Algorithm for Determining whether a Run-in Strategy will be a Cost-effective Design Modification in a Randomized Clinical Trial 111
K. B. Schechtman and M. E. Gordon

Harmonic Regression Analysis of the Effect of Drug Treatment on the Diurnal Rhythm of Blood Pressure and Angina 129
M. Gaffney, C. Taylor and E. Cusenza

On the Efficacy of the Rank Transformation in Stepwise Logistic and Discriminant Analysis 143
T. W. O'Gorman and R. F. Woolson

A Method to Test for a Recent Increase in HIV-1 Seroconversion Incidence: Results from the Multicenter AIDS Cohort Study (MACS) 153
S. Y. J. Zhou, L. A. Kingsley, J. M. G. Taylor, J. S. Chmiel, D. Y. He, D. R. Hoover and the Multicenter AIDS Cohort Study

The Design of Observer Agreement Studies with Binary Assessments 165
L. S. Freedman, M. K. B. Parmar and S. G. Baker

A Pocket-calculator Algorithm for the Shapiro–Francia Test for Non-normality: an Application to Medicine 181
P. Royston

LETTER TO THE EDITOR 185

BOOK REVIEWS 187
David L. Sackett, R. Brian Haynes, Gordon H. Guyatt and Peter Tugwell, Clinical Epidemiology a Basic Science for Clinical Medicine (2nd Edition). *B. S. Everitt*, The Analysis of Contingency Tables (2nd Edition)

Volume 12, *Issue No.* 3/4, February 1993

Papers from the Symposium on Statistical Methods for Evaluation of Intervention and Prevention Strategies, December 1990
Guest Editor: Gladys H. Reynolds

Editorial 191

List of Symposium Staff 193

OVERVIEWS

Evaluation: The Alpha and Omega of Intervention and Prevention Strategies 197
D. R. Hopkins

The Role of NCHS Data Systems in the Evaluation of Intervention and Prevention Strategies 207
M. Feinleib

STATISTICAL AND MATHEMATICAL MODELLING

An Evaluation of Sexual Behaviour Change using Statistical and Cognitive Models 219
D. J. Schnell, C. Galavotti, K. R. O'Reilly and the AIDS Community Demonstration Projects

Analysis of a Measles Epidemic 229
L. J. Allen, T. Lewis, C. F. Martin, M. A. Jones, C. K. Lo, M. Stamp, G. Mundel and A. B. Way

A Bivariate Survival Model with Modified Gamma Frailty for Assessing the Impact of Interventions 241
J. T. Wassell and M. L. Moeschberger

Measuring Vaccine Efficacy from Epidemics of Acute Infectious Agents 249
I. M. Longini, Jr., M. E. Halloran, M. Haber and R. T. Chen

Using Autoregressive and Random Walk Models to Detect Trends and Shifts in Unequally Spaced Tumour Biomarker Data 265
B. R. Schlain, P. T. Lavin and C. L. Hayden

ANALYTIC METHODS

Improved Imputation of Non-responses to Mailback Questionnaires 283
J. Wanzer Drane, C. Stoskopf and D. Richter

Statistical Methods for Preventive Trials in Mental Health 289
C. Hendricks Brown

Evaluation of Protocol Change in Burn-care Management using the Cox Proportional Hazards Model with Time-dependent Covariates 301
J. M. Ichida, J. T. Wassell, M. D. Keller and L. W. Ayers

An Analysis of AIDS Incidence Data by Clustering Trends 311
K. Kafadar and J. M. Karon

STUDY DESIGN

The Effect of Matching on the Power of Randomized Community Intervention Studies 329
D. C. Martin, P. Diehr, E. B. Perrin and T. D. Koepsell

Design and Analysis of Studies to Reduce the Incidence of Colon Polyps 339
S. S. Emerson, D. L. McGee, B. Fennerty, L. Hixson, H. Garewal and D. Alberts

INNOVATIVE METHODS

Evaluating the Effects of Tubal Sterilization on Menstrual Function: Selected Issues in Data Analysis 355
B. Martinez-Schnell, L. S. Wilcox, H. B. Peterson, P. M. Jamison and J. M. Hughes

Refusal Assertion Versus Conversational Skill Role-play Competence: Relevance to Prevention of Tobacco Use 365
S. Sussman, A. W. Stacy, C. W. Dent, C. Burciaga, D. Burton and B. R. Flay

Birth-weight-adjusted Infant Mortality in Evaluations of Perinatal Care: Towards a Useful Summary Measure 377
J. L. Kiely and J. C. Kleinman

Methods for Analysing County-level Mortality Rates 393
J. M. Stevenson and D. R. Olson

Longitudinal Height Velocity Standards for U.S. Adolescents 403
C. S. Berkey, D. W. Dockery, X. Wang, D. Wypij and B. Ferris, Jr.

Volume 12, *Issue No.* 5/6, March 1993

Proceedings of 'Practical Issues in Data Monitoring of Clinical Trials', Bethesda, Maryland, U.S.A., 27–28 January 1992

Guest Editors: Susan Ellenberg, Nancy Geller, Richard Simon and Salim Yusuf

Workshop Sponsored by The National Institute of Allergy and Infectious Diseases
The National Heart, Lung and Blood Institute
The National Cancer Institute

Preface 415

Opening Remarks 417

Behind Closed Doors: The Data Monitoring Board in Randomized Clinical Trials 419
J. Wittes

The NHLBI Model: A 25 Year History 425
L. Friedman

Discussion 433

A Survey of Monitoring Practices in Cancer Clinical Trials 435
S. L. George

Data Monitoring Committees for Southwest Oncology Group Clinical Trials 451
S. Green and J. Crowley

Discussion 457

The Use of External Monitoring Committees in Clinical Trials of the National Institute of Allergy and Infectious Diseases 461
S. S. Ellenberg, M. W. Myers, W. C. Blackwelder and D. F. Hoth

Discussion 469

Data Monitoring and Interim Analyses in the Pharmaceutical Industry: Ethical and Logistical Considerations 471
F. W. Rockhold and G. G. Enas

Monitoring of Clinical Trials and Interim Analyses from a Drug Sponsor's Point of View 481
G. W. Williams, R. L. Davis, A. J. Getson, A. L. Gould, I. K. Hwang, H. Matthews, W. J. Shih, S. M. Snapinn and K. L. Walton-Bowen

Discussion 493

Monitoring Clinical Trials: Experience of, and Proposals under Consideration by, the Cancer Therapy Committee of the British Medical Research Council 497
M. K. B. Parmar and D. Machin

The Use of Data Monitoring Committees in Canadian Trial Groups 505
J. L. Pater

Interim Analyses, Stopping Rules and Data Monitoring in Clinical Trials in Europe 509
M. Buyse

Discussion 521

Panel Discussion; The Operation of Data Monitoring Committees 527

Practical Issues in Data Monitoring of Clinical Trials: Summary of Responses to a Questionnaire at NIH 543
N. L. Geller and M. Stylianou

Discussion 553

Data Monitoring Boards in the Pharmaceutical Industry 555
J. Herson

Discussion 563

Data Monitoring Committees and Capturing Relevant Information of High Quality 565
T. R. Fleming

Discussion 571

Data Monitoring Committees: The Moral Case for Maximum Feasible Independence 575
L. Walters

Discussion 581

Panel Discussion: Scientific Issues in Data Monitoring 583

Some FDA Perspectives on Data Monitoring in Clinical Trials in Drug Development 601
R. T. O'Neill

Discussion 609

Closing Remarks 615

Volume 12, *Issue No.* 7, 15 April 1993

Use of Backcalculation for Estimation of the Probability of Progression from HIV Infection to AIDS 617
S. A. Marion and M. T. Schechter

Using Orthogonal Polynomial Scores in Summarizing and Evaluating Longitudinal Data Collected in Phase I and II Clinical Pharmacology Studies 633
T. E. Bradstreet

Two-stage Tests for Studying Monotherapy and Combination Therapy in Two-by-two Factorial Trials 645
H. M. J. Hung

Markov Chain Modelling of Bioassay Toxicity Procedures 661
G. Hadjinicola and L. Goldstein

P-values after Repeated Significance Testing: A Simple Approximation Method 675
Y. J. Lee and H. Quan

Confidence Limits Based on the First Occurrence of an Event 685
V. T. George and R. C. Elston

Sample Size and Power for Prospective Analysis of Relative Risk 691
W. C. Blackwelder

Exact Conditional and Unconditional Sample Size for Pair-matched Studies with Binary Outcome: A Practical Guide 699
P. Royston

BOOK REVIEWS 713

C. J. Williams (ed.), Introducing New Treatments for Cancer: Practical, Ethical and Legal Problems. *F. L. Bookstein,* Morphometric Tools for Landmark Data: Geometry and Biology

Volume 12, *Issue No.* 8, 30 April 1993

Methods for Epidemiologic Analyses of Multiple Exposures: A Review and Comparative Study of Maximum-likelihood, Preliminary-testing, and Empirical-Bayes Regression 717
S. Greenland

Kaplan–Meier, Marginal or Conditional Probability Curves in Summarizing Competing Risks Failure Time Data? 737
M. Sullivan Pepe and M. Mori

Sequential Monitoring of Clinical Trials: The Role of Information and Brownian Motion 753
K. K. G. Lan and D. M. Zucker

Conditioned Life Tables from Registries with Unidentified Random Losses 767
G. M. Tallis, P. Leppard and T. J. O'Neill

Power of Testing Proportions in Small Two-sample Studies when Sample Sizes are Equal 777
A. B. Davis

The Application of Developments in Theoretical Biostatistics to Epidemiologic Research 789
G. I. Obrams and M. Hjortland

Sir Austin Bradford Hill, 1897–1991 795

Contents of Volume 12, Issues 1–8 v

Volume 12, *Issue No.* 9, 15 May 1993

Confidence Intervals for a Binomial Proportion 809
S. E. Vollset

A Conditional Analysis for Two-treatment Multiple-period Crossover Designs with Binomial or Poisson Outcomes and Subjects who Drop Out 825
B. McKnight and S. K. van den Eeden

Evaluating the Role of CD4-lymphocyte Counts as Surrogate Endpoints in Human Immunodeficiency Virus Clinical Trials 835
D. Y. Lin, M. A. Fischl and D. A. Schoenfeld

Marker-dependent Hazard Estimation: an Application to AIDS 843
R. E. Fusaro, J. P. Nielsen and T. H. Scheike

Pitfalls Inherent in Retrospective Time-to-event Studies: the Example of Time to Pregnancy 867
C. R. Weinberg, D. D. Baird and A. S. Rowland

Generalized Logistic Models for Low-dose Response Data 881
M. Devidas, E. O. George and D. Zelterman

Time-period Effects in Longitudinal Studies Measuring Average Rates of Change 893
D. J. Roe and E. L. Korn

Volume 12, *Issue No.* 10, 30 May 1993

Stopping Guidelines for Clinical Trials with Multiple Treatments 901
M. D. Hughes

Construction of Age-related Reference Centiles using Absolute Residuals 917
D. G. Altman

Measurement Error in Dietary Assessment: An Investigation using Covariance Structure Models. Part I 925
M. Plummer and D. Clayton

Measurement Error in Dietary Assessment: An Investigation using Covariance Structure Models. Part II 937
M. Plummer and D. Clayton

Modelling Lactation using an Inverse Polynomial in a Multilevel Statistical Model 949
R. F. Drewett and H. Goldstein

A Modelling Approach to the Analysis of Menstrual Diary Data 955
D. Collett and N. Weerasooriya

Multivariate Analysis of Cholesterol Distribution for Monitoring the Risk of Coronary Heart Disease 967
D. F. Percy and T. J. Hine

Cox Regression Models for Quality Adjusted Survival Analysis 975
B. F. Cole, R. D. Gelber and A. Goldhirsch

LETTERS TO THE EDITOR 989

BOOK REVIEWS 991

Edward R. Tufte, Envisioning Information. *James H. Dwyer, Manning Feinleib, Peter Lippert and Hans Hoffmeister (eds.),* Statistical Models for Longitudinal Studies of Health

Volume 12, *Issue No.* 11, 15 June 1993

A Comparison of Different Matching Designs in Case-control Studies: an Empirical Example using Continuous Exposures, Continuous Confounders and Incidence of Myocardial Infarction 993
Y. Friedlander, D. L. Merom and J. D. Kark

Reducing Attrition Bias with an Instrumental Variable in a Regression Model: Results from a Panel of Rheumatoid Arthritis Patients 1005
J. P. Leigh, M. M. Ward and J. F. Fries

Robust Inference for Multivariate Survival Data 1019
M. R. Segal and J. M. Neuhaus

Tests for Qualitative Treatment-by-centre Interaction using a 'Pushback' Procedure 1033
J. L. Ciminera, J. F. Heyse, H. H. Nguyen and J. W. Tukey

Evaluation of Multicentre Clinical Trial Data using Adaptations of the Mosteller–Tukey Procedure 1047
J. L. Ciminera, J. F. Heyse, H. H. Nguyen and J. W. Tukey

Calculation of Power and Sample Size with Bounded Outcome Scores 1063
E. Lesaffre, I. Scheys, J. Frölich and E. Bluhmki

Sample Size Determinations using Logistic Regression with Pilot Data 1079
V. F. Flack and T. L. Eudey

LETTERS TO THE EDITOR 1085

BOOK REVIEW 1091

A. B. Miller, J. Chamberlain, N. E. Day, M. Hakama and P. C. Prorok (eds.), Cancer Screening

Volume 12, *Issue No.* 12, 30 June 1993

The Continual Reassessment Method in Cancer Phase 1 Clinical Trials: a Simulation Study 1093
S. Chevret

On Population and Individual Bioequivalence 1109
R. Schall and H. G. Luus

A Note on the Application of Simple Linear Regression Methods for Trend Detection at Multiple Sites and Visits 1125
K.-J. Lui and D. Steffey

A Bayesian Approach to Logistic Regression Models Having Measurement Error Following a Mixture Distribution 1141
C. H. Schmid and B. Rosner

Use of the Gibbs Sampler to Estimate Transition Rates Between Grades of Coronary Disease Following Cardiac Transplantation 1155
L. D. Sharples

An Index of Disease Activity in Rheumatoid Arthritis 1171
P. W. Jones, M. F. M. Ziade, M. J. Davis and P. T. Dawes

VIDEO REVIEW 1183
D. R. Appleton (producer), Designing a Clinical Trial

Volume 12, *Issue No.* 13, 15 July 1993

Analysis As-randomized and the Problem of Non-adherence: an Example from the Veterans Affairs Randomized Trial of Coronary Artery Bypass Surgery 1185
P. Peduzzi, J. Wittes, K. Detre and T. Holford

A Bayesian Strategy for Screening Cancer Treatments Prior to Phase II Clinical Evaluation 1197
P. F. Thall and E. H. Estey

Methods for Assessing Difference between Groups in Change when Initial Measurement is Subject to Intra-individual Variation 1213
L. E. Chambless and J. R. Roeback

A Comparison of the Power of Two Tests for Qualitative Interactions 1239
S. Piantadosi and M. H. Gail

Applications of Extraction Mapping in Environmental Epidemiology 1249
A. B. Lawson and F. L. R. Williams

Design Effects for Binary Regression Models Fitted to Dependent Data 1259
J. M. Neuhaus and M. R. Segal

CORRECTION 1269

BOOK REVIEWS 1271

Jonathon J. Shuster, Practical Handbook of Sample Size Guidelines for Clinical Trials. *F. Dunstan and J. Pickles* (eds.), Statistics in Medicine. *Walter W. Holland, Roger Detels and George Knox* (eds.), Oxford Textbook of Public Health

Volume 12, *Issue No.* 14, 30 July 1993

Visual and Statistical Assessment of Spatial Clustering in Mapped Data 1275
S. D. Walter

Combining Independent Studies of a Diagnostic Test into a Summary ROC Curve: Data-analytic Approaches and Some Additional Considerations 1293
L. E. Moses, D. Shapiro and B. Littenberg

An Empirical Bayes Approach to the Estimation of the Incidence Curve of HIV Infection 1317
D. Commenges and B. Etcheverry

Influence of Model-building Strategies on the Results of a Case-control Study 1325
M. Blettner and W. Sauerbrei

Comparison of Methods for the Analysis of Longitudinal Interval Count Data 1339
T. A. Stukel

How to Establish Equivalence when Data are Censored: a Randomized Trial of Treatments for B Non-Hodgkin Lymphoma 1353
C. Com-Nougue, C. Rodary and C. Patte

The Use of Simulation in the Design of Two Cardiovascular Survival Studies 1365
N. A. Yateman and A. M. Skene

Volume 12, *Issue No.* 15/16, August 1993

Papers from the Conference on Methodological and Ethical Issues in Clinical Trials, 27–28 June 1991
Guest Editor: Deborah Ashby

A Joint Meeting of the London School of Economics Centre for the Philosophy of the Natural and Social Sciences and the Medical Section of the Royal Statistical Society

Sponsored by The Mind Association, The Wellcome Trust, Ciba-Geigy AG, Economic and Social Research Council, and The Analysis Committee

Preface 1373

List of Participants, Speakers and Discussants 1375

A Case for Bayesianism in Clinical Trials 1377
D. A. Berry

Discussion 1395

The Case for Frequentism in Clinical Trials 1405
J. Whitehead

Discussion: The Case against Frequentism 1415

The Value of Randomization and Control in Clinical Trials 1421
P. Urbach

Discussion 1433

The Role of *P*-values in Analysing Trial Results 1443
P. R. Freeman

Discussion 1453

Statistical and Ethical Issues in Monitoring Clinical Trials 1459
S. J. Pocock

Discussion 1471

Clinical Trials and Causation: Bayesian Perspectives 1477
K. F. Schaffner

Discussion 1495

Applying Bayesian Ideas in Drug Development and Clinical Trials 1501
D. J. Spiegelhalter, L. S. Freedman and M. K. B. Parmar

Discussion 1513

Illusion and Reality in the Analysis of Clinical Trials 1519
P. Meier

Chairman's Discussion 1521

General Discussion 1523

Closing Remarks 1533

Contents of Volume 12, Issues 9–16 v

Volume 12, *Issue No.* 17, 15 September 1993

Verifying Keyed Medical Research Data 1535
B. A. Blumenstein

A Regression Model for the Rate of Success of *in vitro* Fertilization 1543
S. Baeten, A. Bouckaert, E. Loumaye and K. Thomas

A Model for Seasonal Changes in Time Series Regression Relationships: with an Application in Psychiatry 1555
P. S. Albert

Further Results on the Non-parametric Linear Regression Model in Survival Analysis 1569
O. O. Aalen

Multiple Imputation for Threshold-crossing Data with Interval Censoring 1589
F. J. Dorey, R. J. A. Little and N. Schenker

Estimating the Causal Effect of Smoking Cessation in the Presence of Confounding Factors using a Rank Preserving Structural Failure Time Model 1605
S. D. Mark and J. M. Robins

Incomplete Factorial Designs for Randomized Clinical Trials 1629
D. P. Byar, A. M. Herzberg and W.-Y. Tan

LETTERS TO THE EDITOR 1643

BOOK REVIEWS 1645

John P. Klein and Prem K. Goel (eds.), Survival Analysis State of the Art. *Social Affairs Unit*, Health, Lifestyle and Environment: Countering the Panic. *M. J. Rovine and A. von Eye*, Applied Computational Statistics in Longitudinal Research. *Bert Spilker*, Guide to Clinical Trials

ANNOUNCEMENT 1649

Volume 12, *Issue No.* 18, 30 September 1993

Reporting Bayesian Analyses of Clinical Trials 1651
M. D. Hughes

The Application of Large Gaussian Mixed Models to the Analysis of 24 Hour Ambulatory Blood Pressure Monitoring Data in Clinical Trials 1665
M. R. Selwyn and D. M. Difranco

Dispersion Tests and Adjustments for Survival and Case-control Studies 1683
P. J. Smith

A Strategy for Assembling Samples of Adult Twin Pairs in the United States 1693
J. Goldberg, W. G. Henderson, S. A. Eisen, W. True, V. Ramakrishnan, M. J. Lyons and M. T. Tsuang

Conditional Independence Models for Epidemiological Studies with Covariate Measurement Error 1703
S. Richardson and W. R. Gilks

A Comparison of the Generalized Estimating Equation Approach with the Maximum Likelihood Approach for Repeated Measurements 1723
T. Park

Risk Ratio and Rate Ratio Estimation in Case-cohort Designs: Hypertension and Cardiovascular Mortality 1733
E. G. Schouten, J. M. Dekker, F. J. Kok, S. Le Cessie, H. C. Van Houwelingen, J. Pool and J. P. Vandenbroucke

BOOK REVIEWS 1747

Robert B. Wallace and Robert F. Woolson (eds.), The Epidemiologic Study of the Elderly. *Keith H. Wallace and Ronald A. Thompson.* Immunointervention in Man. A Critique of Clinical Trial Methodology

Volume 12, *Issue No.* 19/20, October 1993

Papers from the Workshop on Statistics and Computing in Disease Clustering Port Jefferson, NY, U.S.A., 23–24 July 1992

Guest Editor: G. M. Jacquez
Guest Co-editors: R. C. Grimson, L. I. Kheifets, L. A. Waller and D. E. Wartenberg

Introduction 1751
G. M. Jacquez

ISSUES AND APPROACHES

Cluster Analysis: A Perspective 1755
L. I. Kheifets

Approaches to Disease Cluster Investigations in a State Health Department 1757
D. Smith and R. Neutra

Solving the Cluster Puzzle: Clues to Follow and Pitfalls to Avoid 1763
D. Wartenberg and M. Greenberg

STATISTICAL METHODS AND APPLICATIONS

Disease Clusters, Exact Distributions of Maxima, and *P*-values 1773
R. C. Grimson

Assessing Directional Effects in Spatial Data 1795
N. L. Oden

Analysing Post-alarm Data in a Monitoring System in Order to Accept or Reject the Alarm 1807
R. Chen, R. R. Connelly and N. Mantel

Properties of Tango's Index for Detecting Clustering in Time 1813
M. K. Rayens and R. J. Kryscio

Power of the Scan Statistic for Detection of Clustering 1829
S. Wallenstein, J. Naus and J. Glaz

Approximations for the Tail Probabilities and Moments of the Scan Statistic 1845
J. Glaz

Effect of Relative Risk and Cluster Configuration on the Power of the One-dimensional Scan Statistic 1853
S. K. Sahu, R. B. Bendel and C. P. Sison

GEOGRAPHICAL ANALYSIS AND MAPPING

The Effect of Scale on Tests for Disease Clustering 1869
L. A. Waller and B. W. Turnbull

Assessing Spatial Patterns in Disease Rates 1885
S. D. Walter

Disease Mapping using Empirical Bayes and Bayes Methods on Mortality Statistics in the Netherlands 1895
S. H. Heisterkamp, G. Doornbos and M. Gankema

Aggregation of Existing Geographic Regions to Diminish Spurious Variability of Disease Rates 1915
R. D. Morris and R. L. Munasinghe

Synthetic Cancer Variables and the Construction and Testing of Synthetic Risk Maps 1931
G. M. Jacquez and L. I. Kheifets

Mixture Models and Disease Mapping 1943
P. Schlattmann and D. Böhning

COMPUTER RESOURCES

Interfacing U.S. Census Map Files with Statistical Graphics Software: Application and Use in Epidemiology 1953
M. Rizzardi, M. S. Mohr, D. W. Merrill and S. Selvin

Computer Packages C. A. Man (Computer Assisted Mixture Analysis) and Dismap 1965
P. Schlattmann and D. Böhning

The Statistical Description of Disease Clusters 1967
G. M. Jacquez

Volume 12, *Issue No.* 21, 15 November 1993

Distribution-free Fitting of Logit Models with Random Effects for Repeated Categorical Responses 1969
A. Agresti

Controlling for a Confounder Monotonically Related to Exposure by Means of Isotonic Quantile Regression 1989
U. Strömberg

Two-stage Sampling in Pharmaceutical Applications 1999
J. Shao and S.-C. Chow

Sample Sizes for Event Rate Equivalence Trials using Prior Information 2009
A. L. Gould

An Algorithm for Robust Non-linear Analysis of Radioimmunoassays and Other Bioassays 2025
D. P. Normolle

Testing Concomitancy between Two Physiological Pulse Series 2043
M. C. K. Yang and P. V. Rao

BOOK REVIEWS 2057

John Whitehead, The Design and Analysis of Sequential Clinical Trials, 2nd edn. *Karl E. Peace (ed.)*, Biopharmaceutical Sequential Statistical Applications. *Shein-Chung Chow and Jen-Pei Liu*, Design and Analysis of Bioavailability and Bioequivalence Studies

Volume 12, *Issue No.* 22, 30 November 1993

Workshop on Extending Public Health Surveillance of HIV Disease
Guest Editors: S. M. Gore and V. T. Farewell

Editorial 2061

Extending Public Health Surveillance of HIV Infection: Information from a Five Cohort Workshop 2065

Markers as Time-dependent Covariates in Relative Risk Regression 2087

Marker Paths 2099

Markov Models 2127

REGULAR PAPER

Tracking of Markers and Onset of Disease among HIV-1 Seroconverters 2133
N. Galai, A. Muñoz, K. Chen, V. J. Carey, J. Chmiel and S. Y. J. Zhou

LETTERS TO THE EDITOR 2147

Volume 12, *Issue No.* 23, 15 December 1993

Trees and Tracking 2153
M. R. Segal and I. B. Tager

A Technique for Summarizing Longitudinal Data 2169
D. K. Hathaway and R. B. D'Agostino

Bayesian Analysis of Binary Data from an Audit of Cervical Smears 2179
G. M. Raab and R. A. Elton

How Reliable are Change-corrected Measures of Agreement? 2191
I. Guggenmoos-Holzmann

Estimating Kappa from Binocular Data and Comparing Marginal Probabilities 2207
H. J. A. Schouten

Use of Spending Functions for Occasional or Continuous Monitoring of Data in Clinical Trials 2219
K. K. G. Lan, W. F. Rosenberger and J. M. Lachin

Comparison of Two Tests Useful in Situations where Treatment is Expected to Increase Variability Relative to Controls 2233
R. C. Blair and S. Sawilowsky

Discussion 2245
P. C. O'Brien

LETTERS TO THE EDITOR 2247

BOOK REVIEWS 2251
Geoffrey Rose, The Strategy of Preventive Medicine. *Robert P. Hirsch and Richard K. Riegelman*, Statistical First Aid: Interpretation of Health Research Data

Volume 12, *Issue No.* 24, 30 December 1993

Papers from the International Society for Clinical Biostatistics Thirteenth International Meeting, August 1992

Preface 2253

ISCB Committee 2255

Sample Size Calculations for Ordered Categorical Data 2257
J. Whitehead

A Bivariate Approach to Meta-analysis 2273
H. C. Van Houwelingen, K. H. Zwinderman and T. Stijnen

Relative Risk, Risk Difference and Rate Difference Models for Sparse Stratified Data: A Pseudo Likelihood Approach 2285
T. Stijnen and H. C. Van Houwelingen

Cross-validation in Survival Analysis 2305
P. J. M. Verweij and H. C. Van Houwelingen

Plotting Summary Predictions in Multistate Survival Models: Probabilities of Relapse and Death in Remission for Bone Marrow Transplantation Patients 2315
J. P. Klein, N. Keiding and E. A. Copelan

Analysis of Case-crossover Designs 2333
R. J. Marshall and R. T. Jackson

Dynamic Balanced Randomization for Clinical Trials 2343
D. F. Signorini, O. Leung, R. J. Simes, E. Beller, V. J. Gebski and T. Callaghan

Comparison of the Cox Model and the Regression Tree Procedure in Analysing a Randomized Clinical Trial 2351
C. Schmoor, K. Ulm and M. Schumacher

Inherent Difficulties with Active Control Equivalence Studies 2367
S. Senn

The Relative Importance of Prognostic Factors in Studies of Survival 2377
M. Schemper

Alert Systems for Post-marketing Surveillance of Adverse Drug Reactions 2383
M. Praus, F. Schindel, R. Fescharek and S. Schwarz

Relationships between Incidence and Mortality in Non-reversible Diseases 2395
R. Capocaccia

Acknowledgement 2417

Author Index 2419

Subject Index 2423

Contents of Volume 12, Issues 17–24 v

Volume 13, Issue Nos. 1–24

Volume 13, *Issue No.* 1, 15 January 1994

Editorial Announcement 1

Statistics in Medicine: Citations of Papers in the First Ten Years 3
M. J. Campbell and S. A. Julious

A Comparative Study of Several Antibiotic Formulations using a Design Based on a Combination of Balanced Incomplete Blocks and Latin Squares 11
P. Prescott, J. Ryan and P. Shuttleworth

Estimating Age, Period and Cohort Effects using the Multistage Model for Cancer 23
T. R. Holford, Z. Zhang and L. A. McKay

On the Analysis of Life Tables for Dependent Observations 43
B. Eriksson and R. Adell

Network Analytic Methods for Epidemiological Risk Assessment 53
M. Altmann, B. C. Wee, K. Willard, D. Peterson and L. C. Gatewood

Cohort versus Cross-sectional Design in Large Field Trials: Precision, Sample Size, and a Unifying Model 61
H. A. Feldman and S. M. McKinlay

Sample Size Requirements for Stratified Prospective Studies with Null Hypothesis of Non-unity Relative Risk using the Score Test 79
J.-M. Nam

VOLUME CONTENTS 301

Selecting the Best Dose when a Monotonic Dose-response Relation Exists 87
E. Russek-Cohen and R. M. Simon

BOOK REVIEWS 97
J. Olsen and D. Trichopoulos (eds.), Teaching Epidemiology: What you Should Know and What you Could Do. *John C. Duffy (ed.)*, Alcohol and Illness: The Epidemiological Viewpoint

CORRECTIONS 99

Volume 13, *Issue No.* 2, 30 January 1994

Group Sequential Testing in Clinical Trials with Multivariate Observations: A Review 101
J. W. Lee

Estimating the Variations and Autocorrelations in Dietary Intakes on Weekdays and Weekends 113
A. Bhargava, R. Forthofer, S. McPherson and M. Nichaman

Estimating the Accuracy of Dietary Questionnaire Assessments: Validation in Terms of Structural Equation Models 127
R. Kaaks, E. Riboli, J. Estève, A. L. van Kappel and W. A. van Staveren

A Robust Goodness-of-fit Test Statistic with Application to Ordinal Regression Models 143
S. R. Lipsitz and J. F. Buoncristiani

Non-hierarchical Logistic Models and Case-only Designs for Assessing Susceptibility in Population-based Case-control Studies 153
W. W. Piegorsch, C. R. Weinberg and J. A. Taylor

Median Time from Seroconversion to AIDS in Italian HIV-positive Haemophiliacs: Different Parametric Estimates 163
F. Chiarotti, M. Palombi, N. Schinaia, A. Ghirardini and R. Bellocco

Estimation of the Number of People in a Register from the Number of Birthdates 177
S. O. Larsen

Designing an Optimal Experiment for Bayesian Estimation: Application to the Kinetics of Iodine Thyroid Uptake 185
Y. Merlé, F. Mentré, A. Mallet and A. H. Aurengo

LETTERS TO THE EDITOR 197

BOOK REVIEW 199
Michael C. Neale and Lon R. Cardon, Methodology for Genetic Studies of Twins and Families

Volume 13, *Issue No.* 3, 15 February 1994

Foundations of Medical Diagnosis: What Actually are the Parameters Involved in Bayes' Theorem? 201
O. S. Miettinen and J. J. Caro

Commentary 211
C. B. Begg

Rejoinder 213
O. S. Miettinen and J. J. Caro

Fisher's Game with the Devil 217
S. Senn

Estimation of Time Since Infection using Longitudinal Disease-marker Data 231
N. Dubin, S. Berman, M. Marmor, B. Tindall, D. Des Jarlais and M. Kim

Comparative Exposure Ratios: A Non-parametric, Multifactor Technique for Case-control Studies 245
M. Aickin, C. Ritenbaugh, E. Surwit and F. Meyskens, Jr.

A Geometric Approach to the Analysis of Physiological Flow Data 261
W. J. Shih

Analysis of the Wideband External Pulse: An Application of Graphical Methods 275
L. Denby, C. L. Mallows and S. G. Blank

LETTERS TO THE EDITOR 293

BOOK REVIEWS 297

Leslie E. Daly, Geoffrey J. Bourke and James McGilvray, Interpretation and Uses of Medical Statistics. *David A. Ratkowsky, Marc A. Evans and J. Richard Alldredge*, Cross-over Experiments. Design, Analysis and Application. *Stephen Senn*, Cross-over Trials in Clinical Research. *Bryan F. J. Manly*, The Design and Analysis of Research Studies

Volume 13, *Issue No.* 4, 28 February 1994

Practical Problems in Fitting a Proportional Hazards Model to Data with Updated Measurements of the Covariates 301
D. G. Altman and B. L. De Stavola

Application of Sample Survey Methods for Modelling Ratios to Incidence Densities 343
L. M. Lavange, L. L. Keyes, G. G. Koch and P. A. Margolis

Exposure Efficacy and Change in Contact Rates in Evaluating Prophylactic HIV Vaccines in the Field 357
M. E. Halloran, I. M. Longini, Jr., M. J. Haber, C. J. Struchiner and R. C. Brunet

Design and Analysis Considerations in a Cohort Study Involving Repeated Measurement of Both Exposure and Outcome: The Association between Genital Papillomavirus Infection and Risk of Cervical Intraepithelial Neoplasia 379
S. W. Duffy, T. E. Rohan and J. R. McLaughlin

Sample Size Determination for an Exponential Survival Model with an Unrestricted Covariate 391
B. Zhen and J. R. Murphy

Volume 13, *Issue No.* 5/6/7, 15 March–15 April 1994

National Institutes of Health Conference on Current Topics in Biostatistics
Bethesda, Maryland, U.S.A., 25–26 January 1992
Guest Editors: Jonas H. Ellenberg, Mitchell H. Gail and Richard M. Simon

Preface 399
J. H. Ellenberg, M. H. Gail and R. M. Simon

Introduction 401
S. W. Greenhouse

NIH and the Birth of Biostatistics 403
B. Healy

CLINICAL TRIALS

The Utility of Large, Simple Trials in the Evaluation of AIDS Treatment Strategies 405
S. S. Ellenberg and M. A. Foulkes

New Designs for the Selection of Treatments to be Tested in Randomized Clinical Trials 417
R. Simon, P. F. Thall and S. S. Ellenberg

A Multiple Decision Procedure in Clinical Trials 431
T. T. Chen and R. Simon

Discussion 447

REPEATED MEASURES

Time Series for Modelling Counts from a Relapsing–remitting Disease: Application to Modelling Disease Activity in Multiple Sclerosis 453
P. S. Albert, H. F. McFarland, M. E. Smith and J. A. Frank

Modelling Transitional and Joint Marginal Distributions in Repeated Categorical Data 467
D. Follmann

A Comparison of Likelihood-based and Marginal Estimating Equation Methods for Analysing Repeated Ordered Categorical Responses with Missing Data: Application to an Intervention Trial of Vitamin Prophylaxis for Oesophageal Dysplasia 479
S. D. Mark and M. H. Gail

Discussion 495

GENERAL METHODOLOGY I

Advances in Statistical Methodology for the Evaluation of Diagnostic and Laboratory Tests 499
G. Campbell

Regression Analysis with Clustered Data 509
B. I. Graubard and E. L. Korn

Spatial Distribution of Neurons in Tissue Culture Wells: Implications for Sampling Methods to Estimate Population Size 523
L. M. McShane and M. Palmatier

Empirical Bayes Estimation and Inference for the Random Effects Model with Binary Response 541
M. A. Waclawiw and K.-Y. Liang

Discussion 553

COHORT STUDIES

Selection Bias in Observational and Experimental Studies 557
J. H. Ellenberg

A Data-analytic Approach for Estimating Lead Time and Screening Benefit based on Survival Curves in Randomized Cancer Screening Trials 569
K. Kafadar and P. C. Prorok

Mixed-effects Regression Models for Studying the Natural History of Prostate Disease 587
J. D. Pearson, C. H. Morrell, P. K. Landis, H. B. Carter and L. J. Brant

Discussion 603

MISSING DATA

Composite Linear Models for Incomplete Multinomial Data 609
S. G. Baker

The Partial Questionnaire Design for Case-control Studies 623
S. Wacholder, R. J. Carroll, D. Pee and M. H. Gail

Testing for Differences in Changes in the Presence of Censoring: Parametric and Non-parametric Methods 635
M. C. Wu, S. Hunsberger and D. Zucker

Discussion 647

EPIDEMIOLOGIC METHODS

A Comparison of Three Approaches to Estimate Exposure-specific Incidence Rates from Population-based Case-control Data 651
J. Benichou and S. Wacholder

Stochastic Curtailing and Conditional Power in Matched Case-control Studies 663
S. Hunsberger, P. Sorlie and N. L. Geller

Sources of Bias in Studies of Time to Pregnancy 671
C. R. Weinberg, D. D. Baird and A. J. Wilcox

Discussion 683

PRECLINICAL STUDIES

A Comparison of Tumour Incidence Analyses Applicable in Single-sacrifice Animal Experiments 689
G. E. Dinse

Meta-analysis of Animal Experiments on Dietary Fat Intake and Mammary Tumours 709
L. S. Freedman

Discrimination Techniques Applied to the NCI *in vitro* Anti-tumour Drug Screen: Predicting Biochemical Mechanism of Action 719
A. D. Koutsoukos, L. V. Rubinstein, D. Faraggi, R. M. Simon, S. Kalyandrug, J. N. Weinstein, K. W. Kohn and K. D. Paull

Discussion 731

GENERAL METHODOLOGY II

Measures of Agreement: a Single Procedure 737
J. J. Bartko

On Non-parametric and Generalized Tests for the Two-sample Problem with Location and Scale Change Alternatives 747
M. J. Podgor and J. L. Gastwirth

Studying the Relationship between Change and Initial Value in Longitudinal Studies 759
G. O. Zerbe, M. C. Wu and D. M. Zucker

Some Power Considerations when Deciding to Use Transformations 769
A. Kingman and G. Zion

Volume 13, *Issue No.* 8, 30 April 1994

The First *t*-test 785
S. Senn and W. Richardson

Multi-state Markov Models for Analysing Incomplete Disease History Data with Illustrations for HIV Disease 805
R. C. Gentleman, J. F. Lawless, J. C. Lindsey and P. Yan

Bayesian Analysis of Survival on Multiple Time Scales 823
C. Berzuini and D. Clayton

Assessing the Significance of Chromosome-loss Data: Where are Suppressor Genes for Bladder Cancer? 839
M. A. Newton, S.-Q. Wu and C. A. Reznikoff

Sample Size Calculation for Clinical Trials in which Entry Criteria and Outcomes are Counts of Events 859
R. P. McMahon, M. Proschan, N. L. Geller, P. H. Stone and G. Sopko

CORRECTION 871

LETTERS TO THE EDITOR 873

BOOK REVIEWS 881

Alain Spriet and Thérèse Dupin-Spriet, Good Practice of Clinical Drug Trials. *David Magnusson, Lars R. Bergman, Georg Rudinger and Bertil Törestad (eds.),* Problems and Methods in Longitudinal Research-stability and Change. *Elisa Lee,* Statistical Methods for Survival Data Analysis (2nd Edition). *P. Elliott, J. Cuzick, D. English and R. Stern (eds.),* Geographical and Environmental Epidemiology: Methods for Small-area Studies. *R. Barker Bausell,* Advanced Research Methodology: An Annotated Guide to Sources

ANNOUNCEMENTS 887

Contents of Volume 13, Issues 1–8 v

Volume 13, *Issue No.* 9, 15 May 1994

Empirical Bayes Methods for Estimating Hospital-specific Mortality Rates 889
N. Thomas, N. T. Longford and J. E. Rolph

Extending a Bayesian Analysis of the Two-period Crossover to Allow for Baseline Measurements 905
A. P. Grieve

Fitting Multivariate Polynomial Growth Curves in Two-period Crossover Designs 931
J. M. Grender and W. D. Johnson

Use of Surrogate Information Time for Monitoring the Effect of Treatment on the Change in a Response Variable in Clinical Trials 945
M. C. Wu, K. K. G. Lan and J. E. Connett

Surrogate and Auxiliary Endpoints in Clinical Trials, with Potential Applications in Cancer and AIDS Research 955
T. R. Fleming, R. L. Prentice, M. S. Pepe and D. Glidden

Smoothing Grouped Bivariate Data to Obtain the Incubation Period Distribution of AIDS 969
J. M. G. Taylor and Y. Chon

LETTERS TO THE EDITOR 983

BOOK REVIEWS 987

Stephen Lock and Frank Wells (eds.), Fraud and Misconduct in Medical Research. *David G. Hoel and Takashi Yanagawa (eds.)*, Biostatistics in Cancer Risk Assessment

Volume 13, *Issue No.* 10, 30 May 1994

The Interpretation of Multiplicative-model Parameters as Standardized Parameters 989
S. Greenland and G. Maldonado

Evaluating Risk Adjustment by Partitioning Variation in Hospital Mortality Rates 1001
D. W. Smith

Heart Rate Variability and Susceptibility for Sudden Cardiac Death: An Example of Multivariable Optimal Discriminant Analysis 1015
P. R. Yarnold, R. C. Soltysik and G. J. Martin

Comparison of Alternative Regression Models for Paired Binary Data 1023
R. J. Glynn and B. Rosner

A Simple Test for Spatial Pattern in Regional Health Data 1037
S. D. Walter

Assessing Time-by-covariate Interactions in Proportional Hazards Regression Models using Cubic Spline Functions 1045
K. R. Hess

Crossover Designs for Clinical Trials 1063
K. C. Carriere

Confidence Intervals for Weighted Proportions 1071
J. L. Waller, C. L. Addy, K. L. Jackson and C. Z. Garrison

BOOK REVIEWS 1083

Steve Selvin, Statistical Analysis of Epidemiologic Data. *David C. Howell*, Statistical Methods for Psychology (3rd edn). *Peter H. Westfall and S. Stanley Young*, Resampling-based Multiple Testing

ANNOUNCEMENT 1087

Volume 13, Issue No. 11, 15 June 1994

Causal Estimation of Time-varying Treatment Effects in Observational Studies: Application to Depressive Disorder 1089
P. W. Lavori, R. Dawson and T. B. Mueller

Estimating Patterns of CD4 Lymphocyte Decline using Data from a Prevalent Cohort of HIV Infected Individuals 1101
E. Vittinghoff, H. M. Malani and N. P. Jewell

A Constrained Empirical Bayes Estimator for Incidence Rates in Areas with Small Populations 1119
O. J. Devine and T. A. Louis

Corrections for Exposure Measurement Error in Logistic Regression Models with an Application to Nutritional Data 1135
J. Kuha

Analysis of Repeated Categorical Data using Generalized Estimating Equations 1149
S. R. Lipsitz, K. Kim and L. Zhao

Assays for Recombinant Proteins: A Problem in Non-linear Calibration 1165
D. M. Giltinan and M. Davidian

LETTERS TO THE EDITOR 1181

BOOK REVIEWS 1187
P. G. Smith and Richard H. Morrow (eds.), Methods for Field Trials of Interventions against Tropical Diseases. A Toolbox. *B. J. T. Morgan*, Analysis of Quantal Response Data

Volume 13, *Issue No.* 12, 30 June 1994

Survival Analysis and Neural Nets 1189
K. Liestøl, P. K. Andersen and U. Andersen

A Fourier Series Approach for Comparing Groups of Subjects on Ambulatory Blood Pressure Patterns 1201
G. W. Somes, G. A. Harshfield, K. L. Arheart and S. T. Miller

Analysis of Longitudinal Data: Random Coefficient Regression Modelling 1211
C. M. Rutter and R. M. Elashoff

Sample Size for Repeated Measures Studies with Binary Responses 1233
S. R. Lipsitz and G. M. Fitzmaurice

Estimation and Sample Size Considerations for Clustered Binary Responses 1241
E. W. Lee and N. Dubin

A Comparison of Methods for Testing Homogeneity of Proportions in Teratologic Studies 1253
A. Donner, M. Eliasziw and N. Klar

Measurement Error, Instrumental Variables and Corrections for Attenuation with Applications to Meta-analyses 1265
R. J. Carroll and L. A. Stefanski

LETTERS TO THE EDITOR 1283

BOOK REVIEW 1287

Barrie M. Margetts and Michael Nelson, Design Concepts in Nutritional Epidemiology

Volume 13, *Issue No.* 13/14, 15 July–30 July 1994

Workshop on Early Stopping Rules in Cancer Clinical Trials
Robinson College, Cambridge, U.K., 13–15 April 1993
Guest Editors: R. L. Souhami and J. Whitehead

Participants and Authors 1289

The Clinical Importance of Early Stopping of Randomized Trials in Cancer Treatments 1293
R. L. Souhami

The CHART Trials: Design and Monitoring 1297
M. K. B. Parmar, D. J. Spiegelhalter and L. S. Freedman

Stopping a Clinical Trial Early: Frequentist and Bayesian Approaches Applied to a CALGB Trial in Non-Small-Cell Lung Cancer 1313
S. L. George, L. Chengchang, D. A. Berry and M. R. Green

A Reversal of Fortune: Practical Problems in the Monitoring and Interpretation of an EORTC Breast Cancer Trial 1329
R. Sylvester, H. Bartelink and R. Rubens

Timing the Collaborative Analysis of Three Trials Comparing 5-FU plus Folinic (FUFA) to Surgery Alone in the Management of Resected Colorectal Cancer: A National Cancer Institute of Canada Trials Group (NCIC-CTG) Perspective 1337
J. L. Pater

Interim Analysis: The Alpha Spending Function Approach 1341
D. L. DeMets and K. K. G. Lan

Discussion of 'Interim Analysis: The Alpha Spending Approach' 1353
N. L. Geller

Sequential Methods Based on the Boundaries Approach for the Clinical Comparison of Survival Times 1357
J. Whitehead

Discussion of 'Sequential Methods Based on the Boundaries Approach for the Clinical Comparison of Survival Times' 1369
S. L. George

The What, Why and How of Bayesian Clinical Trials Monitoring 1371
L. S. Freedman, D. J. Spiegelhalter and M. K. B. Parmar

Discussion of 'The What, Why and How of Bayesian Clinical Trials Monitoring' 1385
D. Machin

Data Monitoring Committees and Early Stopping Guidelines: The Southwest Oncology Group Experience 1391
J. Crowley, S. Green, P. Y. Liu and M. Wolf

Some Practical Aspects of the Interim Monitoring of Clinical Trials 1401
R. Simon

The Case Against Independent Monitoring Committees 1411
D. Harrington, J. Crowley, S. L. George, T. Pajak, C. Redmond and H. S. Wieand

Triangular Test and Randomized Trials: Practical Problems in a Small Cell Lung Cancer Trial 1415
J. Pignon, R. Arriagada, T. Le Chevalier, M. Tarayre, A. Auquier, A. Rivière, I. Monnet, P. Chomy, C. Tuchais and P. Ruffié

Surrogate Markers in AIDS and Cancer Trials 1423
T. R. Fleming

Discussion of 'Surrogate Markers in AIDS and Cancer Trials' 1437
S. Ellenberg

Monitoring Multi-Armed Trials 1441
M. A. Proschan, D. A. Follman and N. L. Geller

Stopping When the Experimental Regimen Does not Appear to Help 1453
S. Wieand, G. Schroeder and J. R. O'Fallon

Early Stopping Rules—Clinical Perspectives and Ethical Considerations 1459
M. Baum, J. Houghton and K. Abrams

Discussion of 'Early Stopping Rules—Clinical Perspectives and Ethical Considerations' 1471
G. Burke

A Lay Person's Perspective on Starting and Stopping Clinical Trials 1473
J. Robinson

Early Stopping of Prevention Trials When Multiple Outcomes are of Interest: A Discussion 1479
S. B. Green and L. S. Freedman

Conclusions. 1: The Relationship Between Clinical Trials and Clinical Practice: The Risks of Underestimating its Complexity 1485
A. Liberati

Conclusions. 2 1493
R. T. O'Neill

Volume 13, *Issue No.* 15, 15 August 1994

Assessment of Predictive Models for Binary Outcomes: An Empirical Approach Using Operative Death from Cardiac Surgery 1501
G. Marshall, F. L. Grover, W. G. Henderson and K. E. Hammermeister

Precision of Incidence Predictions Based on Poisson Distributed Observations 1513
T. Hakulinen and T. Dyba

Monte Carlo Methods for Exploring Sensitivity to Distributional Assumptions in a Bayesian Analysis of a Series of 2 × 2 Tables 1525
T. E. Raghunathan

Efficient Power Computation for Exact and Mid-*P* Tests for the Common Odds Ratio in Several 2 × 2 Tables 1539
K. F. Hirji, M.-L. Tang, S. E. Vollset and R. M. Elashoff

Efficient Confidence Bounds for ROC Curves 1551
H. Schäfer

Sampling Guidelines for Testing Secondary Attack Rates Associated with Short-Latency Infectious Diseases 1563
N. J. Schork

The Choice of Cancer Treatment Based on Covariate Information 1575
A. Yu. Yakovlev, R. E. Goot and T. T. Osipova

On Closed Test Procedures for Dose-Response Analysis 1583
D. M. Rom, R. J. Costello and L. T. Connel

BOOK REVIEWS 1597

Huw Llewellyn and Anthony Hopkins, Analysing How We Reach Clinical Decisions. *David S. Salsburg*, The Use of Restricted Significance Tests in Clinical Trials. *John C. Bailar III and Frederick Mosteller, (eds.)*, Medical Uses of Statistics (2nd edn)

CORRECTION 1600

Volume 13, *Issue No.* 16, 30 August 1994

The Application of REM1 in Clinical Trials 1601
H. K. Brown and R. A. Kempton

Statistical Analysis of Proliferative Index Data in Clinical Trials 1619
P. Grambsch, T. A. Louis, R. M. Bostick, G. A. Grandits, L. Fosdick, M. Darif and J. D. Potter

Median Analysis of Blood Pressure for a Sample Including Treated Hypertensives 1635
I. R. White, N. Chaturvedi and P. McKeigue

Multilevel Time Series Models with Applications to Repeated Measures Data 1643
H. Goldstein, M. J. R. Healy and J. Rasbash

A Simulation Study Comparing Two Approximations for A Quasi *t*-Quantile, Used in Repeated Measures Anova 1657
A. R. Silverberg

Alternative Models for Ordinal Logistic Regression 1665
S. Greenland

A Simple Frailty Model for Family Studies with Covariates 1679
A. Babiker and J. Cuzick

LETTERS TO THE EDITOR 1693

Contents of Volume 13, Issues 9–16 v

Volume 13, *Issue No.* 17, 15 September 1994

Helping Doctors to Draw Appropriate Inferences From the Analysis of Medical Studies 1699
P. R. Burton

Testing for Baseline Balance in Clinical Trials 1715
S. Senn

An Optimal Three-Stage Design for Phase II Clinical Trials 1727
L. G. Ensign, E. A. Gehan, D. S. Kamen and P. F. Thall

Effect of Verification Bias on Positive and Negative Predictive Values 1737
X.-H. Zhou

Analysing Survival in the Presence of an Auxiliary Variable 1747
D. M. Finkelstein and D. A. Schoenfeld

Projection of Incidence Rates to a Larger Population Using Ecologic Variables 1755
C. M. Frey, E. J. Feuer and M. J. Timmel

Interval Censoring in Longitudinal Data of Respiratory Symptoms in Aluminium Potroom Workers: A Comparison of Methods 1771
S. O. Samuelsen and J. Kongerud

Standardized Rates of Recurrent Outcomes 1781
T. A. Stukel, R. J. Glynn, E. S. Fisher, S. M. Sharp, G. Lu-Yao and J. E. Wennberg

LETTERS TO THE EDITOR 1793

BOOK REVIEW 1797

Per Kragh Andersen, Ørnulf Borgan, Richard D. Gill and Niels Keiding, Statistical Models Based on Counting Processes

Volume 13, *Issue No.* 18, 30 September 1994

A Comparison of Two Phase I Trial Designs 1799
E. L. Korn, D. Midthune, T. T. Chen, L. V. Rubinstein, M. C. Christian and R. M. Simon

Reduction in Burden of Illness: A New Efficacy Measure for Prevention Trials 1807
M. N. Chang, H. A. Guess and J. F. Heyse

A Unified Method for Monitoring and Analysing Controlled Trials 1815
J. Grossman, M. K. Parmar, D. J. Spiegelhalter and L. S. Freeman

Deviance Estimates of Sample Size for Equivalence Tests in Vaccine Trials 1827
J. B. Garner

Bayesian Hierarchical Analysis of Within–Units Variances in Repeated Measures Experiments 1841
T. R. Ten Have and V. M. Chinchilli

Stratification of Summary Statistics Tests According to Missing Data Patterns 1853
J. D. Dawson

Simultaneous Back-Projection of AIDS Incidence Data for Two or More Groups 1865
I. C. Marschner, S. V. Newstead and N. G. Becker

Estimates of Disease Incidence in Women Based on Antenatal or Neonatal Seroprevalence Data: HIV in New York City 1881
A. E. Ades and G. F. Medley

LETTER TO THE EDITOR 1895

CORRECTION 1897

Volume 13, *Issue No.* 19/20, 15 October–30 October 1994

Proceedings of the Conference
Quantitative Methods for Studying AIDS
Blaubeuren, Germany, 14–18 June 1993

Guest Editors: K. Dietz, Peter Bacchetti and Marcello Pagano

Foreword 1899
K. Dietz and D. L. Thomsen

Preface 1901
K. Dietz, P. Bacchetti and M. Pagano

STUDIES OF AIDS AND HIV SURVEILLANCE

Screening Tests: Can We Get More by Doing Less? 1905
X. M. Tu, E. Litvak and M. Pagano

Seasonal and Other Short-term Influences on United States AIDS Incidence 1921
P. Bacchetti

ESTIMATING HIV INCIDENCE AND AIDS PROJECTIONS

Prediction & Validation in the Public Health Modelling of HIV/AIDS 1933
N. T. J. Bailey

Dependent HIV Incidences in Back-projection of AIDS Incidence Data 1945
N. G. Becker and X. Chao

Using Time of First Positive HIV Test and Other Auxiliary Data in Back-projection of AIDS Incidence 1959
I. C. Marschner

Backcalculation Models of Age-specific HIV Incidence Rates 1975
P. S. Rosenberg

Back-projection of German AIDS Data Using Information on Dates of Tests 1991
K. Dietz, J. Seydel and B. Schwartländer

Incorporating HIV Test Data into Forecasts of the AIDS Epidemic in Scotland 2009
G. M. Raab, K. L. Fielding and G. Allardice

MARKERS AND INCUBATION TIMES

The Effect of Covariates on the Induction Time of AIDS Using Improved Imputation of Exact Seroconversion Times 2021
K. Gauvreau, V. DeGruttola and M. Pagano

Distribution of the Latency Period for Perinatally Acquired AIDS 2031
S. MaWhinney and M. Pagano

Non-parametric Analysis of Transfusion-related HIV and AIDS Incidence Data 2043
M. Motika, N. G. Becker, B. Wylie, J. Learmont and J. Kaldor

Marker Values at the Time of an AIDS Diagnosis 2059
J. M. G. Taylor and D. K. Kim

A Model for AIDS Pathogenesis 2067
D. Schenzle

INEFFECTIVITY

Non-parametric Estimation and Doubly-censored Data: General Ideas and Applications to AIDS 2081
N. P. Jewell

Modelling the Female-to-Male Per-Act HIV Transmission Probability in an Emerging Epidemic in Asia 2097
G. A. Satten, T. D. Mastro and I. M. Longini, Jr.

METHODS OF STUDYING INTERVENTIONS

Considerations in Choice of Clinical Endpoint for AIDS Clinical Trials 2107
J. D. Neaton, D. N. Wentworth, F. Rhame, C. Hogan, D. I. Abrams and L. Deyton for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)

The Effectiveness of Interventions on Incubation of AIDS as Measured by Secular Increases within a Population 2127
D. R. Hoover, J. M. G. Taylor, L. Kingsley, J. S. Chmiel, A. Muñoz, Y. He and A. Saah

Assessing Drug Compliance Using Longitudinal Marker Data, with Application to AIDS 2141
H. M. Kim and S. W. Lagakos

Some Statistical Issues in HIV Vaccine Trials 2155
W. N. Rida and D. N. Lawrence

A Method for Evaluating Needle Exchange Programs 2179
E. H. Kaplan

Volume 13, *Issue No.* 21, 15 November 1994

Mid-*P* Confidence Intervals for the Poisson Expectation 2189
G. R. Cohen and S-Y. Yang

On Prediction of Future Observation in Growth Curve Model 2205
J. J. Tian, R. Shukla and R. Buncher

Testing for Omitted Variables and Non-linearity in Regression Models for Longitudinal Data 2219
M. Palta, T-J. Yao and R. Velu

Cox Regression Analysis of Multivariate Failure Time Data: The Marginal Approach 2233
D. Y. Lin

On the Development of the Medical Research Council Trial of α-Interferon in Metastatic Renal Carcinoma 2249
P. M. Fayers, P. A. Cook, D. Machin, N. Donaldson, J. Whitehead, A. Ritchie, R. T. D. Oliver, members of the Urological Working Party Renal Carcinoma Subgroup and P. Yuen

A Step-down Procedure for Multiple Tests of Treatment versus Control in Each of Several Groups 2261
S. H. Cheung and B. Holland

The Paired Availability Design: A Proposal for Evaluating Epidural Analgesia During Labour 2269
S. G. Baker and K. S. Lindeman

LETTERS TO THE EDITOR 2279

BOOK REVIEWS 2287
Stanton A. Glantz, Primer of Biostatistics, Third edn. *J. L. A. van Rijckevorsel and C. C. J. H. Bijleveld (eds.),* A Reader on Applying Statistics in Public Health and Prevention

Volume 13, *Issue No.* 22, 30 November 1994

A Direct, General Approach Based on Isobolograms for Assessing the Joint Action of Drugs in Pre-clinical Experiments 2289
S. G. Machado and G. A. Robinson

Monitoring of a Pilot Toxicity Study with Two Adverse Outcomes 2311
R. Etzioni and M. S. Pepe

On a Model-based Approach to Estimating Efficacy in Clinical Trials 2323
J. M. Albert and D. L. DeMets

The Use of a Square Array Scheme in Blood Testing 2337
R. M. Phatarfod and A. Sudbury

Attributable Fraction Estimates and Case Definitions for Malaria in Endemic Areas 2345
T. Smith, J. A. Schellenberg and R. Hayes

Age-related Reference Ranges: Significance Tests for Models and Confidence Intervals for Centiles 2359
A. M. Wade and A. E. Ades

Determining the Size of a Cross-sectional Sample to Estimate the Age-specific Incidence of an Irreversible Disease 2369
I. C. Marschner

LETTER TO THE EDITOR 2383

BOOK REVIEWS 2385
Brian Everitt and Dale Hay, Talking About Statistics: A Psychologist's Guide to Design and Analysis. *Murin J. Khoury, Terri H. Beaty and Bernice H. Cohen,* Fundamentals of Genetic Epidemiology. *Nicholas P. Jewell, Klaus Dietz and Vernon T. Farewell (eds.),* AIDS Epidemiology: Methodological Issues. *Alfredo Nicolosi (ed.),* AIDS Epidemiology: Models and Methods

Volume 13, *Issue No.* 23/24, 15 December–30 December 1994

Papers from the International Meetings of the International Society for Clinical Biostatistics

Preface 2389

ISCB Committee 2391

Publications from Multicentre Clinical Trials: Statistical Techniques and Accessibility to the Reader 2393
M. J. Marsh and B. S. Hawkins

Correspondence Analysis Applied to Grouped Cohort Data 2407
M. Grassi and S. Visentin

Penalized Likelihood in Cox Regression 2427
P. J. M. Verweij and H. C. van Houwelingen

Separation of Systematic and Random Differences in Ordinal Rating Scales 2437
E. Svensson and S. Holm

Internal Pilot Studies for Estimating Sample Size 2455
M. A. Birkett and S. J. Day

A Critical Discussion of Intraclass Correlation Coefficients 2465
R. Müller and P. Büttner

Growth Charts for Both Cross-Sectional and Longitudinal Data 2477
T. J. Cole

Sample Sizes for Phase II Clinical Trials Derived from Bayesian Decision Theory 2493
H. C. Brunier and J. Whitehead

A Meta-analysis of Clinical Trials Involving Different Classifications of Response into Ordered Categories 2503
A. Whitehead and N. M. B. Jones

Multistate Modelling of Liver Transplantation Data 2517
B. E. Hansen, J. Thorogood, J. Hermans, R. J. Ploeg, J. H. van Bockel and H. C. Van Houwelingen

Fieller's Confidence Intervals for the Ratio of Two Means in the Assessment of Average Bioequivalence from Crossover Data 2531
J. Vuorinen and J. Tuominen

Acknowledgement 2547

Author Index 2549

Subject Index 2553

Contents of Volume 13, Issues 17–24 v

Volume 14, Issue Nos. 1–24

Volume 14, *Issue No.* 1, 15 January 1995

PUBLISHER'S ANNOUNCEMENT iv

EDITORIAL ANNOUNCEMENT 1

Detection and Assessment of Clusters of Disease: An Application to Nuclear Power Plant Facilities and Childhood Leukaemia in Sweden 3
L. A. Waller, B. W. Turnbull, G. Gustavsson, U. Hjalmars and B. Andersson

Adjusting Moran's *I* for Population Density 17
N. Oden

A Direct Approach for Correcting AIDS Incidence: Variance Formula and Comparison with Other Methods 27
A. Alioum and D. Commenges

Estimating the Proportion of Immunes in Censored Samples: A Simulation Study 39
M. E. Ghitany, R. Maller and S. Zhou

Confidence Intervals, Hypothesis Tests, and Sample Sizes for the Prevented Fraction in Cross-sectional Studies 51
P. M. Gargiullo, R. Rothenberg and H. G. Wilson

A Neural Network Model for Survival Data 73
D. Faraggi and R. Simon

Maximum Likelihood Estimation of the Kappa Coefficient from Models of Matched Binary Responses 83
M. M. Shoukri, S. W. Martin and I. U. H. Mian

LETTER TO THE EDITOR 101

BOOK REVIEWS 103

Volume 14, *Issue No.* 2, 30 January 1995

Aspects of Medical Statistics
A Festschrift for David Newell

Guest Editor: David Appleton

Preface 109
D. Appleton

David Newell: The First 65 Years 111
P. Armitage

Small Clinical Trials: Are they all Bad? 115
J. N. S. Matthews

Statistical Issues in the Regulation of Medicines 127
J. A. Lewis

Meta-analysis: Weighing the Evidence 137
D. R. Jones

VOLUME CONTENTS 317

Controversies in Cancer Epidemiology 151
C. E. D. Chilvers

Problems and Prediction in Survival-data Analysis 161
R. Henderson

What Do We Mean by a Statistical Model? 185
D. R. Appleton

Teaching Statistics to Non-specialists 199
J. M. Simpson

Life as an Academic Medical Statistician and How to Survive It 209
S. J. Pocock

David Newell's Publications 1954–1993 223

ANNOUNCEMENT 229

Volume 14, *Issue No.* 3, 15 February 1995

Adaptive Assignment versus Balanced Randomization in Clinical Trials: A Decision Analysis 231
D. A. Berry and S. G. Eick

Binary Regression with Continuous Outcomes 247
S. Suissa and L. Blaiss

Age-related Standards for Ordinal Data: Modelling the Changes in Visual Acuity from 2 to 9 Years of Age 257
A. M. Wade, A. E. Ades, A. T. Salt, R. Jayatunga and P. M. Sonksen

Comparison of Additive and Multiplicative Models for Reproductive Risk Factors and Post-menopausal Breast Cancer 267
E. Lund

Non-parametric Estimation for the Difference or Ratio of Median Failure Times for Paired Observations 275
S-H. Jung and J. Q. Su

A Simulation Study of Estimators for Rates of Change in Longitudinal Studies with Attrition 283
F. Wang-Clow, M. Lange, N. M. Laird and J. H. Ware

Modelling Covariate Effects in Observer Agreement Studies: The Case of Nominal Scale Agreement 299
P. Graham

A Comparison of Methods that Characterize Pulses in a Time Series 311
D. T. Mauger, M. B. Brown and R. H. Kushler

LETTER TO THE EDITOR 327

Volume 14, *Issue No.* 4, 28 February 1995

Methodological and Statistical Problems in the Construction of Composite Measurement Scales: A Survey of Six Medical and Epidemiological Journals 331
J. Coste, J. Fermanian and A. Venot

Comparison of Several Goodness-of-fit Tests for the Kappa Statistics Based on Exact Power and Coverage Probability 347
S. Basu and A. Basu

Bayesian Sequential Monitoring Designs for Single-arm Clinical Trials with Multiple Outcomes 357
P. F. Thall, R. M. Simon and E. H. Estey

A Bayesian Group Sequential Design for a Multiple Arm Randomized Clinical Trial 381
G. L. Rosner and D. A. Berry

A Random-effects Regression Model for Meta-analysis 395
C. S. Berkey, D. C. Hoaglin, F. Mosteller and G. A. Colditz

Association Models for Periodontal Disease Progression: A Comparison of Methods for Clustered Binary Data 413
T. R. Ten Have, J. R. Landis and S. L. Weaver

Using Sign Score Regression Models to Select Variables in Case-control Studies 431
T. W. O'Gorman

LETTER TO THE EDITOR 445

Volume 14, *Issue No.* 5/6/7, 15 March–15 April 1995

Symposium on Quantitative Methods for Utilization of Multi-Source Data in Public Health

Guest Editors: G. David Williamson, James T. Massey, Holly B. Shulman, William K. Sieber, S. Jay Smith

Prologue 447

Staff and Committees 449

Presenters and Discussants 450

Opening Remarks 455
W. R. Dowdle

KEYNOTE ADDRESSES

Meta-Analysis: Reconciling the Results of Independent Studies 457
I. Olkin

Development of the Series of U.S. Cancer Atlases: Implications for Future Epidemiologic Research 473
T. J. Mason

DATA LINKAGE

Linking Public Health Data Using Geographic Information System Techniques: Alaskan Community Characteristics and Infant Mortality 481
N. Andes and J. E. Davis

Probabilistic Linkage of Large Public Health Data Files 491
M. A. Jaro

Evaluating the Quality of Anonymous Record Linkage Using Deterministic Procedures with the New York State AIDS Registry and a Hospital Discharge File 499
A. G. Muse, J. Mikl and P. F. Smith

Verification of Information in a Large Medical Database Using Linkages with External Databases 511
I. P. Shevchenko, J. T. Lynch, A. S. Mattie and L. L. Reed-Fourquet

METHODOLOGIC ISSUES

On Combining Dose-Response Data from Epidemiological Studies by Meta-Analysis 531
S. J. Smith, S. P. Caudill, K. K. Steinberg and S. B. Thacker

Meta-Analytic Approaches to Dose-Response Relationships, with Application in Studies of Lung Cancer and Exposure to Environmental Tobacco Smoke 545
R. L. Tweedie and K. L. Mengersen

A Dual Frame Design for Sampling Elderly Minorities and Persons with Disabilities 571
T. M. Ezzati, K. L. Hoffman, D. R. Judkins, J. T. Massey and T. F. Moore

Multiple Hypothesis Tests in Multiple Investigations 585
S. P. Caudill and R. H. Hill, Jr.

MAPPING AND GEOGRAPHIC DISPLAY DATA

Development and Applications of a City-Level Alcohol Availability and Alcohol Problems Database 591
D. P. MacKinnon, R. Scribner and K. A. Taft

Feasibility of Contour Mapping Epidemiological Data with Missing Values 605
F. F. Nobre and M. M. A. de Macedo

Effects of the Choice of Age-Adjustment Method on Maps of Death Rates 615
L. W. Pickle and A. A. White

UTILIZATION OF SPECIAL DATA SETS

Public Health Surveillance for Chronic Conditions: A Scientific Basis for Decisions 629
S. B. Thacker, D. F. Stroup, R. B. Rothenberg and R. C. Brownson

Differences in Morbidity Measures and Risk Factor Identification Using Multiple Data Sources: The Case of Coronary Heart Disease 643
J. H. Madans, C. A. Reuben, S. T. Rothwell and M. S. Eberhardt

The Price and Purity of Cocaine: The Relationship to Emergency Room Visits and Death, and to Drug Use among Arrestees 655
R. R. Hyatt, Jr. and W. H. Rhodes

Combining National Health Interviews Survey Data Sets, Issues and Approaches 669
S. L. Botman and S. S. Jack

SYMPOSIUM SESSION COMMENTARIES

Meta-Analysis 679
W. H. DuMouchel

Data Linkage 687
H. A. Schwartz

Utilization I—Special Data Sets 691
N. E. Stroup

Utilization II—Special Data Sets 693
V. S. Hertzberg

Study Design and Public Health Planning 695
B. I. Truman

Mapping and Geographic Display of Data: Summary 697
A. A. White

Methodologic Issues 701
G. A. Milliken

Abstracts 703

Poster Presentations 709

Software Demonstrations 711

Presentation of Awards 713
G. D. Williamson

Closing Remarks 715
T. Colton

Volume 14, *Issue No.* 8, 30 April 1995

EDITORIAL ANNOUNCEMENT 719

Statistical Issues in Assessing Comorbidity 721
H. C. Kraemer

Model Inconsistency, Illustrated by the Cox Proportional Hazards Model 735
I. Ford, J. Norrie and S. Ahmadi

The Analysis of Repeated-measures Data on Schizophrenic Reaction Times Using Mixture Models 747
T. R. Belin and D. B. Rubin

Logistic Regression in Case-control Studies: The Effect of Using Independent Variables As Dependent Variables 769
N. J. D. Nagelkerke, S. Moses, F. A. Plummer, R. C. Brunham and D. Fish

Percentile Regression Analysis of Correlated Antibody Responses 777
L. H. Moulton, E. A. Holt, J. S. Job and N. A. Halsey

Effects of Correlated and Uncorrelated Measurement Error on Linear Regression and Correlation in Medical Method Comparison Studies 789
R. D. Rifkin

Spatial Disease Clusters: Detection and Inference 799
M. Kulldorff and N. Nagarwalla

The Log Transformation is Special 811
O. N. Keene

Trends in Mortality from Melanoma in Canada and Prediction of Future Rates 821
I. B. MacNeill, J. M. Elwood, D. Miller and Y. Mao

An Alternative Approach to the Optimal Design of an LD50 Bioassay 841
R. A. Markus, J. Frank, S. Groshen and S. P. Azen

Bias of Two One-sided Tests Procedures in Assessment of Bioequivalence 853
J.-P. Liu and C.-S. Weng

A Comparison of Tests for the κ-sample, Non-decreasing Alternative 863
J. M. Mahrer and R. C. Magel

STATISTICS IN THE MEDICAL LITERATURE: 1 873

CORRECTIONS 875

BOOK REVIEWS 877

Contents of Volume 14, Issues 1–8 v

Volume 14, *Issue No.* 9/10, 15 May–30 May 1995

Statistical Methods in Biopharmacy, Choice and Decisions in Development of Pharmaceutical Products, Paris, 6–7 September 1993

Guest Editors: D. Moccatti, L. Darchy, N. Debbas, J. Orvain, C. Papillon-Downey, D. Serrurier and G. Tap

Preface 881

Scientific and Organizing Committees and List of Referees 883

Choosing the dose of a treatment

Bayesian Decision Procedures for Dose Determining Experiments 885
J. Whitehead and H. Brunier

Re-evaluation of Decisions on the Recommended Dose from Phase III Dose Finding Trials 895
J. Röhmel

Discussion 897

Dose Finding Strategies Involving Interim Analyses and Unbalanced Treatment Allocation 901
M. Wargenau

Discussion 909

An Extension of the Continual Reassessment Methods Using a Preliminary Up-And-Down Design in a Dose Finding Study in Cancer Patients, in Order to Investigate a Greater Range of Doses 911
S. Møller

Discussion 923

Estimating the Minimum Therapeutically Effective Dose of a Compound via Regression Modelling and Percentile Estimation 925
T. G. Filloon

Discussion 933

Constructing a Bootstrap Confidence Interval for the Unknown Concentration in Radioimmunoassay 935
O. Rosen and A. Cohen

Discussion 953

Decisions in dose optimization and population pharmacokinetics and pharmacodynamics

Inferring Systemic Exposure from a Pharmacokinetic Screen: Model-free and Model-based Approaches 955
J. R. Nedelman, A. H. Karara, C.-T. Chang, E. Gibiansky, S. McDonald and W. T. Robinson

Discussion 969

An Application of Bayesian Population Pharmacokinetic/Pharmacodynamic Models to Dose Recommendation 971
J. Wakefield and A. Racine-Poon

Influence of Confounding Factors on Designs for Dose–effect Relationship Estimates 987
P. Girard, S. Laporte-Simitsidis, P. Mismetti, H. Decousus and J.-P. Boissel

Discussion 1006

Analysis of Pseudo-profiles in Organ Pharmacokinetics and Toxicokinetics 1009
H. Mager and G. Göller

Choosing the design of a confirmatory clinical trial

The Case for Cross-over Trials in Phase III 1025
B. Jones and J. A. Lewis

Planning and Revising the Sample Size for a Trial 1039
A. L. Gould

Discussion 1053

Bayesian Predictive Approach for Inference About Proportions 1057
B. Lecoutre, G. Derzko and J. -M. Grouin

Discussion 1065

Use of the Repeated Cross-over Designs in Assessing Bioequivalence 1067
J.-P. Liu

Discussion 1079

Assessing Sensitivity in Suspension to Cytosine Arabinoside: Statistical Analysis, Associations with Clinical Outcome and Experimental Design 1081
S. Minkin and A. Chow

Discussion 1097

Decisions about overall efficacy and safety

Defining, Monitoring and Combining Safety Information in Clinical Trials 1099
G. G. Enas and D. J. Goldstein

Discussion 1113

Statistical Concepts in the Planning and Evaluation of Drug Safety from Clinical Trials in Drug Development: Issues of International Harmonization 1117
R. T. O'Neill

Comparing the Bivariate Effects of Toxicity and Efficacy of Treatments 1129
P. Tubert-Bitter, D. A. Bloch and J.-P. Raynauld

Discussion 1143

LETTER TO THE EDITOR 1145

BOOK REVIEWS 1147

Volume 14, *Issue No.* 11, 15 June 1995

Some Practical Improvements in the Continual Reassessment Method for Phase I Studies 1149
S. N. Goodman, M. L. Zahurak and S. Piantadosi

Multivariate Tests for Multiple Endpoints in Clinical Trials 1163
D. Follman

A Regression Method for Analysing Ordinal Data from Intervention Trials 1177
D. J. Schnell, E. Magee and J. R. Sheridan

Location–scale Cumulative Odds Models for Ordinal Data: A Generalized Non-linear Model Approach 1191
C. Cox

Inference for Smooth Curves in Longitudinal Data with Application to an AIDS Clinical Trial 1205
Y. Wang and J. M. G. Taylor

Longitudinal Data Analysis for Linear Gaussian Models with Random Disturbed-highest-derivative-polynomial Subject Effects 1219
P. D. Wilson

Smoothing Splines for Longitudinal Data 1235
S. J. Anderson and R. H. Jones

A Proportional Regression Model for 20 Year Survival of Colon Cancer in Norway 1249
P. -H. Zahl

LETTER TO THE EDITOR 1263

ANNOUNCEMENT 1264

Volume 14, *Issue No.* 12, 30 June 1995

Graphical Models for Panel Studies, Illustrated on Data from the Framingham Heart Study 1265
J. P. Klein, N. Keiding and S. Kreiner

Experimental Quantiles of Epidemiological Indices in Case-control Studies with Non-differential Misclassification 1291
A. T. Marinos, A. J. Tzonou and M. E. Karantzas

Misclassification of a Prognostic Dichotomous Variable: Sample Size and Parameter Estimate Adjustment 1307
C. J. Tavaré, E. L. Sobel and F. H. Gilles

Logistic Regression with Incomplete Observed Categorical Covariates—Investigating the Sensitivity Against Violation of the Missing at Random Assumption 1315
W. Vach and M. Blettner

Risk Scores from Logistic Regression: Unbiased Estimates of Relative and Attributable Risk 1331
H. Tomasson

A Bivariate Cumulative Probit Regression Model for Ordered Categorical Data 1341
K. Kim

Estimation of the Proportion of Genetic Cases in Late-onset Diseases: An Application to Alzheimer's Disease 1353
C. Tzourio, J. Maccario and A. Alpérovitch

Heterosexual Transmission of HIV Analysed by Generalized Estimating Equations 1365
K. L. Fielding, R. P. Brettle, S. M. Gore, F. O'Brien, R. Wyld, J. R. Robertson and R. Weightman

Robust Bayesian Methods for Monitoring Clinical Trials 1379
J. B. Greenhouse and L. Wasserman

LETTER TO THE EDITOR 1393

BOOK REVIEW 1395

Volume 14, *Issue No.* 13, 15 July 1995

Model Selection Techniques for the Covariance Matrix for Incomplete Longitudinal Data 1397
J. J. Grady and R. W. Helms

Calculation of Unconditional and Conditional Reference Intervals for Foetal Size and Growth from Longitudinal Measurements 1417
P. Royston

Estimating the Reliability of an Exposure Variable in the Presence of Confounders 1437
M. Y. Kim, B. S. Pasternack, R. J. Carroll, K. L. Koenig and P. G. Toniolo

A Comparison of Frailty Models for Multivariate Survival Data 1447
A. Pickles and R. Crouchley

A Hybrid Paired and Unpaired Analysis for the Comparison of Proportions 1463
P. C. Thomson

Confidence Limits for the Population Prevalence Rate Based on the Negative Binomial Distribution 1471
K.-J. Lui

Investigating a Sequence of Randomized Phase II Trials to Discover Promising Treatments 1479
N. Strauss and R. Simon

Breaking the Matches in a Paired *t*-Test for Community Interventions When the Number of Pairs is Small 1491
P. Diehr, D. C. Martin, T. Koepsell and A. Cheadle

Volume 14, *Issue No.* 14, 30 July 1995

Computing Back-calculation Estimates of AIDS Epidemic 1505
Y. Ding

A Back-calculation Method to Estimate the Age and Period HIV Infection Intensity, Considering the Susceptible Population 1513
A. Verdecchia and A. B. Mariotto

Estimation of Mean Sojourn Time in Breast Cancer Screening Using a Markov Chain Model of Both Entry To and Exit From the Preclinical Detectable Phase 1531
S. W. Duffy, H.-H. Chen, L. Tabar and N. E. Day

Analysis of Ordinal Data in a Study of Endometrial Cancer Under a Matched Pairs Case-control Design 1545
S. S. Ganguly and U. V. Naik-Nimbalkar

Transient Effects in the Cox Proportional Hazards Regression Model 1553
E. A. Mauger, R. A. Wolfe and F. K. Port

Estimation of a Common Odds Ratio Under Binary Cluster Sampling 1567
C. W. Ahn and T. Odom-Maryon

A Comparison of Size and Power Calculations for the Wilcoxon Statistic for Ordered Categorical Data 1577
J. E. Kolassa

Comparison of Test and Sample Size Formulae for Providing Therapeutic Equivalence Based on the Difference of Binomial Probabilities 1583
P. Roebruck and A. Kühn

An Adaptive Method for Establishing a Dose–response Relationship 1595
P. Bauer

LETTER TO THE EDITOR 1609

BOOK REVIEW 1611
David Draper, Donald P. Gaver Jan, Prem K. Goel, Joel B. Greenhouse, Larry V. Hedges, Carl N. Morris, John R. Tucker and Christine H. Waternaux, Combining Information: Statistical Issues and Opportunities for Research

Volume 14, *Issue No.* 15, 15 August 1995

EDITORIAL 1613

Some Perspectives on the Career of Samuel W. Greenhouse: The First 75 Years 1615
J. H. Ellenberg

Testing Independence When the Form of the Bivariate Distribution is Unspecified 1621
S. Geisser and W. Johnson

Biostatistical Concepts and Methods in the Legal Setting 1641
J. L. Gastwirth and S. W. Greenhouse

Biostatistical Methodology in Clinical Trials—A European Guideline 1655
J. A. Lewis, D. R. Jones and J. Röhmel

Biostatistical Methodology in Clinical Trials in Applications for Marketing Authorizations for Medicinal Purposes 1659
CPMP Working Party on Efficacy of Medicinal Products

The Biostatistician in Medical Research: Allocating Time and Effort 1683
M. L. Lesser and R. A. Parker

Effects of Model Misspecification in the Estimation of Variance Components and Intraclass Correlation for Paired Data 1693
R. H. Lyles and L. E. Chambless

Graphical Methods for Assessing Violations of the Proportional Hazards Assumption in Cox Regression 1707
K. R. Hess

BOOK REVIEWS 1725

Anthony Swerdlow and Isabel dos Santos Silva, Atlas of Cancer Incidence in England and Wales: 1968–85. *Elisabeth Svennson,* Analysis of Systematic and Random Differences Between Paired Ordinal Categorical Data. *John Adams,* Risk

Volume 14, *Issue No.* 16, 30 August 1995

EDITORIAL 1729

Age-adjusted Survival Curves with Application in the Framingham Study 1731
L. A. Cupples, D. R. Gagnon, R. Ramaswamy and R. B. D'Agostino

Assessment of Cardiovascular Risk Factors in the Elderly: The Framingham Heart Study 1745
M. G. Lawson

Development of Health Risk Appraisal Functions in the Presence of Multiple Indicators: The Framingham Study Nursing Home Institutionalization Model 1757
R. B. D'Agostino, A. J. Belanger, M. Kelly-Hayes and P. A. Wolf

A Quality-adjusted Survival Meta-analysis of Adjuvant Chemotherapy for Premenopausal Breast Cancer 1771
B. F. Cole, R. D. Gelber and A. Goldhirsch

Assessing Goodness-of-Fit of Parametric Regression Models for Lifetime Data–Graphical Methods 1785
A. Cohen and O. Barnett

Methods for Maternal Age-standardization of the Incidence of Congenital Abnormalities 1797
A. D. Carothers

Predicting the Success of *In Vitro* Fertilization: Convectional Semen Analysis Compared to the Hamster Ova Penetration Test 1807
M. Abt, E. Strehler, B. Rosenbusch and K. Sterzik

Analysis of Dependent Survival Data Applied to Lifetimes of Amalgam Fillings 1819
O. O. Aalen, E. Bjertness and T. Sonju

On the Sample Size for One-sided Equivalence of Sensitivities Based Upon McNemar's Test 1831
Y. Lu and J. A. Bean

VOLUME CONTENTS 327

CORRECTIONS 1841

Contents of Volume 14, Issues 9–16 v

Volume 14, *Issue No.* 17, 15 September 1995

An Analysis for Menstrual Data with Time-varying Covariates 1843
S. A. Murphy, G. R. Bentley and M. A. O'Hanesian

Modelling Frailty in Area Mortality 1859
P. Congdon

Simple Confidence Intervals for Standardized Rates Based on the Approximate Bootstrap Method 1875
M. B. Swift

Difference in Clinical Implications of CD4 Counts Among HIV-infected Homosexual Men and Injection Drug Using Men and Women 1889
M. C. Paik, M. D. Begg, W. El-Sadr, J. Gorman and Z. Stein

Combining 2 × 2 Tables That Contain Structural Zeroes 1901
W. D. Johnson and W. L. May

A Multiple Imputation Strategy for Clinical Trials with Truncation of Patient Data 1913
P. W. Lavori, R. Dawson and D. Shera

Toward Vital Status Sweeps: A Case History in Sequential Monitoring 1927
A. Hallstrom, R. McBride and R. Moore

On the Use of a Pilot Sample for Sample Size Determination 1933
R. H. Browne

Additivity Test for Composition of Binomial Effects in Chromosome Aberrations After Radiation Injury 1941
J. Komornik, M. Mikulecky and M. Beno

Volume 14, *Issue No.* 18, 30 September 1995

Decision and Detection Limits for Linear Homoscedastic Assays 1949
A. Dunne

A Comparison of Methods for Correlated Ordinal Measures with Ophthalmic Applications 1961
S. J. Gange, K. L. P. Linton, A. J. Scott, D. L. DeMets and R. Klein

Multi-state Models and Diabetic Retinopathy 1975
G. Marshall and R. H. Jones

Methods for Bounding the Marginal Survival Distribution 1985
J. J. Dignam, L. A. Weissfeld and S. J. Anderson

Construction, Validation and Updating of a Prognostic Model for Kidney Graft Survival 1999
J. C. Van Houwelingen and J. Thorogood

Self-modelling with Random Shift and Scale Parameters and a Free-knot Spline Shape Function 2009
M. J. Lindstrom

Residual Plots for the Censored Data Linear Regression Model 2023
S. L. Hillis

Sample Size Determination in Stratified Trials to Establish the Equivalence of Two Treatments 2037
J.-M. Nam

Notes on Conditional Confidence Limits Under Inverse Sampling 2051
K.-J. Lui

Volume 14, *Issue No.* 19, 15 October 1995

Practical Methodology of Meta-analyses (Overviews) Using Individual Patient Data 2057
L. A. Stewart and M. J. Clarke

The Design and Analysis of Randomized Trials with Recurrent Events 2081
R. J. Cook

An Application of Decision Theory to Patient Screening for an Autologous Tumour Vaccine Trial 2099
W. D. Shannon, J. Bryant, T. F. Logan and R. Day

Two-sample Rank Tests for Acceleration in Cure Models 2111
J. Won Lee

The Restricted Cubic Spline as Baseline Hazard in the Proportional Hazards Model with Step Function Time-dependent Covariables 2119
J. E. Herndon II and F. E. Harrell, Jr.

Standardized Estimates from Categorical Regression Models 2131
M. M. Joffe and S. Greenland

Extract Logistic Regression: Theory and Examples 2143
C. R. Metha and N. R. Patel

Confidence Interval Estimates of an Index of Quality Performance Based on Logistic Regression Models 2161
D. W. Hosmer and S. Lemeshow

Volume 14, *Issue No.* 20, 30 October 1995

Prediction and Decision Making Using Bayesian Hierarchical Models 2173
D. K. Stangl

Modelling Mortality and Morbidity of Newborns 2191
C. Ritter, A. Bouckaert, M. Van Lierde and I. Theunissen

Longitudinal Models for Analysis of Respiratory Function 2205
R. B. D'Agostino, Jr., D. Sparrow, S. Weiss and B. Rosner

A Statistic for Comparing Two Correlated Markers Which Are Prognostic for Time to an Event 2217
S.-H. Jung, S. Wieand and S. S. Cha

A Simulation Study Used to Design the Sequential Monitoring Plan for a Clinical Trial 2227
M. M. Brooks, A. Hallstrom and M. Peckova

Re-evaluating Design Specifications of Longitudinal Clinical Trials without Unblinding When the Key Response is Rate of Change 2239
W. J. Shih and A. L. Gould

Designing a Cost-effective Clinical Trial 2249
J. C. Hornberger, B. W. Brown, Jr. and J. Halpern

Exact Power Computation for Dose-response Studies 2261
M. -L. Tang, K. F. Hirji and S. E. Vollset

Sample Size Determination for Comparing More Than Two Survival Distributions 2273
S. Ahnn and S. J. Anderson

LETTERS TO THE EDITOR 2283

Volume 14, *Issue No.* 21/22, 15 November–30 November 1995

Spatial Disease Patterns

Guest Editors: A. Lawson, L. Waller and A. Biggeri

Preface 2289

The Power of Focused Tests to Detect Disease Clustering 2291
L. A. Waller and A. B. Lawson

The Choice of Test for Detecting Raised Disease Risk Near a Point Source 2309
J. F. Bithell

A Class of Tests for Detecting 'General' and 'Focused' Clustering of Rare Diseases 2323
T. Tango

Non-parametric Estimation of Spatial Variation in Relative Risk 2335
J. E. Kelsall and P. J. Diggle

The Map Comparison Problem: Tests for the Overlap of Geographic Boundaries 2343
G. M. Jacquez

Exploratory Tools for Disease Mapping in Geographical Epidemiology 2363
C. Cislaghi, A. Biggeri, M. Braga, C. Lagazio and M. Marchi

Tests for Directional Space-time Interaction in Epidemiological Data 2383
A. B. Lawson and J. F. Viel

The Spatial Analysis of Covariates in a Study of Environmental Epidemiology 2393
C. A. Donnelly

Bayesian Estimates of Disease Maps: How Important are Priors? 2411
L. Bernardinelli, D. Clayton and C. Montomoli

Bayesian Analysis of Space-time Variation in Disease Risk 2433
L. Bernardinelli, D. Clayton, C. Pascutto, C. Montomoli, M. Ghislandi and M. Songini

Traffic Accident Mapping in Bangkok Metropolis: A Case Study 2445
S. Ayuthya and D. Böhning

Incidence of Leukaemia in Young People around the La Hague Nuclear Waste Reprocessing Plant: A Sensitivity Analysis 2459
J. Viel, D. Pobel and A. Carré

MCMC Methods for Putative Pollution Source Problems in Environmental Epidemiology 2473
A. B. Lawson

Spatial Variation of Natural Radiation and Childhood Leukaemia Incidence in Great Britain 2487
S. Richardson, C. Monfort, M. Green, G. Draper and C. Muirhead

LETTER TO THE EDITOR 2503

BOOK REVIEW 2507

Volume 14, *Issue No.* 23, 15 December 1995

Multiple Comparisons Procedures for Comparing Several Treatments with a Control Based on Binary Data 2509
C. Chuang-Stein and D. M. Tong

A Bayesian Analysis of Bivariate Survival Data from a Multicentre Cancer Clinical Trial 2523
P. Gustafson

Comparison of Median Survival Times with Adjustment for Covariates 2537
T. Karrison

Linear Rank Tests for Doubly Censored Data 2555
M.-X. Tang, W.-Y. Tsai, K. Marder and R. Mayeux

A New Approach to Selection and Weighting of Items in Evaluative Composite Measurement Scales 2565
J. Coste, E. Walter and A. Venot

Determining the Value of Additional Surrogate Exposure Data for Improving the Estimate of an Odds Ratio 2581
P. F. Dahm, M. H. Gail, P. S. Rosenberg and D. Pee

Using a Mixture Model to Predict the Occurrence of Diabetic Retinopathy 2599
P. Young, B. Morgan, P. Sonksen, S. Till and C. Williams

Optimal and Practicable Designs for Measuring Plaque pH-Profiles 2609
V. V. Fedorov, P. Hackl and W. G. Müller

LETTER TO THE EDITOR 2619

BOOK REVIEWS 2621

Goteri Bala Krishnamurty, Patricia Kasovia-Schmitt and David J. Ostroff, Statistics. An Interactive Text for the Health and Life Sciences. *Judith R. Glynn,* (ed.), Facts, Figures and Fallacies, Epidemiological Pitfalls in Medical Research

Volume 14, *Issue No.* 24, 30 December 1995

Papers from the International Meetings of the International Society for Clinical Biostatistics

Preface 2625

ISCB Committee 2626

Validity of the Recording of Ischaemic Heart Disease and Chronic Obstructive Pulmonary Disease in the Saskatchewan Health Care Datafiles 2627
N. S. B. Rawson and E. Malcolm

A Program to Implement a Search Method for Identification of Clinical Subgroups 2645
R. J. Marshall

A Personal View of Some Controversies in Allocating Treatment to Patients in Clinical Trials 2661
S. Senn

Effect of Non-random Missing Data Mechanisms in Clinical Trials 2675
S. C. Choi and I. L. Lu

Bayesian Approaches to Random-effects Meta-analysis: A Comparative Study 2685
T. C. Smith, D. J. Spiegelhalter and A. Thomas

Non-parametric Methods for Analysing Recurrent Complications of Varying Severity 2701
R. Lancar, A. Kramar and C. Haie-Meder

Non-parametric Estimation of the Post-lead Time Survival Distribution of Screen-detected Cancer Cases 2715
J.-L. Xu and P. C. Prorok

Interval Censored Survival Data and Multistate Compartmental Models in the Analysis of First Appearance of *Plasmodium Falciparum* Parasites in Infants 2727
A. Gottschau and B. Hogh

Acknowledgement 2737

Author Index 2739

Subject Index 2743

Contents of Volume 14, Issues 17–24 v

Volume 15, Issue Nos. 1–24

Volume 15, *Issue No.* 1, 15 January 1996

Formulae and Tables for the Determination of Sample Sizes and Power in Clinical Trials for Testing Differences in Proportions for the Two-sample Design: A Review 1
H. Sahai and A. Khurshid

Modelling Nutrition Knowledge, Attitudes, and Diet-disease Awareness: The Case of Dietary Fibre 23
J. N. Variyam, J. Blaylock and D. M. Smallwood

A Tree-based Method of Analysis for Prospective Studies 37
H. Zhang, T. Holford and M. B. Bracken

The Homogenetic Estimate for the Variance of Survival Rate 51
G. Zhao

Polynomials with Asymptotes for Longitudinal Data 61
R. H. Jones

Statistical Analysis of Zidovudine (AZT) Effect on CD4 Cell Counts in HIV Disease 75
A. J. McNeil and S. M. Gore

Estimation of Expected Quality Adjusted Survival by Cross-sectional Survey 93
J.-S. Hwang, J.-Y. Tsauo and J.-D. Wang

Practical *p*-Value Adjustment for Optimally Selected Cutpoints 103
S. G. Hilsenbeck and G. M. Clark

LETTER TO THE EDITOR 113

Volume 15, *Issue No.* 2, 30 January 1996

Robust Procedures for Analysing a Two-period Cross-over Design with Baseline Measurements 117
K. T. Tsai and H. I. Patel

The Analysis of Incomplete Data in the Three-period Two-treatment Cross-over Design for Clinical Trials 127
B. A. Richardson and V. F. Flack

Associations of Types of Lens Opacities Between and Within Eyes of Individuals: An Application of Second-order Generalized Estimating Equations 145
M. J. Podgor, R. Hiller and the Framingham Eye Studies Group

An Empirical Comparison of Expert-derived and Data-derived Classification Trees 157
M. Chiogna, D. J. Spiegelhalter, R. C. G. Franklin and K. Bull

Confidence Intervals for Median Survival Times Under a Piecewise Exponential Model With Proportional Hazards Covariate Effects 171
T. Karrison

Assessment of Small Health Risks Based on Exact Sample Sizes 183
K. Abt and A. Gülich

Characterization of HIV Incubation Distributions and Some Comparative Studies 197
W.-Y. Tan, S. R. Lee and S. C. Tang

The Shape of the Distribution of the Number of Sexual Partners 221
D. Kault

BOOK REVIEW 231
John Ashton, The Epidemiological Imagination. A Reader

Volume 15, *Issue No.* 3, 15 February 1996

Global Tests for Combination Drug Studies in Factorial Trials 233
H. M. Hung

Statistical Reporting of Clinical Trials with Individual Changes from Allocated Treatment 249
I. R. White and S. J. Pocock

Randomized and Non-randomized Patients in Clinical Trials: Experiences with Comprehensive Cohort Studies 263
C. Schmoor, M. Olschewski and M. Schumacher

Autoregressive Age–Period–Cohort Models 273
W. C. Lee and R. S. Lin

Interval Censored Survival Data: A Generalized Linear Modelling Approach 283
C. P. Farrington

Measurement Error Models for Ordinal Exposure Variables Measured with Error 293
B. A. Rosner

Reporting Delay: A Review with a Simulation Study and Application to Spanish AIDS Data 305
C. Sánchez Sellero, E. Vázquez Fernández, W. González-Manteiga, X. L. Otero, X. Hervada, E. Fernández and X. A. Taboada

A Generalized Linear Model for Analysing Receiver Operating Characteristic Curves 323
P. J. Smith, T. J. Thompson, M. E. Engelgau and W. H. Herman

CORRECTIONS 335
S. D. Walter

BOOK REVIEWS 337
Alain Spriet, Thérèse Dupin-Spriet and Pierre Simon, translated by Robert Coluzzi, John Young, Richard Edelstein and Michael Weintraub, Methodology of Clinical Drug Trials. *David G. Kleinbaum,* Logistic Regression. A Self-learning Test. *R. F. Burton,* Physiology by Numbers. An Encouragement to Quantitative Thinking

Volume 15, *Issue No.* 4, 28 February 1996

EDITORIAL 341

TUTORIALS IN BIOSTATISTICS 343
Designing Studies for Dose Response
W. K. Wong and P. A. Lachenbruch

Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors 361
F. E. Harrell, Jr., K. L. Lee and D. B. Mark

Statistical Approaches to Human Brain Mapping by Functional Magnetic Resonance Imaging 389
N. Lange

Non-parametric Two-sample Tests for Repeated Ordinal Responses 429
M. P. Fay and C. Gennings

A Model for Cross-over Trials Evaluating Therapeutic Preferences 443
J. K. Lindsey and B. Jones

Volume 15, *Issue No.* 5, 15 March 1996

The Incidence of Cystic Fibrosis 449
M. R. Kosorok, W.-H. Wei and P. M. Farrell

Bayesian Imputation of Predictive Values When Covariate Information is Available and Gold Standard Diagnosis is Unavailable 463
L. D. Epstein, A. Muñoz and D. He

Robustness and Power of Analysis of Covariance Applied to Data Distorted from Normality by Floor Effects: Homogeneous Regression Slopes 477
L. M. Sullivan and R. B. D'Agostino

Assessment of HIV Testing Rates Among HIV Infected Individuals Using Incidence Data on HIV and AIDS Diagnoses 497
I. C. Marschner

Historical HIV Incidence Modelling in Regional Subgroups: Use of Flexible Discrete Models with Penalized Splines Based on Prior Curves 513
S. Greenland

Analysis of Cross-over Trials for Duration Data 527
J. K. Lindsey, B. Jones and J. A. Lewis

Multiple-outcome Meta-analysis of Clinical Trials 537
C. S. Cerkey, J. J. Anderson and D. C. Hoaglin

STATISTICS IN THE MEDICAL LITERATURE: 2 559

BOOK REVIEWS 561

Phillip J. Brown, Measurement, Regression and Calibration. *H. O. Lancaster,* Quantitative Methods in Biological and Medical Sciences: A Historical Essay. *Edward H. Kaplan and Margaret L. Brandeau (eds.),* Modeling the AIDS Epidemic: Planning, Policy and Prediction.

Volume 15, *Issue No.* 6, 30 March 1996

A Model for the Effect of Cigarette Smoking on Lung Cancer Incidence in Connecticut 565
T. R. Holford, Z. Zhang, T. Zheng and L. A. McKay

Misclassification of Smoking Habits as a Source of Bias in the Study of Environmental Tobacco Smoke and Lung Cancer 581
P. N. Lee and B. A. Forey

Some Techniques for the Analysis of Work Sampling Data 607
M. E. Miller, M. K. James, C. D. Langefeld, M. A. Espeland, J. A. Freedman, D. K. Martin and D. M. Smith

A Likelihood Approach to Meta-analysis with Random Effects 619
R. J. Hardy and S. G. Thompson

The Appropriateness of the Wilcoxon Test in Ordinal Data 631
J. F. Hilton

An Asymptotic Test for the Equality of Coefficients of Variation from k Populations 647
C. J. Feltz and G. E. Miller

The Impact of Patient Compliance on Drug Concentration Profile in Multiple Doses 659
W. Wang, F. Husan and S.-C. Chow

Sample Size for the Exact Conditional Test Under Inverse Sampling 671
K.-J. Lui

BOOK REVIEW 679
M. P. Coleman, J. Esteve, P. Damiecki, A. Arslan and H. Renard, Trends in Cancer Incidence and Mortality

Volume 15, *Issue No.* 7/8/9, 15 April–15 May 1996

Preface 681

APPLIED STUDIES

The Four County Study of Childhood Cancer: Clusters in Context 683
P. Reynolds, D. F. Smith, E. Satariano, D. O. Nelson, L. R. Goldman and R. R. Neutra

Investigating Increased Incidence of Events in the Islands: A Hawaii Department of Health Perspective 699
G. Maskarinec

Childhood Leukaemia in Sweden: Using GIS and a Spatial Scan Statistic for Cluster Detection 707
U. Hjalmars, M. Kulldorff, G. Gustafsson and N. Nagarwalla

Exploratory Spatial Analysis of Birth Defect Rates in an Urban Population 717
G. Rushton and P. Lolonis

Surveillance of Clustering Near Point Sources 727
N. D. Le, A. J. Petkau and R. Rosychuk

Cluster Analysis with Constraints: Its Use with Breast Cancer Mortality Rates in Argentina 741
D. Wojdyla, L. Poletto, C. Cuesta, C. Badler and M. E. Passamonti

Spatial and Temporal Clustering of an Occupational Poisoning: The Example of Green Tobacco Sickness 747
R. H. McKnight, R. J. Kryscio, J. R. Mays and G. C. Rodgers, Jr.

A Potential Risk of Cancer in a Central Laboratory 759
B. Modan, Z. Blumstein, O. Luxenburg, I. Novikov and J. Shemer

POWER COMPARISONS

Statistical Power and Design of Focused Clustering Studies 765
L. A. Waller

Realistic Power Simulations Compare Point- and Area-based Disease Cluster Tests 783
N. Oden, G. Jacquez and R. Grimson

METHODS

Exploratory Analysis as a Sequel to Suspected Increased Rate of Cancer in a Small Residential or Workplace Community 807
R. Chen

Cluster Analysis by Testing the Statistical Hypothesis of Uniformity 817
V. Šaferis and L. A. Vilkauskas

A Longitudinal Study of Emergency Room Visits and Air Pollution for Prince George, British Columbia 823
B. Jørgensen, S. Lundbye-Christensen, X.-K. Song and L. Sun

A Random Graph Model for the Final-size Distribution of Household Infections 837
M. N. Islam, C. D. O'Shaughnessy and B. Smith

A Scan Statistic with a Variable Window 845
N. Nagarwalla

Disease Clusters in Structured Environments 851
R. C. Grimson and N. Oden

Disease Cluster Statistics for Imprecise Space-time Locations 873
G. M. Jacquez

The Spatial Autocorrelation Coefficient Moran's *I* under Heteroscedasticity 887
T. Waldhör

Localization of Disease Clusters Using Regional Measures of Spatial Autocorrelation 893
R. L. Munasinghe and R. D. Morris

An Introduction to Smoothing Incidence Rates by Penalized Likelihood 907
R. G. Downer

Covariate Adjusted Mixture Models and Disease Mapping with the Program DismapWin 919
P. Schlattmann, E. Dietz and D. Böhning

RESOURCES

The Computer Package DismapWin 931
P. Schlattmann

Sorting Variables for Each Case: A New Algorithm to Calculate Injury Severity Score (ISS) using SPSS-PC 933
S. Linn

Quadrat Analysis Software for the Detection of Spatial or Temporal Clustering 939
A. G. Skeleton

CLUSTER: A Software System for Epidemiologic Cluster Analysis 943
H. I. Hall, C. V. Lee and W. E. Kaye

Statistical Software for the Clustering of Health Events 951
G. M. Jacquez

Contents of Volume 15, Issues 1–8 v

Volume 15, *Issue No.* 10, 30 May 1996

Cross-over Trials with Censored Data 953
M. Feingold and B. W. Gillespie

Regret Graphs, Diagnostic Uncertainty, and Youden's Index 969
J. Hilden and P. Glasziou

Testing for Adverse Reactions Using Prescription Event Monitoring 987
J. E. Andrew, P. Prescott, T. M. F. Smith, W. H. W. Inman and K. Kubota

Modelling Lymphocytic Leukaemia Incidence in England and Wales Using Generalizations of the Two-mutation Model of Carcinogenesis of Moolgavkar, Venzon and Knudson 1003
M. P. Little, C. R. Muirhead and C. A. Stiller

A Functional Decline Model for Prevalent Cohort Data 1023
S. Liu, W.-Y. Tsai and Y. Stern

A Robust Method for Proportional Hazards Regression 1033
C. E. Minder and T. Bednarski

Power Calculation for a Score Test in the Dependent Censoring Model 1049
S.-Y. Lee

On the Distribution of the Unpaired *t*-Statistic with Paired Data 1059
M. A. Proschan

LETTER TO THE EDITOR 1065

BOOK REVIEW 1067
A. Bowling, Measuring Disease: A Review of Disease-specific Quality of Life Measurement Scales

Volume 15, *Issue No.* 11, 15 June 1996

On Design Considerations and Randomization-based Inference for Community Intervention Trials 1069
M. H. Gail, S. D. Mark, R. J. Carroll, S. B. Green and D. Pee

Robust Bayesian Approaches for Clinical Trial Monitoring 1093
B. P. Carlin and D. J. Sargent

Control of Familywise Errors in Multiple Endpoint Assessments via Stepwise Permutation Tests 1107
R. C. Blair, J. F. Troendle and R. W. Beck

Effects of Dropouts in a Longitudinal Study: An Application of a Repeated Ordinal Model 1123
E. Lesaffre, G. Molenberghs and L. Dewulf

A Comparative Study of Four Methods for Analysing Repeated Measures Data 1143
O. Manor and J. D. Kark

Simulation Study of Hierarchical Regression 1161
J. S. Witte and S. Greenland

A Bivariate Parametric Model for Survival and Intermediate Event Times 1171
L. D. Epstein and A. Muñoz

Two Sample Comparison for Large Groups of Correlated Binary Responses 1187
E. W. Lee

A Measure of Association for Assessing Prediction Accuracy That is a Generalization of Non-parametric ROC Area 1199
W. D. Smith, R. C. Dutton and N. T. Smith

Global Tests for Analysis of Multiple Tumour Data from Animal Carcinogenicity Experiments 1217
J. J. Chen

LETTER TO THE EDITOR 1227

BOOK REVIEW 1231
P. J. Diggle, K.-Y. Liang and S. L. Zeger, Analysis of Longitudinal Data

Volume 15, *Issue No.* 12, 30 June 1996

Conference on Meta-Analysis in the Design and Monitoring of Clinical Trials

Guest Editor: N. Geller, L. Freedman, Y. J. Lee and R. DerSimonian

Preface 1233

List of Participants 1235

Meta-Analysis in the Design and Monitoring of Clinical Trials 1237
R. DerSimonian

Discussion 1249

Meta-Analysis: Current Issues in Research Synthesis 1253
I. Olkin

Discussion 1259

Changes in Clinical Trials Mandated by the Advent of Meta-Analysis 1263
T. C. Chalmers and J. Lau

Discussion 1269

Meta-Analysis and Meta-Analytic Monitoring of Clinical Trials 1273
A. R. Feinstein

Discussion 1281

The Role of External Evidence in Data Monitoring of a Clinical Trial 1285
S. J. Pocock

Discussion 1295

The Role of Meta-Analysis in Monitoring Clinical Trials 1299
C. B. Begg

Discussion 1307

Role of Meta-Analyses in Design and Monitoring of Randomized Clinical Trials: Summary of First Day of the Workshop 1313
N. L. Geller

Concluding Discussion 1317

Volume 15, *Issue No.* 13, 15 July 1996

Estimating the Surface Area of the Human Body 1325
B. Bailey

A Technique for Measuring Epidemiologically Useful Features of Birthweight Distributions 1333
D. M. Umbach and A. J. Wilcox

Classifying Visual Field Data 1349
S. Hilton, J. Katz and S. Zeger

Mixture Models for Eye-tracking Data: A Case Study 1365
D. K. Pauler, M. D. Escobar, J. A. Sweeney and J. Greenhouse

How Independent are Multiple 'Independent' Diagnostic Classifications? 1377
H. Brenner

A Non-parametric Test for Interval-censored Failure Time Data with Application to AIDS Studies 1387
J. Sun

Analysis of Mortality Rates via Marginal Extended Quasi-likelihood 1397
W.-S. Lu and R. K. Tsutakawa

Maximum Likelihood Estimation of the Kappa Coefficient from Bivariate Logistic Regression 1409
M. M. Shoukri and I. U. H. Mian

An Index for Assessing Blindness in a Multi-centre Clinical Trial: Disulfiram for Alcohol Cessation—A VA Cooperative Study 1421
K. E. James, D. A. Bloch, K. K. Lee, H. C. Kraemer and R. K. Fuller

Modelling and Design of Cross-over Trials 1435
B. Jones and A. N. Donev

Estimating Confidence Intervals for Cost-effectiveness Ratios: An Example from a Randomized Trial 1447
M. A. Chaudhary and S. C. Stearns

BOOK REVIEWS 1459

T. C. Timmreck, An Introduction to Epidemiology. *D. Clayton and M. Hills,* Statistical Models in Epidemiology. *M. Davidian and D. M. Giltiman,* Nonlinear Models for Repeated Measurement Data. *ARME-P,* Methodological Approaches in Pharmacoepidemiology—Application to Spontaneous Reporting

Volume 15, *Issue No.* 14, 30 July 1996

Simple Robust Procedures for Combining Risk Differences in Sets of 2 × 2 Tables 1465
J. D. Emerson, D. C. Hoaglin and F. Mosteller

Testing for Individual and Population Equivalence Based on the Proportion of Similar Responses 1489
D. M. Rom and E. Hwang

A Global Odds Ratio Regression Model for Bivariate Ordered Categorical Data from Ophthalmologic Studies 1507
J. Williamson and K. Kim

Model-Based Estimation of the Excess Fraction (Attributable Fraction): Day Care and Middle Ear Infection 1519
H. Oja, O. P. Alho and E. Laara

Confidence Intervals for the Excess Risk in Case-Control Studies 1535
V. Siskind

Assessment of Postpartum Time-Dependent Disease Risk in Case-Control Studies: An Application for Examining Age-Specific Effect Estimates 1545
C. Hsieh and S. Lan

The Effects of Misclassification of the Actual Cause of Death in Competing Risks Analysis 1557
N. Ebrahimi

Analysis of Serological Surveys using Mixture Models: Application to a Survey of Parvovirus B19 1567
N. J. Gay

The Use of the "Bi-Normal" Model for Parametric ROC Analysis of Quantitative Diagnostic Tests 1575
J. A. Hanley

A Method for Determining the Size of Internal Pilot Studies 1587
L. Sandvik, J. Erikssen, P. Mowinckel and E. A. Rodland

LETTERS TO THE EDITOR 1591

BOOK REVIEWS 1601

Diana B. Petitti, Meta-Analysis, Decision Analysis and Cost Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. *Joachin Vollmar,* Biometrie in der Chemisch-Pharmazeutischen Industrie. *Chap T. Le and James R. Boen,* Health and Numbers—Basic Biostatistical Methods. *D. V. Lindley and W. F. Scott,* New Cambridge Statistical Tables

Volume 15, *Issue No.* 15, 15 August 1996

Improved Designs for Dose Escalation Studies Using Pharmacokinetic Measurements 1605
S. Piantadosi and G. Liu

Design and Analysis of Intra-Subject Variability in Crossover Experiments 1619
V. M. Chinchilli and J. D. Esinhart

Estimating Population Size when Duplicates are Present 1635
E. Laska, M. Meisner, J. A. Wanderling and H. B. Kushner

Analysis of Multivariate Reliability Structures and the Induced Bias in Linear Model Estimation 1647
M. Aickin and C. Ritenbaugh

Simultaneously Modelling Censored Survival Data and Repeatedly Measured Covariates: A Gibbs Sampling Approach 1663
C. L. Faucett and D. C. Thomas

A Simple Method for Comparing Correlated ROC Curves using Incomplete Data 1687
X. H. Zhou and C. A. Gatsonis

Modelling Irregularly Sampled Profiles of Nonnegative Dog Triglyceride Responses under Different Distributional Assumptions 1695
P. Lambert

BOOK REVIEWS 1709
William M. Wooding, Planning Pharmaceutical Clinical Trials. Basic Statistical Principles. *Shein-Chung Chow and Jen-Pei Lio,* Statistical Design and Analysis in Pharmaceutical Science. *Alvin C. Rencher,* Methods of Multivariate Analysis

Volume 15, *Issue No.* 16, 30 August 1996

The Population Risk as an Explanatory Variable in Research Synthesis of Clinical Trials 1713
M. W. McIntosh

An Alternative to the use of Two-sided Tests in Clinical Trials 1729
C. W. Dunnett and M. Gent

Some Optimal and Non-optimal Two-stage Designs using an α-Spending Function 1739
H. I. Patel

Statistical Analysis of Possible Bias of Clinical Judgements Due to Observing an On-therapy Marker Variable 1747
F. Boateng, A. Sampson and B. Schwab

Non-parametric Bayesian Approach to Hazard Regression: a Case Study with a Large Number of Missing Covariate Values 1757
E. Arjas and L. Liu

The Semi-proportional Hazards Model Revisited: Practical Reparametrizations 1771
G. E. Eide, E. Omenaas and A. Gulsvik

Comparison of Trends in HIV Infection for Two Risk Categories 1779
N. G. Becker and J.-S. Cui

A Comparison of Statistical Methods for Clustered Data Analysis with Guassian Error 1793
Z. Feng, D. McLerran and J. Grizzle

Ordinal Regression Methodology for ROC Curves Derived from Correlated Data 1807
A. Toledano and C. Gatsonis

Contents of Volume 15, Issues 10–16 v

Volume 15, *Issue No.* 17/18, 15 September–30 September 1996

Symposium on Small Area Statistics in Public Health: Design, Analysis, Graphic and Spatial Methods

Guest Editor: S. Jay Smith

Preface 1827
S. J. Smith

Staff and Committees 1829

Introduction and Welcome 1835
D. E. Snider

Use of Density Equalizing Map Projections (Demp) in the Analysis of Childhood Cancer in Four California Counties 1837
D. W. Merrill, S. Selvin, E. R. Close and H. H. Holmes

Design Considerations for Estimation of Exposure Effects on Disease Risk, Using Aggregate Data Studies 1849
L. Sheppard, R. L. Prentice and M. Rossing

Toward Congruence Between Theory and Practice in Small Area Analysis and Local Public Health Data 1859
R. S. Kirby

Empirical Bayes Estimation of Small Area Prevalence of Non-Rare Conditions 1867
M. Martuzzi and P. Elliott

An Empirical Bayes Method for Studying Variation in Knee Replacement Rates 1875
X.-H. Zhou, B. P. Katz, E. Holleman, C. A. Melfi and R. Dittus

Spatial Partitioning Using Multivariate Cluster Analysis and a Contiguity Algorithm 1885
M. S. Carvalho, O. G. Cruz and F. F. Nobre

Protecting Confidentiality in Small Population Health and Environmental Statistics 1895
L. H. Cox

The Spatial Relationship Between Infant Mortality and Birth Defect Rates in a U.S. City 1907
G. Rushton, D. Krishnamurti, R. Krishnamurthy, P. Lolonis and H. Song

Classification Methods for Denominators in Small Areas 1921
P. S. Wittie, W. Drane and T. E. Aldrich

Use of Stone's Method in Studies of Disease Risk Around Point Sources of Environmental Pollution 1927
G. Shaddick and P. Elliott

A k Nearest Neighbour Test for Space–Time Interaction 1935
G. M. Jacquez

Power Determination for Geographically Clustered Data Using Generalized Estimating Equations 1951
S. A. Hendricks, J. T. Wassell, J. W. Collins and S. L. Sedlak

Geographic Information Systems (GIS): New Perspectives in Understanding Human Health and Environmental Relationships 1961
C. M. Croner, J. Sperling and F. R. Broome

Poster Presentations 1979

Closing Remarks 1983
T. Colton

Close of Symposium 1985
S. J. Smith

Volume 15, *Issue No.* 19, 15 October 1996

Explained Variation for Logistic Regression 1987
M. Mittlböck and M. Schemper

Explained Variation in Survival Analysis 1999
M. Schemper and J. Stare

Estimating Predictive Values for Blood Pressure Measurements from Multivariate Regression Models with Covariates 2013
N. R. Cook

Statistical Evidence for Shared Transient Causes of Anatomically Distinct Birth Defects 2029
C. R. Weinberg, R. Skjærven and A. J. Wilcox

Continuous and Group Sequential Conditional Probability Ratio Tests for Phase II Clinical Trials 2037
M. Tan and X. Xiong

Analysis of Uncontrolled Treatment Changes in HIV Clinical Trials 2053
H.-M. Lin and M. D. Hughes

Survival Analyses of Randomized Clinical Trials Adjusted for Patients who Switch Treatments 2069
M. G. Law and J. M. Kaldor

Applications of a Mixture Survival Model with Covariates to the Analysis of a Depression Prevention Trial 2077
J. B. Greenhouse and N. P. Silliman

Efficiency Robust Tests of Independence in Contingency Tables with Ordered Classifications 2095
M. J. Podgor, J. L. Gastwirth and C. R. Mehta

A Generalized Michaelis-Menten Response Surface 2107
K. Hirst, G. O. Zerbe and W. W. Hay, Jr.

BOOK REVIEWS 2121
Graham Dunn and Brian Everitt, Clinical Biostatistics. An Introduction to Evidence Based Medicine. *A. Gelman, J. B. Carlin, H. S. Stern and D. B. Rubin,* Bayesian Data Analysis. *J. M. Bernardo and A. F. M. Smith,* Bayesian Theory. *E. B. Anderson,* The Statistical Analysis of Categorical Data

Volume 15, *Issue No.* 20, 30 October 1996

Guidelines for Budgeting Biostatistics Involvement in Research Projects 2127
M. L. Lesser

Logrank, Play the Winner, Power and Ethics 2135
A. Hallstrom, M. M. Brooks and M. Peckova

Sequentially Balanced Three-Squares Cross Over Designs 2143
R. G. Newcombe

Predictive Diagnostics for Logistic Models 2149
F. Seillier-Moiseiwitsc

Bayesian Inference on Prevalence Using a Missing-data Approach with Simulation-based Techniques: Applications to HIV Screening 2161
J. R. Mendoza-Blanco, X. M. Tu and S. Iyengar

Regression Models for Interval Censored Survival Data: Application to HIV Infection in Danish Homosexual Men 2177
B. Cartensen

Missing Cause of Death Information in the Analysis of Survival Data 2191
J. Andersen, E. Goetghebeur and L. Ryan

A Simulation Study of Cross-validation for Selecting an Optimal Cutpoint in Univariate Survival Analysis 2203
D. Faraggi and R. Simon

The Transmission Dynamics and Control of Hepatitis B Virus in The Gambia 2215
W. J. Edmunds, G. F. Medley and D. J. Nokes

A Statistical Model of Transmission of Hib Bacteria in a Family 2235
K. Auranen, J. Ranta, A. K. Takala and E. Arjas

Threshold Models in a Methadone Programme Evaluation 2253
A. Saei, J. Ward and C. A. McGilchrist

BOOK REVIEWS 2261

Bernard Crump and Michael Drummond, Evaluating Clinical Evidence: A Handbook for Managers. *Yvan Toniton and Erhard Haus (eds.),* Biologic Rhythms in Clinical and Laboratory Medicine. *Michael S. Waterman,* Introduction to Computational Biology: Maps Sequences and Genomes. *P. W. Strike,* Measurement in Laboratory Medicine: A Primer on Control and Interpretation. *E. K. Harris and J. C. Boyd,* Statistical Basis of Reference Values in Laboratory Medicine

ANNOUNCEMENT 2267

Volume 15, *Issue No.* 21/22, 15 November–30 November 1996

Symposium on Statistical Issues in HIV/AIDS Research

Guest Editors: Mary A. Foulkes, Dennis O. Dixon, Victor DeGruttola and Steven Self

Preface 2269

Introduction 2271

Use of Observational Data, Including Surveillance Studies, for Evaluating AIDS Therapies 2273
M. H. Gail

Models for Empirical Bayes Estimators of Longitudinal CD4 Counts 2289
M. P. LaValley and V. DeGruttola

Using Multiple Decrement Models to Estimate Risk and Morbidity from Specific AIDS Illnesses 2307
D. R. Hoover, Y. Peng, A. J. Saah, R. R. Detels, R. S. Day and J. P. Phair

Parametric Models to Assess Tracking of Categorical High-risk Sexual Behaviour for HIV Infection 2323
S. J. Gange, L. P. Jacobson and A. Muñoz

Discussion 2337
S. Shiboski

Sequential Monitoring of Clinical Trials with Multiple Survival Endpoints 2341
P. L. Williams

Long-term Follow-up in AIDS Clinical Trials 2359
D. A. Schoenfeld

Discussion 2367
D. Follmann

A Control-conditional Test for Assessing HIV Vaccine Efficacy in Small Sample Preclinical Studies 2371
J. M. Albert

Comparing Methods for Calculating Confidence Intervals for Vaccine Efficacy 2379
M. Ewell

Assessing the Effect of HIV Vaccination on Infectiousness 2393
W. N. Rida

Discussion 2405
M. E. Halloran

Play the Winner for Phase II/III Clinical Trials 2413
Q. Yao and L. J. Wei

HIV Treatment Strategies Utilizing Virologic and Immunologic Markers as Criteria for Changing Treatments 2425
M. Elashoff and S. Lagakos

Data Analysis Issues for Protocols with Overlapping Enrollment 2445
K. Larntz, J. D. Neaton, D. N. Wentworth and T. Yurik

Discussion 2455
R. G. Cornell

Models for the Incubation of AIDS and Variations According to Age and Period 2459
A. Muñoz and J. Xu

Nonparametric Inference of a Failure Time Distribution when the Failure Times are Estimated 2475
H. M. Kim and S. W. Lagakos

Acknowledgement 2491

Volume 15, *Issue No.* 23, 15 December 1996

Models for Estimating the Number of Unpublished Studies 2493
L. J. Gleser and I. Olkin

Non-parametric Methods for Comparing Multiple Treatment Groups to a Control Group, Based on Incomplete Non-decreasing Repeated Measurements 2509
C. S. Davis

Optimal Sample Allocation in Clinical Trials Designed to Investigate Relative Risks 2523
B. J. Eastwood

Smoothing Geographical Data, Particularly Rates of Disease 2539
K. Kafadar

Detection of Overall Space-Time Clustering in a Non-Uniformly Distributed Population 2561
J. Ranta, J. Pikäniemi, M. Karvonen, E. Virtala, J. Rusanen, A. Colpaert, A. Naukkarinen, J. Tuomilehto and the DiMe Study Group

Population-averaged and Cluster-specific Models for Clustered Ordinal Response Data 2573
T. R. Ten Have, J. R. Landis and J. Hartzel

Assessing Interactions of Binary Time-Dependent Covariates with Time in Cox Proportional Hazards Regression Models Using Cubic Spline Functions 2589
H. Heinzl, A. Kaider and G. Zlabinger

Differential Recall Bias and Spurious Associations in Case Control Studies 2603
D. Barry

Use of a Stochastic Model for Repeated Binary Assessment 2617
H. Hassani and A. Ebbutt

BOOK REVIEW 2629
P. R. Rosenbaum, Observational Studies

Volume 15, *Issue No.* 24, 30 December 1996

Papers from the International Meetings of the International Society for Clinical Biostatistics

Preface 2633

ISCB Committee 2634

A Three-step Procedure for Assessing Bioequivalence in the General Mixed Model Framework 2635
J. Vuorinen and J. Turunen

A Comparison of Different Approaches for Fitting Centile Curves to Birthweight Data 2657
S. R. Bonellie and G. M. Raab

Sources of Uncertainty in Estimating HIV Infection Rates by Back-calculation: An Application to Italian Data 2669
S. Mariotti and R. Cascioli

Some Statistical Issues in Project Prioritization in the Pharmaceutical Industry 2689
S. Senn

Sequential Designs for Equivalence Studies 2703
J. Whitehead

Multi-level Models for Repeated Measurement Data: Application to Quality of Life Data in Clinical Trials 2717
H. Beacon and S. Thompson

Borrowing Strength from External Trials in a Meta-analysis 2733
J. P. T. Higgins and A. Whitehead

An Application of a Marked Point Process in Pre-clinical Medicine 2751
D. M. Berridge

Evaluation of Long-Term Survival: Use of Diagnostics and Robust Estimators with Cox's Proportional Hazards Model 2763
M. G. Valsecchi, D. Silvestri and P. Sasieni

Comparison of One-sample Two-sided Sequential *t*-tests for Application in Epidemiological Studies 2781
I. van der Tweel, R. Kaaks and P. A. H. van Noord

On the Relationship Between Response to Treatment and Survival Time 2797
M. Buyse and P. Piedbois

Analysing Non-compliance in Clinical Trials: Ethical Imperative or Mission Impossible? 2813
E. J. T. Goetghebeur and S. H. Shapiro

Acknowledgement 2827

Author Index 2829

Subject Index 2833

Contents of Volume 15, Issues 17–24 v

NOTES FOR CONTRIBUTORS

1. Four copies of the paper (including figures) should be submitted to an Editor. Papers from the North, Central and South America should be sent to **Theodore Colton**, *Boston University School of Public Health, 80 East Concord Street, Boston, Massachusetts 02118, U.S.A. (Tel. No. (617) 638-5172).* Papers from Europe should be sent to **Tony Johnson**, *Institute of Public Health, University Forvie Site, Robinson Way, Cambridge CB2 2SR, U.K. (Tel. No. (01223) 330370).* Papers from Asia and Australasia should be sent to **David Machin**, *NMRC Clinical Trials and Epidemiology Research Unit, 02-14 Bowyer Block, Singapore General Hospital, Singapore 169 608. (Tel. No. 225 7256).* Papers will not be returned to the author(s). To ensure prompt publication, the full postal address should be given for the author who will check proofs, along with telephone, telex and telefax numbers where possible.

2. Only original papers, not published elsewhere, will be accepted.

The transfer of copyright from author to publisher must be made explicit to enable the publisher to ensure maximum dissemination of the author's work. A copy of the Publishing Agreement will be provided by a journal editor or the publisher, and a signed copy will be required for every paper accepted for publication.

3. All papers will be published in English and manuscripts must be submitted in that language.

4. No maximum length for a paper is prescribed but authors should write concisely. Detailed mathematical development will be discouraged; mathematical and statistical terms and symbols must be fully explained and clearly defined. There will be no page charge.

5. The paper should be typed double-spaced on one side of standard size paper with a standard size margin at each edge of the sheet. Pages must be numbered consecutively.

6. The title should be typed on the first page with author's name, address, telephone number and email address. This information should be given for all co-authors. Correspondence will be sent to the first-named author unless otherwise indicated.

7. The second page of the paper should contain the title and a summary.

8. The text should begin on the third page and should not relist the title or author(s). It should be subdivided into sections and subsections as necessary.

9. Accepted papers should be provided on disk if possible. Two identical disk copies of the final version of the paper should be accompanied by a hard copy. If the disk and the hard copy differ, the hard copy will be used as the definitive version. The disks must be labelled with a six letter acronym representing the journal title (3) and the author's name (3), for example, SIMALJ. The label should also include the date, author's name, hardware and software used. Most software is acceptable but WordPerfect, Word or TeX are best.

10. Distinction should be made between the letter l and number 1, between the letter O and the number 0, between the letter Z and the number 2, between the letter k and kappa, between upper and lower case letters, and anywhere confusion may be possible.

11. All abbreviations should be preceded the first time they appear by the full name except the common SI symbols for units.

12. Footnotes should be kept to a minimum, parenthetic inserts within the text being preferred.

13. Line drawings should be supplied on a separate sheet at the same size as the intended printed version (so no enlargement or reduction is required), maximum width 140 mm. Lettering on the artwork should be set in 8pt type. Computer-generated artwork must be submitted as laser printed output at a resolution of 600 dots per inch on high quality paper. Dot matrix printer output is unacceptable. Tints are to be avoided; hatching should be used instead. Drawn artwork should be carefully lettered and drawn in black ink. Provide copies as well as the originals.

Black and white photographs should be supplied as sharp, glossy black and white prints (not photocopies or previously printed material). Laser output photographs are to be avoided.

Both drawings and photographs should be clearly identified on the back with the figure number and the author's name.

Artwork on disk is preferred on 3.5 inch PC or Macintosh format disk in a dedicated drawing package, such as Adobe Illustrator/Corel Draw/Macromedia Freehand *not* presentation, spreadsheet or database packages. Each graphic should be in a separate file, should conform to the information above and be supplied as a source (original) file as well as .EPS file, if different. Provide hard copy print out of each figure, clearly identified.

14. References to published literature should be numbered consecutively in the text using superior numbers and arranged in the same order at the end of the paper in a Reference Section. Journal references should be listed, with journal titles, authorship and page references in full, as follows:

> Bonaifi, C. and Demenais, F. 'Diseases having two classes of severity: Estimation of the proportions of each manifestation by maximum likelihood', *Biometrics*, **36,** 447–460 (1980).

Book references should be given as follows:

> Altman, D. G. *Practical Statistics for Medical Research*, Chapman and Hall, London, 1991.

15. It is the author's responsibility to obtain written permission to reproduce copyright material.

16. Normal editorial policy is to have papers reviewed by two expert referees and their reports sent to the author(s).

17. Page proofs will be supplied to the first author (unless otherwise requested) prior to publication primarily for checking typesetting accuracy. Only minor changes will be accepted at this stage.

18. Twenty-five offprints of each paper will be provided free of charge. Additional copies may be purchased on an offprint order form which will be sent to the authors with the proofs.

19. Letters to the Editors are welcomed and will be published at their discretion. Authors will be given the opportunity to respond to letters which comment upon their papers.

CONTENTS

VOLUMES 1–15 1982–1996

Cumulative Fifteen-year Index

Author Index	1
Subject Index	23
Special Issues Index	183
Tutorials in Biostatistics Index and Statistics in the Medical Literature Index	187
Corrections Index	189
Book Review Index	191
Editors	197
Editorial Board Members	199

VOLUME CONTENTS

Volume 1	205
Volume 2	207
Volume 3	211
Volume 4	215
Volume 5	219
Volume 6	225
Volume 7	232
Volume 8	240
Volume 9	251
Volume 10	261
Volume 11	274
Volume 12	286
Volume 13	300
Volume 14	316
Volume 15	331